FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Kamdar, BB Martin, JL Needham, DM Ong, MK AF Kamdar, Biren B. Martin, Jennifer L. Needham, Dale M. Ong, Michael K. TI Promoting Sleep to Improve Delirium in the ICU SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE critical illness; delirium; intensive care unit; sleep ID RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE C1 [Kamdar, Biren B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Needham, Dale M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Div Pulm & Crit Care Med, Outcomes Crit Illness & Surg OACIS Grp, Baltimore, MD USA. [Ong, Michael K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Ong, Michael K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kamdar, BB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. NR 16 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD DEC PY 2016 VL 44 IS 12 BP 2290 EP 2291 DI 10.1097/CCM.0000000000001982 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA EC3VZ UT WOS:000388056500029 PM 27858818 ER PT J AU Andrikopoulou, E Lloyd, SG Hage, FG AF Andrikopoulou, Efstathia Lloyd, Steven G. Hage, Fadi G. TI Ventricular tachycardia during regadenoson SPECT myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID ADENOSINE C1 [Andrikopoulou, Efstathia; Lloyd, Steven G.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovascular Dis, Cardiovascular Dis Fellowship Program, 1808 7th Ave South,BDB 201, Birmingham, AL 35294 USA. [Lloyd, Steven G.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. [Lloyd, Steven G.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Andrikopoulou, E (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovascular Dis, Cardiovascular Dis Fellowship Program, 1808 7th Ave South,BDB 201, Birmingham, AL 35294 USA. EM eandrikopoulou@uabmc.edu OI Hage, Fadi/0000-0002-1397-4942 NR 4 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD DEC PY 2016 VL 23 IS 6 BP 1518 EP 1520 DI 10.1007/s12350-015-0339-5 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EC5NI UT WOS:000388182100041 PM 26626781 ER PT J AU McFarland, DH Martin-Harris, B Fortin, AJ Humphries, K Hill, E Armeson, K AF McFarland, D. H. Martin-Harris, B. Fortin, A. -J. Humphries, K. Hill, E. Armeson, K. TI Respiratory-swallowing coordination in normal subjects: Lung volume at swallowing initiation SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE Respiration; Deglutition; Lung volume; Respiratory-swallow coordination ID HEALTHY-YOUNG ADULTS; SWALLOW/RESPIRATORY PHASE-RELATIONSHIPS; UPPER ESOPHAGEAL SPHINCTER; SUBGLOTTIC AIR-PRESSURE; BOLUS VOLUME; APNEA DURATION; DYSPHAGIC PATIENTS; STRAW DRINKING; AGE; PHARYNGEAL AB This study was designed to investigate the significance of bolus types and volumes, delivery methods and swallowing instructions on lung volume at swallowing initiation in normal subjects in a single experiment using a multifactorial approach. Our broad range goal was to determine optimal lung volume range associated with swallowing initiation to provide training targets for dysphagic patients with disordered respiratory-swallow coordination. Our hypothesis was that swallows would be initiated within a limited range of quiet breathing lung volumes regardless of bolus volume, consistency or task. Results confirmed this hypothesis and revealed that swallows were initiated at mean lung volume = 244 ml. Cued swallows were initiated at lower quiet breathing volumes than un-cued swallows (cued =201 ml; uncued =367 ml). Water boluses were initiated at slightly higher quiet breathing volumes than solids. Data suggest that swallows occur within a restricted range of lung volumes with variation due to instructions, bolus type and other experimental variables. (C) 2016 Elsevier B.V. All rights reserved. C1 [McFarland, D. H.; Fortin, A. -J.] Univ Montreal, Fac Med, Ecole Orthophonie & Audiol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 2J7, Canada. [McFarland, D. H.] McGill Univ, Fac Med, Sch Commun Sci & Disorders, McGill Coll 2001, 8th Floor, Montreal, PQ H3A 1G1, Canada. [Martin-Harris, B.; Humphries, K.; Hill, E.; Armeson, K.] Med Univ South Carolina, 171 Ashley Ave, Charleston, SC 19425 USA. [Martin-Harris, B.] Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29401 USA. [Martin-Harris, B.; Humphries, K.] Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Martin-Harris, B.; Humphries, K.] Evelyn Trammell Inst Voice & Swallowing, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Martin-Harris, B.; Hill, E.; Armeson, K.] Dept Publ Hlth Sci, 135 Cannon St,Suite 303,MSC 835, Charleston, SC 29425 USA. [Martin-Harris, B.] Northwestern Univ, Roxelyn & Richard Pepper Dept Commun Sci & Disord, 70 Arts Circle Dr, Evanston, IL 60208 USA. RP McFarland, DH (reprint author), Univ Montreal, Fac Med, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 2J7, Canada. EM david.mcfarland@umontreal.ca; bonnie.martinharris@northwestern.edu; annie-joelle.fortin@umontreal.ca; humphrik@musc.edu; hille@musc.edu; armeson@musc.edu FU National Institutes of Health [NIDCD1K24DC1281, NIDCD1R21DC010480-A1]; United States Department of Veteran Affairs [RRDC7135R] FX This work was funded by the National Institutes of Health NIDCD1K24DC1281 and NIDCD1R21DC010480-A1; the United States Department of Veteran Affairs RR&DC7135R. NR 69 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 EI 1878-1519 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD DEC PY 2016 VL 234 BP 89 EP 96 DI 10.1016/j.resp.2016.09.004 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA EC3XQ UT WOS:000388060800011 PM 27612587 ER PT J AU Restrepo, MI Reyes, LF Anzueto, A AF Restrepo, Marcos I. Reyes, Luis F. Anzueto, Antonio TI Complication of Community-Acquired Pneumonia (Including Cardiac Complications) SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE pneumonia; sepsis; complications; multiple organ dysfunction ID INTENSIVE-CARE-UNIT; RANDOMIZED CLINICAL-TRIAL; IN-HOSPITAL MORTALITY; D-DIMER LEVELS; CARDIOVASCULAR-DISEASE; PLEURAL EFFUSION; RISK-FACTORS; PARAPNEUMONIC EFFUSION; PNEUMOCOCCAL PNEUMONIA; CHLAMYDIA-PNEUMONIAE AB Community-acquired pneumonia (CAP) represents an important public health problem and carries significant morbidity, mortality, and costs. The incidence of CAP is highest among children and elderly patients, but the mortality is much higher in patients older than 65 years. Despite the advances in medicine, the administration of antimicrobials, and the overall better care, there are still patients with CAP dying due to systemic complications all over the world. A continuum of CAP disease progression may involve multiple organs beyond the pulmonary parenchyma. These pulmonary and nonpulmonary complications are associated not only with mortality but also with the development of clinical failure, prolonged hospitalization, and the need for more intensive level of care. In this review, we present the characteristics of several CAP-related pulmonary and nonpulmonary organ dysfunction, such as those affecting the heart, kidneys, hematological, neurological, endocrine systems. Multiple severity of illness scores identified a series of systemic findings that indicate the organ dysfunctions and the associated related outcomes. However, further research is required to address the mechanisms, the management, and prevention of organ dysfunction in patients with CAP. C1 [Restrepo, Marcos I.; Reyes, Luis F.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, ALMD 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Reyes, Luis F.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, ALMD 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu FU National Heart, Lung, and Blood Institute [K23HL096054] FX MIR's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health nor the Department of Veterans Affairs. NR 82 TC 0 Z9 0 U1 3 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD DEC PY 2016 VL 37 IS 6 BP 897 EP 904 DI 10.1055/s-0036-1593754 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EC6MR UT WOS:000388250900011 PM 27960213 ER PT J AU Sacks, GD Dawes, AJ Ettner, SL Brook, RH Fox, CR Russell, MM Ko, CY Maggard-Gibbons, M AF Sacks, Greg D. Dawes, Aaron J. Ettner, Susan L. Brook, Robert H. Fox, Craig R. Russell, Marcia M. Ko, Clifford Y. Maggard-Gibbons, Melinda TI Impact of a Risk Calculator on Risk Perception and Surgical Decision Making A Randomized Trial SO ANNALS OF SURGERY LA English DT Article DE risk calculator; risk perception; surgical decision-making; variations in care ID CLINICAL-ASSESSMENT; INFORMED-CONSENT; SURGERY; BENEFITS; TALK; CARE AB Objective: The aim of this study was to determine whether exposure to data from a risk calculator influences surgeons' assessments of risk and in turn, their decisions to operate. Background: Little is known about how risk calculators inform clinical judgment and decision-making. Methods: We asked a national sample of surgeons to assess the risks (probability of serious complications or death) and benefits (recovery) of operative and nonoperative management and to rate their likelihood of recommending an operation (5-point scale) for 4 detailed clinical vignettes wherein the best treatment strategy was uncertain. Surgeons were randomized to the clinical vignettes alone (control group; n = 384) or supplemented by data from a risk calculator (risk calculator group; n = 395). We compared surgeons' judgments and decisions between the groups. Results: Surgeons exposed to the risk calculator judged levels of operative risk that more closely approximated the risk calculator value (RCV) compared with surgeons in the control group [mesenteric ischemia: 43.7% vs 64.6%, P < 0.001 (RCV = 25%); gastrointestinal bleed: 47.7% vs 53.4%, P < 0.001 (RCV = 38%); small bowel obstruction: 13.6% vs 17.5%, P < 0.001 (RCV = 14%); appendicitis: 13.4% vs 24.4%, P < 0.001 (RCV = 5%)]. Surgeons exposed to the risk calculator also varied less in their assessment of operative risk (standard deviations: mesenteric ischemia 20.2% vs 23.2%, P = 0.01; gastrointestinal bleed 17.4% vs 24.1%, P < 0.001; small bowel obstruction 10.6% vs 14.9%, P < 0.001; appendicitis 15.2% vs 21.8%, P < 0.001). However, averaged across the 4 vignettes, the 2 groups did not differ in their reported likelihood of recommending an operation (mean 3.7 vs 3.7, P = 0.76). Conclusions: Exposure to risk calculator data leads to less varied and more accurate judgments of operative risk among surgeons, and thus may help inform discussions of treatment options between surgeons and patients. Interestingly, it did not alter their reported likelihood of recommending an operation. C1 [Sacks, Greg D.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.; Maggard-Gibbons, Melinda] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sacks, Greg D.; Dawes, Aaron J.; Ettner, Susan L.; Brook, Robert H.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Ettner, Susan L.; Brook, Robert H.; Fox, Craig R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Los Angeles, CA USA. [Fox, Craig R.] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA USA. [Fox, Craig R.] Univ Calif Los Angeles, Dept Psychol, Coll Letters & Sci, Los Angeles, CA USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, Dept Surg, 10833 Le Conte Ave,72-227 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu FU Robert Wood Johnson Clinical Scholars program FX Two of the authors (G.D.S. and A.J.D.) received support from the Robert Wood Johnson Clinical Scholars program. NR 31 TC 1 Z9 1 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2016 VL 264 IS 6 BP 889 EP 895 DI 10.1097/SLA.0000000000001750 PG 7 WC Surgery SC Surgery GA EC2UB UT WOS:000387978500008 PM 27192347 ER PT J AU Sacks, GD Dawes, AJ Ettner, SL Brook, RH Fox, CR Maggard-Gibbons, M Ko, CY Russell, MM AF Sacks, Greg D. Dawes, Aaron J. Ettner, Susan L. Brook, Robert H. Fox, Craig R. Maggard-Gibbons, Melinda Ko, Clifford Y. Russell, Marcia M. TI Surgeon Perception of Risk and Benefit in the Decision to Operate SO ANNALS OF SURGERY LA English DT Article DE behavioral science: perception; risk and benefit; surgical decision making; variations ID CLINICAL JUDGMENT; SURGICAL QUALITY; RELIABILITY; RATES AB Objective: To determine how surgeons' perceptions of treatment risks and benefits influence their decisions to operate. Background: Little is known about what makes one surgeon choose to operate on a patient and another chooses not to operate. Methods: Using an online study, we presented a national sample of surgeons (N = 767) with four detailed clinical vignettes (mesenteric ischemia, gastrointestinal bleed, bowel obstruction, appendicitis) where the best treatment option was uncertain and asked them to: (1) judge the risks (probability of serious complications) and benefits (probability of recovery) for operative and nonoperative management and (2) decide whether or not they would recommend an operation. Results: Across all clinical vignettes, surgeons varied markedly in both their assessments of the risks and benefits of operative and nonoperative management (narrowest range 4%-100% for all four predictions across vignettes) and in their decisions to operate (49%-85%). Surgeons were less likely to operate as their perceptions of operative risk increased [absolute difference (AD) = -29.6% from 1.0 standard deviation below to 1.0 standard deviation above mean (95% confidence interval, CI: -31.6, -23.8)] and their perceptions of nonoperative benefit increased [AD = -32.6% (95% CI: -32.8,- -28.9)]. Surgeons were more likely to operate as their perceptions of operative benefit increased [AD = 18.7% (95% CI: 12.6, 21.5)] and their perceptions of nonoperative risk increased [AD = 32.7% (95% CI: 28.7, 34.0)]. Differences in risk/benefit perceptions explained 39% of the observed variation in decisions to operate across the four vignettes. Conclusions: Given the same clinical scenarios, surgeons' perceptions of treatment risks and benefits vary and are highly predictive of their decisions to operate. C1 [Sacks, Greg D.; Dawes, Aaron J.; Maggard-Gibbons, Melinda; Ko, Clifford Y.; Russell, Marcia M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-227 CHS, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Dawes, Aaron J.; Maggard-Gibbons, Melinda; Ko, Clifford Y.; Russell, Marcia M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sacks, Greg D.; Dawes, Aaron J.; Ettner, Susan L.; Brook, Robert H.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Ettner, Susan L.; Brook, Robert H.; Fox, Craig R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Los Angeles, CA USA. [Fox, Craig R.] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA USA. [Fox, Craig R.] Univ Calif Los Angeles, Dept Psychol, Coll Letters & Sci, Los Angeles, CA USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-227 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu FU Robert Wood Johnson/Veterans Affairs Clinical Scholars program FX Two of the authors (G.D.S and A.J.D.) received support from the Robert Wood Johnson/Veterans Affairs Clinical Scholars program. NR 30 TC 2 Z9 2 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2016 VL 264 IS 6 BP 896 EP 903 DI 10.1097/SLA.0000000000001784 PG 8 WC Surgery SC Surgery GA EC2UB UT WOS:000387978500009 PM 27192348 ER PT J AU Cohen, ME Liu, YM Huffman, KM Ko, CY Hall, BL AF Cohen, Mark E. Liu, Yaoming Huffman, Kristopher M. Ko, Clifford Y. Hall, Bruce L. TI On-demand Reporting of Risk-adjusted and Smoothed Rates for Quality Profiling in ACS NSQIP SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; on-demand; risk adjustment; smoothed rates; surgical quality improvement ID SURGICAL QUALITY; HOSPITALS; SURGEONS AB Background: Surgical quality improvement depends on hospitals having accurate and timely information about comparative performance. Profiling accuracy is improved by risk adjustment and shrinkage adjustment to stabilize estimates. These adjustments are included in ACS NSQIP reports, where hospital odds ratios (OR) are estimated using hierarchical models built on contemporaneous data. However, the timeliness of feedback remains an issue. Study Design: We describe an alternative, nonhierarchical approach, which yields risk-and shrinkage-adjusted rates. In contrast to our "Traditional" NSQIP method, this approach uses preexisting equations, built on historical data, which permits hospitals to have near immediate access to profiling results. We compared our traditional method to this new "on-demand" approach with respect to outlier determinations, kappa statistics, and correlations between logged OR and standardized rates, for 12 models (4 surgical groups by 3 outcomes). Results: When both methods used the same contemporaneous data, there were similar numbers of hospital outliers and correlations between logged OR and standardized rates were high. However, larger differences were observed when the effect of contemporaneous versus historical data was added to differences in statistical methodology. Conclusions: The on-demand, nonhierarchical approach provides results similar to the traditional hierarchical method and offers immediacy, an "overtime" perspective, application to a broader range ofmodels and data subsets, and reporting of more easily understood rates. Although the nonhierarchical method results are now available "on-demand" in a web-based application, the hierarchical approach has advantages, which support its continued periodic publication as the gold standard for hospital profiling in the program. C1 [Cohen, Mark E.; Liu, Yaoming; Huffman, Kristopher M.; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63130 USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. RP Cohen, ME (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM markcohen@facs.org NR 16 TC 1 Z9 1 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2016 VL 264 IS 6 BP 966 EP 972 DI 10.1097/SLA.0000000000001551 PG 7 WC Surgery SC Surgery GA EC2UB UT WOS:000387978500021 PM 27115903 ER PT J AU Cruz-Oliver, DM Sanchez-Reilly, S AF Cruz-Oliver, Dulce M. Sanchez-Reilly, Sandra TI Barriers to Quality End-of-Life Care for Latinos Hospice Health Care Professionals' Perspective SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE EOL care; focus group; health care providers; Hispanic; hospice; Latinos ID OLDER LATINOS; CAREGIVERS; EXPERIENCE; WHITE AB Hospice is an option that serves the care needs of terminally ill patients. However, promoting awareness of pursuing end-of-life (EOL) care among Hispanics is challenging. Hispanics are the fastest growing ethnic minority group in the United States but the most unlikely to use hospice services for EOL. This project was intended to identify health care providers' (HCPs') self-perceived barriers/solutions to improve use of hospice among Latino patients in both Hispanic-predominant and white-predominant communities. Focus groups were conducted at 2 hospice agencies to compare views on Hispanic EOL care. Two HCP groups from VITAS hospice in Texas (n = 9, 12) and 1 in Missouri (n = 24) participated. Qualitative analysis was performed. Across groups, all HCPs had similar distributions of professions (predominantly nursing). Despite the differences in ethnicity and few Hispanic patients in Missouri, common EOL barriers were identified, including language, religion, and family culture. Potential solutions identified included education in Spanish to families, the use of community religious leaders, and use of media ("telenovelas = soap operas") to bring the concept of Hospice to Hispanic homes. From the perspective of HCPs, this study identifies barriers and solutions with potential health care implications to improve hospice care among growing Hispanic communities in a culturally appropriate manner. C1 [Cruz-Oliver, Dulce M.] St Louis Univ, Div Geriatr Med, Internal Med, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, GEC, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. RP Cruz-Oliver, DM (reprint author), St Louis Univ, Dept Internal Med, Div Geriatr, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. EM dcruzoli@slu.edu FU Health Resources and Services Administration (HRSA) Geriatric Academic Career Award [K01HP20479-03-00] FX This work was supported by the Health Resources and Services Administration (HRSA) Geriatric Academic Career Award K01HP20479-03-00. NR 17 TC 0 Z9 0 U1 13 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1522-2179 EI 1539-0705 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD DEC PY 2016 VL 18 IS 6 BP 505 EP 511 DI 10.1097/NJH.0000000000000277 PG 7 WC Nursing SC Nursing GA EB9AE UT WOS:000387682700004 ER PT J AU Aliberti, S Reyes, LF Faverio, P Sotgiu, G Dore, S Rodriguez, AH Soni, NJ Restrepo, MI AF Aliberti, Stefano Reyes, Luis F. Faverio, Paola Sotgiu, Giovanni Dore, Simone Rodriguez, Alejandro H. Soni, Nilam J. Restrepo, Marcos I. CA GLIMP Invest TI Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study SO LANCET INFECTIOUS DISEASES LA English DT Article ID CARE-ASSOCIATED PNEUMONIA; INFECTIOUS-DISEASES SOCIETY; COMMUNITY; GUIDELINES; MRSA; HOSPITALIZATION; PATHOGENS; OUTCOMES; THERAPY; AMERICA AB Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3.0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6.21,95% CI 3.25-11.85), recurrent skin infections (2.87,1.10-7.45), and severe pneumonia disease (2.39,1.55-3.68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. C1 [Aliberti, Stefano] Univ Milan, Dept Pathophysiol & Transplantat, Cardiothorac Unit, Milan, Italy. [Aliberti, Stefano] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Adult Cyst Fibrosis Ctr, Milan, Italy. [Reyes, Luis F.; Soni, Nilam J.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Soni, Nilam J.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. [Faverio, Paola] Univ Milano Bicocca, AO San Gerardo, Sch Med & Surg, Monza, Italy. [Sotgiu, Giovanni; Dore, Simone] Univ Sassari, Clin Epidemiol & Med Stat Unit, Dept Biomed Sci, Res Med Educ & Profess Dev Unit,AOU Sassari, Sassari, Italy. [Rodriguez, Alejandro H.] Hosp Univ Joan XXIII, Crit Care Med, Tarragona, Spain. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. FU National Heart, Lung, and Blood Institute [K23HL096054]; Asociacion Latinoamerican de Torax; European Respiratory Society; World Federation of Societies of Intensive and Critical Care Medicine; American College of Chest Physicians FX MIR's time is partially protected by award number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health nor the Department of Veterans Affairs. We would like to thank the Asociacion Latinoamerican de Torax, European Respiratory Society, World Federation of Societies of Intensive and Critical Care Medicine, and American College of Chest Physicians for their support of this project. NR 26 TC 2 Z9 2 U1 8 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD DEC PY 2016 VL 16 IS 12 BP 1364 EP 1376 DI 10.1016/S1473-3099(16)30267-5 PG 13 WC Infectious Diseases SC Infectious Diseases GA EC3YK UT WOS:000388062800046 PM 27593581 ER PT J AU Gibbs, WS Weber, RA Schnellmann, RG Adkins, DL AF Gibbs, Whitney S. Weber, Rachel A. Schnellmann, Rick G. Adkins, DeAnna L. TI Disrupted mitochondrial genes and inflammation following stroke SO LIFE SCIENCES LA English DT Article DE Cerebral ischemia; Respiratory complexes; Oxidative stress; Sensorimotor cortex; Et-1 ID ACUTE KIDNEY INJURY; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; UNCOUPLING PROTEINS; CELL-DEATH; BIOGENESIS; CASPASE-3; APOPTOSIS; ISCHEMIA; CORTEX AB Aims: Determine the subacute time course of mitochondria disruption, cell death, and inflammation in a rat model of unilateral motor cortical ischemic stroke. Main methods: Rats received unilateral ischemia of the motor cortex and were tested on behavioral tasks to determine impairments. Animals were euthanized at 24 h, 72 h and 144 h and mRNA expression of key mitochondria proteins and indicators of inflammation, apoptosis and potential regenerative processes in ipsilesion cortex and striatum, using RT-qPCR. Mitochondrial proteins were examined at 144 h using immunoblot analysis. Key findings: Rats with stroke induced-behavioral deficits had sustained, 144 h post-lesion, decreases in mitochondrial-encoded electron transport chain proteins NADH dehydrogenase subunit-1 and cytochrome c oxidase subunit-1 (mRNA and protein) and mitochondrial DNA content in perilesion motor and sensory cortex. Uncoupling-protein-2 gene expression, but not superoxide dismutase-2, remained elevated in ipsilateral cortex and striatumat this time. Cortical inflammatory cytokine, interleukin-6, was increased early and was followed by increased macrophage marker F4/80 after stroke. Cleaved caspase-3 activation was elevated in cortex and growth associated protein-43 was elevated in the cortex and striatum six days post-lesion. Significance: We identified a relationship between three disrupted pathways, (1) sustained loss of mitochondrial proteins and mitochondrial DNA copy number in the cortex linked to decreased mitochondrial gene transcription; (2) early inflammatory response mediated by interleukin-6 followed by macrophages; (3) apoptosis in conjunction with the activation of regenerative pathways. The stroke-induced spatial and temporal profiles lay the foundation to target pharmacological therapeutics to these three pathways. (C) 2016 Elsevier Inc. All rights reserved. C1 [Gibbs, Whitney S.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC USA. [Weber, Rachel A.; Adkins, DeAnna L.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Adkins, DeAnna L.] Med Univ South Carolina, Ctr Biomed Imaging, Charleston, SC USA. [Adkins, DeAnna L.] Med Univ South Carolina, Hlth Sci & Res, Coll Hlth Profess, Charleston, SC USA. [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Schnellmann, Rick G.] Univ Arizona, Coll Pharm, Dept Pharm & Toxicol, Tucson, AZ 85721 USA. RP Schnellmann, RG; Adkins, DL (reprint author), Univ Arizona, Coll Pharm, Drachman Hall,1295 N Martin Ave POB 210202, Tucson, AZ 85721 USA. EM schnell@pharmacy.arizona.edu; adkinsdl@musc.edu FU MUSC Neuroscience Institute Pilot Grant; National Institutes of Health National Institute of General Medical Science [GM084147]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [BX-000851]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM12345]; National Institutes of Health Ruth L. Kirschstein National Research Service Award [5T32-DK083262] FX This study was funded by MUSC Neuroscience Institute Pilot Grant (D.L.A), National Institutes of Health National Institute of General Medical Sciences: GM084147 (R.G.S), the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs: BX-000851 (R.G.S.), Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health: P20GM12345 (D.L.A), and the National Institutes of Health Ruth L. Kirschstein National Research Service Award: Grant 5T32-DK083262 (W.S.G.) NR 63 TC 1 Z9 1 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 EI 1879-0631 J9 LIFE SCI JI Life Sci. PD DEC 1 PY 2016 VL 166 BP 139 EP 148 DI 10.1016/j.lfs.2016.09.021 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EC4LK UT WOS:000388101300019 PM 27693381 ER PT J AU Cheng, G Werner, TJ Newberg, A Alavi, A AF Cheng, Gang Werner, Thomas J. Newberg, Andrew Alavi, Abass TI Failed PET Application Attempts in the Past, Can We Avoid Them in the Future? SO MOLECULAR IMAGING AND BIOLOGY LA English DT Editorial Material DE Positron emission tomography (PET); Computed tomography (CT); Noninvasive imaging; Radiopharmaceuticals ID POSITRON-EMISSION-TOMOGRAPHY; BETA-CELL MASS; IN-VIVO EVALUATION; ESTROGEN-RECEPTOR-BETA; VESICULAR MONOAMINE TRANSPORTER-2; METASTATIC BREAST-CANCER; BIOLOGICAL EVALUATION; DIABETES-MELLITUS; HUMAN PANCREAS; RADIOLIGANDS C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Cheng, Gang; Werner, Thomas J.; Alavi, Abass] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. [Newberg, Andrew] Thomas Jefferson Univ, Myrna Brind Ctr Integrat Med, 925 Chestnut St, Philadelphia, PA 19107 USA. RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM abass.alavi@uphs.upenn.edu NR 81 TC 0 Z9 0 U1 5 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1536-1632 EI 1860-2002 J9 MOL IMAGING BIOL JI Mol. Imaging. Biol. PD DEC PY 2016 VL 18 IS 6 BP 797 EP 802 DI 10.1007/s11307-016-1017-y PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB4TQ UT WOS:000387367100001 PM 27730470 ER PT J AU Howard, LE De Hoedt, AM Aronson, WJ Kane, CJ Amling, CL Cooperberg, MR Terris, MK Divers, CH Valderrama, A Freedland, SJ AF Howard, L. E. De Hoedt, A. M. Aronson, W. J. Kane, C. J. Amling, C. L. Cooperberg, M. R. Terris, M. K. Divers, C. H. Valderrama, A. Freedland, S. J. TI Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article ID BONE METASTASIS; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; MORTALITY; MEDICARE; TRIAL; PAIN; ENZALUTAMIDE; PREDNISONE; DOCETAXEL AB BACKGROUND: Skeletal-related events (SREs) including pathologic fracture, spinal cord compression, radiation to bone and surgery to bone, are common in men with bone metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC are at high risk of death. Whether SREs predict mortality is unclear. We tested the association between SREs and overall survival (OS) in a multiethnic cohort with bone mCRPC, controlling for key covariates unavailable in claims data such as bone pain, number of bone metastases and PSA doubling time (PSADT). METHODS: We collected data on 233 men diagnosed with nonmetastatic castration-resistant prostate cancer (CRPC) in 2000-2013 at two Veterans Affairs hospitals who later progressed to bone metastases. First occurrence of SRE and OS were collected from the medical records. Cox models were used to test the association between SRE and OS, treating SRE as a time-dependent variable. We adjusted for age, year, race, treatment center, biopsy Gleason, primary treatment to the prostate, PSA, PSADT, months from androgen deprivation therapy to CRPC, months from CRPC to metastasis and number of bone metastases at initial bone metastasis diagnosis. In a secondary analysis, we also adjusted for bone pain. RESULTS: During follow-up, 88 (38%) patients had an SRE and 198 (85%) died. After adjusting for risk factors, SRE was associated with increased mortality (hazard ratio (HR) = 1.67; 95% confidence interval (CI) 1.22-2.30; P = 0.001). When bone pain was added to the model, the association of SREs and OS was attenuated, but remained significant (HR = 1.42; 95% CI 1.01-1.99; P = 0.042). CONCLUSIONS: SREs are associated with increased mortality in men with bone mCRPC. Further studies on the impact of preventing SREs to increase survival are warranted. C1 [Howard, L. E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA. [Howard, L. E.; De Hoedt, A. M.; Freedland, S. J.] Vet Affairs Med Ctr, Dept Surg, Div Urol, Durham, NC USA. [Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Kane, C. J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR USA. [Cooperberg, M. R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Terris, M. K.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Augusta, GA USA. [Terris, M. K.] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA. [Divers, C. H.; Valderrama, A.] Bayer Pharmaceut, US Hlth Econ, Whippany, NJ USA. [Freedland, S. J.] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Samuel Oschin Comprehens Canc Inst, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, Dept Surg, Div Urol, Samuel Oschin Comprehens Canc Inst, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. EM stephen.freedland@cshs.org FU Bayer HealthCare; NIH/NCI [P50CA09231] FX This study was funded by Bayer HealthCare and supported by the NIH/NCI under Award Number P50CA09231. NR 21 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2016 VL 19 IS 4 BP 380 EP 384 DI 10.1038/pcan.2016.26 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EC3CO UT WOS:000388002500008 PM 27377207 ER PT J AU Wadhwa, H Terris, MK Aronson, WJ Kane, CJ Amling, CL Cooperberg, MR Freedland, SJ Abern, MR AF Wadhwa, H. Terris, M. K. Aronson, W. J. Kane, C. J. Amling, C. L. Cooperberg, M. R. Freedland, S. J. Abern, M. R. TI Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article ID BIOCHEMICAL RECURRENCE; PROGNOSTIC-SIGNIFICANCE; ANTIGEN RECURRENCE; RISK-FACTORS; FOLLOW-UP; IMPACT; EXTENT; SPECIMENS; LOCATION; RADIOTHERAPY AB BACKGROUND: Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other PSMs at RP. METHODS: The SEARCH (Shared Equal Access Regional Cancer Hospital) database was used to identify 4031 men with prostate cancer (PCa) managed with RP with complete pathologic grade and stage data. Margin status was categorized as negative, apex only, or other positive. Multivariable Cox regression models adjusted for pathologic stage and grade were developed to test the relationship between margin status and biochemical recurrence (BCR), metastases and PCa death. RESULTS: In the final cohort, 34.3% had PSMs, whereas 65.7% had negative margins. Univariable analysis showed that compared with negative margins, apex-only PSM was associated with BCR (hazard ratio (HR): 1.4 [1.1-1.8]), but not metastases or PCa death, whereas apex and other PSMs were associated with BCR (HR: 3.3 [2.8-4]) and metastases (HR: 1.8 [1.02-3.1]) but not PCa death. Nonapical PSMs were associated with BCR (HR: 2.7 [2.4-3.1]), metastases (1.7 [1.2-2.5)] and PCa death (1.8 [1.05-3]). On multivariable analysis, apex-only, apex and other, and nonapical PSMs were associated with BCR but margin status was not associated with metastases or PCa death. CONCLUSIONS: In a large cohort of men undergoing RP, those with PSMs at the prostatic apex had lower BCR, metastases, or PCa death compared with those with PSMs at other locations. When adjusted for pathologic stage and grade, however, PSMs were associated with BCR but not long-term oncologic outcomes. These data confirm that men with apex-only PSMs may not be ideal candidates for adjuvant therapy after RP. C1 [Wadhwa, H.; Abern, M. R.] Univ Illinois, Dept Urol, 820 South Wood St Suite 515, Chicago, IL 60612 USA. [Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, M. K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA. [Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Kane, C. J.] Univ Calif San Diego, Div Urol, San Diego, CA 92103 USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA. [Cooperberg, M. R.] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Urol, San Francisco, CA 94143 USA. [Cooperberg, M. R.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. [Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Freedland, S. J.] Cedars Sinai, Dept Surg, Div Urol Surg, Los Angeles, CA USA. RP Abern, MR (reprint author), Univ Illinois, Dept Urol, 820 South Wood St Suite 515, Chicago, IL 60612 USA. EM mabern1@uic.edu RI Cooperberg, Matthew/G-6249-2017 OI Cooperberg, Matthew/0000-0003-4339-6685 NR 48 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2016 VL 19 IS 4 BP 423 EP 428 DI 10.1038/pcan.2016.45 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EC3CO UT WOS:000388002500016 PM 27698440 ER PT J AU Pasalic, D Gazelka, HM Topazian, RJ Buchhalter, LC Ottenberg, AL Webster, TL Swetz, KM Mueller, PS AF Pasalic, Dario Gazelka, Halena M. Topazian, Rachel J. Buchhalter, Lillian C. Ottenberg, Abigale L. Webster, Tracy L. Swetz, Keith M. Mueller, Paul S. TI Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE cardiac pacemaker; cardiovascular implantable electronic device; end of life; implantable cardioverter-defibrillator; medical ethics; palliative care ID TERMINALLY-ILL PATIENTS; ADVANCE DIRECTIVES; DECISION-MAKING; MANAGEMENT; ATTITUDES; COMMUNICATION; OUTCOMES; RELIGION; SUICIDE; THERAPY AB The presence of cardiac pacemakers and defibrillators complicates making end-of-life (EOL) medical decisions. Palliative care/medicine consultation (PCMC) may benefit patients and primary providers, but data are lacking. We retrospectively reviewed 150 charts of patients who underwent device deactivation at our tertiary care center (between November 1, 2008, and September 1, 2012), assessing for PCMC and outcomes. Overall, 42% of patients received a PCMC, and 68% of those PCMCs specifically addressed device deactivation. Median survival following deactivation was 2 days, with 42% of deaths occurring within 1 day of deactivation. There was no difference in survival between the groups. The EOL care for patients with implanted cardiac devices is complex, but PCMC may assist with symptom management and clarification of goals of care for such patients. C1 [Pasalic, Dario; Buchhalter, Lillian C.] Mayo Clin, Coll Med, Mayo Med Sch, Rochester, MN 55905 USA. [Gazelka, Halena M.] Mayo Clin, Div Pain Med, 200 First St SW, Rochester, MN 55905 USA. [Topazian, Rachel J.; Swetz, Keith M.; Mueller, Paul S.] Mayo Clin, Biomed Eth Program, Rochester, MN 55905 USA. [Topazian, Rachel J.; Swetz, Keith M.; Mueller, Paul S.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. [Topazian, Rachel J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Ottenberg, Abigale L.; Mueller, Paul S.] Mayo Clin, Program Professionalism & Eth, Rochester, MN 55905 USA. [Ottenberg, Abigale L.] SSH Hlth Miss Legal & Govt Affairs, St Louis, MO USA. [Webster, Tracy L.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Swetz, Keith M.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Gazelka, HM (reprint author), Mayo Clin, Div Pain Med, 200 First St SW, Rochester, MN 55905 USA. EM gazelka.halena@mayo.edu NR 34 TC 0 Z9 0 U1 6 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD DEC PY 2016 VL 33 IS 10 BP 966 EP 971 DI 10.1177/1049909115595017 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EB2ZJ UT WOS:000387230800009 PM 26169518 ER PT J AU Burnett, YJ Echevarria, K Traugott, KA AF Burnett, Yvonne J. Echevarria, Kelly Traugott, Kristi A. TI Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia SO ANNALS OF PHARMACOTHERAPY LA English DT Review DE ceftaroline; MRSA; methicillin-resistant Staphylococcus aureus; bacteremia; salvage therapy; salvage ID STAPHYLOCOCCUS-AUREUS BACTEREMIA; AWARE SURVEILLANCE PROGRAM; METHICILLIN-RESISTANT; INTEGRATED ANALYSIS; PLUS CEFTAROLINE; UNITED-STATES; CASE SERIES; VANCOMYCIN; INFECTIONS; THERAPY AB Objective: To summarize published data regarding the use of ceftaroline as salvage monotherapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Data Sources: PubMed (January 1980-June 2016) was searched using combinations of the search terms methicillin-resistant Staphylococcus aureus, MRSA, bacteremia, ceftaroline, refractory, and persistent. Supplemental references were generated through review of identified literature citations. Study Selection and Data Extraction: Available English-language, full-text articles pertaining to the use of ceftaroline for persistent MRSA bacteremia (MRSAB) were included. Data Synthesis: The PubMed search yielded 23 articles for evaluation. There are no randomized controlled trials to dateonly case series and reports. Four retrospective case series detailing the use of ceftaroline as monotherapy for persistent MRSAB were included. Most patients received at least 4 days of an appropriate anti-MRSA antimicrobial prior to ceftaroline and were able to clear bacteremia within 3 days. The most common rationales for ceftaroline use were progression of disease or nonresponse to current therapy. Higher off-label dosing of ceftaroline is often utilized to achieve optimal pharmacokinetic/pharmacodynamic parameters. Adverse events are not well described due to lack of follow-up; however, neutropenia has been associated with prolonged use. Conclusions: Treatment options for persistent MRSAB remain few and far between. Ceftaroline is an effective agent for the salvage treatment of MRSAB. Off-label doses up to 600 mg every 8 hours are often used to achieve optimal pharmacokinetic/pharmacodynamic parameters. Because of lack of follow-up in these reports, the incidence of adverse effects of prolonged use of ceftaroline is not well defined. C1 [Burnett, Yvonne J.] St Louis Coll Pharm, 4588 Parkview Pl,Acad & Res Bldg,Room 333, St Louis, MO 63110 USA. [Burnett, Yvonne J.] Washington Univ, Sch Med, St Louis, MO USA. [Echevarria, Kelly] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Echevarria, Kelly; Traugott, Kristi A.] Univ Texas Austin, Austin, TX USA. [Echevarria, Kelly; Traugott, Kristi A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Traugott, Kristi A.] Univ Hlth Syst, San Antonio, TX USA. RP Burnett, YJ (reprint author), St Louis Coll Pharm, 4588 Parkview Pl,Acad & Res Bldg,Room 333, St Louis, MO 63110 USA. EM yvonne.burnett@stlcop.edu NR 55 TC 2 Z9 2 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD DEC PY 2016 VL 50 IS 12 BP 1051 EP 1059 DI 10.1177/1060028016664361 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EB4FR UT WOS:000387326200008 PM 27520326 ER PT J AU Amalakuhan, B Habib, SA Mangat, M Reyes, LF Rodriguez, AH Hinojosa, CA Soni, NJ Gilley, RP Bustamante, CA Anzueto, A Levine, SM Peters, JI Aliberti, S Sibila, O Chalmers, JD Torres, A Waterer, GW Martin-Loeches, I Bordon, J Blanquer, J Sanz, F Marcos, PJ Rello, J Ramirez, J Sole-Violan, J Luna, CM Feldman, C Witzenrath, M Wunderink, RG Stolz, D Wiemken, TL Shindo, Y Dela Cruz, CS Orihuela, CJ Restrepo, MI AF Amalakuhan, Bravein Habib, Sheila A. Mangat, Mandeep Reyes, Luis F. Rodriguez, Alejandro H. Hinojosa, Cecilia A. Soni, Nilam J. Gilley, Ryan P. Bustamante, Carlos A. Anzueto, Antonio Levine, Stephanie M. Peters, Jay I. Aliberti, Stefano Sibila, Oriol Chalmers, James D. Torres, Antoni Waterer, Grant W. Martin-Loeches, Ignacio Bordon, Jose Blanquer, Jose Sanz, Francisco Marcos, Pedro J. Rello, Jordi Ramirez, Julio Sole-Violan, Jordi Luna, Carlos M. Feldman, Charles Witzenrath, Martin Wunderink, Richard G. Stolz, Daiana Wiemken, Tim L. Shindo, Yuichiro Dela Cruz, Charles S. Orihuela, Carlos J. Restrepo, Marcos I. TI Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis SO CYTOKINE LA English DT Article DE Biomarkers; Sepsis; Shock; Mortality; Multiple organ failure; Intracellular Adhesion Molecule-1; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor ID SEPTIC SHOCK; GROWTH-FACTOR; POLYMICROBIAL SEPSIS; PATHOGENESIS; DYSFUNCTION; ACTIVATION; MORTALITY; ICAM-1; DEFINITIONS; BIOMARKERS AB Objective: To determine if serum levels of endothelial adhesion molecules were associated with the development of multiple organ failure (MOF) and in-hospital mortality in adult patients with severe sepsis. Design: This study was a secondary data analysis of a prospective cohort study. Setting: Patients were admitted to two tertiary intensive care units in San Antonio, TX, between 2007 and 2012. Patients: Patients with severe sepsis at the time of intensive care unit (ICU) admission were enrolled. Inclusion criteria were consistent with previously published criteria for severe sepsis or septic shock in adults. Exclusion criteria included immunosuppressive medications or conditions. Interventions: None. Measurements: Baseline serum levels of the following endothelial cell adhesion molecules were measured within the first 72 h of ICU admission: Intracellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), and Vascular Endothelial Growth Factor (VEGF). The primary and secondary outcomes were development of MOF ( organ dysfunction) and in-hospital mortality, respectively. Main results: Forty-eight patients were enrolled in this study, of which 29 (60%) developed MOF. Patients that developed MOF had higher levels of VCAM-1 (p = 0.01) and ICAM-1 (p = 0.01), but not VEGF (p = 0.70) compared with patients without MOF (single organ failure only). The area under the curve (AUC) to predict MOF according to VCAM-1, ICAM-1 and VEGF was 0.71, 0.73, and 0.54, respectively. Only increased VCAM-1 levels were associated with in-hospital mortality (p = 0.03). These associations were maintained even after adjusting for APACHE and SOFA scores using logistic regression. Conclusions: High levels of serum ICAM-1 was associated with the development of MOF. High levels of VCAM-1 was associated with both MOF and in-hospital mortality. Published by Elsevier Ltd. C1 [Amalakuhan, Bravein; Habib, Sheila A.; Mangat, Mandeep; Reyes, Luis F.; Hinojosa, Cecilia A.; Soni, Nilam J.; Gilley, Ryan P.; Anzueto, Antonio; Levine, Stephanie M.; Peters, Jay I.; Orihuela, Carlos J.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Reyes, Luis F.; Soni, Nilam J.; Anzueto, Antonio; Levine, Stephanie M.; Peters, Jay I.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Bustamante, Carlos A.] Camino Dist Univ Adelita Char, Barranquilla, Colombia. [Aliberti, Stefano] Univ Milano Bicocca, Clin Pneumol, Monza, Italy. [Sibila, Oriol] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Med, Serv Pneumol, Barcelona, Spain. [Rodriguez, Alejandro H.] Joan XXIII Univ Hosp, Crit Care Dept, Tarragona, Spain. [Rodriguez, Alejandro H.] CIBERES, Pere Virgili Hlth Inst, Tarragona, Spain. [Chalmers, James D.] Univ Dundee, Dundee, Scotland. [Anzueto, Antonio] Univ Barcelona, Hosp Clin, Serv Pneumol, Barcelona, Spain. [Waterer, Grant W.] Univ Western Australia, Royal Perth Hosp Unit, Sch Med & Pharmacol, Perth, WA, Australia. [Martin-Loeches, Ignacio] St James Hosp, Trinity Ctr Hlth Sci, CIBERES, Dublin, Ireland. [Bordon, Jose] Providence Hosp, Infect Dis Sect, Dept Med, Washington, DC USA. [Blanquer, Jose] Hosp Clin Univ, Unidad Cuidados Intens Resp, Valencia, Spain. [Sanz, Francisco] Consorci Hosp Gen Univ Valencia, Dept Pulmonol, Valencia, Spain. [Marcos, Pedro J.] Univ Coruna UDC, CHUAC, Inst Invest Biomed A Coruna INIBIC, Serv Neumol, La Coruna, Spain. [Rello, Jordi] Hosp Univ Vall dHebron, Crit Care Dept, CIBERES, Barcelona, Spain. [Ramirez, Julio; Wiemken, Tim L.] Univ Louisville, Div Infect Dis, Louisville, KY 40292 USA. [Sole-Violan, Jordi] Hosp Univ Dr Negrin, Intens Care Unit, CIBERES, Las Palmas Gran Canaria, Spain. [Luna, Carlos M.] Univ Buenos Aires, Div Pulmonol, Hosp Clin, Div Pulm Med,Dept Med, Buenos Aires, DF, Argentina. [Feldman, Charles] Charlotte Maxeke Johannesburg Acad Hosp, Dept Internal Med, Johannesburg, South Africa. [Feldman, Charles] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Witzenrath, Martin] Charite Univ Med Berlin, Dept Infect Dis & Pulm Med, Berlin, Germany. [Witzenrath, Martin] SFB TR84 Innate Immun Lung, Berlin, Germany. [Wunderink, Richard G.] Northwestern Univ, Dept Med, Div Pulm & Crit Care Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Stolz, Daiana] Univ Basel Hosp, Clin Pulm Med & Resp Cell Res, Basel, Switzerland. [Shindo, Yuichiro] Nagoya Univ, Grad Sch Med, Inst Adv Res, Nagoya, Aichi, Japan. [Shindo, Yuichiro] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan. [Dela Cruz, Charles S.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA. [Orihuela, Carlos J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu OI Wunderink, Richard/0000-0002-8527-4195; martin-loeches, ignacio/0000-0002-5834-4063 FU National Heart, Lung, and Blood Institute [K23HL096054]; Carlos III Health Institute from Spain [M-BAE 15/00063] FX All authors have no conflicts of interest. Dr. Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. Dr. Rodriguez's time is protected by grant M-BAE 15/00063 from Carlos III Health Institute from Spain. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health or the Department of Veterans Affairs. NR 25 TC 0 Z9 0 U1 7 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD DEC PY 2016 VL 88 BP 267 EP 273 DI 10.1016/j.cyto.2016.08.028 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA EA8CE UT WOS:000386862100034 PM 27701021 ER PT J AU Trentalange, M Bielawski, M Murphy, TE Lessard, K Brandt, C Bean-Mayberry, B Maisel, NC Wright, SM Allore, H Skanderson, M Reyes-Harvey, E Gaetano, V Haskell, S Bastian, LA AF Trentalange, Mark Bielawski, Mark Murphy, Terrence E. Lessard, Katarzyna Brandt, Cynthia Bean-Mayberry, Bevanne Maisel, Natalya C. Wright, Steven M. Allore, Heather Skanderson, Melissa Reyes-Harvey, Evelyn Gaetano, Vera Haskell, Sally Bastian, Lori A. TI Patient Perception of Enough Time Spent With Provider Is a Mechanism for Improving Women Veterans' Experiences With VA Outpatient Health Care SO EVALUATION & THE HEALTH PROFESSIONS LA English DT Article DE women; veterans; experiences with health care; primary care; nurse practitioners; structural equation model ID NURSE-PRACTITIONERS; DESIGNATION; MODELS AB We postulated that associations between two specific provider characteristics, class (nurse practitioner relative to physician) and primary care providers who are proficient and interested in women's health (designated women's provider relative to nondesignated) and overall satisfaction with provider, were mediated through women veterans' perception of enough time spent with the provider. A national patient experience survey was administered to 7,620 women veterans. Multivariable models of overall patient satisfaction with provider were compared with and without the proposed mediator. A structural equation model (SEM) of the mediation of the two provider characteristics was also evaluated. Without the mediator, associations of provider class and designation with overall patient satisfaction were significant. With the proposed mediator, these associations became nonsignificant. An SEM showed that the majority (>80%) of the positive associations between provider class and designation and the outcome were exerted through patient perception of enough time spent with provider. Higher ratings of overall satisfaction with provider exhibited by nurse practitioners and designated women's health providers were exerted through patient perception of enough time spent with provider. Future research should examine what elements of provider training can be developed to improve provider-patient communication and patient satisfaction with their health care. C1 [Trentalange, Mark; Murphy, Terrence E.; Allore, Heather] Yale Sch Med, Dept Internal Med, New Haven, CT USA. [Bielawski, Mark; Lessard, Katarzyna; Bastian, Lori A.] VA Connecticut Healthcare Syst, Newington, CT USA. [Brandt, Cynthia] VA Connecticut Healthcare Syst, West Haven, CT USA. [Bean-Mayberry, Bevanne] VA Greater Los Angeles Healthcare Syst, Vet Hlth Adm Hlth Serv Res & Dev, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA. [Maisel, Natalya C.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Wright, Steven M.] Dept Vet Affairs, VHA Off Analyt & Business Intelligence, Off Performance Measurement, Providence, RI USA. [Allore, Heather] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA. [Skanderson, Melissa] Dept Vet Affairs, Pittsburgh, PA USA. [Reyes-Harvey, Evelyn] VHA Off Analyt & Business Intelligence, Off Performance Measurement, Durham, NC USA. [Gaetano, Vera] VA Connecticut HSR&D Pain Res Informat Multimorbi, West Haven, CT USA. [Haskell, Sally] Yale Sch Med, VA Connecticut Healthcare Syst, VA Cent Off, Womens Hlth Serv,Patient Care Serv, West Haven, CT USA. RP Trentalange, M (reprint author), Yale Sch Med, Dept Internal Med, Yale Program Aging, 300 George St Suite 775, New Haven, CT 06511 USA. EM mark.trentalange@yale.edu FU Yale University Claude D. Pepper Older Americans Independence Center grant [P30AG21342] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research was funded in part by a Yale University Claude D. Pepper Older Americans Independence Center grant (P30AG21342). NR 30 TC 1 Z9 1 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0163-2787 EI 1552-3918 J9 EVAL HEALTH PROF JI Eval. Health Prof. PD DEC PY 2016 VL 39 IS 4 BP 460 EP 474 DI 10.1177/0163278716629523 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EB6KD UT WOS:000387490900004 PM 26908572 ER PT J AU Richards, C McIntyre, RS Weisler, R Sambunaris, A Brawman-Mintzer, O Gao, J Geibel, B Dauphin, M Madhoo, M AF Richards, Cynthia McIntyre, Roger S. Weisler, Richard Sambunaris, Angelo Brawman-Mintzer, Olga Gao, Joseph Geibel, Brooke Dauphin, Matthew Madhoo, Manisha TI Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Augmentation; Lisdexamfetamine dimesylate; Major depressive disorder; Selective serotonin reuptake inhibitors; Serotonin-norepinephrine reuptake inhibitors; Amphetamine ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; STAR-ASTERISK-D; CONTROLLED-TRIAL; PSYCHOMETRIC EVALUATION; EFFICACY; METHYLPHENIDATE; SAFETY; OUTPATIENTS; SLEEPINESS; MODAFINIL AB Background: The efficacy, safety, and tolerability of lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy in adults with major depressive disorder (MDD) from two phase 3 studies are reported. Methods: Across study 1 (placebo, n=201; LDX, n=201) and study 2 (placebo, n=213; LDX, n=211), most participants (placebo and LDX) in the safety analysis set were female (study 1: 66.2% and 64.2%; study 2: 67.1% and 66.8%); mean +/- SD ages were 41.8 +/- 12.04 with placebo and 42.2 +/- 12.32 with LDX in study 1 and 42.6 +/- 11.41 with placebo and 42.0 +/- 11.63 with LDX in study 2. Participants (18-65 y) had DSM-IV-TR-diagnosed MDD and lead-in baseline Montgomery-Asberg Depression Rating Scale (MADRS) total scores >= 24. Eight-week antidepressant lead-in phases prospectively assessed antidepressant response. Then, 8 weeks of randomized (1:1), double-blind treatment with dose-optimized LDX (20-70 mg) or placebo in participants exhibiting inadequate antidepressant monotherapy responses (augmentation baseline MADRS total scores >= 18 and < 50% MADRS total score reductions from lead-in baseline to augmentation baseline) was initiated. The primary endpoint was MADRS total score change from augmentation baseline to week 16. Safety and tolerability measures included the occurrence of treatment-emergent adverse events (TEAE5). Results: Least squares mean (95% CI) treatment differences (LDX-placebo) for MADRS total score changes from augmentation baseline to week 16 were not statistically significant in study 1 (0.1 [-1.7, 2.0], P=0.883) or study 2 (-0.5 [-23, 1.3], P=0.583). The only TEAE reported by > 5% of LDX participants at twice the placebo rate in both studies was dry mouth. Limitations: Limitations include the exclusion of participants with psychiatric comorbidities/active medical disorders, the inability to assess specific MDD symptom domains (eg, anhedonia, cognition) or subtypes, the use of telephone-based depression assessments, and the potential influence of placebo response. Conclusion: Contrary to expectations, LDX augmentation was not superior to placebo in reducing C1 [Richards, Cynthia; Gao, Joseph; Geibel, Brooke; Dauphin, Matthew; Madhoo, Manisha] Shire, 300 Shire Way, Lexington, MA 02421 USA. [McIntyre, Roger S.] Univ Toronto, Toronto, ON, Canada. [Weisler, Richard] Duke Univ, Med Ctr, Durham, NC USA. [Weisler, Richard] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. [Sambunaris, Angelo] Atlanta Inst Med & Res, Atlanta, GA USA. [Brawman-Mintzer, Olga] Med Univ South Carolina, Charleston, SC USA. [Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Madhoo, M (reprint author), Shire, 300 Shire Way, Lexington, MA 02421 USA. EM mmadhoo@shire.com NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD DEC PY 2016 VL 206 BP 151 EP 160 DI 10.1016/j.jad.2016.07.006 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EB2LK UT WOS:000387193500020 PM 27474961 ER PT J AU Kopacz, MS Bryan, CJ AF Kopacz, Marek S. Bryan, Craig J. TI If Intergenerational Transmission Is the Problem, Then What Is the Solution? SO NEUROPSYCHOPHARMACOLOGY LA English DT Letter C1 [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov OI Bryan, Craig/0000-0002-9714-0733 NR 5 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2016 VL 41 IS 13 BP 2965 EP 2965 DI 10.1038/npp.2016.23 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA EB7MC UT WOS:000387570700002 PM 27818520 ER PT J AU Hanlon, CA Dowdle, LT Moss, H Canterberry, M George, MS AF Hanlon, Colleen A. Dowdle, Logan T. Moss, Hunter Canterberry, Melanie George, Mark S. TI Mobilization of Medial and Lateral Frontal-Striatal Circuits in Cocaine Users and Controls: An Interleaved TMS/BOLD Functional Connectivity Study SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; DEFAULT-MODE NETWORKS; MOTOR CORTEX; BOLD-FMRI; ORBITOFRONTAL CORTEX; ANTERIOR CINGULATE; DOPAMINE RELEASE; BRAIN ACTIVATION; DRUG-ADDICTION AB The integrity of frontal-striatal circuits is an area of great interest in substance dependence literature, particularly as the field begins to develop neural circuit-specific brain stimulation treatments for these individuals. Prior research indicates that frontal-striatal connectivity is disrupted in chronic cocaine users in a baseline (resting) state. It is unclear, however, if this is also true when these circuits are mobilized by an external source. In this study, we measured the functional and structural integrity of frontal-striatal circuitry involved in limbic arousal and executive control in 36 individuals-18 cocaine-dependent individuals with a history of failed quit attempts and 18 age-matched controls. This was achieved by applying a transcranial magnetic stimulation to the medial prefrontal cortex (Brodmann area 10) and the dorsolateral prefrontal cortex (lateral Brodmann 9) while participants rested in the MRI scanner (TMS/BOLD imaging). Relative to the controls, cocaine users had a lower ventral striatal BOLD response to MPFC stimulation. The dorsal striatal BOLD response to DLPFC stimulation however was not significantly different between the groups. Among controls, DLPFC stimulation led to a reciprocal attenuation of MPFC activity (BA 10), but this pattern did not exist in cocaine users. No relationship was found between regional diffusion metrics and functional activity. Considered together these data suggest that, when engaged, cocaine users can mobilize their executive control system similar to controls, but that the 'set point' for mobilizing their limbic arousal system has been elevated-an interpretation consistent with opponent process theories of addiction. C1 [Hanlon, Colleen A.; Dowdle, Logan T.; Moss, Hunter; Canterberry, Melanie; George, Mark S.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hanlon, Colleen A.; George, Mark S.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Hanlon, Colleen A.; George, Mark S.] Med Univ South Carolina, Ctr Biomed Imaging, Charleston, SC USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ South Carolina, Ctr Adv Imaging Res, Dept Psychiat, Charleston, SC 29425 USA.; Hanlon, CA (reprint author), Med Univ South Carolina, Ctr Adv Imaging Res, Dept Neurosci, Charleston, SC 29425 USA. EM hanlon@musc.edu FU National Institutes of Health; Department of Defense; Veterans Administration; [R01DA0036617]; [T32DA007288]; [R25DA020537]; [UL1 TR001450] FX We would like to thank William DeVries for assisting in participant screening, Jayce Doose for engineering support, James Purl for MRI acquisition support, Dr Truman S. Brown for data quality assessment and interleaved TMS/BOLD imaging sequence optimization, and Scott Henderson for editorial support. This work was supported by R01DA0036617, T32DA007288, R25DA020537, and UL1 TR001450. Dr Hanlon's work has been funded exclusively by the National Institutes of Health. MSG has received funding from the National Institutes of Health, the Department of Defense, and the Veterans Administration. He has also served as a consultant to several major TMS device companies including MagStim, Neuronetics, Magventure, and Brainsway. NR 59 TC 1 Z9 1 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2016 VL 41 IS 13 BP 3032 EP 3041 DI 10.1038/npp.2016.114 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA EB7MC UT WOS:000387570700010 PM 27374278 ER PT J AU Watkins, LE Harpaz-Rotem, I Sippel, LM Krystal, JH Southwick, SM Pietrzak, RH AF Watkins, Laura E. Harpaz-Rotem, Ilan Sippel, Lauren M. Krystal, John H. Southwick, Steven M. Pietrzak, Robert H. TI Hostility and telomere shortening among US military veterans: Results from the National Health and Resilience in Veterans Study SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Hostility; Aging; Telomere length; Veterans; Anger ID PHYSIOLOGICAL-RESPONSES; INFLAMMATORY MARKERS; PSYCHOSOCIAL FACTORS; CIGARETTE-SMOKING; PERCEIVED STRESS; HEART-DISEASE; LENGTH; ASSOCIATION; ADULTS; ANGER AB Chronic disorders of aging are critical concerns for the U.S. veteran population, which is, on average, two decades older than the non-veteran population. Characterization of risk factors that may accelerate biological aging is important in identifying targets for prevention and intervention. In the current study, we analyzed data from a contemporary, and nationally representative sample of U.S. veterans to evaluate the relationship between a broad range of sociodemographic, military, and clinical variables, and peripheral telomere length, which is an indicator of biological age and linked to risk for aging-related disorders and mortality. Data from 468 U.S. military veterans who participated in the National Health and Resilience in Veterans Study were analyzed. Telomere length was assessed from cells isolated from saliva using quantitative polymerase chain reaction methods. A multivariable binary logistic regression analysis was conducted to evaluate the relations between hostility and telomere length, while controlling for sociodemographic, military, and clinical variables. Greater scores on a measure of hostility were independently associated with telomere shortening, even after adjustment for a broad range of other variables (odds ratio (OR] =1.58, 95% confidence interval [CI] = 1.15-2.18). Secondary analyses revealed that this association was driven by difficulties controlling anger (OR = 1.72, 95%CI = 1.14-2.61), which reflect the external manifestation of hostility, rather than aggressive urges or impulses. Hostility, particularly difficulties controlling anger, is associated with peripheral telomere shortening in U.S. military veterans. Prevention and treatment efforts designed to reduce hostility may help mitigate risk for accelerated cellular aging in this growing segment of the U.S. population. Published by Elsevier Ltd. C1 [Watkins, Laura E.; Harpaz-Rotem, Ilan; Sippel, Lauren M.; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Watkins, Laura E.; Harpaz-Rotem, Ilan; Sippel, Lauren M.; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Watkins, LE (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave 151D, West Haven, CT 06516 USA. EM laura.watkins@yale.edu NR 64 TC 0 Z9 0 U1 10 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD DEC PY 2016 VL 74 BP 251 EP 257 DI 10.1016/j.psyneuen.2016.09.006 PG 7 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA EB6VW UT WOS:000387524700029 PM 27689898 ER PT J AU Meyer, JD Koltyn, KF Stegner, AJ Kim, JS Cook, DB AF Meyer, Jacob D. Koltyn, Kelli F. Stegner, Aaron J. Kim, Jee-Seon Cook, Dane B. TI Relationships between serum BDNF and the antidepressant effect of acute exercise in depressed women SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Exercise; Brain-derived neurotrophic factor; Depression; Exercise intensity; Antidepressant response; Mood ID NEUROTROPHIC FACTOR BDNF; MAJOR DEPRESSION; PSYCHIATRIC OUTPATIENTS; SEROTONIN TRANSPORTER; AFFECTIVE-DISORDERS; PHYSICAL-ACTIVITY; MOOD STATES; DSM-IV; BRAIN; NEUROPLASTICITY AB Objective: Brain-derived neurotrophic factor (BDNF) has recently emerged as one potential mechanism with which exercise improves mood in major depressive disorder (MDD). This study examined the relationship between changes in serum total BDNF and mood following acute exercise in MDD. It was hypothesized that acute exercise would increase BDNF in an intensity-dependent manner and that changes in BDNF would be significantly related to improvement in depressed mood post-exercise. Methods: Twenty-four women (age: 38.6 +/- 14.0 years) with MDD exercised for 30 min on a stationary bicycle at light, moderate and hard exercise intensities and performed a quiet rest session using a within subjects, randomized and counter-balanced design. Before, 10 and 30 min after each session, participants completed the profile of mood states (POMS). Blood was drawn before and within 10 min after completion of each session and serum total BDNF (sBDNF) was measured by enzyme-linked immunosorbent assay. Acute exercise-induced changes in POMS Depression and sBDNF were analyzed via 4 session (quiet rest, light, moderate, hard) by 2 measurement (pre, post) ANOVA. Secondary analyses examined the effects of baseline mood and antidepressant usage on sBDNF. Results: Exercise resulted in an acute improvement in depressed mood that was not intensity dependent (p > 0.05), resulting in significant acute increases in sBDNF (p = 0.006) that were also not intensity dependent (p > 0.05). Acute changes in sBDNF were not significantly correlated to changes in POMS depression at 10m (r = -0.171, p = 0.161) or 30m (r = -0.151, p = 0.215) post-exercise. The fourteen participants taking antidepressant medications exhibited lower post-exercise sBDNF (p =0.015) than the participants not currently taking antidepressants, although mood responses were similar. Conclusion: Acute exercise is an effective mood-enhancing stimulus, although sBDNF does not appear to play a role in this short-term response. Patients who are not currently taking antidepressant medications and those who have greater pre-exercise depression may experience a greater sBDNF response to exercise, but the clinical significance of this is currently unclear. Circulating BDNF levels are unlikely to be altered by steady-state acute exercise in a linear dose-dependent manner. This does not eliminate its potential relevance in the antidepressant response to chronic exercise training, but suggests that other mechanisms are involved in the acute affective response to exercise in depression. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Stegner, Aaron J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. [Meyer, Jacob D.; Koltyn, Kelli F.; Stegner, Aaron J.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. [Kim, Jee-Seon] Univ Wisconsin, Dept Educ Psychol, 1025 West Johnson St, Madison, WI 53706 USA. RP Meyer, JD (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM jdmeyer3@wisc.edu NR 52 TC 0 Z9 0 U1 9 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD DEC PY 2016 VL 74 BP 286 EP 294 DI 10.1016/j.psyneuen.2016.09.022 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA EB6VW UT WOS:000387524700033 PM 27697714 ER PT J AU Marino, L Wissow, LS Davis, M Abrams, MT Dixon, LB Slade, EP AF Marino, Leslie Wissow, Lawrence S. Davis, Maryann Abrams, Michael T. Dixon, Lisa B. Slade, Eric P. TI Predictors of outpatient mental health clinic follow-up after hospitalization among Medicaid-enrolled young adults SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Article DE Medicaid; mental health service; young adult ID MISSED 1ST APPOINTMENTS; PSYCHIATRIC-HOSPITALIZATION; SUBSTANCE-ABUSE; CARE; ILLNESS; SCHIZOPHRENIA; INTERVENTION; DEPRESSION; STRATEGIES; DISCHARGE AB AimTo assess demographic and clinical predictors of outpatient mental health clinic follow-up after inpatient psychiatric hospitalization among Medicaid-enrolled young adults. MethodsUsing logistic regression and administrative claims data from the Maryland public mental health system and Maryland Medicaid for young adults ages 18-26 who were enrolled in Medicaid (N = 1127), the likelihood of outpatient mental health follow-up within 30 days after inpatient psychiatric hospitalization was estimated . ResultsOnly 51% of the young adults had any outpatient mental health follow-up visits within 30 days of discharge. Being black and having a co-occurring substance use disorder diagnosis were associated with a lower probability of having a follow-up visit (OR=0.60, P<0.01 and OR=0.36, P<0.01, respectively). In addition, those who utilized any outpatient public mental health services during the 180 days prior to their index hospitalization (N=625, 55.4%) were more likely to have a follow-up visit than those without prior outpatient use (OR=2.45, P<0.01). Prior Medicaid-reimbursed primary care visits were not significantly associated with follow-up. ConclusionsIn this predominantly urban, low-income statewide sample of young adults hospitalized for serious psychiatric conditions, half did not connect with an outpatient mental healthcare provider following their discharge. Outpatient transition supports may be especially needed for young adults who were not receiving outpatient services prior to being admitted for psychiatric inpatient care, as well as for young adults with substance use disorders and African Americans. C1 [Marino, Leslie; Dixon, Lisa B.] Columbia Univ, Med Ctr, Dept Psychiat, New York State Psychiat Inst, New York, NY USA. [Wissow, Lawrence S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Slade, Eric P.] Univ Maryland, Sch Med, Dept Psychiat, US Dept Vet Affairs,Capitol Healthcare Network VI, Baltimore, MD 21201 USA. [Abrams, Michael T.] Univ Maryland Baltimore Cty, HillTop Inst, Catonsville, MD USA. [Davis, Maryann] Univ Massachusetts, Sch Med, Dept Psychiat, Syst & Psychosocial Adv Res Ctr,Learning & Workin, Worcester, MA 01655 USA. RP Marino, L (reprint author), Columbia Univ, Med Ctr, Dept Psychiat, 1051 Riverside Dr,Box 93, New York, NY 10027 USA.; Marino, L (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr,Box 93, New York, NY 10032 USA. EM marinol@nyspi.columbia.edu FU NIDA NIH HHS [T32 DA007294]; NIMH NIH HHS [R34 MH081303] NR 31 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD DEC PY 2016 VL 10 IS 6 BP 468 EP 475 DI 10.1111/eip.12206 PG 8 WC Psychiatry SC Psychiatry GA EA6TS UT WOS:000386762500002 PM 25639939 ER PT J AU Crane, PK Walker, RL Sonnen, J Gibbons, LE Melrose, R Hassenstab, J Keene, CD Postupna, N Montine, TJ Larson, EB AF Crane, Paul K. Walker, Rod L. Sonnen, Joshua Gibbons, Laura E. Melrose, Rebecca Hassenstab, Jason Keene, C. Dirk Postupna, Nadia Montine, Thomas J. Larson, Eric B. TI Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes SO NEUROBIOLOGY OF AGING LA English DT Article DE Glucose; Neuropathology; Neuritic plaques; Hippocampal sclerosis; Lewy bodies; Neurofibrillary tangles ID ALZHEIMERS ASSOCIATION GUIDELINES; PARKINSONS-DISEASE; HIPPOCAMPAL SCLEROSIS; NATIONAL INSTITUTE; DEMENTIA; RISK; DIAGNOSIS; PATHOLOGY; COHORT; CERAD AB We evaluated associations between glucose and dementia-related neuropathologic findings among people without diabetes treatment history to elucidate mechanisms of glucose's potential effect on dementia. We used glucose and hemoglobin A1c values to characterize glucose exposures over 5 years before death (primary) and age bands from 55-59 through 80-84 (secondary). Autopsy evaluations included Braak stage for neurofibrillary tangles, Consortium to Establish a Registry for Alzheimer's Disease grade for neuritic plaques, macroscopic infarcts including lacunar infarcts, Lewy bodies, cerebral microinfarcts, and hippocampal sclerosis. Of 529 who came to autopsy, we included 430 with no history of diabetes treatment. We found no associations between glucose levels and Braak stage or Consortium to Establish a Registry for Alzheimer's Disease grade. There was a suggestion of a relationship between glucose and hippocampal sclerosis, although this was inconsistent across analyses. There was higher risk of Lewy bodies in substantia nigra and locus ceruleus with higher glucose levels in age band analyses. We did not find interactions between glucose levels, neuropathologic findings, and dementia. The mechanism by which glucose may impact dementia risk is still unknown. (C) 2016 Elsevier Inc. All rights reserved. C1 [Crane, Paul K.; Gibbons, Laura E.] Univ Washington, Dept Med, Seattle, WA USA. [Walker, Rod L.; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Sonnen, Joshua] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Melrose, Rebecca] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Melrose, Rebecca] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hassenstab, Jason] Washington Univ, Dept Neurol, St Louis, MO USA. [Keene, C. Dirk; Postupna, Nadia; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Crane, PK (reprint author), Box 359780,325 Ninth Ave, Seattle, WA 98104 USA. EM pcrane@uw.edu OI Gibbons, Laura/0000-0001-5054-2543; Sonnen, Joshua/0000-0001-9267-8705 FU National Institute on Aging [U01 AG006781] FX This study was funded by National Institute on Aging (grant# U01 AG006781). Alzheimer's Disease Patient Registry is also known as the Adult Changes in Thought (ACT) study. Eric B. Larson, MD MPH, and Paul K. Crane, MD MPH, serve as multiple principal investigators for ACT. NR 53 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2016 VL 48 BP 72 EP 82 DI 10.1016/j.neurobiolaging.2016.07.021 PG 11 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EA9PW UT WOS:000386977300008 PM 27644076 ER PT J AU Pu, HJ Jiang, XY Hu, XM Xia, JC Hong, DD Zhang, WT Gao, YQ Chen, J Shi, YJ AF Pu, Hongjian Jiang, Xiaoyan Hu, Xiaoming Xia, Jinchao Hong, Dandan Zhang, Wenting Gao, Yanqin Chen, Jun Shi, Yejie TI Delayed Docosahexaenoic Acid Treatment Combined with Dietary Supplementation of Omega-3 Fatty Acids Promotes Long-Term Neurovascular Restoration After Ischemic Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Angiogenesis; Cognitive function; Glial scar; Hippocampus; Neurogenesis ID SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; BRAIN-BARRIER DISRUPTION; VASCULAR NEURAL-NETWORK; FATTY-ACIDS; COGNITIVE IMPAIRMENT; RAT MODEL; INTRACEREBRAL HEMORRHAGE; CLINICAL TRANSLATION AB Prophylactic dietary intake of omega-3 polyunsaturated fatty acids (n-3 PUFAs) has been shown to remarkably ameliorate ischemic brain injury. However, the therapeutic efficacy of n-3 PUFA administration post-stroke, especially its impact on neurovascular remodeling and long-term neurological recovery, has not been fully characterized thus far. In this study, we investigated the effect of n-3 PUFA supplementation, as well as in combination with docosahexaenoic acid (DHA) injections, on long-term stroke outcomes. Mice were subjected to transient middle cerebral artery occlusion (MCAO) before randomly assigned to four groups to receive the following: (1) low dose of n-3 PUFAs as the vehicle control, (2) intraperitoneal DHA injections, (3) n-3 PUFA dietary supplement, or (4) combined treatment of (2) and (3). Neurological deficits and brain atrophy, neurogenesis, angiogenesis, and glial scar formation were assessed up to 28 days after MCAO. Results revealed that groups 2 and 3 showed only marginal reduction in post-stroke tissue loss and attenuation of cognitive deficits. Interestingly, group 4 exhibited significantly reduced tissue atrophy and improved cognitive functions compared to groups 2 and 3 with just a single treatment. Mechanistically, the combined treatment promoted post-stroke neurogenesis and angiogenesis, as well as reduced glial scar formation, all of which significantly correlated with the improved spatial memory in the Morris water maze. These results demonstrate an effective therapeutic regimen to enhance neurovascular restoration and long-term cognitive recovery in the mouse model of MCAO. Combined post-stroke DHA treatment and n-3 PUFA dietary supplementation thus may be a potential clinically translatable therapy for stroke or related brain disorders. C1 [Pu, Hongjian; Hu, Xiaoming; Chen, Jun; Shi, Yejie] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Jiang, Xiaoyan; Hu, Xiaoming; Zhang, Wenting; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Jiang, Xiaoyan; Hu, Xiaoming; Zhang, Wenting; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Pu, Hongjian; Jiang, Xiaoyan; Hu, Xiaoming; Xia, Jinchao; Hong, Dandan; Gao, Yanqin; Chen, Jun; Shi, Yejie] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA. [Pu, Hongjian; Jiang, Xiaoyan; Hu, Xiaoming; Xia, Jinchao; Hong, Dandan; Gao, Yanqin; Chen, Jun; Shi, Yejie] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. RP Chen, J; Shi, YJ (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.; Chen, J (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.; Chen, J; Shi, YJ (reprint author), Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Chen, J; Shi, YJ (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; shiy3@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU US Department of Veterans Affairs (VA) RRD Merit Review [RX000420]; US National Institutes of Health [NS045048, NS091175, NS095671]; American Heart Association [13SDG14570025]; Chinese Natural Science Foundation [81529002, 81171149, 81371306, 81571285, 81100978]; VA Senior Research Career Scientist Award FX *H.P. and *X.J. contributed equally to this research. This project was supported by the US Department of Veterans Affairs (VA) RR&D Merit Review RX000420; the US National Institutes of Health grants NS045048, NS091175, and NS095671; the American Heart Association grant 13SDG14570025; and the Chinese Natural Science Foundation grants 81529002, 81171149, 81371306, 81571285, and 81100978. J.C. is a recipient of the VA Senior Research Career Scientist Award. The authors are indebted to Pat Strickler for excellent administrative support. The present address of J.X. is Cerebrovascular Center, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou 450003, China. NR 77 TC 0 Z9 0 U1 7 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD DEC PY 2016 VL 7 IS 6 BP 521 EP 534 DI 10.1007/s12975-016-0498-y PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EA1VJ UT WOS:000386379800008 PM 27566736 ER PT J AU Jiang, XY Pu, HJ Hu, XM Wei, ZS Hong, DD Zhang, WT Gao, YQ Chen, J Shi, YJ AF Jiang, Xiaoyan Pu, Hongjian Hu, Xiaoming Wei, Zhishuo Hong, Dandan Zhang, Wenting Gao, Yanqin Chen, Jun Shi, Yejie TI A Post-stroke Therapeutic Regimen with Omega-3 Polyunsaturated Fatty Acids that Promotes White Matter Integrity and Beneficial Microglial Responses after Cerebral Ischemia SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Myelin; Oligodendrogenesis; Corpus callosum; Microglial polarization ID TRAUMATIC BRAIN-INJURY; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; VASCULAR COGNITIVE IMPAIRMENT; DOCOSAHEXAENOIC ACID; NEUROLOGICAL FUNCTION; FUNCTIONAL RECOVERY; MULTIPLE-SCLEROSIS; M2 MICROGLIA; RT-PA; STROKE AB White matter injury induced by ischemic stroke elicits sensorimotor impairments, which can be further deteriorated by persistent proinflammatory responses. We previously reported that delayed and repeated treatments with omega-3 polyunsaturated fatty acids (n-3 PUFAs) improve spatial cognitive functions and hippocampal integrity after ischemic stroke. In the present study, we report a post-stroke n-3 PUFA therapeutic regimen that not only confers protection against neuronal loss in the gray matter but also promotes white matter integrity. Beginning 2 h after 60 min of middle cerebral artery occlusion (MCAO), mice were randomly assigned to receive intraperitoneal docosahexaenoic acid (DHA) injections (10 mg/kg, daily for 14 days), alone or in combination with dietary fish oil (FO) supplements starting 5 days after MCAO. Sensorimotor functions, gray and white matter injury, and microglial responses were examined up to 28 days after MCAO. Our results showed that DHA and FO combined treatment-facilitated long-term sensorimotor recovery and demonstrated greater beneficial effect than DHA injections alone. Mechanistically, n-3 PUFAs not only offered direct protection on white matter components, such as oligodendrocytes, but also potentiated microglial M2 polarization, which may be important for white matter repair. Notably, the improved white matter integrity and increased M2 microglia were strongly linked to the mitigation of sensorimotor deficits after stroke upon n-3 PUFA treatments. Together, our results suggest that post-stroke DHA injections in combination with FO dietary supplement benefit white matter restoration and microglial responses, thereby dictating long-term functional improvements. C1 [Jiang, Xiaoyan; Hu, Xiaoming; Zhang, Wenting; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Jiang, Xiaoyan; Hu, Xiaoming; Zhang, Wenting; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Jiang, Xiaoyan; Pu, Hongjian; Hu, Xiaoming; Wei, Zhishuo; Hong, Dandan; Gao, Yanqin; Chen, Jun; Shi, Yejie] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA. [Jiang, Xiaoyan; Pu, Hongjian; Hu, Xiaoming; Wei, Zhishuo; Hong, Dandan; Gao, Yanqin; Chen, Jun; Shi, Yejie] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Hu, Xiaoming; Chen, Jun; Shi, Yejie] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.; Chen, J; Shi, YJ (reprint author), Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Chen, J; Shi, YJ (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Chen, J; Shi, YJ (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. EM chenj2@upmc.edu; shiy3@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU US Department of Veterans Affairs (VA) RRD Merit Review [RX000420]; US National Institutes of Health [NS045048, NS091175, NS095671]; American Heart Association [13SDG14570025]; Chinese Natural Science Foundation [81529002, 81171149, 81371306, 81571285, 81100978]; VA Senior Research Career Scientist Award FX This project was supported by the US Department of Veterans Affairs (VA) RR&D Merit Review RX000420, the US National Institutes of Health grants NS045048, NS091175 and NS095671, the American Heart Association grant 13SDG14570025, and the Chinese Natural Science Foundation grants 81529002, 81171149, 81371306, 81571285 and 81100978. J.C. is a recipient of the VA Senior Research Career Scientist Award. The authors are indebted to Pat Strickler for excellent administrative support. NR 69 TC 0 Z9 0 U1 7 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD DEC PY 2016 VL 7 IS 6 BP 548 EP 561 DI 10.1007/s12975-016-0502-6 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EA1VJ UT WOS:000386379800010 PM 27714669 ER PT J AU Stauffer, CS Musinipally, V Suen, A Lynch, KL Shapiro, B Woolley, JD AF Stauffer, Christopher S. Musinipally, Vivek Suen, Angela Lynch, Kara L. Shapiro, Brad Woolley, Joshua D. TI A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder SO ADDICTION RESEARCH & THEORY LA English DT Article DE Cocaine; social; addiction; methadone; oxytocin ID TREATMENT RETENTION; SOCIAL ATTACHMENT; OPIATE ADDICTION; DRUG-USERS; STRESS; SEEKING; ASSOCIATION; IMPLICIT; BEHAVIOR; HEROIN AB About 30-60% of the patients receiving methadone for opioid use disorder (OUD) actively use cocaine. Cocaine use disorder (CUD) has no FDA-approved pharmacological treatment; existing psychosocial treatments are inadequate. Oxytocin (OT), a social neuropeptide, has preclinical promise as an adjunctive treatment for both OUD and CUD. Twenty-two individuals receiving methadone for OUD with co-occurring CUD were randomized to receive OT or placebo intranasally 40IU twice daily for two weeks. A priori aims were feasibility and safety. Exploratory effectiveness aims included laboratory-based measures of drug craving, drug-related implicit cognition, and drug use. High retention rates (93.5%), the absence of study-related adverse events, and the fact that OT was well tolerated in this population support the feasibility of larger trials. Two weeks of OT (but not placebo) significantly reduced cocaine craving at day 15 compared to baseline (mean change +/- SD: OT=-0.23 +/- 0.19, p=0.004; PL=-0.16 +/- 0.29, p=0.114). For heroin craving, the placebo group reported a trend-level increase over time while the OT group remained unchanged - with medium to large effect sizes between the groups (Cohen's d=0.71-0.90). OT led to a significant switch from implicit self-association with drugs to implicitly associating drugs with others (mean change +/- SD: 0.25 +/- 0.35, p=0.037) and a trend-level reduction in self-reported cocaine use over time (Z=-1.78, p=0.075). Furthermore, OT significantly increased the accuracy of self-reported cocaine use when correlated with quantitative urine levels of cocaine metabolite. This proof-of-concept study provides promising early evidence that OT may be an effective adjunct to the treatment of co-occurring CUD and OUD. Further investigation with larger trials is warranted. C1 [Stauffer, Christopher S.; Shapiro, Brad; Woolley, Joshua D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Stauffer, Christopher S.; Musinipally, Vivek; Woolley, Joshua D.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Musinipally, Vivek; Suen, Angela] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Lynch, Kara L.] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA 94143 USA. RP Stauffer, CS (reprint author), 4150 Clement St 116-C, San Francisco, CA 94121 USA. EM christopher.stauffer@ucsf.edu FU San Francisco Treatment Research Center at the University of California, San Francisco from National Institute on Drug Abuse [P50 DA009253]; National Institute of Mental Health [R25 MH060482] FX This project was supported by the San Francisco Treatment Research Center at the University of California, San Francisco via grant number P50 DA009253 from the National Institute on Drug Abuse. Additional support was provided by the National Institute of Mental Health via grant number R25 MH060482. NR 46 TC 1 Z9 1 U1 10 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1606-6359 EI 1476-7392 J9 ADDICT RES THEORY JI Addict. Res. Theory PD DEC PY 2016 VL 24 IS 6 BP 490 EP 498 DI 10.3109/16066359.2016.1173682 PG 9 WC Substance Abuse; Social Issues SC Substance Abuse; Social Issues GA DZ4RW UT WOS:000385848200008 ER PT J AU Epstein, AJ Nicholson, S Asch, DA AF Epstein, Andrew J. Nicholson, Sean Asch, David A. TI THE PRODUCTION OF AND MARKET FOR NEW PHYSICIANS' SKILL SO AMERICAN JOURNAL OF HEALTH ECONOMICS LA English DT Article DE physician skill production; market learning ID CARDIAC-SURGEONS; QUALITY; MORTALITY; SERVICES; OUTCOMES; VOLUME; CARE; REGRESSION; SELECTION; PATTERNS AB Our understanding of the determinants of physician skill and the extent to which skill is valued in the marketplace is superficial. Using a large, detailed panel of new obstetricians, we find that, even though physicians' maternal complication rates improve steadily with experience, initial skill (as measured by performance in a physician's first year of practice) explains more of the variation in physician performance over time than experience does. At the same time, we find that the trajectories of new physicians' delivery volume develop in a way consistent with Bayesian learning about physician quality. As physicians gain experience, their volume becomes increasingly sensitive to the information in their accumulated prior belief, while responses to information on recent performance are detectable in only selected settings (e.g., vaginal delivery, commercially insured patients). C1 [Epstein, Andrew J.; Asch, David A.] Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Asch, David A.] Univ Penn, Philadelphia, PA 19104 USA. [Nicholson, Sean] Cornell Univ, Ithaca, NY 14853 USA. RP Epstein, AJ (reprint author), Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.; Epstein, AJ (reprint author), Univ Penn, Philadelphia, PA 19104 USA. EM eandrew@mail.med.upenn.edu NR 36 TC 0 Z9 0 U1 11 U2 11 PU MIT PRESS PI CAMBRIDGE PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA SN 2332-3493 EI 2332-3507 J9 AM J HEALTH ECON JI AM. J. HEALTH ECON. PD WIN PY 2016 VL 2 IS 1 BP 41 EP 65 DI 10.1162/ajhe_a_00033 PG 25 WC Economics; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DS1PG UT WOS:000380367800002 ER PT J AU Anderson, CA Woodcock, JH Filley, CM AF Anderson, C. Alan Woodcock, Jonathan H. Filley, Christopher M. TI Transient Prosopagnosia With Right Temporal Astrocytoma SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Letter ID FACE; SYNESTHESIA C1 [Anderson, C. Alan; Woodcock, Jonathan H.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Aurora, CO USA. [Anderson, C. Alan; Woodcock, Jonathan H.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Behav Neurol Sect, Aurora, CO USA. [Anderson, C. Alan; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Anderson, CA (reprint author), Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Aurora, CO USA.; Anderson, CA (reprint author), Univ Colorado, Sch Med, Dept Psychiat, Behav Neurol Sect, Aurora, CO USA.; Anderson, CA (reprint author), Denver Vet Affairs Med Ctr, Denver, CO USA. EM al.anderson@ucdenver.edu NR 10 TC 0 Z9 0 U1 10 U2 12 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 2016 VL 28 IS 1 BP E13 EP E14 DI 10.1176/appi.neuropsych.15070169 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DM0PB UT WOS:000376046800006 PM 26844963 ER PT J AU Logan, J Bohnert, A Spies, E Jannausch, M AF Logan, Joseph Bohnert, Amy Spies, Erica Jannausch, Mary TI Suicidal ideation among young Afghanistan/Iraq War Veterans and civilians: Individual, social, and environmental risk factors and perception of unmet mental healthcare needs, United States, 2013 SO PSYCHIATRY RESEARCH LA English DT Article DE Suicide; Veterans; Socio-ecological model; Health care needs; Surveillance ID SERVICEMEMBERS ARMY STARRS; POSTTRAUMATIC-STRESS-DISORDER; US ARMY; ACTIVE-DUTY; MILITARY PERSONNEL; PREVALENCE; SAMPLE; RESILIENCE; DEPRESSION; BEHAVIORS AB Suicidal Ideation among Afghanistan/Iraq War Veterans remains a health concern. As young Veterans adjust to civilian life, new risk factors might emerge and manifest differently in this group versus those in the general population. We explored these differences. With 2013 National Survey on Drug Use and Health data, we examined differences in risk of past-year suicidal ideation between Veterans of the Afghanistan/Iraq War periods aged 18-34 years (N=328) and age-comparable civilians (N=23,222). We compared groups based on individual and socio-environmental risk factors as well as perceptions of unmet mental healthcare needs. We report adjusted rate ratios (aRRs); interaction terms tested for between-group differences. PY suicidal ideation rates for Veterans and civilians did not differ (52 versus 59 per 1,000, p=0.60) and both groups shared many risk factors. However, drug problems and perceived unmet mental health care needs were vastly stronger risk factors among Veterans versus civilians (interaction terms indicated that the aRRs were 3.8-8.0 times higher for Veterans versus civilians). Other differences were discovered as well. Past-year suicidal ideation rates did not differ by Veteran status among young adults. However, different risk factors per group were detected, which can inform Veteran suicide prevention efforts. Published by Elsevier Ireland Ltd. C1 [Logan, Joseph; Spies, Erica] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway,MS-F63, Atlanta, GA 30341 USA. [Bohnert, Amy; Jannausch, Mary] Univ Michigan, Ann Arbor, MI 48109 USA. [Bohnert, Amy; Jannausch, Mary] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA. RP Logan, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway,MS-F63, Atlanta, GA 30341 USA. EM ffa3@cdc.gov FU CDC; VA [CDA 09-204] FX All work for this manuscript was funded by CDC and the VA (CDA 09-204). NR 76 TC 0 Z9 0 U1 12 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD NOV 30 PY 2016 VL 245 BP 398 EP 405 DI 10.1016/j.psychres.2016.08.054 PG 8 WC Psychiatry SC Psychiatry GA EA6LV UT WOS:000386741600058 PM 27611069 ER PT J AU Henzler, C Li, YM Yang, RD McBride, T Ho, Y Sprenger, C Liu, G Coleman, I Lakely, B Li, R Ma, SH Landman, SR Kumar, V Hwang, TH Raj, GV Higano, CS Morrissey, C Nelson, PS Plymate, SR Dehm, SM AF Henzler, Christine Li, Yingming Yang, Rendong McBride, Terri Ho, Yeung Sprenger, Cynthia Liu, Gang Coleman, Ilsa Lakely, Bryce Li, Rui Ma, Shihong Landman, Sean R. Kumar, Vipin Hwang, Tae Hyun Raj, Ganesh V. Higano, Celestia S. Morrissey, Colm Nelson, Peter S. Plymate, Stephen R. Dehm, Scott M. TI Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer SO NATURE COMMUNICATIONS LA English DT Article ID STRUCTURAL VARIANT DISCOVERY; SPLICE VARIANTS; RNA-SEQ; SEQUENCING DATA; CELL-GROWTH; RESISTANCE; ENZALUTAMIDE; PROGRESSION; MUTATION; THERAPY AB Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumours. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class and sub-clonal enrichment in tumours within and between patients. Despite this heterogeneity, one common outcome in tumours with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand-binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signalling in CRPC. C1 [Henzler, Christine; Yang, Rendong] Univ Minnesota, Minnesota Supercomp Inst, 117 Pleasant St Southeast, Minneapolis, MN 55455 USA. [Li, Yingming; McBride, Terri; Ho, Yeung; Dehm, Scott M.] Univ Minnesota, Masonic Canc Ctr, Mayo Mail Code 806,420 Delaware St Southeast, Minneapolis, MN 55455 USA. [McBride, Terri] Univ Minnesota, Med Scientist Training Program, Minneapolis, MN 55455 USA. [Sprenger, Cynthia; Liu, Gang; Plymate, Stephen R.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. [Coleman, Ilsa; Higano, Celestia S.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North, Seattle, WA 98109 USA. [Lakely, Bryce; Higano, Celestia S.; Morrissey, Colm; Plymate, Stephen R.] Univ Washington, Dept Urol, 1959 Northeast Pacific St,Box 356510, Seattle, WA 98195 USA. [Li, Rui; Ma, Shihong; Raj, Ganesh V.] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Landman, Sean R.; Kumar, Vipin] Univ Minnesota, Dept Comp Sci & Engn, 200 Union St Southeast, Minneapolis, MN 55455 USA. [Hwang, Tae Hyun] Univ Texas Southwestern Med Ctr Dallas, Quantitat Biomed Res Ctr, 2201 Inwood Rd, Dallas, TX 75390 USA. [Higano, Celestia S.] Univ Washington, Dept Med, 825 Eastlake Ave East, Seattle, WA 98109 USA. [Plymate, Stephen R.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 325 9th Ave,Box 359625, Seattle, WA 98104 USA. [Dehm, Scott M.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Dehm, Scott M.] Univ Minnesota, Dept Urol, Minneapolis, MN 55455 USA. RP Dehm, SM (reprint author), Univ Minnesota, Masonic Canc Ctr, Mayo Mail Code 806,420 Delaware St Southeast, Minneapolis, MN 55455 USA.; Dehm, SM (reprint author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.; Dehm, SM (reprint author), Univ Minnesota, Dept Urol, Minneapolis, MN 55455 USA. EM dehm@umn.edu OI McBride, Terri/0000-0002-9305-8038 FU NIH [R01CA174777]; U.S. Department of Defense Prostate Cancer Research Program Transformative Impact Award [W81XWH-15-1-0430]; Pacific Northwest Prostate Cancer SPORE [P50CA97186]; PO1 NIH grants [PO1CA085859, PO1CA163227]; Richard M. Lucas Foundation; NIH Medical Scientist Training Program [T32GM008244] FX We thank the patients and their families who were willing to participate in the Prostate Cancer Donor Program. We acknowledge Drs Robert Vessella, Bruce Montgomery, Evan Yu, Elahe Mostaghel, Heather Cheng, Paul Lange, Martine Roudier and Lawrence True, and the tissue acquisition teams for their contributions to the University of Washington Prostate Cancer Donor Program. In addition, we thank Dr Eva Corey for access to LuCaP xenograft tissue and Belinda Nghiem for her technical expertise. This research was supported by funding from NIH grants R01CA174777 (to S.M.D.), U.S. Department of Defense Prostate Cancer Research Program Transformative Impact Award W81XWH-15-1-0430 (to S.R.P. and S.M.D.), the Pacific Northwest Prostate Cancer SPORE (P50CA97186 to P.S.N.), PO1 NIH grants (PO1CA085859 and PO1CA163227) and the Richard M. Lucas Foundation. T.M. was supported by NIH Medical Scientist Training Program grant T32GM008244. NR 55 TC 2 Z9 2 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD NOV 29 PY 2016 VL 7 AR 13668 DI 10.1038/ncomms13668 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ED2GM UT WOS:000388662000001 PM 27897170 ER PT J AU Liu, YZ Lin, WJ Liu, C Luo, YJ Wu, JH Bayley, PJ Qin, SZ AF Liu, Yunzhe Lin, Wanjun Liu, Chao Luo, Yuejia Wu, Jianhui Bayley, Peter J. Qin, Shaozheng TI Memory consolidation reconfigures neural pathways involved in the suppression of emotional memories SO NATURE COMMUNICATIONS LA English DT Article ID UNWANTED MEMORIES; AUTOBIOGRAPHICAL MEMORIES; COMPETING MEMORIES; PATTERN SEPARATION; SLEEP; BRAIN; HIPPOCAMPAL; RETRIEVAL; MECHANISMS; NETWORK AB The ability to suppress unwanted emotional memories is crucial for human mental health. Through consolidation over time, emotional memories often become resistant to change. However, how consolidation impacts the effectiveness of emotional memory suppression is still unknown. Using event-related fMRI while concurrently recording skin conductance, we investigated the neurobiological processes underlying the suppression of aversive memories before and after overnight consolidation. Here we report that consolidated aversive memories retain their emotional reactivity and become more resistant to suppression. Suppression of consolidated memories involves higher prefrontal engagement, and less concomitant hippocampal and amygdala disengagement. In parallel, we show a shift away from hippocampal-dependent representational patterns to distributed neocortical representational patterns in the suppression of aversive memories after consolidation. These findings demonstrate rapid changes in emotional memory organization with overnight consolidation, and suggest possible neurobiological bases underlying the resistance to suppression of emotional memories in affective disorders. C1 [Liu, Yunzhe; Lin, Wanjun; Liu, Chao; Qin, Shaozheng] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China. [Liu, Yunzhe; Lin, Wanjun; Liu, Chao; Qin, Shaozheng] Beijing Normal Univ, IDG McGovern Inst Brain Res, Beijing 100875, Peoples R China. [Luo, Yuejia; Wu, Jianhui] Shenzhen Univ, Inst Affect & Social Neurosci, Shenzhen 518060, Peoples R China. [Luo, Yuejia; Wu, Jianhui] Shenzhen Univ, Coll Psychol & Sociol, Shenzhen 518060, Peoples R China. [Luo, Yuejia] Shenzhen Inst Neurosci, Shenzhen 518057, Peoples R China. [Bayley, Peter J.] US Dept Vet Affairs, War Related Illness & Injury Study Ctr, Palo Alto, CA 94304 USA. [Bayley, Peter J.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. RP Qin, SZ (reprint author), Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.; Qin, SZ (reprint author), Beijing Normal Univ, IDG McGovern Inst Brain Res, Beijing 100875, Peoples R China.; Wu, JH (reprint author), Shenzhen Univ, Inst Affect & Social Neurosci, Shenzhen 518060, Peoples R China.; Wu, JH (reprint author), Shenzhen Univ, Coll Psychol & Sociol, Shenzhen 518060, Peoples R China. EM wujh8@szu.edu.cn; szqin@bnu.edu.cn RI Liu, Chao/E-9068-2017 OI Liu, Chao/0000-0003-1149-2314 FU National Natural Science Foundation of China [31530031, 31522028, 81371203, 81571056, 81471376, 2014NT15]; National Key Basic Research Program of China (973 Program) [2014CB744600]; Thousand (Young) Talents Program of China FX This work was supported by the National Natural Science Foundation of China (31530031, 31522028, 81371203, 81571056, 81471376, 2014NT15), the National Key Basic Research Program of China (973 Program, 2014CB744600), and the Thousand (Young) Talents Program of China. We thank Zhi Yang, Xueyi Shen, Xiaping Lu, Wanqing Li and Honghong Tang for their assistance in data collection, and we also thank all of the subjects who participated in this study. NR 70 TC 0 Z9 0 U1 20 U2 20 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD NOV 29 PY 2016 VL 7 AR 13375 DI 10.1038/ncomms13375 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ED6TX UT WOS:000388990400001 PM 27898050 ER PT J AU Song, DL Wilson, B Zhao, LL Bhuyan, R Bandyopadhyay, M Lyubarsky, A Yu, C Li, YF Kanu, L Miwa, T Song, WC Finnemann, SC Rohrer, B Dunaief, JL AF Song, Delu Wilson, Brooks Zhao, Liangliang Bhuyan, Rupak Bandyopadhyay, Mausumi Lyubarsky, Arkady Yu, Chen Li, Yafeng Kanu, Levi Miwa, Takashi Song, Wen-Chao Finnemann, Silvia C. Rohrer, Barbel Dunaief, Joshua L. TI Retinal Pre-Conditioning by CD59a Knockout Protects against Light-Induced Photoreceptor Degeneration SO PLOS ONE LA English DT Article ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIGMENT EPITHELIAL-CELLS; COMPLEMENT REGULATORY PROTEINS; CHELATOR DEFERIPRONE PROTECTS; DECAY-ACCELERATING FACTOR; FACTOR-H DEFICIENCY; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; FUNCTIONAL-CHARACTERIZATION; OXIDATIVE STRESS AB Complement dysregulation plays a key role in the pathogenesis of age-related macular degeneration (AMD), but the specific mechanisms are incompletely understood. Complement also potentiates retinal degeneration in the murine light damage model. To test the retinal function of CD59a, a complement inhibitor, CD59a knockout (KO) mice were used for light damage (LD) experiments. Retinal degeneration and function were compared in WT versus KO mice following light damage. Gene expression changes, endoplasmic reticulum (ER) stress, and glial cell activation were also compared. At baseline, the ERG responses and rhodopsin levels were lower in CD59aKO compared to wild-type (WT) mice. Following LD, the ERG responses were better preserved in CD59aKO compared to WT mice. Correspondingly, the number of photoreceptors was higher in CD59aKO retinas than WT controls after LD. Under normal light conditions, CD59aKO mice had higher levels than WT for GFAP immunostaining in Muller cells, mRNA and protein levels of two ER-stress markers, and neurotrophic factors. The reduction in photon capture, together with the neurotrophic factor upregulation, may explain the structural and functional protection against LD in the CD59aKO. C1 [Song, Delu; Zhao, Liangliang; Bhuyan, Rupak; Lyubarsky, Arkady; Li, Yafeng; Kanu, Levi; Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA. [Wilson, Brooks; Bandyopadhyay, Mausumi; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA. [Zhao, Liangliang] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun, Jilin, Peoples R China. [Yu, Chen; Finnemann, Silvia C.] Fordham Univ, Dept Biol Sci, Ctr Canc Genet Dis & Gene Regulat, Bronx, NY 10458 USA. [Miwa, Takashi; Song, Wen-Chao] Univ Penn, Perelman Sch Med, Dept Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA. [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Dunaief, JL (reprint author), Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.; Rohrer, B (reprint author), Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. EM rohrer@musc.edu; jdunaief@upenn.edu OI Song, Delu/0000-0002-9030-7211 FU NIH [EY015240, CO6RR015455]; Research to Prevent Blindness; FM Kirby Foundation; Paul and Evanina Bell Mackall Foundation Trust; National Center for Advancing Translational Sciences of the NIH [KL2TR001879]; National Institutes of Health [NIH R01EY019320, R01EY013295]; Department for Veteran Affairs merit award [RX000444]; Beckman Initiative for Macular Research; Research to Prevent Blindness (RPB), New York, NY FX This work was supported in the laboratory of J.D. by NIH EY015240, Research to Prevent Blindness, the FM Kirby Foundation, the Paul and Evanina Bell Mackall Foundation Trust, a gift in memory of Dr. Lee F. Mauger, and grant KL2TR001879 from the National Center for Advancing Translational Sciences of the NIH; in the laboratory of B.R. in part by the National Institutes of Health (NIH R01EY019320), a Department for Veteran Affairs merit award RX000444, the Beckman Initiative for Macular Research, an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New York, NY; and in the laboratory of S.C.F. by grants from the National Institutes of Health (R01EY013295) and the Beckman Initiative for Macular Research. B.R.'s animal studies were conducted in a facility constructed with support from the NIH CO6RR015455. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported in the laboratory of J.L.D. by NIH EY015240, Research to Prevent Blindness, the FM Kirby Foundation, the Paul and Evanina Bell Mackall Foundation Trust, a gift in memory of Dr. Lee F. Mauger, and grant KL2TR001879 from the National Center for Advancing Translational Sciences of the NIH; in the laboratory of B.R. in part by the National Institutes of Health (NIH R01EY019320), a Department for Veteran Affairs merit award RX000444, the Beckman Initiative for Macular Research, an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New York, NY; and in the laboratory of S.C.F. by grants from the National Institutes of Health (R01EY013295) and the Beckman Initiative for Macular Research. B.R.'s animal studies were conducted in a facility constructed with support from the NIH C06RR015455. NR 57 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 28 PY 2016 VL 11 IS 11 AR e0166348 DI 10.1371/journal.pone.0166348 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE3FE UT WOS:000389472400022 PM 27893831 ER PT J AU Jhamb, M McNulty, ML Ingalsbe, G Childers, JW Schell, J Conroy, MB Forman, DE Hergenroeder, A Dew, MA AF Jhamb, Manisha McNulty, Mary L. Ingalsbe, Gerald Childers, Julie W. Schell, Jane Conroy, Molly B. Forman, Daniel E. Hergenroeder, Andrea Dew, Mary Amanda TI Knowledge, barriers and facilitators of exercise in dialysis patients: a qualitative study of patients, staff and nephrologists SO BMC Nephrology LA English DT Article DE Exercise; Dialysis patients; Qualitative study ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; PHYSICAL-ACTIVITY; CHRONIC-HEMODIALYSIS; COMPREHENSIVE DIALYSIS; PROSPECTIVE COHORT; MORTALITY; ASSOCIATION; FRAILTY; ADULTS AB Background: Despite growing evidence on benefits of increased physical activity in hemodialysis (HD) patients and safety of intra-dialytic exercise, it is not part of standard clinical care, resulting in a missed opportunity to improve clinical outcomes in these patients. To develop a successful exercise program for HD patients, it is critical to understand patients', staff and nephrologists' knowledge, barriers, motivators and preferences for patient exercise. Methods: In-depth interviews were conducted with a purposive sample of HD patients, staff and nephrologists from 4 dialysis units. The data collection, analysis and interpretation followed Criteria for Reporting Qualitative Research guidelines. Using grounded theory, emergent themes were identified, discussed and organized into major themes and subthemes. Results: We interviewed 16 in-center HD patients (mean age 60 years, 50% females, 63% blacks), 14 dialysis staff members (6 nurses, 3 technicians, 2 dietitians, 1 social worker, 2 unit administrators) and 6 nephrologists (50% females, 50% in private practice). Although majority of the participants viewed exercise as beneficial for overall health, most patients failed to recognize potential mental health benefits. Most commonly reported barriers to exercise were dialysis-related fatigue, comorbid health conditions and lack of motivation. Specifically for intradialytic exercise, participants expressed concern over safety and type of exercise, impact on staff workload and resistance to changing dialysis routine. One of the most important motivators identified was support from friends, family and health care providers. Specific recommendations for an intra-dialytic exercise program included building a culture of exercise in the dialysis unit, and providing an individualized engaging program that incorporates education and incentives for exercising. Conclusion: Patients, staff and nephrologists perceive a number of barriers to exercise, some of which may be modifiable. Participants desired an individualized intra-dialytic exercise program which incorporates education and motivation, and they provided a number of recommendations that should be considered when implementing such a program. C1 [Jhamb, Manisha; Schell, Jane] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, 200 Lothrop St,PUH C-1101, Pittsburgh, PA 15213 USA. [McNulty, Mary L.; Dew, Mary Amanda] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ingalsbe, Gerald] Community Member Receiving Hemodialysis, Pittsburgh, PA USA. [Childers, Julie W.; Schell, Jane] Univ Pittsburgh, Div Gen Internal Med, Dept Med Hosp & Palliat Med, Pittsburgh, PA USA. [Conroy, Molly B.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Clin, Geriatr Res, Educ, Pittsburgh, PA USA. [Hergenroeder, Andrea] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. RP Jhamb, M (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, 200 Lothrop St,PUH C-1101, Pittsburgh, PA 15213 USA. EM jhambm@upmc.edu FU American Heart Association [11FTF7520014]; Junior Scholar Award, University of Pittsburgh; NIA [P30 AG024827, 1R56AG051637-01A1]; PCORI [IH-1304678]; VA Office of Rehabilitation Research and Development grant [F0834-R] FX This work was supported by American Heart Association grant 11FTF7520014 (Jhamb) and Junior Scholar Award, University of Pittsburgh (Jhamb). In addition, Dr. Forman is supported in part by NIA grants P30 AG024827 and 1R56AG051637-01A1, PCORI grant IH-1304678, and VA Office of Rehabilitation Research and Development grant F0834-R. NR 33 TC 0 Z9 0 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD NOV 24 PY 2016 VL 17 AR 192 DI 10.1186/s12882-016-0399-z PG 14 WC Urology & Nephrology SC Urology & Nephrology GA EE0OX UT WOS:000389279300004 PM 27881101 ER PT J AU Padilla, C Mendez, MF Jimenez, EE Teng, E AF Padilla, Claudia Mendez, Mario F. Jimenez, Elvira E. Teng, Edmond TI Bilingualism in older Mexican-American immigrants is associated with higher scores on cognitive screening SO BMC GERIATRICS LA English DT Article DE Bilingualism; Cognitive reserve; Cognitive decline; Aging; SALSA ID ALZHEIMERS-DISEASE; LIFELONG BILINGUALISM; EXECUTIVE CONTROL; DEMENTIA; ADULTS; ONSET; RESERVE; BRAIN; AGE; ACCULTURATION AB Background: Bilingualism may protect against cognitive aging and delay the onset of dementia. However, studies comparing monolinguals and bilinguals on such metrics have produced inconsistent results complicated by confounding variables and methodological concerns. Methods: We addressed this issue by comparing cognitive performance in a more culturally homogeneous cohort of older Spanish-speaking monolingual (n = 289) and Spanish-English bilingual (n = 339) Mexican-American immigrants from the Sacramento Longitudinal Study on Aging. Results: After adjusting for demographic differences and depressive symptoms, both groups performed similarly at baseline on verbal memory but the bilingual group performed significantly better than the monolingual group on a cognitive screening test, the Modified Mini-Mental State Examination (3MS; p < 0.001). Group differences on the 3MS were driven by language/executive and language/praxis factors. Within the bilingual group, neither language of testing nor degree of bilingualism was significantly associated with 3MS or verbal memory scores. Amongst individuals who performed in the normal or better range on both tests at baseline and were followed for an average of 6 years, both monolinguals and bilinguals exhibited similar rates of cognitive decline on both measures. Conclusions: These findings suggest that bilingualism is associated with modest benefits in cognitive screening performance in older individuals in cross-sectional analyses that persist across longitudinal analyses. The effects of bilingualism should be considered when cognitively screening is performed in aging immigrant populations. C1 [Padilla, Claudia; Mendez, Mario F.; Jimenez, Elvira E.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Padilla, Claudia; Mendez, Mario F.; Jimenez, Elvira E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Teng, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.; Teng, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. EM eteng@mednet.ucla.edu FU NIA [P01 AG020166]; Sidell-Kagan Foundation FX Data used for this research was provided by the "Sacramento Area Latino Study on Aging," (SALSA), which is managed by the Institute on Aging, University of Wisconsin and supported by the NIA (P01 AG020166). Additional research support was provided by the Sidell-Kagan Foundation. NR 43 TC 0 Z9 0 U1 15 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PD NOV 24 PY 2016 VL 16 AR 189 DI 10.1186/s12877-016-0368-1 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ED0VH UT WOS:000388559900001 PM 27881073 ER PT J AU Bowlby, W Zelnick, LR Henry, C Himmelfarb, J Kahn, SE Kestenbaum, B Robinson-Cohen, C Utzschneider, KM de Boer, IH AF Bowlby, Wilson Zelnick, Leila R. Henry, Connor Himmelfarb, Jonathan Kahn, Steven E. Kestenbaum, Bryan Robinson-Cohen, Cassianne Utzschneider, Kristina M. de Boer, Ian H. TI Physical activity and metabolic health in chronic kidney disease: a cross-sectional study SO BMC Nephrology LA English DT Article DE Chronic kidney disease; Physical activity; Metabolism; Insulin resistance; Obesity; Triglycerides ID GLOMERULAR-FILTRATION-RATE; INSULIN-RESISTANCE; RENAL-INSUFFICIENCY; GENERAL-POPULATION; OBESITY PARADOX; ALL-CAUSE; CKD; MORTALITY; ASSOCIATION; EXERCISE AB Background: Patients with chronic kidney disease (CKD) are at high risk of progression to end stage renal disease and cardiovascular events. Physical activity may reduce these risks by improving metabolic health. We tested associations of physical activity with central components of metabolic health among people with moderate-severe non-diabetic CKD. Methods: We performed a cross-sectional study of 47 people with CKD (estimated GFR < 60 ml/min/1.73 m(2)) and 29 healthy control subjects. Accelerometry was used to measured physical activity over 7 days, the hyperinsulinemic-euglycemic clamp was used to measure insulin sensitivity, and DXA was used to measured fat mass. We tested associations of physical activity with insulin sensitivity, fat mass, blood pressure, serum lipid concentrations, and serum high sensitivity C-reactive protein concentration using multivariable linear regression, adjusting for possible confounding factors. Results: Participants with CKD were less active than participants without CKD (mean (SD) 468.1 (233.1) versus 662.3 (292.5) counts per minute) and had lower insulin sensitivity (4.1 (2.1) versus 5.2 (2.0 (mg/min)/(mu U/mL)), higher fat mass (32.0 (11.4) versus 29.4 (14.8) kg), and higher triglyceride concentrations (153.2 (91.6) versus 99.6 (66.8) mg/dL). With adjustment for demographics, comorbidity, medications, and estimated GFR, each two-fold higher level of physical activity was associated with a 0.9 (mg/min)/(mu U/mL) higher insulin sensitivity (95% CI 0.2, 1.5, p = 0.006), an 8.0 kg lower fat mass (-12.9, -3.1, p = 0.001), and a 37.9 mg/dL lower triglyceride concentration (-71.9, -3.9, p = 0.03). Associations of physical activity with insulin sensitivity and triglycerides did not differ significantly by CKD status (p-values for interaction > 0.3). Conclusions: Greater physical activity is associated with multiple manifestations of metabolic health among people with moderate-severe CKD. C1 [Bowlby, Wilson] Univ Washington, Sch Med, Seattle, WA USA. [Zelnick, Leila R.; Henry, Connor; Himmelfarb, Jonathan; Kestenbaum, Bryan; Robinson-Cohen, Cassianne; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Zelnick, Leila R.; Henry, Connor; Himmelfarb, Jonathan; Kestenbaum, Bryan; Robinson-Cohen, Cassianne; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Kahn, Steven E.; Utzschneider, Kristina M.; de Boer, Ian H.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Kahn, Steven E.; Utzschneider, Kristina M.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP de Boer, IH (reprint author), Univ Washington, Div Nephrol, Seattle, WA 98195 USA.; de Boer, IH (reprint author), Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.; de Boer, IH (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM ideboer@Nephrology.washington.edu OI Robinson-Cohen, Cassianne/0000-0003-4783-7046; Kahn, Steven/0000-0001-7307-9002 FU National Institute of Diabetes and Digestive and Kidney Diseases [R01DK087726]; Department of Veterans Affairs; National Center for Advancing Translational Sciences, National Institutes of Health [TL1 TR000422]; [ULTR000423]; [P01DK017047]; [P30DK035816]; [R01DK088762]; [R01DK099199] FX SUGAR was funded by R01DK087726 from the National Institute of Diabetes and Digestive and Kidney Diseases with additional support from ULTR000423, P01DK017047, P30DK035816, R01DK088762, and R01DK099199. This project was supported in part by the Department of Veterans Affairs. This project was also made possible by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant TL1 TR000422. NR 37 TC 0 Z9 0 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD NOV 22 PY 2016 VL 17 AR 187 DI 10.1186/s12882-016-0400-x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EE0OW UT WOS:000389279200003 PM 27876008 ER PT J AU Sullivan, DR Forsberg, CW Ganzini, L Au, DH Gould, MK Provenzale, D Slatore, CG AF Sullivan, Donald R. Forsberg, Christopher W. Ganzini, Linda Au, David H. Gould, Michael K. Provenzale, Dawn Slatore, Christopher G. TI Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; INTEGRATED COLLABORATIVE CARE; MAJOR DEPRESSION; OLDER-ADULTS; PSYCHOLOGICAL DISTRESS; OUTCOMES RESEARCH; SUPPORTIVE CARE; BREAST-CANCER; PREVALENCE; ANXIETY AB Purpose Depression symptoms are common among patients with lung cancer patients; however, longitudinal changes and their impact on survival are understudied. Methods This was a prospective, observational study from the Cancer Care Outcomes Research and Surveillance Consortium from five US geographically defined regions from September 2003 through December 2005. Patients enrolled within 3 months of their lung cancer diagnosis were eligible. The eight-item Center for Epidemiologic Studies Depression scale was administered at diagnosis and 12 months' follow-up. The main outcome was survival, which was evaluated using Kaplan-Meyer curves and adjusted Cox proportional hazards modeling. Results Among 1,790 participants, 681 (38%) had depression symptoms at baseline and an additional 105 (14%) developed new-onset depression symptoms during treatment. At baseline, depression symptomswere associated with increased mortality (hazard ratio [HR], 1.17; 95% CI, 1.03 to 1.32; P =.01). Participants were classified into the following four groups based on longitudinal changes in depression symptoms from baseline to follow-up: never depression symptoms (n = 640), new-onset depression symptoms (n = 105), depression symptom remission (n = 156), and persistent depression symptoms (n = 254) and HRs were calculated. Using the never-depression symptoms group as a reference group, HRs were as follows: new-onset depression symptoms, 1.50 (95% CI, 1.12 to 2.01; P =.006); depression symptom remission, 1.02 (95% CI, 0.79 to 1.31; P =.89), and persistent depression symptoms, 1.42 (95% CI, 1.15 to 1.75; P =.001). At baseline, depression symptoms were associated with increased mortality among participants with early-stage disease (stages I and II; HR, 1.61; 95% CI, 1.26 to 2.04), but not late-stage disease (stages III and IV; HR, 1.05; 95% CI, 0.91 to 1.22). At follow-up, depression symptoms were associated with increasedmortality among participants with early-stage disease (HR, 1.71; 95% CI, 1.27 to 2.31) and those with late-stage disease (HR, 1.32; 95% CI, 1.04 to 1.69). Conclusion Among patients with lung cancer, longitudinal changes in depression symptoms are associated with differences in mortality, particularly among patients with early-stage disease. Symptom remission is associated with a similar mortality rate as never having had depression. (C) 2016 by American Society of Clinical Oncology C1 [Sullivan, Donald R.; Ganzini, Linda; Slatore, Christopher G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sullivan, Donald R.; Forsberg, Christopher W.; Ganzini, Linda; Slatore, Christopher G.] Vet Affairs Portland Hlth Care Syst, Portland, OR USA. [Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.] Univ Washington, Seattle, WA 98195 USA. [Gould, Michael K.] Kaiser Permanente Southern Calif, Pasadena, CA USA. [Gould, Michael K.] Univ Southern Calif, Los Angeles, CA USA. [Provenzale, Dawn] Durham VA Med Ctr, Durham, NC USA. [Provenzale, Dawn] Duke Univ, Durham, NC USA. RP Sullivan, DR (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, UHN67, Portland, OR 97239 USA. EM sullivad@ohsu.edu OI Sullivan, Donald/0000-0003-3266-3389 FU American Lung Association [SB-164388-N]; National Center for Advancing Translational Sciences of the National Institutes of Health [5KL2TR000152-08]; National Center for Research Resources through the Oregon Health & Science University Oregon Clinical & Translational Research Institute [UL1TR000128, 1K07CA190706-01A1]; Veterans Affairs (VA) Health Services Research and Development Career Development [CDA 09-025, CDP 11-227]; Portland VA Portland Health Care System, Oregon; National Cancer Institute [U01 CA093344, U01 CA093332]; Harvard Medical School/Northern California Cancer Center [U01 CA093324]; RAND/UCLA [U01 CA093348]; University of Alabama at Birmingham [U01 CA093329]; University of Iowa [U01 CA093339]; University of North Carolina [U01 CA 093326]; Department of Veteran's Affairs [HSRD CRS-02-164] FX This work was supported by Grant No. SB-164388-N from the American Lung Association (C.G.S.). D.R.S. was supported by Grant No. 5KL2TR000152-08 funded through the National Center for Advancing Translational Sciences of the National Institutes of Health and National Center for Research Resources through the Oregon Health & Science University Oregon Clinical & Translational Research Institute Grants No. UL1TR000128 and 1K07CA190706-01A1. C.G.S. was supported by Veterans Affairs (VA) Health Services Research and Development Career Development Awards No. CDA 09-025 and CDP 11-227. D.R.S., L.G., and C.G.S. are supported by resources from the Portland VA Portland Health Care System, Oregon. The work of the CanCORS consortium was supported by Grant No. U01 CA093344 from the National Cancer Institute to the Statistical Coordinating Center and the National Cancer Institute- supported Primary Data Collection and Research Centers (Dana-Farber Cancer Institute/Cancer Research Network, Grant No. U01 CA093332; Harvard Medical School/Northern California Cancer Center, Grant No. U01 CA093324; RAND/UCLA, Grant No. U01 CA093348; University of Alabama at Birmingham, Grant No. U01 CA093329; University of Iowa, Grant No. U01 CA093339; and University of North Carolina, Grant No. U01 CA 093326) and by Department of Veteran's Affairs Grant No. HSRD CRS-02-164 to the Durham VA Medical Center. The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis, interpretation of data, or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US Government. NR 58 TC 0 Z9 0 U1 8 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2016 VL 34 IS 33 BP 3984 EP U80 DI 10.1200/JCO.2016.66.8459 PG 10 WC Oncology SC Oncology GA ED5XU UT WOS:000388927700007 PM 27996350 ER PT J AU Lee, JH Kim, HH Ko, JY Jang, JH Kim, GH Lee, JS Nah, JW Jeon, YJ AF Lee, Ji-Hyeok Kim, Hyung-Ho Ko, Ju-Young Jang, Jun-Ho Kim, Gwang-Hoon Lee, Jung-Suck Nah, Jae-Woon Jeon, You-Jin TI Rapid preparation of functional polysaccharides from Pyropia yezoensis by microwave-assistant rapid enzyme digest system SO CARBOHYDRATE POLYMERS LA English DT Article DE Pyropia yezoensis; Microwave-assisted rapid enzyme digest system; Low molecular weight polysaccharides; Antioxidative effect ID PORPHYRA-YEZOENSIS; ANTIOXIDANT ACTIVITY; SULFATED POLYSACCHARIDES; MASS-SPECTROMETRY; RED ALGAE; IN-VITRO; EXTRACTION; PROTEIN; DEGRADATION; HYDROLYSIS AB This study describes a simple preparation of functional polysaccharides from Pyropia yezoensis using a microwave-assistant rapid enzyme digest system (MAREDS) with various carbohydrases, and evaluates their antioxidative effects. Polysaccharide hydrolysates were prepared using MAREDS under different hydrolytic conditions of the carbohydrases and microwave powers. Polysaccharides less than 10 kDa (Low molecular weight polysaccharides, LMWP, <= 10 kDa) were efficiently obtained using an ultrafiltration (molecular weight cut-off of 10 kDa). MAREDS increases AMG activation via an increased degree of hydrolysis; the best AMG hydrolysate was prepared using a 10:1 ratio of substrate to enzyme for 2 h in MAREDS with 400W. LMWP consisted of galactose (27.3%), glucose (64.5%), and mannose (8.3%) from the AMG hydrolysate had stronger antioxidant effects than the high molecular weight polysaccharides (>10 kDa). We rapidly prepared functional LMWPs by using MAREDS with carbohydrases, and suggest that LMWP might be potentially a valuable algal polysaccharide antioxidant. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Lee, Ji-Hyeok; Kim, Hyung-Ho; Ko, Ju-Young; Jeon, You-Jin] Jeju Natl Univ, Dept Marine Life Sci, Jeju 690756, South Korea. [Jang, Jun-Ho] Univ Pittsburgh, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Pittsburgh, PA 15260 USA. [Jang, Jun-Ho] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Kim, Gwang-Hoon] Kongju Natl Univ, Coll Nat Sci, Dept Biol, Kong Ju 314701, South Korea. [Lee, Jung-Suck] Jeju Natl Univ, Ind Acad Cooperat Fdn, Jeju 690756, South Korea. [Nah, Jae-Woon] Sunchon Natl Univ, Dept High Polymer Engn, Sunchon, Jeollanam Do, South Korea. RP Jeon, YJ (reprint author), Jeju Natl Univ, Dept Marine Life Sci, Jeju 690756, South Korea.; Nah, JW (reprint author), Sunchon Natl Univ, Dept High Polymer Engn, Sunchon, Jeollanam Do, South Korea. EM jwnah@sunchon.ac.kr; youjin2014@gmail.com FU Ministry of Agriculture, Food and Rural Affairs (MAFRA); Ministry of Oceans and Fisheries (MOF); Korea Forest Service (KFS) [213004-04-4-SBA30] FX This research was supported by Ministry of Agriculture, Food and Rural Affairs (MAFRA), Ministry of Oceans and Fisheries (MOF), Rural Development Administration (RDA) and Korea Forest Service (KFS) (213004-04-4-SBA30). NR 31 TC 0 Z9 0 U1 23 U2 28 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0144-8617 EI 1879-1344 J9 CARBOHYD POLYM JI Carbohydr. Polym. PD NOV 20 PY 2016 VL 153 BP 512 EP 517 DI 10.1016/j.carbpol.2016.07.122 PG 6 WC Chemistry, Applied; Chemistry, Organic; Polymer Science SC Chemistry; Polymer Science GA DU6IF UT WOS:000382317200059 PM 27561523 ER PT J AU Strigo, IA Craig, AD AF Strigo, Irina A. Craig, Arthur D. (Bud) TI Interoception, homeostatic emotions and sympathovagal balance SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Article DE anterior cingulate; insula; vagus; asymmetry; respiration ID VAGUS NERVE-STIMULATION; TREATMENT-RESISTANT DEPRESSION; CEREBRAL-BLOOD-FLOW; MACAQUE MONKEY; INSULAR CORTEX; PARASYMPATHETIC CONTROL; PARAFASCICULAR NUCLEUS; CHEMOREFLEX RESPONSE; HEMISPHERE ASYMMETRY; PARABRACHIAL NUCLEUS AB We briefly review the evidence for distinct neuroanatomical substrates that underlie interoception in humans, and we explain how they substantialize feelings from the body (in the insular cortex) that are conjoined with homeostatic motivations that guide adaptive behaviours (in the cingulate cortex). This hierarchical sensorimotor architecture coincides with the limbic cortical architecture that underlies emotions, and thus we regard interoceptive feelings and their conjoint motivations as homeostatic emotions. We describe how bivalent feelings, emotions and sympathovagal balance can be organized and regulated efficiently in the bicameral forebrain as asymmetric positive/negative, approach/avoidance and parasympathetic/sympathetic components. We provide original evidence supporting this organization from studies of cardiorespiratory vagal activity in monkeys and functional imaging studies in healthy humans showing activation modulated by paced breathing and passively viewed emotional images. The neuroanatomical architecture of interoception provides deep insight into the functional organization of all emotional feelings and behaviours in humans. This article is part of the themed issue 'Interoception beyond homeostasis: affect, cognition and mental health'. C1 [Strigo, Irina A.] San Francisco VA Med Ctr, Res Serv, San Francisco, CA 94121 USA. [Strigo, Irina A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Craig, Arthur D. (Bud)] Barrow Neurol Inst, Neurosurg Res, Phoenix, AZ 85013 USA. RP Strigo, IA (reprint author), San Francisco VA Med Ctr, Res Serv, San Francisco, CA 94121 USA.; Strigo, IA (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.; Craig, AD (reprint author), Barrow Neurol Inst, Neurosurg Res, Phoenix, AZ 85013 USA. EM irina.strigo@ucsf.edu; arthur.craig@dignityhealth.org OI Strigo, Irina/0000-0002-8799-716X FU U.S. Department of Veterans Affairs CS RD Service [I01-CX-000816]; Barrow Neurological Foundation; National Chimpanzee Brain Resource (NINDS) [NS092988, AG014308] FX This work was supported in part by I01-CX-000816 from the U.S. Department of Veterans Affairs CS R&D Service and by the Barrow Neurological Foundation, with contributions by the National Chimpanzee Brain Resource (NINDS grant NS092988 to C. C. Sherwood et al.) and grant no. AG014308 (to J. M. Erwin for support of primate histological archives). NR 86 TC 1 Z9 1 U1 7 U2 7 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8436 EI 1471-2970 J9 PHILOS T R SOC B JI Philos. Trans. R. Soc. B-Biol. Sci. PD NOV 19 PY 2016 VL 371 IS 1708 AR 20160010 DI 10.1098/rstb.2016.0010 PG 9 WC Biology SC Life Sciences & Biomedicine - Other Topics GA EC0CU UT WOS:000387766300008 ER PT J AU Lambert-Kerzner, A Lucatorto, M McCreight, M Williams, KM Fehling, KB Peterson, J Hess, E Plumley, R Ladebue, A Battaglia, C AF Lambert-Kerzner, Anne Lucatorto, Michelle McCreight, Marina Williams, Katherine M. Fehling, Kelty B. Peterson, Jamie Hess, Edward Plumley, Robert Ladebue, Amy Battaglia, Catherine TI The Veterans Health Administration's proposal for APRN full-practice authority SO NURSE PRACTITIONER LA English DT Article DE advanced practice registered nurses; APRNs; full-practice authority; US Department of Veterans Affairs; Veterans Health Administration ID NURSE-PRACTITIONERS; VIRGINIA MASON; CARE; OUTCOMES; COSTS AB The Veterans Health Administration (VHA) is proposing full-practice authority for advanced practice registered nurses (APRNs) to improve access, care delivery, and patient choice, as well as reduce costs. The authors performed a mixed-methods assessment to obtain the perspectives of administrators and APRNs on the characterization of the APRN workforce and their present practice in the VHA. C1 [Lambert-Kerzner, Anne] Denver VA Med Ctr, Denver, CO 80220 USA. [Lucatorto, Michelle; Fehling, Kelty B.] Vet Hlth Adm, Washington, DC USA. [McCreight, Marina; Williams, Katherine M.; Peterson, Jamie; Ladebue, Amy; Battaglia, Catherine] Eastern Colorado Hlth Care Syst, Denver, CO USA. [Hess, Edward] Univ Colorado, Aurora, CO USA. [Plumley, Robert] Hlth Serv Res & Dev Ctr, Seattle, WA USA. RP Lambert-Kerzner, A (reprint author), Denver VA Med Ctr, Denver, CO 80220 USA. NR 23 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0361-1817 EI 1538-8662 J9 NURSE PRACT JI Nurse Pract. PD NOV 19 PY 2016 VL 41 IS 11 BP 16 EP 23 DI 10.1097/01.NPR.0000502792.43113.73 PG 8 WC Nursing SC Nursing GA EB0NU UT WOS:000387041500006 PM 27764064 ER PT J AU Geno, KA Kennedy, RE Sawyer, P Brown, CJ Nahm, MH AF Geno, Kimball Aaron Kennedy, Richard E. Sawyer, Patricia Brown, Cynthia J. Nahm, Moon H. TI Ficolin-2 inhibitors are present in sera after prolonged storage at-80 degrees C SO PEERJ LA English DT Article DE Ficolins; Lectins; Storage artifacts; Lectin pathway; Complement ID MANNAN-BINDING LECTIN; COMPLEMENT ACTIVATION; IN-VITRO; ACETYLSALICYLIC-ACID; HUMAN COLLECTIN; H-FICOLIN; PATHWAY; RECOGNITION; VIVO; INTERLEUKIN-6 AB Ficolins can activate the lectin pathway of the complement system that provides innate immune protection against pathogens, marks host cellular debris for clearance, and promotes inflammation. Baseline inflammation increases with aging in a phenomenon known as "inflammaging,." Although IL-6 and C-reacrive protein are known to increase with age, contributions of many complement factors, including ficolins, to inflammaging have been little studied. Ficolin-2 is abundant in human serum and can recognize many target structures; therefore, ficolin-2 has potential to contribute to inflammaging. We hypothesized that inflammaging would alter ficolin-2 levels among older adults and examined 360 archived sera collected from older individuals. We found that these sera had apparently reduced ficolin-2 levels and that 84.2% of archived sera exhibited ficolin-2 inhibitors, which suppressed apparent amounts of ficolin-2 detected by enzyme linked immunosorbent assay. Fresh serum samples were obtained from donors whose archived sera showed inhibitors, but the fresh sera did not have ficolin-2 inhibitors. Ficolin-2 inhibitors were present in other long-stored sera from younger persons. Furthermore, noninhibiting samples and fresh sera from older adults had apparently normal amounts of ficolin-2. Thus, ficolin-2 inhibitors may arise as an artifact of long-term storage of serum at -80 degrees C. C1 [Geno, Kimball Aaron; Nahm, Moon H.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kennedy, Richard E.; Sawyer, Patricia; Brown, Cynthia J.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Kennedy, Richard E.; Sawyer, Patricia] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Nahm, Moon H.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. RP Nahm, MH (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.; Nahm, MH (reprint author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. EM mnahm@uabmc.edu FU NIH [HL105346, AG0500607, AG015062] FX This work was funded by NIH grants HL105346 (KAG) and AG0500607 (MHN). The UAB Study of Aging was funded by NIH grant AG015062. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 0 Z9 0 U1 0 U2 0 PU PEERJ INC PI LONDON PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND SN 2167-8359 J9 PEERJ JI PeerJ PD NOV 17 PY 2016 VL 4 AR e2705 DI 10.7717/peerj.2705 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EC8XE UT WOS:000388425600005 PM 27896034 ER PT J AU Zanchi, D Brody, A Borgwardt, S Haller, S AF Zanchi, Davide Brody, Arthur Borgwardt, Stefan Haller, Sven TI Sex Effects on Smoking Cue Perception in Non-Smokers, Smokers, and Ex-Smokers: A Pilot Study SO FRONTIERS IN PSYCHIATRY LA English DT Article DE nicotine; tobacco; fMRI; sex; females; males ID PATHOLOGICAL GAMBLERS; NICOTINE ABSTINENCE; CIGARETTE SMOKERS; BRAIN ACTIVITY; FMRI; WOMEN; DEPENDENCE; RESPONSES; HEALTH; ROBUST AB Introduction: Recent neuroimaging research suggests sex-related brain differences in smoking addiction, In the present pilot study, we assessed gender-related differences in brain activation in response to cigarette-related video cues, investigating non-smokers, smokers, and ex-smokers. Methods: First, we compared 29 females (28.6 +/- 5.3) vs. 23 males (31.5 +/- 6.4), regardless of current smoking status to assess global gender-related effects. Second, we performed a post hoc analysis of non-smokers (9 females and 7 males). Participants performed a block-design functional magnetic resonance imaging paradigm contrasting smoking with control cue video exposures. Data analyses included task-related general linear model, voxel-based morphometry of gray matter (GM), and tract-based spatial statistics of white matter (WM). Results: First, the global effect regardless of current smoking status revealed higher activation in the bilateral superior frontal gyrus and anterior cingulate cortex (ACC) for females compared to males. Second, the analysis according to current smoking status demonstrated higher activation in female vs. male smokers vs. non-smokers in the superior frontal gyrus, anterior and posterior cingulate cortex, and precuneus, and higher activationi in female vs. male ex-smokers vs. non-smokers in the right precentral gyrus, in the right insula and ACC. No structural differences were found in GM or WM. Conclusion: The current study identifies gender-related brain functional differences in smokers and ex-smokers compared to non-smokers. The current work can be considered as a starting point for future investigations into gender differences in brain responses to cigarette-related cues C1 [Zanchi, Davide; Borgwardt, Stefan] Univ Basel, Dept Psychiat UPK, Basel, Switzerland. [Brody, Arthur] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Haller, Sven] Affidea Ctr Diagnost Radiol Carouge CDRC, Geneva, Switzerland. [Haller, Sven] Univ Geneva, Fac Med, Geneva, Switzerland. [Haller, Sven] Uppsala Univ, Radiol, Dept Surg Sci, Uppsala, Sweden. [Haller, Sven] Univ Hosp Freiburg, Dept Neuroradiol, Freiburg, Germany. RP Zanchi, D (reprint author), Univ Basel, Dept Psychiat UPK, Basel, Switzerland. EM davide.zanchi@upkbs.ch NR 25 TC 0 Z9 0 U1 4 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD NOV 17 PY 2016 VL 7 AR 187 DI 10.3389/fpsyt.2016.00187 PG 7 WC Psychiatry SC Psychiatry GA EC1DZ UT WOS:000387845100001 PM 27909413 ER PT J AU Reyes, LF Restrepo, MI Hinojosa, CA Soni, NJ Shenoy, AT Gilley, RP Gonzalez-Juarbe, N Noda, JR Winter, VT de la Garza, MA Shade, RE Coalson, JJ Giavedoni, LD Anzueto, A Orihuela, CJ AF Reyes, Luis F. Restrepo, Marcos I. Hinojosa, Cecilia A. Soni, Nilam J. Shenoy, Anukul T. Gilley, Ryan P. Gonzalez-Juarbe, Norberto Noda, Julio R. Winter, Vicki T. de la Garza, Melissa A. Shade, Robert E. Coalson, Jacqueline J. Giavedoni, Luis D. Anzueto, Antonio Orihuela, Carlos J. TI A Non-Human Primate Model of Severe Pneumococcal Pneumonia SO PLOS ONE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; CARDIOVASCULAR-DISEASE; INFLAMMATORY RESPONSE; LUNG ULTRASOUND; CRITICALLY-ILL; BLUE-PROTOCOL; HOSPITALIZATION; DIAGNOSIS; MOUSE AB Rationale Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and infectious death in adults worldwide. A non-human primate model is needed to study the molecular mechanisms that underlie the development of severe pneumonia, identify diagnostic tools, explore potential therapeutic targets, and test clinical interventions during pneumococcal pneumonia. Objective To develop a non-human primate model of pneumococcal pneumonia. Methods Seven adult baboons (Papio cynocephalus) were surgically tethered to a continuous monitoring system that recorded heart rate, temperature, and electrocardiography. Animals were inoculated with 10(9) colony-forming units of S. pneumoniae using bronchoscopy. Three baboons were rescued with intravenous ampicillin therapy. Pneumonia was diagnosed using lung ultrasonography and ex vivo confirmation by histopathology and immunodetection of pneumococcal capsule. Organ failure, using serum biomarkers and quantification of bacteremia, was assessed daily. Results Challenged animals developed signs and symptoms of pneumonia 4 days after infection. Infection was characterized by the presence of cough, tachypnea, dyspnea, tachycardia and fever. All animals developed leukocytosis and bacteremia 24 hours after infection. A severe inflammatory reaction was detected by elevation of serum cytokines, including Interleukin (IL)1Ra, IL-6, and IL-8, after infection. Lung ultrasonography precisely detected the lobes with pneumonia that were later confirmed by pathological analysis. Lung pathology positively correlated with disease severity. Antimicrobial therapy rapidly reversed symptomology and reduced serum cytokines. Conclusions We have developed a novel animal model for severe pneumococcal pneumonia that mimics the clinical presentation, inflammatory response, and infection kinetics seen in humans. This is a novel model to test vaccines and treatments, measure biomarkers to diagnose pneumonia, and predict outcomes. C1 [Reyes, Luis F.; Restrepo, Marcos I.; Hinojosa, Cecilia A.; Soni, Nilam J.; Noda, Julio R.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Reyes, Luis F.; Restrepo, Marcos I.; Hinojosa, Cecilia A.; Soni, Nilam J.; Noda, Julio R.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. [Gilley, Ryan P.; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Shenoy, Anukul T.; Gonzalez-Juarbe, Norberto; Orihuela, Carlos J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Winter, Vicki T.; Coalson, Jacqueline J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [de la Garza, Melissa A.; Shade, Robert E.; Giavedoni, Luis D.] Texas Biomed Res Inst, San Antonio, TX USA. RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA.; Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. EM restrepom@uthscsa.edu FU National Heart, Lung, and Blood Institute [K23HL096054]; NIH [AI114800]; Southwest National Primate Research Center grant from the Office of Research Infrastructure Programs, NIH [P51 OD011133] FX MIR's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. CJO receives support from NIH grant AI114800. This investigation used resources that were supported by the Southwest National Primate Research Center grant P51 0D011133 from the Office of Research Infrastructure Programs, NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies or sources of support received during this specific study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 17 PY 2016 VL 11 IS 11 AR e0166092 DI 10.1371/journal.pone.0166092 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EC2AC UT WOS:000387910200018 PM 27855182 ER PT J AU Zhao, S Chen, C Chang, K Karnad, A Jagirdar, J Kumar, AP Freeman, JW AF Zhao, Shujie Chen, Chen Chang, Katherine Karnad, Anand Jagirdar, Jaishree Kumar, Addanki P. Freeman, James W. TI CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy SO CLINICAL CANCER RESEARCH LA English DT Article ID STEM-CELLS; ADHESION MOLECULES; BREAST-CANCER; COLON-CANCER; METASTASIS; ADENOCARCINOMA; PROGRESSION; GROWTH; EMT; PROLIFERATION AB Purpose: A subpopulation of pancreatic ductal adenocarcinoma (PDAC) cells is thought to be inherently resistant to chemotherapy or to give rise to tumor cells that become resistant during treatment. Here we determined the role of CD44 expression and its isoforms as a marker and potential target for tumor cells that give rise to invasive and gemcitabineresistant tumors. Experimental Design: RT-PCR, Western blotting, and DNA sequencing was used to determine CD44 isoform and expression levels. Flow cytometry was used to sort cells on the basis of their CD44 expression level. CD44 expression was knocked down using shRNA. Tumorigenic properties were determined by clonogenic and Matrigel assays, IHC, tumor growth in vivo using luciferase imaging and by tumor weight. Results: Weidentified an invasive cell population that gives rise to gemcitabine-resistant tumors. These cancer cells express a high level of CD44 standard isoform and have an EMT phenotype (CD44s/EMT). In vivo, CD44s/EMT engraft and expand rapidly and give rise to tumors that express high levels of CD44 isoforms that contain multiple exon variants. CD44low-expressing cells show continued sensitivity to gemcitabine in vivo and knockdown of CD44 in CD44s/EMT cells increases sensitivity to gemcitabine and decreases invasiveness. Conclusions: PDAC cells expressing high levels of CD44s with a mesenchymal-like phenotype were highly invasive and developed gemcitabine resistance in vivo. Thus, initial targeting CD44 or reversing the CD44high phenotype may improve therapeutic response. (C) 2016 AACR. C1 [Zhao, Shujie; Chen, Chen; Chang, Katherine; Karnad, Anand; Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Chang, Katherine; Karnad, Anand; Freeman, James W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, 4450 Med Dr, San Antonio, TX 78229 USA. [Jagirdar, Jaishree] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Kumar, Addanki P.; Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA. RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu FU William and Ella Owens Medical Research Foundation; VA Merit Award; Cancer Center Grant [NIH-P30CA054174]; CPRIT training grant FX This work was supported by grants from the William and Ella Owens Medical Research Foundation, VA Merit Award, Cancer Center Grant to CTRC and NIH-P30CA054174 (to J. W. Freeman), and CPRIT training grant (to K. Chang). NR 41 TC 0 Z9 0 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 15 PY 2016 VL 22 IS 22 BP 5592 EP 5604 DI 10.1158/1078-0432.CCR-15-3115 PG 13 WC Oncology SC Oncology GA ED3IU UT WOS:000388743600024 PM 27267855 ER PT J AU Sakata, K Araki, K Nakano, H Nishina, T Komazawa-Sakon, S Murai, S Lee, GE Hashimoto, D Suzuki, C Uchiyama, Y Notohara, K Gukovskaya, AS Gukovsky, I Yamamura, K Baba, H Ohmuraya, M AF Sakata, Kazuya Araki, Kimi Nakano, Hiroyasu Nishina, Takashi Komazawa-Sakon, Sachiko Murai, Shin Lee, Grace E. Hashimoto, Daisuke Suzuki, Chigure Uchiyama, Yasuo Notohara, Kenji Gukovskaya, Anna S. Gukovsky, Ilya Yamamura, Ken-ichi Baba, Hideo Ohmuraya, Masaki TI Novel method to rescue a lethal phenotype through integration of target gene onto the X-chromosome SO SCIENTIFIC REPORTS LA English DT Article ID PANCREATIC ACINAR-CELLS; TRYPSINOGEN ACTIVATION; MICE; AUTOPHAGY; PATHOGENESIS; CANCER; EXPRESSION; DEFICIENT; ALPHA AB The loss-of-function mutations of serine protease inhibitor, Kazal type 1 (SPINK1) gene are associated with human chronic pancreatitis, but the underlying mechanisms remain unknown. We previously reported that mice lacking Spink3, the murine homologue of human SPINK1, die perinatally due to massive pancreatic acinar cell death, precluding investigation of the effects of SPINK1 deficiency. To circumvent perinatal lethality, we have developed a novel method to integrate human SPINK1 gene on the X chromosome using Cre-loxP technology and thus generated transgenic mice termed "X-SPINK1". Consistent with the fact that one of the two X chromosomes is randomly inactivated, X-SPINK1 mice exhibit mosaic pattern of SPINK1 expression. Crossing of X-SPINK1 mice with Spink3(-/-) mice rescued perinatal lethality, but the resulting Spink3(-/-); XXSPINK1 mice developed spontaneous pancreatitis characterized by chronic inflammation and fibrosis. The results show that mice lacking a gene essential for cell survival can be rescued by expressing this gene on the X chromosome. The Spink3(-/-); XXSPINK1 mice, in which this method has been applied to partially restore SPINK1 function, present a novel genetic model of chronic pancreatitis. C1 [Sakata, Kazuya; Araki, Kimi; Yamamura, Ken-ichi; Ohmuraya, Masaki] Kumamoto Univ, Inst Resource Dev & Anal, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan. [Sakata, Kazuya; Hashimoto, Daisuke; Baba, Hideo] Kumamoto Univ, Dept Surg Gastroenterol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8600811, Japan. [Nakano, Hiroyasu; Nishina, Takashi; Komazawa-Sakon, Sachiko; Murai, Shin] Toho Univ, Dept Biochem, Sch Med, Ota Ku, 5-21-16 Omori Nishi, Tokyo 1438540, Japan. [Lee, Grace E.; Gukovskaya, Anna S.; Gukovsky, Ilya] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lee, Grace E.; Gukovskaya, Anna S.; Gukovsky, Ilya] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Suzuki, Chigure; Uchiyama, Yasuo] Juntendo Univ, Dept Cellular & Mol Neuropathol, Grad Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan. [Notohara, Kenji] Kurashiki Cent Hosp, Dept Pathol, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan. RP Ohmuraya, M (reprint author), Kumamoto Univ, Inst Resource Dev & Anal, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan. EM ohmuraya@kumamoto-u.ac.jp FU MEXT (Ministry of Education, Culture, Sports, Science and Technology) [26111516, 26110003]; KAKENHI Scientific Research from Japan Society for the Promotion of Science (JSPS); Challenging Exploratory Research from Japan Society for the Promotion of Science (JSPS); Takeda Science Foundation; Naito Science Foundation; Uehara Science Foundation; Novartis Science Foundation; American Pancreatic Association FX We thank Y. Fukuchi and M. Nakata for technical assistance. This work was supported by MEXT (Ministry of Education, Culture, Sports, Science and Technology) grants (#26111516 and 26110003), KAKENHI Scientific Research (B and C) and Challenging Exploratory Research from Japan Society for the Promotion of Science (JSPS), and the Takeda Science Foundation, the Naito Science Foundation, the Uehara Science Foundation, and Novartis Science Foundation. M.O. is especially grateful to the American Pancreatic Association for a mini-sabbatical award that made possible for him to spend several months at the Gukovskaya laboratory in Los Angeles. NR 31 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 15 PY 2016 VL 6 AR 37200 DI 10.1038/srep37200 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EB9WZ UT WOS:000387749700001 PM 27845447 ER PT J AU Kudaravalli, M Althouse, AD Marroquin, OC Khandhar, SJ Sharbaugh, MS Toma, C Smith, AJC Schindler, JT Lee, JS Mulukutla, SR AF Kudaravalli, Mrudula Althouse, Andrew D. Marroquin, Oscar C. Khandhar, Sameer J. Sharbaugh, Michael S. Toma, Catalin Smith, A. J. Conrad Schindler, John T. Lee, Joon S. Mulukutla, Suresh R. TI Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Thienopyridine; P2Y12 inhibitor; Percutaneous coronary intervention; Coronary disease ID ACUTE MYOCARDIAL-INFARCTION; PLATO PLATELET INHIBITION; INTERVENTION INSIGHTS; CONTEMPORARY PRACTICE; ANTIPLATELET AGENTS; ARTERY-DISEASE; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ASPIRIN AB Background: Dual antiplatelet therapy is recommended for patients with acute coronary syndrome (ACS) that undergo percutaneous coronary intervention (PCI). However, the effect of switching P2Y12 inhibitors between the loading dose and therapy after discharge is not well described. Methods: This post-hoc analysis of a prospectively collected registry included 3219 consecutive ACS patients who underwent PCI. Patients were categorized into four groups: clopidogrel at load and discharge (C-C), loading dose of clopidogrel and discharged on prasugrel/ticagrelor (C-PT), loading dose of prasugrel/ticagrelor and discharged on clopidogrel (PT-C), and prasugrel/ticagrelor at load and discharge (PT-PT). Results: While 77.6% of patients received the C-C treatment regimen and 13.6% received the PT-PT strategy, the strategy of P2Y12 switching was fairly common with 6.2% in the PT-C group and 2.6% in the C-PT group. While C-C was the most common treatment regimen, PT-C and PT-PT were more commonly used in STEMI patients than in NSTEMI or unstable angina patients. A significantly lower unadjusted incidence of the composite outcome (death, MI, and repeat revascularization) was appreciated in both the PT-C (1.0%) and PT-PT (2.3%) groups than the C-C group (4.0%). Propensity-score matched analysis still showed significantly reduced risk (HR = 0.22, 95% CI 0.05-0.93, p = 0.04) in the PT-C group vs. a matched group of C-C controls. Conclusions: The strategy of utilizing a newer P2Y12 inhibitor and then switching to clopidogrel in ACS patients following PCI is used with some frequency in routine clinical practice and further studies should evaluate the safety and efficacy of such a strategy. Published by Elsevier Ireland Ltd. C1 [Althouse, Andrew D.; Marroquin, Oscar C.; Sharbaugh, Michael S.; Toma, Catalin; Smith, A. J. Conrad; Schindler, John T.; Lee, Joon S.; Mulukutla, Suresh R.] Univ Pittsburgh, Dept Med, Inst Heart & Vasc, Pittsburgh, PA USA. [Mulukutla, Suresh R.] Vet Affairs Hosp, Div Cardiol, Pittsburgh, PA USA. [Khandhar, Sameer J.] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Kudaravalli, Mrudula] Allegheny Gen Hosp, Dept Med, Pittsburgh, PA 15212 USA. RP Mulukutla, SR (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Cardiol, Univ Dr C,Cardiol Cath Lab 111C-U, Pittsburgh, PA 15240 USA. EM mulukutlasr@upmc.edu FU Abbott Vascular grant; St. Jude Medical; University of Pittsburgh Medical Center FX This research was funded, in part, by funds from an Abbott Vascular grant and from St. Jude Medical. The remaining funding was from the University of Pittsburgh Medical Center. NR 24 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 15 PY 2016 VL 223 BP 854 EP 859 DI 10.1016/j.ijcard.2016.08.144 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB0LV UT WOS:000387036200225 PM 27592042 ER PT J AU Demissei, BG Postmus, D Liu, LCY Cleland, JG O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Cotter, G Davison, BA Edwards, C Givertz, MM Bloomfield, DM Dittrich, HC Voors, AA Hillege, HL AF Demissei, Biniyam G. Postmus, Douwe Liu, Licette C. Y. Cleland, John G. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth A. Edwards, Christopher Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. Voors, Adriaan A. Hillege, Hans L. TI Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Acute heart failure; Rolofylline; Multivariable risk; Heterogeneity of treatment effect; Subgroup analysis; STEPP ID RECEPTOR ANTAGONIST ROLOFYLLINE; DIURETIC RESPONSE; CLINICAL-TRIALS; INDIVIDUAL PATIENTS; VOLUME OVERLOAD; RENAL-FUNCTION; RELAX-AHF; THERAPY; HETEROGENEITY; PREDICTORS AB Background: The selective adenosine A1 receptor antagonist rolofylline showed a neutral overall result on clinical outcomes in the PROTECT trial. However, we hypothesized that response to rolofylline treatment could be influenced by underlying clinical risk. Methods: We performed a post-hoc analysis of the PROTECT trial -a large, double-blind, randomized, placebo-controlled trial that enrolled 2033 patients. Baseline risk of 180-day all-cause mortality was estimated using a previously published 8-item model. Evaluation of efficacy of rolofylline across subpopulations defined based on estimated risk of mortality was performed using subpopulation treatment effect pattern plot (STEPP) analysis. Findings were validated in an independent cohort of acute heart failure patients. Results: Median estimated risk of mortality was 13.0%, IQR [8.0%-23.0%] and was comparable between the rolofylline and placebo arms. In low to intermediate risk subgroups of patients, rolofylline was associated with a higher rate of 180-day all-cause mortality (11.9% in the rolofylline versus 8.4% in the placebo arms, p = 0.050). In the high risk subgroup of patients, particularly those with estimated risk of mortality between 20% and 30%, 180-day all-cause mortality rate was markedly lower in the rolofylline arm(18.4% in the rolofylline versus 34.0% in the placebo arms, p = 0.003). The trend towards potential harm with rolofylline treatment in the low to intermediate risk subpopulations and significant benefit in high risk patients was also observed in the validation cohort. Conclusion: Our findings suggest that selective adenosine A1 receptor antagonism could be harmful in low risk acute heart failure patients, while it might significantly benefit higher risk patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Demissei, Biniyam G.; Liu, Licette C. Y.; Voors, Adriaan A.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Demissei, Biniyam G.; Postmus, Douwe; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Cleland, John G.] Imperial Coll, London, England. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth A.; Edwards, Christopher] Momentum Res, Durham, NC USA. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Abboud Cardiovasc Res Ctr, Iowa City, IA 52242 USA. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU NovaCardia, a subsidiary of Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. NR 33 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 15 PY 2016 VL 223 BP 967 EP 975 DI 10.1016/j.ijcard.2016.08.271 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB0LV UT WOS:000387036200247 PM 27589047 ER PT J AU Raskind, MA Millard, SP Petrie, EC Peterson, K Williams, T Hoff, DJ Hart, K Holmes, H Hill, J Daniels, C Hendrickson, R Peskind, ER AF Raskind, Murray A. Millard, Steven P. Petrie, Eric C. Peterson, Kris Williams, Tammy Hoff, David J. Hart, Kimberly Holmes, Hollie Hill, Jeffrey Daniels, Colin Hendrickson, Rebecca Peskind, Elaine R. TI Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With Prazosin SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Biomarker; Blood pressure; Military; Noradrenergic; Posttraumatic stress disorder (PTSD); Prazosin; Treatment response ID COMBAT VETERANS; SLEEP QUALITY; PTSD; TRAUMA; METHOXAMINE; NIGHTMARES; BRAIN; CYCLE; RAT AB BACKGROUND: In a previously reported positive randomized controlled trial of the alpha(1)-adrenoreceptor (alpha(1)AR) antagonist prazosin for combat posttraumatic stress disorder (PTSD) in 67 active duty soldiers, baseline symptoms did not predict therapeutic response. If increased brain alpha(1)AR activation in PTSD is the target of prazosin treatment action, higher brain alpha(1)AR activation should predict greater prazosin efficacy. Although brain alpha(1)AR activation is not measurable, coregulated peripheral alpha(1)AR activation could provide an estimate of brain alpha(1)AR activation. Standing blood pressure (BP) is an accessible biological parameter regulated by norepinephrine activation of alpha(1)ARs on peripheral arterioles. METHODS: Effects of baseline standing systolic and other BP parameters on PTSD outcome measures from the previously reported randomized controlled trial were analyzed using linear mixed-effects models. Prazosin participants (n = 32) and placebo participants (n = 35) were analyzed separately. RESULTS: In prazosin participants, each 10-mm Hg higher baseline standing systolic BP increment resulted in an additional 14-point reduction (improvement) of Clinician-Administered PTSD Scale total score at end point (p = .002). All other combinations of baseline BP parameters and PTSD outcome measures were similarly significant or demonstrated trends in the predicted direction. In placebo participants, there was no signal for a baseline BP effect on PTSD outcome measures. CONCLUSIONS: These findings suggest that higher standing BP is a biomarker that helps identify persons with combat PTSD who are likely to benefit from prazosin. These results also are consistent with alpha(1)AR activation contributing to PTSD pathophysiology in a subgroup of patients. C1 [Raskind, Murray A.; Millard, Steven P.; Petrie, Eric C.; Hoff, David J.; Hart, Kimberly; Holmes, Hollie; Hendrickson, Rebecca; Peskind, Elaine R.] Northwest Network Vet Integrated Serv, Network Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. [Raskind, Murray A.; Holmes, Hollie; Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peterson, Kris; Williams, Tammy; Hill, Jeffrey; Daniels, Colin] Madigan Army Med Ctr, Tacoma, WA 98431 USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 MIRECC, Seattle, WA 98108 USA. EM murray.raskind@va.gov FU Department of Veterans Affairs; US Army Medical Research and Materiel Command, Fort Detrick, MD; Pfizer; Merck; Takeda Pharmaceuticals; Eli Lilly and Company; INSYS Therapeutics; Avanir Pharmaceuticals FX This work was supported by the Department of Veterans Affairs and the US Army Medical Research and Materiel Command, Fort Detrick, MD.; MAR is a paid advisory board member for Pfizer, Merck, and Takeda Pharmaceuticals. ERP is a paid advisory board member for Eli Lilly and Company, Takeda Pharmaceuticals, INSYS Therapeutics, and Avanir Pharmaceuticals. The other authors report no biomedical financial interests or potential conflicts of interest. NR 33 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2016 VL 80 IS 10 BP 736 EP 742 DI 10.1016/j.biopsych.2016.03.2108 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DZ0FS UT WOS:000385513500004 PM 27320368 ER PT J AU Rush, G O'Donovan, A Nagle, L Conway, C McCrohan, A O'Farrelly, C Lucey, JV Malone, KM AF Rush, Gavin O'Donovan, Aoife Nagle, Laura Conway, Catherine McCrohan, AnnMaria O'Farrelly, Cliona Lucey, James V. Malone, Kevin M. TI Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Depression; Melancholic subtype; Psychoneuroimmunology; Cytokines; Electroconvulsive therapy ID C-REACTIVE PROTEIN; GROWTH-FACTOR-BETA; CORONARY-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; NONMELANCHOLIC MAJOR DEPRESSION; TREATMENT-RESISTANT DEPRESSION; NEUROTROPHIC FACTOR; PROINFLAMMATORY CYTOKINES; PLASMA NORADRENALINE; ANXIETY DISORDERS AB Background: Immune system dysfunction is implicated in the pathophysiology of major depression, and is hypothesized to normalize with successful treatment. We aimed to investigate immune dysfunction in melancholic depression and its response to ECT. Methods: 55 melancholic depressed patients and 26 controls participated. 33 patients (60%) were referred for ECT. Blood samples were taken at baseline, one hour after the first ECT session, and 48 h after ECT series completion. Results: At baseline, melancholic depressed patients had significantly higher levels of the pro-inflammatory cytokine IL-6, and lower levels of the regulatory cytokine TGF-beta than controls. A significant surge in IL-6 levels was observed one hour after the first ECT session, but neither IL-6 nor TGF-beta levels normalized after completion of ECT series. Seventy per cent (n=23) of ECT recipients showed clinical response and 42% (n=10) reached remission. Neither IL-6 nor TGF-beta changes correlated with clinical improvement following ECT. No significant changes in IL-10, TNF-alpha and CRP levels were found in relation to melancholia or response to ECT. Limitations: As a naturalistic study, some potential confounders could not be eliminated or controlled, including medication use. Conclusions: Melancholic depressed patients demonstrated a peripheral increase in IL-6 and reduction in TGF-beta, which did not normalize despite clinical response to ECT. These findings may be consistent with emerging hypotheses of the role of inflammation in mediating neurotrophin expression. The implications of chronic inflammation in the melancholic depressed population for future medical health, particularly cardiovascular risk, are largely unknown and warrant further investigation. (C) 2016 Elsevier B.V. All rights reserved. C1 [Rush, Gavin; Nagle, Laura; Conway, Catherine; Lucey, James V.] St Patricks Univ Hosp, Dublin, Ireland. [O'Donovan, Aoife; McCrohan, AnnMaria; Malone, Kevin M.] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland. [O'Donovan, Aoife; McCrohan, AnnMaria; Malone, Kevin M.] St Vincents Univ Hosp, Dept Psychiat Psychotherapy & Mental Hlth Res, Dublin, Ireland. [O'Donovan, Aoife] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA USA. [O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [O'Farrelly, Cliona] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin, Ireland. RP Rush, G (reprint author), St Patricks Univ Hosp, Dublin, Ireland. EM grush@stpatsmail.com OI Malone, Kevin M/0000-0001-5665-4706 FU NIMH NIH HHS [K01 MH109871] NR 97 TC 0 Z9 0 U1 8 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD NOV 15 PY 2016 VL 205 BP 60 EP 68 DI 10.1016/j.jad.2016.06.035 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DY9GC UT WOS:000385440900007 PM 27414954 ER PT J AU Banerjee, S Jeon-Slaughter, H Tsai, S Mohammad, A Foteh, M Abu-Fadel, M Gigliotti, OS Cawich, I Rodriguez, G Kumbhani, D Addo, T Luna, M Das, TS Prasad, A Armstrong, EJ Shammas, NW Brilakis, ES AF Banerjee, Subhash Jeon-Slaughter, Haekyung Tsai, Shirling Mohammad, Atif Foteh, Mazin Abu-Fadel, Mazen Gigliotti, Osvaldo S. Cawich, Ian Rodriguez, Gerardo Kumbhani, Dharam Addo, Tayo Luna, Michael Das, Tony S. Prasad, Anand Armstrong, Ehrin J. Shammas, Nicolas W. Brilakis, Emmanouil S. TI Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE chronic total occlusion; cost-benefit analysis; peripheral artery disease ID VASCULAR INTERVENTION; CARE AB OBJECTIVES The aim of this study was to assess actual procedural costs and outcomes comparing wire-catheter and dedicated chronic total occlusion (CTO) device strategies to cross peripheral artery CTOs. BACKGROUND Peripheral artery CTO interventions are frequently performed, but there are limited data on actual procedural costs and outcomes comparing wire-catheter and dedicated CTO devices. METHODS The XLPAD (Excellence in Peripheral Artery Disease Intervention) registry (NCT01904851) was accessed to retrospectively compare cost and 30-day and 12-month outcomes of wire-catheter and crossing device strategies for treatment of infrainguinal peripheral artery CTO. RESULTS Of all 3,234 treated lesions, 42% (n = 1,362) were CTOs in 1,006 unique patients. Wire-catheter approaches were used in 82% of CTOs, whereas dedicated CTO devices were used in 18% (p < 0.0001). CTO crossing device use was associated with significantly higher technical success (74% vs. 65%; p < 0.0001) and mean procedure cost($7,800.09 vs. $4,973.24; p < 0.0001). Because 12-month repeat revascularization (11.3% vs. 17.2%; p = 0.02) and amputation rates (2.8% vs. 8.5%; p = 0.002) in the CTO crossing device arm were lower compared with the wire-catheter group, the net cost for an initial CTO crossing device strategy was $423.80 per procedure. CONCLUSIONS An initial wire-catheter approach to cross a peripheral artery CTO is most frequently adopted. The use of dedicated CTO crossing devices provides significantly higher technical success and lower reintervention and amputation rates, at a net cost of $423.80 per procedure at 12 months. (C) 2016 by the American College of Cardiology Foundation. C1 [Banerjee, Subhash; Jeon-Slaughter, Haekyung; Tsai, Shirling; Mohammad, Atif; Kumbhani, Dharam; Addo, Tayo; Luna, Michael; Brilakis, Emmanouil S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Banerjee, Subhash; Jeon-Slaughter, Haekyung; Tsai, Shirling; Brilakis, Emmanouil S.] VA North Texas Hlth Care Syst, 4500 S Lancaster Rd,111a, Dallas, TX 75216 USA. [Foteh, Mazin] Cardiothorac & Vasc Surg, Austin, TX USA. [Abu-Fadel, Mazen] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Gigliotti, Osvaldo S.] Seton Med Ctr, Austin, TX USA. [Cawich, Ian; Rodriguez, Gerardo] Arkansas Heart Hosp, Little Rock, AR USA. [Das, Tony S.] Walnut Hill Med Ctr, Dallas, TX USA. [Prasad, Anand] Univ Texas San Antonio, San Antonio, TX USA. [Armstrong, Ehrin J.] Denver VA Med Ctr, Denver, CO USA. [Shammas, Nicolas W.] Midwest Cardiovasc Res Fdn, Davenport, IA USA. EM subhash.banerjee@utsouthwestern.edu FU Academic Information Systems National Institutes of Health [UL1-RR024982] FX The authors acknowledge the contributions of M. Ishti Ali, MD, to the XLPAD registry. We also acknowledge the support of the University of Texas Southwestern Medical Center in establishing and managing the RedCap database software used in the XLPAD registry (Academic Information Systems National Institutes of Health grant UL1-RR024982). NR 12 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD NOV 14 PY 2016 VL 9 IS 21 BP 2243 EP 2252 DI 10.1016/j.jcin.2016.08.010 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EI6PG UT WOS:000392617300013 PM 27832850 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Gout: will the "King of Diseases" be the first rheumatic disease to be cured? SO BMC MEDICINE LA English DT Editorial Material DE Gout; Urate-lowering therapy; Serum urate; Lesinurad; Allopurinol ID US GENERAL-POPULATION; URIC-ACID CRYSTALS; AMERICAN-COLLEGE; SERUM URATE; ALLOPURINOL; HYPERURICEMIA; PREVALENCE; MANAGEMENT; ARTHRITIS; THERAPY AB Gout is the most common inflammatory arthritis in adults in the Western world. Characterized by hyperuricemia and the effects of acute and chronic inflammation in joints and bursa, gout leads to an agonizing, chronically painful arthritis. Arthritis can also be accompanied by urate nephropathy and subcutaneous urate deposits (tophi). Exciting new developments in the last decade have brought back the focus on this interesting, crystal-induced chronic inflammatory condition. New insights include the role of NALP3 inflammasome-induced inflammation in acute gout, the characterization of diagnostic signs on ultrasound and dual-energy computed tomography imaging modalities, the recognition of target serum urate less than 6 mg/day as the goal for urate-lowering therapies, and evidence-based treatment guidelines. A better understanding of disease mechanisms has enabled drug discovery - three new urate-lowering drugs have been approved in the last decade, with several more in the pipeline. We now recognize the important role that environment and genetics play in the causation of gout. A focus on the cardiac, renal, and metabolic comorbidities of gout will help translational research and discovery over the next decade. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com NR 42 TC 0 Z9 0 U1 7 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD NOV 11 PY 2016 VL 14 AR 180 DI 10.1186/s12916-016-0732-1 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA EB9QH UT WOS:000387729600001 PM 27832792 ER PT J AU Pugh, MJ Van Cott, AC Amuan, M Baca, C Rutecki, P Zack, MM Kobau, R AF Pugh, Mary Jo Van Cott, Anne C. Amuan, Megan Baca, Christine Rutecki, Paul Zack, Matthew M. Kobau, Rosemarie TI Epilepsy Among Iraq and Afghanistan War Veterans - United States, 2002-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID MORTALITY; PEOPLE C1 [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, US Dept Vet Affairs, Epilepsy Ctr Excellence, San Antonio, TX 78229 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Van Cott, Anne C.] VA Pittsburgh Hlth Care Syst, US Dept Vet Affairs, Pittsburgh, PA USA. [Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Amuan, Megan] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Baca, Christine] Univ Colorado, Sch Med, Aurora, CO USA. [Rutecki, Paul] Univ Wisconsin, US Dept Vet Affairs, Epilepsy Ctr Excellence, Middleton Mem Vet Hosp,Dept Neurol, Madison, WI 53706 USA. [Zack, Matthew M.; Kobau, Rosemarie] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, US Dept Vet Affairs, Epilepsy Ctr Excellence, San Antonio, TX 78229 USA.; Pugh, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu NR 10 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 11 PY 2016 VL 65 IS 44 BP 1224 EP 1227 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC3XJ UT WOS:000388060100005 PM 27832054 ER PT J AU Michaelidis, CI Fine, MJ Lin, CJ Linder, JA Nowalk, MP Shields, RK Zimmerman, RK Smith, KJ AF Michaelidis, Constantinos I. Fine, Michael J. Lin, Chyongchiou Jeng Linder, Jeffrey A. Nowalk, Mary Patricia Shields, Ryan K. Zimmerman, Richard K. Smith, Kenneth J. TI The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis SO BMC INFECTIOUS DISEASES LA English DT Article DE Societal costs; Antibiotic resistance; Primary care; Stewardship; Negative externality ID RESPIRATORY-TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; AMBULATORY-CARE; HEALTH; OUTCOMES; ADULTS; MANAGEMENT; PROGRAM AB Background: Ambulatory antibiotic prescribing contributes to the development of antibiotic resistance and increases societal costs. Here, we estimate the hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States. Methods: In an exploratory analysis, we used published data to develop point and range estimates for the hidden societal cost of antibiotic resistance (SCAR) attributable to each ambulatory antibiotic prescription in the United States. We developed four estimation methods that focused on the antibiotic-resistance attributable costs of hospitalization, second-line inpatient antibiotic use, second-line outpatient antibiotic use, and antibiotic stewardship, then summed the estimates across all methods. Results: The total SCAR attributable to each ambulatory antibiotic prescription was estimated to be $13 (range: $3-$95). The greatest contributor to the total SCAR was the cost of hospitalization ($9; 69 % of the total SCAR). The costs of second-line inpatient antibiotic use ($1; 8 % of the total SCAR), second-line outpatient antibiotic use ($2; 15 % of the total SCAR) and antibiotic stewardship ($1; 8 %). This apperars to be an error.; of the total SCAR) were modest contributors to the total SCAR. Assuming an average antibiotic cost of $20, the total SCAR attributable to each ambulatory antibiotic prescription would increase antibiotic costs by 65 % (range: 15-475 %) if incorporated into antibiotic costs paid by patients or payers. Conclusions: Each ambulatory antibiotic prescription is associated with a hidden SCAR that substantially increases the cost of an antibiotic prescription in the United States. This finding raises concerns regarding the magnitude of misalignment between individual and societal antibiotic costs. C1 [Michaelidis, Constantinos I.; Linder, Jeffrey A.] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA. [Fine, Michael J.; Shields, Ryan K.; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Lin, Chyongchiou Jeng; Nowalk, Mary Patricia; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA USA. [Michaelidis, Constantinos I.] Brigham & Womens Hosp, Internal Med, PGY 3, 75 Frances St, Boston, MA 02115 USA. RP Michaelidis, CI (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA.; Michaelidis, CI (reprint author), Brigham & Womens Hosp, Internal Med, PGY 3, 75 Frances St, Boston, MA 02115 USA. EM cmichaelidis@partners.org FU National Institutes of Health [T32AG21885, RC4 AG039115, KL2TR000146]; National Institute of Allergy and Infectious Diseases [R21 AI097759, R01AI076256]; Agency for Healthcare Research and Quality [R18 HS018419]; Doris Duke Charitable Foundation; University of Pittsburgh School of Medicine Clinical Scientist Training Program FX This work was supported by the National Institutes of Health [grant numbers T32AG21885 to CIM, RC4 AG039115 to JAL, KL2TR000146 to RKS], the National Institute of Allergy and Infectious Diseases [grant numbers R21 AI097759 to JAL, R01AI076256 to KJS], the Agency for Healthcare Research and Quality [grant number R18 HS018419 to JAL], the Doris Duke Charitable Foundation, and the University of Pittsburgh School of Medicine Clinical Scientist Training Program. NR 39 TC 0 Z9 0 U1 7 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD NOV 8 PY 2016 VL 16 AR 655 DI 10.1186/s12879-016-1990-4 PG 8 WC Infectious Diseases SC Infectious Diseases GA EB9PQ UT WOS:000387727900002 PM 27825306 ER PT J AU Verhulst, S Best, J Syn, WK Reynaert, H Hellemans, KH Canbay, A Dolle, L van Grunsven, LA AF Verhulst, Stefaan Best, Jan Syn, Wing-Kin Reynaert, Hendrik Hellemans, Karine H. Canbay, Ali Dolle, Laurent van Grunsven, Leo A. TI Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice SO SCIENTIFIC REPORTS LA English DT Article ID LIVER PROGENITOR CELLS; ETHIONINE-SUPPLEMENTED DIET; SEVERE ALCOHOLIC HEPATITIS; TUMOR-NECROSIS-FACTOR; INDUCED MOUSE MODEL; OVAL CELL; STEM/PROGENITOR CELLS; CHOLINE-DEFICIENT; DISEASE SEVERITY; TNF-ALPHA AB Chronic hepatic injury is accompanied by a ductular response that is strongly correlated with disease severity and progression of fibrosis. To investigate whether anti-inflammatory drugs can modulate the ductular response, we treated mice suffering from a steatotic or cholestatic injury with anti-TNF-alpha antibodies (Infliximab) or glucocorticoids (Dexamethasone). We discovered that Dexamethasone and Infliximab can both modulate the adaptive remodeling of the biliary architecture that occurs upon liver injury and limit extracellular matrix deposition. Infliximab treatment, at least in these steatotic and cholestatic mouse models, is the safer approach since it does not increase liver injury, allows inflammation to take place but inhibits efficiently the ductular response and extracellular matrix deposition. Infliximab-based therapy could, thus, still be of importance in multiple chronic liver disorders that display a ductular response such as alcoholic liver disease or sclerosing cholangitis. C1 [Verhulst, Stefaan; Best, Jan; Reynaert, Hendrik; Dolle, Laurent; van Grunsven, Leo A.] Vrije Univ Brussel, Lab Liver Cell Biol, Brussels, Belgium. [Best, Jan; Canbay, Ali] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, Duisburg, Germany. [Syn, Wing-Kin] Ralph H Johnson VAMC, Gastroenterol Sect, Charleston, SC USA. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC USA. [Hellemans, Karine H.] VUB, Unit Diabet Pathol & Therapy, Brussels, Belgium. RP van Grunsven, LA (reprint author), Vrije Univ Brussel, Lab Liver Cell Biol, Brussels, Belgium. EM lvgrunsv@vub.ac.be RI van Grunsven, Leo/E-5839-2010 OI van Grunsven, Leo/0000-0002-0990-7034 FU Institute for the Promotion of Innovation through Science and Technology in Flanders [IWT/SB/121548]; Foundation for Liver Research, UK; Research Foundation Flanders (FWO) [G.0428.09N]; VUB-research council [OZR1914]; Interuniversity Attraction Poles (Federal Science Policy) [BELSPO P7/47]; Innoviris-Impulse program (Brussels Government) [2011-IPLS-104-Brustem]; FWO [G.0348.13N] FX We thank D. Blyweert and K. Lagaisse for their excellent technical assistance. The TROMA-III antibody was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of NICHD and maintained by The University of Iowa. We are grateful to Prof. P. In 't Veld for the use of the Nikon microscope. S.V. was supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT/SB/121548), W.K.S.: Foundation for Liver Research, UK; K.H.: Research Foundation Flanders (FWO; G.0428.09N); VUB-research council-OZR1914; L.D., J.B. and L.v.G.: Interuniversity Attraction Poles (Federal Science Policy -BELSPO P7/47); Innoviris-Impulse program 2011-IPLS-104-Brustem (Brussels Government) and FWO G.0348.13N. NR 52 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 8 PY 2016 VL 6 AR 36586 DI 10.1038/srep36586 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EB4EI UT WOS:000387322300001 PM 27824131 ER PT J AU Rogal, SS Mankaney, G Udawatta, V Chinman, M Good, CB Zickmund, S Bielefeldt, K Chidi, A Jonassaint, N Jazwinski, A Shaikh, O Hughes, C Fontes, P Humar, A DiMartini, A AF Rogal, Shari S. Mankaney, Gautham Udawatta, Viyan Chinman, Matthew Good, Chester B. Zickmund, Susan Bielefeldt, Klaus Chidi, Alexis Jonassaint, Naudia Jazwinski, Alison Shaikh, Obaid Hughes, Christopher Fontes, Paulo Humar, Abhinav DiMartini, Andrea TI Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation SO PLOS ONE LA English DT Article ID HEALTH-CARE UTILIZATION; LONG-TERM SURVIVAL; HEART-FAILURE; ANTIDEPRESSANT USE; ELDERLY-PATIENTS; HEPATITIS-C; MORTALITY; SYMPTOMS; OUTCOMES; DISEASE AB Depression after liver transplantation has been associated with decreased survival, but the effects of pre-transplant depression on early and late post-transplant outcomes remain incompletely evaluated. We assessed all patients who had undergone single-organ liver transplantation at a single center over the prior 10 years. A diagnosis of pre-transplant depression, covariates, and the outcomes of interest were extracted from the electronic medical record. Potential covariates included demographics, etiology and severity of liver disease, comorbidities, donor age, graft type, immunosuppression, and ischemic times. In multivariable models adjusting for these factors, we evaluated the effect of pre-transplant depression on transplant length of stay (LOS), discharge disposition (home vs. facility) and long-term survival. Among 1115 transplant recipients with a median follow-up time of 5 years, the average age was 56 +/- 11 and MELD was 12 +/- 9. Nineteen percent of the study population had a history of pre-transplant depression. Pre-transplant depression was associated with longer LOS (median = 19 vs. 14 days, IRR = 1.25, CI = 1.13,1.39), discharge to a facility (36% vs. 25%, OR 1.70, CI = 1.18,2.45), and decreased survival (HR = 1.54, CI = 1.14,2.08) in this cohort, accounting for other potential confounders. In conclusion, pre-transplant depression was significantly associated with longer transplant length of stay, discharge to a facility, and mortality in this cohort. C1 [Rogal, Shari S.; Chinman, Matthew; Good, Chester B.; Zickmund, Susan; Chidi, Alexis] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. [Rogal, Shari S.; Shaikh, Obaid; Hughes, Christopher; Fontes, Paulo; Humar, Abhinav] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. [Rogal, Shari S.; Bielefeldt, Klaus; Jonassaint, Naudia; Jazwinski, Alison; Shaikh, Obaid] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA. [Mankaney, Gautham; Udawatta, Viyan; Good, Chester B.; Zickmund, Susan; Chidi, Alexis] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA USA. [DiMartini, Andrea] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Rogal, SS (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA.; Rogal, SS (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.; Rogal, SS (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA. EM rogalss@upmc.edu FU Rand Corporation FX The authors received no specific funding for this work. MC is employed by Rand Corporation. Rand Corporation provided support in the form of salaries for author MC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the "author contributions" section. NR 28 TC 0 Z9 0 U1 6 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2016 VL 11 IS 11 AR e0165517 DI 10.1371/journal.pone.0165517 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EB8BB UT WOS:000387614800010 PM 27820828 ER PT J AU Henihan, AM McCombe, G Klimas, J Swan, D Leahy, D Anderson, R Bury, G Dunne, CP Keenan, E Lambert, JS Meagher, D O'Gorman, C O'Toole, TP Saunders, J Shorter, GW Smyth, BP Kaner, E Cullen, W AF Henihan, Anne Marie McCombe, Geoff Klimas, Jan Swan, Davina Leahy, Dorothy Anderson, Rolande Bury, Gerard Dunne, Colum P. Keenan, Eamon Lambert, John S. Meagher, David O'Gorman, Clodagh O'Toole, Tom P. Saunders, Jean Shorter, Gillian W. Smyth, Bobby P. Kaner, Eileen Cullen, Walter TI Feasibility of alcohol screening among patients receiving opioid treatment in primary care SO BMC FAMILY PRACTICE LA English DT Article DE Alcohol; Primary care; Screening; Agonist treatment; Methadone; General practice; Implementation; Feasibility; Brief intervention; SBIRT ID PRIMARY-HEALTH-CARE; PROBLEM DRUG-USERS; GENERAL-PRACTITIONERS; BRIEF INTERVENTIONS; TREATMENT SBIRT; AUDIT-C; PILOT; IMPLEMENTATION; CONSUMPTION; STRATEGIES AB Background: Identifying and treating problem alcohol use among people who also use illicit drugs is a challenge. Primary care is well placed to address this challenge but there are several barriers which may prevent this occurring. The objective of this study was to determine if a complex intervention designed to support screening and brief intervention for problem alcohol use among people receiving opioid agonist treatment is feasible and acceptable to healthcare providers and their patients in a primary care setting. Methods: A randomised, controlled, pre- and-post design measured feasibility and acceptability of alcohol screening based on recruitment and retention rates among patients and practices. Efficacy was measured by screening and brief intervention rates and the proportion of patients with problem alcohol use. Results: Of 149 practices that were invited, 19 (12.8 %) agreed to participate. At follow up, 13 (81.3 %) practices with 81 (62.8 %) patients were retained. Alcohol screening rates in the intervention group were higher at follow up than in the control group (53 % versus 26 %) as were brief intervention rates (47 % versus 19 %). Four (18 %) people reduced their problem drinking (measured by AUDIT-C), compared to two (7 %) in the control group. Conclusions: Alcohol screening among people receiving opioid agonist treatment in primary care seems feasible. A definitive trial is needed. Such a trial would require over sampling and greater support for participating practices to allow for challenges in recruitment of patients and practices. C1 [Henihan, Anne Marie; McCombe, Geoff; Klimas, Jan; Swan, Davina; Leahy, Dorothy; Dunne, Colum P.; Meagher, David; O'Gorman, Clodagh; Saunders, Jean; Cullen, Walter] Univ Limerick, Grad Entry Med Sch, Fac Educ & Hlth Sci, Limerick, Ireland. [Henihan, Anne Marie; McCombe, Geoff; Klimas, Jan; Swan, Davina; Bury, Gerard; Lambert, John S.; Cullen, Walter] Univ Coll Dublin, UCD Sch Med, Dublin 4, Ireland. [Klimas, Jan] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada. [Swan, Davina] Kings Coll London, Inst Psychiat Psychol & Neurosci, Addict Dept, 4 Windsor Walk,Denmark Hill, London SE5 8BB, England. [Anderson, Rolande] Addict Counsellor, Suite 33,Morrison Chambers 32,Nassau St, Dublin 2, Ireland. [Keenan, Eamon] Hlth Serv Execut, Addict Serv, Dublin, Ireland. [O'Toole, Tom P.] Brown Alpert Med Sch, Providence, RI USA. [Saunders, Jean] Univ Limerick, CSTAR Ctr, Limerick, Ireland. [Shorter, Gillian W.; Smyth, Bobby P.] Trinity Coll Dublin, Sch Nursing & Midwifery, Trinity Ctr Practice & Healthcare Innovat, Dublin, Ireland. [Smyth, Bobby P.] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland. [Kaner, Eileen] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England. [Cullen, Walter] US Dept Vet Affairs, Washington, DC USA. RP Cullen, W (reprint author), Univ Limerick, Grad Entry Med Sch, Fac Educ & Hlth Sci, Limerick, Ireland.; Cullen, W (reprint author), Univ Coll Dublin, UCD Sch Med, Dublin 4, Ireland.; Cullen, W (reprint author), US Dept Vet Affairs, Washington, DC USA. EM Walter.Cullen@ucd.ie RI Smyth, Bobby/D-1205-2017 OI Kaner, Eileen/0000-0002-7169-9344 FU Health Research Board of Ireland [HRA-HSR-2012-14]; ELEVATE: Irish Research Council International Career Development Fellowship (Marie Cure Actions) [ELEVATEPD/2014/6]; 'Hepcare Europe' (European Commission 3rd Health Programme) FX Health Research Board of Ireland funded the study (Grant ID: HRA-HSR-2012-14). Dr Klimas work was also part funded by ELEVATE: Irish Research Council International Career Development Fellowship (Marie Cure Actions ELEVATEPD/2014/6); Dr Lambert's work on the project was part funded by 'Hepcare Europe' (European Commission 3rd Health Programme). NR 38 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2296 J9 BMC FAM PRACT JI BMC Fam. Pract. PD NOV 5 PY 2016 VL 17 AR 153 DI 10.1186/s12875-016-0548-2 PG 10 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA EA9QD UT WOS:000386978000002 PM 27816057 ER PT J AU Lee, J Horan, WP Wynn, JK Green, MF AF Lee, Junghee Horan, William P. Wynn, Jonathan K. Green, Michael F. TI Neural Correlates of Belief and Emotion Attribution in Schizophrenia SO PLOS ONE LA English DT Article ID SOCIAL COGNITION; BRAIN IMAGES; MIND; FMRI; METAANALYSIS; EMPATHY; ROBUST; OPTIMIZATION; REGISTRATION; IMPAIRMENT AB Impaired mental state attribution is a core social cognitive deficit in schizophrenia. With functional magnetic resonance imaging (fMRI), this study examined the extent to which the core neural system of mental state attribution is involved in mental state attribution, focusing on belief attribution and emotion attribution. Fifteen schizophrenia outpatients and 14 healthy controls performed two mental state attribution tasks in the scanner. In a Belief Attribution Task, after reading a short vignette, participants were asked infer either the belief of a character (a false belief condition) or a physical state of an affair (a false photograph condition). In an Emotion Attribution Task, participants were asked either to judge whether character(s) in pictures felt unpleasant, pleasant, or neutral emotion (other condition) or to look at pictures that did not have any human characters (view condition). fMRI data were analyzing focusing on a priori regions of interest (ROIs) of the core neural systems of mental state attribution: the medial prefrontal cortex (mPFC), temporoparietal junction (TPJ) and precuneus. An exploratory whole brain analysis was also performed. Both patients and controls showed greater activation in all four ROIs during the Belief Attribution Task than the Emotion Attribution Task. Patients also showed less activation in the precuneus and left TPJ compared to controls during the Belief Attribution Task. No significant group difference was found during the Emotion Attribution Task in any of ROIs. An exploratory whole brain analysis showed a similar pattern of neural activations. These findings suggest that while schizophrenia patients rely on the same neural network as controls do when attributing beliefs of others, patients did not show reduced activation in the key regions such as the TPJ. Further, this study did not find evidence for aberrant neural activation during emotion attribution or recruitment of compensatory brain regions in schizophrenia. C1 [Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lee, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.; Lee, J (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM jungheelee@ucla.edu FU Department of Veterans Affairs, Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC) PALA Pilot Grant; National Institute of Mental Health [MH43292, MH065707]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund FX This study is supported by Department of Veterans Affairs, Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC) PALA Pilot Grant (PI: JL), and National Institute of Mental Health Grants MH43292 and MH065707 (PI: MFG). For generous support, we would like to thank the Brain Mapping Medical Research Organization, the Brain Mapping Support Foundation, the Pierson-Lovelace Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation, the Capital Group Companies Charitable Foundation, the Robson Family and the Northstar Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 0 Z9 0 U1 4 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 3 PY 2016 VL 11 IS 11 AR e0165546 DI 10.1371/journal.pone.0165546 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EA8SX UT WOS:000386910000035 PM 27812142 ER PT J AU Nyendak, M Swarbrick, GM Duncan, A Cansler, M Huff, EW Hokey, D Evans, T Barker, L Blatner, G Sadoff, J Douoguih, M Pau, MG Lewinsohn, DA Lewinsohn, DM AF Nyendak, Melissa Swarbrick, Gwendolyn M. Duncan, Amanda Cansler, Meghan Huff, Ervina Winata Hokey, David Evans, Tom Barker, Lewellys Blatner, Gretta Sadoff, Jerald Douoguih, Macaya Pau, Maria Grazia Lewinsohn, Deborah A. Lewinsohn, David M. TI Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine SO SCIENTIFIC REPORTS LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; PROTECTIVE IMMUNITY; CD8+T CELLS; BCG; CD4(+); RESPONSES; ANTIGEN; EPITOPE; MEMORY; ESAT-6 AB The development of a vaccine for Mycobacterium tuberculosis (Mtb) has been impeded by the absence of correlates of protective immunity. One correlate would be the ability of cells induced by vaccination to recognize the Mtb-infected cell. AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA expressing a fusion protein of Mtb antigens 85A, 85B and TB10.4. We undertook a phase I double-blind, randomized placebo controlled trial of vaccination with AERAS-402 following BCG. Analysis of the vaccine-induced immune response revealed strong antigen-specific polyfunctional CD4(+) and CD8(+) T cell responses. However, analysis of the vaccine-induced CD8(+) T cells revealed that in many instances these cells did not recognize the Mtb-infected cell. Our findings highlight the measurement of vaccine-induced, polyfunctional T cells may not reflect the extent or degree to which these cells are capable of identifying the Mtb-infected cell and correspondingly, the value of detailed experimental medicine studies early in vaccine development. C1 [Nyendak, Melissa; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Swarbrick, Gwendolyn M.; Duncan, Amanda; Cansler, Meghan; Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Swarbrick, Gwendolyn M.; Huff, Ervina Winata; Lewinsohn, David M.] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. [Hokey, David; Evans, Tom; Barker, Lewellys; Blatner, Gretta] Aeras, Rockville, MD USA. [Sadoff, Jerald; Douoguih, Macaya; Pau, Maria Grazia] Janssen Infect Dis & Vaccines, Leiden, Netherlands. RP Nyendak, M; Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.; Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.; Lewinsohn, DM (reprint author), Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. EM nyendakm@ohsu.edu; lewinsod@ohsu.edu FU Aeras Global Tuberculosis Vaccine Foundation; NIH [HHSN272200900053C, R01 AI048090]; NIH National Center for Research Resources grant [KL2RR02414]; Merit Review Awards from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development [I01 BX000533] FX The authors acknowledge the contributions of Sean Bennett MD (AERAS), Melissa Kumagai, Phyllis Carello and staff from the Oregon Clinical and Translational Institute at Oregon Health and Science University, and Erin Merrifield (OHSU) for IRB support. We also acknowledge Jenny Hendriks and Maria Grazia Pau for review of the manuscript. We thank the study participants without whom this study would not be possible. This work was supported by the following agency and institutes: the Aeras Global Tuberculosis Vaccine Foundation, NIH contract, HHSN272200900053C, and the NIH National Center for Research Resources grant KL2RR02414 (MN). This work was also supported by Merit Review Awards I01 BX000533 (DML) from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development and resources and the use of facilities at the VA Portland Health Care System and from the NIH R01 AI048090 (DML); The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 44 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 2 PY 2016 VL 6 AR 36355 DI 10.1038/srep36355 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EA6TP UT WOS:000386762200001 PM 27805026 ER PT J AU Zuschlag, Z Kennedy, A Korte, J Franko-Tobin, L Hartwell, K Hamner, M AF Zuschlag, Zachary Kennedy, Alyssa Korte, Jeffrey Franko-Tobin, Laura Hartwell, Karen Hamner, Mark TI DSM-5-defined attenuated psychosis syndrome and conversion to full-scale schizophrenia spectrum disorders: An institution-wide retrospective review SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Review ID HIGH-CLINICAL-RISK; ULTRA-HIGH RISK; UNTREATED PSYCHOSIS; CANNABIS USE; UNITED-STATES; FOLLOW-UP; DSM-V; AMERICAN; RELIABILITY; DIAGNOSIS AB BACKGROUND: The objective of the studywas to determine if DSM-5-defined attenuated psychosis syndrome (APS) could identify individuals with prodromal psychosis and predict conversion to schizophrenia spectrum disorders at a rate similar to that observed in previous studies that utilized structured interviews and specialized rating scales. METHODS: A retrospective review of patients' medical records was used to identify individuals meeting diagnostic criteria for the APS, followed by further evaluation 2 to 3 years after the initial diagnosis, to determine if they converted to schizophrenia spectrum disorders. Results then were compared with previous studies. RESULTS: Of our study population, 43.4% converted to schizophrenia or schizoaffective disorder 2 to 3 years after initial diagnosis of APS. Comparison at the 3-year mark indicated that there was no significant difference between our observed rates and previously published conversion rates (P =.066). Three covariates were found to increase significantly the rates of conversion when added to the APS criteria: Cannabis use (P =.048), lack of previous Axis I diagnosis (P =.005), and lack of previous treatment with psychotropic medications (P =.009). CONCLUSIONS: APS accurately predicts conversion to full-scale schizophrenia spectrum disorders at a rate similar to that observed in previous studies using structured interviews and specialized rating scales. C1 [Zuschlag, Zachary; Kennedy, Alyssa; Franko-Tobin, Laura; Hartwell, Karen; Hamner, Mark] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Korte, Jeffrey] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Hamner, Mark] Ralph H Johnson VA Med Ctr, Dept Psychiat, Charleston, SC USA. RP Zuschlag, Z (reprint author), 102 Doughty St, Charleston, SC 29425 USA. EM zuschlagzd@gmail.com FU Medical University of South Carolina - NIDA [R25 DA020537]; American Psychiatric Association Resident Psychiatric Research Scholars Fellowship (APA, Arlington, VA) FX This work was conducted as part of a research fellowship/resident research-training track at the Medical University of South Carolina, funded by NIDA grant R25 DA020537: PI Kathleen Brady, MD (NIDA, Bethesda, MD). Dr. Brady (PI), Dr. Sudie Back (co-I), and Dr. Sarah Book (co-I) are investigators on the grant, and provide guidance and mentorship throughout the duration of the fellowship. Dr. Brady, Dr. Back, and Dr. Book have no conflicts of interest to declare. Additional support was provided to Dr. Zuschlag as a recipient of an American Psychiatric Association Resident Psychiatric Research Scholars Fellowship (APA, Arlington, VA). NR 51 TC 0 Z9 0 U1 2 U2 2 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD NOV PY 2016 VL 28 IS 4 BP 245 EP 254 PG 10 WC Psychiatry SC Psychiatry GA EQ5RF UT WOS:000398139600004 PM 27490838 ER PT J AU D'Souza, SL Holub, JL Pavic, BT Rodriguez, SA AF D'Souza, Sharlene L. Holub, Jennifer L. Pavic, Brian T. Rodriguez, Sarah A. TI Multicenter evaluation of the utilization of endoscopic ultrasound SO DIGESTIVE ENDOSCOPY LA English DT Article DE bile ducts; endoscopic ultrasonography (EUS); endoscopic ultrasound; guided fine-needle aspiration (EUS-FNA); endoscopy; pancreas ID FINE-NEEDLE-ASPIRATION; SOLID PANCREATIC MASSES; EUS-GUIDED FNA; UNITED-STATES; AMERICAN SOCIETY; RECOMMENDATIONS; MANAGEMENT; PATTERNS; TUMORS AB Background and Aim: There are currently no data regarding the number and type of endoscopic ultrasound (EUS) procedures being carried out in the USA. The aims of the present study are to: (i) estimate the annual number of EUS procedures being carried out in a nationwide database; (ii) describe the indications and types of EUS carried out; and (iii) examine short-term trends in volume. Methods: Retrospective analysis from the Clinical Outcomes Research Initiative (CORI) of EUS procedures carried out on patients >18 years of age from 1 January 2010 through 31 December 2013. Results: EUS cases (n = 7614) were carried out by 68 endoscopists at 18 sites over the study period, representing 1.7% of the total number of endoscopic procedures. The most common indications were evaluation of a pancreatic mass (14.7%), diagnostic sampling with fine-needle aspiration (14.1%), and evaluation of a pancreatic cyst (14.0%). The number of EUS examinations and cases undergoing same-day endoscopic retrograde cholangiopancreatography (ERCP) increased over the study period (P < 0.0001). Use of general anesthesia or deep sedation increased markedly from 37.8% to 82.8% of procedures (P < 0.0001). Conclusions: This is the largest survey of EUS practice in the USA. Evaluation of the pancreas accounts for approximately 40% of the indications for EUS. Use of EUS increased over the study period, and the proportion carried out with deep sedation or general anesthesia also increased. These data may have implications regarding the number of endosonographers who should be trained, as well as cost issues pertaining to increasing use of anesthesia providers and same-day ERCP. C1 [D'Souza, Sharlene L.] Portland VA Med Ctr, Dept Gastroenterol & Hepatol, Portland, OR USA. [D'Souza, Sharlene L.; Holub, Jennifer L.] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR 97201 USA. [Pavic, Brian T.] Legacy Meridian Pk Med Ctr, Dept Internal Med, Tualatin, OR USA. [Rodriguez, Sarah A.] Oregon Clin, Portland, OR USA. RP D'Souza, SL (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3GI, Portland, OR 97230 USA. EM dsouzas@ohsu.edu FU NIDDK [U01DK57132, R33-DK61778-01] FX THE CORI DATABASE is supported with funding from NIDDK U01DK57132 and R33-DK61778-01. NR 18 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0915-5635 EI 1443-1661 J9 DIGEST ENDOSC JI Dig. Endosc. PD NOV PY 2016 VL 28 IS 7 BP 738 EP 743 DI 10.1111/den.12659 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA EQ9HA UT WOS:000398394300005 PM 27010598 ER PT J AU Wright, R Malec, M Shega, JW Rodriguez, E Kulas, J Morrow, L Rodakowski, J Semla, T Weiner, DK AF Wright, Rollin Malec, Monica Shega, Joseph W. Rodriguez, Eric Kulas, Joseph Morrow, Lisa Rodakowski, Juleen Semla, Todd Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part XI: Dementia SO PAIN MEDICINE LA English DT Article DE Dementia; Chronic Pain; Low Back Pain; Lumbar; Primary Care ID MILD COGNITIVE IMPAIRMENT; SELF-REPORT; MINI-COG; PEOPLE; EXPERIENCE; MANAGEMENT; RESIDENTS; DIAGNOSIS; HEALTH AB Objective. To present the 11th in a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults. The series presents CLBP as a syndrome, a final common pathway for the expression of multiple contributors rather than a disease localized exclusively to the lumbosacral spine. Each article addresses one of 12 important contributions to pain and disability in older adults with CLBP. This article focuses on dementia. Methods. A modified Delphi technique was used to develop an algorithm for an approach to treatment for older adults living with CLBP and dementia. A panel of content experts on pain and cognition in older adults developed the algorithm through an iterative process. Though developed using resources available within Veterans Health Administration (VHA) facilities, the algorithm is applicable across all health care settings. A case taken from the clinical practice of one of the contributors demonstrates application of the algorithm. Results. We present an evidence-based algorithm and biopsychosocial rationale to guide providers evaluating CLBP in older adults who may have dementia. The algorithm considers both subtle and overt signs of dementia, dementia screening tools to use in practice, referrals to appropriate providers for a complete a workup for dementia, and clinical considerations for persons with dementia who report pain and/or exhibit pain behaviors. A case of an older adult with CLBP and dementia is presented that highlights how an approach that considers the impact of dementia on verbal and nonverbal pain behaviors may lead to more appropriate and successful pain management. Conclusions. Comprehensive pain evaluation for older adults in general and for those with CLBP in particular requires both a medical and a biopsychosocial approach that includes assessment of cognitive function. A positive screen for dementia may help explain why reported pain severity does not improve with usual or standard-of-care pain management interventions. Pain reporting in a person with dementia does not always necessitate pain treatment. Pain reporting in a person with dementia who also displays signs of pain-associated suffering requires concerted pain management efforts targeted to improving function while avoiding harm in these vulnerable patients. C1 [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Wright, Rollin; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Morrow, Lisa] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Malec, Monica] Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Semla, Todd] VITAS Healthcare, Miami, FL USA. [Shega, Joseph W.] Univ Cent Florida, Orlando, FL 32816 USA. [Kulas, Joseph] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Kulas, Joseph] Yale Sch Med, New Haven, CT USA. [Semla, Todd] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA USA. Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Semla, Todd] Natl Pharm Benefits Management Serv, US Dept Vet Affairs, Hines, IL USA. [Semla, Todd] Northwestern Univ, Dept Psychiat, Chicago, IL 60611 USA. [Semla, Todd] Northwestern Univ, Dept Behav Sci, Chicago, IL 60611 USA. RP Wright, R (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. OI Rodakowski, Juleen/0000-0002-6397-8124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 49 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD NOV PY 2016 VL 17 IS 11 BP 1993 EP 2002 DI 10.1093/pm/pnw247 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA ER4DA UT WOS:000398748100005 PM 27880650 ER PT J AU Mizoguchi, T Liu, R Xuan, Y Dvir, D Ye, J Ge, L Tseng, E AF Mizoguchi, Trek Liu, Raymond Xuan, Yue Dvir, Danny Ye, Jian Ge, Liang Tseng, Elaine TI Leaflet Stresses of Sapien 3 Transcatheter Aortic Valve: Implications for Durability SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 28th Annual Transcatheter Cardiovascular Therapeutics Symposium (TCT) CY OCT 29-NOV 02, 2016 CL Washington, DC C1 [Mizoguchi, Trek; Liu, Raymond; Xuan, Yue; Ge, Liang; Tseng, Elaine] UCSF Med Ctr, San Francisco, CA USA. [Mizoguchi, Trek; Liu, Raymond; Xuan, Yue; Ge, Liang; Tseng, Elaine] San Francisco VA Med Ctr, San Francisco, CA USA. [Dvir, Danny] Univ Washington, Seattle, WA 98195 USA. [Ye, Jian] Univ British Columbia, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 1 PY 2016 VL 68 IS 18 SU S MA TCT-741 BP B299 EP B300 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ER1YF UT WOS:000398590400261 PM 27970122 ER PT J AU Yee, J Higgins, J Kumar, V Anuwatworn, AS Li, SJ Pham, A Stys, J Petraskova, T Thompson, P Stys, A Petrasko, M Stys, T AF Yee, Jimmy Higgins, James Kumar, Vishesh Anuwatworn, Amornpol (Song) Li, Shenjing Pham, Alexander Stys, Julia Petraskova, Terezia Thompson, Paul Stys, Adam Petrasko, Marian Stys, Tomasz TI Patient Characteristics Influencing Physician Selection of Radial vs. Femoral Access in patients presenting emergently with STElevation Myocardial Infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 28th Annual Transcatheter Cardiovascular Therapeutics Symposium (TCT) CY OCT 29-NOV 02, 2016 CL Washington, DC C1 [Yee, Jimmy; Anuwatworn, Amornpol (Song)] Univ South Dakota, Sanford Sch Med, Sioux Falls, SD USA. [Higgins, James] Sandro Pertini Hosp, Intervent Cardiol, Rome, Italy. [Kumar, Vishesh] CSI, Sioux Falls, SD USA. [Pham, Alexander] MedStar Washington Hosp Ctr, Washington, DC USA. [Stys, Julia; Thompson, Paul] Dallas VA Med Ctr, Dallas, TX USA. [Stys, Julia; Thompson, Paul] UT Southwestern, Dallas, TX USA. [Petraskova, Terezia] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Stys, Adam; Petrasko, Marian; Stys, Tomasz] Sanford Cardiovasc Inst, Sioux Falls, SD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 1 PY 2016 VL 68 IS 18 SU S MA TCT-363 BP B149 EP B149 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4EG UT WOS:000397332900358 PM 27969711 ER PT J AU Almario, CV Chey, WD Khanna, D Mosadeghi, S Ahmed, S Afghani, E Whitman, C Fuller, G Reid, M Bolus, R Dennis, B Encarnacion, R Martinez, B Soares, J Modi, R Agarwal, N Lee, A Kubomoto, S Sharma, G Bolus, S Spiegel, BMR AF Almario, Christopher V. Chey, William D. Khanna, Dinesh Mosadeghi, Sasan Ahmed, Shahzad Afghani, Elham Whitman, Cynthia Fuller, Garth Reid, Mark Bolus, Roger Dennis, Buddy Encarnacion, Rey Martinez, Bibiana Soares, Jennifer Modi, Rushaba Agarwal, Nikhil Lee, Aaron Kubomoto, Scott Sharma, Gobind Bolus, Sally Spiegel, Brennan M. R. TI Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PATIENT-REPORTED OUTCOMES; INFORMATION-SYSTEM PROMIS; PSYCHOMETRIC PROPERTIES; SYMPTOM SCALES; LIFE; CARE; DISPARITIES; COMPUTER AB OBJECTIVES: The National Institutes of Health (NIH) created the Patient Reported Outcomes Measurement Information System (PROMIS) to allow efficient, online measurement of patient-reported outcomes (PROs), but it remains untested whether PROMIS improves outcomes. Here, we aimed to compare the impact of gastrointestinal (GI) PROMIS measures vs. usual care on patient outcomes. METHODS: We performed a pragmatic clinical trial with an off-on study design alternating weekly between intervention (GI PROMIS) and control arms at one Veterans Affairs and three university-affiliated specialty clinics. Adults with GI symptoms were eligible. Intervention patients completed GI PROMIS symptom questionnaires on an e-portal 1 week before their visit; PROs were available for review by patients and their providers before and during the clinic visit. Usual care patients were managed according to customary practices. Our primary outcome was patient satisfaction as determined by the Consumer Assessment of Healthcare Providers and Systems questionnaire. Secondary outcomes included provider interpersonal skills (Doctors' Interpersonal Skills Questionnaire (DISQ)) and shared decision-making (9-item Shared Decision Making Questionnaire (SDM-Q-9)). RESULTS: There were 217 and 154 patients in the GI PROMIS and control arms, respectively. Patient satisfaction was similar between groups (P>0.05). Intervention patients had similar assessments of their providers' interpersonal skills (DISQ 89.4 +/- 11.7 vs. 89.8 +/- 16.0, P=0.79) and shared decisionmaking (SDM-Q-9 79.3 +/- 12.4 vs. 79.0 +/- 22.0, P=0.85) vs. controls. CONCLUSIONS: This is the first controlled trial examining the impact of NIH PROMIS in clinical practice. One-time use of GI PROMIS did not improve patient satisfaction or assessment of provider interpersonal skills and shared decision-making. Future studies examining how to optimize PROs in clinical practice are encouraged before widespread adoption. C1 [Almario, Christopher V.; Afghani, Elham; Whitman, Cynthia; Fuller, Garth; Martinez, Bibiana; Soares, Jennifer; Spiegel, Brennan M. R.] Cedars Sinai Med Ctr, Div Gastroenterol, Pacific Theatres Bldg,116 North Robertson Blvd, Los Angeles, CA 90048 USA. [Almario, Christopher V.; Reid, Mark; Martinez, Bibiana; Soares, Jennifer; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Almario, Christopher V.; Mosadeghi, Sasan; Ahmed, Shahzad; Whitman, Cynthia; Fuller, Garth; Reid, Mark; Bolus, Roger; Martinez, Bibiana; Soares, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Lee, Aaron; Kubomoto, Scott; Sharma, Gobind; Bolus, Sally; Spiegel, Brennan M. R.] CS CORE, Los Angeles, CA USA. [Chey, William D.] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Dennis, Buddy; Encarnacion, Rey] Univ Calif Los Angeles, CTRL, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Cedars Sinai Med Ctr, Div Gastroenterol, Pacific Theatres Bldg,116 North Robertson Blvd, Los Angeles, CA 90048 USA. EM Brennan.Spiegel@cshs.org FU NIH/NIAMS research grant [U01 AR057936-05]; Career Development Award from the American College of Gastroenterology; Ironwood Pharmaceuticals FX This study was supported by an NIH/NIAMS research grant (U01 AR057936-05). Dr Almario was supported by a Career Development Award from the American College of Gastroenterology. The PROMIS-triggered HPI generator was developed under a separate grant from Ironwood Pharmaceuticals. NR 32 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2016 VL 111 IS 11 BP 1546 EP 1556 DI 10.1038/ajg.2016.305 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK6PT UT WOS:000394047300016 PM 27481311 ER PT J AU Adler, J Dominitz, JA AF Adler, Jeffrey Dominitz, Jason A. TI Financial Incentives to Improve Colorectal Cancer Screening: Does it Make Cents? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID OCCULT BLOOD-TESTS; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; UNITED-STATES; COLONOSCOPY; NAVIGATION; ADHERENCE; INCREASES; VETERANS; CARE AB While colorectal cancer screening reduces colorectal cancer incidence and mortality, there is much room for improvement in screening adherence particularly among the uninsured and ethnic minorities. In this issue, Gupta et al. conducted a randomized controlled study to test the impact of a small financial incentive on screening adherence. Their negative study, taken in the context of prior studies and behavioral economics literature, leads us to conclude that it does not pay to add this small financial incentive to community outreach. Instead, we should invest in a systematic approach to screening, including patient navigation. C1 [Adler, Jeffrey] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Adler, J (reprint author), Dartmouth Hitchcock Med Ctr, Gastroenterol & Hepatol, 1 Med Ctr Dr, Lebanon, NH 03766 USA. EM jeffrey.m.adler@hitchcock.org FU Veterans Health Administration FX This material is the result of work supported in part by resources from The Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 25 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2016 VL 111 IS 11 BP 1637 EP 1639 DI 10.1038/ajg.2016.459 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK6PT UT WOS:000394047300029 PM 27808152 ER PT J AU Okita, K Mandelkern, MA London, ED AF Okita, Kyoji Mandelkern, Mark A. London, Edythe D. TI Cigarette Use and Striatal Dopamine D2/3 Receptors: Possible Role in the Link between Smoking and Nicotine Dependence SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Article DE nicotine dependence; dopamine; D2 receptors; positron emission tomography ID REFERENCE TISSUE MODEL; UNITED-STATES; BINDING; PET; RELEASE; HUMANS; AVAILABILITY; IMPULSIVITY; TRENDS AB Background: Cigarette smoking induces dopamine release in the striatum, and smoking- or nicotine-induced ventral striatal dopamine release is correlated with nicotine dependence. Smokers also exhibit lower dopamine D2/3 receptor availability in the dorsal striatum than nonsmokers. Negative correlations of striatal dopamine D2/3 receptor availability with smoking exposure and nicotine dependence, therefore, might be expected but have not been tested. Methods: Twenty smokers had positron emission tomography scans with [F-18] fallypride to measure dopamine D2/3 receptor availability in ventral and dorsal regions of the striatum and provided self-report measures of recent and lifetime smoking and of nicotine dependence. Results: As reported before, lifetime smoking was correlated with nicotine dependence. New findings were that ventral striatal dopamine D2/3 receptor availability was negatively correlated with recent and lifetime smoking and also with nicotine dependence. Conclusion: The results suggest an effect of smoking on ventral striatal D2/3 dopamine receptors that may contribute to nicotine dependence. C1 [Okita, Kyoji; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. [London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Okita, Kyoji; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 740 Westwood Plaza,POB 175919, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu FU National Institute on Drug Abuse [R01 DA015179, R01 DA020726, P20 DA022539, T32 DA024635]; National Center for Research Resources [M01 RR00865]; Department of Psychiatry, Chiba University, DOMONKAI fund FX This research was supported, in part, by grants from the National Institute on Drug Abuse (R01 DA015179, R01 DA020726, P20 DA022539, T32 DA024635, E.D.L.) and the National Center for Research Resources (M01 RR00865), and endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies and the Marjorie M. Greene Trust. K.O. was, in part, supported by Department of Psychiatry, Chiba University, DOMONKAI fund. NR 25 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD NOV PY 2016 VL 19 IS 11 DI 10.1093/ijnpp/pyw074 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA EK4QO UT WOS:000393912100009 ER PT J AU Rabago, CA Clouser, M Dearth, CL Farrokhi, S Galarneau, MR Highsmith, MJ Wilken, JM Wyatt, MP Hill, OT AF Rabago, Christopher A. Clouser, Mary Dearth, Christopher L. Farrokhi, Shawn Galarneau, Michael R. Highsmith, M. Jason Wilken, Jason M. Wyatt, Marilynn P. Hill, Owen T. TI The Extremity Trauma and Amputation Center of Excellence: Overview of the Research and Surveillance Division SO MILITARY MEDICINE LA English DT Article ID LOWER-LIMB LOSS; ACTIVITY MOBILITY PREDICTOR; OPERATION IRAQI FREEDOM; ANKLE-FOOT PROSTHESES; TRANSTIBIAL AMPUTATION; DESTABILIZING ENVIRONMENTS; MALE SERVICEMEMBERS; C-LEG; TRANSFEMORAL AMPUTATION; DYNAMIC STABILITY AB Congress authorized creation of the Extremity Trauma and Amputation Center of Excellence (EACE) as part of the 2009 National Defense Authorization Act. The legislation mandated the Department of Defense (DoD) and Department of Veterans Affairs (VA) to implement a comprehensive plan and strategy for the mitigation, treatment, and rehabilitation of traumatic extremity injuries and amputation. The EACE also was tasked with conducting clinically relevant research, fostering collaborations, and building partnerships across multidisciplinary international, federal, and academic networks to optimize the quality of life of service members and veterans who have sustained extremity trauma or amputations. To fulfill themandate to conduct research, the EACE developed a Research and Surveillance Division that complements and collaborates with outstanding DoD, VA, and academic research programs across the globe. The EACE researchers have efforts in four key research focus areas relevant to extremity trauma and amputation: (1) Novel Rehabilitation Interventions, (2) Advanced Prosthetic and Orthotic Technologies, (3) Epidemiology and Surveillance, and (4) Medical and Surgical Innovations. This overview describes the EACE efforts to innovate, discover, and translate knowledge gleaned from collaborative research partnerships into clinical practice and policy. C1 [Rabago, Christopher A.; Clouser, Mary; Dearth, Christopher L.; Farrokhi, Shawn; Galarneau, Michael R.; Highsmith, M. Jason; Wilken, Jason M.; Hill, Owen T.] Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Joint Base San Antonio F, TX 78234 USA. [Rabago, Christopher A.; Wilken, Jason M.; Hill, Owen T.] Brooke Army Med Ctr, Dept Rehabil Med, Ctr Intrepid, 3551 Roger Brooke Dr, Joint Base San Antonio F, TX 78234 USA. [Clouser, Mary; Galarneau, Michael R.] Naval Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA. [Dearth, Christopher L.] Walter Reed Natl Mil Med Ctr, Dept Rehabil, Res & Dev Sect, 8901 Rockville Pike, Bethesda, MD 20889 USA. [Farrokhi, Shawn; Wyatt, Marilynn P.] Naval Med Ctr San Diego, Dept Phys & Occupat Therapy, 34800 Bob Wilson Dr, San Diego, CA 92134 USA. [Highsmith, M. Jason] James A Haley Vet Adm Hosp, Ctr Innovat Disabil & Rehabil Res, 8900 Grand Oak Circle 151R, Tampa, FL 33637 USA. [Highsmith, M. Jason] Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, 3515 E Fletcher Ave, Tampa, FL 33612 USA. [Highsmith, M. Jason] US Dept Vet Affairs, Rehabil Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Highsmith, M. Jason] US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. RP Rabago, CA (reprint author), Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Joint Base San Antonio F, TX 78234 USA.; Rabago, CA (reprint author), Brooke Army Med Ctr, Dept Rehabil Med, Ctr Intrepid, 3551 Roger Brooke Dr, Joint Base San Antonio F, TX 78234 USA. OI Rabago, Christopher/0000-0002-4484-0613 NR 74 TC 0 Z9 0 U1 2 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2016 VL 181 SU 4 SI SI BP 3 EP 12 DI 10.7205/MILMED-D-16-00279 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA EL3EA UT WOS:000394501200002 PM 27849455 ER PT J AU Highsmith, MJ Kahle, JT Miro, RM Lura, DJ Carey, SL Wernke, MM Kim, SH Quillen, WS AF Highsmith, M. Jason Kahle, Jason T. Miro, Rebecca M. Lura, Derek J. Carey, Stephanie L. Wernke, Matthew M. Kim, Seok Hun Quillen, William S. TI Differences in Military Obstacle Course Performance Between Three Energy-Storing and Shock-Adapting Prosthetic Feet in High-Functioning Transtibial Amputees: A Double-Blind, Randomized Control Trial SO MILITARY MEDICINE LA English DT Article ID BELOW-KNEE AMPUTEES; PHYSICAL PERFORMANCE; CURRENT CONFLICTS; GAIT; AMPUTATION; RETURN; FOOT; AFGHANISTAN; EXPENDITURE; AMBULATION AB Background: Approximately 683 persons engaged in military service experienced transtibial amputation (TTA) related to recent war in Iraq and Afghanistan. Military TTAs function at a level beyond basic ambulation. No empirical data demonstrate which higher functioning prosthetic feet maximize injured service personnel's ability to continue performing at a level commensurate with return to duty. This study's purpose was to determine which of three high-functioning, energy-storing prosthetic feet maximize performance and preference in a field obstacle course (OC) and to quantify physical performance differences between TTAs and high-functioning nonamputees. Procedures: A randomized, double-blind, repeated measures experimental design compared three prosthetic feet (Ossur Variflex, Endolite Elite Blade, and Ossur Re-Flex Rotate) during performance on a field OC. TTAs accommodated with study feet and the OC before assessment. 14 TTAs and 14 nonamputee controls completed the course. Subjective and objective performance differences were compared across feet conditions and between groups. Results: Total OC completion times were similar between prosthetic feet: Elite-Blade (419 seconds +/- 130), Variflex (425 seconds +/- 144), and Re-Flex Rotate (444 seconds +/- 220). Controls' OC completion time (287.2 seconds +/- 58) was less (p <= 0.05) than TTA times. In total, controls had faster completion times (p <= 0.05) compared to all prosthetic feet conditions in 13/17 obstacles. Re-Flex Rotate had 2 additional obstacles different (p <= 0.05) than controls and required more time to complete. Median RPE values were lower (p <= 0.05) for controls than TTA regardless of foot. Regarding foot preference for OC completion, 7/14 (50%) preferred Elite Blade, 5/14 (36%) preferred Re-Flex Rotate, and the remaining 2/14 (14%) preferred Variflex. Conclusion: Controls completed the OC faster and with less effort than TTAs regardless of prosthetic foot. No clear differences in prosthetic feet emerged during OC completion; however, individual task performance, perceived effort, and preference resulted in trends of slight performance improvement with and preference for Elite Blade, a dual function energy-storing and return foot combined with vertical shock absorption. Understanding how to maximally improve performance in such functional tasks may allow service members to best sustain physical fitness, return to their military occupational specialty and possibly in-theater duty. C1 [Highsmith, M. Jason] Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA. [Highsmith, M. Jason] James A Haley Vet Adm Hosp, Ctr Innovat Disabil & Rehabil Res, 8900 Grand Oak Circle 151R, Tampa, FL 33637 USA. [Highsmith, M. Jason; Kahle, Jason T.; Miro, Rebecca M.; Kim, Seok Hun; Quillen, William S.] Univ S Florida, Sch Phys Therapy & Rehabil Sci, 3515 E,Fletcher Ave, Tampa, FL 33612 USA. [Highsmith, M. Jason] US Dept Vet Affairs, Rehabil Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Highsmith, M. Jason] US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Miro, Rebecca M.; Quillen, William S.] Univ S Florida, Ctr Neuromusculoskeletal Res, 3515 E,Fletcher Ave, Tampa, FL 33612 USA. [Lura, Derek J.] Florida Gulf Coast Univ, Dept Bioengn & Software Engn, 10501 FGCU Blvd South, Ft Myers, FL 33965 USA. [Carey, Stephanie L.] Univ S Florida, Dept Mech Engn, 4202 E,Fowler Ave,ENB 118, Tampa, FL 33612 USA. [Wernke, Matthew M.] Willow Wood, 15441 Scioto Darby Rd,POB 130, Mt Sterling, OH 43143 USA. RP Highsmith, MJ (reprint author), Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA.; Highsmith, MJ (reprint author), James A Haley Vet Adm Hosp, Ctr Innovat Disabil & Rehabil Res, 8900 Grand Oak Circle 151R, Tampa, FL 33637 USA.; Highsmith, MJ (reprint author), Univ S Florida, Sch Phys Therapy & Rehabil Sci, 3515 E,Fletcher Ave, Tampa, FL 33612 USA.; Highsmith, MJ (reprint author), US Dept Vet Affairs, Rehabil Serv, 810 Vermont Ave NW, Washington, DC 20420 USA.; Highsmith, MJ (reprint author), US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. FU U.S. Department of Defense, Congressionally Directed Medical Research Program (DOD-CDMRP) Project [W81XWH-112-0170, 10193006] FX We wish to thank Ms. Kaitlin Lostroscio for assistance processing study data and Mr. Steven Springer for assistance with subject recruitment. Sheriff David Gee, Maj Alan Hill, and Sgt. Edmond Shea of the Hillsborough County Sheriff's Department provided vital assistance with facility access, training, and safety monitoring throughout study activities. This project was funded by the U.S. Department of Defense, Congressionally Directed Medical Research Program (DOD-CDMRP) Project No. W81XWH-112-0170 (U.S.F. Grant No. 10193006). NR 37 TC 0 Z9 0 U1 1 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2016 VL 181 SU 4 SI SI BP 45 EP 54 DI 10.7205/MILMED-D-16-00286 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA EL3EA UT WOS:000394501200008 PM 27849461 ER PT J AU Randolph, BJ Nelson, LM Highsmith, MJ AF Randolph, Billie J. Nelson, Leif M. Highsmith, M. Jason TI A Review of Unique Considerations for Female Veterans With Amputation SO MILITARY MEDICINE LA English DT Review ID GENDER-DIFFERENCES; LIMB; AMPUTEES; PREVALENCE; SERVICES; WOMEN AB This article explores unique considerations that face both women living with limb loss and their health care providers. This demographic of patient has a higher rate of artificial limb rejection, thus challenging providers to address needs for cosmesis and function that varies from those of male counterparts. Health care providers for women with amputations, such as the Veterans Affairs, must evolve health care delivery, research practices, and work jointly with industry in order to meet the needs of this population. C1 [Randolph, Billie J.; Nelson, Leif M.; Highsmith, M. Jason] Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA. [Randolph, Billie J.; Nelson, Leif M.; Highsmith, M. Jason] US Dept Vet Affairs, Rehabil Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Randolph, Billie J.; Nelson, Leif M.; Highsmith, M. Jason] US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Highsmith, M. Jason] Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, 3515 E,Fletcher Ave, Tampa, FL 33613 USA. RP Randolph, BJ (reprint author), Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA.; Randolph, BJ (reprint author), US Dept Vet Affairs, Rehabil Serv, 810 Vermont Ave NW, Washington, DC 20420 USA.; Randolph, BJ (reprint author), US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. NR 23 TC 0 Z9 0 U1 1 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2016 VL 181 SU 4 SI SI BP 66 EP 68 DI 10.7205/MILMED-D-16-00262 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EL3EA UT WOS:000394501200011 PM 27849464 ER PT J AU Highsmith, MJ Nelson, LM Carbone, NT Klenow, TD Kahle, JT Hill, OT Maikos, JT Kartel, MS Randolph, BJ AF Highsmith, M. Jason Nelson, Leif M. Carbone, Neil T. Klenow, Tyler D. Kahle, Jason T. Hill, Owen T. Maikos, Jason T. Kartel, Mike S. Randolph, Billie J. TI Outcomes Associated With the Intrepid Dynamic Exoskeletal Orthosis (IDEO): A Systematic Review of the Literature SO MILITARY MEDICINE LA English DT Review ID LOWER-EXTREMITY TRAUMA; LIMB SALVAGE; PRISMA STATEMENT; AMPUTATION; PERFORMANCE; WALKING; RETURN; METAANALYSES; DISABILITY; INJURY AB High-energy lower extremity trauma is a consequence of modern war and it is unclear if limb amputation or limb salvage enables greater recovery. To improve function in the injured extremity, a passive dynamic ankle-foot orthosis, the Intrepid Dynamic Exoskeletal Orthosis (IDEO), was introduced with specialized return to run (RTR) therapy program. Recent research suggests, these interventions may improve function and return to duty rates. This systematic literature review sought to rate available evidence and formulate empirical evidence statements (EESs), regarding outcomes associated with IDEO utilization. PubMed, CINAHL, and Google Scholar were systematically searched for pertinent articles. Articles were screened and rated. EESs were formulated based upon data and conclusions from included studies. Twelve studies were identified and rated. Subjects (n = 487, 6 females, mean age 29.4 year) were studied following limb trauma and salvage. All included studies had high external validity, whereas internal validity was mixed because of reporting issues. Moderate evidence supported development of four EESs regarding IDEO use with specialized therapy. Following high-energy lower extremity trauma and limb salvage, use of IDEO with RTR therapy can enable return to duty, return to recreation and physical activity, and decrease pain in some high-functioning patients. In higher functioning patients following limb salvage or trauma, IDEO use improved agility, power and speed, compared with no-brace or conventional bracing alternatives. C1 [Highsmith, M. Jason; Nelson, Leif M.; Hill, Owen T.; Randolph, Billie J.] Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA. [Highsmith, M. Jason; Nelson, Leif M.; Randolph, Billie J.] US Dept Vet Affairs, Rehabil & Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Highsmith, M. Jason; Nelson, Leif M.; Randolph, Billie J.] US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Highsmith, M. Jason; Kahle, Jason T.] Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, 3515 E,Fletcher Ave, Tampa, FL 33613 USA. [Carbone, Neil T.; Maikos, Jason T.] Vet Affairs New York Harbor Healthcare Syst, 423 E,23rd St, New York, NY USA. [Klenow, Tyler D.; Kartel, Mike S.] James A Haley Vet Adm Hosp, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA. [Hill, Owen T.] Brooke Army Med Ctr, Headquarters & Headquarters Co, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. RP Highsmith, MJ (reprint author), Extrem Trauma & Amputat Ctr Excellence, 2748 Worth Rd,Suite 29, Ft Sam Houston, TX 78234 USA.; Highsmith, MJ (reprint author), US Dept Vet Affairs, Rehabil & Serv, 810 Vermont Ave NW, Washington, DC 20420 USA.; Highsmith, MJ (reprint author), US Dept Vet Affairs, Prosthet Serv, 810 Vermont Ave NW, Washington, DC 20420 USA.; Highsmith, MJ (reprint author), Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, 3515 E,Fletcher Ave, Tampa, FL 33613 USA. NR 32 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2016 VL 181 SU 4 SI SI BP 69 EP 76 DI 10.7205/MILMED-D-16-00280 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EL3EA UT WOS:000394501200012 PM 27849465 ER PT J AU Slane, JD Levine, MD Borrero, S Mattocks, KM Ozier, AD Silliker, N Bathulapalli, H Brandt, C Haskell, SG AF Slane, Jennifer D. Levine, Michele D. Borrero, Sonya Mattocks, Kristin M. Ozier, Amy D. Silliker, Norman Bathulapalli, Harini Brandt, Cynthia Haskell, Sally G. TI Eating Behaviors: Prevalence, Psychiatric Comorbidity, and Associations With Body Mass Index Among Male and Female Iraq and Afghanistan Veterans SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS; GENDER-DIFFERENCES; NATIONAL SAMPLE; SEXUAL TRAUMA; HEALTH-CARE; DISORDERS; OBESITY; QUESTIONNAIRE; OVERWEIGHT; APPRAISAL AB Objective: There is a dearth of research examining eating behaviors, such as binge eating, among male and female veterans. The present study evaluated the prevalence of self-reported eating problems as well as associations with body mass index and psychiatric disorders among male and female Iraq and Afghanistan veterans. Methods: Participants were 298 male and 364 female veterans (M = 33.3 +/- 10.6 years old) from the Women Veterans Cohort Study, a study of male and female veterans enrolled for Veterans Affairs care in New England or Indiana. Veterans self-reported on emotion-and stress-related eating, eating disorder diagnoses, and disordered eating behaviors. Diagnoses of post-traumatic stress disorder, major depressive disorder, and alcohol abuse were obtained from administrative records. Results: Female veterans reported higher rates of eating problems than did their male counterparts. Women and men who engage in disordered eating had higher rates of post-traumatic stress disorder and major depressive disorder, and women who engage in disordered eating had greater rates of alcohol abuse than did female veterans without eating disordered behaviors. Conclusions: Disordered eating may be a significant issue among Iraq and Afghanistan veterans, and veterans with eating problems are more likely to have comorbid mental health conditions that further increase their health risks. C1 [Slane, Jennifer D.; Borrero, Sonya] VA Pittsburgh Healthcare Syst, Res Off Bldg,Univ Dr C, Pittsburgh, PA 15240 USA. [Slane, Jennifer D.; Levine, Michele D.] Univ Pittsburgh, Dept Psychiat, Med Ctr, 3811 OHara St, Pittsburgh, PA 15213 USA. [Borrero, Sonya] Univ Pittsburgh, Dept Med, 230 McKee Pl, Pittsburgh, PA 15213 USA. [Mattocks, Kristin M.] VA Cent Western Massachusetts, 421 North Main St, Leeds, MA 01053 USA. [Mattocks, Kristin M.; Ozier, Amy D.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, 55 Lake Ave North, Worcester, MA 01655 USA. [Mattocks, Kristin M.; Ozier, Amy D.] Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave North, Worcester, MA 01655 USA. [Ozier, Amy D.] Northern Illinois Univ, Sch Family Consumer & Nutr Sci, 118 Wirtz Hall, De Kalb, IL 60115 USA. [Silliker, Norman; Bathulapalli, Harini; Brandt, Cynthia; Haskell, Sally G.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Silliker, Norman; Bathulapalli, Harini; Brandt, Cynthia; Haskell, Sally G.] Yale Sch Med, 333 Cedar St, New Haven, CT 06510 USA. RP Slane, JD (reprint author), VA Pittsburgh Healthcare Syst, Res Off Bldg,Univ Dr C, Pittsburgh, PA 15240 USA.; Slane, JD (reprint author), Univ Pittsburgh, Dept Psychiat, Med Ctr, 3811 OHara St, Pittsburgh, PA 15213 USA. RI Bathulapalli, Harini/B-7451-2015 FU VA Health Services Research and Development [DHI 07-065] FX This research was supported by VA Health Services Research and Development, Project no. DHI 07-065-Women Veterans Cohort Study (2007-2012). NR 28 TC 0 Z9 0 U1 3 U2 3 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2016 VL 181 IS 11 BP E1650 EP E1656 DI 10.7205/MILMED-D-15-00482 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DS UT WOS:000394500400028 PM 27849502 ER PT J AU Back, SE McCauley, JL Korte, KJ Gros, DF Leavitt, V Gray, KM Hamner, MB DeSantis, SM Malcolm, R Brady, KT Kalivas, PW AF Back, Sudie E. McCauley, Jenna L. Korte, Kristina J. Gros, Daniel F. Leavitt, Virginia Gray, Kevin M. Hamner, Mark B. DeSantis, Stacia M. Malcolm, Robert Brady, Kathleen T. Kalivas, Peter W. TI A double-Blind, Randomized,Controlled pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COMORBID ALCOHOL DEPENDENCE; FUNCTIONAL CONNECTIVITY; DSM-IV; PTSD; ADDICTION; STATE; MECHANISMS; PLACEBO; MINI AB Objective:The antioxidant N-acetylcysteine is being increasingly investigated as a therapeutic agent in the treatment of substance use disorders (SUDs). This study explored the efficacy of N-acetylcysteine in the treatment of posttraumatic stress disorder (PTSD), which frequently co-occurs with SUD and shares impaired prefrontal cortex regulation of basal ganglia circuitry, in particular at glutamate synapses in the nucleus accumbens. Methods: Veterans with PTSD and SUD per D5M-IV/criteria (N=35) were randomly assigned to receive a double-blind, 8-week course of N-acetylcysteine (2,400 mg/d) or placebo plus cognitive-behavioral therapy for SUD (between March 2013 and April 2014). Primary outcome measures included PTSD symptoms (Clinician-Administered PTSD Scale, PTSD Checklist-Military) and craving (Visual Analog Scale). Substance use and depression were also assessed. Results: Participants treated with N-acetylcysteine compared to placebo evidenced significant improvements in PTSD symptoms, craving, and depression (p values< 0.33; P values <.05). Substance use was low for both groups, and no significant between-group differences were observed. N-acetylcysteine was well tolerated, and retention was high. Conclusions:This is the first randomized controlled trial to investigate N-acetylcysteine as a pharrnacologic treatment for PTSD and SUD. Although preliminary, the findings provide initial support for the use of N-acetylcysteine in combination with psychotherapy among individuals with co-occurring PTSD and SUD. (C) Copyright 2016 Physicians Postgraduate Press,inc. C1 [Back, Sudie E.; McCauley, Jenna L.; Korte, Kristina J.; Gros, Daniel F.; Leavitt, Virginia; Gray, Kevin M.; Hamner, Mark B.; DeSantis, Stacia M.; Malcolm, Robert; Brady, Kathleen T.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Ste 151, Charleston, SC 29407 USA. [Kalivas, Peter W.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Back, Sudie E.; Korte, Kristina J.; Gros, Daniel F.; Hamner, Mark B.; Malcolm, Robert; Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Back, SE (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Ste 151, Charleston, SC 29407 USA. EM backs@musc.edu FU US Department of Defense [W81XWH-11-2-0145]; National Institute on Drug Abuse [K02 DA039229]; Department of Veterans Affairs Clinical Science Research and Development Career Development Award [CX000845] FX The authors acknowledge support from the US Department of Defense grant number W81XWH-11-2-0145 (Dr Kalivas), National Institute on Drug Abuse grant number K02 DA039229 (Dr Back), and Department of Veterans Affairs Clinical Science Research and Development Career Development Award CX000845 (Dr Gros). NR 42 TC 0 Z9 0 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2016 VL 77 IS 11 BP E1439 EP E1446 DI 10.4088/JCP.15m10239 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DY UT WOS:000393021300002 PM 27736051 ER PT J AU York, J Sternke, LM Myrick, D Lauerer, J Hair, C AF York, Janet Sternke, Lisa Marie Myrick, Donald (Hugh) Lauerer, Joy Hair, Carole TI Development of Veteran-Centric Competency Domains for Psychiatric-Mental Health Nurse Practitioner Residents SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID CULTURAL COMPETENCE; MEDICAL-EDUCATION; CARE; IMPLEMENTATION; PREVENTION; PROGRAMS AB The mental health needs of military service members, Veterans, and their families are a designated national priority; however, there has been little emphasis on the inclusion of Veteran-centric domains in competency-based nursing education for psychiatric-mental health nurse practitioners (PMHNPs). The current article describes the identification and application of Veteran-centric domains in an innovative pilot residency program for PMHNPs, funded by the Veterans Health Administration Office of Academic Affiliations. Fourteen Veteran-centric competency domains were developed from literature review, including knowledge, attitudes, and skill behaviors. Adoption and application of these domains in curricular components included the resident competency evaluation, baseline assessment of military experience, and evidence-based practice seminars and training. Methods of competency domain evaluation are presented, along with gaps related to the evaluation of competency skills. The delivery of mental health services reflecting these domains is consistent with the VA core values and goal of developing a positive service culture. C1 [York, Janet] VISN7, Duluth, GA USA. [York, Janet] Mental Hlth Serv Line, Mental Hlth, Decatur, GA USA. [Sternke, Lisa Marie] Ralph H Johnson VA Med Ctr, Staffs Off, Charleston, SC USA. [York, Janet; Lauerer, Joy] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Myrick, Donald (Hugh)] Med Univ South Carolina, Dept Psychiat, Charleston, SC USA. [Hair, Carole] VA Off Acad Affiliat, Washington, DC USA. RP York, J (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv Line, Room A575,109 Bee St, Charleston, SC 29425 USA. EM Janet.York@va.gov FU Office of Academic Affiliations (OAA); Department of Veterans Affairs FX The RHJ VAMC Psychiatric Mental Health Nurse Practitioner Residency is supported by the Office of Academic Affiliations (OAA) and the Department of Veterans Affairs. The authors acknowledge the mentorship of Dr. Mary Dougherty, Nursing Education, VA Office of Academic Affiliations; the RHJ VAMC Center for Innovation; and the contributions of Teena McGuinness, PhD, CRNP, Professor of Nursing, University of Alabama at Birmingham, and Co-Director of BVAMC/UAB SON Mental Health Nurse Practitioner Residency, Birmingham VAMC, and Audry Gorman, PMHNP, previous Director of Birmingham Residency. NR 38 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD NOV PY 2016 VL 54 IS 11 BP 31 EP + DI 10.3928/02793695-20161024-06 PG 9 WC Nursing SC Nursing GA EJ2SF UT WOS:000393060700012 PM 27805714 ER PT J AU Bensing, BA Khedri, Z Deng, LQ Yu, H Prakobphol, A Fisher, SJ Chen, X Iverson, TM Varki, A Sullam, PM AF Bensing, Barbara A. Khedri, Zahra Deng, Lingquan Yu, Hai Prakobphol, Akraporn Fisher, Susan J. Chen, Xi Iverson, Tina M. Varki, Ajit Sullam, Paul M. TI Novel aspects of sialoglycan recognition by the Siglec-like domains of streptococcal SRR glycoproteins SO GLYCOBIOLOGY LA English DT Article DE endocarditis; MUC7; platelet GPIb; sialyl-T antigen; Siglec ID ACID-BINDING ADHESIN; EXPERIMENTAL BACTERIAL-ENDOCARDITIS; WEIGHT SALIVARY MUCIN; SURFACE PROTEIN; GORDONII DL1; IB-ALPHA; HUMAN PLATELETS; GSPB; FAMILY; HSA AB Serine-rich repeat glycoproteins are adhesins expressed by commensal and pathogenic Gram-positive bacteria. A subset of these adhesins, expressed by oral streptococci, binds sialylated glycans decorating human salivary mucin MG2/MUC7, and platelet glycoprotein GPIb. Specific sialoglycan targets were previously identified for the ligand-binding regions (BRs) of GspB and Hsa, two serine-rich repeat glycoproteins expressed by Streptococcus gordonii. While GspB selectively binds sialyl-T antigen, Hsa displays broader specificity. Here we examine the binding properties of four additional BRs from Streptococcus sanguinis or Streptococcus mitis and characterize the molecular determinants of ligand selectivity and affinity. Each BR has two domains that are essential for sialoglycan binding by GspB. One domain is structurally similar to the glycan-binding module of mammalian Siglecs (sialic acid-binding immunoglobulin-like lectins), including an arginine residue that is critical for glycan recognition, and that resides within a novel, conserved YTRY motif. Despite low sequence similarity to GspB, one of the BRs selectively binds sialyl-T antigen. Although the other three BRs are highly similar to Hsa, each displayed a unique ligand repertoire, including differential recognition of sialyl Lewis antigens and sulfated glycans. These differences in glycan selectivity were closely associated with differential binding to salivary and platelet glycoproteins. Specificity of sialoglycan adherence is likely an evolving trait that may influence the propensity of streptococci expressing Siglec-like adhesins to cause infective endocarditis. C1 [Bensing, Barbara A.; Sullam, Paul M.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Bensing, Barbara A.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Khedri, Zahra; Deng, Lingquan; Varki, Ajit] Univ Calif San Diego, Glycobiol Res & Training Ctr, San Diego, CA 92093 USA. [Khedri, Zahra; Deng, Lingquan; Varki, Ajit] Univ Calif San Diego, Dept Cellular & Mol Med, San Diego, CA 92093 USA. [Yu, Hai; Chen, Xi] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA. [Prakobphol, Akraporn; Fisher, Susan J.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Iverson, Tina M.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 27232 USA. [Deng, Lingquan] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA. RP Bensing, BA (reprint author), VA Med Ctr 111W2, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. EM barbara.bensing@ucsf.edu FU Department of Veterans Affairs; Northern California Institute for Research and Education; National Institutes of Health [AI41513, R21CA199881, AI106987, R01GM32373, U01CA199792, R01DE021041]; American Heart Association [14GRNT20390021] FX This work was supported by the Department of Veterans Affairs, the Northern California Institute for Research and Education, the National Institutes of Health (AI41513 and R21CA199881 to P.M.S.; AI106987 to P.M.S./T.M.I.; R01GM32373 and U01CA199792 to A.V.; R01DE021041 to S.J.F.) and the American Heart Association (14GRNT20390021 to T.M.I.). NR 42 TC 5 Z9 5 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0959-6658 EI 1460-2423 J9 GLYCOBIOLOGY JI Glycobiology PD NOV PY 2016 VL 26 IS 11 BP 1222 EP 1234 DI 10.1093/glycob/cww042 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EJ0XF UT WOS:000392933600010 PM 27037304 ER PT J AU D'Ambruoso, SF Coscarelli, A Hurvitz, S Wenger, N Coniglio, D Donaldson, D Pietras, C Walling, AM AF D'Ambruoso, Sarah F. Coscarelli, Anne Hurvitz, Sara Wenger, Neil Coniglio, David Donaldson, Dusty Pietras, Christopher Walling, Anne M. TI Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Article ID OF-LIFE; PERFORMANCE; ROLES AB Our case describes the efforts of team members drawn from oncology, palliative care, supportive care, and primary care to assist a woman with advanced cancer in accepting care for her psychosocial distress, integrating prognostic information so that she could share in decisions about treatment planning, involving family in her care, and ultimately transitioning to hospice. Team members in our setting included a medical oncologist, oncology nurse practitioner, palliative care nurse practitioner, oncology social worker, and primary care physician. The core members were the patient and her sister. Our team grew organically as a result of patient need and, in doing so, operationalized an explicitly shared understanding of care priorities. We refer to this shared understanding as a shared mental model for care delivery, which enabled our team to jointly set priorities for care through a series of warm handoffs enabled by the team's close proximity within the same clinic. When care providers outside our integrated team became involved in the case, significant communication gaps exposed the difficulty in extending our shared mental model outside the integrated team framework, leading to inefficiencies in care. Integration of this shared understanding for care and close proximity of team members proved to be key components in facilitating treatment of our patient's burdensome cancer-related distress so that she could more effectively participate in treatment decision making that reflected her goals of care. C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Simms Mann UCLA Ctr Integrat Oncol, Los Angeles, CA USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Campbell Univ, Coll Pharm & Hlth Sci, Buies Creek, NC 27506 USA. Dusty Joy Fdn LiveLung, High Point, NC USA. RP Walling, AM (reprint author), UCLA Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM awalling@mednet.ucla.edu FU Genentech (Inst); Novartis (Inst); GlaxoSmithKline (Inst); Boehringer Ingelheim (Inst); Sanofi (Inst); Pfizer (Inst); Amgen (Inst); OBI Pharma (Inst); Puma Biotechnology (Inst); Dignitana (Inst); Bayer (Inst); Biomarin (Inst); Lilly (Inst); Merrimack (Inst) FX Genentech (Inst), Novartis (Inst), GlaxoSmithKline (Inst), Boehringer Ingelheim (Inst), Sanofi (Inst), Pfizer (Inst), Amgen (Inst), OBI Pharma (Inst), Puma Biotechnology (Inst), Dignitana (Inst), Bayer (Inst), Biomarin (Inst), Lilly (Inst), Merrimack (Inst) NR 31 TC 1 Z9 1 U1 3 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD NOV PY 2016 VL 12 IS 11 BP 1039 EP + DI 10.1200/JOP.2016.013722 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EI3HS UT WOS:000392381400012 PM 27577617 ER PT J AU Neuwelt, E Ambady, P Muldoon, L McConnell, H Doolittle, N AF Neuwelt, Edward Ambady, Prakash Muldoon, Leslie McConnell, Heather Doolittle, Nancy TI Outwitting the Blood-Brain Barrier SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID PRIMARY CNS LYMPHOMA; FERUMOXYTOL; PSEUDOPROGRESSION; THERAPY; GLIOBLASTOMA; GADOTERIDOL; EFFICACY C1 [Neuwelt, Edward; Ambady, Prakash; Muldoon, Leslie; McConnell, Heather; Doolittle, Nancy] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Neuwelt, Edward] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Neuwelt, Edward] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.; Neuwelt, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. NR 12 TC 0 Z9 0 U1 1 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD NOV PY 2016 VL 30 IS 11 BP 963 EP 967 PG 3 WC Oncology SC Oncology GA EI0WC UT WOS:000392194900003 PM 27854098 ER PT J AU Lourdault, K Matsunaga, J Haake, DA AF Lourdault, Kristel Matsunaga, James Haake, David A. TI High-Throughput Parallel Sequencing to Measure Fitness of Leptospira interrogans Transposon Insertion Mutants during Acute Infection SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID GENE-EXPRESSION; BORRELIA-BURGDORFERI; MOLECULAR-CLONING; URBAN EPIDEMIC; VIRULENCE; GENOME; PROTEINS; HOST; DISSEMINATION; PATHOGENESIS AB Pathogenic species of Leptospira are the causative agents of leptospirosis, a zoonotic disease that causes mortality and morbidity worldwide. The understanding of the virulence mechanisms of Leptospira spp is still at an early stage due to the limited number of genetic tools available for this microorganism. The development of random transposon mutagenesis in pathogenic strains a decade ago has contributed to the identification of several virulence factors. In this study, we used the transposon sequencing (Tn-Seq) technique, which combines transposon mutagenesis with massive parallel sequencing, to study the in vivo fitness of a pool of Leptospira interrogans mutants. We infected hamsters with a pool of 42 mutants (input pool), which included control mutants with insertions in four genes previously analyzed by virulence testing (loa22, ligB, flaA1, and lic20111) and 23 mutants with disrupted signal transduction genes. We quantified the mutants in different tissues (blood, kidney and liver) at 4 days post-challenge by high-throughput sequencing and compared the frequencies of mutants recovered from tissues to their frequencies in the input pool. Control mutants that were less fit in the Tn-Seq experiment were attenuated for virulence when tested separately in the hamster model of lethal leptospirosis. Control mutants with unaltered fitness were as virulent as the wild-type strain. We identified two mutants with the transposon inserted in the same putative adenylate/guanylate cyclase gene (lic12327) that had reduced in vivo fitness in blood, kidney and liver. Both lic12327 mutants were attenuated for virulence when tested individually in hamsters. Growth of the control mutants and lic12327 mutants in culture medium were similar to that of the wild-type strain. These results demonstrate the feasibility of screening large pools of L. interrogans transposon mutants for those with altered fitness, and potentially attenuated virulence, by transposon sequencing. C1 [Lourdault, Kristel; Matsunaga, James; Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Lourdault, Kristel; Matsunaga, James; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90024 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, Dept Mol Genet, Los Angeles, CA USA. RP Lourdault, K (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.; Lourdault, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM kristel.lourdault@gmail.com FU Veterans Affairs Merit Award; National Institutes of Health [R01 AI 034431] FX This work was supported by a Veterans Affairs Merit Award to DAH (http://www.research.va.gov/services/shared_docs/merit_review.cfm) and a National Institutes of Health grant R01 AI 034431 to DAH (https://www.niaid.nih.gov/research/research-funded-niaid). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD NOV PY 2016 VL 10 IS 11 AR e0005117 DI 10.1371/journal.pntd.0005117 PG 27 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EI0HR UT WOS:000392154400039 PM 27824878 ER PT J AU Ben-Hamo, M Larson, TA Duge, LS Sikkema, C Wilkinson, CW de la Iglesia, HO Gonzalez, MMC AF Ben-Hamo, Miriam Larson, Tracy A. Duge, Leanne S. Sikkema, Carl Wilkinson, Charles W. de la Iglesia, Horacio O. Gonzalez, Monica M. C. TI Circadian Forced Desynchrony of the Master Clock Leads to Phenotypic Manifestation of Depression in Rats SO ENEURO LA English DT Article DE behavior; circadian rhythms; depression; emotion; rat ID MOOD DISORDERS; SUPRACHIASMATIC NUCLEUS; SEXUAL DYSFUNCTION; MAJOR DEPRESSION; LIGHT THERAPY; RHYTHM DISTURBANCES; PREFRONTAL CORTEX; CHRONIC STRESS; SLEEP-WAKE; BEHAVIOR AB In mammals, a master circadian clock within the suprachiasmatic nucleus (SCN) of the hypothalamus maintains the phase coherence among a wide array of behavioral and physiological circadian rhythms. Affective disorders are typically associated with disruption of this fine-tuned "internal synchronization," but whether this internal misalignment is part of the physiopathology of mood disorders is not clear. To date, depressive-like behavior in animal models has been induced by methods that fail to specifically target the SCN regulation of internal synchronization as the mode to generate depression. In the rat, exposure to a 22-h light-dark cycle (LD22) leads to the uncoupling of two distinct populations of neuronal oscillators within the SCN. This genetically, neurally, and pharmacologically intact animal model represents a unique opportunity to assess the effect of a systematic challenge to the central circadian pacemaker on phenotypic manifestations of mood disorders. We show that LD22 circadian forced desynchrony in rats induces depressive-like phenotypes including anhedonia, sexual dysfunction, and increased immobility in the forced swim test (FST), as well as changes in the levels and turnover rates of monoamines within the prefrontal cortex. Desynchronized rats show increased FST immobility during the dark (active) phase but decreased immobility during the light (rest) phase, suggesting a decrease in the amplitude of the normal daily oscillation in this behavioral manifestation of depression. Our results support the notion that the prolonged internal misalignment of circadian rhythms induced by environmental challenge to the central circadian pacemaker may constitute part of the etiology of depression. C1 [Ben-Hamo, Miriam; Larson, Tracy A.; Duge, Leanne S.; de la Iglesia, Horacio O.; Gonzalez, Monica M. C.] Univ Washington, Dept Biol, Seattle, WA 98195 USA. [Ben-Hamo, Miriam; de la Iglesia, Horacio O.] Univ Washington, Program Neurosci, Seattle, WA 98195 USA. [Sikkema, Carl; Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Sikkema, Carl; Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Gonzalez, Monica M. C.] Inst Ferrero Neurol & Sueno, Buenos Aires, DF, Argentina. [Larson, Tracy A.] Univ Virginia, Dept Biol, Charlottesville, VA USA. RP de la Iglesia, HO (reprint author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.; Gonzalez, MMC (reprint author), Inst Ferrero Neurol & Sueno IFN, RA-1120 Junin, Caba, Argentina. EM horaciod@uw.edu; mgonzalez@ifn.com.ar OI Ben-Hamo, Miriam/0000-0002-4879-3658 FU HHS, National Institutes of Health [R01MH075016, R01NS094211]; National Science Foundation [IOS0909716]; National Alliance for Research on Schizophrenia and Depression; Israeli Committee for Higher Education; Washington Research Foundation Innovation postdoctoral fellowship in Neuroengineering]; Geriatric Research, Education and Clinical Center; Research and Development Service of the VA Puget Sound Health Care System FX Supported by HHS, National Institutes of Health [R01MH075016 R01NS094211]; National Science Foundation [IOS0909716]; National Alliance for Research on Schizophrenia and Depression [Young Investigator Award]; Israeli Committee for Higher Education [Postdoctoral Fellowship for Women]; Washington Research Foundation Innovation postdoctoral fellowship in Neuroengineering]; Geriatric Research, Education and Clinical Center, and the Research and Development Service of the VA Puget Sound Health Care System. NR 63 TC 0 Z9 0 U1 2 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 2373-2822 J9 ENEURO JI eNeuro PD NOV-DEC PY 2016 VL 3 IS 6 AR UNSP e0237 DI 10.1523/ENEURO.0237-16.2016 PG 13 WC Neurosciences SC Neurosciences & Neurology GA EH7CQ UT WOS:000391930900019 ER PT J AU Kumbhar, SS O'Malley, RB Robinson, TJ Maximin, S Lalwani, N Byrd, DR Wang, CL AF Kumbhar, Sachin S. O'Malley, Ryan B. Robinson, Tracy J. Maximin, Suresh Lalwani, Neeraj Byrd, David R. Wang, Carolyn L. TI Why Thyroid Surgeons Are Frustrated with Radiologists: Lessons Learned from Pre- and Postoperative US SO RADIOGRAPHICS LA English DT Article ID CONSENSUS STATEMENT; NECK DISSECTION; LYMPH-NODES; CANCER; ULTRASOUND; NODULES; CARCINOMA; ULTRASONOGRAPHY; CLASSIFICATION; MALIGNANCY AB Optimal treatment of thyroid cancer is highly dependent on accurate staging of the extent of disease at presentation. Preoperative ultrasonography (US) is the most sensitive method for detecting metastatic lymph nodes and is recommended as part of the standard preoperative workup. Missed findings on preoperative scans may lead to understaging and inadequate surgical management, which subsequently predispose these patients to residual disease postoperatively and a higher risk for recurrence, possibly requiring repeat surgery. Traditionally, thyroid US for pre- and postoperative staging has been performed by radiologists. However, there is a growing trend away from radiologist-performed US in favor of surgeon-performed US. Recent surgical and endocrinology literature has shown that, when compared with surgeon-performed US, radiologist-performed preoperative staging US is less accurate and is inadequate for presurgical planning, with higher local recurrence rates. This review highlights the importance of accurate preoperative US for patients with differentiated thyroid cancer, with specific attention to deficiencies that exist in general radiology department thyroid US reports. We present a standardized approach to neck US reporting that incorporates the newly updated 2015 recommendations from the American Thyroid Association and also addresses the pertinent questions for thyroid surgeons. By ensuring comprehensive preoperative assessment and improving thyroid US reporting, we seek to improve patient access to optimized care. (C) RSNA, 2016 center dot radiographics.rsna.org C1 [Kumbhar, Sachin S.; O'Malley, Ryan B.; Lalwani, Neeraj; Wang, Carolyn L.] Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. [Byrd, David R.] Univ Washington, Dept Surg, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. [Robinson, Tracy J.] Seattle Radiologists, Western Div Integra Imaging, Seattle, WA USA. [Maximin, Suresh] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. RP Wang, CL (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM wangcl@uw.edu NR 35 TC 1 Z9 1 U1 4 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD NOV-DEC PY 2016 VL 36 IS 7 BP 2141 EP 2153 DI 10.1148/rg.2016150250 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH0AO UT WOS:000391424800013 PM 27768542 ER PT J AU Kohli, P Schlosser, RJ Storck, K Soler, ZM AF Kohli, Preeti Schlosser, Rodney J. Storck, Kristina Soler, Zachary M. TI Olfactory cleft computed tomography analysis and olfaction in chronic rhinosinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID ENDOSCOPIC SINUS; NASAL POLYPOSIS; SURGERY; RECOVERY; QUALITY; LIFE AB Background: Volumetric analysis of the olfactory cleft by using computed tomography has been associated with olfaction in patients with chronic rhinosinusitis (CRS). However, existing studies have not comprehensively measured olfaction, and it thus remains unknown whether correlations differ across specific dimensions of odor perception. Objective: To use comprehensive measures of patient-reported and objective olfaction to evaluate the relationship between volumetric olfactory cleft opacification and olfaction. Methods: Olfaction in patients with CRS was evaluated by using "Sniffin' Sticks"tests and a modified version of the Questionnaire of Olfactory Disorders. Olfactory cleft opacification was quantified by using two-and three-dimensional, computerized volumetric analysis. Correlations between olfactory metrics and olfactory cleft opacification were then calculated. Results: The overall CRS cohort included 26 patients without nasal polyposis (CRSsNP) (68.4%) and 12 patients with nasal polyposis (CRSwNP) (31.6%). Across the entire cohort, total olfactory cleft opacification was 82.8%, with greater opacification in the CRSwNP subgroup compared with CRSsNP (92.3 versus 78.4%, p < 0.001). The percent total volume opacification correlated with the total Sniffin' Sticks score (r = -0.568, p < 0.001) as well as individual threshold, discrimination, and identification scores (p < 0.001 for all). Within the CRSwNP subgroup, threshold (r = -0.616, p = 0.033) and identification (r = -0.647, p = 0.023) remained highly correlated with total volume opacification. In patients with CRSsNP, the threshold correlated with total volume scores (r = -0.457, p = 0.019), with weaker and nonsignificant correlations for discrimination and identification. Correlations between total volume opacification and the Questionnaire of Olfactory Disorders were qualitatively similar to objective olfactory findings in both CRSwNP (r = -0.566, p = 0.070) and CRSsNP (r = -0.310, p = 0.141) subgroups, although neither reached significance. When examined by two-dimensional planes, the percent opacification of the anterior plane had the strongest correlations with objective olfaction. Conclusion: Olfactory cleft opacification correlated with objective measures of olfaction in patients with CRS, which correlated with threshold values in patients with CRSsNP and all dimensions of olfaction in those with CRSwNP. C1 [Kohli, Preeti; Schlosser, Rodney J.; Storck, Kristina; Soler, Zachary M.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. RP Soler, ZM (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC550, Charleston, SC 29425 USA. EM solerz@musc.edu FU National Institute on Deafness and Other Communication Disorders, National Institutes of Health [R03 DC013651-01]; OptiNose; IntersectENT FX Z.M. Soler is supported for this investigation by a grant from the National Institute on Deafness and Other Communication Disorders, National Institutes of Health (P.I., Z.M. Soler; R03 DC013651-01); is a consultant for Olympus, which is not affiliated with this manuscript. R.J. Schlosser is supported by grants from OptiNose and IntersectENT, neither are associated with this manuscript; is also a consultant for Olympus, Meda, and Arrinex, which are not affiliated with this study. The remaining authors have no conflicts of interest pertaining to this article NR 21 TC 0 Z9 0 U1 1 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD NOV-DEC PY 2016 VL 30 IS 6 BP 402 EP 406 DI 10.2500/ajra.2016.30.4365 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA EG2EW UT WOS:000390857000012 ER PT J AU Tucker, PW Evans, DD Clevenger, CK Ardisson, M Hwang, U AF Tucker, Paula W. Evans, Dian Dowling Clevenger, Carolyn K. Ardisson, Michelle Hwang, Ula TI Feasibility of nurses measuring gait speed in older community-dwelling Emergency Department patients SO GERIATRIC NURSING LA English DT Article DE Gait speed; Emergency Department; Screening; Routine assessment ID GERIATRIC ASSESSMENT; ADULTS; PEOPLE; CARE AB Gait speed assessment is a rapid, simple and objective measure for predicting risk of unfavorable outcomes which may provide better prognostic and reliable information than existing geriatric ED (Emergency Department) screening tools. This descriptive pilot project was designed to determine feasibility of implementing gait speed screening into routine nursing practice by objectively identifying patients with sub-optimal gait speeds. Participants included community-dwelling adults 65 years and older with plans for discharge following ED treatment Patients with a gait speed <1.0 m/s were identified as "high-risk" for an adverse event, and referred to the ED social worker for individualized resources prior to discharge. Thirty-five patients were screened and nurse initiated gait speed screens were completed 60% of the time. This project demonstrates ED gait speed screening may be feasible. Implications for practice should consider incorporating gait speed screening into routine nursing assessment to improve provider ED decision-making and disposition planning. Published by Elsevier Inc. C1 [Tucker, Paula W.; Clevenger, Carolyn K.] Atlanta VA Med Ctr, 1670 Clairmont Rd, Decatur, GA 30033 USA. [Tucker, Paula W.; Evans, Dian Dowling] Emory Univ Hosp, Emergency Dept, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Tucker, Paula W.; Evans, Dian Dowling; Clevenger, Carolyn K.] Nell Hodgson Woodruff Sch Nursing, 1520 Clifton Rd, Atlanta, GA 30322 USA. [Ardisson, Michelle] Vanderbilt Univ, Sch Nursing, 461 21st Ave South, Nashville, TN 37240 USA. [Hwang, Ula] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, Dept Emergency Med, One Gustave L Levy Pl,POB 1620, New York, NY 10029 USA. [Hwang, Ula] James J Peters VA Med Ctr, GRECC, 130 Kingsbridge Rd, Bronx, NY 10468 USA. RP Tucker, PW (reprint author), 3425 Sims Rd, Snellville, GA 30039 USA. EM paula.tucker@emory.edu FU Department of Veterans Affairs FX This review is the result of work supported with resources and use of facilities by fellows in the VA Quality Scholars Fellowship Program located at the Atlanta VA Medical Center, Decatur, GA, funded by the Department of Veterans Affairs. The conclusions in this publication are those of the authors and they do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 20 TC 0 Z9 0 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4572 EI 1528-3984 J9 GERIATR NURS JI Geriatr. Nurs. PD NOV-DEC PY 2016 VL 37 IS 6 BP 453 EP 457 DI 10.1016/j.gerinurse.2016.06.015 PG 5 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA EG6LG UT WOS:000391157200006 PM 27477084 ER PT J AU Vergnes, L Davies, GR Lin, JY Yeh, MW Livhits, MJ Harari, A Symonds, ME Sacks, HS Reue, K AF Vergnes, Laurent Davies, Graeme R. Lin, Jason Y. Yeh, Michael W. Livhits, Masha J. Harari, Avital Symonds, Michael E. Sacks, Harold S. Reue, Karen TI Adipocyte Browning and Higher Mitochondrial Function in Periadrenal But Not SC Fat in Pheochromocytoma SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID WHITE ADIPOSE-TISSUE; ADULT HUMANS; NONSHIVERING THERMOGENESIS; GENE-EXPRESSION; MOUSE; TEMPERATURE; DISTINCT; OBESITY; BRITE; CELL AB Context: Patients with pheochromocytoma (pheo) show presence of multilocular adipocytes that express uncoupling protein 1 within periadrenal (pADR) and omental (OME) fat depots. It has been hypothesized that this is due to adrenergic stimulation by catecholamines produced by the pheo tumors. Objective: To characterize the prevalence and respiratory activity of brown-like adipocytes within pADR, OME, and SC fat depots in human adult pheo patients. Design: This was an observational cohort study. Setting: The study took place in a university hospital. Patients: We studied 46 patients who underwent surgery for benign adrenal tumors (21 pheos and 25 controls with adrenocortical adenomas). Main outcome measure: We characterized adipocyte browning in pADR, SC, and OME fat depots for histological and immunohistological features, mitochondrial respiration rate, and gene expression. We also determined circulating levels of catecholamines and other browning-related hormones. Results: Eleven of 21 pheo pADR adipose samples, but only one of 25 pADR samples from control patients exhibited multilocular adipocytes. The pADR browning phenotype was associated with higher plasma catecholamines and raised uncoupling protein 1. Mitochondria from multilocular pADR fat of pheo patients exhibited increased rates of coupled and uncoupled respiration. Global gene expression analysis in pADR fat revealed enrichment in beta-oxidation genes in pheo patients with multilocular adipocytes. No SC or OME fat depots exhibited aspects of browning. Conclusion: Browning of the pADR depot occurred in half of pheo patients and was associated with increased catecholamines and mitochondrial activity. No browning was detected in other fat depots, suggesting that other factors are required to promote browning in these depots. C1 [Vergnes, Laurent; Lin, Jason Y.; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, 695 Charles E Young Dr South, Los Angeles, CA 90095 USA. [Davies, Graeme R.; Symonds, Michael E.] Univ Nottingham, Queens Med Ctr, Acad Div Child Hlth Obstet & Gynaecol, Sch Med, Nottingham, England. [Yeh, Michael W.; Livhits, Masha J.; Harari, Avital] Univ Calif Los Angeles, David Geffen Sch Med, Sect Endocrine Surg, Los Angeles, CA 90095 USA. [Sacks, Harold S.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div,Dept Med, Los Angeles, CA 90095 USA. [Reue, Karen] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. RP Vergnes, L (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, 695 Charles E Young Dr South, Los Angeles, CA 90095 USA. EM lvergnes@ucla.edu FU Fondation Leducq [12CVD04]; National Institutes of Health [P01 HL28481]; National Center for Research Resources [S10RR026744] FX This work was supported by the Fondation Leducq 12CVD04 (L.V., K.R.), National Institutes of Health P01 HL28481 (K.R.), the National Center for Research Resources Grant S10RR026744 (K.R.). NR 40 TC 0 Z9 0 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2016 VL 101 IS 11 BP 4440 EP 4448 DI 10.1210/jc.2016-2670 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG3MK UT WOS:000390948600066 PM 27575944 ER PT J AU Brinson, CW Lu, ZY Li, YC Lopes-Virella, MF Huang, Y AF Brinson, Colleen W. Lu, Zhongyang Li, Yanchun Lopes-Virella, Maria F. Huang, Yan TI Lipopolysaccharide and IL-1 beta coordinate a synergy on cytokine production by upregulating MyD88 expression in human gingival fibroblasts SO MOLECULAR IMMUNOLOGY LA English DT Article DE Lipopolysaccharide; Interleukin-1 beta; Inflammation; MyD88 ID TOLL-LIKE RECEPTORS; PORPHYROMONAS-GINGIVALIS; PERIODONTITIS; LEUKOCYTES; DISEASE; ALPHA AB Both lipopolysaccharide (LPS) and interleukin (IL)-1 beta activate the MyD88-dependent signaling pathways to stimulate proinflammatory cytokine expression. However, it remains unknown how LPS and IL -1 beta interact with each other to coordinate the stimulation. In this study, we sought to investigate the interaction between LPS and IL -1 beta on MyD88-dependent signaling pathways in human gingival fibroblasts (HGFs). Results showed that LPS derived from Porphyromonas gingivalis (Pg LPS) and IL -1 beta cooperatively stimulated mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF kappa B) signaling pathways, and subsequent expression of proinflammatory cytokine expression. Furthermore, our results showed that Pg LPS and IL -1 beta exerted a synergy on MyD88 expression and knockdown of MyD88 expression by small interfering RNA diminished the synergistic effect of Pg LPS and IL -1 beta on 1L-6 expression, suggesting that upregulation of MyD88 is involved in the coordinated stimulation by Pg LPS and IL -1 beta of proinflammatory cytokine expression. Finally, our results showed that pharmacological inhibitors for MAPK and NF kappa B significantly reduced IL-6 secretion stimulated by Pg LPS and IL -1 beta, indicating that the MyD88-dependent MAPK and NF kappa B signaling pathways are essential for the upregulation of proinflammatory cytokine expression by Pg LPS and IL -1 beta. Taken together, this study showed that LPS and IL -1 beta coordinate a synergy on cytokine production by upregulating MyD88 expression in HGFs. Published by Elsevier Ltd. C1 [Brinson, Colleen W.; Lu, Zhongyang; Li, Yanchun; Lopes-Virella, Maria F.; Huang, Yan] Med Univ South Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29403 USA. [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Huang, Y (reprint author), Med Univ South Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29403 USA.; Huang, Y (reprint author), Med Univ South Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; NIH [R01 DE016353] FX This work was supported by a Merit Review grant from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs and NIH grant R01 DE016353 (to Y.H.). NR 26 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD NOV PY 2016 VL 79 BP 47 EP 54 DI 10.1016/j.molimm.2016.09.020 PG 8 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA EG0JL UT WOS:000390718500006 PM 27697591 ER PT J AU Kocarnik, BM Boyko, EJ Matsumoto, AM Fujimoto, WY Hayashi, T Leonetti, DL Page, ST AF Kocarnik, Beverly M. Boyko, Edward J. Matsumoto, Alvin M. Fujimoto, Wilfred Y. Hayashi, Tomoshige Leonetti, Donna L. Page, Stephanie T. TI Baseline estradiol concentration in community-dwelling Japanese American men is not associated with intra-abdominal fat accumulation over 10 years SO OBESITY RESEARCH & CLINICAL PRACTICE LA English DT Article DE Estradiol; Intra-abdominal fat; Japanese Americans ID SEX STEROID-HORMONES; TO-HIP RATIO; ADIPOSE-TISSUE; BODY-COMPOSITION; COMPUTED-TOMOGRAPHY; WAIST CIRCUMFERENCE; SERUM TESTOSTERONE; VISCERAL ADIPOSITY; INSULIN-RESISTANCE; RISK-FACTORS AB Problem: The role of plasma estradiol in the accumulation of intra-abdominal fat (IAF) in men is uncertain. Cross-sectional studies using imaging of IAF have shown either a positive or no association. In contrast, a randomised controlled trial using an aromatase inhibitor to suppress estradiol production found an association between oestrogen deficiency and short-term IAF accumulation. No longitudinal study has been conducted to examine the relationship between plasma estradiol concentration and the change in IAF area measured using direct imaging. Methods: This is a longitudinal observational study in community-dwelling Japanese-American men (n = 215, mean age 52 years, BMI 25.4 kg/m(2)). IAF and subcutaneous fat areas were assessed using computerized tomography (CT) at baseline, 5 and 10 years. Baseline plasma estradiol concentrations were measured using liquid chromatography-tandem mass spectrometry. Results: Univariate analysis found no association between baseline estradiol concentration and baseline IAF, or 5- or 10-year changes in IAF area (r = -0.05 for both time points, p = 0.45 and p = 0.43, respectively). Multivariate linear regression analysis of the change in IAF area by baseline estradiol concentration adjusted for age, baseline IAF area, and weight change found no association with either the 5- or 10-year IAF area change (p = 0.52 and p = 0.55, respectively). Conclusions: Plasma estradiol concentration was not associated with baseline IAF nor with change in IAF area over 5 or 10 years based on serial CT scans in community-dwelling Japanese-American men. These results do not support a role for oestrogen deficiency in IAF accumulation in men. (C) 2015 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved. C1 [Kocarnik, Beverly M.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med & Hosp & Specialty Med Serv, Seattle, WA USA. [Kocarnik, Beverly M.; Boyko, Edward J.; Fujimoto, Wilfred Y.; Page, Stephanie T.] Univ Washington, Dept Med, Div Endocrinol Metab & Nutr, Seattle, WA USA. [Kocarnik, Beverly M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.; Hayashi, Tomoshige] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Hayashi, Tomoshige] Osaka City Univ, Dept Prevent Med & Environm Hlth, Grad Sch Med, Osaka, Japan. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Kocarnik, BM (reprint author), Univ Washington, Endocrinol Diabet Care Ctr, 3rd Floor,4245 Roosevelt Way NE, Seattle, WA 98105 USA. EM bmkocarnik@gmail.com OI Boyko, Edward/0000-0002-3695-192X FU Medical Research Service, Geriatric Research, Education and Clinical Center; NIH [DK-031170, HL-049293, DK-002654, DK-017047, DK-035816, RR-000037]; VA Advanced Fellowship in Geriatrics; Cooperative Studies Program of the Department of Veterans Affairs, Seattle, Washington FX This study was supported in part by the Medical Research Service, Geriatric Research, Education and Clinical Center and Cooperative Studies Program of the Department of Veterans Affairs, Seattle, Washington as well as NIH Grants DK-031170, HL-049293, DK-002654, DK-017047, DK-035816 and RR-000037. Dr. Kocarnik was supported by a VA Advanced Fellowship in Geriatrics. NR 35 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1871-403X EI 1878-0318 J9 OBES RES CLIN PRACT JI Obes. Res. Clin. Pract. PD NOV-DEC PY 2016 VL 10 IS 6 BP 624 EP 632 DI 10.1016/j.orcp.2015.12.002 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EF8AR UT WOS:000390551000002 PM 26747209 ER PT J AU Hamid, T Xu, YY Ismahil, MA Li, QH Jones, SP Bhatnagar, A Bolli, R Prabhu, SD AF Hamid, Tariq Xu, Yuanyuan Ismahil, Mohamed Ameen Li, Qianhong Jones, Steven P. Bhatnagar, Aruni Bolli, Roberto Prabhu, Sumanth D. TI TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE cardiac stem cell; tumor necrosis factor; TNF receptor; cell differentiation ID TUMOR-NECROSIS-FACTOR; HEART-FAILURE; MYOCARDIAL-INFARCTION; FACTOR-ALPHA; MURINE MODEL; KAPPA-B; REGENERATION; CARDIOMYOCYTES; EXPRESSION; PATHWAYS AB Despite expansion of resident cardiac stem cells (CSCs; c-kit(+) Lin(-)) after myocardial infarction, endogenous repair processes are insufficient to prevent adverse cardiac remodeling and heart failure (HF). This suggests that the microenvironment in post-ischemic and failing hearts compromises CSC regenerative potential. Inflammatory cytokines, such as tumor necrosis factor-alpha (TNF), are increased after infarction and in HF; whether they modulate CSC function is unknown. As the effects of TNF are specific to its two receptors (TNFRs), we tested the hypothesis that TNF differentially modulates CSC function in a TNFR-specific manner. CSCs were isolated from wild-type (WT), TNFR1 -/-, and TNFR2 -/- adult mouse hearts, expanded and evaluated for cell competence and differentiation in vitro in the absence and presence of TNF. Our results indicate that TNF signaling in murine CSCs is constitutively related primarily to TNFR1, with TNFR2 inducible after stress. TNFR1 signaling modestly diminished CSC proliferation, but, along with TNFR2, augmented CSC resistance to oxidant stress. Deficiency of either TNFR1 or TNFR2 did not impact CSC telomerase activity. Importantly, TNF, primarily via TNFR1, inhibited cardiomyogenic commitment during CSC differentiation, and instead promoted smooth muscle and endothelial fates. Moreover, TNF, via both TNFR1 and TNFR2, channeled an alternate CSC neuroadrenergic-like fate (capable of catecholamine synthesis) during differentiation. Our results suggest that elevated TNF in the heart restrains cardiomyocyte differentiation of resident CSCs and may enhance adrenergic activation, both effects that would reduce the effectiveness of endogenous cardiac repair and the response to exogenous stem cell therapy, while promoting adverse cardiac remodeling. C1 [Hamid, Tariq; Xu, Yuanyuan; Ismahil, Mohamed Ameen; Prabhu, Sumanth D.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hamid, Tariq; Xu, Yuanyuan; Ismahil, Mohamed Ameen; Prabhu, Sumanth D.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Li, Qianhong; Jones, Steven P.; Bhatnagar, Aruni; Bolli, Roberto] Univ Louisville, Dept Med, Inst Mol Cardiol, Diabet & Obes Ctr, Louisville, KY 40292 USA. RP Prabhu, SD (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 311 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA. EM sprabhu@uab.edu RI Jones, Steven/D-5092-2009 OI Jones, Steven/0000-0001-5376-8089 FU National Institutes of Health [HL-78825, RR-024489, HL-113530, HL-99014]; Veterans Affairs Merit Award FX This work was supported by National Institutes of Health Grants HL-78825 (to R. Bolli, S. D. Prabhu, A. Bhatnagar, and S. P. Jones), RR-024489 (to A. Bhatnagar and S. P. Jones), HL-113530 (to R. Bolli), and HL-99014 (to S. D. Prabhu), and a Veterans Affairs Merit Award (to S. D. Prabhu). NR 45 TC 0 Z9 0 U1 3 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD NOV PY 2016 VL 311 IS 5 BP H1189 EP H1201 DI 10.1152/ajpheart.00904.2015 PG 13 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA EF1WY UT WOS:000390117000012 PM 27591224 ER PT J AU Kristensen, SL Martinez, F Jhund, PS Arango, JL Belohlavek, J Boytsov, S Cabrera, W Gomez, E Hagege, AA Huang, J Kiatchoosakun, S Kim, KS Mendoza, I Senni, M Squire, IB Vinereanu, D Wong, RCC Gong, JJ Lefkowitz, MP Rizkala, AR Rouleau, JL Shi, VC Solomon, SD Swedberg, K Zile, MR Packer, M McMurray, JJV AF Kristensen, Soren Lund Martinez, Felipe Jhund, Pardeep S. Arango, Juan Luis Belohlavek, Jan Boytsov, Sergey Cabrera, Walter Gomez, Efrain Hagege, Albert A. Huang, Jun Kiatchoosakun, Songsak Kim, Kee-Sik Mendoza, Ivan Senni, Michele Squire, Iain B. Vinereanu, Dragos Wong, Raymond Ching-Chiew Gong, Jianjian Lefkowitz, Martin P. Rizkala, Adel R. Rouleau, Jean L. Shi, Victor C. Solomon, Scott D. Swedberg, Karl Zile, Michael R. Packer, Milton McMurray, John J. V. TI Geographic variations in the PARADIGM-HF heart failure trial SO EUROPEAN HEART JOURNAL LA English DT Article DE Heart failure; Treatment outcome; Geographical variation; Clinical trial; Prognosis ID REDUCED EJECTION FRACTION; CLINICAL-TRIALS; ATRIAL-FIBRILLATION; GLOBAL VARIATION; OUTCOMES; MANAGEMENT; MORTALITY; EFFICACY; PROGRAM; EUROPE AB Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative trial in heart failure (HF) to date. Methods and results We looked at five regions: North America (NA) 602 (8%), Western Europe (WE) 1680 (20%), Central/Eastern Europe/Russia (CEER) 2762 (33%), Latin America (LA) 1433 (17%), and Asia-Pacific (AP) 1487 (18%). Notable differences included: WE patients (mean age 68 years) and NA (65 years) were older than AP (58 years) and LA (63 years) and had more coronary disease; NA and CEER patients had the worst signs, symptoms, and functional status. North American patients were the most likely to have a defibrillating-device (54 vs. 2% AP) and least likely prescribed a mineralocorticoid receptor antagonist (36 vs. 65% LA). Other evidence-based therapies were used most frequently in NA and WE. Rates of the primary composite outcome of cardiovascular (CV) death or HF hospitalization (per 100 patient-years) varied among regions: NA 13.6 (95% CI 11.7-15.7) WE 9.6 (8.6-10.6), CEER 12.3 (11.4-13.2), LA 11.2 (10.0-12.5), and AP 12.5 (11.3-13.8). After adjustment for prognostic variables, relative to NA, the risk of CV death was higher in LA and AP and the risk of HF hospitalization lower in WE. The benefit of sacubitril/valsartan was consistent across regions. Conclusion There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan. C1 [Kristensen, Soren Lund; Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Kristensen, Soren Lund] Rigshosp, Dept Cardiol, Copenhagen, Denmark. [Martinez, Felipe] Univ Nacl Cordoba, Med, Cordoba, Argentina. [Arango, Juan Luis] Guatemalan Heart Inst, Guatemala City, Guatemala. [Belohlavek, Jan] Charles Univ Prague, Gen Univ Hosp, Dept Med 2, Cardiovasc Med, Prague, Czech Republic. [Belohlavek, Jan] Charles Univ Prague, Med Sch 1, Prague, Czech Republic. [Boytsov, Sergey] Natl Res Ctr Prevent Med, Moscow, Russia. [Cabrera, Walter] Clin Vesalio, Lima, Peru. [Gomez, Efrain] Clin Shaio, Bogota, Colombia. [Hagege, Albert A.] Paris Descartes Univ, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Dept Cardiol,Sorbonne Paris Cite,INSERM U970,Pari, Paris, France. [Huang, Jun] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China. [Kiatchoosakun, Songsak] Khon Kaen Univ, Cardiol, Med, Khon Kaen, Thailand. [Kim, Kee-Sik] Daegu Catholic Univ Hosp, Daegu, South Korea. [Mendoza, Ivan] Cent Univ Venezuela, Venezuela Inst Trop Med, Caracas, Venezuela. [Senni, Michele] Azienda Osped Papa Giovanni XXIII, Cardiol Scompenso & Trapianti Cuore 1, Bergamo, Italy. [Squire, Iain B.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Squire, Iain B.] Glenfield Hosp, NIHR Cardiovasc Biomed Res Unit, Leicester, Leics, England. [Vinereanu, Dragos] Univ Med & Pharm Carol Davila, Univ & Emergency Hosp, Bucharest, Romania. [Wong, Raymond Ching-Chiew] Natl Univ Heart Ctr, Dept Cardiol, Singapore, Singapore. [Gong, Jianjian; Lefkowitz, Martin P.; Rizkala, Adel R.; Shi, Victor C.] Novartis Pharmaceut, E Hanover, NJ USA. [Rouleau, Jean L.] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada. [Solomon, Scott D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden. [Swedberg, Karl] Imperial Coll, Natl Heart & Lung Inst, London, England. [Zile, Michael R.] Med Univ South Carolina, Charleston, SC USA. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Packer, Milton] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA. RP McMurray, JJV (reprint author), Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk FU Novartis; Danish Independent Research Council; Heart Failure Association of the European Society of Cardiology (ESC) FX The study was funded by Novartis. S.L.K. is supported by a Postdoctoral grant from the Danish Independent Research Council, and a Research Fellowship from the Heart Failure Association of the European Society of Cardiology (ESC). NR 24 TC 5 Z9 5 U1 7 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD NOV 1 PY 2016 VL 37 IS 41 BP 3167 EP + DI 10.1093/eurheartj/ehw226 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EF4MR UT WOS:000390303700013 PM 27354044 ER PT J AU Lancaster, CL Teeters, JB Gros, DF Back, SE AF Lancaster, Cynthia L. Teeters, Jenni B. Gros, Daniel F. Back, Sudie E. TI Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment SO JOURNAL OF CLINICAL MEDICINE LA English DT Review DE posttraumatic stress disorder; evidence based; empirically supported; assessment; psychotherapy; pharmacotherapy; prolonged exposure; cognitive processing therapy; eye movement desensitization and reprocessing; selective serotonin reuptake inhibitors ID COGNITIVE-PROCESSING THERAPY; EYE-MOVEMENT DESENSITIZATION; RANDOMIZED CONTROLLED-TRIAL; PROLONGED EXPOSURE; REPROCESSING EMDR; RAPE VICTIMS; LIFE EVENTS; PSYCHOMETRIC PROPERTIES; SCREENING INSTRUMENT; SERTRALINE TREATMENT AB Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associated risk factors, and describe brief, evidence-based measures that can be used to screen for PTSD and monitor symptom changes over time. In regard to treatment, we highlight commonly used, evidence-based psychotherapies and pharmacotherapies for PTSD. Among psychotherapeutic approaches, evidence-based approaches include cognitive-behavioral therapies (e.g., Prolonged Exposure and Cognitive Processing Therapy) and Eye Movement Desensitization and Reprocessing. A wide variety of pharmacotherapies have received some level of research support for PTSD symptom alleviation, although selective serotonin reuptake inhibitors have the largest evidence base to date. However, relapse may occur after the discontinuation of pharmacotherapy, whereas PTSD symptoms typically remain stable or continue to improve after completion of evidence-based psychotherapy. After reviewing treatment recommendations, we conclude by describing critical areas for future research. C1 [Lancaster, Cynthia L.; Teeters, Jenni B.; Gros, Daniel F.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Lancaster, Cynthia L.; Teeters, Jenni B.; Gros, Daniel F.; Back, Sudie E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29401 USA. RP Back, SE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.; Back, SE (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29401 USA. EM lancascy@musc.edu; teeters@musc.edu; grosd@musc.edu; backs@musc.edu NR 95 TC 1 Z9 1 U1 24 U2 24 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD NOV PY 2016 VL 5 IS 11 AR 105 DI 10.3390/jcm5110105 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA EF1QC UT WOS:000390098800013 ER PT J AU Switzer, GE Bruce, J Kiefer, DM Kobusingye, H Drexler, R Besser, RM Confer, DL Horowitz, MM King, RJ Shaw, BE van Walraven, SM Wiener, L Packman, W Varni, JW Pulsipher, MA AF Switzer, Galen E. Bruce, Jessica Kiefer, Deidre M. Kobusingye, Hati Drexler, Rebecca Besser, RaeAnne M. Confer, Dennis L. Horowitz, Mary M. King, Roberta J. Shaw, Bronwen E. van Walraven, Suzanna M. Wiener, Lori Packman, Wendy Varni, James W. Pulsipher, Michael A. TI Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors SO JOURNAL OF PEDIATRICS LA English DT Article ID BONE-MARROW DONATION; SIBLING DONOR; THE-LITERATURE; EXPERIENCE; TRANSPLANTATION; PEDSQL(TM)-4.0; RELIABILITY; VALIDITY; HARVEST; SAFETY AB Objectives To examine health-related quality of life (HRQoL) among sibling pediatric hematopoietic stem cell donors from predonation through 1 year postdonation, to compare donor-reported HRQoL scores with proxy-reports by parents/guardians and those of healthy norms, and to identify predonation factors (including donor age) potentially associated with postdonation HRQoL, to better understand the physical and psychosocial effects of pediatric hematopoietic stem cell donation. Study design A random sample of 105 pediatric donors from US centers and a parent/guardian were interviewed by telephone predonation and 4 weeks and 1 year postdonation. The interview included sociodemographic, psychosocial, and HRQoL items. A sample of healthy controls matched to donors by age, gender, and race/ethnicity was generated. Results Key findings included (1) approximately 20% of donors at each time point had very poor HRQoL; (2) child self-reported HRQoL was significantly lower than parent proxy-reported HRQoL at all 3 time points and significantly lower than that of norms at predonation and 4 weeks postdonation; and (3) younger children were at particular risk of poor HRQoL. Conclusions Additional research to identify the specific sources of poorer HRQoL among at-risk donors (eg, the donation experience vs having a chronically ill sibling) and the reasons that parents may be overestimating HRQoL in their donor children is critical and should lead to interventions and policy changes that ensure positive experiences for these minor donors. C1 [Switzer, Galen E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, Galen E.; Bruce, Jessica] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kiefer, Deidre M.; Kobusingye, Hati; Drexler, Rebecca; Besser, RaeAnne M.; Confer, Dennis L.; King, Roberta J.] Natl Marrow Donor Program Be Match, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Horowitz, Mary M.; Shaw, Bronwen E.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [van Walraven, Suzanna M.] Sanquin Blood Supply, Dept Donor Serv, Amsterdam, Netherlands. [van Walraven, Suzanna M.] Leiden Univ, Med Ctr, Dept Pediat Stem Cell Transplantat, Willem Alexander Childrens Hosp, Leiden, Netherlands. [Wiener, Lori] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Packman, Wendy] Palo Alto Univ, Dept Psychol, Palo Alto, CA USA. [Varni, James W.] Texas A&M Univ, Dept Pediat, College Stn, TX USA. [Varni, James W.] Texas A&M Univ, Ctr Hlth Syst & Design, Dept Landscape Architecture & Urban Planning, College Stn, TX USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Div Hematol Oncol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA. RP Switzer, GE (reprint author), Univ Pittsburgh, 3501 Forbes Ave,Oxford Bldg,Suite 410, Pittsburgh, PA 15213 USA. EM SwitzerGE@upmc.edu OI Switzer, Galen/0000-0001-8541-9449 FU National Heart, Lung, and Blood Institute [R01 HL085707]; Mapi Research Trust FX Supported by the National Heart, Lung, and Blood Institute (R01 HL085707). J.V. holds the copyright and the trademark for the Pediatric Quality of Life Inventory and receives financial compensation from the Mapi Research Trust, which is a nonprofit research institute that charges distribution fees to for-profit companies that use the Pediatric Quality of Life Inventory. The other authors declare no conflicts of interest. NR 27 TC 2 Z9 2 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD NOV PY 2016 VL 178 BP 164 EP + DI 10.1016/j.jpeds.2016.07.009 PG 8 WC Pediatrics SC Pediatrics GA EF0ON UT WOS:000390025400031 PM 27522440 ER PT J AU Chung, J Valentine, W Sharath, SE Pathak, A Barshes, NR Pisimisis, G Kougias, P Mills, JL AF Chung, Jayer Valentine, Wilmer Sharath, Sherene E. Pathak, Amite Barshes, Neal R. Pisimisis, George Kougias, Panagiotis Mills, Joseph L. TI Percutaneous intervention for carotid in-stent restenosis does not improve outcomes compared with nonoperative management SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ULTRASOUND VELOCITY CRITERIA; RECURRENT STENOSIS; ARTERY STENOSIS; ENDARTERECTOMY; ANGIOPLASTY; STROKE; DISEASE; RISK; TRIAL AB Background: The appropriateness of percutaneous intervention for moderate to severe carotid in-stent restenosis (C-ISR) is unclear. We therefore sought to compare stroke/death/myocardial infarction (MI) rates between percutaneous interventions and nonoperative management for 50% C-ISR. Methods: We performed a single-center retrospective review of consecutive patients presenting with 50% C-ISR to the vascular surgery service. Demographics, comorbidities, and intraoperative and postoperative variables were obtained. The degree of stenosis was verified by review of digital subtraction or computed tomography angiograms. The primary outcome was stroke/death/MI after the diagnosis of 50% C-ISR. x2, Kruskal-Wallis, and Kaplan-Meier analysis was used to quantify outcomes of the patients treated percutaneously vs nonoperatively. Results: During a 13-year period, 59 patients (75 C-ISRs) presented with 50% C-ISRs (n = 58 male [98%]; n = 57 C-ISRs asymptomatic [76%]) with a median age of 67.5 years (62.8-74.6). The initial pathologic process underlying the original stent was atherosclerosis in 33 (70%), radiation induced in 10 (21%), prior carotid endarterectomy in 4 (9%), and unknown in 28 (37%). Forty C-ISRs underwent a percutaneous intervention (19 percutaneous angioplasty only [48%]; 21 repeated stent and percutaneous angioplasty [52%]). Median follow-up for the entire cohort was 948 days (283-2322) and similar between the intervention and nonintervention arms. There were no significant differences between the arms with respect to age (P=.16), medical comorbidities (P>.05), original stent type (P=.46), or clopidogrel use (P=.74). At 30 days, there was one stroke and subsequent death in the intervention arm and none in the nonintervention arm. During the follow-up period, a median of 1.0 procedure was required to maintain patency. By Kaplan-Meier analysis, there were no statistically significant differences between the intervention and nonintervention arms with respect to stroke/death/MI as a composite or any of the individual components at last follow-up (P =.82). Kaplan-Meier estimated patency was not significantly superior in the intervention vs the nonintervention arm (8.0 years 1.1 vs 5.3 years 0.7; P =.14). Conclusions: Over 13 years, percutaneous interventions for 50% C-ISR were safe and durable. However, interventions fail to improve long-term stroke/death/MI or patency rates relative to nonintervention. Intervention for C-ISR may not be necessary, although future appropriately powered, prospective trials will be necessary to confirm these findings and to determine the appropriateness of interventions for C-ISR. C1 [Chung, Jayer; Valentine, Wilmer; Sharath, Sherene E.; Pathak, Amite; Barshes, Neal R.; Pisimisis, George; Kougias, Panagiotis; Mills, Joseph L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. RP Chung, J (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM jayer.chung@bcm.edu OI Mills, Joseph/0000-0002-4955-4384 FU Michael E. DeBakey Department of Surgery at Baylor College of Medicine FX The work was funded by intramural funding from the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. NR 31 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD NOV PY 2016 VL 64 IS 5 BP 1286 EP + DI 10.1016/j.jvs.2016.05.086 PG 10 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EF0UQ UT WOS:000390042100013 PM 27462003 ER PT J AU Harris, NM Ritzel, R Mancini, N Jiang, YH Yi, X Manickam, DS Banks, WA Kabanov, AV McCullough, LD Verma, R AF Harris, Nia M. Ritzel, Rodney Mancini, Nikolas Jiang, Yuhang Yi, Xiang Manickam, Devika S. Banks, William A. Kabanov, Alexander V. McCullough, Louise D. Verma, Rajkumar TI Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE Stroke; Neuroprotection; Neuro-restorative; BDNF; Depressive behavior ID ADULT HIPPOCAMPAL NEUROGENESIS; ENTRAPPING ENZYME MOLECULES; FUNCTIONAL RECOVERY; DEPRESSIVE BEHAVIOR; SOCIAL-INTERACTION; STROKE RECOVERY; BDNF; MICELLES; CELLS; INFARCTION AB Background: Low levels of brain-derived neurotrophic factor (BDNF) are linked to delayed neurological recovery, depression, and cognitive impairment following stroke. Supplementation with BDNF reverses these effects. Unfortunately, systemically administered BDNF in its native form has minimal therapeutic value due to its poor blood brain barrier permeability and short serum half-life. In this study, a novel nano-particle polyion Complex formulation of BDNF (nano-BDNF) was administered to mice after experimental ischemic stroke. Methods: Male C57BL/6J (8-10 weeks) mice were randomly assigned to receive nano-BDNF, native-BDNF, or saline treatment after being subjected to 60 min of reversible middle cerebral artery. occlusion (MCAo). Mice received the first dose at 3 (early treatment), 6 (intermediate treatment), or 12 h (delayed treatment) following stroke onset; a second dose was given in all cohorts at 24 h after stroke onset Post-stroke outcome was evaluated by behavioral, histological, and molecular analysis for 15 days after stroke. Results: Early and intermediate nano-BDNF treatment led to a significant reduction in cerebral tissue loss. Delayed treatment led to improved memory/cognition, reduced post-stroke depressive phenotypes, and maintained myelin basic protein and brain BDNF levels, but had no effect on tissue atrophy. Conclusions: The results indicate that administration of a novel nano-particle formulation of BDNF leads to both neuroprotective and neuro-restorative effects after stroke. (C) 2016 Elsevier Inc. All rights reserved. C1 [Harris, Nia M.; Ritzel, Rodney; Mancini, Nikolas; McCullough, Louise D.; Verma, Rajkumar] Univ Connecticut, Dept Neurosci, Ctr Hlth, Farmington, CT 06032 USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [Jiang, Yuhang; Yi, Xiang; Manickam, Devika S.; Kabanov, Alexander V.] Univ North Carolina Chapel Hill, UNC Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA. [McCullough, Louise D.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA. [Manickam, Devika S.] Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA. RP Verma, R (reprint author), UCONN Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA. EM raverma@uchc.edu OI Jiang, Yuhang/0000-0003-1982-3237 FU National Institutes of Health [R01NSO77769, R21NS088152]; AHA postdoctoral fellowship [14POST20380612]; University Cancer Research Fund; UNC Eshelman School of Pharmacy FX This work was supported by the National Institutes of Health grants R01NSO77769 (to Louise McCullough) and R21NS088152 (to Alexander V Kabanov); AHA postdoctoral fellowship 14POST20380612 (to Rajkumar Verma); and the Carolina Partnership, a strategic partnership between the UNC Eshelman School of Pharmacy and The University Cancer Research Fund. NR 57 TC 2 Z9 2 U1 4 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD NOV-DEC PY 2016 VL 150 BP 48 EP 56 DI 10.1016/j.pbb.2016.09.003 PG 9 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA EF1KU UT WOS:000390084500007 PM 27619636 ER PT J AU Goren, JL Rose, AJ Engle, RL Smith, EG Christopher, MLD Rickles, NM Semla, TP McCullough, MB AF Goeren, Jessica L. Rose, Adam J. Engle, Ryann L. Smith, Eric G. Christopher, Melissa L. D. Rickles, Nathaniel M. Semla, Todd P. McCullough, Megan B. TI Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine SO PSYCHIATRIC SERVICES LA English DT Article ID IMPLEMENTATION RESEARCH; CONSOLIDATED FRAMEWORK; HEALTH-CARE; SCHIZOPHRENIA; POLYPHARMACY; MANAGEMENT; SERVICES; TRIAL AB Objective: Twenty to thirty percent of patients with schizophrenia experience treatment resistance. Clozapine is the only medication proven effective for treatment-resistant schizophrenia. However, in most settings less than 25% of patients with treatment-resistant schizophrenia receive clozapine. This study was conducted to identify facilitators of and barriers to clozapine use to inform development of interventions to maximize appropriate clozapine utilization. Methods: Seventy semistructured phone interviews were conducted with key informants of clozapine processes at U.S. Department of Veterans Affairs medical centers in various U.S. regions, including urban and rural areas, with high (N=5) and low (N=5) rates of clozapine utilization. Interviewees included members of mental health leadership, psychiatrists, clinical pharmacists, and advanced practice nurses. Interviews were analyzed by using an emergent thematic strategy to identify barriers and facilitators related to clozapine prescribing. Results: High utilization was associated with integration of nonphysician psychiatric providers and clear organizational processes and infrastructure for treatment of severe mental illness, for example, use of clozapine clinics and mental health intensive case management. Low utilization was associated with a lack of champions to support clozapine processes and with limited-capacity care systems. Obstacles identified at both high-and low-utilization sites included complex, time-consuming paperwork; reliance on a few individuals to facilitate processes; and issues related to transportation for patients living far from care facilities. Conclusions: Implementation efforts to organize, streamline, and simplify clozapine processes; development of a multidisciplinary clozapine clinic; increased capacity of existing clinics; and provision of transportation are reasonable targets to increase clozapine utilization. C1 [Goeren, Jessica L.] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, Kingston, RI 02881 USA. [Goeren, Jessica L.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlthcare Org & Implementat Res, Bedford, MA USA. [Rose, Adam J.; Smith, Eric G.; McCullough, Megan B.] Boston Univ, Dept Med, Boston, MA 02215 USA. [Smith, Eric G.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01003 USA. [McCullough, Megan B.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Engle, Ryann L.] US Dept Vet Affairs Boston Hlthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Christopher, Melissa L. D.] US Dept Vet Affairs, Natl Pharm Benefits Management Acad Detailing Ser, San Diego, CA USA. [Rickles, Nathaniel M.] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Storrs, CT 06268 USA. [Rickles, Nathaniel M.] US Dept Vet Affairs, Natl Pharm Benefits Management Serv, San Diego, CA USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Gen Internal Med, Chicago, IL 60611 USA. RP Goren, JL (reprint author), Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, Kingston, RI 02881 USA.; Goren, JL (reprint author), Edith Nourse Rogers Mem Vet Hosp, Ctr Hlthcare Org & Implementat Res, Bedford, MA USA. EM jgoren@challiance.org FU U.S. Department of Veterans Affairs' HSR&D Service Mental Health QUERI; Center for Healthcare Organization and Implementation Research FX This work was supported in part by locally initiated projects from the U.S. Department of Veterans Affairs' HSR&D Service Mental Health QUERI and Center for Healthcare Organization and Implementation Research. The contents of this article do not necessarily represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 40 TC 0 Z9 0 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV 1 PY 2016 VL 67 IS 11 BP 1189 EP 1196 DI 10.1176/appi.ps.201500506 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EF1YX UT WOS:000390122200010 PM 27301765 ER PT J AU Cameron, M Wan, CKV Vu, AV Woo, DT Lie, JD Tu, KN AF Cameron, Madison Wan, Chew King Victoria Vu, Amanda V. Woo, Denny T. Lie, Janette D. Tu, Kristie N. TI Suicide in the Veteran Population SO US PHARMACIST LA English DT Article AB In 2014, the Office of Suicide Prevention of the U.S. Department of Veterans Affairs reported that veterans have a 21% higher risk for suicide when compared to civilian adults. Greater prevalence of mental health conditions, such as depression and posttraumatic stress disorder (PTSD), as well as substance use disorders, place veterans at a higher risk for suicide. Early identification of high-risk patients allows for appropriate intervention and assistance to recovery. Understanding the unique risk factors associated with veterans, being aware of the warning signs of suicidality, possessing knowledge of medications associated with an increased risk of suicide, and being familiar with available suicide-related resources can better equip pharmacists with the tools needed to help prevent suicide in this population. C1 [Cameron, Madison; Wan, Chew King Victoria; Vu, Amanda V.; Woo, Denny T.] Univ Southern Calif, Sch Pharm, Los Angeles, CA 90007 USA. [Cameron, Madison; Wan, Chew King Victoria; Vu, Amanda V.; Woo, Denny T.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm VA Learning Opportun Residency VALOR, Los Angeles, CA 90073 USA. [Lie, Janette D.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm Educ & Training, Los Angeles, CA USA. [Tu, Kristie N.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr, North Hills, CA USA. RP Cameron, M (reprint author), Univ Southern Calif, Sch Pharm, Los Angeles, CA 90007 USA.; Cameron, M (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Pharm VA Learning Opportun Residency VALOR, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOBSON PUBLISHING LLC PI NEW YORK PA 100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA SN 0148-4818 EI 2331-3501 J9 US PHARM JI US Pharm. PD NOV PY 2016 VL 41 IS 11 BP HS12 EP HS18 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EF1XS UT WOS:000390119100005 ER PT J AU Howe, JL Hintenach, A Melendez, L Kramer, J AF Howe, J. L. Hintenach, A. Melendez, L. Kramer, J. TI IMPROVING TEAM-BASED CARE OF OLDER VETERANS THROUGH A QUALITY IMPROVEMENT PROJECT IN RURAL CLINICS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Howe, J. L.] Icahn Sch Med Mt Sinai, Geriatr & Palliat Med, New York, NY 10029 USA. [Howe, J. L.; Hintenach, A.] James J Peters VAMC, New York, NY USA. [Melendez, L.; Kramer, J.] Greater Los Angeles VA GRECC, Sepulveda, CA USA. [Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 74 EP 74 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000269 ER PT J AU Elliott, M Beckett, M Ritenour, D Giordano, LA Saliba, D AF Elliott, M. Beckett, M. Ritenour, D. Giordano, L. A. Saliba, D. TI EVALUATING A POTENTIAL HEALTH PLAN-LEVEL MEASURE OF LIMITING GAIN IN BODY MASS INDEX AMONG SENIORS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Elliott, M.; Beckett, M.; Saliba, D.] RAND Corp, Hlth, Santa Monica, CA USA. [Ritenour, D.; Giordano, L. A.] Hlth Serv Advisory Grp, Phoenix, AZ USA. [Saliba, D.] US Dept Vet Affairs, Los Angeles, CA USA. [Saliba, D.] Univ Calif Los Angeles, Borun Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 437 EP 437 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002080 ER PT J AU Ruis, AR Shaffer, DW Shirley, DK Safdar, N AF Ruis, A. R. Shaffer, David Williamson Shirley, Daniel K. Safdar, Nasia TI Teaching health care workers to adopt a systems perspective for improved control and prevention of health care-associated infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material DE Systems; infection; Clostridium difficile infection; Cognitive simulation ID GRADUATE MEDICAL-EDUCATION; NATIONAL-SURVEY; INTERVENTIONS; METAANALYSIS; HOSPITALS; PERSONNEL; IMPACT; COSTS C1 [Ruis, A. R.; Shaffer, David Williamson] Univ Wisconsin Madison, Wisconsin Ctr Educ Res, Madison, WI USA. [Ruis, A. R.] Univ Wisconsin Madison, Dept Surg, Madison, WI USA. [Shirley, Daniel K.; Safdar, Nasia] Univ Wisconsin Madison, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, 5138 Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin Madison, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, 5138 Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU AHRQ HHS [R03 HS023791, R18 HS024039] NR 43 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV 1 PY 2016 VL 44 IS 11 BP 1360 EP 1364 DI 10.1016/j.ajic.2016.04.211 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QQ UT WOS:000389510700047 PM 27424302 ER PT J AU Lang, J Shlipak, MG AF Lang, Joshua Shlipak, Michael G. TI Kidney Disease, Income, and Life Expectancy SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID UNITED-STATES; SOCIOECONOMIC-STATUS; HEALTH; RISK; DISPARITIES; MORTALITY; INEQUALITIES; ASSOCIATION; POPULATION; CKD C1 [Lang, Joshua; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lang, Joshua] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu NR 25 TC 0 Z9 0 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2016 VL 68 IS 5 BP 674 EP 676 DI 10.1053/j.ajkd.2016.07.004 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA EE3QT UT WOS:000389511300007 PM 27772630 ER PT J AU Surolia, R Karki, S Wang, Z Kulkarni, T Li, FJ Vohra, S Batra, H Nick, JA Duncan, SR Thannickal, VJ Steyn, AJC Agarwal, A Antony, VB AF Surolia, Ranu Karki, Suman Wang, Zheng Kulkarni, Tejaswini Li, Fu Jun Vohra, Shikhar Batra, Hitesh Nick, Jerry A. Duncan, Steven R. Thannickal, Victor J. Steyn, Adrie J. C. Agarwal, Anupam Antony, Veena B. TI Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE aging; heme oxygenase 1; nontuberculosis mycobacterium; SOCS3; cell death ID TUBERCULOSIS-INDUCED APOPTOSIS; LUNG-DISEASE; CELL-DEATH; SIGNALING PATHWAY; HUMAN MACROPHAGES; GENE-EXPRESSION; AVIUM COMPLEX; T-CELLS; RESISTANCE; NECROSIS AB Pulmonary infections with nontuberculous mycobacteria (P-NTM), such as by Mycobacterium avium complex (M. avium), are increasingly found in the elderly, but the underlying mechanisms are unclear. Recent studies suggest that adaptive immunity is necessary, but not sufficient, for host defense against mycobacteria. Heme oxygenase-1 (HO-1) has been recognized as a critical modulator of granuloma formation and programmed cell death in mycobacterial infections. Old mice (18-21 mo) infected with M. avium had attenuated HO-1 response with diffuse inflammation, high burden of mycobacteria, poor granuloma formation, and decreased survival (45%), while young mice (4-6 mo) showed tight, well-defined granuloma, increased HO-1 expression, and increased survival (95%). To further test the role of HO-1 in increased susceptibility to P-NTM infections in the elderly, we used old and young HO-1(+/+) and HO-1(-/-) mice. The transcriptional modulation of the JAK/STAT signaling pathway in HO-1 (-/-) mice due to M. avium infection demonstrated similarities to infected wild-type old mice with upregulation of SOCS3 and inhibition of Bcl2. Higher expression of SOCS3 with downregulation of Bcl2 resulted in higher macrophage death via cellular necrosis. Finally, peripheral blood monocytes (PBMCs) from elderly patients with P-NTM also demonstrated attenuated HO-1 responses after M. avium stimulation and increased cell death due to cellular necrosis (9.69% +/- 2.02) compared with apoptosis (4.75% +/- 0.98). The augmented risk for P-NTM in the elderly is due, in part, to attenuated HO-1 responses, subsequent upregulation of SOCS3, and inhibition of Bcl2, leading to programmed cell death of macrophages, and sustained infection. C1 [Surolia, Ranu; Karki, Suman; Wang, Zheng; Kulkarni, Tejaswini; Li, Fu Jun; Vohra, Shikhar; Batra, Hitesh; Duncan, Steven R.; Thannickal, Victor J.; Antony, Veena B.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA. [Nick, Jerry A.] Univ Colorado, Dept Med, Natl Jewish Hlth, Denver, CO 80202 USA. [Steyn, Adrie J. C.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Agarwal, Anupam] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [Steyn, Adrie J. C.] KwaZulu Natal Res Inst TB & HIV, Durban, South Africa. [Agarwal, Anupam] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. RP Antony, VB (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. EM vantony@uabmc.edu FU NIDDK NIH HHS [R01 DK059600] NR 59 TC 0 Z9 1 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD NOV 1 PY 2016 VL 311 IS 5 BP L928 EP L940 DI 10.1152/ajplung.00397.2015 PG 13 WC Physiology; Respiratory System SC Physiology; Respiratory System GA EE5IS UT WOS:000389640700011 PM 27694475 ER PT J AU Zhao, JP Yu, H Liu, YD Gibson, SA Yan, ZQ Xu, X Gaggar, A Li, PK Li, CL Wei, S Benveniste, EN Qin, HW AF Zhao, Jiping Yu, Hao Liu, Yudong Gibson, Sara A. Yan, Zhaoqi Xu, Xin Gaggar, Amit Li, Pui-Kai Li, Chenglong Wei, Shi Benveniste, Etty N. Qin, Hongwei TI Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE acute lung injury; JAK/STAT pathway; suppressor of cytokine signaling-3; STAT3 inhibitor ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; ALVEOLAR MACROPHAGES; SYSTEMIC INFLAMMATION; SIGNALING PATHWAY; GENE-EXPRESSION; INNATE IMMUNITY; IN-VIVO; ACTIVATION AB Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are diseases with high mortality. Macrophages and neutrophils are responsible for inflammatory responses in ALI and ARDS, which are characterized by excessive production of proinflammatory mediators in bronchoalveolar lavage fluid (BALF) and plasma. Aberrant activation of the JAK/STAT pathway is critical for persistent inflammation in many conditions such as infection and autoimmunity. Given the importance of the STAT3 transcription factor in activating macrophages and neutrophils and augmenting inflammation, we investigated the therapeutic potential of inhibiting STAT3 activity using the small-molecule STAT3 inhibitor, LLL12. Our results demonstrate that LPS induces STAT3 activation in macrophages in vitro and in CD45(+)CD11b(+) cells from BALF in the LPS-induced ALI model in vivo. LLL12 treatment inhibits LPS-induced lung inflammation in the ALI model, which is accompanied by suppression of LPS-induced STAT3 activation and an inhibition of macrophage and inflammatory cell infiltration in lung and BALF. LLL12 treatment also suppresses expression of proinflammatory genes including IL-1 beta, IL-6, TNF-alpha, iNOS, CCL2, and MHC class II in macrophages and inflammatory cells from BALF and serum as determined by ELISA. Furthermore, hyperactivation of STAT3 in LysMCre-SOCS3(fl/fl) mice accelerates the severity of inflammation in the ALI model. Both pre- and post-LPS treatment with LLL12 decrease LPS-induced inflammatory responses in mice with ALI. Importantly, LLL12 treatment attenuates STAT3 phosphorylation in human peripheral blood mononuclear cells induced by plasma from patients with ARDS, which suggests the feasibility of targeting the STAT3 pathway therapeutically for patients with ALI and ARDS. C1 [Zhao, Jiping] Shandong Univ, Dept Resp Med, Qilu Hosp, Jinan, Shandong, Peoples R China. [Zhao, Jiping; Yu, Hao; Liu, Yudong; Gibson, Sara A.; Yan, Zhaoqi; Benveniste, Etty N.; Qin, Hongwei] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, 1918 Univ Blvd,MCLM 390, Birmingham, AL 35294 USA. [Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Wei, Shi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL USA. [Li, Pui-Kai; Li, Chenglong] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA. RP Qin, HW (reprint author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, 1918 Univ Blvd,MCLM 390, Birmingham, AL 35294 USA. EM hqin@uab.edu FU National Institutes of Health [NS45290, NS57563, T32 AI007051, HL102371]; Veterans Administration [1I01 BX 001756]; China Scholarship Council [201406220200] FX This work was supported in part by National Institutes of Health grants NS45290 and NS57563 (to E. Benveniste and H. Qin), T32 AI007051 (to S. Gibson), National Institutes of Health grant HL102371 (A. Gaggar), and the Veterans Administration 1I01 BX 001756 (A. Gaggar). J. Zhao was supported by the China Scholarship Council (201406220200). NR 67 TC 1 Z9 1 U1 10 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD NOV 1 PY 2016 VL 311 IS 5 BP L868 EP L880 DI 10.1152/ajplung.00281.2016 PG 13 WC Physiology; Respiratory System SC Physiology; Respiratory System GA EE5IS UT WOS:000389640700005 PM 27638904 ER PT J AU Vargas, LA Pinilla, OA Diaz, RG Sepulveda, DE Swenson, ER Perez, NG Alvarez, BV AF Vargas, Lorena A. Pinilla, Oscar A. Diaz, Romina G. Sepulveda, Diana E. Swenson, Erik R. Perez, Nestor G. Alvarez, Bernardo V. TI Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats SO CARDIOVASCULAR PATHOLOGY LA English DT Article DE Heart failure; Carbonic anhydrase inhibitors; Intracellular pH; Myocardial infarction ID HEART-FAILURE; MYOCARDIAL-INFARCTION; CARDIOMYOCYTE HYPERTROPHY; EXCHANGE INHIBITION; ENHANCED ACTIVITY; INTRACELLULAR PH; IN-VIVO; IX; HYPOXIA; ACTIVATION AB Background: Two potent carbonic anhydrase (CA) inhibitors with widely differing membrane permeability, poorly diffusible benzolamide (BZ), and highly diffusible ethoxzolamide (ETZ) were assessed to determine whether they can reduce cardiac dysfunction in rats subjected to coronary artery ligation (CAL)-induced myocardial infarction. Methods and results: Rats with evidence of heart failure (HF) at 32 weeks following a permanent left anterior coronary artery occlusion were treated with placebo, BZ, or ETZ (4 mg kg day(-1)) for 4 weeks at which time left ventricular function and structure were evaluated. Lung weight/body weight (LW/BW) ratio increased in CAL rats by 17 +/- 1% vs. control, suggesting pulmonary edema. There was a trend for BZ and ETZ to ameliorate the increase in LW/BW by almost 50% (9 +/- 5% and 9 +/- 8%, respectively, versus CAL) (P=.16, NS). Echocardiographic assessment showed decreased left ventricular midwall shortening in HF rats, 21 +/- 1% vs. control 32 +/- 1%, which was improved by BZ to 29 +/- 1% and ETZ to 27 +/- 1%, and reduced endocardial shortening in HF rats 38 +/- 3% vs. control 62 +/- 1%, partially restored by BZ and ETZ to similar to 50%. Expression of the hypoxia-inducible membrane-associated CAIX isoform increased by similar to 60% in HF rat hearts, and this effect was blocked by ETZ. Conclusions: We conclude that CAL-induced myocardial interstitial fibrosis and associated decline in left ventricular function were diminished with BZ or ETZ treatment. The reductions in cardiac remodeling in HF with both ETZ and BZ CA inhibitors suggest that inhibition of a membrane-bound CA appears to be the critical site for this protection. (C) 2016 Elsevier Inc. All rights reserved. C1 [Vargas, Lorena A.; Pinilla, Oscar A.; Diaz, Romina G.; Perez, Nestor G.; Alvarez, Bernardo V.] Univ Nacl La Plata, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina. [Sepulveda, Diana E.] Univ Favaloro, Dept Patol, Buenos Aires, DF, Argentina. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med Pulm & Crit Care Med, Seattle, WA 98108 USA. Fac Ciencias Med, RA-1900 La Plata, Buenos Aires, Argentina. RP Alvarez, BV (reprint author), Fac Ciencias Med, Calle 60 & 120, RA-1900 La Plata, Buenos Aires, Argentina. EM balvarez@med.unlp.edu.ar FU Agencia Nacional de Promocion Cientifica y Tecnologica (FONCyT, PICT) [1976]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Type II Postdoctoral Fellowship) FX This work was funded by a grant from Agencia Nacional de Promocion Cientifica y Tecnologica to BVA (FONCyT, PICT2013 No. 1976). LAV was a recipient of a fellowship from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Type II Postdoctoral Fellowship). NR 51 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-8807 EI 1879-1336 J9 CARDIOVASC PATHOL JI Cardiovasc. Pathol. PD NOV-DEC PY 2016 VL 25 IS 6 BP 468 EP 477 DI 10.1016/j.carpath.2016.08.003 PG 10 WC Cardiac & Cardiovascular Systems; Pathology SC Cardiovascular System & Cardiology; Pathology GA EE3SU UT WOS:000389519500004 PM 27614168 ER PT J AU O'Neil, PM Garvey, WT Gonzalez-Campoy, JM Mora, P Ortiz, RV Guerrero, G Claudius, B Pi-Sunyer, X AF O'Neil, Patrick M. Garvey, W. Timothy Gonzalez-Campoy, J. Michael Mora, Pablo Ortiz, Rafael Violante Guerrero, German Claudius, Birgitte Pi-Sunyer, Xavier CA Satiety Clin Adiposity Liraglutide TI EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HISPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS SO ENDOCRINE PRACTICE LA English DT Article ID LIFE-STYLE INTERVENTION; CLINICAL-TRIAL; OBESITY; ADULTS; OVERWEIGHT; MANAGEMENT; SAFETY; TOLERABILITY; LORCASERIN; PREVALENCE AB Objective: Scarce data exist on pharmacotherapy for obesity in Hispanic individuals. This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups. Methods: We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m(2) with at least 1 comorbidity, or a minimum BMI of 30 kg/m(2), at clinical research sites worldwide. In this analysis, we investigated possible differences in treatment effects between 534 Hispanics (10.4% of the population) and 4,597 non-Hispanics (89.6%) through statistical tests of interaction between subgroups and treatment. Variables examined included mean and categorical weight change, cardiovascular risk markers, and safety data. Results: Both subgroups achieved clinically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: Hispanics 7.0% versus 1.5%, treatment difference -5.1% (95% CI, -6.2 to -4.0); non-Hispanics 7.5% versus 2.3%, -5.2% (95% CI, -5.5 to -4.8). More individuals in both subgroups lost >= 5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo. Efficacy endpoints generally did not vary with ethnicity (P>.05). Adverse events were comparable between ethnic subgroups, with more gastrointestinal disorders reported with liraglutide 3.0 mg than placebo. Conclusion: Efficacy and safety were largely similar between Hispanic and non-Hispanic subgroups. Results support that liraglutide 3.0 mg, used with a reduced-calorie diet and physical activity, can facilitate Weight loss in Hispanic individuals. C1 [O'Neil, Patrick M.] Med Univ South Carolina, Charleston, SC 29425 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Gonzalez-Campoy, J. Michael] Minnesota Ctr Obes Metab & Endocrinol, Eagan, MN USA. [Mora, Pablo] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Ortiz, Rafael Violante] Inst Mexicano Segura Social, Dept Endocrinol, Cuidad Madero, Mexico. [Guerrero, German] Novo Nordisk Inc, Plainsboro, NJ USA. [Claudius, Birgitte] Novo Nordisk AS, Soborg, Denmark. [Pi-Sunyer, Xavier] Columbia Univ, New York, NY USA. RP O'Neil, PM (reprint author), Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, IOP South, 67 President St Suite 410 POB 250861, Charleston, SC 29425 USA. EM oneilp@musc.edu FU Novo Nordisk; Novo Nordisk A/S FX We gratefully acknowledge the contribution of all trial participants and the trial site personnel who assisted with the trials. We also thank Ana-Paula Canino, M.D., M.Sc. (Novo Nordisk) for researching data and contributing to the manuscript, Henrik F. Thomsen, Ph.D. (Novo Nordisk) for assistance with the statistical analyses, as well as Angela Stocks, Ph.D. (Larix A/S, funded by Novo Nordisk) for editorial and medical writing contributions. Under the direction of the authors and according to an agreed outline, Angela Stocks drafted the initial version of the manuscript; all authors reviewed all drafts and revisions of the manuscript and commented and/or provided edits.; Novo Nordisk A/S funded the trials and provided the trial products. Novo Nordisk provided overall management of the trials, performed the statistical analyses, and verified the accuracy of the data presented. Novo Nordisk was also responsible for the overall trial designs. They provided a formal review of the manuscript, but the authors had final authority, including journal choice. The studies included in the pooled analysis are registered with ClinicalTrials.gov (NCT01272219, NCT00781937, NCT00781937, and NCT01557166). NR 33 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD NOV PY 2016 VL 22 IS 11 BP 1277 EP 1287 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EE7ZB UT WOS:000389842900003 PM 27482610 ER PT J AU Schreiber, DR Shoji, K Imel, J Tighe, CA Dautovich, N AF Schreiber, D. R. Shoji, K. Imel, J. Tighe, C. A. Dautovich, N. TI SLEEP PREDICTS EMOTION-FOCUSED COPING ACROSS THE ADULT LIFESPAN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Schreiber, D. R.; Imel, J.; Dautovich, N.] Virginia Commonwealth Univ, Psychol, Richmond, VA USA. [Shoji, K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Tighe, C. A.] Univ Alabama, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 63 EP 63 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000231 ER PT J AU Hall, KS Gregg, J Bosworth, H Beckham, J Sloane, R Hoerster, K Morey, M AF Hall, K. S. Gregg, J. Bosworth, H. Beckham, J. Sloane, R. Hoerster, K. Morey, M. TI PROMOTING PHYSICAL AND PSYCHOLOGICAL RESILIENCE IN OLDER VETERANS WITH PTSD: A CASE FOR EXERCISE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hall, K. S.; Bosworth, H.; Beckham, J.; Sloane, R.; Morey, M.] Duke Univ, Med Ctr, Med, Durham, NC USA. [Hoerster, K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hall, K. S.; Gregg, J.; Bosworth, H.; Beckham, J.; Morey, M.] Vet Affairs Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 88 EP 88 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000317 ER PT J AU Kim, G Parmelee, P Bryant, A Crowther, M Park, S Parton, JM Chae, D AF Kim, G. Parmelee, P. Bryant, A. Crowther, M. Park, S. Parton, J. M. Chae, D. TI PERCEIVED RACIAL DISCRIMINATION AND PSYCHIATRIC DISORDERS AMONG BLACK ELDERS: THE ROLE OF GEOGRAPHY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kim, G.; Parmelee, P.; Crowther, M.; Park, S.; Parton, J. M.] Univ Alabama, Dept Psychol, Alabama Res Inst Aging, Box 870348, Tuscaloosa, AL 35487 USA. [Bryant, A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chae, D.] Univ Maryland, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 93 EP 93 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000332 ER PT J AU Espinoza, S Quiben, M Hazuda, H AF Espinoza, S. Quiben, M. Hazuda, H. TI ONSET OF FRAILTY CHARACTERISTICS IN A BI-ETHNIC COHORT: THE SAN ANTONIO LONGITUDINAL STUDY OF AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S.; Hazuda, H.] Univ Texas Hlth Sci Ctr San Antonio, Med, San Antonio, TX 78229 USA. [Espinoza, S.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Quiben, M.] Univ North Texas, Hlth Sci Ctr, Ft Worth, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 175 EP 175 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000641 ER PT J AU Roberts, T Gilmore-Bykovskyi, A Lor, M Liebzeit, D Saliba, D Crnich, C AF Roberts, T. Gilmore-Bykovskyi, A. Lor, M. Liebzeit, D. Saliba, D. Crnich, C. TI IMPORTANT DAILY CARE AND ACTIVITY PREFERENCES AMONG NURSING HOME RESIDENTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Roberts, T.; Gilmore-Bykovskyi, A.; Crnich, C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Roberts, T.; Gilmore-Bykovskyi, A.; Lor, M.; Liebzeit, D.] Univ Wisconsin, Madison Sch Nursing, Madison, WI USA. [Saliba, D.] VA GLAHS GRECC & HSR&D Ctr Innovat, Los Angeles, CA USA. [Saliba, D.] UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, D.] RAND Corp, Santa Monica, CA USA. [Crnich, C.] Univ Wisconsin, Madison Sch Med & Publ Hlth, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 263 EP 264 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001237 ER PT J AU Romo, R AF Romo, R. TI THE "SURPRISE" QUESTION: PREDICTING DEATH OR THE NEED FOR CARE? A SYSTEMATIC REVIEW SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Romo, R.] San Francisco VA Med Ctr, Geriatr Extended & Pallait Care, San Jose, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 341 EP 342 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001549 ER PT J AU Romo, R AF Romo, R. TI WHAT IS KNOWN ABOUT THE PATIENT EXPERIENCE AFTER LIVE DISCHARGE FROM HOSPICE? NOT MUCH SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Romo, R.] San Francisco VA Med Ctr, Geriatr Extended & Pallait Care, San Jose, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 342 EP 342 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001551 ER PT J AU Tighe, CA Imel, J Shoji, K Schreiber, DR Allen, RS Dautovich, N AF Tighe, C. A. Imel, J. Shoji, K. Schreiber, D. R. Allen, R. S. Dautovich, N. TI THE LINK BETWEEN SLEEP IMPAIRMENT AND FUTURE TIME PERSPECTIVE ACROSS ADULTHOOD SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Tighe, C. A.; Shoji, K.; Allen, R. S.] Univ Alabama, Psychol, Tuscaloosa, AL USA. [Imel, J.; Schreiber, D. R.; Dautovich, N.] Virginia Commonwealth Univ, Richmond, VA USA. [Shoji, K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 360 EP 361 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001613 ER PT J AU Byers, A Li, Y Barnes, D Boscardin, J Seal, K Yaffe, K AF Byers, A. Li, Y. Barnes, D. Boscardin, J. Seal, K. Yaffe, K. TI MILD TRAUMATIC BRAIN INJURY AND RISK OF MORTALITY IN LATE LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A.; Barnes, D.; Boscardin, J.; Seal, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, A.; Li, Y.; Barnes, D.; Boscardin, J.; Seal, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 440 EP 440 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002088 ER PT J AU McCaskill, GM Burgio, K AF McCaskill, G. M. Burgio, K. TI "OLD FOOTBALL KNEES:" PAIN AS A BARRIER AND A FACILITATOR TO PHYSICAL ACTIVITY AMONG OLDER VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McCaskill, G. M.; Burgio, K.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [McCaskill, G. M.; Burgio, K.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 597 EP 598 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002707 ER PT J AU OConnor, M Moriarty, H Hoban, M Bowles, K AF OConnor, M. Moriarty, H. Hoban, M. Bowles, K. TI HOW DO WE KNOW THEY ARE READY? DETERMINING READINESS FOR DISCHARGE FROM SKILLED HOME HEALTH SERVICES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [OConnor, M.; Moriarty, H.] Villanova Univ, Villanova, PA 19085 USA. [Hoban, M.] Main Line Hlth Home Care & Hosp, Radnor, PA USA. [Bowles, K.] Univ Penn, Philadelphia, PA 19104 USA. [Moriarty, H.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Bowles, K.] Visiting Nurse Serv New York, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 628 EP 628 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003033 ER PT J AU Whiteman, KL Lohman, M Batsis, J Di Napoli, E Bruce, M Bartels, S AF Whiteman, K. L. Lohman, M. Batsis, J. Di Napoli, E. Bruce, M. Bartels, S. TI DISPARITIES IN PATIENT HEALTHCARE EXPERIENCE AMONG OLDER ADULTS WITH SERIOUS MENTAL ILLNESS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] Dartmouth Ctr Hlth & Aging, Lebanon, NH USA. [Di Napoli, E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] CDC Hlth Promot Res Ctr Dartmouth, Lebanon, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 642 EP 642 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003094 ER PT J AU Elliott, M Martsolf, GR Haviland, AM Burkhart, Q Orr, NE Gaillot, S Saliba, D AF Elliott, M. Martsolf, G. R. Haviland, A. M. Burkhart, Q. Orr, N. E. Gaillot, S. Saliba, D. TI HEALTH CARE EXPERIENCES AMONG MEDICARE BENEFICIARIES WITH AND WITHOUT A PERSONAL PHYSICIAN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Elliott, M.; Martsolf, G. R.; Burkhart, Q.; Orr, N. E.; Saliba, D.] RAND Corp, Santa Monica, CA USA. [Haviland, A. M.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Gaillot, S.] Ctr Medicare Serv, Baltimore, MD USA. [Gaillot, S.] Ctr Medicaid Serv, Baltimore, MD USA. [Saliba, D.] US Dept Vet Affairs, Los Angeles, CA USA. [Saliba, D.] Univ Calif Los Angeles, Borun Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 663 EP 663 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003180 ER PT J AU Hung, WW Rossi, M Thielke, S Caprio, T Barczi, S Espinoza, S Garner, K Moo, L AF Hung, W. W. Rossi, M. Thielke, S. Caprio, T. Barczi, S. Espinoza, S. Garner, K. Moo, L. TI TELEMEDICINE APPROACHES TO EXTEND GERIATRIC CARE TO RURAL AREAS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.] James J Peters VA Med Ctr, Bronx, NY USA. [Rossi, M.] Univ Pittsburgh, Pittsburgh, PA USA. [Thielke, S.] Univ Washington, Seattle, WA 98195 USA. [Caprio, T.] Univ Rochester, Rochester, NY USA. [Barczi, S.] William S Middleton VA Med Ctr, Madison, WI USA. [Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garner, K.] Univ Arkansas, Little Rock, AR 72204 USA. [Moo, L.] Bedford VA Med Ctr, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 694 EP 694 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003299 ER PT J AU Cigolle, C Quinones, A Nagel, C AF Cigolle, C. Quinones, A. Nagel, C. TI PATIENTS' UNCERTAINTY ABOUT THEIR CHRONIC DISEASE DIAGNOSES: THE HEALTH AND RETIREMENT STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cigolle, C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Cigolle, C.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Quinones, A.; Nagel, C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Quinones, A.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 703 EP 703 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003332 ER PT J AU Wright, RS Waldstein, S Gerassimakis, C Sprung, M Moody, DLB Taylor, A Evans, MK Zonderman, AB AF Wright, R. S. Waldstein, S. Gerassimakis, C. Sprung, M. Moody, D. L. Beatty Taylor, A. Evans, M. K. Zonderman, A. B. TI PREDICTORS OF NEUROCOGNITIVE PERFORMANCE AMONG AFRICAN AMERICANS ENROLLED IN THE HANDLS STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wright, R. S.; Gerassimakis, C.] Univ Delaware, Sch Nursing, Newark, DE USA. [Waldstein, S.; Moody, D. L. Beatty; Taylor, A.] Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA. [Sprung, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Evans, M. K.; Zonderman, A. B.] NIA, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 733 EP 734 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003446 ER PT J AU Bala, H Venkatesh, V Venkatraman, S Bates, J AF Bala, Hillol Venkatesh, Viswanath Venkatraman, Srinivasan Bates, Jack TI If the Worst Happens: Five Strategies for Developing and Leveraging Information Technology-Enabled Disaster Response in Healthcare SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS LA English DT Article DE Disaster response; information technology (IT) strategy; IT architecture; natural disaster; universal data repository (UDR) ID US AB Natural disasters, such as hurricanes, tornadoes, cyclones, earthquakes, volcanic eruptions, wildfires, and floods, have a profound impact on healthcare by limiting healthcare providers' ability to effectively provide patient care in the affected areas and respond to myriad healthcare needs of the affected population. The situation can potentially be exacerbated if healthcare providers do not have effective mechanisms in place for disaster response. The response to Hurricane Katrina, a Category 3 hurricane that made landfall in August 2005 and affected several states in the southwestern U.S., was a vivid example of how the lack of effective planning and responsiveness can affect healthcare services. In this paper, based on an extensive case study, which included a rigorous examination of the Veterans Health Administration's information technology (IT) infrastructure and its response to Hurricane Katrina, we present five strategies that healthcare organizations can undertake to develop and leverage IT-enabled disaster response. These include the development of: 1) an integrated IT architecture; 2) a universal data repository; 3) web-based disaster communication and coordination; 4) an IT-enabled disaster support system; and 5) standardized and integrated IT-enabled disaster response processes. We discuss how these strategies can help healthcare providers manage continuity and offer quality healthcare during natural disasters. C1 [Bala, Hillol] Indiana Univ, Kelley Sch Business, Dept Operat & Decis Technol, Bloomington, IN 47401 USA. [Venkatesh, Viswanath] Univ Arkansas, Walton Coll Business, Dept Informat Syst, Fayetteville, AR 72701 USA. [Bates, Jack] US Dept Vet Affairs, Business Intelligence Serv, Washington, DC 20420 USA. RP Bala, H (reprint author), Indiana Univ, Kelley Sch Business, Dept Operat & Decis Technol, Bloomington, IN 47401 USA. EM hbala@indiana.edu; vvenkatesh@vvenkatesh.us; srini@srinivenkatraman.com; jack.bates@va.gov NR 25 TC 0 Z9 0 U1 9 U2 9 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2194 J9 IEEE J BIOMED HEALTH JI IEEE J. Biomed. Health Inform. PD NOV PY 2016 VL 20 IS 6 BP 1545 EP 1551 DI 10.1109/JBHI.2015.2477371 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Medical Informatics SC Computer Science; Mathematical & Computational Biology; Medical Informatics GA EE8AN UT WOS:000389846700010 PM 26357415 ER PT J AU Lamoureux, L Radhakrishnan, J Mason, TG Kraut, JA Gazmuri, RJ AF Lamoureux, Lorissa Radhakrishnan, Jeejabai Mason, Thomas G. Kraut, Jeffrey A. Gazmuri, Raul J. TI Adverse postresuscitation myocardial effects elicited by buffer-induced alkalemia ameliorated by NHE-1 inhibition in a rat model of ventricular fibrillation SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE buffer agents; cardiopulmonary resuscitation; CO2-consuming buffer; cytochrome c; sodium-hydrogen exchanger isoform-1; ventricular fibrillation ID CLOSED-CHEST RESUSCITATION; MITOCHONDRIAL BIOENERGETIC FUNCTION; HYDROGEN EXCHANGER ISOFORM-1; AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HYPERCARBIC ACIDOSIS; NA+/H+ EXCHANGE; REPERFUSION INJURY; BLOOD-FLOW; CARIPORIDE AB Major myocardial abnormalities occur during cardiac arrest and resuscitation including intracellular acidosis-partly caused by CO2 accumulation-and activation of the Na+-H+ exchanger isoform-1 (NHE-1). We hypothesized that a favorable interaction may result from NHE-1 inhibition during cardiac resuscitation followed by administration of a CO2-consuming buffer upon return of spontaneous circulation (ROSC). Ventricular fibrillation was electrically induced in 24 male rats and left untreated for 8 min followed by defibrillation after 8 min of cardiopulmonary resuscitation (CPR). Rats were randomized 1:1:1 to the NHE-1 inhibitor zoniporide or vehicle during CPR and disodium carbonate/ sodium bicarbonate buffer or normal saline (30 ml/ kg) after ROSC. Survival at 240 min declined from 100% with Zoniporide/ Saline to 50% with Zoniporide/ Buffer and 25% with Vehicle/ Buffer (P = 0.004), explained by worsening postresuscitation myocardial dysfunction. Marked alkalemia occurred after buffer administration along with lactatemia that was maximal after Vehicle/ Buffer, attenuated by Zoniporide/ Buffer, and minimal with Zoniporide/ Saline [ 13.3 +/- 4.8 (SD), 9.2 +/- 4.6, and 2.7 +/- 1.0 mmol/ l; P <= 0.001]. We attributed the intense postresuscitation lactatemia to enhanced glycolysis consequent to severe buffer-induced alkalemia transmitted intracellularly by an active NHE-1. We attributed the worsened postresuscitation myocardial dysfunction also to severe alkalemia intensifying Na+ entry via NHE-1 with consequent Ca2+ overload injuring mitochondria, evidenced by increased plasma cytochrome c. Both buffer-induced effects were ameliorated by zoniporide. Accordingly, buffer-induced alkalemia after ROSC worsened myocardial function and survival, likely through enhancing NHE-1 activity. Zoniporide attenuated these effects and uncovered a complex postresuscitation acid-base physiology whereby blood pH drives NHE-1 activity and compromises mitochondrial function and integrity along with myocardial function and survival. C1 [Lamoureux, Lorissa; Radhakrishnan, Jeejabai; Gazmuri, Raul J.] Rosalind Franklin Univ Med & Sci, Resuscitat Inst, 3333 Green Bay Rd, N Chicago, IL 60064 USA. [Gazmuri, Raul J.] Captain James A Lovell Fed Hlth Care Ctr, Sect Crit Care Med, N Chicago, IL USA. [Mason, Thomas G.] Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90024 USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA USA. [Kraut, Jeffrey A.] David Geffen Sch Med, Los Angeles, CA USA. RP Gazmuri, RJ (reprint author), Rosalind Franklin Univ Med & Sci, Resuscitat Inst, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM raul.gazmuri@rosalindfranklin.edu FU Friends Medical Research Institute; Veterans Administration; UCLA Academic Senate; Department of Medicine at Rosalind Franklin University of Medicine and Science FX This work was supported by funds from the Friends Medical Research Institute (J. A. Kraut and R. J. Gazmuri), the Veterans Administration (J. A. Kraut), the UCLA Academic Senate (J. A. Kraut and T. G. Mason), a gift in memory of U.S. Navy Retired SKC Robert W. Ply by Monica Ply for research in heart disease and Parkinson's disease (R. J. Gazmuri), and a discretionary fund from the Department of Medicine at Rosalind Franklin University of Medicine and Science (R. J. Gazmuri). NR 59 TC 0 Z9 0 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV 1 PY 2016 VL 121 IS 5 BP 1160 EP 1168 DI 10.1152/japplphysiol.00336.2016 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA EE5MH UT WOS:000389651700015 PM 27633736 ER PT J AU Woodhouse, E AF Woodhouse, Erik TI TOXIC MEGACOLON: A REVIEW FOR EMERGENCY DEPARTMENT CLINICIANS SO JOURNAL OF EMERGENCY NURSING LA English DT Review ID CLOSTRIDIUM-DIFFICILE INFECTION; SURGICAL-MANAGEMENT; ULCERATIVE-COLITIS; ETIOLOGY; DISEASES; UPDATE C1 [Woodhouse, Erik] William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA. RP Woodhouse, E (reprint author), 418 S Livingston St, Madison, WI 53703 USA. EM ewoodhouse@wisc.edu NR 24 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 EI 1527-2966 J9 J EMERG NURS JI J. Emerg. Nurs. PD NOV PY 2016 VL 42 IS 6 BP 481 EP 486 DI 10.1016/j.jen.2016.04.007 PG 6 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA EE3YU UT WOS:000389539300010 PM 27185628 ER PT J AU Graves, LL Giaconi, JA Mallya, SM Chang, TI Friedlander, AH AF Graves, Lindsay L. Giaconi, Joann A. Mallya, Sanjay M. Chang, Tina I. Friedlander, Arthur H. TI Facial Trauma: Delayed Development of a Subluxated Traumatic Cataract as Visualized on a Panoramic Image SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article AB The immediate and long-term consequences of blunt orbital trauma leading to a subluxated lens and its subsequent calcification and opacification are reviewed. The accompanying panoramic image documents the process. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons C1 [Graves, Lindsay L.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Dent Serv, Los Angeles, CA USA. [Giaconi, Joann A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ophthalmol, Los Angeles, CA USA. [Giaconi, Joann A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Giaconi, Joann A.] UCLA Jules Stein Eye Inst, Los Angeles, CA USA. [Mallya, Sanjay M.] UCLA Sch Dent, Sect Oral & Maxillofacial Radiol, Los Angeles, CA USA. [Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA USA. [Chang, Tina I.] UCLA Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] UCLA Sch Dent, Oral & Maxillofacial Surg, Residence, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Qual Assurance, Hosp Dent Serv, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Arthur.Friedlander@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD NOV PY 2016 VL 74 IS 11 DI 10.1016/j.joms.2016.07.025 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3QY UT WOS:000389512200031 ER PT J AU Lang, HN Nishimoto, E Xing, YZ Brown, LN Noble, KV Barth, JL LaRue, AC Ando, K Schulte, BA AF Lang, Hainan Nishimoto, Eishi Xing, Yazhi Brown, LaShardai N. Noble, Kenyaria V. Barth, Jeremy L. LaRue, Amanda C. Ando, Kiyoshi Schulte, Bradley A. TI Contributions of Mouse and Human Hematopoietic Cells to Remodeling of the Adult Auditory Nerve After Neuron Loss SO MOLECULAR THERAPY LA English DT Article ID SPIRAL GANGLION NEURONS; MARROW-DERIVED CELLS; BONE-MARROW; STEM-CELLS; GERBIL COCHLEA; INNER-EAR; ACOUSTIC TRAUMA; SDF-1/CXCR4 INTERACTIONS; MICROGLIAL CELLS; TISSUE-REPAIR AB The peripheral auditory nerve (AN) carries sound information from sensory hair cells to the brain. The present study investigated the contribution of mouse and human hematopoietic stem cells (HSCs) to cellular diversity in the AN following the destruction of neuron cell bodies, also known as spiral ganglion neurons (SGNs). Exposure of the adult mouse cochlea to ouabain selectively killed type I SGNs and disrupted the blood-labyrinth barrier. This procedure also resulted in the upregulation of genes associated with hematopoietic cell homing and differentiation, and provided an environment conducive to the tissue engraftment of circulating. stem/progenitor cells into the AN. Experiments were performed using both a mouse-mouse bone marrow transplantation model and a severely immune-incompetent mouse model transplanted with human CD34(+) cord blood cells. Quantitative immunohistochemical analysis of recipient mice demonstrated that ouabain injury promoted an increase in the number of both HSC-derived macrophages and HSC-derived nonmacrophages in the AN. Although rare, a few HSC-derived cells in the injured AN exhibited glial-like qualities. These results suggest that human hematopoietic cells participate in remodeling of the AN after neuron cell body loss and that hematopoietic cells can be an important resource for promoting AN repair/regeneration in the adult inner ear. C1 [Lang, Hainan; Nishimoto, Eishi; Xing, Yazhi; Brown, LaShardai N.; Noble, Kenyaria V.; LaRue, Amanda C.; Schulte, Bradley A.] Med Univ South Carolina, Dept Pathol & Lab Med, 765 Ashley Ave,POB 250908, Charleston, SC 29425 USA. [Barth, Jeremy L.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC USA. [LaRue, Amanda C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Ando, Kiyoshi] Tokai Univ, Sch Med, Div Hematopoiesis, Res Ctr Regenerat Med, Tokyo, Japan. RP Lang, HN (reprint author), Med Univ South Carolina, Dept Pathol & Lab Med, 765 Ashley Ave,POB 250908, Charleston, SC 29425 USA. EM langh@musc.edu FU National Institutes of Health [R01DC012058, P50DC00422]; MUSC's Office of the Vice President for Research; [GM103342]; [GM103499] FX This work has been supported by National Institutes of Health Grants R01DC012058 (H.L.), and P50DC00422 (H.L., B.A.S.). J.L.B. and microarray data analyses were additionally supported through GM103342, GM103499, and MUSC's Office of the Vice President for Research. We thank Makio Ogawa for preliminary planning of this project, Meenal Mehrotra for her help with the hematopoietic cell transplantation, Juhong Zhu for cochlear tissue preparations, and Mary Bridges, Clarisse Panganiban, and Linda McCarson for their critical comments on the manuscript. The authors declare no competing financial interests. NR 78 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD NOV PY 2016 VL 24 IS 11 BP 2000 EP 2011 DI 10.1038/mt.2076.174 PG 12 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EE6PL UT WOS:000389734600016 PM 27600399 ER PT J AU Graves, LL Friedlander, AH Chang, TI AF Graves, Lindsay L. Friedlander, Arthur H. Chang, Tina I. TI Differences in the risk of osteoporotic femur fractures among Japanese and white women as predicted by carotid artery calcification visualized on panoramic images SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Letter ID GEOMETRY C1 [Graves, Lindsay L.; Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. RP Graves, LL (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Los Angeles, CA 90073 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 EI 1528-395X J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD NOV PY 2016 VL 122 IS 5 BP 654 EP 655 DI 10.1016/j.oooo.2016.06.097 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3WT UT WOS:000389532400025 PM 27765337 ER PT J AU Johnson, TM Arya, S AF Johnson, Theodore M., II Arya, Shipra TI Untitled SO UROLOGY LA English DT Editorial Material ID OLDER-ADULTS; DISCHARGE; FRAILTY; CARE; SURGERY C1 [Johnson, Theodore M., II] US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA. [Johnson, Theodore M., II] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Johnson, Theodore M., II] Emory Univ, Dept Family & Prevent Med, Atlanta, GA 30322 USA. [Arya, Shipra] Emory Univ, Sch Med, Div Vasc Surg, Atlanta, GA USA. [Arya, Shipra] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA USA. RP Johnson, TM (reprint author), US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA.; Johnson, TM (reprint author), Emory Univ, Dept Med, Atlanta, GA 30322 USA.; Johnson, TM (reprint author), Emory Univ, Dept Family & Prevent Med, Atlanta, GA 30322 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2016 VL 97 BP 31 EP 32 DI 10.1016/j.urology.2016.03.074 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA EE4CS UT WOS:000389550300018 PM 27492668 ER PT J AU Valeshabad, AK Walsh, A Lloyd, GL AF Valeshabad, Ali Kord Walsh, Anne Lloyd, Granville L. TI An Important Mimic of Inguinal Hernia SO UROLOGY LA English DT Editorial Material AB Spermatic cord malignancy is a rare and challenging diagnosis, often misdiagnosed as an inguinal hernia or cord lipoma. In these images, we show a 61-year-old male for whom laparoscopic repair of clinically diagnosed hernia was attempted. Laparoscopy revealed closed internal ring without hernia. Imaging showed large paratesticular mass; radical inguinal excision of testicle, cord, and mass was performed. Pathology showed mixed low-grade and high-grade sarcoma. Liposarcoma should be considered in cases of unusual inguinal mass; appropriate imaging can guide surgical approach and optimize outcomes. Published by Elsevier Inc. C1 Univ Illinois, Dept Radiol, Chicago, IL USA. Univ Illinois, Dept Radiol, Aurora, CO USA. Univ Colorado Denver, Dept Surg, Aurora, CO USA. Univ Wisconsin, Dept Urol, Madison, WI USA. [Lloyd, Granville L.] Univ Colorado, Sch Med, Denver Vet Affairs Hosp, Dept Surg,Div Urol, 1055 Clermont St, Denver, CO 80220 USA. RP Lloyd, GL (reprint author), Univ Colorado, Sch Med, Denver Vet Affairs Hosp, Dept Surg,Div Urol, 1055 Clermont St, Denver, CO 80220 USA. EM granville.lloyd@ucdenver.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2016 VL 97 BP E11 EP E11 DI 10.1016/j.urology.2016.08.001 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA EE4CS UT WOS:000389550300005 PM 27502033 ER PT J AU Kadosh, D Najvar, LK Bocanegra, R Olivo, M Kirkpatrick, WR Wiederhold, NP Patterson, TF AF Kadosh, David Najvar, Laura K. Bocanegra, Rosie Olivo, Marcos Kirkpatrick, William R. Wiederhold, Nathan P. Patterson, Thomas F. TI Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID SYSTEMIC CANDIDIASIS; PURIFIED DIETS; INFANT MICE; ALBICANS; COLONIZATION; MUCOSAL; SUSCEPTIBILITY; PATHOGENESIS; NEUTROPENIA; CANDIDEMIA AB Candida albicans, normally found as a commensal in the gut, is a major human fungal pathogen responsible for both mucosal and systemic infections in a wide variety of immunocompromised individuals, including cancer patients and organ transplant recipients. The gastrointestinal tract represents a major portal of entry for the establishment of disseminated candidiasis in many of these individuals. Here we report the development of a diet-based mouse model for disseminated candidiasis acquired via the gastrointestinal tract. Using this model, as well as an appropriate immunosuppression regimen, we demonstrate that dissemination of C. albicans from the gastrointestinal tract can result in mortality within 30 days postinfection. We also show a significant increase in fungal burden in systemic organs, but not gastrointestinal tract organs, upon immunosuppression. Importantly, we demonstrate that the administration of two widely used antifungals, fluconazole and caspofungin, either pre-or postimmunosuppression, significantly reduces fungal burdens. This model should prove to be of significant value for testing the ability of both established and experimental therapeutics to inhibit C. albicans dissemination from the gastrointestinal tract in an immunocompromised host as well as the subsequent mortality that can result from disseminated candidiasis. C1 [Kadosh, David] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kadosh, D (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA. EM kadosh@uthscsa.edu FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272201000038I]; Voelcker Young Investigator Award from the Max and Minnie Tomerlin Voelcker Fund (Voelcker Fund) FX This work, including the efforts of Thomas F. Patterson, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) Task Order A13 (HHSN272201000038I). This work, including the efforts of David Kadosh, was funded by a Voelcker Young Investigator Award from the Max and Minnie Tomerlin Voelcker Fund (Voelcker Fund). NR 40 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2016 VL 60 IS 11 BP 6703 EP 6708 DI 10.1128/AAC.01144-16 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QH UT WOS:000389063500029 PM 27572393 ER PT J AU Boockvar, KS AF Boockvar, Kenneth S. TI Reducing Sedative-hypnotic Medication Use in Older Adults with Sleep Problems SO CLINICAL THERAPEUTICS LA English DT Editorial Material C1 [Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Boockvar, Kenneth S.] New Jewish Home, New York, NY 10025 USA. RP Boockvar, KS (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.; Boockvar, KS (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.; Boockvar, KS (reprint author), New Jewish Home, New York, NY 10025 USA. EM Kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 NR 10 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2330 EP 2331 DI 10.1016/j.clinthera.2016.10.003 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000002 PM 27789042 ER PT J AU Culver, NC Song, YS McGowan, SK Fung, CH Mitchell, MN Rodriguez, JC Dzierzewski, JM Josephson, KR Jouldjian, S Washington, DL Yano, EM Schweizer, CA Alessi, CA Martin, JL AF Culver, Najwa C. Song, Yeonsu McGowan, Sarah Kate Fung, Constance H. Mitchell, Michael N. Carlos Rodriguez, Juan Dzierzewski, Joseph M. Josephson, Karen R. Jouldjian, Stella Washington, Donna L. Yano, Elizabeth M. Schweizer, C. Amanda Alessi, Cathy A. Martin, Jennifer L. TI Acceptability of Medication and Nonmedication Treatment for Insomnia Among Female Veterans: Effects of Age, Insomnia Severity, and Psychiatric Symptoms SO CLINICAL THERAPEUTICS LA English DT Article DE cognitive-behavioral therapy; female veterans; insomnia; medications; sleep; treatment acceptability ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; PHARMACOLOGICAL THERAPIES; PATIENT PREFERENCE; GOOD SLEEPERS; PREVALENCE; DEPRESSION; DISORDERS; DISSEMINATION AB Purpose: Female veterans are at high risk for sleep problems, and there is a need to provide effective treatment for this population who experience insomnia. This study's primary goal was to compare the acceptability of medication versus nonmedication treatments for insomnia among female veterans. In addition, we examined the role of patient age, severity of sleep disturbance, and psychiatric symptoms on acceptability of each treatment approach and on the differences in acceptability between these approaches. Methods: A large nationwide postal survey was sent to a random sample of 4000 female veterans who had received health care at a Veterans Administration (VA) facility in the previous 6 months (May 29, 2012 November 28, 2012). A total of 1559 completed surveys were returned. Survey items used for the current analyses included: demographic characteristics, sleep quality, psychiatric symptoms, military service experience, and acceptability of medication and non medication treatments for insomnia. For analysis, only ratings of "very acceptable" were used to indicate an interest in the treatment approach (vs ratings of "not at all acceptable," "a little acceptable," "somewhat acceptable," and "no opinion/don't know"). Findings: In the final sample of 1538 women with complete data, 57.7% rated nonmedication treatment as very acceptable while only 33.5% rated medication treatment as very acceptable. This difference was statistically significant for the group as a whole and when examining subgroups of patients based on age, sleep quality, psychiatric symptoms, and military experience. The percentage of respondents rating medication treatment as very acceptable was higher for women who were younger, had more severe sleep disturbances, had more psychiatric symptoms, who were not combat exposed, and who had experienced military sexual trauma. By contrast, the percentage of respondents rating nonmedication treatment as very acceptable differed only by age (younger women were more likely to find nonmedication treatment acceptable) and difficulty falling asleep. Implications: Female veterans are more likely to find nonmedication insomnia treatment acceptable compared with medication treatment. Thus, it is important to match these patients with effective behavioral interventions such as cognitive behavioral therapy for insomnia. Efforts to educate providers about these preferences and about the efficacy of cognitive behavioral therapy for insomnia may serve to connect female veterans who have insomnia to the treatment they prefer. These findings also suggest that older female veterans may be less likely to find either approach as acceptable as their younger counterparts. Published by Elsevier HS Journals, Inc. C1 [Culver, Najwa C.; Song, Yeonsu; McGowan, Sarah Kate; Fung, Constance H.; Mitchell, Michael N.; Carlos Rodriguez, Juan; Dzierzewski, Joseph M.; Josephson, Karen R.; Jouldjian, Stella; Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Song, Yeonsu; Fung, Constance H.; Washington, Donna L.; Schweizer, C. Amanda; Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Carlos Rodriguez, Juan] Pontificia Univ Catolica Chile, Dept Med, Santiago, Region Metropol, Chile. [Dzierzewski, Joseph M.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [Washington, Donna L.; Yano, Elizabeth M.; Schweizer, C. Amanda] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv, Res & Dev Ctr Study Healthcare Innovat Implementa, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Culver, NC (reprint author), 11E,16111 Plummer St, North Hills, CA 91343 USA. EM najwa.culver@va.gov FU VA Quality Enhancement Research Initiative (QUERI) [RRP 12-189]; Research Services, of the VA Greater Los Angeles Healthcare System; VAGLAHS Geriatric Research, Education and Clinical Center; VA Health Services Research and Development Service (Senior Research Career Scientist Award) [RCS 05-195] FX This research was supported the VA Quality Enhancement Research Initiative (QUERI; RRP 12-189; Principal Investigator: Dr. Martin), Research Services, of the VA Greater Los Angeles Healthcare System and VAGLAHS Geriatric Research, Education and Clinical Center; VA Health Services Research and Development Service (Senior Research Career Scientist Award, RCS 05-195; Principal Investigator: Dr. Yano). Preparation of this publication was also supported by the Office of Academic Affiliations, Department of Veterans Affairs. The authors thank Julia Yosef, MA, RN, Simone Vukelich, and Sergio Martinez for their assistance with the study. They thank Terry Vandenberg, MA, posthumously, for her many contributions to this project as well. NR 41 TC 2 Z9 2 U1 4 U2 4 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2373 EP 2385 DI 10.1016/j.clinthera.2016.09.019 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000005 PM 28314434 ER PT J AU Johnson, TM Vaughan, CP Goode, PS Bliwise, DL Markland, AD Huisingh, C Redden, DT McGwin, G Eisenstein, R Ouslander, JG Issa, M Burgio, KL AF Johnson, Theodore M., II Vaughan, Camille P. Goode, Patricia S. Bliwise, Donald L. Markland, Alayne D. Huisingh, Carrie Redden, David T. McGwin, Gerald, Jr. Eisenstein, Rina Ouslander, Joseph G. Issa, Muta Burgio, Kathryn L. TI Pilot Results from a Randomized Trial in Men Comparing Alpha-Adrenergic Antagonist versus Behavior and Exercise for Nocturia and Sleep SO CLINICAL THERAPEUTICS LA English DT Article DE alpha-blocker; behavioral treatment and exercise therapy; nocturia; sleep disorder ID BENIGN PROSTATIC HYPERPLASIA; DWELLING OLDER-ADULTS; OVERACTIVE BLADDER; INCONTINENCE; ASSOCIATION; THERAPY; WOMEN; INDEX AB Purpose: Nocturia and sleep problems are common in older adults. We developed and tested a novel intervention, multicomponent behavioral treatment and exercise therapy (M-BET), that may reduce nocturia and improve sleep in men. We compared reductions in nocturia and improvement in sleep in men with M-BET versus an active drug comparator (alpha-blocker) used alone or in combination (M-BET + alpha-blocker) Methods: This randomized, controlled trial was conducted in the ambulatory setting in 2 US Department of Veterans Affairs medical centers in men at least 40 years of age with nocturia (defined as >= 2 nightly episodes). Participants were randomized to receive either M-BET, including pelvic floor muscle training, urge-suppression techniques, delayed voiding, fluid management, sleep hygiene, and peripheral edema management; an active comparator of known efficacy (the alpha-blocker tamsulosin, one 0.4-mg tablet nightly); or both therapies combined. Participants received interventions over 12 weeks. Outcomes were assessed via voiding diaries, wrist actigraphy, and validated questionnaires. The primary outcome was change in diary-recorded nocturia, assessed using ANCOVA for the between-group changes and paired t tests for within-group changes. Findings: A total of 72 men with a mean age of 65.8 years participated. At 12 weeks, mean diary recorded nocturia changed with M-BET by 1.39 episodes/night (P < 0.001), with alpha-blocker therapy by -0.59 episodes/night (P < 0.01), and with combination therapy by -1.03 episodes/night (P < 0.01). Reductions were not statistically different across treatment groups (P = 0.41). M-BET also showed statistically significant improvements in sleep quality, bother from nocturia, and nocturia-specific quality of life. All treatment groups indicated global satisfaction with treatment. Implications: Behavioral therapy in men, alone or combined with a-blocker therapy, consistently showed large and statistically significant nocturia reductions and favorable effects on sleep and quality of life. Based on these findings, behavioral therapy, while not statistically superior to alpha-blocker therapy, may provide a meaningful treatment option for men with nocturia. Future research should include the development of behavioral treatment and exercise therapy interventions that could be more easily deployed. Published by Elsevier HS Journals, Inc. C1 [Johnson, Theodore M., II; Vaughan, Camille P.; Eisenstein, Rina; Ouslander, Joseph G.] Atlanta VAMC, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Decatur, GA USA. [Johnson, Theodore M., II; Vaughan, Camille P.; Eisenstein, Rina; Ouslander, Joseph G.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Goode, Patricia S.; Markland, Alayne D.; Redden, David T.; McGwin, Gerald, Jr.; Burgio, Kathryn L.] Birmingham VAMC, Birmingham Atlanta GRECC, Birmingham, AL USA. [Goode, Patricia S.; Markland, Alayne D.; Burgio, Kathryn L.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Bliwise, Donald L.] Emory Univ, Sch Med, Dept Neurol, Program Sleep Aging & Chronobiol, Atlanta, GA 30322 USA. [Huisingh, Carrie; McGwin, Gerald, Jr.] Dept Epidemiol, Birmingham, AL USA. [Redden, David T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Issa, Muta] Atlanta Vet Affairs Med Ctr VAMC, Dept Urol, Decatur, GA USA. RP Johnson, TM (reprint author), Birmingham Atlanta GRECC, Wesley Woods Ctr, Floor 5,1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM tmjohns@emory.edu OI Markland, Alayne/0000-0002-6567-6744 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Services [E6110-R] FX This work was funded by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Services grant E6110-R (T.M.J., K.B., P.G., A.M., D.R., C.V.). The Department of Veterans Affairs did not exert control over the design and conduct of the study; the collection, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 38 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2394 EP 2406 DI 10.1016/j.clinthera.2016.10.001 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000007 ER PT J AU Carballo, NJ Alessi, CA Martin, JL Mitchell, MN Hays, RD Col, N Patterson, ES Jouldjian, S Josephson, K Fung, CH AF Carballo, Nancy J. Alessi, Cathy A. Martin, Jennifer L. Mitchell, Michael N. Hays, Ron D. Col, Nananda Patterson, Emily S. Jouldjian, Stella Josephson, Karen Fung, Constance H. TI Perceived Effectiveness, Self-efficacy, and Social Support for Oral Appliance Therapy Among Older Veterans With Obstructive Sleep Apnea SO CLINICAL THERAPEUTICS LA English DT Article DE attitude to health; oral appliance therapy; patient reported measures; sleep apnea syndromes ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIALS; CPAP ADHERENCE; RATED HEALTH; METAANALYSIS; UPDATE; ADULTS; USERS AB Purpose: Obstructive sleep apnea is a prevalent sleep disorder among older adults. Oral appliances are increasingly prescribed as therapy for obstructive sleep apnea. Adherence to oral appliance therapy is highly variable. Based on value-expectancy theory and other social psychological theories, adherence to oral appliance therapy may be influenced by patients' perceived effectiveness of the therapy, self-efficacy, and availability of social support. We examined these perceptions among older adults with obstructive sleep apnea who were prescribed oral appliance therapy. Methods: We mailed surveys to all patients aged >= 65 years who had been prescribed oral appliance therapy for obstructive sleep apnea over the prior 36 months at a Veterans Affairs medical center. We examined frequencies of responses to items that assessed perceived effectiveness, self-efficacy, and social support for nightly use of oral appliances from friends, family, or health care staff. Findings: Thirty-nine individuals responded (response rate, 30%; mean [SD] age 71.4 [SD 6.3] years; 97% male). Thirty-six percent of the respondents perceived regular use of oral appliance therapy to be effective in managing obstructive sleep apnea; 39% agreed that they felt confident about using oral appliances regularly; 41% felt supported by people in their life in using oral appliance therapy; and 38% agreed that health care staff would help them to use their oral appliance regularly. These rates represented less than half of respondents despite the finding that 65% of patients believed that they would use their oral appliance regularly. Implications: Although oral appliance therapy is increasingly prescribed for obstructive sleep apnea, only about one third of older adults prescribed it perceived it to be an effective treatment, were confident about oral appliance use, and/or believed that they would receive needed support. Future research is needed to better understand older adults' perceptions so that interventions can be designed to improve the effectiveness of oral appliances, their self-efficacy for using oral appliances, and their social support for this therapy, which may, in turn, improve oral appliance therapy adherence. Published by Elsevier HS Journals, Inc. C1 [Carballo, Nancy J.; Alessi, Cathy A.; Martin, Jennifer L.; Mitchell, Michael N.; Jouldjian, Stella; Josephson, Karen; Fung, Constance H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Alessi, Cathy A.; Hays, Ron D.; Fung, Constance H.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Col, Nananda] Univ New England, Ctr Excellence Neurosci, Biddeford, ME USA. [Patterson, Emily S.] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA. [Carballo, Nancy J.; Alessi, Cathy A.; Martin, Jennifer L.; Fung, Constance H.] Univ Calif Los Angelesz, David Geffen Sch Med, Los Angeles, CA USA. RP Fung, CH (reprint author), Univ Calif Los Angeles, Los Angeles, CA USA.; Fung, CH (reprint author), VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. EM constance.fung@va.gov FU NIH National Institute on Aging (NIA) [K23AG045937]; Beeson Career Development in Aging Research Award Program; NIA; American Federation for Aging Research (AFAR) AFAR; John A. Hartford Foundation; Atlantic Philanthropies FX This work was supported by NIH National Institute on Aging (NIA) award K23AG045937 and the Beeson Career Development in Aging Research Award Program (supported by NIA, American Federation for Aging Research (AFAR) AFAR, the John A. Hartford Foundation, and the Atlantic Philanthropies). NR 23 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2407 EP 2415 DI 10.1016/j.clinthera.2016.09.008 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000008 PM 27751674 ER PT J AU Ventura, MI Barnes, DE Ross, JM Lanni, KE Sigvardt, KA Disbrow, EA AF Ventura, Maria I. Barnes, Deborah E. Ross, Jessica M. Lanni, Kimberly E. Sigvardt, Karen A. Disbrow, Elizabeth A. TI A pilot study to evaluate multi-dimensional effects of dance for people with Parkinson's disease SO Contemporary Clinical Trials LA English DT Article DE Parkinson's disease; Dance; Rehabilitation; Quality of life ID QUALITY-OF-LIFE; TEST-RETEST RELIABILITY; MINI-MENTAL-STATE; EXERCISE; VALIDITY; MOTOR; INDIVIDUALS; VALIDATION; TRIAL; NEUROPLASTICITY AB Parkinson's disease (PD) is a progressive neurodegenerative disease associated with deficits in motor, cognitive, and emotion/quality of life (QOL) domains, yet most pharmacologic and behavioral interventions focus only on motor function. Our goal was to perform a pilot study of Dance for Parkinson's-a community-based program that is growing-in popularity in order to compare effect sizes across multiple outcomes and to inform selection of primary and secondary outcomes for a larger trial. Study participants were people with PD who self-enrolled in either Dance for Parkinson's classes (intervention group, N = 8) or PD support groups (control group, N = 7). Assessments of motor function (Timed-Up-and-Go, Gait Speed, Standing Balance Test), cognitive function (Test of Everyday Attention, Verbal Fluency, Alternate Uses, Digit Span Forward and Backward), and emotion/QOL (Geriatric Depression Scale, Falls Efficacy Scale-International, Parkinson's Disease Questionnaire-39 (total score and Activities of Daily Living subscale)) were performed in both groups at baseline and follow-up. Standardized effect sizes were calculated within each group and between groups for all 12 measures. Effect sizes were positive (suggesting improvement) for all 12 measures within the intervention group and 7 of 12 measures within the control group. The largest between-group differences were observed for the Test of Everyday Attention (a measure of cognitive switching), gait speed and falls efficacy. Our findings suggest that dance has potential to improve multiple outcomes in people with PD. Future trials should consider co-primary outcomes given potential benefits in motor, cognitive and emotion/QOL domains. (C) 2016 Elsevier Inc. All rights reserved. C1 [Ventura, Maria I.; Barnes, Deborah E.] UC, Dept Epidemiol & Biostat, San Francisco, CA USA. [Barnes, Deborah E.] UC San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Mental Hlth Res Serv, San Francisco, CA USA. [Ross, Jessica M.] UC Merced, Dept Cognit Sci, Merced, CA USA. [Lanni, Kimberly E.] William Jessup Univ, Dept Psychol, Rocklin, CA USA. [Sigvardt, Karen A.] Univ Calif Davis, Dept Neurol, Davis, CA USA. [Disbrow, Elizabeth A.] LSU Hlth Sci Ctr Shreveport, Dept Neurol, POB 33932, Shreveport, LA 71130 USA. RP Disbrow, EA (reprint author), LSU Hlth Sci Ctr Shreveport, Dept Neurol, POB 33932, Shreveport, LA 71130 USA. EM edisbr@lsuhsc.edu FU Neuroscience Scholars Program Fellowship; UC Office of the President Dissertation Year Fellowship (UC Davis Dept. of Psychology); NIH [5-T32-AG000212, 1-T32-AG049663]; NINDS [R01NS064040]; Department of Veterans Affairs [1I01RX000181, 1I01RX001507]; Alzheimer's Association [NPSASA-15-364656]; S.D. Bechtel, Jr. Foundation FX This study was performed as part of the first author's doctoral dissertation in Psychology/Cognitive Neuroscience at the University of California, Davis. The authors would like to thank all participants who graciously volunteered their time to take part in this study; Ruth Rosenberg, Artist Engagement Coordinator for the Robert & Margrit Mondavi Center for the Performing Arts; Pamela Trokanski, director of the Pamela Trokanski Dance Theatre; and our Dance for PD (R) supporters from the Mark Morris Dance Group. We would also like to thank Christine Lee, RN and Hoang Nguyen for their contributions to the project MIV was supported by a Neuroscience Scholars Program Fellowship, UC Office of the President Dissertation Year Fellowship (UC Davis Dept. of Psychology), NIH grants 5-T32-AG000212 and 1-T32-AG049663. EAD was supported by grants from the NINDS (R01NS064040) and the Department of Veterans Affairs (1I01RX000181). DEB was supported in part by the Alzheimer's Association (NPSASA-15-364656), Department of Veterans Affairs (1I01RX001507), the S.D. Bechtel, Jr. Foundation and philanthropic support from the Osher Center for Integrative Medicine at UCSF. NR 54 TC 1 Z9 1 U1 19 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2016 VL 51 BP 50 EP 55 DI 10.1016/j.cct.2016.10.001 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA ED9BW UT WOS:000389166100007 PM 27765693 ER PT J AU Kelmenson, LB Demoruelle, MK Deane, KD AF Kelmenson, Lindsay B. Demoruelle, M. Kristen Deane, Kevin D. TI The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Rheumatoid arthritis; Lung; Anti-citrullinated protein antibodies; Rheumatoid factor ID RESOLUTION COMPUTED-TOMOGRAPHY; CYCLIC CITRULLINATED PEPTIDES; EXTRAARTICULAR MANIFESTATIONS; INTERSTITIAL PNEUMONIA; MUCOSAL INFLAMMATION; PULMONARY-FIBROSIS; INCREASED RISK; DISEASE; ANTIBODIES; AUTOANTIBODIES AB While the primary manifestation of rheumatoid arthritis (RA) is articular disease, extra-articular disease may also occur. In particular, pulmonary disease is a frequent extra-articular manifestation of seropositive RA and a leading cause of morbidity and mortality in this population. This review will highlight studies published in the last several years and will, in particular, discuss the relationship of antibodies to citrullinated protein/peptide antigens (ACPA) and lung disease in patients with RA. We will also review the data regarding the potential role of the lung and generation of RA-related autoantibodies in a period of disease development termed "preclinical RA." Finally, we will discuss the role of ACPA and other Abs in non-RA pulmonary diseases and discuss a research agenda for next steps in the understanding and management of the lung in RA. C1 [Kelmenson, Lindsay B.; Demoruelle, M. Kristen; Deane, Kevin D.] Univ Colorado Denver, Div Rheumatol, 1635 Aurora Court,MS F721, Aurora, CO 80045 USA. [Deane, Kevin D.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kelmenson, LB (reprint author), Univ Colorado Denver, Div Rheumatol, 1635 Aurora Court,MS F721, Aurora, CO 80045 USA. EM lindsay.kelmenson@ucdenver.edu FU NIH [AR-07534, AR066712]; Rheumatology Research & Education Foundation; VA Accreditation Council for Graduate Medical Education Enhancement Award FX LBK and MKD were supported by the NIH grants (AR-07534, AR066712) and the Rheumatology Research & Education Foundation. In addition, LBK was supported in part by funding through a VA Accreditation Council for Graduate Medical Education Enhancement Award. NR 76 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD NOV PY 2016 VL 18 IS 11 AR 69 DI 10.1007/s11926-016-0618-4 PG 10 WC Rheumatology SC Rheumatology GA ED4QX UT WOS:000388836400004 PM 27796844 ER PT J AU Xu, JG Wang, HD Won, SJ Basu, J Kapfhamer, D Swanson, RA AF Xu, Jianguo Wang, Handong Won, Seok Joon Basu, Jayinee Kapfhamer, David Swanson, Raymond A. TI Microglial Activation Induced by the Alarmin S100B is Regulated by Poly(ADP-ribose) Polymerase-1 SO GLIA LA English DT Article DE stroke; trauma; astrocyte; PARP-1; nitric oxide; MMP9; veliparib ID TRAUMATIC BRAIN-INJURY; GENE-EXPRESSION; INHIBITION; NEUROINFLAMMATION; VELIPARIB; SIGNAL; PARPS; HMGB1 AB Brain injury resulting from stroke or trauma can be exacerbated by the release of proinflammatory cytokines, proteases, and reactive oxygen species by activated microglia. The microglial activation resulting from brain injury is mediated in part by alarmins, which are signaling molecules released from damaged cells. The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been shown to regulate microglial activation after brain injury, and here we show that signaling effects of the alarmin S100B are regulated by PARP-1. S100B is a protein localized predominantly to astrocytes. Exogenous S100B added to primary microglial cultures induced a rapid change in microglial morphology, upregulation of IL-1 beta, TNF alpha, and iNOS gene expression, and release of matrix metalloproteinase 9 and nitric oxide. Most, though not all of these effects were attenuated in PARP-1(-/-) microglia and in wild-type microglia treated with the PARP inhibitor, veliparib. Microglial activation and gene expression changes induced by S100B injected directly into brain were likewise attenuated by PARP-1 inhibition. The anti-inflammatory effects of PARP-1 inhibitors in acutely injured brain may thus be mediated in part through effects on S100B signaling pathways. C1 [Xu, Jianguo; Wang, Handong] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing, Jiangsu, Peoples R China. [Xu, Jianguo; Won, Seok Joon; Basu, Jayinee; Kapfhamer, David; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Xu, Jianguo; Won, Seok Joon; Basu, Jayinee; Kapfhamer, David; Swanson, Raymond A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Swanson, RA (reprint author), VAMC, Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM Raymond.Swanson@ucsf.edu FU U.S. Department of Veterans Affairs; National Institutes of Health [NS041421]; China Scholarship Council FX Grant sponsor: U.S. Department of Veterans Affairs (RAS).; Grant sponsor: the National Institutes of Health; Grant numbers: NS041421 (RAS); the China Scholarship Council (JX) NR 40 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD NOV PY 2016 VL 64 IS 11 BP 1869 EP 1878 DI 10.1002/glia.23026 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EA6PR UT WOS:000386751600005 PM 27444121 ER PT J AU Mackey, DC Lui, LY Cawthon, PM Ensrud, K Yaffe, K Cummings, SR AF Mackey, Dawn C. Lui, Li-Yung Cawthon, Peggy M. Ensrud, Kristine Yaffe, Kristine Cummings, Steven R. TI Life-Space Mobility and Mortality in Older Women: Prospective Results from the Study of Osteoporotic Fractures SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aged; mobility; death; independence; survival ID MILD COGNITIVE IMPAIRMENT; ALL-CAUSE MORTALITY; PROSPECTIVE COHORT; CARDIOVASCULAR-DISEASE; PHYSICAL PERFORMANCE; ADULTS; MEN; RISK; CONSTRICTION; ASSOCIATION AB ObjectivesTo evaluate the relationship between life-space mobility (extent, frequency, independence of movement) and mortality in older women. DesignProspective cohort study. SettingFour U.S. clinical sites. ParticipantsWomen (N = 1,498) aged 75 to 102 (mean 87.6) followed from 2006 to 2015. MeasurementsLife-space during the past 4 weeks was assessed in an interview, scored from 0 (daily restriction to bedroom) to 120 (daily trips outside town without assistance), and categorized (0-20, 21-40, 41-60, 61-80, 81-120). All-cause mortality was the primary outcome; noncancer, cardiovascular, cancer, and noncardiovascular noncancer mortality were secondary outcomes. ResultsOver a mean 5.2 years, 842 (56.2%) women died. Unadjusted risk of all-cause mortality was 82.6% in women with the lowest level of life-space (0-20 points) and 36.2% in those with the highest level (81-120 points). In multivariable proportional hazards models, there was a strong relationship between less life-space and greater risk of all-cause mortality (P-trend < .001). Women with the lowest level of life-space (0-20 points) had a risk of all-cause mortality that was 2.4 times as high (95% confidence interval (CI) = 1.5-4.0) as that of women with the highest level (81-120 points); women with life-space scores between 21 and 60 had a risk of all-cause mortality that was 1.5 times as high as that of women with the highest level. Each standard deviation decrease in life-space was associated with a 1.2 times greater (95% CI = 1.1-1.4) risk of all-cause mortality. Women unable to travel beyond their neighborhood without assistance had a risk of all-cause mortality that was 1.4 times (95% CI = 1.1-1.7) as high as that of women who could travel beyond their neighborhood without assistance. Results were similar for noncancer, cardiovascular, and other mortality and did not change after controlling for underlying disease or living arrangement. ConclusionLife-space scores of 60 or less were associated with mortality in older women independent of other strong risk factors. C1 [Mackey, Dawn C.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, K9625 Shrum Sci Ctr Bldg K,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada. [Mackey, Dawn C.] Univ British Columbia, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada. [Lui, Li-Yung; Cawthon, Peggy M.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Ensrud, Kristine] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Mackey, DC (reprint author), Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, K9625 Shrum Sci Ctr Bldg K,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada. EM dmackey@sfu.ca FU National Institutes of Health; National Institute on Aging [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576] FX SOF is supported by National Institutes of Health funding. The National Institute on Aging provides support under Grants R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NR 35 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2226 EP 2234 DI 10.1111/jgs.14474 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600035 PM 27696354 ER PT J AU Berlowitz, DR Breaux-Shropshire, T Foy, CG Gren, LH Kazis, L Lerner, AJ Newman, JC Powell, JR Riley, WT Rosman, R Wadley, VG Williams, JA AF Berlowitz, Dan R. Breaux-Shropshire, Tonya Foy, Capri G. Gren, Lisa H. Kazis, Lewis Lerner, Alan J. Newman, Jill C. Powell, James R. Riley, William T. Rosman, Robert Wadley, Virginia G. Williams, Julie A. CA SPRINT Res Grp TI Hypertension Treatment and Concern About Falling: Baseline Data from the Systolic Blood Pressure Intervention Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hypertension; falls; concern about falling ID OLDER-PEOPLE; FES-I; FEAR; PREVALENCE; HEALTH; POPULATION; VALIDITY AB ObjectivesTo determine the extent of concern about falling in older adults with hypertension, whether lower blood pressure (BP) and greater use of antihypertensive medications are associated with greater concern about falling, and whether lower BP has a greater effect on concern about falling in older and more functionally impaired individuals. DesignSecondary analysis involving cross-sectional study of baseline characteristics of participants enrolled in the Systolic Blood Pressure Intervention Trial (SPRINT). SettingApproximately 100 outpatient sites. ParticipantsSPRINT enrollees aged 50 and older (mean age 69) diagnosed with hypertension (N=2,299). MeasurementsConcern about falling was determined using the shortened version of the Falls Efficacy Scale International as measured at the baseline examination. ResultsMild concern about falling was present in 29.3% of participants and moderate to severe concern in 17.9%. Neither low BP (systolic BP<120mmHg, diastolic BP <70mmHg) nor orthostatic hypotension was associated with concern about falling (P>.10). Participants with moderate to severe concern about falling were taking significantly more antihypertensive medications than those with mild or no concern. After adjusting for baseline characteristics, no associations were evident between BP, medications, and concern about falling. Results were similar in older and younger participants; interactions between BP and age and functional status were not significantly associated with concern about falling. ConclusionAlthough concern about falling is common in older adults with hypertension, it was not found to be associated with low BP or use of more antihypertensive medications in baseline data from SPRINT. C1 [Berlowitz, Dan R.; Kazis, Lewis] Bedford Vet Affairs Hosp, Bedford, MA USA. [Berlowitz, Dan R.; Kazis, Lewis] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA. [Breaux-Shropshire, Tonya] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Breaux-Shropshire, Tonya; Wadley, Virginia G.] Univ Alabama Birmingham, Birmingham, AL USA. [Foy, Capri G.; Newman, Jill C.] Wake Forest Univ, Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC USA. [Gren, Lisa H.] Univ Utah, Sch Med, Dept Family & Prevent Med, Salt Lake City, UT USA. [Lerner, Alan J.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH USA. [Powell, James R.] East Carolina Univ, Brody Sch Med, Div Gen Internal Med, Greenville, NC USA. [Riley, William T.] NIH, Off Behav & Social Sci Res, Bethesda, MD USA. [Rosman, Robert] Univ Illinois, Div Acad Internal Med & Geriatr, Coll Med, Chicago, IL USA. [Williams, Julie A.] Wake Forest Univ, Sch Med, Sect Gerontol & Geriatr Med, Winston Salem, NC USA. RP Berlowitz, DR (reprint author), Bedford VA Hosp, 200 Springs Rd, Bedford, MA 01730 USA. EM dan.berlowitz@va.gov FU National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C]; CTSAs funded by NCATS [UL1TR000439, UL1RR025755, UL1RR024134, UL1TR000003, UL1RR025771, UL1TR000093, UL1RR025752, UL1TR000073, UL1TR001064, UL1TR000050, UL1TR000005, 9U54TR 000017-06, UL1TR000105-05, UL1TR000445, UL1TR000075, UL1TR000002, UL1TR000064, UL1TR000433, P30GM103337]; [A-HL-13-002-001] FX SPRINT is funded with funds from the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS), under Contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and Inter-Agency Agreement A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. The investigators designed and implemented all components of the SPRINT protocol. The investigative team collected, analyzed, and interpreted the data. For a full list of contributors to SPRINT, please see the supplementary acknowledgment list. We also acknowledge the support from the following CTSAs funded by NCATS: CWRU: UL1TR000439, OSU: UL1RR025755, U Penn: UL1RR024134 & UL1TR000003, U Boston: UL1RR025771, U Stanford: UL1TR000093, U Tufts: UL1RR025752, UL1TR000073 & UL1TR001064, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, UT Southwestern: 9U54TR 000017-06, University of Utah: UL1TR000105-05, Vanderbilt University: UL1TR000445, George Washington University: UL1TR000075, University of CA, Davis: UL1TR000002, University of Florida: UL1TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337 COBRE Award NIGMS. NR 18 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2302 EP 2306 DI 10.1111/jgs.14441 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600045 PM 27640987 ER PT J AU Kramer, BJ Creekmur, B Howe, JL Trudeau, S Douglas, JR Garner, K Bales, C Callaway-Lane, C Barczi, S AF Kramer, B. Josea Creekmur, Beth Howe, Judith L. Trudeau, Scott Douglas, Joseph R. Garner, Kimberly Bales, Connie Callaway-Lane, Carol Barczi, Steven TI Veterans Affairs Geriatric Scholars Program: Enhancing Existing Primary Care Clinician Skills in Caring for Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE education; VA; continuing professional development; rural ID CONTINUING MEDICAL-EDUCATION; OUTCOMES; BEHAVIOR; IMPACT; MODEL AB The Veterans Affairs Geriatric Scholars Program (GSP) is a continuing professional development program to integrate geriatrics into the clinical practices of primary care providers and select associated health professions that support primary care teams. GSP uses a blended program educational format, and the minimal requirements are to attend an intensive course in geriatrics, participate in an interactive workshop on quality improvement (QI), and initiate a local QI project to demonstrate application of new knowledge to benefit older veterans. Using a retrospective post/pre survey design, the effect of GSP on clinical practices and behaviors and variation of that effect on clinicians working in rural and nonrural settings were evaluated. Significant improvement was found in the frequency of using evidence-based brief standardized assessments, clinical decision-making, and standards of care. Significant subgroup differences were observed in peer-to-peer information sharing between rural and nonrural clinicians. Overall, 77% of the sample reported greater job satisfaction after participating in GSP. The program is a successful model for advancing postgraduate education in geriatrics and a model that might be replicated to increase access to quality health care, particularly in rural areas. C1 [Kramer, B. Josea; Creekmur, Beth; Douglas, Joseph R.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA USA. [Howe, Judith L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Vet Integrated Serv Network 2, Bronx, NY USA. [Howe, Judith L.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY USA. [Howe, Judith L.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA. [Trudeau, Scott] Bedford Vet Affairs Med Ctr, New England Geriatr Res Educ & Clin Ctr, Bedford, MA USA. [Trudeau, Scott] Tufts Univ, Dept Occupat Therapy, Medford, MA USA. [Trudeau, Scott] Amer Occupat Therapy Assoc, Prod Aging & Collaborat Practice, Bethesda, MD USA. [Garner, Kimberly] Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Vet Integrated Serv Network 16, Little Rock, AR USA. [Garner, Kimberly] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR USA. [Bales, Connie] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Bales, Connie] Duke Univ, Sch Med, Durham, NC USA. [Callaway-Lane, Carol] Vanderbilt Univ, Sch Nursing, Nashville, TN USA. [Callaway-Lane, Carol] Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Barczi, Steven] William S Middleton Memorial Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Barczi, Steven] Univ Wisconsin, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA. RP Kramer, BJ (reprint author), Greater Angeles Healthcare Syst GREGG, 16111 Plummer St 11E, Sepulveda, CA 91343 USA. EM josea.kramer@va.gov OI Creekmur, Beth/0000-0001-7802-1125 FU VA FX The VA funding sources for the Geriatric Scholars Program had no role in the design, methods, subject recruitment, data collection, analysis, or preparation of this paper. NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2343 EP 2348 DI 10.1111/jgs.14382 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600052 PM 27696341 ER PT J AU Andy, UU Vaughan, CP Burgio, KL Alli, FM Goode, PS Markland, AD AF Andy, Uduak U. Vaughan, Camille P. Burgio, Kathryn L. Alli, Foluke M. Goode, Patricia S. Markland, Alayne D. TI Shared Risk Factors for Constipation, Fecal Incontinence, and Combined Symptoms in Older US Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE constipation; fecal incontinence; epidemiology; older adults; geriatrics ID QUALITY-OF-LIFE; PREVALENCE; WOMEN; IMPACT; POPULATION; COMMUNITY; EPIDEMIOLOGY; MORTALITY; SEVERITY; HOME AB ObjectivesTo estimate the prevalence of constipation, fecal incontinence (FI), and combined symptoms and to identify shared factors associated with bowel symptoms in older U.S. men and women DesignPopulation-based cross-sectional study. SettingNational Health and Nutrition Examination Survey (2005-2010). ParticipantsWomen and men aged 50 and older. MeasurementsConstipation was defined as hard stool consistency on the validated Bristol Stool Form Scale or stool frequency of fewer than three bowel movements per week. FI was defined as at least monthly loss of solid, liquid, or mucus stool. Combined symptoms was defined as constipation and FI. Multinomial multivarible models adjusted for age, race, socioeconomic status, education, self-rated health, depression, impairments in activities of daily living, and number of comorbidities. ResultsWomen (n = 3,078) reported higher prevalence of bowel symptoms than men (constipation 11.8% vs 4.7%%, FI 11.2% vs 8.6%, combined symptoms 1.4% vs 0.4%). In adjusted models, women had greater odds of having constipation (odds ratio (OR) = 3.0, 95% confidence interval (CI) = 2.3-3.8), FI (OR = 1.4, 95% CI = 1.1-1.8), and combined symptoms (OR = 4.6, 95% CI = 2.0-10.2) than men. Shared risk factors included poor self-rated health and depression symptoms (constipation: OR = 1.8, 95% CI = 1.4-2.4 and OR = 1.8, 95% CI = 1.0-3.2; FI: OR = 1.6, 95% CI = 1.2-2.2 and OR = 2.3 95% CI = 1.4-3.6; combined symptoms: OR = 2.6 95% CI = 1.5-4.8 and OR = 4.6, 95% CI = 1.3-16.4). ConclusionWhen defining constipation and FI using validated instruments, women had a much higher prevalence of constipation than men, whereas men had a higher prevalence of FI than constipation. Shared risk factors reflect the negative effect that bowel symptoms have on quality of life. C1 [Andy, Uduak U.] Univ Penn, Sch Med, Dept Obstet & Gynecol, Div Urogynecol, Philadelphia, PA 19104 USA. [Vaughan, Camille P.] Atlanta Vet Affairs Med Ctr, Birmingham Atlanta Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Decatur, GA USA. [Vaughan, Camille P.] Emory Univ, Dept Med, Div Gen Med & Geriatr, Atlanta, GA 30322 USA. [Burgio, Kathryn L.; Alli, Foluke M.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham Atlanta Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. RP Andy, UU (reprint author), Div Urogynecol, 1000 Courtyard Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM uduakumoh.andy@uphs.upenn.edu OI Markland, Alayne/0000-0002-6567-6744 FU National Institute of Diabetes and Digestive and Kidney Diseases [R21 D096201]; Veterans Health Administration Career Development Award from Rehabilitation Research and Development [1 IK2 RX000747-01] FX Support was received from the National Institute of Diabetes and Digestive and Kidney Diseases (R21 D096201; PI: Markland). Dr. Vaughan is supported by a Veterans Health Administration Career Development Award from Rehabilitation Research and Development (1 IK2 RX000747-01). NR 26 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP E183 EP E188 DI 10.1111/jgs.14521 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600011 PM 27783401 ER PT J AU Brody, AA Gibson, B Tresner-Kirsch, D Kramer, H Thraen, I Coarr, ME Rupper, R AF Brody, Abraham A. Gibson, Bryan Tresner-Kirsch, David Kramer, Heidi Thraen, Iona Coarr, Matthew E. Rupper, Randall TI High Prevalence of Medication Discrepancies Between Home Health Referrals and Centers for Medicare and Medicaid Services Home Health Certification and Plan of Care and Their Potential to Affect Safety of Vulnerable Elderly Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE safety; medication reconciliation; care coordination; home health; transitional care ID TRANSITIONS; RECONCILIATION; COMMUNICATION; ADHERENCE; RECORDS AB ObjectivesTo describe the prevalence of discrepancies between medication lists that referring providers and home healthcare (HH) nurses create. DesignThe active medication list from the hospital at time of HH initiation was compared with the HH agency's plan of care medication list. An electronic algorithm was developed to compare the two lists for discrepancies. SettingSingle large hospital and HH agency in the western United States. ParticipantsIndividuals referred for HH from the hospital in 2012 (N = 770, 96.3% male, median age 71). MeasurementsPrevalence was calculated for discrepancies, including medications missing from one list or the other and differences in dose, frequency, or route for medications contained on both lists. ResultsParticipants had multiple medical problems (median 16 active problems) and were taking a median of 15 medications (range 1-93). Every participant had at least one discrepancy; 90.1% of HH lists were missing at least one medication that the referring provider had prescribed, 92.1% of HH lists contained medications not on the referring provider's list, 89.8% contained medication naming errors. 71.0% contained dosing discrepancies, and 76.3% contained frequency discrepancies. ConclusionDiscrepancies between HH and referring provider lists are common. Future work is needed to address possible safety and care coordination implications of discrepancies in this highly complex population. C1 [Brody, Abraham A.] James J Peters Bronx Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Brody, Abraham A.] NYU, Coll Nursing, Harttord Inst Geriatr Nursing, 433 First Ave, New York, NY 10010 USA. [Gibson, Bryan; Kramer, Heidi] George E Wahlen Vet Affairs Med Ctr, Informat Decis Enhancement & Analyt Sci, Salt Lake City, UT USA. [Gibson, Bryan; Kramer, Heidi] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. [Tresner-Kirsch, David; Coarr, Matthew E.] Mitre Corp, Burlington Rd, Bedford, MA 01730 USA. [Tresner-Kirsch, David] Brandeis Univ, Waltham, MA USA. [Thraen, Iona; Rupper, Randall] George E Wahlen Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Thraen, Iona] Univ Utah, Coll Social Work, Salt Lake City, UT USA. [Rupper, Randall] Univ Utah, Dept Geriatr, Salt Lake City, UT USA. RP Brody, AA (reprint author), NYU, Coll Nursing, Harttord Inst Geriatr Nursing, 433 First Ave, New York, NY 10010 USA. EM ab.brody@nyu.edu OI Brody, Abraham/0000-0002-3405-7043 FU Department of Veterans Affairs Office of Rural Health FX This research was funded by a grant from the Department of Veterans Affairs Office of Rural Health. NR 20 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP E166 EP E170 DI 10.1111/jgs.14457 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600008 PM 27673753 ER PT J AU Armato, SG Blyth, KG Keating, JJ Katz, S Tsim, S Coolen, J Gudmundsson, E Opitz, I Nowak, AK AF Armato, Samuel G., III Blyth, Kevin G. Keating, Jane J. Katz, Sharyn Tsim, Selina Coolen, Johan Gudmundsson, Eyjolfur Opitz, Isabelle Nowak, Anna K. TI Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group SO LUNG CANCER LA English DT Review DE Near-infrared imaging; Perfusion MRI; Dynamic contrast-enhanced CT; Tumor response assessment; Tumor volume; Modified RECIST ID THORACIC CT SCANS; RESPONSE EVALUATION; TUMOR VOLUME; MALIGNANT MESOTHELIOMA; PATIENT RESPONSE; RECIST CRITERIA; PERFUSION CT; SOLID TUMORS; LUNG-CANCER; EXPERIENCE AB Imaging plays an important role in the detection, diagnosis, staging, response assessment, and surveillance of malignant pleural mesothelioma. The etiology, biology, and growth pattern of mesothelioma present unique challenges for each modality used to capture various aspects of this disease. Clinical implementation of imaging techniques and information derived from images continue to evolve based on active research in this field worldwide. This paper summarizes the imaging-based research presented orally at the 2016 International Conference of the International Mesothelioma Interest Group (iMig) in Birmingham, United Kingdom, held May 1-4, 2016. Presented topics included intraoperative near-infrared imaging of mesothelioma to aid the assessment of resection completeness, an evaluation of tumor enhancement improvement with increased time delay between contrast injection and image acquisition in standard clinical magnetic resonance imaging (MRI) scans, the potential of early contrast enhancement analysis to provide MRI with a role in mesothelioma detection, the differentiation of short and long-term survivors based on MRI tumor volume and histogram analysis, the response-assessment potential of hemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans, the correlation of CT-based tumor volume with post-surgical tumor specimen weight, and consideration of the need to update the mesothelioma tumor response assessment paradigm. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Armato, Samuel G., III] Univ Chicago, Dept Radiol, 5841 South Maryland Ave MC 2026, Chicago, IL 60637 USA. [Blyth, Kevin G.; Tsim, Selina] Queen Elizabeth Univ Hosp, Dept Resp Med, Glasgow, Lanark, Scotland. [Blyth, Kevin G.; Tsim, Selina] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland. [Keating, Jane J.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Keating, Jane J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Keating, Jane J.] Univ Penn, Abramson Canc Ctr, Ctr Precis Surg, Pearlman Sch Med, Philadelphia, PA 19104 USA. [Katz, Sharyn] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Coolen, Johan] Univ Hosp Leuven, Dept Radiol, Leuven, Belgium. [Opitz, Isabelle] Univ Zurich Hosp, Div Thorac Surg, Zurich, Switzerland. [Nowak, Anna K.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia. [Nowak, Anna K.] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia. [Nowak, Anna K.] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia. RP Armato, SG (reprint author), Univ Chicago, Dept Radiol, 5841 South Maryland Ave MC 2026, Chicago, IL 60637 USA. EM s-armato@uchicago.edu RI Nowak, Anna/B-2487-2013 OI Nowak, Anna/0000-0002-9317-9526 FU National Institutes of Health [R0I CA193556]; Belgian Foundation against Cancer [ARC211]; Kazan Law Firm's Charitable Foundation; Paul C. Hodges Alumni Society, Department of Radiology, The University of Chicago; University of Chicago; National Health and Medical Research Council of Australia; National Research Scotland Career Research Fellowship FX JJK would like to thank Jarrod D. Predina, M.D., Sarah Nims, Ollin Venegas, John C. Kucharczuk, M.D., Charuhas Deshpande, M.D., Ryan Zeh, Sunil Singhal, M.D. The study of JJK was supported by National Institutes of HealthR0I CA193556.; JC acknowledges F. De Keyzer, P. Nafteux, W. De Weyer, E. Verbeken, J. Vansteenkiste, K. Nackaerts, and J. Verschakelen. The mesothelioma study of JC was supported by a grant (#ARC211) from the Belgian Foundation against Cancer.; EG would like to thank Samuel G. Armato III, Ph.D., Zacariah E. Labby, Ph.D., Christopher Straus, M.D., Feng Li, M.D., Ph.D., Buerkley Rose, R.N., and Hedy L. Kindler, M.D. EG was funded in part by the Kazan Law Firm's Charitable Foundation and the Paul C. Hodges Alumni Society, Department of Radiology, The University of Chicago.; SGA receives royalties and licensing fees through The University of Chicago for computer-aided diagnosis technology. SGA is a consultant for Aduro Biotech, Inc.; AKN acknowledges the National Health and Medical Research Council of Australia for funding the National Centre for Asbestos Related Diseases Centre of Research Excellence.; KGB is funded by a National Research Scotland Career Research Fellowship. NR 48 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD NOV PY 2016 VL 101 BP 48 EP 58 DI 10.1016/j.lungcan.2016.09.003 PG 11 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EC3SN UT WOS:000388046700009 PM 27794408 ER PT J AU Taylor, MV Priefer, BA Alt-White, AC AF Taylor, Melissa V. Priefer, Beverly A. Alt-White, Anna C. TI Evidence-based practice: Embracing integration SO NURSING OUTLOOK LA English DT Article DE Evidence-based practice; EBP process; Evidence; Patient preferences; Clinical expertise; Leadership; Nurses; Education; Culture; Infrastructure ID SHARED DECISION-MAKING; HEALTH-CARE; CLINICAL-PRACTICE; COMPETENCES AB Background: The Veterans Health Administration's Office of Nursing Services launched several initiatives to support evidence-based practice (EBP) initiatives throughout its system. From evaluation of these initiatives and reflection on discussions with nurse leaders and direct care nurses, our thinking about and approach to EBP has evolved from a project-focused to a practice-focused interpretation. Purpose: (a) Offer an expanded view that moves beyond interpreting EBP as process-driven projects to a "way of practicing" where nurses assume ownership for a practice that integrates best available evidence, clinical expertise, and patient preferences, and (b) describe and generate discussion on the educational, cultural, and role modeling implications of this expanded view. Methods: We illustrate EBP integration using a point-of-care interaction scenario. Conclusion: Commitment to EBP is reflected at the point-of-care where each nurse demonstrates the ability to integrate evidence-based interventions, patient preferences, and clinical expertise to arrive at patient-centric health care decisions. C1 [Taylor, Melissa V.] VA Pittsburgh Healthcare Syst, Patient Care Serv, Univ Dr, Pittsburgh, PA 15240 USA. [Priefer, Beverly A.] Off Nursing Serv, Dept Vet Affairs, Fitchburg, WI USA. [Alt-White, Anna C.] Off Nursing Serv, Dept Vet Affairs, Washington, DC USA. RP Taylor, MV (reprint author), VA Pittsburgh Healthcare Syst, Patient Care Serv, Univ Dr, Pittsburgh, PA 15240 USA. EM melissa.taylor5@va.gov NR 27 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD NOV-DEC PY 2016 VL 64 IS 6 BP 575 EP 582 DI 10.1016/j.outlook.2016.04.004 PG 8 WC Nursing SC Nursing GA EE0VH UT WOS:000389296500010 PM 27318385 ER PT J AU O'Neil, PM Miller-Kovach, K Tuerk, PW Becker, LE Wadden, TA Fujioka, K Hollander, PL Kushner, RF Garvey, WT Rubino, DM Malcolm, RJ Weiss, D Raum, WJ Salyer, JL Hermayer, KL Rost, SL Veliko, JL Sora, ND AF O'Neil, Patrick M. Miller-Kovach, Karen Tuerk, Peter W. Becker, Lynne E. Wadden, Thomas A. Fujioka, Ken Hollander, Priscilla L. Kushner, Robert F. Garvey, W. Timothy Rubino, Domenica M. Malcolm, Robert J. Weiss, Daniel Raum, William J. Salyer, Jonny L. Hermayer, Kathie L. Rost, Stephanie L. Veliko, Jan L. Sora, Nicoleta D. TI Randomized Controlled Trial of a Nationally Available Weight Control Program Tailored for Adults with Type 2 Diabetes SO Obesity LA English DT Article ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR RISK-FACTORS; SELF-MANAGEMENT EDUCATION; OBESE-PATIENTS; CLINICAL-TRIAL; UNITED-STATES; NUTRITION; METAANALYSIS; PREVALENCE; OVERWEIGHT AB Objective: Modest weight loss from clinical interventions improves glycemic control in type 2 diabetes (T2DM). Data are sparse on the effects of weight loss via commercial weight loss programs. This study examined the effects on glycemic control and weight loss of the standard Weight Watchers program, combined with telephone and email consultations with a certified diabetes educator (WW), compared with standard diabetes nutrition counseling and education (standard care, SC). Methods: In a 12-month randomized controlled trial at 16 U.S. research centers, 563 adults with T2DM (HbA(1c) 7-11%; BMI 27-50 kg/m(2)) were assigned to either the commercially available WW program (regular community meetings, online tools), plus telephone and email counseling from a certified diabetes educator, or to SC (initial in-person diabetes nutrition counseling/education, with follow-up informational materials). Results: Follow-up rate was 86%. Twelve-month HbA(1c) changes for WW and SC were 20.32 and 10.16, respectively; 24% of WW versus 14% of SC achieved HbA(1c) <7.0% (P = 0.004). Weight losses were -4.0% for WW and -1.9% for SC (Ps < 0.001). 26% of WW versus 12% of SC reduced diabetes medications (P < 0.001). WW participants had greater reductions in waist circumference (P < 0.001) and C-reactive protein (P = 0.02) but did not differ on other cardiovascular risk factors. Conclusions: Widely available commercial weight loss programs with community and online components, combined with scalable complementary diabetes education, may represent accessible and effective components of management plans for adults with overweight/obesity and T2DM. C1 [O'Neil, Patrick M.; Tuerk, Peter W.; Becker, Lynne E.; Malcolm, Robert J.] Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Miller-Kovach, Karen; Rost, Stephanie L.; Veliko, Jan L.] Weight Watchers Int, New York, NY USA. [Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Wadden, Thomas A.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Fujioka, Ken] Scripps Clin Res, La Jolla, CA USA. [Hollander, Priscilla L.] Baylor Endocrine Ctr, Dallas, TX USA. [Kushner, Robert F.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Rubino, Domenica M.] Washington Ctr Weight Management & Res, Arlington, VA USA. [Weiss, Daniel] Your Diabet Endocrine Nutr Grp, Mentor, OH USA. [Raum, William J.] Oregon Weight Loss Surg, Portland, OR USA. [Salyer, Jonny L.] Lovelace Sci Resources, Albuquerque, NM USA. [Hermayer, Kathie L.; Sora, Nicoleta D.] Med Univ South Carolina, Div Endocrinol Diabet & Med Genet, Coll Med, Charleston, SC USA. RP O'Neil, PM (reprint author), Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM oneilp@musc.edu FU Weight Watchers International (WWI) FX This study was funded by a grant from Weight Watchers International (WWI) to the Medical University of South Carolina (MUSC). NR 33 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD NOV PY 2016 VL 24 IS 11 BP 2269 EP 2277 DI 10.1002/oby.21616 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA ED8VG UT WOS:000389148400004 PM 27804264 ER PT J AU Good, MM Riad, FS Good, CB Shalaby, AA AF Good, Meghan M. Riad, Fady S. Good, Chester B. Shalaby, Alaa A. TI Provider Response to QTc Prolongation on Standard 12-Lead EKG: Do We Notice or Do We Care? SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE QTc; EKG; drug interaction ID AMERICAN-HEART-ASSOCIATION; OF-CARDIOLOGY FOUNDATION; IN-HOSPITAL SETTINGS; TORSADE-DE-POINTES; INTERVAL PROLONGATION; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY; MEDICATION ERRORS; PATIENT SAFETY; RISK AB Background: Drugs and electrolyte imbalances are widely recognized as common triggers of a prolonged QT interval. We conducted a chart review to assess provider response to prolonged QT reported on a standard 12-lead electrocardiogram (EKG). Methods: We identified all Veterans Affairs Pittsburgh Healthcare System patients in a 6-month period with an EKG reporting a corrected QT (QTc) >500 ms. We excluded confounding or uninterpretable EKGs. Charts were reviewed to assess medications and electrolytes at the time of the EKG as well as the setting (inpatient vs outpatient) in which the EKG was obtained. Provider documentation of QTc and any corrective measures were sought. Results: After exclusions, 106 patients were included in this analysis (87 [82%] inpatient and 19 [18%] outpatient). Most were male (101, 95%) with a mean age of 63.5 +/- 10.6 years. At the time of index EKG, most patients were receiving at least one (72, 68%), and frequently two or more (35, 33%), QTc prolonging medications. Providers documented QTc prolongation in 20 inpatients (19%). Drugs were adjusted or discontinued in only two inpatients (2%). There were 14 patients (14%) with potassium level <3.6 mmol/L and 10 of 69 (14%) patients had a magnesium level <1.7 mg/dL. Conclusion: Patients with prolonged QTc on EKG were more likely to be inpatients than outpatients. Inpatients were more likely to be receiving multiple types and classes of QTc prolonging medications. In the vast majority of cases, providers did not address the prolonged QTc and only rarely initiated remedial actions. C1 [Good, Meghan M.] Vet Affairs Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA USA. [Riad, Fady S.; Good, Chester B.; Shalaby, Alaa A.] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA USA. [Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.; Shalaby, Alaa A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Shalaby, Alaa A.] Vet Affairs Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. RP Shalaby, AA (reprint author), 111C Univ Dr, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@va.gov OI Riad, Fady/0000-0001-7874-2328 NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0147-8389 EI 1540-8159 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD NOV PY 2016 VL 39 IS 11 BP 1174 EP 1180 DI 10.1111/pace.12951 PG 7 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA ED8US UT WOS:000389147000002 PM 27628760 ER PT J AU Feemster, L AF Feemster, L. TI E-CIGARETTES UPDATE SO RESPIROLOGY LA English DT Meeting Abstract C1 [Feemster, L.] Univ Washington, VA Puget Sound HCS, Med Pulm & Crit Care, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0839 BP 7 EP 7 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600018 ER PT J AU Feemster, L AF Feemster, L. TI FACILITATING ADOPTION OF COPD EVIDENCE BASED CARE IN OUTPATIENT SETTINGS (FACES) SO RESPIROLOGY LA English DT Meeting Abstract C1 [Feemster, L.] Univ Washington, VA Puget Sound HCS, Med Pulm & Crit Care, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0840 BP 15 EP 15 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600045 ER PT J AU Mcgarvey, L Calverley, PM Metzdorf, N Mueller, A Wise, RA Anzueto, A Dusser, D AF Mcgarvey, L. Calverley, P. M. Metzdorf, N. Mueller, A. Wise, R. A. Anzueto, A. Dusser, D. TI PRODUCTIVE COUGH AS A PREDICTOR OF MORTALITY, EXACERBATIONS AND CARDIAC EVENTS IN THE TIOSPIR (R) TRIAL SO RESPIROLOGY LA English DT Meeting Abstract C1 [Mcgarvey, L.] Queens Univ, Ctr Infect & Immun, Belfast, Antrim, North Ireland. [Calverley, P. M.] Univ Liverpool, Ctr Clin Sci, Inst Ageing & Chron Dis, Liverpool, Merseyside, England. [Metzdorf, N.] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Med, Ingelheim, Germany. [Mueller, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci Europe, Biberach, Germany. [Wise, R. A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, Pulm Crit Care, San Antonio, TX USA. [Dusser, D.] Univ Paris 05, Hosp Cochin, AP HP, Dept Pneumol, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0703 BP 120 EP 120 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600357 ER PT J AU Lao, LF Shen, J Tian, HJ Yao, QQ Li, YW Qian, L Murray, SS Wang, JC AF Lao, Lifeng Shen, Jia Tian, Haijun Yao, Qingqiang Li, Yawei Qian, Lie Murray, Samuel S. Wang, Jeffrey C. TI Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2 SO ANTICANCER RESEARCH LA English DT Article DE Prostate cancer; bone morphogenetic protein 2; secreted phosphoprotein 24 kD; bone metastasis ID BONE MORPHOGENETIC PROTEIN-2; TUMOR-GROWTH; SPP24; EXPRESSION; METASTASIS; ACTIVATION; LESIONS AB Background/Aim: Secreted phosphoprotein 24 kD (spp24) has been shown to inhibit bone morphogenetic protein 2 (BMP2)-induced cancer growth in several tumor models. In this study, we aimed to investigate the effects spp24 on the growth of prostate cancer caused by BMP2 in vitro and in vivo. Materials and Methods: The effects of BMP2 and spp24 on PC-3 cell viability were analyzed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. A subcutaneous tumor model and intratibial tumor model was established using PC-3 cells. Tumor growth was assessed through gross examination and radiography during the experiment. Then, after sacrifice, tumor cell apoptosis and tumor cell proliferation were assessed by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and immunochemical analysis. Results: BMP2 stimulated the PC-3 cell proliferation in vitro and spp24 could abolish the effect of BMP2. In a xeneograft tumor model, BMP2 promoted the subcutaneous and intratibial tumor growth, while spp24 dramatically inhibited the tumor growth induced by BMP2. Histological examination showed that spp24 also abolished the BMP2-induced proliferating cell nuclear antigen (PCNA) expression and promoted tumor cell apoptosis. Conclusion: Spp24 can inhibit the growth of prostate cancer and its bone metastasis induced by BMP2; spp24 may have great potential to be a therapeutic agent in clinical situations. C1 [Lao, Lifeng; Qian, Lie] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, 160 Pujian Rd, Shanghai 200127, Peoples R China. [Shen, Jia; Tian, Haijun; Yao, Qingqiang; Li, Yawei] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA. [Murray, Samuel S.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. [Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Murray, Samuel S.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA USA. [Wang, Jeffrey C.] Univ Southern Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA USA. RP Qian, L (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, 160 Pujian Rd, Shanghai 200127, Peoples R China. EM lqianrj@sina.com FU Shanghai Pujiang Program [15PJD026]; Medical-Engineering Joint Fund of Shanghai Jiao Tong University [YG2014MS51]; Shanghai Fund for Young Physician Development [20141051]; Incubating Program for Clinical Research and Innovation of Renji Hospital [PYXJS16-006] FX This research was funded by Shanghai Pujiang Program (NO. 15PJD026), Medical-Engineering Joint Fund of Shanghai Jiao Tong University (NO. YG2014MS51), Shanghai Fund for Young Physician Development (NO. 20141051), Incubating Program for Clinical Research and Innovation of Renji Hospital (NO. PYXJS16-006). NR 30 TC 1 Z9 1 U1 0 U2 0 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD NOV PY 2016 VL 36 IS 11 SI SI BP 5773 EP 5780 DI 10.21873/anticanres.11161 PG 8 WC Oncology SC Oncology GA EC9TI UT WOS:000388486700020 PM 27793899 ER PT J AU Braunberger, T Lynn, D Reimer, C Doctor, M Hill, MK Mounessa, J Dunnick, CA AF Braunberger, Taylor Lynn, Darren Reimer, Christie Doctor, Monica Hill, Mary K. Mounessa, Jessica Dunnick, Cory A. TI Disease Severity and Quality of Life Measurements in Contact Dermatitis: A Systematic Review 2005-2015 SO DERMATITIS LA English DT Review ID SODIUM-LAURYL-SULFATE; TRANSEPIDERMAL WATER-LOSS; CUMULATIVE SKIN IRRITATION; LASER-DOPPLER FLOWMETRY; RANDOMIZED CLINICAL-TRIAL; NICKEL ALLERGY SYNDROME; GLOBAL ASSESSMENT IGA; DOUBLE-BLIND; STRATUM-CORNEUM; IN-VIVO AB Background: Contact dermatitis (CD) has been assessed by numerous disease severity indices resulting in heterogeneity across published research. Objective: This study aims to evaluate published CD severity scales and identify a criterion standard for assessment. Methods: Scopus and Ovid MEDLINE were searched for human randomized controlled trials (RCTs) on CD severity measures published during a 10-year period. Eligible studies were English-language RCTs reporting disease severity outcome measures for CD in humans. Studies were excluded if they were duplicates, not available in English, not related to CD, not RCTs, not conducted on human subjects, or did not report relevant outcome measures. Results: A total of 22 disease outcome measures were used in 81 included RCTs. Instrument-based measures were used in 40 (49.4%) studies, and visual assessments were used in 66 (81.5%) RCTs. Only 5 (6.2%) studies reported quality of life (QoL) outcomes. Two (2.5%) studies used a clinical severity scale, which combined both QoL and visual assessments. Limitations: This study was limited by the exclusion of non-RCTs and gray literature. Conclusions: Wide variation in CD outcome measures exists including instrument-based measures, visual assessments, and QoL outcomes. A standardized outcome measure must be generated to reduce heterogeneity. C1 [Braunberger, Taylor] Univ North Dakota, Sch Med, Grand Forks, ND USA. [Lynn, Darren; Hill, Mary K.] Univ Colorado, Sch Med, Aurora, CO USA. [Reimer, Christie] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Doctor, Monica] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Mounessa, Jessica; Dunnick, Cory A.] Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. [Dunnick, Cory A.] Denver Vet Affairs Med Ctr, Dept Dermatol, Denver, CO USA. RP Dunnick, CA (reprint author), Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. EM cory.dunnick@ucdenver.edu NR 111 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1710-3568 EI 2162-5220 J9 DERMATITIS JI Dermatitis PD NOV-DEC PY 2016 VL 27 IS 6 BP 362 EP 371 DI 10.1097/DER.0000000000000235 PG 10 WC Dermatology SC Dermatology GA ED1KG UT WOS:000388603700007 PM 27775978 ER PT J AU Amini, A Waxweiler, TV Brower, JV Jones, BL McDermott, JD Raben, D Ghosh, D Bowles, DW Karam, SD AF Amini, Arya Waxweiler, Timothy V. Brower, Jeffrey V. Jones, Bernard L. McDermott, Jessica D. Raben, David Ghosh, Debashis Bowles, Daniel W. Karam, Sana D. TI Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma Data From the National Cancer Data Base SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; POSTOPERATIVE RADIATION-THERAPY; ADENOID CYSTIC CARCINOMA; LOCALLY ADVANCED HEAD; PROGNOSTIC-FACTORS; NECK-CANCER; PHASE-II; MALIGNANT-TUMORS; CONCURRENT CHEMORADIOTHERAPY; CONCOMITANT CHEMOTHERAPY AB IMPORTANCE Data on adjuvant concurrent chemoradiotherapy (CRT) after resection of salivary gland carcinomas (SGCs) are limited. OBJECTIVE To examine overall survival (OS) outcomes of patients who receive CRT vs radiotherapy (RT) alone after resection of SGCs. DESIGN, SETTING, AND PARTICIPANTS The National Cancer Data Base (NCDB), a hospital-based registry that represents 70% of all cancer cases in the United States, was queried for patients who underwent resection of major SGCs with at least 1 high-risk feature (T3-T4 stage, N1-N3 stage, or positive margins). Included patients had histologic findings for malignant SGC with grades 2 to 3 disease and at least 1 high-risk feature. All patients underwent resection with postoperative CRT or RT alone. Patients were treated from 1998 to 2011. Data were analyzed from January to March 2016. EXPOSURES Patients received CRT, defined as chemotherapy start within 14 days of RT initiation, or RT alone. MAIN OUTCOMES AND MEASURES Univariate, multivariate, and propensity score-matched analyses were performed to compare OS for patients undergoing CRT vs RT alone. RESULTS Analyses included 2210 eligible patients (1372 men [62.1%] and 838 women [37.9%]; median age [range], 63 [18-90] years); of these, 1842 (83.3%) received RT alone and 368 (16.7%) received CRT. Median follow-up was 39 (range, 2-188) months. Most of the resected major SGCs occurred at the parotid gland (1852 [83.8%]), followed by the submandibular gland (276 [12.5%]), major gland not otherwise specified (66 [3.0%]), and sublingual gland (16 [0.7%]). Unadjusted 2-year OS was worse with adjuvant CRT vs RT alone (71.3% vs 80.2%), as was 5-year OS (38.5% vs 54.2%) (hazard ratio [HR], 1.51; 95% CI, 1.29-1.76; P < .001). Overall survival was inferior with adjuvant CRT on multivariate analysis (HR, 1.22; 95% CI, 1.03-1.44; P = .02) and propensity score-matched analysis (HR, 1.20; 95% CI, 0.98-1.47; P = .08) compared with RT alone. Subgroup analyses by age, comorbidity score, primary site, histologic type, grade, T stage, N stage, margin status, and chemotherapy (single agent vs multiagent) demonstrated equivalent or shorter OS with the addition of chemotherapy to RT. CONCLUSIONS AND RELEVANCE This large analysis compared survival outcomes between postoperative CRT and RT alone in patients undergoing resection of high-risk major SGCs using a nationally representative database. The addition of concurrent chemotherapy to RT in patients with high-risk major SGCs did not offer an advantage in OS. C1 [Amini, Arya; Waxweiler, Timothy V.; Jones, Bernard L.; Raben, David; Karam, Sana D.] Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Ct,Room 1032, Aurora, CO 80045 USA. [Brower, Jeffrey V.] Univ Wisconsin, Carbone Canc Ctr, Dept Human Oncol, Sch Med, Madison, WI 53706 USA. [McDermott, Jessica D.; Bowles, Daniel W.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO USA. [McDermott, Jessica D.; Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Div Med Oncol, Dept Med, Denver Vet Affairs Med Ctr, Denver, CO USA. [Ghosh, Debashis] Univ Colorado, Sch Med, Dept Biostat, Aurora, CO 80045 USA. RP Karam, SD (reprint author), Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Ct,Room 1032, Aurora, CO 80045 USA. EM sana.karam@ucdenver.edu FU National Cancer Institute, National Institutes of Health; Cancer League of Colorado; Golfers Against Cancer FX This study was supported by a Paul Calabresi Career Development Award for Clinical Oncology K12 from the National Cancer Institute, National Institutes of Health (Dr Karam); by a grant from the Cancer League of Colorado; and by Golfers Against Cancer. NR 52 TC 2 Z9 2 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD NOV PY 2016 VL 142 IS 11 BP 1100 EP 1110 DI 10.1001/jamaoto.2016.2168 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA ED3GI UT WOS:000388737200013 PM 27541166 ER PT J AU Metrik, J Jackson, K Bassett, SS Zvolensky, MJ Seal, K Borsari, B AF Metrik, Jane Jackson, Kristina Bassett, Shayna S. Zvolensky, Michael J. Seal, Karen Borsari, Brian TI The Mediating Roles of Coping, Sleep, and Anxiety Motives in Cannabis Use and Problems Among Returning Veterans With PTSD and MDD SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE cannabis; motives; PTSD; depression; sleep ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; MARIJUANA USE MOTIVES; NATIONAL EPIDEMIOLOGIC SURVEY; COGNITIVE-BEHAVIORAL THERAPY; MENTAL-HEALTH DIAGNOSES; AFGHANISTAN VETERANS; MOTIVATIONAL MODEL; DISTRESS TOLERANCE; COMORBIDITY SURVEY AB Veterans with posttraumatic stress disorder (PTSD) and major depressive disorder (MDD), the 2 most prevalent mental health disorders in the Iraq and Afghanistan veterans, are at increased risk for cannabis use and problems including cannabis use disorder (CUD). The present study examined the relationship of PTSD and MDD with cannabis use frequency, cannabis problems, and CUD as well as the role of 3 coping-oriented cannabis use motives (coping with negative affect, situational anxiety, and sleep) that might underlie this relationship. Participants were veterans (N = 301) deployed post-9/11/2001 recruited from a Veterans Health Administration facility in the Northeast United States based on self-reported lifetime cannabis use. There were strong unique associations between PTSD and MDD and cannabis use frequency, cannabis problems, and CUD. Mediation analyses revealed the 3 motives accounted, in part, for the relationship between PTSD and MDD with 3 outcomes in all cases but for PTSD with cannabis problems. When modeled concurrently, sleep motives, but not situational anxiety or coping with negative affect motives, significantly mediated the association between PTSD and MDD with use. Together with coping motives, sleep motives also fully mediated the effects of PTSD and MDD on CUD and in part the effect of MDD on cannabis problems. Findings indicate the important role of certain motives for better understanding the relation between PTSD and MDD with cannabis use and misuse. Future work is needed to explore the clinical utility in targeting specific cannabis use motives in the context of clinical care for mental health and CUD. C1 [Metrik, Jane; Bassett, Shayna S.] Providence VA Med Ctr, Providence, RI USA. [Metrik, Jane; Jackson, Kristina] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Bassett, Shayna S.] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Zvolensky, Michael J.] Univ Houston, Dept Behav Sci, Houston, TX 77004 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Seal, Karen; Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA. [Seal, Karen; Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Metrik, J (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. EM Jane_Metrik@brown.edu FU National Institute on Drug Abuse [R01 DA033425]; [K02 AA13938] FX All authors contributed in a significant way to the manuscript and have all read and approved the final manuscript. This study was funded by a National Institute on Drug Abuse grant (R01 DA033425), awarded to Jane Metrik and Brian Borsari. Kristina Jackson's work on this project was supported by K02 AA13938. The funding sources had no other role other than financial support. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors have no financial relationship with the study sponsor. The authors gratefully acknowledge Cassandra Delapaix, Rebecca Swagger, Madeline Benz, Hannah Wheeler, Suzanne Sales, and Julie Evon for their contribution to the project. NR 85 TC 1 Z9 1 U1 10 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD NOV PY 2016 VL 30 IS 7 BP 743 EP 754 DI 10.1037/adb0000210 PG 12 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA ED3HM UT WOS:000388740200004 PM 27786514 ER PT J AU Gros, DF Flanagan, JC Korte, KJ Mills, AC Brady, KT Back, SE AF Gros, Daniel F. Flanagan, Julianne C. Korte, Kristina J. Mills, Adam C. Brady, Kathleen T. Back, Sudie E. TI Relations Among Social Support, PTSD Symptoms, and Substance Use in Veterans SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE posttraumatic stress disorder; social support; alcohol; veterans ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE; DEPRESSIVE SYMPTOMS; ENDURING FREEDOM; EXPOSED ADULTS; IRAQI FREEDOM; COMORBIDITY; DEPENDENCE; RESILIENCE; NETWORKS AB Social support plays a significant role in the development, maintenance, and treatment of posttraumatic stress disorder (PTSD). However, there has been little investigation of social support with PTSD and its frequent comorbid conditions and related symptoms. Substance use disorders (SUDs) are 1 set of conditions that have yet to be investigated in combination with PTSD and social support. As compared with civilians, veterans are at increased risk for developing both PTSD and SUD. In this study, veterans (N = 171) with symptoms of PTSD (76% met diagnostic criteria) and SUD (83% met diagnostic criteria for any dependence) were recruited and completed clinician-rated and self-report measures of PTSD, SUD, and social support. Overall, low social support was reported in the sample. When controlled for the other disorder's symptoms, PTSD symptoms demonstrated a significant negative relation and SUD symptoms demonstrated a significant positive relation to social support. The PTSD findings are consistent with previous studies on PTSD and social support without SUD comorbidity. However, the SUD findings are inconsistent with previous studies, which focused primarily on older veterans. Together, these findings highlight the significance of social support in individuals with PTSD and SUD and promote future research within comorbid presentations. C1 [Gros, Daniel F.; Flanagan, Julianne C.; Korte, Kristina J.; Mills, Adam C.; Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Gros, Daniel F.; Flanagan, Julianne C.; Korte, Kristina J.; Mills, Adam C.; Brady, Kathleen T.; Back, Sudie E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU National Institute on Drug Abuse (NIDA) [DA030143]; Department of Veteran Affairs [CX000845]; National Institute on Child Health and Human Development; Office of Research on Women's Health [K12HD055885]; National Institute of Alcohol Abuse and Alcoholism [T32AA007474] FX This research was supported by the National Institute on Drug Abuse (NIDA) grant DA030143 (Principal Investigator [PI]: S. E. B.), the Department of Veteran Affairs Clinical Science Research and Development Career Development Award CX000845 (PI: D. F. G.), the National Institute on Child Health and Human Development and the Office of Research on Women's Health grant K12HD055885 (PI: J. C. F.), and by the National Institute of Alcohol Abuse and Alcoholism grant T32AA007474 (K. J. K.). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIDA, the Department of Veterans Affairs, or the U.S. government. NR 45 TC 1 Z9 1 U1 8 U2 8 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD NOV PY 2016 VL 30 IS 7 BP 764 EP 770 DI 10.1037/adb0000205 PG 7 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA ED3HM UT WOS:000388740200006 PM 27786511 ER PT J AU Montgomery, AE Szymkowiak, D Marcus, J Howard, P Culhane, DP AF Montgomery, Ann Elizabeth Szymkowiak, Dorota Marcus, Jessica Howard, Paul Culhane, Dennis P. TI Homelessness, Unsheltered Status, and Risk Factors for Mortality: Findings From the 100000 Homes Campaign SO PUBLIC HEALTH REPORTS LA English DT Article DE homeless; unsheltered; mortality ID FOSTER-CARE; PHYSICAL HEALTH; ADULTS; DEATH; BOSTON; SERVICES; BEHAVIOR; OUTCOMES; HISTORY; IMPACT AB Objectives: People who live in unsheltered situations, such as the streets, often have poorer health, less access to health care, and an increased risk of premature mortality as compared with their sheltered counterparts. The objectives of this study were to (1) compare the characteristics of people experiencing homelessness who were sleeping primarily in unsheltered situations with those who were accessing homeless shelters and other sheltered situations, (2) identify correlates of unsheltered status, and (3) assess the relationship between unsheltered status and increased risk of mortality. Methods: Using primary data collected as part of the 100000 Homes Campaigna national effort to help communities find homes for vulnerable and chronically homeless Americanswe estimated 2 generalized linear mixed models to understand the correlates of unsheltered status and risk factors for mortality. Independent variables included demographic characteristics; history of homelessness, incarceration, foster care, and treatment for mental illness or substance use; sources of income; and past and present medical conditions. The study sample comprised 25489 people experiencing homelessness who responded to an assessment of their housing and health as part of the 100000 Homes Campaign from 2008 to 2014. Results: In the full model, the following characteristics were associated with unsheltered status: being a veteran (adjusted odds ratio [aOR] = 1.10); having 5 years), incarceration (aOR = 1.32), or substance use (aOR = 1.10 for ever abusing drugs or alcohol, aOR = 1.13 for ever using intravenous drugs, aOR = 1.98 for drinking alcohol every day for past month). Being unsheltered (aOR = 1.12), being female (aOR = 1.22), or receiving entitlements (aOR = 1.63) increased respondents' odds of having risk factors for mortality. Conclusions: These findings highlight the need to assertively reach out to vulnerable populations and provide interventions to assist them during their transitionfor example, as they exit incarceration or age out of foster care. Such a response could prevent unsheltered homelessness and thereby address increased mortality risk. Connecting people with resources to increase their access to employment, benefits, and other sources of income is especially important. C1 [Montgomery, Ann Elizabeth] Birmingham Vet Affairs Med Ctr, Hlth Serv Res, Birmingham, AL USA. [Montgomery, Ann Elizabeth; Szymkowiak, Dorota; Culhane, Dennis P.] Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Montgomery, Ann Elizabeth] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Marcus, Jessica; Howard, Paul] Community Solut, Data & Performance Management, New York, NY USA. [Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Montgomery, AE (reprint author), Birmingham VA Med Ctr, Mail Stop 151 A Pickwick,700 South 19th St, Birmingham, AL 35233 USA. EM ann.montgomery2@va.gov NR 30 TC 0 Z9 0 U1 11 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 765 EP 772 DI 10.1177/0033354916667501 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400006 PM 28123222 ER PT J AU Hoffmire, C Stephens, B Morley, S Thompson, C Kemp, J Bossarte, RM AF Hoffmire, Claire Stephens, Brady Morley, Sybil Thompson, Caitlin Kemp, Janet Bossarte, Robert M. TI VA Suicide Prevention Applications Network: A National Health Care System-Based Suicide Event Tracking System SO PUBLIC HEALTH REPORTS LA English DT Article DE veterans; suicide; prevention AB Objectives: The US Department of Veterans Affairs' Suicide Prevention Applications Network (SPAN) is a national system for suicide event tracking and case management. The objective of this study was to assess data on suicide attempts among people using Veterans Health Administration (VHA) services. Methods: We assessed the degree of data overlap on suicide attempters reported in SPAN and the VHA's medical records from October 1, 2010, to September 30, 2014-overall, by year, and by region. Data on suicide attempters in the VHA's medical records consisted of diagnoses documented with E95 codes from the International Classification of Diseases, Ninth Revision. Results: Of 50 518 VHA patients who attempted suicide during the 4-year study period, data on fewer than half (41%) were reported in both SPAN and the medical records; nearly 65% of patients whose suicide attempt was recorded in SPAN had no data on attempted suicide in the VHA's medical records. Conclusion: Evaluation of administrative data suggests that use of SPAN substantially increases the collection of data on suicide attempters as compared with the use of medical records alone, but neither SPAN nor the VHA's medical records identify all suicide attempters. Further research is needed to better understand the strengths and limitations of both systems and how to best combine information across systems. C1 [Hoffmire, Claire] US Dept Vet Affairs, Rocky Mt Mental Illness Res Educ & Clin Ctr Suici, 1055 Clermont St, Denver, CO 80220 USA. [Stephens, Brady; Kemp, Janet] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY USA. [Morley, Sybil; Bossarte, Robert M.] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth, Off Publ Hlth, Washington, DC USA. [Thompson, Caitlin] US Dept Vet Affairs, Suicide Prevent Program, Mental Hlth Serv, Washington, DC USA. RP Hoffmire, C (reprint author), US Dept Vet Affairs, Rocky Mt Mental Illness Res Educ & Clin Ctr Suici, 1055 Clermont St, Denver, CO 80220 USA. EM claire.hoffmire@va.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 816 EP 821 DI 10.1177/0033354916670133 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400012 PM 28123228 ER PT J AU Barth, SK Kang, HK Bullman, T AF Barth, Shannon K. Kang, Han K. Bullman, Tim TI All-Cause Mortality Among US Veterans of the Persian Gulf War: 13-Year Follow-up SO PUBLIC HEALTH REPORTS LA English DT Article DE gulf war; mortality; veterans ID POPULATION-BASED SURVEY; LOW-LEVEL SARIN; MULTISYMPTOM ILLNESS; CYCLOSARIN EXPOSURE; HEALTH-STATUS; FIRE SMOKE; I VETERANS; ARMY; KHAMISIYAH; ASTHMA AB Objective: We determined cause-specific mortality prevalence and risks of Gulf War deployed and nondeployed veterans to determine if deployed veterans were at greater risk than nondeployed veterans for death overall or because of certain diseases or conditions up to 13 years after conflict subsided. Methods: Follow-up began when the veteran left the Gulf War theater or May 1, 1991, and ended on the date of death or December 31, 2004. We studied 621901 veterans who served in the 1990-1991 Persian Gulf War and 746247 veterans who served but were not deployed during the Gulf War. We used Cox proportional hazard models to calculate rate ratios adjusted for age at entry to follow-up, length of follow-up, race, sex, branch of service, and military unit. We compared the mortality of (1) Gulf War veterans with non-Gulf War veterans and (2) Gulf War army veterans potentially exposed to nerve agents at Khamisiyah in March 1991 with those not exposed. We compared standardized mortality ratios of deployed and nondeployed Gulf War veterans with the US population. Results: Male Gulf War veterans had a lower risk of mortality than male non-Gulf War veterans (adjusted rate ratio [aRR] = 0.97; 95% confidence interval [CI], 0.95-0.99), and female Gulf War veterans had a higher risk of mortality than female non-Gulf War veterans (aRR = 1.15; 95% CI, 1.03-1.28). Khamisiyah-exposed Gulf War army veterans had >3 times the risk of mortality from cirrhosis of the liver than nonexposed army Gulf War veterans (aRR = 3.73; 95% CI, 1.64-8.48). Compared with the US population, female Gulf War veterans had a 60% higher risk of suicide and male Gulf War veterans had a lower risk of suicide (standardized mortality ratio = 0.84; 95% CI, 0.80-0.88). Conclusion: The vital status and mortality risk of Gulf War and non-Gulf War veterans should continue to be investigated. C1 [Barth, Shannon K.; Kang, Han K.; Bullman, Tim] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv, Off Patient Care Serv,Vet Hlth Adm, Washington, DC USA. RP Barth, SK (reprint author), US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv 10P4Q, Off Patient Care Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. EM shannon.barth@va.gov FU US Department of Veterans Affairs, Office of Research and Development [GWRA-019-04 S] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was based on work supported by merit review funding (GWRA-019-04 S) awarded by the US Department of Veterans Affairs, Office of Research and Development. NR 50 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 822 EP 830 DI 10.1177/0033354916676278 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400013 PM 28123229 ER PT J AU Kalinich, JF Kasper, CE AF Kalinich, John F. Kasper, Christine E. TI Are Internalized Metals a Long-term Health Hazard for Military Veterans? SO PUBLIC HEALTH REPORTS LA English DT Article DE heavy metal; inhalation; embedded fragments ID PARTICULATE MATTER; AIR-POLLUTION; SOFT-TISSUE; BRAIN; EXPOSURE; INJURY; URANIUM; RATS; INHALATION; FRAGMENTS C1 [Kalinich, John F.] Uniformed Serv Univ Hlth Sci, Armed Forces Radiobiol Res Inst, Internal Contaminat & Met Toxic Program, Bethesda, MD USA. [Kasper, Christine E.] US Dept Vet Affairs, Off Nursing Serv, Bethesda, MD USA. [Kasper, Christine E.] Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. RP Kasper, CE (reprint author), Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM christine.kasper@va.gov FU Veterans Affairs grant [B5044 R]; US Army Medical Research and Materiel Command [DAMD17-01-1-0821] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by Veterans Affairs grant B5044 R to C.E.K. and US Army Medical Research and Materiel Command grant DAMD17-01-1-0821 to J.F.K. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 831 EP 833 DI 10.1177/0033354916669324 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400014 PM 28123230 ER PT J AU Dursa, EK Barth, SK Bossarte, RM Schneiderman, AI AF Dursa, Erin K. Barth, Shannon K. Bossarte, Robert M. Schneiderman, Aaron I. TI Demographic, Military, and Health Characteristics of VA Health Care Users and Nonusers Who Served in or During Operation Enduring Freedom or Operation Iraqi Freedom, 2009-2011 SO PUBLIC HEALTH REPORTS LA English DT Article DE OEF/OIF; veterans; Department of Veterans Affairs ID VETERANS AB An estimated 60% of all Operation Enduring Freedom / Operation Iraqi Freedom (OEF/OIF) veterans who have left the military had used the US Department of Veterans Affairs (VA) for health care services as of March 31, 2015. What is not known, however, are the differences in demographic, military, and health characteristics between OEF/OIF veterans who use the VA for health care and OEF/OIF veterans who do not. We used data from the 2009-2011 National Health Study for a New Generation of US Veterans to explore these differences. We found that VA health care users were more likely than non-VA health care users to be non-Hispanic black, to be unmarried, to have served on active duty and in the army, to have been deployed to OEF/OIF, and to have an annual income less than $35000. The prevalence of 21 chronic medical conditions was higher among VA health care users than among non-VA health care users. OEF/OIF veterans using the VA for health care differ from nonusers with respect to demographic, military, and health characteristics. These data may be useful for developing programs and policies to address observed health disparities and achieve maximum benefit for the VA beneficiary population. C1 [Dursa, Erin K.; Barth, Shannon K.; Bossarte, Robert M.; Schneiderman, Aaron I.] US Dept Vet Affairs, Postdeployment Hlth Epidemiol Serv, Off Patient Care Serv, 810 Vermont Ave NW,MS 10PQ4, Washington, DC 20420 USA. [Bossarte, Robert M.] Univ West Virginia, Sch Publ Hlth, Morgantown, WV 26506 USA. RP Dursa, EK (reprint author), US Dept Vet Affairs, Postdeployment Hlth Epidemiol Serv, Off Patient Care Serv, 810 Vermont Ave NW,MS 10PQ4, Washington, DC 20420 USA. EM erin.dursa2@va.gov FU US Department of Veterans Affairs FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the US Department of Veterans Affairs. NR 11 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 839 EP 843 DI 10.1177/0033354916676279 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400016 PM 28123232 ER PT J AU Waxman, DA Min, L Setodji, CM Hanson, M Wenger, NS Ganz, DA AF Waxman, Daniel A. Min, Lillian Setodji, Claude M. Hanson, Mark Wenger, Neil S. Ganz, David A. TI Does Medicare Advantage Enrollment Affect Home Healthcare Use? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID TRADITIONAL MEDICARE; GEOGRAPHIC-VARIATION; SERVICES; PLANS; RISK AB OBJECTIVES: To compare home health utilization and clinical outcomes between Medicare beneficiaries in the fee-for-service (FFS) and Medicare Advantage (MA) programs, and to compare regional variation. STUDY DESIGN: We used the 2010 and 2011 Outcome and Assessment Information Set to identify all home health episodes begun in 2010 and to measure 7 clinical home health outcomes that are defined by CMS for public reporting. METHODS: We modeled the probability of home health use, the duration of home health episodes, and each clinical outcome measure as a function of MA versus FFS enrollment and model-specific risk adjustors. Empirical Bayes predictions from generalized linear mixed models were aggregated by hospital referral region (HRR) to create standardized regional measures of home health utilization and mean episode duration. RESULTS: We identified 30,837,130 FFS and 10,594,658 MA beneficiaries (excluding those dually eligible for Medicaid). After adjusting for demographic and clinical patient characteristics, the odds of receiving home health among FFS enrollees were 1.83 times those of MA (95% CI, 1.82-1.84). Adjusted home health duration was 34% longer for FFS (95% CI, 32%-34%). Outcomes differences were small in magnitude and inconsistent across measures. Regional variations in use and duration were substantial for both FFS and MA enrollees. Within HRRs, correlations between FFS and MA utilization rates and between FFS and MA episode durations were 0.51 and 0.94, respectively. CONCLUSIONS: MA beneficiaries use less home health than their FFS counterparts, but regional factors affect utilization, independent of insurance status. C1 [Waxman, Daniel A.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA. [Wenger, Neil S.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Waxman, Daniel A.; Min, Lillian; Setodji, Claude M.; Hanson, Mark; Wenger, Neil S.; Ganz, David A.] RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. [Min, Lillian] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Min, Lillian] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Ganz, David A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Waxman, DA (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM dwaxman@rand.org FU CMS [HHSM-500-2005-00028I, HHSM-500-T0004]; HHS [HHSM-500-2005-00028I, HHSM-500-T0004] FX The analyses upon which this article is based were performed under contract HHSM-500-2005-00028I, task order number HHSM-500-T0004, entitled "Evaluation and Development of Outcome Measures for Quality Assessment in MAOs and SNPs," funded by CMS and HHS. The content of this article does not necessarily reflect the views or policies of HHS, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government. The author assumes full responsibility for the accuracy and completeness of the ideas presented. NR 19 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2016 VL 22 IS 11 BP 714 EP 720 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EC7WP UT WOS:000388351800007 PM 27870545 ER PT J AU Roberts, AW Gellad, WF Skinner, AC AF Roberts, Andrew W. Gellad, Walid F. Skinner, Asheley Cockrell TI Lock-In Programs and the Opioid Epidemic: A Call for Evidence SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 [Roberts, Andrew W.] Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Sci, Omaha, NE 68178 USA. [Roberts, Andrew W.] Creighton Univ, Ctr Hlth Serv Res & Patient Safety, Omaha, NE 68178 USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Skinner, Asheley Cockrell] Duke Univ, Duke Clin Res Inst, Durham, NC USA. RP Roberts, AW (reprint author), Creighton Univ, Dept Pharm Sci, 2500 Calif Plaza,Hixson Lied Room 166, Omaha, NE 68178 USA. EM drewroberts@creighton.edu RI Skinner, Asheley/Q-5793-2016 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2016 VL 106 IS 11 BP 1918 EP 1919 DI 10.2105/AJPH.2016.303404 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4IE UT WOS:000388090200016 PM 27715305 ER PT J AU Morgan, AU Grande, DT Carter, T Long, JA Kangovi, S AF Morgan, Anna U. Grande, David T. Carter, Tamala Long, Judith A. Kangovi, Shreya TI Penn Center for Community Health Workers: Step-by-Step Approach to Sustain an Evidence-Based Community Health Worker Intervention at an Academic Medical Center SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID LOW SOCIOECONOMIC-STATUS; CARE AB Community-engaged researchers who work with low-income communities can be reliant on grant funding. We use the illustrative case of the Penn Center for Community Health Workers (PCCHW) to describe a step-by-step framework for achieving financial sustainability for community-engaged research interventions. PCCHW began as a small grant-funded research project but followed an 8-step framework to engage both low-income patients and funders, determine outcomes, and calculate return on investment. PCCHW is now fully funded by Penn Medicine and delivers the Individualized Management for Patient-Centered Targets (IMPaCT) community health worker intervention to 2000 patients annually. C1 [Morgan, Anna U.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Grande, David T.; Kangovi, Shreya] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Grande, David T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Carter, Tamala; Kangovi, Shreya] Penn Ctr Community Hlth Workers, Philadelphia, PA USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Morgan, AU (reprint author), Robert Wood Johnson Clin Scholars Program, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM amorga@mail.med.upenn.edu NR 11 TC 0 Z9 0 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2016 VL 106 IS 11 BP 1958 EP 1960 DI 10.2105/AJPH.2016.303366 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4IE UT WOS:000388090200026 PM 27631747 ER PT J AU Fleming, JN Taber, DJ Pilch, NA Srinivas, TR Chavin, KD AF Fleming, J. N. Taber, D. J. Pilch, N. A. Srinivas, T. R. Chavin, K. D. TI Yes, We Still Need IL-2 Receptor Antagonists SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Letter ID KIDNEY-TRANSPLANTATION C1 [Fleming, J. N.] Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. [Taber, D. J.; Chavin, K. D.] Med Univ South Carolina, Dept Surg, Charleston, SC USA. [Taber, D. J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Pilch, N. A.] Med Univ South Carolina, Transplant Ctr, Charleston, SC USA. [Srinivas, T. R.] Med Univ South Carolina, Dept Nephrol, Charleston, SC USA. RP Fleming, JN (reprint author), Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. EM fleminj@musc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD NOV PY 2016 VL 16 IS 11 BP 3308 EP 3309 DI 10.1111/ajt.13930 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA EC5VE UT WOS:000388204600037 PM 27321737 ER PT J AU Groeneveld, PW Rumsfeld, JS AF Groeneveld, Peter W. Rumsfeld, John S. TI Can Big Data Fulfill Its Promise? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE algorithms; analysis; database; machine learning; patient-specific modeling ID RISK; INDEX C1 [Groeneveld, Peter W.] Michael J Crescenz Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Groeneveld, Peter W.] Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med,Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Ctr Cardiovasc Outcomes Qual & Evaluat Res, Philadelphia, PA 19104 USA. [Rumsfeld, John S.] Univ Colorado, Sch Med, Aurora, CO USA. [Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Syst, Denver, CO USA. [Rumsfeld, John S.] Amer Coll Cardiol, Washington, DC USA. RP Groeneveld, PW (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Serv Dr, Philadelphia, PA 19104 USA. EM petergro@upenn.edu FU AHRQ HHS [R01 HS023615] NR 14 TC 1 Z9 1 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 679 EP 682 DI 10.1161/CIRCOUTCOMES.116.003097 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600010 PM 28263942 ER PT J AU Blewer, AL Putt, ME Becker, LB Riegel, BJ Li, JQ Leary, M Shea, JA Kirkpatrick, JN Berg, RA Nadkarni, VM Groeneveld, PW Abella, BS AF Blewer, Audrey L. Putt, Mary E. Becker, Lance B. Riegel, Barbara J. Li, Jiaqi Leary, Marion Shea, Judy A. Kirkpatrick, James N. Berg, Robert A. Nadkarni, Vinay M. Groeneveld, Peter W. Abella, Benjamin S. CA CHIP Study Grp TI Video-Only Cardiopulmonary Resuscitation Education for High-Risk Families Before Hospital Discharge A Multicenter Pragmatic Trial SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiopulmonary resuscitation; cardiovascular diseases; randomized controlled trial; resuscitation; heart arrest ID AMERICAN-HEART-ASSOCIATION; ACUTE CORONARY SYNDROMES; ELEVATION MYOCARDIAL-INFARCTION; CARDIAC-ARREST RESUSCITATION; CHEST COMPRESSION DEPTH; SELF-INSTRUCTION; LAY RESPONDERS; UNITED-STATES; CPR; OUTCOMES AB Background-Cardiopulmonary resuscitation (CPR) training rates in the United States are low, highlighting the need to develop CPR educational approaches that are simpler, with broader dissemination potential. The minimum training required to ensure long-term skill retention remains poorly characterized. We compared CPR skill retention among laypersons randomized to training with video-only (VO; no manikin) with those trained with a video self-instruction kit (VSI; with manikin). We hypothesized that VO training would be noninferior to the VSI approach with respect to chest compression (CC) rate. Methods and Results-We performed a prospective, cluster randomized trial of CPR education for family members of patients with high-risk cardiac conditions on hospital cardiac units, using a multicenter pragmatic design. Eight hospitals were randomized to offer either VO or VSI training before discharge using volunteer trainers. CPR skills were assessed 6 months post training. Mean CC rate among those trained with VO compared with those trained with VSI was assessed with a noninferiority margin set at 8 CC per min; as a secondary outcome, mean differences in CC depth were assessed. From February 2012 to May 2015, 1464 subjects were enrolled and 522 subjects completed a skills assessment. The mean CC rates were 87.7 (VO) CC per min and 89.3 (VSI) CC per min; we concluded noninferiority for VO based on a mean difference of -1.6 (90% confidence interval, -5.2 to 2.1). The mean CC depth was 40.2 mm (VO) and 45.8 mm (VSI) with a mean difference of -5.6 (95% confidence interval, -7.6 to -3.7). Results were similar after multivariate regression adjustment. Conclusions-In this large, prospective trial of CPR skill retention, VO training yielded a noninferior difference in CC rate compared with VSI training. CC depth was greater in the VSI group. These findings suggest a potential trade-off in efforts for broad dissemination of basic CPR skills; VO training might allow for greater scalability and dissemination, but with a potential reduction in CC depth. C1 [Blewer, Audrey L.; Becker, Lance B.; Leary, Marion; Abella, Benjamin S.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Blewer, Audrey L.; Becker, Lance B.; Leary, Marion; Abella, Benjamin S.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA. [Blewer, Audrey L.; Putt, Mary E.; Li, Jiaqi] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Riegel, Barbara J.; Leary, Marion] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Riegel, Barbara J.] Univ Penn, New Courtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Shea, Judy A.; Kirkpatrick, James N.; Groeneveld, Peter W.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Berg, Robert A.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Berg, Robert A.; Nadkarni, Vinay M.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Abella, BS (reprint author), Univ Penn, Dept Emergency Med, Ctr Resuscitat Sci, 3400 Spruce St, Philadelphia, PA 19104 USA. EM benjamin.abella@uphs.upenn.edu FU National Institutes of Health [R18HL107217]; American Heart Association FX This work was supported by grants from the National Institutes of Health (R18HL107217) and the American Heart Association (Clinical Research Program award). NR 38 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 740 EP 748 DI 10.1161/CIRCOUTCOMES.116.002493 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600019 PM 27703033 ER PT J AU Jackevicius, CA Choi, K Krumholz, HM AF Jackevicius, Cynthia A. Choi, Katie Krumholz, Harlan M. TI Access to Evidence-Based Statins in Low-Cost Generic Drug Programs SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE drug costs; evidence-based medicine; generic drugs; 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors; prescription drugs ID RISK C1 [Jackevicius, Cynthia A.; Choi, Katie] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pharm, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada. Yale Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA. [Krumholz, Harlan M.] Dept Hlth Policy & Management, New Haven, CT USA. [Krumholz, Harlan M.] Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 785 EP 787 DI 10.1161/CIRCOUTCOMES.116.002985 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600024 PM 27803089 ER PT J AU Musher, DM AF Musher, Daniel M. TI Polymerase Chain Reaction for the tpp47 Gene: A New Test for Neurosyphilis SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE syphilis; neurosyphilis; syphilitic meningitis ID CEREBROSPINAL-FLUID; SYPHILIS; DIAGNOSIS C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 12 TC 0 Z9 0 U1 8 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2016 VL 63 IS 9 BP 1187 EP 1188 DI 10.1093/cid/ciw518 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC2WY UT WOS:000387986200011 PM 27585980 ER PT J AU Blanco-Centurion, C Liu, M Konadhode, RP Zhang, XB Pelluru, D van den Pol, AN Shiromani, PJ AF Blanco-Centurion, Carlos Liu, Meng Konadhode, Roda P. Zhang, Xiaobing Pelluru, Dheeraj van den Pol, Anthony N. Shiromani, Priyattam J. TI Optogenetic activation of melanin-concentrating hormone neurons increases non-rapid eye movement and rapid eye movement sleep during the night in rats SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE channelrhodopsin-2; melanin-concentrating hormone; rapid eye movement sleep; rat; recombinant adeno-associated virus ID LOCUS-COERULEUS NEURONS; MCH NEURONS; PARADOXICAL SLEEP; OREXIN NEURONS; DORSAL RAPHE; REM-SLEEP; PROJECTIONS; DISCHARGE; MICE; HYPOTHALAMUS AB Neurons containing melanin-concentrating hormone (MCH) are located in the hypothalamus. In mice, optogenetic activation of the MCH neurons induces both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep at night, the normal wake-active period for nocturnal rodents [R. R. Konadhode etal. (2013) J. Neurosci., 33, 10257-10263]. Here we selectively activate these neurons in rats to test the validity of the sleep network hypothesis in another species. Channelrhodopsin-2 (ChR2) driven by the MCH promoter was selectively expressed by MCH neurons after injection of rAAV-MCHp-ChR2-EYFP into the hypothalamus of Long-Evans rats. An invitro study confirmed that the optogenetic activation of MCH neurons faithfully triggered action potentials. In the second study, in Long-Evans rats, rAAV-MCH-ChR2, or the control vector, rAAV-MCH-EYFP, were delivered into the hypothalamus. Three weeks later, baseline sleep was recorded for 48h without optogenetic stimulation (0Hz). Subsequently, at the start of the lights-off cycle, the MCH neurons were stimulated at 5, 10, or 30Hz (1mW at tip; 1min on - 4min off) for 24h. Sleep was recorded during the 24-h stimulation period. Optogenetic activation of MCH neurons increased both REM and NREM sleep at night, whereas during the day cycle, only REM sleep was increased. Delta power, an indicator of sleep intensity, was also increased. In control rats without ChR2, optogenetic stimulation did not increase sleep or delta power. These results lend further support to the view that sleep-active MCH neurons contribute to drive sleep in mammals. C1 [Blanco-Centurion, Carlos; Liu, Meng; Konadhode, Roda P.; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 114 Doughty St,MSC 404-STB 404, Charleston, SC 29425 USA. [Zhang, Xiaobing; van den Pol, Anthony N.] Yale Univ, Dept Neurosurg, New Haven, CT USA. [Shiromani, Priyattam J.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Shiromani, PJ (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 114 Doughty St,MSC 404-STB 404, Charleston, SC 29425 USA.; Shiromani, PJ (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM shiroman@musc.edu RI ZHANG, XIAOBING /J-4076-2015 OI ZHANG, XIAOBING /0000-0002-5707-193X FU Medical Research Service of the Department of Veterans Affairs [101 BX000798]; NIH [1K01AG041520, NS052287, NS084477, NS079940, NS048476] FX We thank Wengxue Wang for assistance with the study and Dr. Amanda LaRue for use of the confocal microscope. This study was supported by Medical Research Service of the Department of Veterans Affairs (101 BX000798) and NIH grants 1K01AG041520 (to ML), NS052287, NS084477, NS079940, NS048476 (to AVP). NR 52 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD NOV PY 2016 VL 44 IS 10 BP 2846 EP 2857 DI 10.1111/ejn.13410 PG 12 WC Neurosciences SC Neurosciences & Neurology GA EC9YJ UT WOS:000388499900011 PM 27657541 ER PT J AU Edelman, EJ Gordon, KS Tate, JP Becker, WC Bryant, K Crothers, K Gaither, JR Gibert, CL Gordon, AJ Marshall, BDL Rodriguez-Barradas, MC Samet, JH Skanderson, M Justice, AC Fiellin, DA AF Edelman, E. J. Gordon, K. S. Tate, J. P. Becker, W. C. Bryant, K. Crothers, K. Gaither, J. R. Gibert, C. L. Gordon, A. J. Marshall, B. D. L. Rodriguez-Barradas, M. C. Samet, J. H. Skanderson, M. Justice, A. C. Fiellin, D. A. TI The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy SO HIV MEDICINE LA English DT Article DE analgesics; antiretroviral therapy; CD4 lymphocyte count; disease progression; HIV; opioid ID HUMAN-IMMUNODEFICIENCY-VIRUS; ILLICIT DRUG-USE; COMMUNITY-BASED COHORT; VETERANS AGING COHORT; DISEASE PROGRESSION; TREATMENT OUTCOMES; UNINFECTED PATIENTS; RHESUS MACAQUES; INDIGENT ADULTS; IMMUNE FUNCTION AB Objectives Certain prescribed opioids have immunosuppressive properties, yet their impact on clinically relevant outcomes, including antiretroviral therapy (ART) response among HIV-infected patients, remains understudied. Methods Using the Veterans Aging Cohort Study data, we conducted a longitudinal analysis of 4358 HIV-infected patients initiating ART between 2002 and 2010 and then followed them for 24 months. The primary independent variable was prescribed opioid duration, categorized using pharmacy data as none prescribed, short-term (< 90 days) and long-term (>= 90 days). Outcomes included CD4 cell count over time. Analyses adjusted for demographics, comorbid conditions, ART type and year of initiation, and overall disease severity [ascertained with the Veterans Aging Cohort Study (VACS) Index]. Sensitivity analyses examined whether effects varied according to baseline CD4 cell count, achievement of viral load suppression, and opioid properties (i.e. dose and known immunosuppressive properties). Results Compared to those with none, patients with short-term opioids had a similar increase in CD4 cell count (mean rise per year: 74 vs. 68 cells/mu L; P = 0.11), as did those with long-term prescribed opioids (mean rise per year: 74 vs. 75 cells/mu L; P = 0.98). In sensitivity analysis, compared with no opioids, the effects of short-term prescribed opioids were statistically significant among those with a baseline CD4 cell count >= 500 cells/mu L (mean rise per year: 52 cells/mu L for no opioids vs. 20 cells/mu L for short-term opioids; P = 0.04); findings were otherwise unchanged. Conclusions Despite immunosuppressive properties intrinsic to opioids, prescribed opioids appeared to have no effect on CD4 cell counts over 24 months among HIV-infected patients initiating ART. C1 [Edelman, E. J.; Tate, J. P.; Becker, W. C.; Gaither, J. R.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Sch Med, POB 208025, New Haven, CT 06520 USA. [Edelman, E. J.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Gordon, K. S.; Tate, J. P.; Becker, W. C.; Gaither, J. R.; Skanderson, M.; Justice, A. C.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Bryant, K.] NIAAA, HIV AIDS Program, Bethesda, MD USA. [Crothers, K.] Univ Washington, Seattle, WA 98195 USA. [Gaither, J. R.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Gibert, C. L.] DC Vet Affairs Med Ctr, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Washington, DC USA. [Gordon, A. J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, A. J.] Univ Pittsburgh, Pittsburgh, PA USA. [Marshall, B. D. L.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Samet, J. H.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Samet, J. H.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Edelman, EJ (reprint author), Yale Univ, Sch Med, POB 208025, New Haven, CT 06520 USA. EM ejennifer.edelman@yale.edu OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU NCATS NIH HHS [UL1 TR001863, UL1 TR000142]; NIAAA NIH HHS [U10 AA013566]; NIDA NIH HHS [K12 DA033312] NR 79 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD NOV PY 2016 VL 17 IS 10 BP 728 EP 739 DI 10.1111/hiv.12377 PG 12 WC Infectious Diseases SC Infectious Diseases GA EC9DA UT WOS:000388443100003 PM 27186715 ER PT J AU Schopfer, DW Takemoto, S Allsup, K Helfrich, CD Ho, PM Forman, DE Whooley, MA AF Schopfer, David W. Takemoto, Steven Allsup, Kelly Helfrich, Christian D. Ho, P. Michael Forman, Daniel E. Whooley, Mary A. TI Notice of Retraction and Replacement. Schopfer DW, et al. Cardiac Rehabilitation Use Among Veterans With Ischemic Heart Disease. JAMA Intern Med. 2014; 174(10): 1687-1689 SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Schopfer, David W.; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Takemoto, Steven] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. [Allsup, Kelly; Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res & Clin Ctr, Pittsburgh, PA USA. [Helfrich, Christian D.] Vet Affairs Puget Sound Healthcare Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. RP Schopfer, DW (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM david.schopfer@ucsf.edu OI Schopfer, David/0000-0002-7244-9857 NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1726 EP + DI 10.1001/jamainternmed.2016.5831 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700044 PM 27723859 ER PT J AU Elwy, AR Itani, KMF Bokhour, BG Mueller, NM Glickman, ME Zhao, SB Rosen, AK Lynge, D Perkal, M Brotschi, EA Sanchez, VM Gallagher, TH AF Elwy, A. Rani Itani, Kamal M. F. Bokhour, Barbara G. Mueller, Nora M. Glickman, Mark E. Zhao, Shibei Rosen, Amy K. Lynge, Dana Perkal, Melissa Brotschi, Erica A. Sanchez, Vivian M. Gallagher, Thomas H. TI Surgeons' Disclosures of Clinical Adverse Events SO JAMA SURGERY LA English DT Article ID HARMFUL MEDICAL ERRORS; FALSE DISCOVERY RATE; PHYSICIANS; IMPLEMENTATION; COMMUNICATION; ATTITUDES; PROGRAMS; APOLOGY; BURNOUT; HEALTH AB IMPORTANCE Surgeons are frequently faced with clinical adverse events owing to the nature of their specialty, yet not all surgeons disclose these events to patients. To sustain open disclosure programs, it is essential to understand how surgeons are disclosing adverse events, factors that are associated with reporting such events, and the effect of disclosure on surgeons. OBJECTIVE To quantitatively assess surgeons' reports of disclosure of adverse events and aspects of their experiences with the disclosure process. DESIGN, SETTING, AND PARTICIPANTS An observational study was conducted from January 1, 2011, to December 31, 2013, involving a 21-item baseline questionnaire administered to 67 of 75 surgeons (89%) representing 12 specialties at 3 Veterans Affairs medical centers. Sixty-two surveys of their communication about adverse events and experiences with disclosing such events were completed by 35 of these 67 surgeons (52%). Data were analyzed using mixed linear random-effects and logistic regression models. MAIN OUTCOMES AND MEASURES Self-reports of disclosure assessed by 8 items from guidelines and pilot research, surgeons' perceptions of the adverse event, reported personal effects from disclosure, and baseline attitudes toward disclosure. RESULTS Most of the surgeons completing the web-based surveys (41 responses from men and 21 responses from women) used 5 of the 8 recommended disclosure items: explained why the event happened (55 of 60 surveys [92%]), expressed regret for what happened (52 of 60 [87%]), expressed concern for the patient's welfare (57 of 60 [95%]), disclosed the adverse event within 24 hours (58 of 60 [97%]), and discussed steps taken to treat any subsequent problems (59 of 60 [98%]). Fewer surgeons apologized to patients (33 of 60 [55%]), discussed whether the event was preventable (33 of 60 [55%]), or how recurrences could be prevented (19 of 59 [32%]). Surgeons who were less likely to have discussed prevention (33 of 60 [55%]), those who stated the event was very or extremely serious (40 of 61 surveys [66%]), or reported very or somewhat difficult experiences discussing the event (16 of 61 [26%]) were more likely to have been negatively affected by the event. Surgeons with more negative attitudes about disclosure at baseline reported more anxiety about patients' surgical outcomes or events following disclosure (odds ratio, 1.54; 95% CI, 1.16-2.06). CONCLUSIONS AND RELEVANCE Surgeons who reported they were less likely to discuss preventability of the adverse event, or who reported difficult communication experiences, were more negatively affected by disclosure than others. Quality improvement efforts focused on recognizing the association between disclosure and surgeons' well-beingmay help sustain open disclosure policies. C1 [Elwy, A. Rani; Rosen, Amy K.] Vet Affairs Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Mailstop 152,150 S Huntington Ave, Boston, MA 02130 USA. [Elwy, A. Rani; Bokhour, Barbara G.; Mueller, Nora M.; Glickman, Mark E.; Zhao, Shibei] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Elwy, A. Rani; Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA. [Itani, Kamal M. F.; Brotschi, Erica A.; Sanchez, Vivian M.] Vet Affairs Boston Healthcare Syst, Dept Surg, West Roxbury, MA USA. [Itani, Kamal M. F.; Rosen, Amy K.; Brotschi, Erica A.; Sanchez, Vivian M.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA. [Mueller, Nora M.] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Glickman, Mark E.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA. [Lynge, Dana] Vet Affairs Puget Sound Healthcare Syst, Dept Surg, Seattle, WA USA. [Lynge, Dana] Univ Washington Healthcare Syst, Dept Surg, Seattle, WA USA. [Perkal, Melissa] Vet Affairs Connecticut Healthcare Syst, Dept Surg, West Haven, CT USA. [Perkal, Melissa] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Gallagher, Thomas H.] Univ Washington, Sch Med, Dept Bioeth, Seattle, WA USA. [Gallagher, Thomas H.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Elwy, AR (reprint author), Vet Affairs Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Mailstop 152,150 S Huntington Ave, Boston, MA 02130 USA. EM rani.elwy@va.gov FU Department of Veterans Affairs, Health Services Research and Development Service [IIR07-199] FX This study was funded by grant IIR07-199 from the Department of Veterans Affairs, Health Services Research and Development Service. NR 32 TC 0 Z9 0 U1 6 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD NOV PY 2016 VL 151 IS 11 BP 1015 EP 1021 DI 10.1001/jamasurg.2016.1787 PG 7 WC Surgery SC Surgery GA EC8PM UT WOS:000388404500008 PM 27438083 ER PT J AU Liu, JSB Weber, SM Berian, JR Chen, SL Cohen, ME Ko, CY Bilimoria, KY AF Liu, Jason B. Weber, Sharon M. Berian, Julia R. Chen, Shenglin Cohen, Mark E. Ko, Clifford Y. Bilimoria, Karl Y. TI Role of Operative Complexity Variables in Risk Adjustment for Patients With Cancer SO JAMA SURGERY LA English DT Letter ID OUTCOMES C1 [Liu, Jason B.; Berian, Julia R.; Chen, Shenglin; Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. [Liu, Jason B.; Berian, Julia R.] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. [Weber, Sharon M.] Univ Wisconsin, Carbone Canc Ctr, Dept Surg, Madison, WI 53706 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. RP Liu, JSB (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. EM jliu@facs.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD NOV PY 2016 VL 151 IS 11 BP 1084 EP 1086 DI 10.1001/jamasurg.2016.2253 PG 4 WC Surgery SC Surgery GA EC8PM UT WOS:000388404500026 PM 27486963 ER PT J AU Rahaghi, FN Wells, JM Come, CE De La Bruere, IA Bhatt, SP Ross, JC Vegas-Sanchez-Ferrero, G Diaz, AA Minhas, J Dransfield, MT Estepar, RS Washko, GR AF Rahaghi, Farbod N. Wells, J. Michael Come, Carolyn E. De La Bruere, Isaac A. Bhatt, Surya P. Ross, James C. Vegas-Sanchez-Ferrero, Gonzalo Diaz, Alejandro A. Minhas, Jasleen Dransfield, Mark T. Estepar, Raul San Jose Washko, George R. CA COPDGene Investigators TI Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in Smokers SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE 3D reconstruction; arterial; cardiac magnetic resonance imaging; chronic obstructive pulmonary disease; computed tomography; emphysema; pulmonary vascular; venous ID DISEASE; EMPHYSEMA; COPD; HYPERTENSION AB Objective: Prior work has described the relationship between pulmonary vascular pruning on computed tomography (CT) scans and metrics of right-sided heart dysfunction in smokers. In this analysis, we sought to look at pruning on a lobar level, as well as examine the effect of the arterial and venous circulation on this association. Methods: Automated vessel segmentation applied to noncontrast CT scans from the COPDGene Study in 24 subjects with cardiac magnetic resonance imaging scans was used to create a blood volume distribution profile. These vessels were then manually tracked to their origin and characterized as artery or vein. Results: Assessment of pruning on a lobar level revealed associations between pruning and right ventricular function previously not observed on a global level. The right ventricular mass index, the right ventricular endsystolic volume index, and pulmonary arterial-to-aorta ratio were associated with both arterial and venous pruning, whereas right ventricular ejection fraction was associated with only arterial pruning. Conclusions: Lobar assessment and segmentation of the parenchymal vasculature into arterial and venous components provide additional information about the relationship between loss of vasculature on CT scans and right ventricular dysfunction. C1 [Rahaghi, Farbod N.; Come, Carolyn E.; De La Bruere, Isaac A.; Diaz, Alejandro A.; Minhas, Jasleen; Washko, George R.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Div, 75 Francis St,PBB-CA 3, Boston, MA 02115 USA. [Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ross, James C.; Vegas-Sanchez-Ferrero, Gonzalo; Estepar, Raul San Jose] Harvard Sch Med, Dept Radiol, Surg Planning Lab, Boston, MA USA. RP Rahaghi, FN (reprint author), Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Div, 75 Francis St,PBB-CA 3, Boston, MA 02115 USA. EM frahaghi@partners.org FU NHLBI [5T32HL007633, 1R01HL116931, K08 HL123940] FX The authors in this study were supported by NHLBI grants 5T32HL007633 (F.N.R.), 1R01HL116931 (R.S.J.E. and G.R.W), and K08 HL123940 (JMW). NR 24 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD NOV-DEC PY 2016 VL 40 IS 6 BP 948 EP 952 DI 10.1097/RCT.0000000000000465 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EC9YA UT WOS:000388499000019 PM 27636250 ER PT J AU Won, JS Singh, AK Singh, I AF Won, Je-Seong Singh, Avtar K. Singh, Inderjit TI Biochemical, Cell Biological, Pathological, and Therapeutic Aspects of Krabbe's Disease SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Review DE globoid cell leukodystrophy; Krabbe's disease; myelin; therapy ID CENTRAL-NERVOUS-SYSTEM; BONE-MARROW TRANSPLANTATION; ENZYME REPLACEMENT THERAPY; BLOOD-BRAIN-BARRIER; SECRETORY PHOSPHOLIPASE A(2); PSYCHOSINE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; FIBER-TYPE DISPROPORTION; AXO-GLIAL INTERACTIONS; TNF-ALPHA PRODUCTION AB Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems. The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form. KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, especially in oligodendrocytes and Schwann cells. This ultimately results in damage to myelin in both CNS and PNS with associated morbidity and mortality. Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis. Moreover, subthreshold concentrations of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage. From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacological, gene, and stem cell approaches to attenuate PSY-induced neurotoxicity. This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. (C) 2016 Wiley Periodicals, Inc. C1 [Won, Je-Seong; Singh, Avtar K.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA. [Singh, Inderjit] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ South Carolina, 173 Ashley Ave,DCRI Room 509, Charleston, SC 29425 USA. EM singhi@musc.edu FU National Institutes of Health [NS064195] FX Contract grant sponsor: National Institutes of Health; Contract grant number: NS064195 NR 217 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0360-4012 EI 1097-4547 J9 J NEUROSCI RES JI J. Neurosci. Res. PD NOV PY 2016 VL 94 IS 11 SI SI BP 990 EP 1006 DI 10.1002/jnr.23873 PG 17 WC Neurosciences SC Neurosciences & Neurology GA EC9DE UT WOS:000388443500005 PM 27638584 ER PT J AU Lenoue, SR Wongngamnit, N Thurstone, C AF Lenoue, Sean R. Wongngamnit, Narin Thurstone, Christian TI Practical Aspects of Discussing Marijuana in a New Era SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Editorial Material DE marijuana; evidence-based medicine; informed consent ID POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE-SCLEROSIS; MEDICAL MARIJUANA; CONTROLLED-TRIAL; CANNABIS USE; EPILEPSY; SYMPTOMS; SPASTICITY; EXPOSURE; ALCOHOL AB The use of marijuana for the treatment of medical conditions is a highly controversial topic. Misconceptions by both patients and providers concerning the safety of and evidence-based indications for marijuana can complicate treatment planning and outcomes. Maintaining skills such as motivational interviewing, providing evidence-based informed consent, and increasing access to care remain top priorities for providing quality patient care. The goal of this article is to offer guidance to clinical providers who are adapting to the changing realities of medical marijuana and legalized recreational marijuana. C1 [Lenoue, Sean R.] Univ Colorado, Sch Med, Clin & Res Fellowship Addict Psychiat, Aurora, CO USA. [Wongngamnit, Narin] Denver Vet Affairs Med Ctr, Subst Abuse Treatment Program, Aurora, CO USA. [Wongngamnit, Narin] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Thurstone, Christian] Denver Hlth & Hosp Author, Subst Treatment Educ & Prevent STEP Program, Aurora, CO USA. [Thurstone, Christian] Univ Colorado, Psychiat, Sch Med, Aurora, CO USA. RP Lenoue, SR (reprint author), 13001 E 17th Pl,Campus POB F546,Bldg 500, Aurora, CO 80045 USA. EM sean.lenoue@ucdenver.edu NR 49 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD NOV PY 2016 VL 22 IS 6 BP 471 EP 477 DI 10.1097/PRA.0000000000000189 PG 7 WC Psychiatry SC Psychiatry GA EC5BF UT WOS:000388147400008 PM 27824781 ER PT J AU Kohno, M Okita, K Morales, AM Robertson, CL Dean, AC Ghahremani, DG Sabb, FW Rawson, RA Mandelkern, MA Bilder, RM London, ED AF Kohno, M. Okita, K. Morales, A. M. Robertson, C. L. Dean, A. C. Ghahremani, D. G. Sabb, F. W. Rawson, R. A. Mandelkern, M. A. Bilder, R. M. London, E. D. TI Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users SO MOLECULAR PSYCHIATRY LA English DT Article ID INCENTIVE-SENSITIZATION THEORY; REFERENCE TISSUE MODEL; NUCLEUS-ACCUMBENS; RESPONSE-INHIBITION; PREFRONTAL CORTEX; DECISION-MAKING; TRAIT IMPULSIVITY; SEX-DIFFERENCES; BRAIN IMAGES; ADDICTION AB Stimulant use disorders are associated with deficits in striatal dopamine receptor availability, abnormalities in mesocorticolimbic resting-state functional connectivity (RSFC) and impulsivity. In methamphetamine-dependent research participants, impulsivity is correlated negatively with striatal D2-type receptor availability, and mesocorticolimbic RSFC is stronger than that in controls. The extent to which these features of methamphetamine dependence are interrelated, however, is unknown. This question was addressed in two studies. In Study 1, 19 methamphetamine-dependent and 26 healthy control subjects underwent [F-18] fallypride positron emission tomography to measure ventral striatal dopamine D2-type receptor availability, indexed by binding potential (BPND), and functional magnetic resonance imaging (fMRI) to assess mesocorticolimbic RSFC, using a midbrain seed. In Study 2, an independent sample of 20 methamphetamine-dependent and 18 control subjects completed the Barratt Impulsiveness Scale in addition to fMRI. Study 1 showed a significant group by ventral striatal BPND interaction effect on RSFC, reflecting a negative relationship between ventral striatal BPND and RSFC between the midbrain and striatum, orbitofrontal cortex and insula in methamphetamine-dependent participants, but a positive relationship in the control group. In Study 2, an interaction of the group with RSFC on impulsivity was observed. Methamphetamine-dependent users exhibited a positive relationship of midbrain RSFC to the left ventral striatum with cognitive impulsivity, whereas a negative relationship was observed in healthy controls. The results indicate that ventral striatal D2-type receptor signaling may affect the system-level activity within the mesocorticolimbic system, providing a functional link that may help explain high impulsivity in methamphetamine-dependent individuals. C1 [Kohno, M.; Okita, K.; Morales, A. M.; Robertson, C. L.; Dean, A. C.; Ghahremani, D. G.; Sabb, F. W.; Rawson, R. A.; Bilder, R. M.; London, E. D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Okita, K.; Robertson, C. L.; London, E. D.] Univ Calif Irvine, Vet Adm Greater Los Angeles Healthcare Syst, Irvine, CA USA. [Robertson, C. L.; London, E. D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. [Dean, A. C.; London, E. D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, M. A.; Bilder, R. M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. [Mandelkern, M. A.] Univ Calif Los Angeles, Dept Phys, 405 Hilgard Ave, Los Angeles, CA 90024 USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza,C8-831, Los Angeles, CA 90095 USA. EM elondon@mednet.ucla.edu RI Bilder, Robert/A-8894-2008 OI Bilder, Robert/0000-0001-5085-7852 FU NIH [P20 DA022539, R01 DA020726]; NIDA [R01DA027633, K23DA027734, R21DA034928, UL1TR000124]; Consortium for Neuropsychiatric Phenomics (NIH Roadmap for Medical Research grants) [UL1- DE019580, RL1DA024853]; Marjorie Greene Trust; Thomas P and Katherine P. Pike Chair in Addiction Studies FX The research described here was funded in part by NIH grants P20 DA022539, R01 DA020726 (EDL), NIDA R01DA027633 (RAR), K23DA027734 (ACD), R21DA034928 (ACD), UL1TR000124 (UCLA CTSA), the Consortium for Neuropsychiatric Phenomics (NIH Roadmap for Medical Research grants UL1- DE019580 and RL1DA024853) and endowments from the Thomas P and Katherine P. Pike Chair in Addiction Studies, and the Marjorie Greene Trust. NR 65 TC 2 Z9 2 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2016 VL 21 IS 11 BP 1554 EP 1560 DI 10.1038/mp.2015.223 PG 7 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA ED2ZU UT WOS:000388719600010 PM 26830141 ER PT J AU Zackular, JP Moore, JL Jordan, AT Juttukonda, LJ Noto, MJ Nicholson, MR Crews, JD Semler, MW Zhang, Y Ware, LB Washington, MK Chazin, WJ Caprioli, RM Skaar, EP AF Zackular, Joseph P. Moore, Jessica L. Jordan, Ashley T. Juttukonda, Lillian J. Noto, Michael J. Nicholson, Maribeth R. Crews, Jonathan D. Semler, Matthew W. Zhang, Yaofang Ware, Lorraine B. Washington, M. Kay Chazin, Walter J. Caprioli, Richard M. Skaar, Eric P. TI Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection SO NATURE MEDICINE LA English DT Article ID ANTIBIOTIC-ASSOCIATED COLITIS; FECAL CALPROTECTIN; EPIDEMIOLOGY; COMMENSALS; INTERFACE AB Clostridium difficile is the most commonly reported nosocomial pathogen in the United States and is an urgent public health concern worldwide(1). Over the past decade, incidence, severity and costs associated with C. difficile infection (CDI) have increased dramatically(2). CDI is most commonly initiated by antibiotic-mediated disruption of the gut microbiota; however, non-antibiotic-associated CDI cases are well documented and on the rise(3,4). This suggests that unexplored environmental, nutrient and host factors probably influence CDI. Here we show that excess dietary zinc (Zn) substantially alters the gut microbiota and, in turn, reduces the minimum amount of antibiotics needed to confer susceptibility to CDI. In mice colonized with C. difficile, excess dietary Zn severely exacerbated C. difficile associated disease by increasing toxin activity and altering the host immune response. In addition, we show that the Zn-binding S100 protein calprotectin has antimicrobial effects against C. difficile and is an essential component of the innate immune response to CDI. Taken together, these data suggest that nutrient Zn levels have a key role in determining susceptibility to CDI and severity of disease, and that calprotectin-mediated metal limitation is an important factor in the host immune response to C. difficile. C1 [Zackular, Joseph P.; Jordan, Ashley T.; Juttukonda, Lillian J.; Noto, Michael J.; Zhang, Yaofang; Ware, Lorraine B.; Washington, M. Kay; Skaar, Eric P.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Moore, Jessica L.; Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Chem, Nashville, TN USA. [Moore, Jessica L.; Caprioli, Richard M.] Vanderbilt Univ, Mass Spectrometry Res Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Noto, Michael J.; Semler, Matthew W.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Nicholson, Maribeth R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Crews, Jonathan D.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA. [Chazin, Walter J.] Vanderbilt Univ, Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Caprioli, Richard M.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU US Department of Veterans Affairs (Merit Review Award) [1I01BX002482]; US National Institutes of Health (NIH) [R01 AI101171, P41 GM103391-05]; Vanderbilt Digestive Disease Research Center (VDDRC) [P30DK058404]; NIH-NIDDK [T32DK007673]; NIH-NIAID [F32AI120553]; NIH-NIGMS [T32GM065086]; Thrasher Research Fund Early Career Award FX We thank P. Schloss and J. Sorg for critical feedback on this study, and D. Aronoff and S. Walk for providing C. difficile strains. This research was supported by the US Department of Veterans Affairs (Merit Review Award no. 1I01BX002482; E.P.S.), the US National Institutes of Health (NIH) (grant no. R01 AI101171 (E.P.S.) and P41 GM103391-05 (R.M.C.)) and the Vanderbilt Digestive Disease Research Center (VDDRC) (grant no. P30DK058404; E.P.S.). J.P.Z. was supported by NIH-NIDDK grant no. T32DK007673 and NIH-NIAID grant no. F32AI120553. J.L.M. was supported by NIH-NIGMS grant no. T32GM065086. M.R.N. was supported by the Thrasher Research Fund Early Career Award. NR 29 TC 2 Z9 2 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD NOV PY 2016 VL 22 IS 11 BP 1330 EP 1334 DI 10.1038/nm.4174 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA EB3XK UT WOS:000387302300026 PM 27668938 ER PT J AU Bradley, KA Rubinsky, AD Lapham, GT Berger, D Bryson, C Achtmeyer, C Hawkins, EJ Chavez, LJ Williams, EC Kivlahan, DR AF Bradley, Katharine A. Rubinsky, Anna D. Lapham, Gwen T. Berger, Douglas Bryson, Christopher Achtmeyer, Carol Hawkins, Eric J. Chavez, Laura J. Williams, Emily C. Kivlahan, Daniel R. TI Predictive validity of clinical AUDIT-C alcohol screening scores and changes in scores for three objective alcohol-related outcomes in a Veterans Affairs population SO ADDICTION LA English DT Article DE Alcohol drinking; alcohol-induced disorders; alcohol-related disorders; alcohol screening; biomarkers; prevention ID IDENTIFICATION TEST AUDIT; HIGH-DENSITY-LIPOPROTEIN; US GENERAL-POPULATION; SELF-CARE BEHAVIORS; SERVICES TASK-FORCE; PRIMARY-HEALTH-CARE; USE DISORDERS; BRIEF INTERVENTION; SUBSTANCE-ABUSE; GLOBAL BURDEN AB AimsTo evaluate the association between Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) alcohol screening scores, collected as part of routine clinical care, and three outcomes in the following year (Aim 1), and the association between changes in AUDIT-C risk group at 1-year follow-up and the same outcomes in the subsequent year (Aim 2). DesignCohort study. SettingTwenty-four US Veterans Affairs (VA) healthcare systems (2004-07), before systematic implementation of brief intervention. ParticipantsA total of 486115 out-patients with AUDIT-Cs documented in their electronic health records (EHRs) on two occasions 12months apart (baseline' and follow-up'). MeasurementsIndependent measures were baseline AUDIT-C scores and change in standard AUDIT-C risk groups (no use, low-risk use and mild, moderate, severe misuse) from baseline to follow-up. Outcome measures were (1) high-density lipoprotein cholesterol (HDL), (2) alcohol-related gastrointestinal hospitalizations (GI hospitalizations') and (3) physical trauma, each in the years after baseline and follow-up. FindingsBaseline AUDIT-C scores had a positive association with outcomes in the following year. Across AUDIT-C scores 0-12, mean HDL ranged from 41.4 [95% confidence interval (CI)=41.3-41.5] to 53.5 (95% CI=51.4-55.6) mg/l, and probabilities of GI hospitalizations from 0.49% (95% CI=0.48-0.51%) to 1.8% (95% CI=1.3-2.3%) and trauma from 3.0% (95% CI=2.95-3.06%) to 6.0% (95% CI=5.2-6.8%). At follow-up, patients who increased to moderate or severe alcohol misuse had consistently higher mean HDL and probabilities of subsequent GI hospitalizations or trauma compared with those who did not (P-values all <0.05). For example, among those with baseline low-risk use, in those with persistent low-risk use versus severe misuse at follow-up, the probabilities of subsequent trauma were 2.65% (95% CI=2.54-2.75%) versus 5.15% (95% CI=3.86-6.45%), respectively. However, for patients who decreased to lower AUDIT-C risk groups at follow-up, findings were inconsistent across outcomes, with only mean HDL decreasing in most groups that decreased use (P-values all <0.05). ConclusionsWhen AUDIT-C screening is conducted in clinical settings, baseline AUDIT-C scores and score increases to moderate-severe alcohol misuse at follow-up screening appear to have predictive validity for HDL cholesterol, alcohol-related gastrointestinal hospitalizations and physical trauma. Decreasing AUDIT-C scores collected in clinical settings appear to have predictive validity for only HDL. C1 [Bradley, Katharine A.; Rubinsky, Anna D.; Lapham, Gwen T.; Bryson, Christopher; Achtmeyer, Carol; Hawkins, Eric J.; Chavez, Laura J.; Williams, Emily C.; Kivlahan, Daniel R.] Seattle Ctr Innovat Veteran Ctr & Value Driven Ca, HSR&D, Seattle, WA USA. [Bradley, Katharine A.; Rubinsky, Anna D.; Achtmeyer, Carol; Hawkins, Eric J.; Kivlahan, Daniel R.] Vet Affairs VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. [Bradley, Katharine A.; Lapham, Gwen T.] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [Berger, Douglas; Bryson, Christopher; Achtmeyer, Carol] Dept Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Bradley, Katharine A.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.; Berger, Douglas; Kivlahan, Daniel R.] Univ Washington, Dept Med, Seattle, WA USA. [Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rubinsky, Anna D.] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA. [Rubinsky, Anna D.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Bradley, KA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM bradley.k@ghc.org FU Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Health Services Research and Development Merit Review Award [IIR 08-314]; Group Health Research Institute; Career Development Award from VA Health Services Research Development [CDA 12-276] FX This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Health Services Research and Development Merit Review Award #IIR 08-314 and Group Health Research Institute. Support for VA/CMS data for this project is provided by the VA Information Resource Center. E.C.W. is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 66 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2016 VL 111 IS 11 BP 1975 EP 1984 DI 10.1111/add.13505 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DZ8WR UT WOS:000386153700016 PM 27349855 ER PT J AU Banerjee, G Edelman, EJ Barry, DT Becker, WC Cerda, M Crystal, S Gaither, JR Gordon, AJ Gordon, KS Kerns, RD Martins, SS Fiellin, DA Marshall, BDL AF Banerjee, Geetanjoli Edelman, E. Jennifer Barry, Declan T. Becker, William C. Cerda, Magdalena Crystal, Stephen Gaither, Julie R. Gordon, Adam J. Gordon, Kirsha S. Kerns, Robert D. Martins, Silvia S. Fiellin, David A. Marshall, Brandon D. L. TI Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study SO ADDICTION LA English DT Article DE Heroin; longitudinal study; non-medical prescription drug use; opioid-related disorders; polysubstance use; veterans ID POSTTRAUMATIC-STRESS-DISORDER; UNITED-STATES; VIETNAM VETERANS; CHRONIC PAIN; INVERSE PROBABILITY; UNINFECTED PATIENTS; MILITARY PERSONNEL; THERAPEUTIC-USE; MENTAL-ILLNESS; MEDICAL USE AB AimsTo estimate the influence of non-medical use of prescription opioids (NMUPO) on heroin initiation among US veterans receiving medical care. DesignUsing a multivariable Cox regression model, we analyzed data from a prospective, multi-site, observational study of HIV-infected and an age/race/site-matched control group of HIV-uninfected veterans in care in the United States. Approximately annual behavioral assessments were conducted and contained self-reported measures of NMUPO and heroin use. SettingVeterans Health Administration (VHA) infectious disease and primary care clinics in Atlanta, Baltimore, New York, Houston, Los Angeles, Pittsburgh and Washington, DC. ParticipantsA total of 3396 HIV-infected and uninfected patients enrolled into the Veterans Aging Cohort Study who reported no life-time NMUPO or heroin use, had no opioid use disorder diagnoses at baseline and who were followed between 2002 and 2012. MeasurementsThe primary outcome measure was self-reported incident heroin use and the primary exposure of interest was new-onset NMUPO. Our final model was adjusted for socio-demographics, pain interference, prior diagnoses of post-traumatic stress disorder and/or depression and self-reported other substance use. FindingsUsing a multivariable Cox regression model, we found that non-medical use of prescription opioids NMUPO was associated positively and independently with heroin initiation [adjusted hazard ratio (AHR)=5.43, 95% confidence interval (CI)=4.01, 7.35]. ConclusionsNew-onset non-medical use of prescription opioids (NMUPO) is a strong risk factor for heroin initiation among HIV-infected and uninfected veterans in the United States who reported no previous history of NMUPO or illicit opioid use. C1 [Banerjee, Geetanjoli; Marshall, Brandon D. L.] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA. [Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA. [Edelman, E. Jennifer; Gaither, Julie R.; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Barry, Declan T.] Yale Univ, Sch Med, New Haven, CT USA. [Barry, Declan T.] APT Fdn Pain Treatment Serv, New Haven, CT USA. [Becker, William C.; Kerns, Robert D.] VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Cerda, Magdalena] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA. [Gaither, Julie R.] Yale Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Kirsha S.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Kerns, Robert D.] Yale Univ, Dept Neurol, New Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychol, New Haven, CT USA. [Martins, Silvia S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. RP Marshall, BDL (reprint author), Brown Univ, Dept Epidemiol, 121 South Main St, Providence, RI 02912 USA. EM brandon_marshall@brown.edu OI Fiellin, David/0000-0002-4006-010X FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, P01-AA019072]; National Institute of Allergy and Infectious Diseases US Department of Veterans Affairs; National Institute on Drug Abuse [F31-DA035567, R03-DA037770, R01-DA037866]; AHRQ [1U19HS021112, R18-HS023258]; Center of Innovation grant from the Health Services Research and Development Service of the Department of Veterans Affairs [CIN 13-047] FX This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA: U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, U10-AA013566, and P01-AA019072), the National Institute of Allergy and Infectious Diseases (P30-AI042853), and in kind by the US Department of Veterans Affairs. J.R.G. is supported by the National Institute on Drug Abuse (F31-DA035567). E.J.E. is a Yale-Drug Abuse, Addiction, and HIV research scholar (K12-DA033312). B.D.L.M. is supported by the National Institute on Drug Abuse (R03-DA037770). S.S.M. is supported by the National Institute on Drug Abuse (R01-DA037866). S.C. is supported by AHRQ awards 1U19HS021112 and R18-HS023258. R.D.K. is supported by a Center of Innovation grant from the Health Services Research and Development Service of the Department of Veterans Affairs (CIN 13-047). The sponsors had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; and in the decision to submit the article for publication. We would like to acknowledge the veterans who participate in the Veterans Aging Cohort Study (VACS) and the study coordinators and staff at each VACS site and at the West Haven Coordinating Center. We would also like to thank Melissa Skanderson for her assistance and support during data acquisition. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 57 TC 7 Z9 7 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2016 VL 111 IS 11 BP 2021 EP 2031 DI 10.1111/add.13491 PG 11 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DZ8WR UT WOS:000386153700022 PM 27552496 ER PT J AU Fargo, KN Carrillo, MC Weiner, MW Potter, WZ Khachaturian, Z Vradenburg, G Weiner, MW AF Fargo, Keith N. Carrillo, Maria C. Weiner, Michael W. Potter, William Z. Khachaturian, Zaven Vradenburg, George Weiner, Michael W. TI The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions SO ALZHEIMERS & DEMENTIA LA English DT Editorial Material ID PREVENTION TRIALS; DRUG TRIALS; TASK-FORCE; DISEASE C1 [Fargo, Keith N.; Carrillo, Maria C.] Alzheimers Assoc, Chicago, IL USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Potter, William Z.] NIMH, Bethesda, MD USA. [Khachaturian, Zaven] Journal Alzheimers Assoc, Rockville, MD USA. RP Khachaturian, Z (reprint author), Journal Alzheimers Assoc, Rockville, MD USA. EM zaven@kra.net NR 15 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2016 VL 12 IS 11 BP 1113 EP 1115 DI 10.1016/j.jalz.2016.19.001 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EC1AJ UT WOS:000387835600001 PM 27836052 ER PT J AU Shi, M Kovac, A Korff, A Cook, TJ Ginghina, C Bullock, KM Yang, L Stewart, T Zheng, DF Aro, P Atik, A Kerr, KF Zabetian, CP Peskind, ER Hu, SC Quinn, JF Galasko, DR Montine, TJ Banks, WA Zhang, J AF Shi, Min Kovac, Andrej Korff, Ane Cook, Travis J. Ginghina, Carmen Bullock, Kristin M. Yang, Li Stewart, Tessandra Zheng, Danfeng Aro, Patrick Atik, Anzari Kerr, Kathleen F. Zabetian, Cyrus P. Peskind, Elaine R. Hu, Shu-Ching Quinn, Joseph F. Galasko, Douglas R. Montine, Thomas J. Banks, William A. Zhang, Jing TI CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE Central nervous system protein efflux; Central nervous system-derived exosomes; Tau; Blood plasma; Alzheimer's disease; Parkinson's disease; Biomarkers ID BLOOD-BRAIN-BARRIER; CELL-ADHESION MOLECULE; ALPHA-SYNUCLEIN; CEREBROSPINAL-FLUID; PATHOLOGY; PLASMA; PROTEINS; L1; ASSOCIATION; DJ-1 AB Introduction: Alzheimer's disease (AD) and Parkinson's disease (PD) involve tau pathology. Tau is detectable in blood, but its clearance from neuronal cells and the brain is poorly understood. Methods: Tau efflux from the brain to the blood was evaluated by administering radioactively labeled and unlabeled tau intracerebroventricularly in wild-type and tau knock-out mice, respectively. Central nervous system (CNS) derived tau in L1CAM-containing exosomes was further characterized extensively in human plasma, including by single molecule array technology with 303 subjects. Results: The efflux of Tau, including a fraction via CNS-derived L1CAM exosomes, was observed in mice. In human plasma, tau was explicitly identified within L1CAM exosomes. In contrast to AD patients, L1CAM exosomal tau was significantly higher in PD patients than controls and correlated with cerebrospinal fluid tau. Conclusions: Tau is readily transported from the brain to the blood. The mechanisms of CNS tau efflux are likely different between AD and PD. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Shi, Min; Korff, Ane; Cook, Travis J.; Ginghina, Carmen; Yang, Li; Stewart, Tessandra; Zheng, Danfeng; Aro, Patrick; Atik, Anzari; Montine, Thomas J.; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Kovac, Andrej; Bullock, Kristin M.; Zabetian, Cyrus P.; Hu, Shu-Ching; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kovac, Andrej; Bullock, Kristin M.; Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kovac, Andrej] Slovak Acad Sci, Inst Neuroimmunol, Bratislava, Slovakia. [Zheng, Danfeng; Zhang, Jing] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China. [Zheng, Danfeng; Zhang, Jing] Peking Univ, Hosp 3, Beijing, Peoples R China. [Kerr, Kathleen F.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Galasko, Douglas R.] Univ Calif San Diego, Shiley Marcos Alzheimers Dis Res Ctr, La Jolla, CA 92093 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.; Zhang, J (reprint author), Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China.; Zhang, J (reprint author), Peking Univ, Hosp 3, Beijing, Peoples R China. EM zhangj@uw.edu RI Kerr, Kathleen/A-2893-2013 FU National Institutes of Health (NIH) [U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684-6221, R21 NS085425, R01 NS065070, P50 AG05131]; Alzheimer's Association grant [2015-NIRG-342009]; Department of Veterans Affairs [1I01BX000531, 5I01BX002113]; University of Washington's Proteomics Resource [UWPR95794] FX We deeply appreciate the participants for their generous donation of samples. This study was supported by grants from the National Institutes of Health (NIH) (U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221 to JZ, R21 NS085425 to M.S., R01 NS065070 to C.P.Z., and P50 AG05131 to D.R.G.), partially by an Alzheimer's Association grant (2015-NIRG-342009) to M.S., and by grants from the Department of Veterans Affairs (to Parkinson's Disease, Mental illness, and Geriatric Research, Education, and Clinical Centers, VA Puget Sound Health Care System - C.P.Z., E.R.P., and W.A.B.; 1I01BX000531 to C.P.Z., and 5I01BX002113 to J.F.Q.). It was also supported in part by the University of Washington's Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; or decision to submit the manuscript for publication. NR 29 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2016 VL 12 IS 11 BP 1125 EP 1131 DI 10.1016/j.jalz.2016.04.003 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EC1AJ UT WOS:000387835600003 PM 27234211 ER PT J AU Schopfer, DW Regan, M Heidenreich, PA Whooley, MA AF Schopfer, David W. Regan, Mathilda Heidenreich, Paul A. Whooley, Mary A. TI Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIOVASCULAR EVENTS; ANGINA-PECTORIS; PRIMARY-CARE; ASSOCIATION; RISK; MORTALITY; FAILURE; REHABILITATION; CLASSIFICATION; EPIDEMIOLOGY AB Patient-reported health status is highly valued as a key measure of health care quality, yet little is known about the extent to which it is determined by subjective perception compared with objective measures of disease severity. We sought to compare the associations of depressive symptoms and objective measures of cardiac disease severity with perceived functional status in patients with stable coronary artery disease. We assessed depressive symptoms, severity of cardiovascular disease, and perceived functional status in a cross-sectional study of 1,023 patients with stable coronary artery disease. We compared the extent to which patient-reported functional status was influenced by depressive symptoms versus objective measures of disease severity. We then evaluated perceived functional status as a predictor of subsequent cardiovascular hospitalizations during 8.8 years of follow-up. Patients with depressive symptoms were more likely to report poor functional status than those without depressive symptoms (44% vs 17%; p <0.001). After adjustment for traditional risk factors and co-morbid conditions, independent predictors of poor functional status were depressive symptoms (odds ratio [OR] 2.68, 95% confidence interval [CI] 1.89 to 3.79), poor exercise capacity (OR 2.30, 95% CI 1.65 to 3.19), and history of heart failure (OR 1.61, 95% CI 1.12 to 2.29). Compared with patients who had class I functional status, those with class II functional status had a 96% greater rate (hazard ratio 1.96, 95% CI 1.15 to 3.34) and those with class III or IV functional status had a 104% greater rate (hazard ratio 2.04, 95% CI 1.12 to 3.73) of hospitalization for HF, adjusted for baseline demographic characteristics, co-morbidities, cardiac disease severity, and depressive symptoms. In conclusion, depressive symptoms and cardiac disease severity were independently associated with patient-reported functional status. This suggests that perceived functional status may be as strongly influenced by depressive symptoms as it is by cardiovascular disease severity. Published by Elsevier Inc. C1 [Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schopfer, David W.; Regan, Mathilda; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Heidenreich, Paul A.] Stanford Univ, Dept Cardiol, Palo Alto, CA 94304 USA. [Heidenreich, Paul A.] VA Palo Alto Healthcare Syst, Dept Cardiol, Palo Alto, CA USA. RP Schopfer, DW (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Schopfer, DW (reprint author), San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. EM david.schopfer@ucsf.edu OI Schopfer, David/0000-0002-7244-9857 FU National Center for Advancing Translational Sciences, Bethesda; Maryland of the National Institutes of Health, Bethesda, Maryland [KL2TR000143]; Department of Veterans Affairs, Washington, DC (Epidemiology Merit Review Program); National Heart, Lung, and Blood Institute, Bethesda, Maryland [R01 HL079235]; Robert Wood Johnson Foundation, Princeton, New Jersey (Generalist Physician Faculty Scholars Program); American Federation for Aging Research, New York, New York (Paul Beeson Faculty Scholars in Aging Regearch Program); Ischemia Research and Education Foundation, South San Francisco, California; Nancy Kirwan Heart Research Fund, San Francisco, California FX Dr. Schopfer is supported by the National Center for Advancing Translational Sciences, Bethesda, Maryland of the National Institutes of Health, Bethesda, Maryland under award number KL2TR000143. The Heart and Soul Study was supported by grants from the Department of Veterans Affairs, Washington, DC (Epidemiology Merit Review Program), the National Heart, Lung, and Blood Institute, Bethesda, Maryland (R01 HL079235), the Robert Wood Johnson Foundation, Princeton, New Jersey (Generalist Physician Faculty Scholars Program), the American Federation for Aging Research, New York, New York (Paul Beeson Faculty Scholars in Aging Regearch Program), the Ischemia Research and Education Foundation, South San Francisco, California, and Nancy Kirwan Heart Research Fund, San Francisco, California. NR 29 TC 0 Z9 0 U1 3 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 1 PY 2016 VL 118 IS 9 BP 1287 EP 1292 DI 10.1016/j.amjcard.2016.07.062 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC2JJ UT WOS:000387937700003 PM 27665203 ER PT J AU Clark, LR Koscik, RL Nicholas, CR Okonkwo, OC Engelman, CD Bratzke, LC Hogan, KJ Mueller, KD Bendlin, BB Carlsson, CM Asthana, S Sager, MA Hermann, BP Johnson, SC AF Clark, Lindsay R. Koscik, Rebecca L. Nicholas, Christopher R. Okonkwo, Ozioma C. Engelman, Corinne D. Bratzke, Lisa C. Hogan, Kirk J. Mueller, Kimberly D. Bendlin, Barbara B. Carlsson, Cynthia M. Asthana, Sanjay Sager, Mark A. Hermann, Bruce P. Johnson, Sterling C. TI Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Mild cognitive impairment; Alzheimer's disease; Norms/normative studies; Elderly/Geriatrics/Aging; Dementia; Learning and Memory ID INFORMANT QUESTIONNAIRE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; HEALTHY-ADULTS; ELDERLY IQCODE; DISEASE; DECLINE; DEMENTIA; CRITERIA AB Objective: Detecting cognitive decline in presymptomatic Alzheimer's disease (AD) and early mild cognitive impairment (MCI) is challenging, but important for treatments targeting AD-related neurodegeneration. The current study aimed to investigate the utility and performance of internally developed robust norms and standard norms in identifying cognitive impairment in late middle-age (baseline age range = 36-68; M = 54). Method: Robust norms were developed for neuropsychological measures based on longitudinally confirmed cognitively normal (CN) participants (n = 476). Seven hundred and seventy-nine participants enriched for AD risk were classified as psychometric MCI (pMCI) or CN based on standard and robust norms and "single-test" versus "multi-test" criteria. Results: Prevalence of pMCI ranged from 3% to 49% depending on the classification scheme used. Those classified as pMCI using robust norms exhibited greater subjective cognitive complaints, diagnostic stability, and mild clinical symptoms at follow-up. Conclusions: Results suggest that identifying early clinically relevant cognitive decline in late middle-age is feasible using robust norms and multi-test criteria. C1 [Clark, Lindsay R.; Koscik, Rebecca L.; Okonkwo, Ozioma C.; Engelman, Corinne D.; Bratzke, Lisa C.; Hogan, Kirk J.; Mueller, Kimberly D.; Carlsson, Cynthia M.; Asthana, Sanjay; Sager, Mark A.; Hermann, Bruce P.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53705 USA. [Clark, Lindsay R.; Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Bratzke, Lisa C.] Univ Wisconsin, Sch Nursing, Madison, WI 53705 USA. [Hogan, Kirk J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI 53705 USA. [Hermann, Bruce P.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Bratzke, Lisa/0000-0002-0321-4501 FU Clinical Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS) [UL1TR00427]; National Institutes of Health (NIH) [R01 AG027161, R01 AG021155, ADRC P50 AG033514]; Wisconsin Alzheimer's Institute (WAI) Holland Research Fund FX This work was supported by the Clinical Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS), and grant UL1TR00427. Funding support was also provided by the National Institutes of Health (NIH) (R01 AG027161 to S.C.J., R01 AG021155 to S.C.J., ADRC P50 AG033514 to S.A.) and the Wisconsin Alzheimer's Institute (WAI) Holland Research Fund. The content is solely the responsibility of the authors and does not represent the official views of NIH. NR 48 TC 3 Z9 3 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD NOV PY 2016 VL 31 IS 7 BP 675 EP 688 DI 10.1093/arclin/acw024 PG 14 WC Psychology, Clinical; Psychology SC Psychology GA EC2PH UT WOS:000387965300001 ER PT J AU Woodbury, ML Anderson, K Finetto, C Fortune, A Dellenbach, B Grattan, E Hutchison, S AF Woodbury, Michelle L. Anderson, Kelly Finetto, Christian Fortune, Andrew Dellenbach, Blair Grattan, Emily Hutchison, Scott TI Matching Task Difficulty to Patient Ability During Task Practice Improves Upper Extremity Motor Skill After Stroke: A Proof-of-Concept Study SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Occupational therapy; Rehabilitation; Stroke ID FUGL-MEYER ASSESSMENT; ADULT SQUIRREL-MONKEYS; MOVEMENT REPRESENTATIONS; THERAPY; CORTEX; RECOVERY; STRATEGIES AB Objective: To test the feasibility of the Fugl-Meyer Assessment of the Upper Extremity "keyform," derived from Rasch analysis, as a method for systematically planning and progressing rehabilitation. Design: Feasibility study, single group design. Setting: University rehabilitation research laboratory. Participants: Participants (N=10; mean age, 59.70 +/- 9.96y; 24.1 +/- 30.54mo poststroke) with ischemic or hemorrhagic stroke >3 months prior, voluntarily shoulder flexion >= 30 degrees, and simultaneous elbow extension >= 20 degrees. Interventions: The keyform method defined initial rehabilitation targets (goals) and progressed the rehabilitation program after every third session. Targets were repetitively practiced within the context of client-selected functional tasks not in isolation. Main Outcome Measures: Feasibility was defined by subject's pain or fatigue, upper extremity motor function (Wolf Motor Function Test), and movement patterns (kinematics). Assessments were administered pre- and posttreatment and compared using paired t tests. Task-difficulty and patient-ability measures were calculated using Rasch analysis and compared using paired t tests (P<.05). Results: Ten participants completed 9 sessions, 200 movement repetitions per session in <2 hours without pain or fatigue. Participants gained upper extremity motor function (Wolf Motor Function Test: pretreatment, 22.23 +/- 24.26s; posttreatment, 15.46 +/- 22.12s; P=.01), improved shoulder elbow coordination (index of curvature: pretreatment, 1.30 +/- 0.15; posttreatment, 1.21 +/- 0.11; P =.01), and exhibited reduced trunk compensatory movement (trunk displacement: pretreatment, 133.97 +/- 74.15mm; posttreatment, 108.08 +/- 64.73mm; P=.02). Task-difficulty and patient-ability measures were not statistically different throughout the program (person-ability measures of 1.01 +/- 0.05, 1.64 +/- 0.45, and 2.22 +/- 0.65 logits and item-difficulty measures of 0.93 +/- 0.37, 1.70 +/- 0.20, and 2.06 +/- 0.24 logits at the 3 testing time points, respectively; P>.05). Conclusions: The Fugl-Meyer Assessment of the Upper Extremity keyform is a feasible method to ensure that the difficulty of tasks practiced were well matched to initial and evolving levels of upper extremity motor ability. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Woodbury, Michelle L.; Fortune, Andrew; Hutchison, Scott] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Woodbury, Michelle L.; Anderson, Kelly; Finetto, Christian; Fortune, Andrew; Dellenbach, Blair; Grattan, Emily; Hutchison, Scott] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Woodbury, Michelle L.; Hutchison, Scott] Med Univ South Carolina, Dept Hlth Profess, Div Occupat Therapy, Charleston, SC 29425 USA. RP Woodbury, ML (reprint author), Med Univ South Carolina, Coll Hlth Profess, 77 President St, Charleston, SC 29425 USA. EM WoodbuML@musc.edu FU Ralph H. Johnson Veterans Affairs Medical Center; Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award [B-6332W]; Veterans Affairs Merit Review Awards [N0799-R]; Medical University of South Carolina Center of Biomedical Research Excellence for Stroke Recovery, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM12345] FX Supported in part by the Ralph H. Johnson Veterans Affairs Medical Center and the Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award (award no. B-6332W); and Veterans Affairs Merit Review Awards (award no. N0799-R). Also supported by the Medical University of South Carolina Center of Biomedical Research Excellence for Stroke Recovery, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (grant no. P20GM12345). NR 30 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2016 VL 97 IS 11 BP 1863 EP 1871 DI 10.1016/j.apmr.2016.03.022 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EB8IK UT WOS:000387634500005 PM 27117385 ER PT J AU Kozora, E Ulug, AM Erkan, D Vo, A Filley, CM Ramon, G Burleson, A Zimmerman, R Lockshin, MD AF Kozora, E. Ulug, A. M. Erkan, D. Vo, A. Filley, C. M. Ramon, G. Burleson, A. Zimmerman, R. Lockshin, M. D. TI Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients SO ARTHRITIS CARE & RESEARCH LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CLINICAL-DISEASE ACTIVITY; NEUROPSYCHIATRIC LUPUS; COGNITIVE DEFICITS; BRAIN; MANIFESTATIONS; ABNORMALITIES; INDEX; TASK; CLASSIFICATION AB ObjectiveStandardized cognitive tests and functional magnetic resonance imaging (fMRI) studies of systemic lupus erythematosus (SLE) patients demonstrate deficits in working memory and executive function. These neurobehavioral abnormalities are not well studied in antiphospholipid syndrome, which may occur independently of or together with SLE. This study compares an fMRI paradigm involving motor skills, working memory, and executive function in SLE patients without antiphospholipid antibody (aPL) (the SLE group), aPL-positive non-SLE patients (the aPL-positive group), and controls. MethodsBrain MRI, fMRI, and standardized cognitive assessment results were obtained from 20 SLE, 20 aPL-positive, and 10 healthy female subjects with no history of neuropsychiatric abnormality. ResultsAnalysis of fMRI data showed no differences in performance across groups on bilateral motor tasks. When analysis of variance was used, significant group differences were found in 2 executive function tasks (word generation and word rhyming) and in a working memory task (N-Back). Patients positive for aPL demonstrated higher activation in bilateral frontal, temporal, and parietal cortices compared to controls during working memory and executive function tasks. SLE patients also demonstrated bilateral frontal and temporal activation during working memory and executive function tasks. ConclusionCompared to controls, both aPL-positive and SLE patients had elevated cortical activation, primarily in the frontal lobes, during tasks involving working memory and executive function. These findings are consistent with cortical overactivation as a compensatory mechanism for early white matter neuropathology in these disorders. C1 [Kozora, E.; Burleson, A.] Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. [Kozora, E.; Filley, C. M.] Univ Colorado, Sch Med, Denver, CO USA. [Kozora, E.; Erkan, D.; Lockshin, M. D.] Cornell Univ, Hosp Special Surg, New York, NY 10021 USA. [Kozora, E.; Erkan, D.; Zimmerman, R.; Lockshin, M. D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Ulug, A. M.; Vo, A.] Feinstein Inst Med Res, Manhasset, NY USA. [Ulug, A. M.] Hofstra Univ, Hempstead, NY 11550 USA. [Ulug, A. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ulug, A. M.] Bogazici Univ, Inst Biomed Engn, Istanbul, Turkey. [Filley, C. M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ramon, G.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. RP Kozora, E (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. EM kozorae@njhealth.org FU Mary Kirkland Center, Hospital for Special Surgery, New York, New York FX Supported by the Mary Kirkland Center, Hospital for Special Surgery, New York, New York. NR 49 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2016 VL 68 IS 11 BP 1655 EP 1663 DI 10.1002/acr.22873 PG 9 WC Rheumatology SC Rheumatology GA EB0TN UT WOS:000387058800010 PM 26946337 ER PT J AU Bednash, JS Mallampalli, RK AF Bednash, Joseph S. Mallampalli, Rama K. TI Regulation of inflammasomes by ubiquitination SO CELLULAR & MOLECULAR IMMUNOLOGY LA English DT Review DE deubiquitinase; E3 ligase; inflammasome; innate immunity; ubiqutin ID NF-KAPPA-B; NLRP3 INFLAMMASOME; CUTTING EDGE; CELL-DEATH; ASSEMBLY COMPLEX; E3 LIGASE; ACTIVATION; PROTEASOME; IL-1-BETA; MACROPHAGES AB Inflammasomes are multi-protein complexes that regulate the innate immune response by facilitating the release of inflammatory cytokines in response to pathogen exposure or cellular damage. Pro-inflammatory inflammasome signaling is vital to host defense and helps initiate the process of tissue repair following an insult to the host, but can be injurious, when excessive or chronic. As such, inflammasome activity is tightly regulated. Here we discuss one critical mechanism of inflammasome regulation, ubiquitination, that functions as a universal modulator of protein stability and trafficking. Recent studies have provided important insights into the regulation of inflammasome activation by protein ubiquitination. We review the molecular regulation of inflammasome function, specifically, as it relates to ubiquitination, and discuss the implications for the development of therapeutics to specifically target aberrant inflammasome signaling. C1 [Bednash, Joseph S.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Div Pulm Allergy & Crit Care Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Div Pulm Allergy & Crit Care Med,UPMC Montefiore, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU Flight Attendant Medical Research Institute FX This work was supported by the Flight Attendant Medical Research Institute. NR 62 TC 1 Z9 1 U1 6 U2 6 PU CHIN SOCIETY IMMUNOLOGY PI BEING PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA SN 1672-7681 EI 2042-0226 J9 CELL MOL IMMUNOL JI Cell. Mol. Immunol. PD NOV PY 2016 VL 13 IS 6 BP 722 EP 728 DI 10.1038/cmi.2016.15 PG 7 WC Immunology SC Immunology GA EC2SN UT WOS:000387974300002 PM 27063466 ER PT J AU Roussos, P Guennewig, B Kaczorowski, DC Barry, G Brennand, KJ AF Roussos, Panos Guennewig, Boris Kaczorowski, Dominik C. Barry, Guy Brennand, Kristen J. TI Activity-Dependent Changes in Gene Expression in Schizophrenia Human-Induced Pluripotent Stem Cell Neurons SO JAMA PSYCHIATRY LA English DT Article ID DE-NOVO MUTATIONS; AUTISM SPECTRUM DISORDER; SEVERE INTELLECTUAL DISABILITY; EPILEPTIC ENCEPHALOPATHIES; PATTERNS AB IMPORTANCE Schizophrenia candidate genes participate in common molecular pathways that are regulated by activity-dependent changes in neurons. One important next step is to further our understanding on the role of activity-dependent changes of gene expression in the etiopathogenesis of schizophrenia. OBJECTIVE To examine whether neuronal activity-dependent changes of gene expression are dysregulated in schizophrenia. DESIGN, SETTING, AND PARTICIPANTS Neurons differentiated from human-induced pluripotent stem cells derived from 4 individuals with schizophrenia and 4 unaffected control individuals were depolarized using potassium chloride. RNA was extracted followed by genome-wide profiling of the transcriptome. Neurons were planted on June 21, 2013, and harvested on August 2, 2013. MAIN OUTCOMES AND MEASURES We performed differential expression analysis and gene coexpression analysis to identify activity-dependent or disease-specific changes of the transcriptome. Gene expression differences were assessed with linear models. Furthermore, we used gene set analyses to identify coexpressed modules that are enriched for schizophrenia risk genes. RESULTS We identified 1669 genes that were significantly different in schizophreniaassociated vs control human-induced pluripotent stem cell-derived neurons and 1199 genes that are altered in these cells in response to depolarization (linear models at false discovery rate <= 0.05). The effect of activity-dependent changes of gene expression in schizophrenia-associated neurons (59 significant genes at false discovery rate <= 0.05) was attenuated compared with control samples (594 significant genes at false discovery rate <= 0.05). Using gene coexpression analysis, we identified 2 modules (turquoise and brown) that were associated with diagnosis status and 2 modules (yellow and green) that were associated with depolarization at a false discovery rate of <= 0.05. For 3 of the 4 modules, we found enrichment with schizophrenia-associated variants: brown (chi(2) = 20.68; P =.002), turquoise (chi(2) = 12.95; P =.04), and yellow (chi(2) = 15.34; P =.02). CONCLUSIONS AND RELEVANCE In this analysis, candidate genes clustered within gene networks that were associated with a blunted effect of activity-dependent changes of gene expression in schizophrenia-associated neurons. Overall, these findings link schizophrenia candidate genes with specific molecular functions in neurons, which could be used to examine underlying mechanisms and therapeutic interventions related to schizophrenia. C1 [Roussos, Panos; Brennand, Kristen J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Guennewig, Boris] Univ New South Wales, St Vincents Clin Sch, Kensington, NSW, Australia. [Guennewig, Boris] Univ New South Wales, Sch Biotechnol & Biomol Sci, Kensington, NSW, Australia. [Guennewig, Boris; Kaczorowski, Dominik C.] Garvan Inst Med Res, Sydney, NSW, Australia. [Barry, Guy] Res Berghofer Med Res Inst, Queensland Inst Med, Herston, Qld, Australia. [Brennand, Kristen J.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA. RP Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 1470 Madison Ave, New York, NY 10029 USA.; Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Genet, 1470 Madison Ave, New York, NY 10029 USA.; Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Genom Sci, 1470 Madison Ave, New York, NY 10029 USA. EM panagiotis.roussos@mssm.edu RI Brennand, Kristen/J-8704-2012 OI Brennand, Kristen/0000-0003-0993-5956 FU National Institutes of Health [R01AG050986, R01MH109677, R01MH101454, R01MH106056]; New York Stem Cell Foundation; Brain Behavior Research Foundation; Alzheimer's Association grant [NIRGf-340998]; Veterans Affairs merit grant [BX002395]; Swiss National Science Foundation [P2EZP3_152143]; Geoff and Dawn Dixon fellowship; Office of Research Infrastructure of the National Institutes of Health [S10OD018522] FX This work was supported by the National Institutes of Health grants R01AG050986 and R01MH109677 (Dr Roussos) and R01MH101454 and R01MH106056 (Dr Brennand), New York Stem Cell Foundation (Dr Brennand), Brain Behavior Research Foundation (Drs Roussos and Brennand), Alzheimer's Association grant NIRGf-340998 (Dr Roussos), the Veterans Affairs merit grant BX002395 (Dr Roussos), the Swiss National Science Foundation grant P2EZP3_152143 (Dr Guennewig), and a Geoff and Dawn Dixon fellowship (Dr Guennewig). This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this article was supported by the Office of Research Infrastructure of the National Institutes of Health award S10OD018522. NR 31 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2016 VL 73 IS 11 BP 1180 EP 1188 DI 10.1001/jamapsychiatry.2016.2575 PG 9 WC Psychiatry SC Psychiatry GA EC2GJ UT WOS:000387927400014 PM 27732689 ER PT J AU Friedman, MJ Kilpatrick, DG Schnurr, PP AF Friedman, Matthew J. Kilpatrick, Dean G. Schnurr, Paula P. TI Changes to the Definition of Posttraumatic Stress Disorder in the DSM-5 Reply SO JAMA PSYCHIATRY LA English DT Letter C1 [Friedman, Matthew J.; Schnurr, Paula P.] US Dept Vet Affairs, Natl Ctr PTSD, White River Jct, VT USA. [Friedman, Matthew J.; Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Kilpatrick, Dean G.] Med Univ South Carolina, Charleston, SC USA. RP Friedman, MJ (reprint author), VA Med Ctr, Natl Ctr PTSD 116D, 215 N Main St, White River Jct, VT 05009 USA. EM matthew.j.friedman@dartmouth.edu FU National Institute of Mental Health; Department of Veterans Affairs; Department of Defense FX Dr Kilpatrick receives funding from the National Institute of Mental Health. Dr Schnurr receives research funding from the Department of Veterans Affairs, Department of Defense, and National Institute of Mental Health. NR 4 TC 1 Z9 1 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2016 VL 73 IS 11 BP 1203 EP 1203 DI 10.1001/jamapsychiatry.2016.2401 PG 1 WC Psychiatry SC Psychiatry GA EC2GJ UT WOS:000387927400021 PM 27732695 ER PT J AU Konstam, MA Kiernan, M Chandler, A Dhingra, R Mody, F Eisen, H Haught, WH Wagoner, L Gupta, D Patten, R Gordon, P Korr, K Fileccia, R Gregory, D Wedge, P Romeling, M Konstam, JM Udelson, JE AF Konstam, Marvin A. Kiernan, Michael Chandler, Arthur Dhingra, Ravi Mody, Freny Eisen, Howard Haught, W. Herbert Wagoner, Lynne Gupta, Divya Patten, Richard Gordon, Paul Korr, Kenneth Fileccia, Russell Gregory, Douglas Wedge, Patricia Romeling, Matthew Konstam, Jeremy M. Udelson, James E. CA SECRET CHF Investigators TI Acute Effect of the V-2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [Konstam, Marvin A.; Kiernan, Michael; Udelson, James E.] Tufts Med Ctr, Boston, MA USA. [Chandler, Arthur] Univ Cardiol Associates, Augusta, GA USA. [Dhingra, Ravi] Univ Wisconsin, Madison, WI USA. [Mody, Freny] VA Greater Los Angeles, Los Angeles, CA USA. [Eisen, Howard] Drexel Univ, Philadelphia, PA 19104 USA. [Haught, W. Herbert] Heart Ctr Res, Huntsville, AL USA. [Wagoner, Lynne] Mercy Hosp, Fairfield, OH USA. [Gupta, Divya] Emory Univ, Atlanta, GA 30322 USA. [Patten, Richard] Lahey Med Ctr, Burlington, MA USA. [Gordon, Paul; Korr, Kenneth] Miriam Hosp, Providence, RI 02906 USA. [Fileccia, Russell] Ark La Tex Cardiol, Shreveport, LA USA. [Gregory, Douglas; Wedge, Patricia; Romeling, Matthew; Konstam, Jeremy M.] Cardiovasc Clin Sci Fdn, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD NOV PY 2016 VL 22 IS 11 BP 939 EP 939 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC3XA UT WOS:000388059200020 ER PT J AU Sadasivam, RS Borglund, EM Adams, R Marlin, BM Houston, TK AF Sadasivam, Rajani Shankar Borglund, Erin M. Adams, Roy Marlin, Benjamin M. Houston, Thomas K. TI Impact of a Collective Intelligence Tailored Messaging System on Smoking Cessation: The Perspect Randomized Experiment SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE recommender system; health communication; computer tailoring; smoking cessation ID PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; QUIT-PRIMO; INTERVENTIONS; ENGAGEMENT; PROGRAMS; ENHANCE; TRIAL AB Background: Outside health care, content tailoring is driven algorithmically using machine learning compared to the rule-based approach used in current implementations of computer-tailored health communication (CTHC) systems. A special class of machine learning systems ("recommender systems") are used to select messages by combining the collective intelligence of their users (ie, the observed and inferred preferences of users as they interact with the system) and their user profiles. However, this approach has not been adequately tested for CTHC. Objective: Our aim was to compare, in a randomized experiment, a standard, evidence-based, rule-based CTHC (standard CTHC) to a novel machine learning CTHC: Patient Experience Recommender System for Persuasive Communication Tailoring (PERSPeCT). We hypothesized that PERSPeCT will select messages of higher influence than our standard CTHC system. This standard CTHC was proven effective in motivating smoking cessation in a prior randomized trial of 900 smokers (OR 1.70, 95% CI 1.03-2.81). Methods: PERSPeCT is an innovative hybrid machine learning recommender system that selects and sends motivational messages using algorithms that learn from message ratings from 846 previous participants (explicit feedback), and the prior explicit ratings of each individual participant. Current smokers (N=120) aged 18 years or older, English speaking, with Internet access were eligible to participate. These smokers were randomized to receive either PERSPeCT (intervention, n=74) or standard CTHC tailored messages (n=46). The study was conducted between October 2014 and January 2015. By randomization, we compared daily message ratings (mean of smoker ratings each day). At 30 days, we assessed the intervention's perceived influence, 30-day cessation, and changes in readiness to quit from baseline. Results: The proportion of days when smokers agreed/strongly agreed (daily rating >= 4) that the messages influenced them to quit was significantly higher for PERSPeCT (73%, 23/30) than standard CTHC (44%, 14/30, P=.02). Among less educated smokers (n=49), this difference was even more pronounced for days strongly agree (intervention: 77%, 23/30; comparison: 23%, 7/30, P<.001). There was no significant difference in the frequency which PERSPeCT randomized smokers agreed or strongly agreed that the intervention influenced them to quit smoking (P=.07) and use nicotine replacement therapy (P=.09). Among those who completed follow-up, 36% (20/55) of PERSPeCT smokers and 32% (11/34) of the standard CTHC group stopped smoking Conclusions: Compared to standard CTHC with proven effectiveness, PERSPeCT outperformed in terms of influence ratings and resulted in similar cessation rates. C1 [Sadasivam, Rajani Shankar; Borglund, Erin M.; Houston, Thomas K.] Univ Massachusetts Med Scool, Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [Adams, Roy; Marlin, Benjamin M.] Univ Massaachusttes Amherst, Coll Informat & Comp Sci, Amherst, MA USA. [Houston, Thomas K.] Bedford VA Med Ctr, US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. RP Sadasivam, RS (reprint author), Univ Massachusetts Med Scool, Albert Sherman Ctr, Div Hlth Informat & Implementat Sci, Quantitat Hlth Sci, 368 Plantat St, Worcester, MA 01605 USA. EM rajani.sadasivam@umassmed.edu OI Borglund, Erin/0000-0003-0492-1803; Sadasivam, Rajani/0000-0001-8406-6207 FU Patient-Centered Outcomes Research Institute [PI12-001]; National Cancer Institute [R01 CA129091, K07CA172677]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000161]; National Science Foundation CAREER award [1350522] FX Funding for these studies was received from the Patient-Centered Outcomes Research Institute (PI12-001), the National Cancer Institute grants R01 CA129091, and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000161. Dr Sadasivam is funded by a National Cancer Institute Career Development Award (K07CA172677). Dr Marlin is also funded by a National Science Foundation CAREER award (1350522). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health, or the Department of Veterans Affairs or the United States government. NR 34 TC 0 Z9 0 U1 9 U2 9 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD NOV PY 2016 VL 18 IS 11 AR e285 DI 10.2196/jmir.6465 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA EC4OC UT WOS:000388111100002 PM 27826134 ER PT J AU Teichert, T Gurnsey, K Salisbury, D Sweet, RA AF Teichert, Tobias Gurnsey, Kate Salisbury, Dean Sweet, Robert A. TI Contextual processing in unpredictable auditory environments: the limited resource model of auditory refractoriness in the rhesus SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE auditory deficits; EEG; habituation; response suppression; rhesus ID EVENT-RELATED POTENTIALS; NEOCORTICAL PYRAMIDAL NEURONS; PRIMARY VISUAL-CORTEX; MISMATCH NEGATIVITY; RECEPTIVE-FIELD; EVOKED-POTENTIALS; CORTICAL-NEURONS; SENSORY MEMORY; MACAQUE MONKEY; IN-VIVO AB Auditory refractoriness refers to the finding of smaller electroencephalographic (EEG) responses to tones preceded by shorter periods of silence. To date, its physiological mechanisms remain unclear, limiting the insights gained from findings of abnormal refractoriness in individuals with schizophrenia. To resolve this roadblock, we studied auditory refractoriness in the rhesus, one of the most important animal models of auditory function, using grids of up to 32 chronically implanted cranial EEG electrodes. Four macaques passively listened to sounds whose identity and timing was random, thus preventing animals from forming valid predictions about upcoming sounds. Stimulus onset asynchrony ranged between 0.2 and 12.8 s, thus encompassing the clinically relevant timescale of refractoriness. Our results show refractoriness in all 8 previously identified middle-and long-latency components that peaked between 14 and 170 ms after tone onset. Refractoriness may reflect the formation and gradual decay of a basic sensory memory trace that may be mirrored by the expenditure and gradual recovery of a limited physiological resource that determines generator excitability. For all 8 components, results were consistent with the assumption that processing of each tone expends similar to 65% of the available resource. Differences between components are caused by how quickly the resource recovers. Recovery time constants of different components ranged between 0.5 and 2 s. This work provides a solid conceptual, methodological, and computational foundation to dissect the physiological mechanisms of auditory refractoriness in the rhesus. Such knowledge may, in turn, help develop novel pharmacological, mechanism-targeted interventions. C1 [Teichert, Tobias; Gurnsey, Kate; Salisbury, Dean; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Teichert, Tobias] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Teichert, T (reprint author), Univ Pittsburgh, BST W 1658,200 Lothrop St, Pittsburgh, PA 15261 USA. EM teichert@pitt.edu FU National Institute of Mental Health [R01 MH094328, R01 MH071533] FX This work was supported by National Institute of Mental Health Grants R01 MH094328 (to D. Salisbury) and R01 MH071533 (to R.A. Sweet). NR 67 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD NOV PY 2016 VL 116 IS 5 BP 2125 EP 2139 DI 10.1152/jn.00419.2016 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA EC2VV UT WOS:000387983300012 PM 27512021 ER PT J AU Vance, CG Kopacz, MS AF Vance, C. Garland Kopacz, Marek S. TI After the Spiritual Assessment SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Letter C1 [Vance, C. Garland] Charles George VA Med Ctr, Asheville, NC USA. [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. EM marekskopacz@hotmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2016 VL 52 IS 5 BP E3 EP E4 DI 10.1016/j.jpainsymman.2016.09.001 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EC2OE UT WOS:000387961500004 PM 27660083 ER PT J AU Morgan, AE Pantoja, JL Grossi, EA Ge, L Weinsaft, JW Ratcliffe, MB AF Morgan, Ashley E. Pantoja, Joe L. Grossi, Eugene A. Ge, Liang Weinsaft, Jonathan W. Ratcliffe, Mark B. TI Neochord placement versus triangular resection in mitral valve repair: A finite element model SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Finite element modeling; Mitral valve repair; Cardiac mechanics; Surgical simulation ID POSTERIOR LEAFLET PROLAPSE; VENTRICULAR-WALL STRESS; EXPANDED POLYTETRAFLUOROETHYLENE; CHORDAE TENDINEAE; REGURGITATION; REPLACEMENT; SIMULATION; DISEASE; SHAPE AB Background: Recurrent mitral regurgitation after mitral valve repair is common, occurring in nearly 50% of patients within 10 years of surgery. Durability of repair is partly related to stress distribution over the mitral leaflets. We hypothesized that repair with neochords (NCs) results in lower stress than leaflet resection (LR). Materials and methods: Magnetic resonance imaging and 3D echocardiography were performed before surgical repair of P2 prolapse in a single patient. A finite element model of the left ventricle and mitral valve was created previously, and the modeling program LS-DYNA was used to calculate leaflet stress for the following repairs: Triangular LR; LR with ring annuloplasty (LR + RA); One NC; Two NCs; and 2NC + RA. Results: (1) NC placement resulted in stable posterior leaflet stress: Baseline versus 2 NC at end diastole (ED), 12.1 versus 12.0 kPa, at end systole (ES) 20.3 versus 21.7 kPa. (2) In contrast, LR increased posterior leaflet stress: Baseline versus LR at ED 12.1 versus 40.8 kPa, at ES 20.3 versus 46.1 kPa. (3) All repair types reduced anterior leaflet stress: Baseline versus 2 NC versus LR 34.2 versus 25.8 versus 20.6 kPa at ED and 80.8 versus 76.8 versus 67.8 kPa at ES. (4) The addition of RA reduced leaflet stress relative to repair without RA. Conclusions: Neochord repair restored normal leaflet coaptation without creating excessive leaflet stress, whereas leaflet resection more than doubled stress across the posterior leaflet. The excess stress created by leaflet resection was partially, but not completely, mitigated by ring annuloplasty. (C) 2016 Elsevier Inc. All rights reserved. C1 [Morgan, Ashley E.] Univ Calif San Francisco, East Bay Surg Residency, San Francisco, CA 94143 USA. [Pantoja, Joe L.] Univ Calif San Francisco, Coll Med, San Francisco, CA 94143 USA. [Grossi, Eugene A.] NYU, Dept Cardiothorac Surg, New York, NY USA. [Grossi, Eugene A.] New York Harbor Vet Affairs Med Ctr, Dept Cardiothorac Surg, New York, NY USA. [Ge, Liang; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Ge, Liang; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. [Ge, Liang; Ratcliffe, Mark B.] Vet Affairs Med Ctr, Dept Surg, San Francisco, CA 94121 USA. [Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Med Cardiol, New York, NY USA. [Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@med.va.gov OI GROSSI, eugene/0000-0002-2066-7035 FU NIH-R01 [HL128278-01] FX Funding support provided by NIH-R01 HL128278-01, Dr. Weinsaft. NR 26 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD NOV PY 2016 VL 206 IS 1 BP 98 EP 105 DI 10.1016/j.jss.2016.07.011 PG 8 WC Surgery SC Surgery GA EC2VR UT WOS:000387982900016 PM 27916382 ER PT J AU Hardy, SM AF Hardy, Seth M. TI Engaging Employees and Improving Care at the Veterans Health Administration SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Hardy, Seth M.] VA Maine Healthcare Syst, VA Ctr 1, US Dept Vet Affairs, Serv Radiol, Augusta, ME 04330 USA. RP Hardy, SM (reprint author), VA Maine Healthcare Syst, VA Ctr 1, US Dept Vet Affairs, Serv Radiol, Augusta, ME 04330 USA. EM sethmhardy@gmail.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1322 EP 1323 DI 10.1016/j.jacr.2016.06.039 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400010 PM 27526973 ER PT J AU Gyftopoulos, S Rosenberg, ZS Roberts, CC Bencardino, JT Appel, M Baccei, SJ Cassidy, RC Chang, EY Fox, MG Greenspan, BS Hochman, MG Jacobson, JA Mintz, DN Newman, JS Shah, NA Small, KM Weissman, BN AF Gyftopoulos, Soterios Rosenberg, Zehava S. Roberts, Catherine C. Bencardino, Jenny T. Appel, Marc Baccei, Steven J. Cassidy, R. Carter Chang, Eric Y. Fox, Michael G. Greenspan, Bennett S. Hochman, Mary G. Jacobson, Jon A. Mintz, Douglas N. Newman, Joel S. Shah, Nehal A. Small, Kirstin M. Weissman, Barbara N. TI ACR Appropriateness Criteria Imaging After Shoulder Arthroplasty SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness Criteria; shoulder arthroplasty; aseptic loosening; periprosthetic infection; MRI; CT ID POLYETHYLENE WEAR DEBRIS; TOTAL-HIP-ARTHROPLASTY; BRACHIAL-PLEXUS; ROTATOR CUFF; COMPUTED-TOMOGRAPHY; GLENOID COMPONENT; QUANTITATIVE ASSESSMENT; FATTY DEGENERATION; JOINT ASPIRATION; CT-SCAN AB There has been a rapid increase in the number of shoulder arthroplasties, including partial or complete humeral head resurfacing, hemiarthroplasty, total shoulder arthroplasty, and reverse total shoulder arthroplasty, performed in the United States over the past two decades. Imaging can play an important role in diagnosing the complications that can occur in the setting of these shoulder arthroplasties. This review is divided into two parts. The first part provides a general discussion of various imaging modalities, comprising radiography, CT, MRI, ultrasound, and nuclear medicine, and their role in providing useful, treatment-guiding information. The second part focuses on the most appropriate imaging algorithms for shoulder arthroplasty complications such as aseptic loosening, infection, fracture, rotator cuff tendon tear, and nerve injury. The evidence-based ACR Appropriateness Criteria guidelines offered in this report were reached via an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (the RAND/UCLA Appropriateness Method and the Grading of Recommendations Assessment, Development, and Evaluation) for rating the appropriateness of imaging and treatment procedures for specific clinical scenarios. Further analysis and review of the guidelines were performed by a multidisciplinary expert panel. In those instances in which there was insufficient or equivocal data for recommending the appropriate imaging algorithm, expert opinion may have supplemented the available evidence. C1 [Gyftopoulos, Soterios] NYU, Med Ctr, 550 1St Ave, New York, NY 10016 USA. [Rosenberg, Zehava S.] Hosp Joint Dis & Med Ctr, New York, NY USA. [Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA. [Bencardino, Jenny T.] NYU, Sch Med, New York, NY USA. [Appel, Marc] James J Peters VA Med Ctr, Bronx, NY USA. [Appel, Marc; Cassidy, R. Carter] Amer Acad Orthopaed Surg, Rosemont, IL USA. [Baccei, Steven J.] UMass Mem Med Ctr, Worcester, MA USA. [Cassidy, R. Carter] UK Healthcare Spine & Total Joint Serv, Lexington, KY USA. [Chang, Eric Y.] VA San Diego Healthcare Syst, San Diego, CA USA. [Fox, Michael G.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Greenspan, Bennett S.] Augusta Univ, Med Coll Georgia, Augusta, GA USA. [Hochman, Mary G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Jacobson, Jon A.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Mintz, Douglas N.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Newman, Joel S.] New England Baptist Hosp, Boston, MA USA. [Shah, Nehal A.; Small, Kirstin M.; Weissman, Barbara N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Gyftopoulos, S (reprint author), NYU, Hosp Joint Dis, Dept Radiol, 301 E 7th St, New York, NY 10003 USA. EM soterios.gyftopoulos@nyumc.org OI Rosenberg MD, Zehava/0000-0003-1902-6350 NR 67 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1324 EP 1336 DI 10.1016/j.jacr.2016.07.028 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400011 PM 27814833 ER PT J AU Mazzola, P Rea, F Merlino, L Bellelli, G Dubner, L Corrao, G Pasinetti, GM Annoni, G AF Mazzola, Paolo Rea, Federico Merlino, Luca Bellelli, Giuseppe Dubner, Lauren Corrao, Giovanni Pasinetti, Giulio M. Annoni, Giorgio TI Hip Fracture Surgery and Survival in Centenarians SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Centenarians; Hip fracture; Hip fracture surgery; Orthogeriatric; Survival ID EXCESS MORTALITY; AGE; OLDER; MANAGEMENT; WOMEN; RISK; HOME AB Background: Hip fracture (HF) is increasingly frequent with advancing age. Studies describing the HF incidence rate and survival after surgery in centenarians are scanty. To fill this gap, we performed a large population-based investigation on Lombardy centenarians (Italy). Methods: Retrospective observational cohort study based on information from the Healthcare Utilization Database. Among the cohort of 7,830 residents that reached 100 years of age between 2004 and 2011, incidence rate of HF was calculated. Two hundred fifty-nine patients were discharged alive from a hospital after HF and surgical repair (HF cohort). For each HF cohort member, a control was randomly selected from the initial cohort to be matched for gender and date of birth, and who did not experience HF from the date of their hundredth birthday until the date of hospital discharge of the corresponding HF cohort member. The survival curves and the hazard functions of HF and control cohort were calculated within 2 years. Results: Over a mean follow-up of 1.85 years, HF incidence rate was 23.1 per 1,000 centenarians per year. Survival probability was significantly lower in HF cohort than in control cohort (31.5 vs 48.1%, p < .001). Hazard functions showed an increased risk of death in HF cohort than in control cohort, especially in the 3 months after surgery. Conclusion: Survival analysis exhibited an excess mortality in the first 3 months among HF cohort members, but not beyond this period. Every effort to counteract HF is warranted, including prevention of falls and high quality of care, especially in the early postsurgical time. C1 [Mazzola, Paolo; Bellelli, Giuseppe; Annoni, Giorgio] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy. [Mazzola, Paolo; Bellelli, Giuseppe] San Gerardo Univ Hosp, Geriatr Clin, Monza, Italy. [Mazzola, Paolo; Bellelli, Giuseppe; Dubner, Lauren; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Mazzola, Paolo; Bellelli, Giuseppe; Annoni, Giorgio] NeuroMI Milan Ctr Neurosci, Clin Neurosci Res Area, Milan, Italy. [Rea, Federico; Corrao, Giovanni] Univ Milano Bicocca, Div Biostat Epidemiol & Publ Hlth, Dept Stat & Quantitat Methods, Milan, Italy. [Merlino, Luca] Operat Unit Terr Hlth Serv, Milan, Italy. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Mazzola, P (reprint author), Geriatr Unit, 7 C,Via Pergolesi 33, I-20900 Monza, MB, Italy. EM paolo.mazzola@unimib.it OI Bellelli, Giuseppe/0000-0001-5430-0947 FU Career Scientist Award in the Research and Development unit FX Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 27 TC 1 Z9 1 U1 4 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD NOV PY 2016 VL 71 IS 11 BP 1514 EP 1518 DI 10.1093/gerona/glw016 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC3AG UT WOS:000387995800018 PM 26883679 ER PT J AU Moriarty, H Winter, L True, G Robinson, K Short, TH AF Moriarty, Helene Winter, Laraine True, Gala Robinson, Keith Short, Thomas H. TI Depressive Symptomatology Mediates Associations With Community Reintegration in Veterans With TBI SO MILITARY PSYCHOLOGY LA English DT Article DE traumatic brain injury; veterans; community reintegration; depression; posttraumatic stress disorder ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; REHABILITATION OUTCOMES; TEMPORAL RELATIONSHIP; SOCIAL SUPPORT; INTEGRATION; MODERATORS; SYMPTOMS; IRAQ; WAR AB Community reintegration (CR) is a challenge for military veterans with traumatic brain injury (TBI). Posttraumatic stress disorder (PTSD), depression, bodily pain, and limitations in physical functioning-common comorbidities with TBI in veterans-have all been associated with problems in CR, but their interrelationships are unclear. The role of depression as a possible mediator of effects on CR has not been examined. We tested depressive symptoms as a possible mediator of CR's associations with physical limitations, PTSD, and bodily pain. This cross-sectional study used baseline data from a larger randomized controlled trial that evaluated the impact of an in-home intervention for veterans with TBI and their families. Eighty-three military veterans with TBI recruited from a medical rehabilitation service at an urban U.S. Department of Veterans Affairs medical center participated in the study. Interview instruments measured CR, depressive symptoms, physical limitations (limitations in physical functioning), bodily pain, quality of the relationship with key family members, and sociodemographic characteristics. PTSD was determined through review of the electronic medical record. Interview data were collected in veterans' homes. Depressive symptoms totally mediated the association between physical limitations and CR and the association between PTSD and CR. The bodily pain-CR association was not significant after quality of relationship had been entered into the regression models. Findings suggest that interventions to increase CR of veterans with TBI should address depression, a treatable condition. Replication of our mediation findings in larger veteran and civilian samples with TBI is needed. C1 [Moriarty, Helene] Villanova Univ, Coll Nursing, Driscoll Hall,800 Lancaster Ave, Villanova, PA 19085 USA. [Moriarty, Helene] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA. [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA. [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA. [True, Gala] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [True, Gala; Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Robinson, Keith] Corporal Michael J Crescenz VA Med Ctr, Rehabil Med Serv, Polytrauma Network Site Vet Integrated Serv Netwo, Philadelphia, PA USA. [Short, Thomas H.] John Carroll Univ, Dept Math & Comp Sci, University Hts, OH USA. RP Moriarty, H (reprint author), Villanova Univ, Coll Nursing, Driscoll Hall,800 Lancaster Ave, Villanova, PA 19085 USA. EM helene.moriarty@villanova.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [R21 HD068857-01] FX The project described was supported by Award R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. NR 74 TC 0 Z9 0 U1 5 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD NOV PY 2016 VL 28 IS 6 BP 376 EP 389 DI 10.1037/mil0000122 PG 14 WC Psychology, Multidisciplinary SC Psychology GA EC2PJ UT WOS:000387965500002 ER PT J AU Brown, W Grubaugh, AL Knapp, RG Acierno, RE AF Brown, Wilson Grubaugh, Anouk L. Knapp, Rebecca G. Acierno, Ronald E. TI Interplay Between Service Era, PTSD Symptom Expression, and Treatment Completion Among Veterans SO MILITARY PSYCHOLOGY LA English DT Article DE PTSD; service era; veterans; exposure therapy ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; PROLONGED EXPOSURE THERAPY; MENTAL-HEALTH; PROCESSING THERAPY; VIETNAM VETERANS; WAR VETERANS; AFGHANISTAN; IRAQ; PSYCHOTHERAPY AB The current veteran population has grown significantly as a result of 3 recent major conflicts: Vietnam, Persian Gulf War, and Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Despite a strong presence in VA PTSD specialty clinics nationwide, little is known about how these veteran cohort groups differ in PTSD symptom presentation. Additionally, it is unclear how variations in PTSD symptom presentation may in turn affect treatment adherence and completion. Understanding factors associated with treatment dropout from exposure-based therapy for PTSD is an important area of study, as individuals who drop out of treatment are likely to remain symptomatic and experience significant impairment across a number of psychosocial domains. The present study examined the relationship between service theater affiliation and pretreatment symptom expression as predictors of treatment completion in a sample of 164 veterans. Although treatment completion did not differ by service era, study data revealed statistically significant differences in initial PTSD symptom expression. Implications of the results and future directions are discussed. C1 [Brown, Wilson; Grubaugh, Anouk L.; Knapp, Rebecca G.; Acierno, Ronald E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Brown, Wilson] Summa St Thomas Hosp, Ctr Treatment & Study Traumat Stress, Akron, OH USA. [Grubaugh, Anouk L.; Acierno, Ronald E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brown, W (reprint author), St Thomas Hosp, Ctr Treatment & Study Traumat Stress, Summa Hlth Syst, 444 North Main St,Suite 426, Akron, OH 44310 USA. EM brownwj@summahealth.org FU Department of Defense (DoD) [W81XWH-08-2-0047] FX This study was supported by Department of Defense (DoD) grant W81XWH-08-2-0047 awarded to Ronald E. Acierno. NR 42 TC 0 Z9 0 U1 4 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD NOV PY 2016 VL 28 IS 6 BP 418 EP 428 DI 10.1037/mil0000133 PG 11 WC Psychology, Multidisciplinary SC Psychology GA EC2PJ UT WOS:000387965500005 ER PT J AU Berman, BD Smucny, J Wylie, KP Shelton, E Kronberg, E Leehey, M Tregellas, JR AF Berman, Brian D. Smucny, Jason Wylie, Korey P. Shelton, Erika Kronberg, Eugene Leehey, Maureen Tregellas, Jason R. TI Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson disease; resting-state fMRI; graph theory; levodopa ID RATING-SCALE; CONNECTIVITY; ORGANIZATION; EFFICIENCY; DISORDER AB BackgroundPD is associated with disrupted connectivity to a large number of distributed brain regions. How the disease alters the functional topological organization of the brain, however, remains poorly understood. Furthermore, how levodopa modulates network topology in PD is largely unknown. The objective of this study was to use resting-state functional MRI and graph theory to determine how small-world architecture is altered in PD and affected by levodopa administration. MethodsTwenty-one PD patients and 20 controls underwent functional MRI scanning. PD patients were scanned off medication and 1 hour after 200mg levodopa. Imaging data were analyzed using 226 nodes comprising 10 intrinsic brain networks. Correlation matrices were generated for each subject and converted into cost-thresholded, binarized adjacency matrices. Cost-integrated whole-brain global and local efficiencies were compared across groups and tested for relationships with disease duration and severity. ResultsData from 2 patients and 4 controls were excluded because of excess motion. Patients off medication showed no significant changes in global efficiency and overall local efficiency, but in a subnetwork analysis did show increased local efficiency in executive (P=0.006) and salience (P=0.018) networks. Levodopa significantly decreased local efficiency (P=0.039) in patients except within the subcortical network, in which it significantly increased local efficiency (P=0.007). ConclusionsLevodopa modulates global and local efficiency measures of small-world topology in PD, suggesting that degeneration of nigrostriatal neurons in PD may be associated with a large-scale network reorganization and that levodopa tends to normalize the disrupted network topology in PD. (c) 2016 International Parkinson and Movement Disorder Society C1 [Berman, Brian D.; Shelton, Erika; Leehey, Maureen] Univ Colorado Anschutz Med Campus, Dept Neurol, 12631 E 17th Ave,Mail Stop B-185, Aurora, CO 80045 USA. [Berman, Brian D.] Denver VA Med Ctr, Neurol Sect, Denver, CO USA. [Smucny, Jason; Wylie, Korey P.; Kronberg, Eugene; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Berman, BD (reprint author), Univ Colorado Anschutz Med Campus, Dept Neurol, 12631 E 17th Ave,Mail Stop B-185, Aurora, CO 80045 USA. EM brian.berman@ucdenver.edu FU NIH/NCATS Colorado CTSI grant [KL2 TR001080]; University of Colorado Department of Neurology; University of Colorado Center for NeuroScience FX This work was supported by NIH/NCATS Colorado CTSI grant number KL2 TR001080, the University of Colorado Department of Neurology, and the University of Colorado Center for NeuroScience. NR 47 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2016 VL 31 IS 11 BP 1676 EP 1684 DI 10.1002/mds.26713 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EB5LK UT WOS:000387415700015 PM 27461405 ER PT J AU Gan, JJ Lin, A Samimi, MS Mendez, MF AF Gan, Joanna J. Lin, Andrew Samimi, Mersal S. Mendez, Mario F. TI Somatic Symptom Disorder in Semantic Dementia: The Role of Alexisomia SO PSYCHOSOMATICS LA English DT Article DE semantic dementia; alexisomia; alexithymia; somatization; somatic symptom disorder ID PRIMARY PROGRESSIVE APHASIA; FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; FRONTOTEMPORAL DEMENTIA; DIAGNOSIS; KNOWLEDGE; ATROPHY AB Background: Semantic dementia (SD) is a neurodegenerative disorder characterized by loss of semantic knowledge. SD may be associated with somatic symptom disorder due to excessive preoccupation with unidentified somatic sensations. Objective: To evaluate the frequency of somatic symptom disorder among patients with SD in comparison to comparably demented patients with Alzheimer's disease. Methods: A retrospective cohort study was conducted using clinical data from a referral-based behavioral neurology program. Fifty-three patients with SD meeting criteria for imaging-supported semantic variant primary progressive aphasia (another term for SD) were compared with 125 patients with clinically probable Alzheimer disease. Logistic regression controlled for sex, age, disease duration, education, overall cognitive impairment, and depression. Results: The prevalence of somatic symptom disorder was significantly higher among patients with SD (41.5%) compared to patients with Alzheimer disease (11.2%) (odds ratio = 6:1; p < 0.001). Somatic symptom disorder was associated with misidentification and preoccupation with normal bodily sensations such as hunger, bladder filling, borborygmi, rhinorrhea, and reflux; excessive concern over the incompletely understood meaning or source of pain or other symptoms; and Cotard syndrome or the delusion that unidentified somatic symptoms signify death or deterioration. Conclusions: SD, a disorder of semantic knowledge, is associated with somatic symptom disorder from impaired identification of somatic sensations. Their inability to read and name somatic sensations, or "alexisomia," results in disproportionate and persistent concern about somatic sensations with consequent significant disability. C1 [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU U.S. National Institutes of Health, United States, National Institute on Aging, United States [R01AG050967, R01 AG034499] FX This work was supported by the U.S. National Institutes of Health, United States, National Institute on Aging, United States (Grants R01AG050967 and R01 AG034499). NR 25 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2016 VL 57 IS 6 BP 598 EP 604 PG 7 WC Psychiatry; Psychology SC Psychiatry; Psychology GA EC3YY UT WOS:000388064200006 PM 27647568 ER PT J AU Fullard, JF Halene, TB Giambartolomei, C Haroutunian, V Akbarian, S Roussos, P AF Fullard, John F. Halene, Tobias B. Giambartolomei, Claudia Haroutunian, Vahram Akbarian, Schahram Roussos, Panos TI Understanding the genetic liability to schizophrenia through the neuroepigenome SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Postmortem; Brain; Gene expression; Chromatin; Epigenetics ID DNA-METHYLATION CHANGES; DORSOLATERAL PREFRONTAL CORTEX; CHROMATIN STATE DYNAMICS; HUMAN BRAIN-TISSUE; HUMAN CELL-TYPES; BIPOLAR DISORDER; CHIP-SEQ; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; REGULATORY ELEMENTS AB The Psychiatric Genomics Consortium-Schizophrenia Workgroup (PGC-SCZ) recently identified 108 loci associated with increased risk for schizophrenia (SCZ). The vast majority of these variants reside within non-coding sequences of the genome and are predicted to exert their effects by affecting the mechanism of action of cis regulatory elements (CREs), such as promoters and enhancers. Although a number of large-scale collaborative efforts (e.g. ENCODE) have achieved a comprehensive mapping of CREs in human cell lines or tissue homogenates, it is becoming increasingly evident that many risk-associated variants are enriched for expression Quantitative Trait Loci (eQTLs) and CREs in specific tissues or cells. As such, data derived from previous research endeavors may not capture fully cell-type and/or region specific changes associated with brain diseases. Coupling recent technological advances in genomics with cell-type specific methodologies, we are presented with an unprecedented opportunity to better understand the genetics of normal brain development and function and, in turn, the molecular basis of neuropsychiatric disorders. In this review, we will outline ongoing efforts towards this goal and will discuss approaches with the potential to shed light on the mechanism(s) of action of cell-type specific cis regulatory elements and their putative roles in disease, with particular emphasis on understanding the manner in which the epigenome and CREs influence the etiology of SCZ. Published by Elsevier B.V. C1 [Fullard, John F.; Halene, Tobias B.; Giambartolomei, Claudia; Haroutunian, Vahram; Akbarian, Schahram; Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY 10029 USA. [Haroutunian, Vahram; Akbarian, Schahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Halene, Tobias B.; Haroutunian, Vahram; Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. RP Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Dept Genet & Genom Sci, One Gustave L Levy Pl, New York, NY 10029 USA.; Roussos, P (reprint author), Inst Multiscale Biol, One Gustave L Levy Pl, New York, NY 10029 USA. EM Panagiotis.roussos@mssm.edu FU Office of Academic Affiliations; Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; National Institutes of Health [R01AG050986]; Brain Behavior Research Foundation [20540]; Alzheimer's Association [NIRG-340998]; Veterans Affairs (Merit grant) [BX002395] FX Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (Halene), the National Institutes of Health (R01AG050986 Roussos), Brain Behavior Research Foundation (20540 Roussos), Alzheimer's Association (NIRG-340998 Roussos) and the Veterans Affairs (Merit grant BX002395 Roussos). NR 150 TC 3 Z9 3 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2016 VL 177 IS 1-3 BP 115 EP 124 DI 10.1016/j.schres.2016.01.039 PG 10 WC Psychiatry SC Psychiatry GA EC2OR UT WOS:000387963200016 PM 26827128 ER PT J AU Bauman, WA La Fountaine, MF Cirnigliaro, CM Kirshblum, SC Spungen, AM AF Bauman, W. A. La Fountaine, M. F. Cirnigliaro, C. M. Kirshblum, S. C. Spungen, A. M. TI Provocative stimulation of the hypothalamic-pituitary-testicular axis in men with spinal cord injury SO SPINAL CORD LA English DT Article ID TESTOSTERONE REPLACEMENT THERAPY; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; BODY-COMPOSITION; HEALTH; PAIN; INDIVIDUALS; PREVALENCE; MORTALITY; MALES AB Study design: Prospective study. Objective: To determine the integrity of the hypothalamic-pituitary-testicular axis in healthy men with spinal cord injury (SCI). Methods: Thirty healthy men with chronic SCI (37 +/- 10 years) and thirty-eight able-bodied (AB) controls (36 +/- 10 years) participated. Gonadotropin-releasing hormone (GnRH; 100 mu g IV) was administered to determine gonadotropin release, and human chorionic gonadotropin (hCG; 4000 IU IM) was administered to determine testosterone (T) secretion. Responses to stimulation were categorized as 'responder' or 'non-responder' by clinical criteria. Single factor ANOVA with repeated measures was performed to identify group differences. Results: The proportion of responders to pituitary GnRH stimulation was similar in the SCI group (22 subjects (73%) for the follicular-stimulating hormone (FSH) and 23 subjects (76%) for the luteinizing hormone (LH) to that of the AB group. The SCI-responder group had an increased FSH response after stimulation compared with the AB-responder group (P<0.05). The SCI-responder group had a greater LH area under the curve to GnRH stimulation than the AB-responder group (P=0.06). The peak FSH response was at 60 min and the peak LH response at 30min, regardless of group designation. All groups had similar increases in serum T concentration to hCG stimulation. Conclusions: The pituitary response to stimulation in healthy men with SCI revealed an augmented FSH response; LH response only trended higher. The testicular response to provocative stimulation was similar in hypogonadal and eugondal subjects and in GnRH responders and non-responders. These findings suggest a lack of hypothalamic drive of pituitary gonadotropin release in healthy people with chronic SCI. C1 [Bauman, W. A.; La Fountaine, M. F.; Cirnigliaro, C. M.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs, Rehabil Res & Dev Serv, Bronx, NY USA. [Bauman, W. A.; La Fountaine, M. F.; Spungen, A. M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, W. A.; Spungen, A. M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [La Fountaine, M. F.] Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. [Kirshblum, S. C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, S. C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. RP Bauman, WA (reprint author), James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, 130 West Kingsbridge Rd,Room 7A-13, Bronx, NY 10468 USA. EM william.bauman@va.gov FU James J Peters VA Medical Center, Bronx, NY; Department of Veterans Affairs Rehabilitation Research and Development Service; Kessler Institute for Rehabilitation, West Orange, NJ; Veteran Affairs Rehabilitation Research and Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B2648-C, B4162-C, B9212-C] FX We thank the James J Peters VA Medical Center, Bronx, NY, the Department of Veterans Affairs Rehabilitation Research and Development Service and the Kessler Institute for Rehabilitation, West Orange, NJ, for their support. This work was funded by the Veteran Affairs Rehabilitation Research and Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B2648-C, #B4162-C and #B9212-C). NR 35 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD NOV PY 2016 VL 54 IS 11 BP 961 EP 966 DI 10.1038/sc.2016.50 PG 6 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EC2OO UT WOS:000387962900009 PM 27112842 ER PT J AU Davis, TD Campbell, DG Bonner, LM Bolkan, CR Lanto, A Chaney, EF Waltz, T Zivin, K Yano, EM Rubenstein, LV AF Davis, Teri D. Campbell, Duncan G. Bonner, Laura M. Bolkan, Cory R. Lanto, Andrew Chaney, Edmund F. Waltz, Thomas Zivin, Kara Yano, Elizabeth M. Rubenstein, Lisa V. TI Women Veterans with Depression in Veterans Health Administration Primary Care: An Assessment of Needs and Preferences SO WOMENS HEALTH ISSUES LA English DT Article ID QUALITY IMPROVEMENT PROGRAMS; RANDOMIZED CONTROLLED-TRIAL; AFFAIRS PRIMARY-CARE; COLLABORATIVE CARE; GENDER-DIFFERENCES; AFGHANISTAN VETERANS; CLINICAL-PRACTICE; WAR VETERANS; PTSD; DIAGNOSES AB Objective: Depression is the most prevalent mental health condition in primary care (PC). Yet as the Veterans Health Administration increases resources for PC/mental health integration, including integrated care for women, there is little detailed information about depression care needs, preferences, comorbidity, and access patterns among women veterans with depression followed in PC. Methods: We sampled patients regularly engaged with Veterans Health Administration PC. We screened 10,929 (10,580 men, 349 women) with the two-item Patient Health Questionnaire. Of the 2,186 patients who screened positive (2,092 men, 94 women), 2,017 men and 93 women completed the full Patient Health Questionnaire-9 depression screening tool. Ultimately, 46 women and 715 men with probable major depression were enrolled and completed a baseline telephone survey. We conducted descriptive statistics to provide information about the depression care experiences of women veterans and to examine potential gender differences at baseline and at seven month follow-up across study variables. Results: Among those patients who agreed to screening, 20% of women (70 of 348) had probable major depression, versus only 12% of men (1,243 of 10,505). Of the women, 48% had concurrent probable posttraumatic stress disorder and 65% reported general anxiety. Women were more likely to receive adequate depression care than men (57% vs. 39%, respectively; p <.05); 46% of women and 39% of men reported depression symptom improvement at the 7-monthfollow-up. Women veterans were less likely than men to prefer care from a PC physician ( p < .01) at baseline and were more likely than men to report mental health specialist care ( p < .01) in the 6 months before baseline. Conclusion and Implications for Practice: PC/mental health integration planners should consider methods for accommodating women veterans unique care needs and preferences for mental health care delivered by health care professionals other than physicians. C1 [Davis, Teri D.; Lanto, Andrew; Yano, Elizabeth M.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Davis, Teri D.] Univ Calif Los Angeles, Sch Med, Div Psychiat & Behav Sci, Semel Inst, Los Angeles, CA USA. [Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Bonner, Laura M.] VA Puget Sound Healthcare Syst, VA HSR&D Northwest Ctr Outcomes Res Older Adults, Seattle, WA USA. [Bonner, Laura M.] GRECC, Seattle, WA USA. [Bonner, Laura M.; Chaney, Edmund F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bolkan, Cory R.] Washington State Univ, Dept Human Dev, Vancouver, WA USA. [Waltz, Thomas] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA. [Waltz, Thomas] VA Ann Arbor Hlth Care Syst, Ctr Clin Management Res, Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. [Zivin, Kara] VA Ann Arbor Med Ctr, CCMR, Ann Arbor, MI USA. [Zivin, Kara] Univ Michigan, Dept Psychiat, Sch Med, Ann Arbor, MI 48109 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Corp, RAND Hlth Program, Santa Monica, CA USA. RP Davis, TD (reprint author), VA Greater Los Angeles Healthcare Syst, West Los Angeles VAMC, 11301 Wilshire Blvd 111G,Bldg 500,Room 3233, Los Angeles, CA 90073 USA. EM davis127@yahoo.com FU Department of Veterans Affairs (VA) Health Services Research and Development Service (HSRD); VA Quality Enhancement Research Initiative (QUERI) [MHI 99-375, MNT 01-027, MHQ 10-06, RRP 12-175] FX This project was funded by the Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) and the VA Quality Enhancement Research Initiative (QUERI) (Project nos. MHI 99-375, MNT 01-027, MHQ 10-06, RRP 12-175). The views expressed here are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs, the United States Government, and the authors' other institutions. NR 58 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2016 VL 26 IS 6 BP 656 EP 666 DI 10.1016/j.whi.2016.08.001 PG 11 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA EC3OU UT WOS:000388036300011 PM 27697494 ER PT J AU Schapira, MM Aggarwal, C Akers, S Aysola, J Imbert, D Langer, C Simone, CB Strittmatter, E Vachani, A Fraenkel, L AF Schapira, Marilyn M. Aggarwal, Charu Akers, Scott Aysola, Jaya Imbert, Diana Langer, Corey Simone, Charlie B., II Strittmatter, Emily Vachani, Anil Fraenkel, Liana TI How Patients View Lung Cancer Screening The Role of Uncertainty in Medical Decision Making SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Radiographic lung cancer screening guidelines and coverage requirements warrant a shared decision-making process. Guidance is needed regarding how to conduct shared decision making effectively. A useful organizing theme should include consideration of a patient's response to and tolerance of uncertainty associated with lung cancer screening. Objectives: The objectives of this study are to: (1) describe how patients respond to specific categories of uncertainty in the context of lung cancer screening, and (2) inform strategies for addressing concerns about uncertainty as part of the shared decision making. Methods: We performed two series of structured interviews on participants in a convenience sample of current or former cigarette smokers recruited from primary care and pulmonary practices in Philadelphia. An interview guide included prompts related to benefits, harms, and responses to general and specific types of uncertainty (stochastic, statistical, and evidentiary) associated with lung cancer screening. Interviews were audio-recorded, transcribed, and independently coded by two investigators. An inductive analysis was conducted, and major themes were identified. Measurements and Main Results: Twenty-two adults participated in the study. Sixty-eight percent were men, 72% were black or African American, and 50% met U.S. Preventive Services Task Force criteria for lung cancer screening. The primary themes to emerge from our study were: (1) the desire to decrease uncertainty may motivate lung cancer screening decisions; (2) uncertainty is an attribute of health states that impacts how patients weigh benefits and harms of lung cancer screening; (3) patient understanding and tolerance of uncertainty varies across stochastic, statistical, and evidentiary uncertainty; and (4) provider-patient communication may mitigate intolerance of uncertainty in the context of lung cancer screening. Conclusions: A systematic approach to understanding and addressing patients' concerns about uncertainty in the context of lung cancer screening can guide a patient-centered approach to shared decision making. The results of this study can inform provider-patient communication strategies regarding the decision to perform radiographic lung cancer screening. C1 [Schapira, Marilyn M.; Aysola, Jaya; Imbert, Diana; Strittmatter, Emily] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Aggarwal, Charu; Langer, Corey] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA. [Vachani, Anil] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Dept Med, Philadelphia, PA 19104 USA. [Akers, Scott] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104 USA. [Simone, Charlie B., II] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Akers, Scott; Vachani, Anil] Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA. [Fraenkel, Liana] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Fraenkel, Liana] Yale Univ, Dept Med, New Haven, CT 06520 USA. RP Schapira, MM (reprint author), Univ Penn, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU National Institutes of Health [P30 CA016520]; Department of Veterans Affairs Health Services Research and Development Service Program [HX001334-01A1] FX Supported by National Institutes of Health grant P30 CA016520 and the Department of Veterans Affairs Health Services Research and Development Service Program grant HX001334-01A1. NR 0 TC 3 Z9 3 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1969 EP 1976 DI 10.1513/AnnalsATS.201604-290OC PG 8 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900018 PM 27676595 ER PT J AU Kanodra, NM Pope, C Halbert, CH Silvestri, GA Rice, LJ Tanner, NT AF Kanodra, Neeti M. Pope, Charlene Halbert, Chanita H. Silvestri, Gerard A. Rice, LaShanta J. Tanner, Nichole T. TI Primary Care Provider and Patient Perspectives on Lung Cancer Screening A Qualitative Study SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: The U.S. Preventive Services Task Force recommends annual low-dose computed tomography (LDCT) for lung cancer screening in high-risk individuals. Preventive healthcare is provided predominantly by primary care providers (PCPs). Successful implementation of a screening program requires acceptance and participation by both providers and patients, with available collaboration with pulmonologists. Objectives: To identify perceptions of and perspectives on lung cancer screening and implementation among PCPs and eligible veteran patients at high risk for lung cancer. Methods: We conducted a qualitative study using grounded theory in which 28 veterans and 13 PCPs completed a questionnaire and participated in focus groups. Sessions were recorded, transcribed verbatim, and analyzed with NVivo 10 software. Counts and percentages were used to report questionnaire results. Measurements and Main Results: While 58% percent of providers were aware of lung cancer screening guidelines, many could not recall the exact patient eligibility criteria. Most patients were willing to undergo LDCT screening and identified smoking as a risk factor for lung cancer, but they did not recall their PCP explaining the reason for the testing. All providers assessed smoking behavior, but only 23% referred active smokers for formal cessation services. Patients volunteered information regarding their hurdles with smoking cessation while discussing risk factors for cancer. PCPs cited time constraints as a reason for lack of appropriate counseling and shared decision making. Both parties were willing to explore modalities and decision aid tools to improve shared decision making; however, while patients were interested in individual risk prediction, few PCPs believed statistical approaches to counseling would confuse patients. Conclusions: While patients and providers are receptive to LDCT screening, efforts are needed to improve guideline knowledge and adherence among providers. System-level interventions are necessary to facilitate time and resources for shared decision making and smoking cessation counseling and treatment. Further research is needed to identify optimal strategies for effective lung cancer screening in the community. C1 [Kanodra, Neeti M.; Silvestri, Gerard A.; Tanner, Nichole T.] Med Univ South Carolina, Dept Med, Div Pulm Crit Care & Sleep Med, 96 Jonathan Lucas St,CSB 816, Charleston, SC 29425 USA. [Pope, Charlene] Med Univ South Carolina, Coll Nursing, Charleston, SC 29425 USA. [Halbert, Chanita H.; Rice, LaShanta J.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Hollings Canc Ctr, Charleston, SC 29425 USA. [Pope, Charlene; Halbert, Chanita H.; Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, HEROIC, Charleston, SC USA. RP Tanner, NT (reprint author), Med Univ South Carolina, Dept Med, Div Pulm Crit Care & Sleep Med, 96 Jonathan Lucas St,CSB 816, Charleston, SC 29425 USA. EM tripici@musc.edu FU Veterans Affairs (VA) Health Equity and Rural Outreach Innovation Center (HEROIC) at the Ralph H. Johnson VA Medical Center, Charleston, SC FX Supported by the Veterans Affairs (VA) Health Equity and Rural Outreach Innovation Center (HEROIC) at the Ralph H. Johnson VA Medical Center, Charleston, SC. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1977 EP 1982 DI 10.1513/AnnalsATS.201604-286OC PG 6 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900019 PM 27676369 ER PT J AU Slatore, CG Wiener, RS Golden, SE Au, DH Ganzini, L AF Slatore, Christopher G. Wiener, Renda Soylemez Golden, Sara E. Au, David H. Ganzini, Linda TI Longitudinal Assessment of Distress among Veterans with Incidental Pulmonary Nodules SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Millions of patients are diagnosed with pulmonary nodules every year. Increased distress may be a common harm, but methods of mitigating this distress are unclear. Objectives: We aimed to determine whether high-quality communication regarding the discovery of a pulmonary nodule is associated with a lower level of patient distress. Methods: We conducted a prospective, repeated-measures cohort study of 121 patients with newly reported, incidentally detected pulmonary nodules. The primary exposure was participant-reported quality of communication regarding the nodule. Secondary exposures included communication measures regarding participants' values, preferences, and decision making. The main outcome was nodule-related distress measured using the Impact of Event Scale. We used adjusted generalized estimating equations to measure the association between nodule communication quality and at least mild distress. Measurements and Main Results: Most participants (57%) reported at least mild distress at least once. While average distress scores decreased over time, one-fourth still had elevated distress after 2 years of surveillance for a nodule. The average calculated risk of cancer at baseline was 10% (SD, 13%), but 52.4% believed they had a greater than 30% risk of lung cancer at baseline, and this percentage remained fairly constant at all visits. High-quality nodule communication was associated with decreased odds of distress (adjusted odds ratio, 0.42; 95% confidence interval, 0.24-0.73). Lower-quality communication processes regarding participants' values and preferences were also associated with increased odds of distress, but concordance between the actual and preferred decision-making roles was not. Conclusions: Among patients with incidentally discovered pulmonary nodules, distress is common and persistent for about 25%. Many participants substantially overestimate their risk of lung cancer. Incorporating patients' values and preferences into communication about a pulmonary nodule and its evaluation may mitigate distress. C1 [Slatore, Christopher G.; Golden, Sara E.; Ganzini, Linda] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Slatore, Christopher G.] VA Portland Hlth Care Syst, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Dept Med, Portland, OR 97201 USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. RP Slatore, CG (reprint author), Portland VA Med Ctr, Hlth Serv Res & Dev, 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU VA Health Services Research & Development career development award [CDA 09-025, CDP 11-227]; VA Portland Health Care System, Portland, Oregon; VA Puget Sound Healthcare System, Seattle, Washington; Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts FX This study was sponsored by a VA Health Services Research & Development career development award (CDA 09-025 and CDP 11-227) (C.G.S.). It was also supported by resources from the VA Portland Health Care System, Portland, Oregon; the VA Puget Sound Healthcare System, Seattle, Washington; and the Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts. The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1983 EP 1991 DI 10.1513/AnnalsATS.201607-555OC PG 9 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900020 PM 27599153 ER PT J AU Crothers, K Kross, EK Reisch, LM Shahrir, S Slatore, C Zeliadt, SB Triplette, M Meza, R Elmore, JG AF Crothers, Kristina Kross, Erin K. Reisch, Lisa M. Shahrir, Shahida Slatore, Christopher Zeliadt, Steven B. Triplette, Matthew Meza, Rafael Elmore, Joann G. TI Patients' Attitudes Regarding Lung Cancer Screening and Decision Aids A Survey and Focus Group Study SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Little is known about vulnerable patients' perceptions and understanding of, and preferences for, lung cancer screening decision aids. Objectives: To determine, in a low-income, racially diverse population, (1) participants' experience, preferences, and reactions to web-based and paper decision aids, and (2) their understanding of harms and benefits of lung cancer screening. Methods: We enrolled outpatients at an urban county hospital in six focus group discussions that included review of a web-based and a paper-based lung-cancer screening decision aid. Participants completed surveys before and after the focus groups. Measurements and Main Results: Forty-five patients participated (mean age, 61 yr; 76% current smokers; 24% former smokers); 27% had not completed high school; 50% had an annual income not exceeding $ 15,000; 42% were nonwhite; and 96% reported chronic illness requiring at least three health care visits yearly. Comparing the proportion with correct answers on pre- and postsurveys, participants' understanding of lung cancer screening increased, particularly of the harms of screening including the potential for false positives, extra testing, and complications. However, after conclusion of the focus groups, more than 50% believed that screening lowered the chance of getting lung cancer. Five major themes emerged from qualitative analyses. Participants (1) were not aware of the purpose of lung cancer screening; (2) wanted to know about the benefits and harms; (3) believed physicians need to communicate more effectively; (4) found decision aids helpful and influential for decision-making about screening; and (5) wanted the discussion to be personalized and tailored. Participants expressed surprise that the magnitude of their lung cancer risk and benefits of screening were lower than anticipated. Conclusions: Vulnerable patients find lung cancer screening decision aids helpful and generally show increased knowledge after reviewing decision aids, particularly of harms. Our results can inform future implementation efforts. C1 [Crothers, Kristina; Kross, Erin K.; Reisch, Lisa M.; Shahrir, Shahida; Triplette, Matthew; Elmore, Joann G.] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. [Slatore, Christopher] Vet Affairs Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Slatore, Christopher] Vet Affairs Portland Hlth Care Syst, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Zeliadt, Steven B.] Vet Affairs Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Zeliadt, Steven B.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Meza, Rafael] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359765, Seattle, WA 98104 USA. EM crothk@uw.edu OI Slatore, Christopher/0000-0003-0958-8122; Crothers, Kristina/0000-0001-9702-0371; Meza, Rafael/0000-0002-1076-5037 FU Lung Cancer Discovery Grant from the American Lung Association [K05 CA104699]; VA Portland Health Care System FX Supported by a Lung Cancer Discovery Grant from the American Lung Association (K.C.), K05 CA104699 (J.G.E.), and by resources from the VA Portland Health Care System (C.S.). The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1992 EP 2001 DI 10.1513/AnnalsATS.201604-289OC PG 10 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900021 PM 27652509 ER PT J AU Sibila, O Mateus, EF Restrepo, MI Chalmers, JD Vidal, S AF Sibila, Oriol Mateus, Eder F. Restrepo, Marcos I. Chalmers, James D. Vidal, Silvia TI Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization Reply SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Letter C1 [Sibila, Oriol; Mateus, Eder F.; Vidal, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Sibila, Oriol; Mateus, Eder F.; Vidal, Silvia] Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chalmers, James D.] Univ Dundee, Dundee, Scotland. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Barcelona, Spain.; Sibila, O (reprint author), Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 PG 2 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900039 ER PT J AU Williams, NR Short, EB Hopkins, T Bentzle, BS Sahlem, GL Pannu, J Schmidt, M Borckardt, JJ Korte, JE George, MS Takacs, I Nahas, Z AF Williams, Nolan R. Short, E. Baron Hopkins, Thomas Bentzle, Brandon S. Sahlem, Greg L. Pannu, Jaspreet Schmidt, Matt Borckardt, Jeff J. Korte, Jeffrey E. George, Mark S. Takacs, Istvan Nahas, Ziad TI Five Year Follow-Up of Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression SO BRAIN STIMULATION LA English DT Article DE Deep brain stimulation; Treatment-resistant depression; Epidural cortical stimulation; Brain stimulation; Interventional psychiatry ID DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX STIMULATION; MAJOR DEPRESSION; RATING-SCALE; INTERVENTIONAL PSYCHIATRY; FUNCTIONAL CONNECTIVITY; NEUROPATHIC PAIN; CONTROLLED-TRIAL; THERAPY AB Background: Epidural prefrontal cortical stimulation (EpCS) represents a novel therapeutic approach with many unique benefits that can be used for treatment-resistant depression (TRD). Objective: To examine the long-term safety and efficacy of EpCS of the frontopolar cortex (FPC) and dorsolateral prefrontal cortex (DLPFC) for treatment of TRD. Methods: Adults (N = 5) who were 21-80 years old with severe TRD [failure to respond to adequate courses of at least 4 antidepressant medications, psychotherapy and >= 20 on the Hamilton Rating Scale for Depression (HRSD24)] were recruited. Participants were implanted with bilateral EpCS over the FPC and DLPFC and received constant, chronic stimulation throughout the five years with Medtronic IPGs. They were followed for 5 years (2/1/2008-10/14/2013). Efficacy of EpCS was assessed with the HRSD24 in an open-label design as the primary outcome measure at five years. Results: All 5 patients continued to tolerate the therapy. The mean improvements from pre-implant baseline on the HRSD24 were [7 months] 54.9% (+/- 37.7), [1 year] 41.2% (+/- 36.6), [2 years] 53.8% (+/- 21.7), and [5 years] 45% (+/- 47). Three of 5 (60%) subjects continued to be in remission at 5 years. There were 5 serious adverse events: 1 electrode 'paddle' infection and 4 device malfunctions, all resulting in suicidal ideation and/or hospitalization. Conclusion: These results suggest that chronic bilateral EpCS over the FPC and DLPFC is a promising and potentially durable new technology for treating TRD, both acutely and over 5 years. (C) 2016 Elsevier Inc. All rights reserved. C1 [Williams, Nolan R.; Bentzle, Brandon S.; Pannu, Jaspreet] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Short, E. Baron; Hopkins, Thomas; Sahlem, Greg L.; Schmidt, Matt; Borckardt, Jeff J.; George, Mark S.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Korte, Jeffrey E.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [George, Mark S.; Takacs, Istvan] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Nahas, Ziad] Amer Univ, Beirut Med Ctr, Beirut, Lebanon. RP Williams, NR (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. EM nolanw@stanford.edu OI Williams, Nolan/0000-0003-4368-3203; Bentzley, Brandon/0000-0001-6014-4514 FU NIH [F30 DA035065, T32 GM008716, R25 DA020537]; National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award FX Medtronic, Inc. (Minneapolis, MN) donated the devices but was otherwise not involved in the study, particularly data acquisition, analysis, or drafting the article. Ziad Nahas, MD, declares no conflict of interest in relation to the work described and was funded by a National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award. Brandon Bentzley, MD, PhD, declares no conflict of interest in relation to the work described and was supported by NIH grants F30 DA035065 and T32 GM008716. Nolan Williams, MD, and Thomas Hopkins, BA, declare no conflict of interest in relation to the work described and were supported by NIH grant R25 DA020537. No other contributors declare a conflict of interest in relation to the work described. NR 72 TC 1 Z9 1 U1 10 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV-DEC PY 2016 VL 9 IS 6 BP 897 EP 904 DI 10.1016/j.brs.2016.06.054 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB2MW UT WOS:000387197500013 PM 27443912 ER PT J AU Badran, BW Glusman, CE Austelle, CW Jenkins, S DeVries, WH Galbraith, V Thomas, T Adams, TG George, MS Revuelta, GJ AF Badran, Bashar W. Glusman, Chloe E. Austelle, Chris W. Jenkins, Shonna DeVries, William H. Galbraith, Virginia Thomas, Tiffani Adams, Thomas G., Jr. George, Mark S. Revuelta, Gonzalo J. TI A Double-Blind, Sham-Controlled Pilot Trial of Pre-Supplementary Motor Area (Pre-SMA) 1 Hz rTMS to Treat Essential Tremor SO BRAIN STIMULATION LA English DT Letter ID TRANSCRANIAL MAGNETIC STIMULATION; CORTEX C1 [Badran, Bashar W.; Glusman, Chloe E.; Austelle, Chris W.; DeVries, William H.; Galbraith, Virginia; George, Mark S.] Med Univ South Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Jenkins, Shonna; George, Mark S.; Revuelta, Gonzalo J.] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA. [Thomas, Tiffani; Revuelta, Gonzalo J.] Med Univ South Carolina, Coll Med, Charleston, SC USA. [Adams, Thomas G., Jr.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Adams, Thomas G., Jr.] VA Natl Ctr PTSD, Clin Neurosci Div, Washington, DC USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Badran, BW (reprint author), MUSC Inst Psychiat, 67 President St,504N, Charleston, SC 29425 USA. EM basharwbadran@gmail.com NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV-DEC PY 2016 VL 9 IS 6 BP 945 EP 947 DI 10.1016/j.brs.2016.08.003 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB2MW UT WOS:000387197500020 PM 27567469 ER PT J AU Palevsky, PM Zhang, JH Seliger, SL Emanuele, N Fried, LF AF Palevsky, Paul M. Zhang, Jane H. Seliger, Stephen L. Emanuele, Nicholas Fried, Linda F. CA VA NEPHRON-D Study TI Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CONVERTING ENZYME-INHIBITOR; GLOMERULAR-FILTRATION-RATE; DOUBLE-BLIND CROSSOVER; ACUTE KIDNEY INJURY; DIABETIC-NEPHROPATHY; RECEPTOR BLOCKER; CONTROLLED-TRIAL; RENAL-DISEASE; METAANALYSIS; TELMISARTAN AB Background and objectives The benefit of dual blockade of the renin-angiotensin system is limited by adverse effects. We performed a secondary analysis of the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) Study to describe the effect of increased intensity Of renin-angiotensin system blockade on the incidence, risk factors, and outcomes of AKI. Design, setting, participants, & measurements In the VA NEPHRON-D Study, we randomized 1148 veterans receiving outpatient care with type 2 diabetes mellitus, eGFR of between 30 and 89.9 ml/min per 1.73 m(2), and urinary albumin excretion of at least 300 mu g/mg creatinine (or a urinary total protein of at least 0.5 mg/mg creatinine) to either combination therapy with losartan and lisinopril or monotherapy with losartan. We identified hospitalized AKI events and their outcomes during a median follow-up of 2.2 years through systematic reporting of serious adverse events. Results The incidence of AKI was 12.2 (95% confidence interval, 10.5 to 14.0) versus 6.7 (95% confidence interval, 5.6 to 8.2) per 100 patient-years in the combination arm versus monotherapy arms (P<0.001). Individuals with AKI were more likely to develop the primary study end point of death, ESRD, or decline in kidney function (hazard ratio; 1.78; 95% confidence interval, 1.34 to 2.26; P<0.001). Patients with AKI in the combination arm had greater recovery of kidney function (75.9% versus 66.3%; P=0.04), lower 30-day mortality (4.7% versus 15.0%; P<0.01), and lower hazard for development of the primary study end point (hazard ratio, 0.60; 95% confidence interval, 0.37 to 0.98). Conclusions Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease. C1 [Palevsky, Paul M.; Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA USA. [Palevsky, Paul M.; Fried, Linda F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Zhang, Jane H.] Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Seliger, Stephen L.] Vet Affairs Maryland Healthcare Syst, Med Serv, Baltimore, MD USA. [Seliger, Stephen L.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Emanuele, Nicholas] Edward Hines Jr Vet Affairs Hosp, Med Serv, Hines, IL USA. [Emanuele, Nicholas] Loyola Univ, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Room 7E123,111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM Palevsky@pitt.edu FU Department of Veterans Affairs (VA) Office of Research and Development FX This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs (VA) Office of Research and Development. The Investigator Initiated Studies Program of Merck GmbH donated the study medications losartan and lisinopril/placebo for the study. NR 29 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2016 VL 11 IS 11 BP 1944 EP 1953 DI 10.2215/CJN.03470316 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA EA8DA UT WOS:000386864300007 PM 27679519 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; WARFARIN; APIXABAN; EFFICACY; STROKE; RIVAROXABAN; OUTCOMES; RISK; METAANALYSIS AB Warfarin has had a thin margin of benefit over risk for the prevention of stroke and systemic embolism in patients with ESRD because of higher bleeding risks and complications of therapy. The successful use of warfarin has been dependent on the selection of patients with nonvalvular atrial fibrillation at relatively high risk of stroke and systemic embolism and lower risks of bleeding over the course of therapy. Without such selection strategies, broad use of warfarin has not proven to be beneficial to the broad population of patients with ESRD and nonvalvular atrial fibrillation. In a recent meta-analysis of use of warfarin in patients with nonvalvular atrial fibrillation and ESRD, warfarin had no effect on the risks of stroke (hazard ratio, 1.12; 95% confidence interval, 0.69 to 1.82; P=0.65) or mortality (hazard ratio, 0.96; 95% confidence interval, 0.81 to 1.13; P=0.60) but was associated with increased risk of major bleeding (hazard ratio, 1.30; 95% confidence interval, 1.08 to 1.56; P<0.01). In pivotal trials, novel oral anticoagulants were generally at least equal to warfarin for efficacy and safety in nonvalvular atrial fibrillation and mild to moderate renal impairment. Clinical data for ESRD are limited, because pivotal trials excluded such patients. Given the very high risk of stroke and systemic embolism and the early evidence of acceptable safety profiles of novel oral anticoagulants, we think that patients with ESRD should be considered for treatment with chronic anticoagulation provided that there is an acceptable bleeding profile. Apixaban is currently indicated in ESRD for this application and may be preferable to warfarin given the body of evidence for warfarin and its difficulty of use and attendant adverse events. C1 [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst & Renal El, Renal Sect, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Div, Renal Sect 111F U, Pittsburgh, PA 15240 USA. EM palevsky@cjasn.org FU Baylor Healthcare System Foundation FX This paper was supported, in part, by the Baylor Healthcare System Foundation. NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2016 VL 11 IS 11 BP 2078 EP 2084 DI 10.2215/CJN.09700916 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA EA8DA UT WOS:000386864300025 PM 27821638 ER PT J AU Naples, JG Gellad, WF Hanlon, JT AF Naples, Jennifer Greene Gellad, Walid F. Hanlon, Joseph T. TI The Role of Opioid Analgesics in Geriatric Pain Management SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Opioid; Aged; Pharmacokinetics; Adverse drug event ID NURSING-HOME RESIDENTS; CHRONIC NONCANCER PAIN; OLDER-ADULTS; RISK; MEDICATIONS; AGE; PEOPLE; PHARMACOKINETICS; FRACTURES; OSTEOARTHRITIS AB When possible, chronic noncancer pain (CNCP) in older adults should be managed by nonpharmacologic modalities in conjunction with nonopioid analgesics. If moderate-to-severe pain persists despite these approaches, however, nonparenteral opioids may be considered as adjunctive therapy. This article reviews the epidemiology of opioid use and their effectiveness for CNCP in older adults and summarizes important age-related changes in opioid pharmacokinetics and pharmacodynamics that increase the risks of adverse effects in the elderly. Finally, to assist clinicians with selecting appropriate therapy, the article concludes with an evidence-based approach to optimize opioid prescribing in older adults with CNCP. C1 [Naples, Jennifer Greene] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Med, Univ Dr,151C, Pittsburgh, PA 15240 USA. [Hanlon, Joseph T.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU National Institute on Aging [T32AG021885, P30AG024827, R01AG037451]; Donoghue Foundation; Agency for Healthcare Research and Quality [R18 HS023779]; VA Health Services Research and Development (HSR&D) Service Merit awards [IIR 12-379, 1 I01 HX001765]; VA HSRD award [I01 HX001765] FX Dr J.G. Naples's fellowship is supported by a National Institute on Aging grant (T32AG021885). Dr J.T. Hanlon is supported by National Institute of Aging grants (P30AG024827 and R01AG037451), a grant from the Donoghue Foundation, a grant from the Agency for Healthcare Research and Quality (R18 HS023779), and VA Health Services Research and Development (HSR&D) Service Merit awards (IIR 12-379 and 1 I01 HX001765). Dr W.F. Gellad is supported by VA HSR&D award I01 HX001765. NR 50 TC 0 Z9 0 U1 9 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2016 VL 32 IS 4 BP 725 EP + DI 10.1016/j.cger.2016.06.006 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA EB2OT UT WOS:000387202400008 PM 27741966 ER PT J AU Forster, SE Finn, PR Brown, JW AF Forster, Sarah E. Finn, Peter R. Brown, Joshua W. TI A preliminary study of longitudinal neuroadaptation associated with recovery from addiction SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE fMRI; Treatment outcome; Decision-making; Balloon analogue risk task; Anterior cingulate cortex; Ventromedial prefrontal cortex; Monetary reward ID MEDIAL PREFRONTAL CORTEX; RISK-TASK BART; METHAMPHETAMINE-DEPENDENT INDIVIDUALS; SUBSTANCE USE DISORDERS; COCAINE DEPENDENCE; COGNITIVE CONTROL; TEST-RETEST; FOLLOW-UP; ABSTINENT ALCOHOLICS; NEURAL ACTIVATION AB Background: Few studies have explored longitudinal change in event-related brain responses during early recovery from addiction. Moreover, existing findings yield evidence of both increased and decreased signaling within reward and control centers over time. The current study explored reward- and control related signals in a risky decision-making task and specifically investigated parametric modulations of the BOLD signal, rather than signal magnitude alone. It was hypothesized that risk-related signals during decision-making and outcome evaluation would reflect recovery and that change in specific signals would correspond with improved treatment outcomes. Methods: Twenty-one substance dependent individuals were recruited upon enrollment in community based substance use treatment programs, wherein they received treatment-as-usual. Participants completed functional neuroimaging assessments at baseline and 3-month follow-up while performing the Balloon Analogue Risk Task (BART). Risk- and reward-sensitive signals were identified using parametric modulators. Substance use was tracked throughout the 3-month study interval using the timeline follow-back procedure. Results: Longitudinal contrasts of parametric modulators suggested improved formation of risk-informed outcome expectations at follow-up. Specifically, a greater response to high risk (low-likelihood) positive feedback was identified in caudal anterior cingulate cortex (ACC) and a greater response to low risk (low-likelihood) negative feedback was identified in caudal ACC and inferior frontal gyrus. In addition, attenuation of a ventromedial prefrontal cortex (vmPFC) "reward-seeking" signal (i.e., increasing response with greater reward) during risky decisions at follow-up was associated with less substance use during the study interval. Conclusions: Changes in risk- and reward-related signaling in ACC/vmPFC appear to reflect recovery and may support sobriety. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Forster, Sarah E.; Finn, Peter R.; Brown, Joshua W.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA. [Forster, Sarah E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Forster, Sarah E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. RP Brown, JW (reprint author), Indiana Univ, 1101 E 10th St, Bloomington, IN 47405 USA. EM jwmbrown@indiana.edu FU NIH [DA026457, AA13650]; [TL1 RR025759] FX This research was supported by NIH R01 grant DA026457 to JWB and NIH R01 grant AA13650 to PRF. SEF was partly supported by TL1 RR025759 (A. Shekhar, PI) during early stages of the project. The authors would also like to thank William Hetrick, PhD and Brian O'Donnell, PhD for helpful comments on the dissertation of which this work was a part. NR 45 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2016 VL 168 BP 52 EP 60 DI 10.1016/j.drugalcdep.2016.08.626 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EB6VN UT WOS:000387523800008 PM 27620345 ER PT J AU McGinnis, KA Tate, JP Williams, EC Skanderson, M Bryant, KJ Gordon, AJ Kraemer, KL Maisto, SA Crystal, S Fiellin, DA Justice, AC AF McGinnis, Kathleen A. Tate, Janet P. Williams, Emily C. Skanderson, Melissa Bryant, Kendall J. Gordon, Adam J. Kraemer, Kevin L. Maisto, Stephen A. Crystal, Steven Fiellin, David A. Justice, Amy C. TI Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol consumption; Population-based screening; AUDIT-C; Electronic health record; Veterans; HIV ID RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE; PRIMARY-CARE; HEAVY DRINKING; BRIEF INTERVENTION; UNHEALTHY ALCOHOL; SCREENING-TEST; DRUG-USE; VETERANS; QUALITY AB Background: Using electronic medical record (EMR) data for clinical decisions, quality improvement, and research is common. While unhealthy alcohol use is particularly risky among HIV infected individuals (HIV+), the validity of EMR data for identifying unhealthy alcohol use among HIV+ is unclear. Among HIV+ and uninfected, we: (1) assess agreement of EMR and research AUDIT-C at validated cutoffs for unhealthy alcohol use; (2) explore EMR cutoffs that maximize agreement; and (3) assess subpopulation variation in agreement. Methods: Using data from the Veterans Aging Cohort Study (VACS), EMR AUDIT-C cutoffs of 2+, 3+, and 4+ for men (2+ and 3+ for women) were compared to research AUDIT-C 4+ for men (3+ for women). Agreement was compared by demographics, HIV, hepatitis C infection, and alcohol related diagnosis. Results: Among 1082 HIV+ and 1160 uninfected men, 14% and 22% had an EMR and research AUDIT-C 4+, respectively. Among 32 HIV+ and 115 uninfected women, 9% and 14% had an EMR and research AUDIT-C 3+. For men, EMR agreement with the research AUDIT-C 4+ was highest at a cutoff of 3+ (kappa = 0.49). For women, EMR agreement with AUDIT-C 3+ was highest at a cutoff of 2+ (kappa =0.46). Moderate agreement was consistent across subgroups. Conclusions: EMR AUDIT-C underestimates unhealthy alcohol use compared to research AUDIT-C in both HIV+ and uninfected individuals. Methods for improving quality of clinical screening may be in need of investigation. Researchers and clinicians may consider alternative EMR cutoffs that maximize agreement given limitations of clinical screening. Published by Elsevier Ireland Ltd. C1 [McGinnis, Kathleen A.; Tate, Janet P.; Skanderson, Melissa; Fiellin, David A.; Justice, Amy C.] VA CT Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. [Tate, Janet P.; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. [Williams, Emily C.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Williams, Emily C.] VA Hlth Serv Res & Dev, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Seattle, WA USA. [Bryant, Kendall J.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Gordon, Adam J.; Kraemer, Kevin L.] Natl Inst Alcohol Abuse & Alcoholism, Bethesda, MD USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Maisto, Stephen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Crystal, Steven] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Fiellin, David A.; Justice, Amy C.] Rutgers State Univ, Hlth Serv Res, New Brunswick, NJ USA. RP McGinnis, KA (reprint author), VA CT Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. EM kathleen.mcginnis3@va.gov OI Fiellin, David/0000-0002-4006-010X FU National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism [U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U10 AA013566]; Career Development Award from VA Health Services Research Development [CDA 12-276] FX The views are not those of the Department of Veterans Affairs or the United States Government. COMpAAAS/Veterans Aging Cohort Study, a CHAART Cooperative Agreement, is supported by the National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799; U10 AA013566-completed) and in kind by the US Department of Veterans Affairs. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). NR 39 TC 0 Z9 0 U1 10 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2016 VL 168 BP 196 EP 202 DI 10.1016/j.drugalcdep.2016.09.015 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EB6VN UT WOS:000387523800028 PM 27694059 ER PT J AU de Vries, YA Roest, AM Beijers, L Turner, EH de Jonge, P AF de Vries, Ymkje Anna Roest, Annelieke M. Beijers, Lian Turner, Erick H. de Jonge, Peter TI Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Bias; Antidepressants; Depression; Anxiety; Harms ID RANDOMIZED CONTROLLED-TRIAL; CONTROLLED-RELEASE FLUVOXAMINE; DOUBLE-BLIND; PANIC DISORDER; MAJOR DEPRESSION; SERTRALINE TREATMENT; EXTENDED-RELEASE; RESULTS DATABASE; VENLAFAXINE ER; PLACEBO AB Previous research has shown that reporting bias has inflated the apparent efficacy of antidepressants. We investigated whether apparent safety was also affected. We included 133 trials, involving 31,296 patients, of second-generation antidepressants for the treatment of major depressive disorder (MDD) or anxiety disorders, obtained from Food and Drug Administration (FDA) reviews. We extracted data on overall discontinuation, discontinuation due to adverse events, and serious adverse events (SAEs). Meta-analysis was used to compare discontinuation rates between FDA reviews and matching journal articles, while SAEs were compared qualitatively. The odds ratio for overall discontinuation, comparing drug to placebo, was 1.0 for both sources, while that for discontinuation due to adverse events was 2.4 for both sources. Seventy-seven of 97 (79%) journal articles provided incomplete information on SAEs; sixty-one (63%) articles made no mention of SAEs at all. Of 21 articles which could be compared to the FDA, only 6 (29%) had full reporting without discrepancies. Nine (43%) articles reported a discrepant number of SAEs. Descriptions were absent or discrepant in 6 (29%) additional articles, even for important SAEs such as suicide attempts. In conclusion, reporting bias has not affected average discontinuation rates over trials. However, SAE reporting is not only very poor, with over half of articles failing to discuss SAEs altogether, but discrepancies between the FDA and articles were common and often led to a more favorable drug-placebo comparison.These findings suggest that journal articles are an unreliable source of data on SAEs in antidepressant trials. (C) 2016 Elsevier B.V. and ECNP. All rights reserved. C1 [de Vries, Ymkje Anna; Roest, Annelieke M.; Beijers, Lian; de Jonge, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands. [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [de Jonge, Peter] Univ Groningen, Dept Psychol, Dev Psychol, Groningen, Netherlands. RP de Vries, YA (reprint author), Univ Med Ctr Groningen, Dept Psychiat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM y.a.de.vries@umcg.nl NR 50 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X EI 1873-7862 J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD NOV PY 2016 VL 26 IS 11 BP 1752 EP 1759 DI 10.1016/j.euroneuro.2016.09.370 PG 8 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA EB6VL UT WOS:000387523600003 PM 27659240 ER PT J AU Ruggiero, NA Chang, M Brown, S AF Ruggiero, Nicole A. Chang, Mei Brown, Sheldon TI Pseudomonas mendocina Bacteremia, A Case Study and Review of Literature SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Review DE Pseudomonas mendocina; bacteremia; cellulitis ID INFECTIVE ENDOCARDITIS; PATIENT AB Infections with Pseudomonas mendocina have rarely been reported. P. mendocina seems to be a less virulent and less resistant organism compared to P. aeruginosa. We present a case of P. mendocina bacteremia likely secondary to cellulitis and a brief review of P. mendocina infections reported in the literature. C1 [Ruggiero, Nicole A.; Chang, Mei] James J Peters VA Med Ctr, Dept Pharm, Bronx, NY USA. [Brown, Sheldon] James J Peters VA Med Ctr, Dept Infect Dis, Bronx, NY USA. RP Ruggiero, NA (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA. EM nicole.ruggiero@va.gov NR 9 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1056-9103 EI 1536-9943 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD NOV PY 2016 VL 24 IS 6 BP 314 EP 317 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EB6CJ UT WOS:000387468200023 ER PT J AU Rosenfeld, EA Marx, J Terry, MA Stall, R Flatt, J Borrero, S Miller, E AF Rosenfeld, E. A. Marx, J. Terry, M. A. Stall, R. Flatt, J. Borrero, S. Miller, E. TI Perspectives on expedited partner therapy for chlamydia: a survey of health care providers SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Expedited partner therapy; providers; survey; sexually transmitted infection; treatment ID SEXUALLY-TRANSMITTED INFECTIONS; VIOLENCE; NOTIFICATION; KNOWLEDGE; ATTITUDES; ADOLESCENTS; PHYSICIANS; TRIAL AB There is a lack of research on health care providers' use of and perspectives on expedited partner therapy in a state where expedited partner therapy is not prohibited or explicitly allowed. The aim of our study was to understand if and how health care providers use expedited partner therapy, if specific demographic factors and knowledge contribute to increased use of expedited partner therapy, and to describe barriers and facilitators to the use of expedited partner therapy in Pittsburgh, Pennsylvania. A convenience sample of 112 health care providers from diverse disciplines who treat young women at risk for chlamydia completed an online survey. About 11% of health care providers used expedited partner therapy consistently. Those who self-reported that they were knowledgeable about expedited partner therapy were more likely to use expedited partner therapy (73% vs. 49%, p=.009) as were those who said no or were unsure about their institution's guidelines for expedited partner therapy (35% vs. 22%, p=0.01) (62% vs. 57%, p=0.01). The most commonly reported facilitator of expedited partner therapy was having clear legal guidelines (86%). This study finds that in a setting where expedited partner therapy is not expressly permitted, health care providers still use the practice but also experience barriers that limit uptake. Legislation expressly endorsing expedited partner therapy in the state and in medical institutions is needed to increase expedited partner therapy use. C1 [Rosenfeld, E. A.] VA Pittsburgh Healthcare Syst, VA Womens Hlth, Pittsburgh, PA USA. [Marx, J.; Terry, M. A.; Stall, R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Flatt, J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Borrero, S.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Miller, E.] Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, Div Adolescent Med, Pittsburgh, PA USA. RP Rosenfeld, EA (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C 151C Bldg 30, Pittsburgh, PA 15240 USA. EM Elian.rosenfeld@va.gov NR 29 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2016 VL 27 IS 13 BP 1180 EP 1186 DI 10.1177/0956462415610689 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA9XX UT WOS:000386999100005 PM 26446138 ER PT J AU Gaither, JR Goulet, JL Becker, WC Crystal, S Edelman, EJ Gordon, K Kerns, RD Rimland, D Skanderson, M Justice, AC Fiellin, DA AF Gaither, Julie R. Goulet, Joseph L. Becker, William C. Crystal, Stephen Edelman, E. Jennifer Gordon, Kirsha Kerns, Robert D. Rimland, David Skanderson, Melissa Justice, Amy C. Fiellin, David A. TI The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE mortality; opioid analgesics; practice guideline; quality of health care; substance use disorders ID CHRONIC NONCANCER PAIN; VETERANS AGING COHORT; OF-HEALTH PATHWAYS; PRESCRIPTION OPIOIDS; CLINICAL GUIDELINES; ANTIRETROVIRAL THERAPY; PREVENTION WORKSHOP; UNINFECTED VETERANS; UNITED-STATES; MENTAL-HEALTH AB Objective:Patients with substance use disorders (SUDs) prescribed long-term opioid therapy (LtOT) are at risk for overdose and mortality. Prior research has shown that receipt of LtOT in accordance with clinical practice guidelines has the potential to mitigate these outcomes. Our objective was to determine whether the presence of a SUD modifies the association between guideline-concordant care and 1-year all-cause mortality among patients receiving LtOT for pain.Methods:Among HIV+ and HIV- patients initiating LtOT (90 days opioids) between 2000 and 2010 as part of the Veterans Aging Cohort Study, we used time-updated Cox regression and propensity-score matching to examinestratified by SUD statusthe association between 1-year all-cause mortality and 3 quality indicators derived from national opioid-prescribing guidelines. Specifically, we examined whether patients received psychotherapeutic cointerventions (2 outpatient mental health visits), benzodiazepine coprescriptions (7 days), and SUD treatment (1 inpatient day or outpatient visit). These indicators were among those found in a previous study to have a strong association with mortality.Results:Among 17,044 patients initiating LtOT, there were 1048 (6.1%) deaths during 1 year of follow-up. Receipt of psychotherapeutic cointerventions was associated with lower mortality in the overall sample and was more protective in patients with SUDs (adjusted hazard ratio [AHR] 0.43, 95% confidence interval [CI] 0.33-0.56 vs AHR 0.65, 95% CI 0.53-0.81; P for interaction=0.002). Benzodiazepine coprescribing was associated with higher mortality in the overall sample (AHR 1.41, 95% CI 1.22-1.63), but we found no interaction by SUD status (P for interaction=0.11). Among patients with SUDs, receipt of SUD treatment was associated with lower mortality (AHR 0.43, 95% CI 0.33-0.57).Conclusions:For clinicians prescribing LtOT to patients with untreated SUDs, engaging patients with psychotherapeutic and SUD treatment services may reduce mortality. Clinicians should also avoid, when possible, prescribing opioids with benzodiazepines. C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, New Haven, CT USA. [Gaither, Julie R.; Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Gaither, Julie R.; Justice, Amy C.] Yale Univ, Yale Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gaither, Julie R.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Yale Sch Med, Dept Psychiat, New Haven, CT USA. [Becker, William C.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gaither, JR (reprint author), 950 Campbell Ave, West Haven, CT 06516 USA. EM julie.gaither@yale.edu OI Goulet, Joseph/0000-0002-0842-804X FU National Institute on Drug Abuse [F31DA035567, K12DA033312]; National Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790, U24AA020794]; National Institute of Mental Health [P30MH062294]; Agency for Healthcare Research and Quality [U19HS21112]; VA Health Services Research and Development Center of Innovation [CIN13047] FX Research reported in this paper was supported by grants from the National Institute on Drug Abuse (grant nos. F31DA035567, K12DA033312), National Institute on Alcohol Abuse and Alcoholism (grant nos. U10AA013566, U01AA020790, U24AA020794), National Institute of Mental Health (grant no. P30MH062294), the Agency for Healthcare Research and Quality (grant no. U19HS21112), and the VA Health Services Research and Development Center of Innovation (grant no. CIN13047). NR 72 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2016 VL 10 IS 6 BP 418 EP 428 DI 10.1097/ADM.0000000000000255 PG 11 WC Substance Abuse SC Substance Abuse GA EB3PB UT WOS:000387276500008 PM 27610580 ER PT J AU Reger, GM Koenen-Woods, P Zetocha, K Smolenski, DJ Holloway, KM Rothbaum, BO Difede, J Rizzo, AA Edwards-Stewart, A Skopp, NA Mishkind, M Reger, MA Gahm, GA AF Reger, Greg M. Koenen-Woods, Patricia Zetocha, Kimberlee Smolenski, Derek J. Holloway, Kevin M. Rothbaum, Barbara O. Difede, JoAnn Rizzo, Albert A. Edwards-Stewart, Amanda Skopp, Nancy A. Mishkind, Matthew Reger, Mark A. Gahm, Gregory A. TI Randomized Controlled Trial of Prolonged Exposure Using Imaginal Exposure vs. Virtual Reality Exposure in Active Duty Soldiers With Deployment-Related Posttraumatic Stress Disorder (PTSD) SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE exposure therapy; virtual reality; military; posttraumatic stress disorder; Army ID MENTAL-HEALTH PROBLEMS; COGNITIVE-PROCESSING THERAPY; PSYCHOMETRIC PROPERTIES; RAPE VICTIMS; PSYCHOLOGICAL HELP; BEHAVIORAL THERAPY; ANXIETY DISORDERS; CLINICAL-TRIALS; D-CYCLOSERINE; VETERANS AB Objective: Prolonged exposure (PE) is an evidence-based psychotherapy for posttraumatic stress disorder (PTSD) but there is limited research with active-duty military populations. Virtual reality exposure (VRE) has shown promise but randomized trials are needed to evaluate efficacy relative to existing standards of care. This study evaluated the efficacy of VRE and PE for active duty soldiers with PTSD from deployments to Iraq and Afghanistan. Method: Active-duty soldiers (N = 162) were randomized to 10-sessions of PE, VRE, or a minimal attention waitlist (WL). Blinded assessors evaluated symptoms at baseline, halfway through treatment, at posttreatment, and at 3- and 6-month follow-ups using the Clinician Administered PTSD Scale (CAPS). Results: Intent-to-treat analyses found that both PE and VRE resulted in significant reductions in PTSD symptoms relative to those in the WL. The majority of patients demonstrated reliable change in PTSD symptoms. There was no difference between PE and VRE regarding treatment drop out before completing 10 sessions (44 and 41% for VRE and PE, respectively). Contrary to hypotheses, analyses at posttreatment did not show that VRE was superior to PE. Post hoc analyses found that PE resulted in significantly greater symptom reductions than VRE at 3- and 6-month follow-up. Both treatments significantly reduced self-reported stigma. Conclusions: PE is an efficacious treatment for active-duty Army soldiers with PTSD from deployments to Iraq or Afghanistan. Results extend previous evidence supporting the efficacy of PE to active-duty military personnel and raise important questions for future research on VRE. What is the public health significance of this article? Results provide convergent evidence suggesting that exposure therapy is an effective treatment for active duty U.S. Army soldiers with posttraumatic stress disorder from deployments to Iraq and Afghanistan. C1 [Reger, Greg M.; Koenen-Woods, Patricia; Zetocha, Kimberlee; Smolenski, Derek J.; Holloway, Kevin M.; Edwards-Stewart, Amanda; Skopp, Nancy A.; Mishkind, Matthew; Reger, Mark A.; Gahm, Gregory A.] Natl Ctr Telehlth & Technol, Tacoma, WA USA. [Reger, Greg M.] VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. [Reger, Greg M.; Reger, Mark A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Holloway, Kevin M.] Ctr Deployment Psychol, Bethesda, MD USA. [Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. [Difede, JoAnn] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Rizzo, Albert A.] Univ So Calif, Inst Creat Technol, Los Angeles, CA USA. [Mishkind, Matthew] Univ Colorado, Arthur E Johnson Depress Ctr, Sch Med, Anschutz Med Campus, Boulder, CO 80309 USA. RP Reger, GM (reprint author), VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. EM greg.reger@va.gov FU Genentech; U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program [W81XWH-08-2-0015] FX Dr. Barbara Rothbaum owns equity in Virtually Better, Inc., which is developing products related to virtual reality, and Dr. Rothbaum is a consultant for Virtually Better, Inc. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. However, the virtual reality used in this study was created by Dr. Skip Rizzo and the ICT lab at USC, not Virtually Better, Inc. Dr. Rothbaum receives royalties from Oxford University Press, Guilford, APPI, and Emory University and received one advisory board payment from Genentech.; This research was supported by Grant W81XWH-08-2-0015 from the U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program. Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Army, the Department of Defense, or the Department of Veterans Affairs. The authors would like to acknowledge Emily Fantelli, Amber Shaw, Lauren Bartlett, and Elizabeth Bullock for extensive assistance coordinating this study. We would also like to thank Russell McCann, Erin O'brien, Erika Ast, and Charnette Munroe for their efforts treating and assessing soldiers. We also thank Colette Candy, Jay Earles, Vicki Ingram, and the providers at the two respective Departments of Psychology for their support. Finally, we are grateful to Frank Andrasik and the late Andrew Leon for their consultation. NR 76 TC 0 Z9 0 U1 26 U2 26 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD NOV PY 2016 VL 84 IS 11 BP 946 EP 959 DI 10.1037/ccp0000134 PG 14 WC Psychology, Clinical SC Psychology GA EA8YS UT WOS:000386926800003 PM 27606699 ER PT J AU Cubo-Romano, P Torres-Macho, J Soni, NJ Reyes, LF Rodriguez-Almodovar, A Fernandez-Alonso, JM Gonzalez-Davia, R Casas-Rojo, JM Restrepo, MI de Casasola, GG AF Cubo-Romano, Pilar Torres-Macho, Juan Soni, Nilam J. Reyes, Luis F. Rodriguez-Almodovar, Ana Manuel Fernandez-Alonso, Juan Gonzalez-Davia, Rosa Manuel Casas-Rojo, Jose Restrepo, Marcos I. Garcia de Casasola, Gonzalo TI Admission inferior vena cava measurements are associated with mortality after hospitalization for acute decompensated heart failure SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HAND-CARRIED ULTRASOUND; RIGHT ATRIAL PRESSURE; NATRIURETIC PEPTIDE LEVELS; NATIONAL REGISTRY ADHERE; EUROPEAN-SOCIETY; PROGNOSTIC-SIGNIFICANCE; MEDICARE BENEFICIARIES; DIAGNOSTIC-ACCURACY; AMERICAN-SOCIETY; RE-ADMISSION AB BACKGROUNDPrognostication of patients hospitalized with acute decompensated heart failure (ADHF) is important to patients, providers, and healthcare systems. Few bedside tools exist to prognosticate patients hospitalized with ADHF. OBJECTIVEThe objective of this study was to assess the relationship between inferior vena cava (IVC) diameter and postdischarge mortality in patients hospitalized with ADHF. DESIGNProspective observational study. SETTINGA 247-bed urban teaching hospital in Spain PATIENTSNinety-seven patients hospitalized with ADHF. INTERVENTIONNone. MEASUREMENTSThe IVC diameter and collapsibility were measured by a hospitalist at the time of admission and discharge. Primary outcome was 90-day all-cause mortality. Secondary outcomes were readmission rates at 90 and 180 days, and 180-day all-cause mortality. Patients were followed for 180 days. RESULTSData from 80 patients were analyzed. From admission to discharge, a significant improvement in IVC maximum (IVCmax) diameter (2.12 vs 1.87 cm; P < 0.001) and IVC collapsibility (25.7% vs 33.1%; P < 0.001) was seen in the total study cohort. During the 90-day follow-up period, 11 patients (13.7%) died. An admission IVCmax diameter 1.9 cm was associated with a higher mortality rate at 90 days (25.4% vs 3.4%; P = 0.009) and 180 days (29.3% vs 3.4%; P = .003). In a multivariate Cox proportional hazards regression analysis, admission IVCmax diameter was an independent predictor of 90-day mortality (hazard ratio [HR]: 5.88; 95% confidence interval [CI]: 1.21-28.10; P = 0.025) and 90-day readmission (HR: 3.20; 95% CI: 1.24-8.21; P = 0.016). CONCLUSIONIn patients hospitalized with acute decompensated heart failure, a dilated IVC by bedside ultrasound at the time of admission is associated with a higher 90-day mortality after hospitalization. Journal of Hospital Medicine 2016;11:778-784. (c) 2016 Society of Hospital Medicine C1 [Cubo-Romano, Pilar; Torres-Macho, Juan; Manuel Casas-Rojo, Jose; Garcia de Casasola, Gonzalo] Infanta Cristina Univ Hosp, Dept Internal Med & Emergency Med, Madrid, Spain. [Cubo-Romano, Pilar; Torres-Macho, Juan; Rodriguez-Almodovar, Ana; Gonzalez-Davia, Rosa; Manuel Casas-Rojo, Jose; Garcia de Casasola, Gonzalo] Univ Complutense, Dept Med, Madrid, Spain. [Soni, Nilam J.; Reyes, Luis F.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Sect Pulm & Crit Care Med, San Antonio, TX USA. [Soni, Nilam J.; Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soni, Nilam J.] Univ Texas Sch Med San Antonio, Div Hosp Med, San Antonio, TX USA. [Rodriguez-Almodovar, Ana; Gonzalez-Davia, Rosa] Infanta Cristina Univ Hosp, Dept Cardiol, Madrid, Spain. [Manuel Fernandez-Alonso, Juan] Infanta Cristina Univ Hosp, Dept Biochem, Madrid, Spain. RP Soni, NJ (reprint author), 7703 Floyd Curl Dr,MC 7982, San Antonio, TX 78229 USA. EM sonin@uthscsa.edu FU Madrid-Castilla la Mancha Society of Internal Medicine; National Heart, Lung, and Blood Institute [K23HL096054] FX This study was supported by a grant from the Madrid-Castilla la Mancha Society of Internal Medicine. Dr. Restrepo is partially supported by award number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The authors report no conflicts of interest. NR 42 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD NOV PY 2016 VL 11 IS 11 BP 778 EP 784 DI 10.1002/jhm.2620 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EB0ZH UT WOS:000387075100007 PM 27264844 ER PT J AU Melton, DW Roberts, AC Wang, HZ Sarwar, Z Wetzel, MD Wells, JT Porter, L Berton, MT McManus, LM Shireman, PK AF Melton, David W. Roberts, Alexander C. Wang, Hanzhou Sarwar, Zaheer Wetzel, Michael D. Wells, Jason T. Porter, Laurel Berton, Michael T. McManus, Linda M. Shireman, Paula K. TI Absence of CCR2 results in an inflammaging environment in young mice with age-independent impairments in muscle regeneration SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE sarcopenia; monocytes/macrophages; TLRs; myogenic progenitor cells ID SKELETAL-MUSCLE; SATELLITE CELLS; STEM-CELLS; FIBRO/ADIPOGENIC PROGENITORS; ALTERED INFLAMMATION; SIGNALING PATHWAY; INJURY; RECEPTOR; CHEMOKINES; MONOCYTES AB Skeletal muscle regeneration requires coordination between dynamic cellular populations and tissue microenvironments. Macrophages, recruited via CCR2, are essential for regeneration; however, the contribution of macrophages and the role of CCR2 on nonhematopoietic cells has not been defined. In addition, aging and sex interactions in regeneration and sarcopenia are unclear. Muscle regeneration was measured in young (3-6 mo), middle (11-15 mo), old (24-32 mo) male and female CCR2(-/-) mice. Whereas age-related muscle atrophy/sarcopenia was present, regenerated myofiber cross-sectional area (CSA) in CCR2(-/-) mice was comparably impaired across all ages and sexes, with increased adipocyte area compared with wild-type (WT) mice. CCR2(-/-) mice myofibers achieved approximately one third of baseline CSA even 84 d after injury. Regenerated CSA and clearance of necrotic tissue were dependent on bone marrow-derived cellular expression of CCR2. Myogenic progenitor cells isolated from WT and CCR2(-/-) mice exhibited comparable proliferation and differentiation capacity. The most striking cellular anomaly in injured muscle of CCR2(-/-) mice was markedly decreased macrophages, with a predominance of Ly6C2 anti-inflammatory monocytes/macrophages. Ablation of proinflammatory TLR signaling did not affect muscle regeneration or resolution of necrosis. Of interest, many proinflammatory, proangiogenic, and chemotactic cytokines were markedly elevated in injured muscle of CCR2(-/-) relative to WT mice despite impairments in macrophage recruitment. Collectively, these results suggest that CCR2 on bone marrow-derived cells, likely macrophages, were essential to muscle regeneration independent of TLR signaling, aging, and sex. Decreased proinflammatory monocytes/macrophages actually promoted a proinflammatory microenvironment, which suggests that inflammaging was present in young CCR2(-/-) mice. C1 [Melton, David W.; Roberts, Alexander C.; Sarwar, Zaheer; Wetzel, Michael D.; Wells, Jason T.; Porter, Laurel; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Wang, Hanzhou] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Berton, Michael T.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Melton, David W.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Melton, David W.; Roberts, Alexander C.; Wang, Hanzhou; Sarwar, Zaheer; Wetzel, Michael D.; Wells, Jason T.; Porter, Laurel; Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wetzel, Michael D.] Shriners Hosp Children, Houston, TX USA. [Wells, Jason T.] Lahey Hosp & Med Ctr, Burlington, MA USA. [Porter, Laurel] Bexar Cty Med Examiners Off, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc & Endovasc Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [HL074236, HL110743]; NIH National Institute of Allergy and Infectious Diseases [AI095951]; Nathan Shock Centers of Excellence in Basic Biology of Aging [AG013319]; Veterans Administration Merit Review [1I01BX001186]; NIH National Cancer Institute [UL1-TR001120] FX We thank Joel Michalek, Ph.D., and Ken Ouyang for expert assistance in performing statistical analyses for these studies. These studies were supported, in part, by grants from the U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (HL074236 and HL110743), NIH National Institute of Allergy and Infectious Diseases (AI095951), Nathan Shock Centers of Excellence in Basic Biology of Aging AG013319, and Veterans Administration Merit Review 1I01BX001186. Data was generated in the Flow Cytometry Shared Resource Facility, which is supported by the University of Texas Health Science Center at San Antonio (UTHSCSA), NIH National Cancer Institute P30-CA054174-20 (Cancer Therapy & Research Center at UTHSCSA) and UL1-TR001120 (Clinical and Translational Science Award). NR 78 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD NOV PY 2016 VL 100 IS 5 BP 1011 EP 1025 DI 10.1189/jlb.3MA0316-104R PG 15 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA DZ6YA UT WOS:000386007500020 PM 27531927 ER PT J AU O'Leary, T Muralidhar, S Przygodzki, R Gaziano, JM Concato, J AF O'Leary, T. Muralidhar, S. Przygodzki, R. Gaziano, J. M. Concato, J. TI The Department of Veterans Affairs Million Veteran Program: An Update SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [O'Leary, T.; Muralidhar, S.; Przygodzki, R.] US Dept Vet Affairs, Washington, DC USA. [Gaziano, J. M.] US Dept Vet Affairs, Boston, MA USA. [Concato, J.] US Dept Vet Affairs, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA G19 BP 941 EP 941 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000037 ER PT J AU Costa-Mallen, P Zabetian, CP Hu, SC Agarwal, P Yearout, D Checkoway, H AF Costa-Mallen, Paola Zabetian, Cyrus P. Hu, Shu-Ching Agarwal, Pinky Yearout, Dora Checkoway, Harvey TI Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE Tobacco smoking; Haptoglobin concentration; Ferritin concentration; Haptoglobin phenotype; Parkinson's disease ID HEMOGLOBIN-BINDING; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISEASES; CIGARETTE-SMOKING; IRON; ASSOCIATION; SMOKERS; SUSCEPTIBILITY; ECHOGENICITY; POLYMORPHISM AB The phenotype Hp 2-1 of haptoglobin has been previously associated with increased risk of Parkinson disease (PD) and with serum iron abnormalities in PD patients. Tobacco smoking has been consistently observed in epidemiology studies to be inversely related to PD risk, with mechanisms that remain uncertain. We recently observed that the protective effect of smoking on PD risk is stronger among subjects of haptoglobin Hp 2-2 and Hp 1-1 phenotypes, and weaker among subjects of haptoglobin Hp 2-1 phenotype. In this PD case-control study, we investigated whether tobacco smoking was associated with changes in serum haptoglobin and ferritin concentration that depended on haptoglobin phenotype among 106 PD patients and 238 controls without PD or other neurodegenerative disorders. Serum ferritin concentration, serum haptoglobin concentration, haptoglobin phenotype, and smoking data information of cases and controls were obtained. Differences in haptoglobin and ferritin concentration by smoking status and pack-years of smoking were calculated as well as regression between pack-years and haptoglobin and ferritin concentration, and the effect of haptoglobin phenotype on these parameters. Tobacco smoking was associated with an elevation in serum haptoglobin concentration, especially among healthy controls of haptoglobin Hp 2-2 phenotype, and with an elevation in ferritin concentration especially among PD patients of haptoglobin Hp 2-1 phenotype. These findings suggest that an elevation in haptoglobin concentration, preferentially among subjects of haptoglobin Hp 2-2 phenotype, could be a contributing factor to the protective effect of smoking on PD risk. C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA. [Zabetian, Cyrus P.; Yearout, Dora] Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Dept Neurol, 325 Ninth Ave,3EH70, Seattle, WA 98104 USA. [Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, 12040 NE 128th St,Mailstop 11, Kirkland, WA 98034 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Publ Hlth, 9500 Gilman Dr 0725, La Jolla, CA 92093 USA. RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA. EM pcostamallen@bastyr.edu FU NIH [R21 NS070202, P50 NS062684, R01 NS065070]; Department of Veteran Affairs [1I01BX000531]; Bastyr University [4 2009-2011] FX The authors would like to thank all the individual study participants. This study was funded by grants from NIH (Grants # R21 NS070202, P50 NS062684, R01 NS065070), the Department of Veteran Affairs (Grant # 1I01BX000531), and Bastyr University (Faculty Seed Grants # 3 and # 4 2009-2011). NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 EI 1435-1463 J9 J NEURAL TRANSM JI J. Neural Transm. PD NOV PY 2016 VL 123 IS 11 BP 1319 EP 1330 DI 10.1007/s00702-016-1590-x PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DZ7TD UT WOS:000386068700007 PM 27349967 ER PT J AU Catafau, AM Bullich, S Seibyl, JP Barthel, H Ghetti, B Leverenz, J Ironside, JW Schulz-Schaeffer, WJ Hoffmann, A Sabri, O AF Catafau, Ana M. Bullich, Santiago Seibyl, John P. Barthel, Henryk Ghetti, Bernardino Leverenz, James Ironside, James W. Schulz-Schaeffer, Walter J. Hoffmann, Anja Sabri, Osama TI Cerebellar Amyloid-beta Plaques: How Frequent Are They, and Do They Influence F-18-Florbetaben SUV Ratios? SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE Alzheimer disease; florbetaben; positron emission tomography ID PRESENILIN-1 MUTATION CARRIERS; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; REFERENCE REGION; SENILE PLAQUES; COMPOUND-B; PET SCANS; DEPOSITION; BRAIN; IMPACT AB SUV ratios (SUVRs) are used for relative quantification of F-18-florbetaben scans. The cerebellar cortex can be used as a reference region for quantification. However, cerebellar amyloid-beta (A beta) plaques may be present in Alzheimer disease (AD). The aim of this study was to assess the influence of A beta pathology, including neuritic plaques, diffuse plaques, and vascular deposits, in F-18-florbetaben SUVR when cerebellum is used as the reference. Methods: Using immunohistochemistry to demonstrate A beta plaques and vascular deposits, and using the Bielschowsky method to demonstrate neuritic plaques, we performed a neuropathologic assessment of the frontal, occipital, anterior cingulate, and posterior cingulate cerebral cortices and the cerebellar cortex of 87 end-of-life patients (64 with AD, 14 with other types of dementia, and 9 nondemented aged volunteers; mean age +/- SD, 80.4 +/- 10.2 y) who had undergone F-18-florbetaben PET before death. The lesions were rated as absent (none or sparse) or present (moderate or frequent). Mean cortical SUVRs were compared among cases with different cerebellar A beta loads. Results: None of the 83 evaluable cerebellar samples showed frequent diffuse A beta or neuritic plaques; 8 samples showed frequent vascular A beta deposits. Diffuse A beta plaques were rated as absent in 78 samples (94%) and present in 5 samples (6%). Vascular A beta was rated as absent in 62 samples (74.7%) and present in 21 samples (25.3%). No significant differences in cerebellar SUVs were found among cases with different amounts or types of A beta deposits in the cerebral cortex. Both diffuse and neuritic plaques were found in the cerebral cortex of 26-44 cases. No significant SUVR differences were found between these brains with different cerebellar A beta loads. Conclusion: The effect of cerebellar plaques on cortical F-18-florbetaben SUVRs appears to be negligible even in advanced stages of AD with a higher cerebellar A beta load. C1 [Catafau, Ana M.; Bullich, Santiago] Piramal Imaging GmbH, Tegelerstr 6-7, D-13353 Berlin, Germany. [Seibyl, John P.] Mol Neuroimaging, New Haven, CT USA. [Barthel, Henryk; Sabri, Osama] Univ Leipzig, Leipzig, Germany. [Ghetti, Bernardino] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Leverenz, James] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leverenz, James] Univ Washington, Seattle, WA 98195 USA. [Ironside, James W.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Schulz-Schaeffer, Walter J.] Georg August Univ Gottingen, Gottingen, Germany. [Hoffmann, Anja] Bayer Pharma AG, Berlin, Germany. RP Bullich, S (reprint author), Piramal Imaging GmbH, Tegelerstr 6-7, D-13353 Berlin, Germany. EM santi.bullich@piramal.com FU Bayer Pharma AG, Berlin (Germany); Piramal Imaging S.A., Matran (Switzerland) FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. The trial was funded by Bayer Pharma AG, Berlin (Germany), and Piramal Imaging S.A., Matran (Switzerland). No other potential conflict of interest relevant to this article was reported. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD NOV PY 2016 VL 57 IS 11 BP 1740 EP 1745 DI 10.2967/jnumed.115.171652 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB1GG UT WOS:000387097000020 PM 27363836 ER PT J AU Yambo, TW Johnson, ME Delaney, KR Hamilton, R Miller, AM York, JA AF Yambo, Teresa W. Johnson, Mary E. Delaney, Kathleen R. Hamilton, Rebekah Miller, Arlene Michaels York, Janet A. TI Experiences of Military Spouses of Veterans With Combat-Related Posttraumatic Stress Disorder SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE Spouse; posttraumatic stress disorder; phenomenology; military; Colaizzi ID MALE VIETNAM VETERANS; SECONDARY TRAUMATIZATION; MENTAL-HEALTH; PARTNERS; WAR; SATISFACTION; PRISONERS; SYMPTOMS AB PurposeTo explore the experiences of military spouses living with veterans with combat-related posttraumatic stress disorder (PTSD). DesignHusserlian phenomenology was chosen as the theoretical framework because it allowed a deeper understanding of the unfolding of the spouses' daily experience. MethodsA purposive sample of 14 spouses living with veterans with symptoms of PTSD participated in unstructured interviews. Data were analyzed using a modification of the Colaizzi phenomenological method. FindingsSpouses recognized that the veteran was no longer the same person, with life becoming one of living with the unpredictability of PTSD. The spouses bore the burden to maintain normalcy in the family and eventually created a new life. ConclusionsMilitary spouses endure psychological stress and strain, while living with a veteran with PTSD. There is a need for more programs to support the resilience of military spouses. Clinical RelevanceLife for military spouses of veterans with PTSD is ever-changing and unpredictable. Practitioners need to be aware of the stress that spouses experience and develop programs and interventions that bolster the resilience of military families. C1 [Yambo, Teresa W.] Air Force Aid Soc, Spouse Employment Program, Osan Air Base, South Korea. [Johnson, Mary E.; Hamilton, Rebekah] Rush Univ, Specialty Educ, Chicago, IL 60612 USA. [Johnson, Mary E.] Rush Univ, Dept Community Syst & Mental Hlth Nursing, Chicago, IL 60612 USA. [Delaney, Kathleen R.] Rush Univ, PMH NP Program, Chicago, IL 60612 USA. [Delaney, Kathleen R.] Rush Univ, Grad Nursing Educ Demonstrat, Chicago, IL 60612 USA. [Hamilton, Rebekah] Rush Univ, Women Children & Family Hlth Nursing, Chicago, IL 60612 USA. [Miller, Arlene Michaels] Rush Univ, Commun Syst & Mental Hlth Nursing, Chicago, IL 60612 USA. [York, Janet A.] Med Univ South Carolina, PMHNP Residency Program, Mental Hlth Serv Line, Ralph H Johnson VAMC, Charleston, SC USA. [York, Janet A.] Med Univ South Carolina, Nursing, Charleston, SC USA. RP Yambo, TW (reprint author), Rush Univ, Coll Nursing, 600 S Paulina St, Chicago, IL 60612 USA. EM Teresa_w_yambo@rush.edu FU Jonas Center for Nursing and Veterans Healthcare; Bob Woodruff Foundation; National Military Family Association FX We appreciate the Jonas Center for Nursing and Veterans Healthcare, Bob Woodruff Foundation, and the National Military Family Association, which partially funded this research. NR 39 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6546 EI 1547-5069 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PD NOV PY 2016 VL 48 IS 6 BP 543 EP 551 DI 10.1111/jnu.12237 PG 9 WC Nursing SC Nursing GA EB2DB UT WOS:000387166400003 PM 27518829 ER PT J AU Cypel, YS Kress, AM Eber, SM Schneiderman, AI Davey, VJ AF Cypel, Yasmin S. Kress, Amii M. Eber, Stephanie M. Schneiderman, Aaron I. Davey, Victoria J. TI Herbicide Exposure, Vietnam Service, and Hypertension Risk in Army Chemical Corps Veterans SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID AIR-FORCE VETERANS; AGENT-ORANGE EXPOSURE; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT ORGANIC POLLUTANTS; NUTRITION EXAMINATION SURVEY; OPERATION RANCH HAND; AMERICAN-HEART-ASSOCIATION; HEALTH-STATUS; SERUM CONCENTRATIONS; MILITARY SERVICE AB Objective:We examined hypertension risk in Army Chemical Corps (ACC) veterans who sprayed defoliant in Vietnam.Methods:We analyzed data from the 2013 health survey of 3086 ACC veterans and investigated the association between self-reported physician-diagnosed-hypertension (SRH) and herbicide-spray-history adjusting for Vietnam-service-status, rank, age, tobacco/alcohol use, race, and body mass index (BMI). Spray-history was verified against serum 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (n=636). SRH was confirmed by blood pressure (BP) measurement by trained medical technicians and medical record reviews.Results:Herbicide-spray-history (ORadjusted[95%confidence interval {CI}]=1.74[1.44,2.11]) and Vietnam-service-status (ORadjusted=1.26[1.05,1.53]) were significantly associated with SRH. The association was highest when comparing Vietnam-service-sprayers to non-Vietnam-service-nonsprayers (ORadjusted=2.21[1.76,2.77]). Serum TCDD was highest for Vietnam-service-sprayers. Mean systolic BPs were significantly higher among veterans with SRH than those without (P0.001). Medical records and SRH overall agreement was 89%.Conclusion:Occupational herbicide exposure history and Vietnam-service-status were significantly associated with hypertension risk. C1 [Cypel, Yasmin S.; Kress, Amii M.; Eber, Stephanie M.; Schneiderman, Aaron I.] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv 10P4Q, Off Patient Care Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. [Davey, Victoria J.] Vet Hlth Adm, Off Res & Dev, Washington, DC USA. RP Cypel, YS (reprint author), US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv 10P4Q, Off Patient Care Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. EM yasmin.cypel@va.gov FU Epidemiology Program, Post-Deployment Health Services, Office of Patient Care Services, Department ofVeterans Affairs (VA) FX This study was funded by the Epidemiology Program, Post-Deployment Health Services, Office of Patient Care Services, Department ofVeterans Affairs (VA). No conflicts of interest for any co-authors are declared. NR 85 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2016 VL 58 IS 11 BP 1127 EP 1136 DI 10.1097/JOM.0000000000000876 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB3OD UT WOS:000387273800017 PM 27820763 ER PT J AU Meyer, JD Ellingson, LD Koltyn, KF Stegner, AJ Kim, JS Cook, DB AF Meyer, Jacob D. Ellingson, Laura D. Koltyn, Kelli F. Stegner, Aaron J. Kim, Jee-Seon Cook, Dane B. TI Psychobiological Responses to Preferred and Prescribed Intensity Exercise in Major Depressive Disorder SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE ANTIDEPRESSANT RESPONSE; BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF); PREFERRED EXERTION; AFFECT; ACUTE EXERCISE; EXERCISE PRESCRIPTION ID NEUROTROPHIC FACTOR BDNF; MAXIMAL OXYGEN-UPTAKE; PHYSICAL-ACTIVITY; PERCEIVED EXERTION; GRADED-EXERCISE; MOOD STATES; DSM-IV; VALIDITY; QUESTIONNAIRE; PRESCRIPTION AB Exercise acutely improves mood in major depressive disorder (MDD). However, it is unknown whether benefits differ depending on whether exercise intensity is self-selected or prescribed. Purpose This study aimed to compare psychological and biological responses to preferred and prescribed steady-state exercise intensities to a patient-selected preferred intensity. Method Female adults (N = 24, age = 38.6 14.0 yr) diagnosed with MDD completed four 30-min sessions of cycling exercise at three prescribed intensities (RPE of 11, 13, and 15) and one session with a self-selected intensity (preferred). Order was randomized and counterbalanced. Depressed mood (DM) was evaluated before, 10 min, and 30 min postexercise using the Profile of Mood States. Serum brain-derived neurotrophic factor (BDNF) was measured before and within 10 min postexercise. Changes in BDNF and DM for the preferred session were compared with the following prescribed sessions: 1) performed at the most similar intensity (matched on RPE; closest) and 2) with the greatest improvement in DM (greatest). Results Compared with the preferred session, improvement in DM was significantly larger after the greatest session (30 min postexercise: -11.8 +/- 7.4 vs -3.4 +/- 4.8), and the BDNF response was significantly greater after the closest session (5.4 +/- 6.9 vs -1.4 +/- 9.8 ngmL(-1)). Conclusions Permitting patients to select their own exercise intensity did not maximize improvements in mood. Further, preferred intensity exercise was also associated with a smaller BDNF response. Overall, the results suggest that exercise undertaken to improve mood should be prescribed on an individual basis in MDD and not necessarily based on the patient's preferred intensity. Clinicians, psychologists, and other practitioners should consider providing clear exercise intensity recommendations for symptom management in depression rather than allowing patients to self-select their intensity. C1 [Meyer, Jacob D.] Univ Wisconsin, Dept Family Med & Community Hlth, Madison, WI USA. [Meyer, Jacob D.; Koltyn, Kelli F.; Stegner, Aaron J.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI USA. [Ellingson, Laura D.] Iowa State Univ, Dept Kinesiol, Ames, IA USA. [Stegner, Aaron J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kim, Jee-Seon] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. RP Meyer, JD (reprint author), 2000 Observ Dr, Madison, WI 53706 USA. EM jdmeyer3@wisc.edu FU Virginia Horne Henry Gift Fund; University of Wisconsin-Madison Graduate School; Wisconsin Center for Education Research; National Research Service Award from Health Resources and Services Administration [T32HP10010] FX This project was funded, in part, by the Virginia Horne Henry Gift Fund, the University of Wisconsin-Madison Graduate School, and the Wisconsin Center for Education Research. Jacob Meyer was partially supported by a National Research Service Award from the Health Resources and Services Administration T32HP10010 to the University of Wisconsin Department of Family Medicine and Community Health. None of the funding sources were involved in the study design, collection, analysis, or interpretation of the data. The authors would like to thank Lauren Schlapman, Hannah Feinstein, Shawn Tipple, Matthew Patton, Caroline Wickler, and Rachel Prince for their assistance. The authors report no conflicts of interest. Results of this study do not constitute endorsement by the American College of Sports Medicine. NR 44 TC 0 Z9 0 U1 10 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD NOV PY 2016 VL 48 IS 11 BP 2207 EP 2215 DI 10.1249/MSS.0000000000001022 PG 9 WC Sport Sciences SC Sport Sciences GA EA4OU UT WOS:000386593200017 PM 27387295 ER PT J AU Duboc, H Tolstanova, G Yuan, PQ Wu, VS Kaji, I Biraud, M Akiba, Y Kaunitz, JD Million, M Tache, Y Larauche, M AF Duboc, H. Tolstanova, G. Yuan, P. -Q. Wu, V. S. Kaji, I. Biraud, M. Akiba, Y. Kaunitz, J. D. Million, M. Tache, Y. Larauche, M. TI Reduction of epithelial secretion in male rat distal colonic mucosa by bile acid receptor TGR5 agonist, INT-777: role of submucosal neurons SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE bile acids; distal colon; secretion; submucosal neurons; TGR5; Ussing chambers ID ENTERIC NERVOUS-SYSTEM; GUINEA-PIG; SMALL-INTESTINE; ION-TRANSPORT; NITRIC-OXIDE; MOUSE COLON; GASTROINTESTINAL-TRACT; ELECTROLYTE TRANSPORT; MYENTERIC NEURONS; SODIUM-CHANNELS AB BackgroundRecent evidence from rat neuron-free mucosa study suggests that the membrane bile acid receptor TGR5 decreases colonic secretion under basal and stimulated conditions. As submucosal neurons are key players in secretory processes and highly express TGR5, we investigated their role in TGR5 agonist-induced inhibition of secretion and the pathways recruited. MethodsTGR5 expression and localization were assessed in rat proximal (pC) and distal (dC) colon by qPCR and immunohistochemistry with double labeling for cholinergic neurons in whole-mount preparations. The influence of a selective (INT-777) or weak (ursodeoxycholic acid, UDCA) TGR5 agonist on colonic secretion was assessed in Ussing chambers, in dC preparation removing seromuscular submucosal tissues, in the presence of different inhibitors of secretion pathways. Key ResultsTGR5 mRNA is expressed in full thickness dC and pC and immunoreactivity is located in colonocytes and pChAT-positive neurons. Addition of INT-777, and less potently UDCA, decreased colonic secretion in seromuscular stripped dC by -58.17 +/- 2.6%. INT-777 effect on basal secretion was reduced in neuron-free and TTX-treated mucosal-submucosal preparations. Atropine, hexamethonium, indomethacin, and L-NAME all reduced significantly INT-777's inhibitory effect while the 5-HT4 antagonist, RS-39604, and lidocaine abolished it. INT-777 inhibited stimulated colonic secretion induced by nicotine, but not cisapride, carbachol or PGE2. Conclusions & InferencesTGR5 activation inhibits basal and stimulated distal colonic secretion in rats by acting directly on epithelial cells and also inhibiting submucosal neurons. This could represent a counter-regulatory mechanism, at the submucosal level, of the known prosecretory effect of bile acids in the colon. C1 [Duboc, H.; Tolstanova, G.; Yuan, P. -Q.; Wu, V. S.; Biraud, M.; Million, M.; Tache, Y.; Larauche, M.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Duboc, H.; Tolstanova, G.; Yuan, P. -Q.; Wu, V. S.; Biraud, M.; Million, M.; Tache, Y.; Larauche, M.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress & Resilience, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. [Duboc, H.; Tolstanova, G.; Yuan, P. -Q.; Wu, V. S.; Biraud, M.; Akiba, Y.; Kaunitz, J. D.; Million, M.; Tache, Y.; Larauche, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Duboc, H.] Univ Paris Diderot, Sorbonne Paris Cite, DHU UNITY, INSERM,UMR 1149, Paris, France. [Duboc, H.] Univ Paris Diderot, Sorbonne Paris Cite, Louis Mourier Hosp, AP HP,Dept Gastroenterol & Hepatol, Paris, France. [Tolstanova, G.] Taras Shevchenko Natl Univ Kyiv, Inst Biol, Educ Sci Ctr, Kiev, Ukraine. [Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Kaunitz, J. D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA. RP Larauche, M (reprint author), West Los Angeles VA Med Ctr, CURE Digest Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115 Rm 111, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu FU NIDDK NIH HHS [P50 DK064539, R01 DK078676, K01 DK088937, P30 DK041301] NR 67 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 EI 1365-2982 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD NOV PY 2016 VL 28 IS 11 BP 1663 EP 1676 DI 10.1111/nmo.12866 PG 14 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA EB0KM UT WOS:000387032700007 PM 27259385 ER PT J AU Biagianti, B Fisher, M Neilands, TB Loewy, R Vinogradov, S AF Biagianti, Bruno Fisher, Melissa Neilands, Torsten B. Loewy, Rachel Vinogradov, Sophia TI Engagement With the Auditory Processing System During Targeted Auditory Cognitive Training Mediates Changes in Cognitive Outcomes in Individuals With Schizophrenia SO NEUROPSYCHOLOGY LA English DT Article DE cognitive training; target engagement; auditory processing; schizophrenia; neuroplasticity ID CLINICAL HIGH-RISK; VERBAL MEMORY; REMEDIATION; PSYCHOSIS; VALIDITY; METAANALYSIS; METHODOLOGY; RELIABILITY; PERSPECTIVE; DYSFUNCTION AB Background: Individuals with schizophrenia who engage in targeted cognitive training (TCT) of the auditory system show generalized cognitive improvements. The high degree of variability in cognitive gains maybe due to individual differences in the level of engagement of the underlying neural system target. Method: 131 individuals with schizophrenia underwent 40 hours of TCT. We identified target engagement of auditory system processing efficiency by modeling subject-specific trajectories of auditory processing speed (APS) over time. Lowess analysis, mixed models repeated measures analysis, and latent growth curve modeling were used to examine whether APS trajectories were moderated by age and illness duration, and mediated improvements in cognitive outcome measures. Results: We observed significant improvements in APS from baseline to 20 hours of training (initial change), followed by a flat APS trajectory (plateau) at subsequent time-points. Participants showed interindividual variability in the steepness of the initial APS change and in the APS plateau achieved and sustained between 20 and 40 hours. We found that participants who achieved the fastest APS plateau, showed the greatest transfer effects to untrained cognitive domains. Conclusions: There is a significant association between an individual's ability to generate and sustain auditory processing efficiency and their degree of cognitive improvement after TCT, independent of baseline neurocognition. APS plateau may therefore represent a behavioral measure of target engagement mediating treatment response. Future studies should examine the optimal plateau of auditory processing efficiency required to induce significant cognitive improvements, in the context of interindividual differences in neural plasticity and sensory system efficiency that characterize schizophrenia. C1 [Biagianti, Bruno; Fisher, Melissa; Loewy, Rachel; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, 513 Parnassus Ave,S362, San Francisco, CA 94134 USA. [Biagianti, Bruno; Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Biagianti, Bruno] Univ Milan, Dept Psychiat, I-20122 Milan, Italy. [Neilands, Torsten B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Biagianti, B (reprint author), Univ Calif San Francisco, Dept Psychiat, 513 Parnassus Ave,S362, San Francisco, CA 94134 USA. EM bruno.biagianti@ucsf.edu FU Posit Science; National Institute of Health [R01MH82818-01A2, MH068725-06A2]; Stanley Foundation [06TAF-972] FX The cognitive training software used in these studies was supplied to the last author free of charge by Posit Science. Vinogradov is a site PI on an SBIR grant to Posit Science, a company with a commercial interest in the cognitive training software used in these studies. Biagianti is a post-doctoral research fellow partially funded through Posit Science. None of the other authors have any financial interest in Brain Plasticity Inc. or Posit Science. Vinogradov serves on an advisory board for Forum pharmaceuticals. This work was supported by National Institute of Health grants R01MH82818-01A2, MH068725-06A2 and by the Stanley Foundation grant 06TAF-972 NR 46 TC 0 Z9 0 U1 3 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD NOV PY 2016 VL 30 IS 8 BP 998 EP 1008 DI 10.1037/neu0000311 PG 11 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA EB3DI UT WOS:000387242200011 PM 27617637 ER PT J AU Kimmel, SE Troxel, AB French, B Loewenstein, G Doshi, JA Hecht, TEH Laskin, M Brensinger, CM Meussner, C Volpp, K AF Kimmel, Stephen E. Troxel, Andrea B. French, Benjamin Loewenstein, George Doshi, Jalpa A. Hecht, Todd E. H. Laskin, Mitchell Brensinger, Colleen M. Meussner, Chris Volpp, Kevin TI A randomized trial of lottery-based incentives and reminders to improve warfarin adherence: the Warfarin Incentives (WIN2) Trial SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE anticoagulants; trials; incentives; economics; behavioral; pharmacoepidemiology; pharmacoepidemiology ID IN-RANGE; ANTICOAGULATION AB BackgroundPrevious research has suggested that daily lottery incentives could improve medication adherence. Such daily incentives include implicit reminders. However, the comparative effectiveness of reminders alone versus daily incentives has not been tested. MethodsA total of 270 patients on warfarin were enrolled in a four-arm, multi-center, randomized controlled trial comparing a daily lottery-based incentive, a daily reminder, and a combination of the two against a control group (usual care). ResultsParticipants in the reminder group had the lowest percentage of time out of target international normalized ratio (INR) range, the primary outcome, with an adjusted odds of an out-of-range INR 36% lower than among those in the control group, 95%CI [7%, 55%]. No other group had a statistically significant improvement in anticoagulation control relative to the control group or to each other. The only group that had significant improvement in incorrect adherence was the lottery group (incorrect adherence: 12.1% compared with 23.7% in the control group, difference of -7.4% 95%CI [-14%, -0.3%]). However, there was no relationship between changes in adherence and anticoagulation control in the lottery group. ConclusionsAutomated reminders led to the largest improvements in anticoagulation control, although without impacting measured adherence. Lottery-based reminders improved measured adherence but did not lead to improved anticoagulation control. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Kimmel, Stephen E.] Univ Penn, Ctr Therapeut Effectiveness Res, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.; Troxel, Andrea B.; French, Benjamin; Brensinger, Colleen M.; Meussner, Chris] Univ Penn, Dept Biostat & Epidemiol, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.; Doshi, Jalpa A.; Hecht, Todd E. H.; Volpp, Kevin] Univ Penn, Dept Med, Perelman Sch Med, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.; Troxel, Andrea B.; French, Benjamin; Loewenstein, George; Doshi, Jalpa A.; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Laskin, Mitchell] Hosp Univ Penn, Dept Pharm Serv, 3400 Spruce St, Philadelphia, PA 19104 USA. [Volpp, Kevin] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Dept Hlth Care Management, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Dept Med Eth & Hlth Policy, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Med & Epidemiol, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM stevek@mail.med.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU National Institutes of Health, National Heart Lung Blood Institute (NHLBI) [R01-HL-090929] FX Funded by the National Institutes of Health, National Heart Lung Blood Institute (NHLBI), grant # R01-HL-090929. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 18 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD NOV PY 2016 VL 25 IS 11 BP 1219 EP 1227 DI 10.1002/pds.4094 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA EB1OX UT WOS:000387124000001 PM 27592594 ER PT J AU Conhaim, RL Segal, GS Watson, KE AF Conhaim, Robert L. Segal, Gilad S. Watson, Kal E. TI Arterio-venous anastomoses in isolated, perfused rat lungs SO PHYSIOLOGICAL REPORTS LA English DT Article DE Alveolar capillary; arterio-venous anastomoses; pulmonary circulation; pulmonary microcirculation; sheet flow ID INTERALVEOLAR PERFUSION; HEALTHY HUMANS; MICROVESSELS; EXERCISE; FLOW AB Several studies have suggested that large-diameter (>25 mu m) arterio-venous shunt pathways exist in the lungs of rats, dogs, and humans. We investigated the nature of these pathways by infusing specific-diameter fluorescent latex particles (4, 7, 15, 30, or 50 mu m) into isolated, ventilated rat lungs perfused at constant pressure. All lungs received the same mass of latex (5 mg), which resulted in infused particle numbers that ranged from 1.7 x 10(7) 4 mu m particles to 7.5 x 10(4) 50 mu m particles. Particles were infused over 2 min. We used a flow cytometer to count particle appearances in venous effluent samples collected every 0.5 min for 12 min from the start of particle infusion. Cumulative percentages of infused particles that appeared in the samples averaged 3.17 +/- 2.46% for 4 mu m diameter particles, but ranged from 0.01% to 0.17% for larger particles. Appearances of 4 mu m particles followed a rapid upslope beginning at 30 sec followed by a more gradual downslope that lasted for up to 12 min. All other particle diameters also began to appear at 30 sec, but followed highly irregular time courses. Infusion of 7 and 15 mu m particles caused transient but significant perfusate flow reductions, while infusion of all other diameters caused insignificant reductions in flow. We conclude that small numbers of bypass vessels exist that can accommodate particle diameters of 7-to-50 mu m. We further conclude that our 4 mu m particle data are consistent with a well-developed network of serial and parallel perfusion pathways at the acinar level. C1 [Conhaim, Robert L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Conhaim, Robert L.; Segal, Gilad S.; Watson, Kal E.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Conhaim, RL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Res Off, 2500 Overlook Terrace, Madison, WI 53705 USA. EM rconhaim@wisc.edu NR 20 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2051-817X J9 PHYSIOL REP JI PHYSIOL. REP. PD NOV PY 2016 VL 4 IS 21 AR e13023 DI 10.14814/phy2.13023 PG 9 WC Physiology SC Physiology GA EB5UP UT WOS:000387446300001 ER PT J AU Katz, LS AF Katz, Lori S. TI Efficacy of Warrior Renew Group Therapy for Female Veterans Who Have Experienced Military Sexual Trauma SO PSYCHOLOGICAL SERVICES LA English DT Article DE sexual trauma; women veterans; military sexual trauma; group therapy ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; WOMEN VETERANS; MENTAL-HEALTH; PROLONGED EXPOSURE; PRIMARY-CARE; GENDER-DIFFERENCES; WAR VETERANS; PTSD; AFGHANISTAN AB This is a program evaluation of the Warrior Renew treatment protocol delivered in an outpatient therapy group for survivors of military sexual trauma (MST) at a Department of Veterans Affairs medical center. The group was delivered via a manualized protocol with 12 weekly topics. It includes coping skills for affect management (e.g., triggers and anxiety) and addresses unique aspects of MST including anger/resentments because of injustice and lack of closure, betrayal, and self-blame. It also addresses interpersonal factors such as relationship patterns and healthy interpersonal skills. This evaluation was conducted as part of routine clinical care in a naturalistic setting. Forty-three female veterans started and 34 completed treatment (21% dropout rate). Of the 34 graduates, 32 opted to complete pre- and posttreatment assessments. Findings revealed significant decreases in symptoms of anxiety, depression, posttraumatic negative thinking, and posttraumatic stress disorder (PTSD) all with large effect sizes. In addition, 75% of the sample had a reliable clinical change at the 95% confidence interval. These results are promising and further investigation is warranted to examine Warrior Renew to address the unique issues related to MST. C1 [Katz, Lori S.] VA Puget Sound Hlth Care Syst, 9600 Vet Dr SW, Tacoma, WA 98493 USA. [Katz, Lori S.] Univ Southern Calif, Ctr Innovat & Res Vet & Mil Families, Los Angeles, CA 90089 USA. RP Katz, LS (reprint author), VA Puget Sound Hlth Care Syst, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM lori.katz@va.gov NR 55 TC 0 Z9 0 U1 9 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2016 VL 13 IS 4 BP 364 EP 372 DI 10.1037/ser0000103 PG 9 WC Psychology, Clinical SC Psychology GA EB3EE UT WOS:000387244600005 PM 27537615 ER PT J AU Blackledge, C Graham, LA Gullick, AA Richman, J Stahl, R Grams, J AF Blackledge, Camille Graham, Laura A. Gullick, Allison A. Richman, Joshua Stahl, Richard Grams, Jayleen TI Outcomes associated with preoperative weight loss after laparoscopic Roux-en-Y gastric bypass SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Obesity; Bariatric surgery; Preoperative weight loss; Outcomes; Laparoscopic Roux-en-Y gastric bypass ID TYPE-2 DIABETES-MELLITUS; BARIATRIC SURGERY; COMPLICATIONS; METAANALYSIS; OBESITY AB Laparoscopic Roux-en-Y gastric bypass (LRYGB) is an effective treatment for achieving and maintaining weight loss and for improving obesity-related comorbidities. As part of the approval process for bariatric surgery, many insurance companies require patients to have documented recent participation in a supervised weight loss program. The goal of this study was to evaluate the relationship of preoperative weight changes with outcomes following LRYGB. A retrospective review was conducted of adult patients undergoing LRYGB between 2008 and 2012 at a single institution. Patients were stratified into quartiles based on % excess weight gain (0-4.99 % and aeyen5 % EWG) and % excess weight loss (0-4.99 % and aeyen5 % EWL). Generalized linear models were used to examine differences in postoperative weight outcomes at 6, 12, and 24 months. Covariates included in the final adjusted models were determined using backwards stepwise selection. Of the 300 patients included in the study, there were no significant demographic differences among the quartiles. However, there was an increased time to operation for patients who gained or lost aeyen5 % excess body weight (p < 0.001). Although there was no statistical significance in postoperative complications, there was a higher rate of complications in patients with aeyen5 % EWG compared to those with aeyen5 % EWL (12.5 vs. 4.8 %, respectively; p = 0.29). Unadjusted and adjusted generalized linear models showed no statistically significant association between preoperative % excess weight change and weight loss outcomes at 24 months. Patients with the greatest % preoperative excess weight change had the longest intervals from initial visit to operation. No significant differences were seen in perioperative and postoperative outcomes. This study suggests preoperative weight loss requirements may delay the time to operation without improving postoperative outcomes or weight loss. C1 [Blackledge, Camille; Graham, Laura A.; Gullick, Allison A.; Richman, Joshua; Stahl, Richard; Grams, Jayleen] Univ Alabama Birmingham, Dept Surg, 1720 2nd Ave South,KB 401, Birmingham, AL 35294 USA. [Graham, Laura A.; Richman, Joshua] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Blackledge, Camille; Grams, Jayleen] Birmingham Vet Affairs Med Ctr, Dept Surg, Birmingham, AL 35233 USA. RP Grams, J (reprint author), Univ Alabama Birmingham, Dept Surg, 1720 2nd Ave South,KB 401, Birmingham, AL 35294 USA.; Grams, J (reprint author), Birmingham Vet Affairs Med Ctr, Dept Surg, Birmingham, AL 35233 USA. EM jgrams@uab.edu FU Foundation for Surgical Fellowships FX Dr. Camille Blackledge was sponsored in part by the Foundation for Surgical Fellowships. NR 27 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD NOV PY 2016 VL 30 IS 11 BP 5077 EP 5083 DI 10.1007/s00464-016-4856-3 PG 7 WC Surgery SC Surgery GA EB2XJ UT WOS:000387225600048 PM 26969666 ER PT J AU Maree, RD Marcum, ZA Saghafi, E Weiner, DK Karp, JF AF Maree, Rachel D. Marcum, Zachary A. Saghafi, Ester Weiner, Debra K. Karp, Jordan F. TI A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Review DE Aging; geriatrics; prescription drug abuse; primary care; substance abuse ID SUBSTANCE-ABUSE TREATMENT; DRUG-MONITORING PROGRAMS; PRESCRIPTION OPIOIDS; BRIEF INTERVENTION; NONMEDICAL USE; USERS; CARE; DISCONTINUATION; PREVALENCE; DEPENDENCE AB Objective: The authors assessed the prevalence of opioid and benzodiazepine prescription drug misuse in older adults, the risk factors associated with misuse, and age-appropriate interventions. Methods: Following PRISMA guidelines, a literature search of PubMed, PsycINFO, and EMBASE for peer-reviewed journal articles in English through April 2014 with updates through November 2015 was conducted for reports on misuse of prescription benzodiazepines and opioids in older adults. Relevant publications were reviewed that included participants age >= 65 years. Reference listswere manually searched for key identified articles and geriatric journals through April 2016. Information on the study design, sample, intervention, comparators, outcome, time frame, and risk of bias were abstracted for each article. Results: Of 4,932 reviewed reports, 15 were included in this systematic review. Thirteen studies assessed the prevalence of prescription drug misuse and included studies related to opioid shopping behavior, assessment of morbidity and mortality associated with opioid and/or benzodiazepine use, frequency and characteristics of opioid prescribing, frequency of substance use disorders and nonprescription use of pain relievers, and health conditions and experiences of longterm benzodiazepine users. One study identified risk factors for misuse, and one study described the effects of provider education and an electronic support tool as an intervention. Conclusion: There is a dearth of high quality research on prescription drug misuse in older adults. Existing studies are heterogeneous, making it difficult to draw broad conclusions. The need for further research specific to prescription drug misuse among older adults is discussed. C1 [Maree, Rachel D.; Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Saghafi, Ester] Univ Pittsburgh, Sch Med, Dept Informat Sci, Pittsburgh, PA 15213 USA. [Marcum, Zachary A.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Weiner, Debra K.; Karp, Jordan F.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Karp, JF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM karpjf@upmc.edu FU NIH [AG033575, MH101371] FX Dr. Marcum is a consultant for Purdue Pharma. Dr. Karp has received medication supplies for investigator initiated trials from Invidior and Pfizer. Funding was provided in part by NIH grants AG033575 and MH101371 (to JFK). NR 65 TC 0 Z9 0 U1 18 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2016 VL 24 IS 11 BP 949 EP 963 DI 10.1016/j.jagp.2016.06.003 PG 15 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EA6XA UT WOS:000386771200002 PM 27567185 ER PT J AU Hogaboom, NS Huang, BL Worobey, LA Koontz, AM Boninger, ML AF Hogaboom, Nathan S. Huang, Bernice L. Worobey, Lynn A. Koontz, Alicia M. Boninger, Michael L. TI Cross-Sectional Investigation of Acute Changes in Ultrasonographic Markers for Biceps and Supraspinatus Tendon Degeneration After Repeated Wheelchair Transfers in People With Spinal Cord Injury SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Spinal Cord Injuries; Wheelchairs; Ultrasonography; Cumulative Trauma Disorders; Tendinopathy ID ROTATOR CUFF TENDINOPATHY; QUANTITATIVE ULTRASOUND; SHOULDER PATHOLOGY; TRANSFER SKILLS; USERS; INDIVIDUALS; PAIN; ABNORMALITIES; PARAPLEGIA; PREVALENCE AB Objective The objectives of this work were to investigate how wheelchair transfers influence acute changes in ultrasound markers for biceps and supraspinatus tendon degeneration and to determine how such changes correlate with transfer technique and demographic characteristics. Design Participants underwent quantitative ultrasound examinations for markers of biceps and supraspinatus tendon degeneration (tendon width, echogenicity, variance, and contrast) before and after a stressful repeated-transfers protocol. The Transfer Assessment Instrument was completed for each participant to identify transfer skills. Linear regression tested whether demographics and transfer skills correlated with ultrasound measures. Results Sixty-two wheelchair users with spinal cord injury were included (39 with paraplegia and 23 with tetraplegia). Biceps tendon width increased after repeated transfers (P < 0.001). Participants with greater body weight experienced greater increases in biceps width after transfers ( = 0.109, P < 0.05). Skills evaluating body position relative to the target surface and safe and stable hand and arm positions affected changes in biceps and supraspinatus width and echogenicity (P < 0.05). Conclusions Repeated transfers caused measurable changes in biceps tendon width in a subset of participants. Changes in biceps and supraspinatus ultrasound measures were related to body weight and performance of specific transfer skills. Further testing is needed to confirm whether the clinical meaning of the observed relationships and whether using certain transfer skills and reducing body weight can attenuate the development of tendinopathy. C1 [Hogaboom, Nathan S.; Worobey, Lynn A.; Koontz, Alicia M.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Worobey, Lynn A.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Hogaboom, Nathan S.; Koontz, Alicia M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Huang, Bernice L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Boninger, ML (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, US Department of Education [H133N110011]; National Science Foundation Graduate Research Fellowship [1247842] FX This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. This project was supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, US Department of Education (H133N110011). This material is based on work supported by the National Science Foundation Graduate Research Fellowship (Grant #1247842). Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the view of the National Science Foundation. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 31 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2016 VL 95 IS 11 BP 818 EP 830 DI 10.1097/PHM.0000000000000509 PG 13 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EA6TK UT WOS:000386761700011 PM 27088477 ER PT J AU Khamashta, M Merrill, JT Werth, VP Furie, R Kalunian, K Illei, GG Drappa, J Wang, LW Greth, W AF Khamashta, Munther Merrill, Joan T. Werth, Victoria P. Furie, Richard Kalunian, Kenneth Illei, Gabor G. Drappa, Jorn Wang, Liangwei Greth, Warren CA CD1067 Study Investigators TI Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID INDUCIBLE GENE-EXPRESSION; DISEASE-ACTIVITY INDEX; REVISED CRITERIA; PHASE-I; THERAPY; SLE; CLASSIFICATION; ACTIVATION; SIGNATURES; BLOCKADE AB Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE). Methods 431 patients were randomised and received monthly intravenous sifalimumab (200 mg, 600 mg or 1200 mg) or placebo in addition to standard-of-care medications. Patients were stratified by disease activity, interferon gene-signature test (high vs low based on the expression of four genes) and geographical region. The primary efficacy end point was the percentage of patients achieving an SLE responder index response at week 52. Results Compared with placebo, a greater percentage of patients who received sifalimumab (all dosages) met the primary end point (placebo: 45.4%; 200 mg: 58.3%; 600 mg: 56.5%; 1200 mg 59.8%). Other improvements were seen in Cutaneous Lupus Erythematosus Disease Area and Severity Index score (200 mg and 1200 mg monthly), Physician's Global Assessment (600 mg and 1200 mg monthly), British Isles Lupus Assessment Group-based Composite Lupus Assessment (1200 mg monthly), 4-point reductions in the SLE Disease Activity Index-2000 score and reductions in counts of swollen joints and tender joints. Serious adverse events occurred in 17.6% of patients on placebo and 18.3% of patients on sifalimumab. Herpes zoster infections were more frequent with sifalimumab treatment. Conclusions Sifalimumab is a promising treatment for adults with SLE. Improvement was consistent across various clinical end points, including global and organ-specific measures of disease activity. C1 [Khamashta, Munther] Kings Coll London, Rayne Inst, St Thomas Hosp, Graham Hughes Lupus Res Lab,Div Womens Hlth, Lambeth Wing 4th Floor, London SE1 7EH, England. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Lupus Res Inst, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA. [Furie, Richard] Northwell Hlth, Div Rheumatol, Great Neck, NY USA. [Kalunian, Kenneth] UCSD Sch Med, Dept Rheumatol, La Jolla, CA USA. [Illei, Gabor G.; Drappa, Jorn; Greth, Warren] MedImmune, Clin Dev Resp Inflammat & Autoimmun, Gaithersburg, MD USA. [Wang, Liangwei] MedImmune, Dept Biostat, Gaithersburg, MD USA. RP Khamashta, M (reprint author), Kings Coll London, Rayne Inst, St Thomas Hosp, Graham Hughes Lupus Res Lab,Div Womens Hlth, Lambeth Wing 4th Floor, London SE1 7EH, England. EM munther.khamashta@kcl.ac.uk FU MedImmune FX The study was funded by MedImmune. NR 37 TC 25 Z9 25 U1 3 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2016 VL 75 IS 11 BP 1909 EP 1916 DI 10.1136/annrheumdis-2015-208562 PG 8 WC Rheumatology SC Rheumatology GA EA3AH UT WOS:000386469300006 PM 27009916 ER PT J AU Deng, Y Zhao, J Sakurai, D Sestak, AL Osadchiy, V Langefeld, CD Kaufman, KM Kelly, JA James, JA Petri, MA Bae, SC Alarcon-Riquelme, ME Alarcon, GS Anaya, JM Criswell, LA Freedman, BI Kamen, DL Gilkeson, GS Jacob, CO Merrill, JT Gaffney, PM Sivils, KM Niewold, TB Ramsey-Goldman, R Reveille, JD Scofield, RH Stevens, AM Boackle, SA Vila, LM Sohn, IIW Lee, S Chang, DM Song, YW Vyse, TJ Harley, JB Brown, EE Edberg, JC Kimberly, RP Cantor, RM Hahn, BH Grossman, JM Tsao, BP AF Deng, Yun Zhao, Jian Sakurai, Daisuke Sestak, Andrea L. Osadchiy, Vadim Langefeld, Carl D. Kaufman, Kenneth M. Kelly, Jennifer A. James, Judith A. Petri, Michelle A. Bae, Sang-Cheol Alarcon-Riquelme, Marta E. Alarcon, Graciela S. Anaya, Juan-Manuel Criswell, Lindsey A. Freedman, Barry I. Kamen, Diane L. Gilkeson, Gary S. Jacob, Chaim O. Merrill, Joan T. Gaffney, Patrick M. Sivils, Kathy Moser Niewold, Timothy B. Ramsey-Goldman, Rosalind Reveille, John D. Scofield, R. Hal Stevens, Anne M. Boackle, Susan A. Vila, Luis M. Sohn, I. I. Woong Lee, Seung Chang, Deh-Ming Song, Yeong Wook Vyse, Timothy J. Harley, John B. Brown, Elizabeth E. Edberg, Jeffrey C. Kimberly, Robert P. Cantor, Rita M. Hahn, Bevra H. Grossman, Jennifer M. Tsao, Betty P. TI Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID MESSENGER-RNA DECAY; WHOLE-GENOME ASSOCIATION; HUMAN PREFRONTAL CORTEX; GENE-EXPRESSION; WIDE ASSOCIATION; DISEASE-ACTIVITY; TARGET GENES; HUMAN BRAIN; ERYTHEMATOSUS; SUSCEPTIBILITY AB Objectives Following up the systemic lupus erythematosus (SLE) genome-wide association studies (GWAS) identification of NMNAT2 at rs2022013, we fine-mapped its 150 kb flanking regions containing NMNAT2 and SMG7 in a 15 292 case-control multi-ancestry population and tested functions of identified variants. Methods We performed genotyping using custom array, imputation by IMPUTE 2.1.2 and allele specific functions using quantitative real-time PCR and luciferase reporter transfections. SLE peripheral blood mononuclear cells (PBMCs) were cultured with small interfering RNAs to measure antinuclear antibody (ANA) and cyto/chemokine levels in supernatants using ELISA. Results We confirmed association at NMNAT2 in European American (EA) and Amerindian/Hispanic ancestries, and identified independent signal at SMG7 tagged by rs2702178 in EA only (p=2.4x10(-8), OR=1.23 (95% CI 1.14 to 1.32)). In complete linkage disequilibrium with rs2702178, rs2275675 in the promoter region robustly associated with SMG7 mRNA levels in multiple expression quantitative trait locus (eQTL) datasets. Its risk allele was dose-dependently associated with decreased SMG7 mRNA levels in PBMCs of 86 patients with SLE and 119 controls (p=1.1x10(-3) and 6.8x10(-8), respectively) and conferred reduced transcription activity in transfected HEK-293 (human embryonic kidney cell line) and Raji cells (p=0.0035 and 0.0037, respectively). As a critical component in the nonsense-mediated mRNA decay pathway, SMG7 could regulate autoantigens including ribonucleoprotein (RNP) and Smith (Sm). We showed SMG7 mRNA levels in PBMCs correlated inversely with ANA titres of patients with SLE (r=-0.31, p=0.01), and SMG7 knockdown increased levels of ANA IgG and chemokine (C-C motif) ligand 19 in SLE PBMCs (p=2.0x10(-5) and 2.0x10(-4), respectively). Conclusion We confirmed NMNAT2 and identified independent SMG7 association with SLE. The inverse relationship between levels of the risk allele-associated SMG7 mRNAs and ANA suggested the novel contribution of mRNA surveillance pathway to SLE pathogenesis. C1 [Deng, Yun; Zhao, Jian; Sakurai, Daisuke; Osadchiy, Vadim; Hahn, Bevra H.; Grossman, Jennifer M.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Sestak, Andrea L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA. [Langefeld, Carl D.] Wake Forest Sch Med, Ctr Publ Hlth Genom, Dept Biostat Sci, Winston Salem, NC USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Kelly, Jennifer A.; James, Judith A.; Alarcon-Riquelme, Marta E.; Gaffney, Patrick M.; Sivils, Kathy Moser; Scofield, R. Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. [James, Judith A.; Sivils, Kathy Moser] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Bae, Sang-Cheol; Sohn, I. I. Woong; Lee, Seung] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea. [Alarcon-Riquelme, Marta E.] Univ Granada Junta de Andalucia, Pfizer, Ctr Genom & Oncol Res, Granada, Spain. [Alarcon, Graciela S.; Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Ephraim P Engleman Rheumatol Res, San Francisco, CA 94143 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Kamen, Diane L.; Gilkeson, Gary S.] Med Univ South Carolina, Div Rheumatol & Immunol, Charleston, SC USA. [Jacob, Chaim O.] Univ Southern Calif, Dept Med, Los Angeles, CA USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Rheumatol & Clin Immunogenet, Houston, TX 77030 USA. [Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. [Boackle, Susan A.] US Dept Vet Affairs, Med Ctr, Denver, CO USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, Div Rheumatol, Med Sci Campus, San Juan, PR 00936 USA. [Chang, Deh-Ming] Taipei Vet Gen Hosp, Taipei, Taiwan. [Song, Yeong Wook] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea. [Song, Yeong Wook] Seoul Natl Univ, Coll Med, Med Res Ctr, Seoul, South Korea. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med & Immunol, London, England. [Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. RP Tsao, BP (reprint author), Med Univ South Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Clin Sci Bldg Suite 936C, Charleston, SC 29425 USA. EM tsaob@musc.edu OI Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Anaya, Juan-Manuel/0000-0002-6444-1249 FU US NIH [R01AR043814, R21AR065626, P01AI083194, P01AR049084, R01AR064820, P30GM103510, P30AR053483, U01AI101934, U19AI082714, R01CA141700, RC1AR058621, P60AR053308, UL1TR000004, P60AR062755, UL1RR029882, R01AR057172, R01AI063274, R01AR043274, K08AI083790, LRPAI071651, UL1RR024999, R01AR43727, K24AR002138, P60AR066464, 1U54TR001018, U54RR023417, R01AR051545, UL1RR025014, R21AI070304, R01AR042460, N01AR062277, P20RR020143, R37AI024717, P30AR048311, P30AR055385, R01AR033062]; Lupus Foundation of America; Alliance for Lupus Research; Lupus Research Institute; US Department of Veterans Affairs; US Department of Defense [PR094002]; Arthritis National Research Foundation; Arthritis Foundation; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [HI13C2124]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI13C1754]; European Science Foundation RNP (BIOLUPUS Research Network); Wellcome Trust; Arthritis Research UK; Kirkland Scholar Award; Wake Forest School of Medicine Center for Public Health Genomics; University of California Los Angeles (UCLA) Clinical and Translational Science Institute (CTSI) [UL1RR033176, UL1TR000124]; NIH [P30AI028697] FX This work was supported by the US NIH (R01AR043814 and R21AR065626 (BPT), P01AI083194 (JBH, KMS, RPK, LAC, TJV, MEAR, COJ, BPT and PMG), P01AR049084 (RPK, JCE, EEB, GSA, JDR, RRG and MAP), R01AR064820 (EEB, MAP, RRG, JDR and LMV), P30GM103510, P30AR053483, U01AI101934 and U19AI082714 (JAJ), R01CA141700 and RC1AR058621 (MEAR), P60AR053308 and UL1TR000004 (LAC), P60AR062755 and UL1RR029882 (GSG and DLK), R01AR057172 (COJ), R01AI063274 (PMG), R01AR043274 (KMS), K08AI083790, LRPAI071651 and UL1RR024999 (TBN), R01AR43727 (MAP), K24AR002138, P60AR066464 and 1U54TR001018 (RRG), U54RR023417 (JDR), R01AR051545 and UL1RR025014 (AMS), R21AI070304 (SAB), R01AR042460, N01AR062277, P20RR020143 and R37AI024717 (JBH), P30AR048311 and P30AR055385 (EEB), R01AR033062 (RPK)), the Lupus Foundation of America (BPT), the Alliance for Lupus Research (BPT, YD, KMS, TBN, LAC, COJ and SAB), the Lupus Research Institute (TBN), the US Department of Veterans Affairs (Merit Awards; JBH and GSG), the US Department of Defense (PR094002, JBH), the Arthritis National Research Foundation (Eng Tan Scholar Award; JZ and TBN), the Arthritis Foundation (AMS and PMG), the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI13C2124; SCB), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI13C1754; YWS), the European Science Foundation RNP (BIOLUPUS Research Network), the Wellcome Trust (TJV), Arthritis Research UK (TJV), a Kirkland Scholar Award (LAC), the Wake Forest School of Medicine Center for Public Health Genomics (CDL) and University of California Los Angeles (UCLA) Clinical and Translational Science Institute (CTSI) UL1RR033176 and UL1TR000124. Some RNA samples of healthy controls used in this study were provided by the UCLA/Center for AIDS Research Virology Core Lab which was supported by the NIH grant P30AI028697. NR 47 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2016 VL 75 IS 11 BP 2007 EP 2013 DI 10.1136/annrheumdis-2015-208441 PG 7 WC Rheumatology SC Rheumatology GA EA3AH UT WOS:000386469300020 PM 26783109 ER PT J AU Munroe, ME Lu, RF Zhao, YD Fife, DA Robertson, JM Guthridge, JM Niewold, TB Tsokos, GC Keith, MP Harley, JB James, JA AF Munroe, Melissa E. Lu, Rufei Zhao, Yan D. Fife, Dustin A. Robertson, Julie M. Guthridge, Joel M. Niewold, Timothy B. Tsokos, George C. Keith, Michael P. Harley, John B. James, Judith A. TI Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID CONNECTIVE-TISSUE DISEASE; IMMUNE-COMPLEXES; RHEUMATOID-ARTHRITIS; IFN-GAMMA; ACTIVATION; CELLS; ALPHA; HYDROXYCHLOROQUINE; PATHOGENESIS; CHEMOKINES AB Objectives The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-alpha) activity, and IFN-associated soluble mediators to disease development leading to SLE. Methods Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3 years) and unaffected healthy controls matched by age (+/-5 years), gender, race and time of sample procurement were obtained from the Department of Defense Serum Repository. Levels of serum IFN-a activity, IFN-associated mediators and autoantibodies were evaluated and temporal relationships assessed by growth curve modelling, path analysis, analysis of covariance and random forest models. Results In cases, but not matched controls, autoantibody specificities and IFN-associated mediators accumulated over a period of years, plateauing near the time of disease classification (p<0.001). Autoantibody positivity coincided with or followed type II IFN dysregulation, preceding IFN-a activity in growth curve models, with elevated IFN-a activity and B-lymphocyte stimulator levels occurring shortly before SLE classification (p <= 0.005). Cases were distinguished by multivariate random forest models incorporating IFN-gamma, macrophage chemoattractant protein (MCP)-3, antichromatin and anti-spliceosome antibodies (accuracy 93% >4 years pre-classification; 97% within 2 years of SLE classification). Conclusions Years before SLE classification, enhancement of the type II IFN pathway allows for accumulation of autoantibodies and subsequent elevations in IFN-a activity immediately preceding SLE classification. Perturbations in select immunological processes may help identify at-risk individuals for further clinical evaluation or participation in prospective intervention trials. C1 [Munroe, Melissa E.; Lu, Rufei; Fife, Dustin A.; Robertson, Julie M.; Guthridge, Joel M.; James, Judith A.] Oklahoma Med Res Fdn, Dept Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Lu, Rufei; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med & Pathol, Oklahoma City, OK USA. [Zhao, Yan D.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Tsokos, George C.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Rheumatol, Boston, MA USA. [Keith, Michael P.] Walter Reed Natl Mil Med Ctr, Dept Rheumatol, Bethesda, MD USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP James, JA (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Judith-James@omrf.org OI Niewold, Timothy/0000-0003-3532-6660; Munroe, Melissa/0000-0002-6933-9745 FU National Institute of Allergy, Immunology and Infectious Diseases; Office of Research on Women's Health; National Institute of General Medical Sciences; National Institute of Arthritis, Musculoskeletal and Skin Diseases [U01AI101934, U19AI082714, U54GM104938, P30GM103510, P30AR053483, S10RR026735, AI071651, AR060861]; US Department of Veterans Affairs; NIH [U01HG006828, UL1TR000077, R37AI024717, R21AI103980, P01AI083194, P01AI049084] FX Research reported in this publication was supported by the National Institute of Allergy, Immunology and Infectious Diseases, Office of Research on Women's Health, National Institute of General Medical Sciences and the National Institute of Arthritis, Musculoskeletal and Skin Diseases under award numbers U01AI101934, U19AI082714, U54GM104938, P30GM103510, P30AR053483 and S10RR026735. This material is also the result of work supported with resources and the use of facilities through the Department of Veterans Affairs. Additional support was provided by the National Institute of Allergy, Immunology and Infectious Diseases and National Institute of Arthritis, Musculoskeletal and Skin Diseases under award numbers AI071651 and AR060861 (TBN). JBH would like to acknowledge support from the US Department of Veterans Affairs and NIH grants U01HG006828, UL1TR000077, R37AI024717, R21AI103980, P01AI083194 and P01AI049084. NR 41 TC 8 Z9 8 U1 3 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2016 VL 75 IS 11 BP 2014 EP 2021 DI 10.1136/annrheumdis-2015-208140 PG 8 WC Rheumatology SC Rheumatology GA EA3AH UT WOS:000386469300021 PM 27088255 ER PT J AU Tan, J Linos, E Sendelweck, MA van Zuuren, EJ Ersser, S Dellavalle, RP Williams, H AF Tan, J. Linos, E. Sendelweck, M. A. van Zuuren, E. J. Ersser, S. Dellavalle, R. P. Williams, H. TI Shared decision making and patient decision aids in dermatology SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID FRAMEWORK; PSORIASIS AB Shared decision making combines individual patient interests and values with clinical best evidence under the guiding principle of patient autonomy. Patient decision aids can support shared decision making and facilitate decisions that have multiple options with varying outcomes for which patients may attribute different values. Given the variable psychosocial impact of skin disease on individuals and relative uncertainty regarding best treatments and their adherence in many dermatological conditions, informed shared decision making, supported by patient decision aids, should constitute a central component of dermatological care. C1 [Tan, J.] Western Univ, London, ON, Canada. [Linos, E.] Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA USA. [Sendelweck, M. A.] Univ Colorado, Aurora, CO USA. [van Zuuren, E. J.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands. [Ersser, S.] Univ Leeds, Sch Healthcare, Leeds, W Yorkshire, England. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Williams, H.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England. RP Tan, J (reprint author), Western Univ, London, ON, Canada. EM jerrytan@bellnet.ca RI van Zuuren, Esther/A-9512-2011 OI van Zuuren, Esther/0000-0002-4780-0182 NR 18 TC 0 Z9 0 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD NOV PY 2016 VL 175 IS 5 BP 1045 EP 1048 DI 10.1111/bjd.14803 PG 4 WC Dermatology SC Dermatology GA EA2ZD UT WOS:000386465300042 PM 27790692 ER PT J AU Moon, AM Dominitz, JA Ioannou, GN Lowy, E Beste, LA AF Moon, Andrew M. Dominitz, Jason A. Ioannou, George N. Lowy, Elliott Beste, Lauren A. TI Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE MELD; VA System; NAFLD; Treatment ID OF-VETERANS-AFFAIRS; STAGE LIVER-DISEASE; VARICEAL HEMORRHAGE; PORTAL-HYPERTENSION; BACTERIAL-INFECTION; RANDOMIZED-TRIAL; ENDOSCOPIC SCLEROTHERAPY; HEPATOCELLULAR-CARCINOMA; ESOPHAGEAL-VARICES; PROPHYLAXIS AB BACKGROUND & AIMS: Prophylactic antibiotics are recommended for all patients with cirrhosis hospitalized for upper gastrointestinal bleeding (UGIB). We evaluated the association between use of antibiotics, outcomes of re-admissions, and mortality in these patients. METHODS: We performed a retrospective study of 6451 patients with cirrhosis (mean age, 60.6 y) in the Veterans Affairs health care system hospitalized for UGIB from January 1, 2005, through December 31, 2013 (8655 hospitalizations). We collected information on patients' baseline features, hospitalizations, etiology of UGIB, antibiotics given, hospital re-admission within 30 days of discharge, and mortality. We defined timely administration of antibiotics as receipt from 8 hours before admission through 48 hours afterward. RESULTS: Timely administration of antibiotics occurred during 48.6% of admissions (n = 4210), increasing from 30.6% in 2005 to 58.1% in 2013. Independent predictors of antibiotic receipt included ascites, high model for end-stage liver disease score, esophageal variceal hemorrhage, and administration of octreotide or intravenous proton pump inhibitors. Variables associated with decreased odds of antibiotic provision included black race and nonalcoholic fatty liver disease. In multivariate analysis, timely administration of antibiotics was associated with a reduced 30-day mortality rate (adjusted odds ratio, 0.70; 95% confidence interval, 0.52-0.93; P = .012). CONCLUSIONS: In a study of patients with cirrhosis and UGIB in the VA health care system, timely administration of antibiotics was associated with a 30% reduction in 30-day mortality. The proportion of patients with cirrhosis and UGIB receiving timely antibiotics nearly doubled from 2005 to 2013, but many patients-particularly those with less-advanced cirrhosis-did not receive this intervention. Targeted efforts are needed to promote the appropriate use of antibiotics among patients with cirrhosis and UGIB C1 [Moon, Andrew M.; Dominitz, Jason A.; Ioannou, George N.; Beste, Lauren A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Lowy, Elliott] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Dominitz, Jason A.; Ioannou, George N.; Lowy, Elliott; Beste, Lauren A.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111-GI, Seattle, WA 98108 USA. RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111-GI, Seattle, WA 98108 USA. EM lab25@uw.edu FU HIV, Hepatitis, and Public Health Pathogens Program of the Office of Public Health, Veterans Health Administration; VA Puget Sound Health Care System (Seattle, Washington) FX Supported by the HIV, Hepatitis, and Public Health Pathogens Program of the Office of Public Health, Veterans Health Administration (L.B. and E.L.).; This material is the result of work supported by resources from the VA Puget Sound Health Care System (Seattle, Washington). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 34 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2016 VL 14 IS 11 BP 1629 EP + DI 10.1016/j.cgh.2016.05.040 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA6SV UT WOS:000386760200022 PM 27311621 ER PT J AU Moon, C Phelan, CH Lauver, DR Bratzke, LC AF Moon, Chooza Phelan, Cynthia H. Lauver, Diane R. Bratzke, Lisa C. TI A Narrative Review of How Sleep-Related Breathing Disorders and Cardiovascular Diseases Are Linked An Update for Advanced Practice Registered Nurses SO CLINICAL NURSE SPECIALIST LA English DT Article DE advanced practice registered nurses; apnea syndromes; cardiovascular diseases ID POSITIVE AIRWAY PRESSURE; CORONARY-ARTERY-DISEASE; CONGESTIVE-HEART-FAILURE; ADAPTIVE SERVO-VENTILATION; ACUTE ISCHEMIC-STROKE; BLOOD-PRESSURE; RISK-FACTOR; ATRIAL-FIBRILLATION; APNEA SYNDROME; FOLLOW-UP AB Purpose/Objectives: Sleep-related breathing disorders (SRBDs), including obstructive sleep apnea and central sleep apnea, are common among patients with cardiovascular disease (CVD), but clinicians often do not pay enough attention to SRBDs. The purpose of this narrative review is to update advanced practice registered nurses on the literature focusing on the relationship between SRBDs and CVD (eg, hypertension, heart failure, coronary artery disease, arrhythmias, and stroke) and on treatments that can improve SRBDs in patients with CVD. Description of the Project: We conducted an electronic search of the literature published between 1980 and 2016 from PubMed, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Academic Search Premier, and related health resource Web sites to address the aims of this study. Outcomes: Fifty-six primary research articles (42 observational studies and 14 experimental and quasi-experimental studies) were selected based on our study aims and inclusion criteria. The studies revealed that individuals with CVD are at a greater risk for SRBDs and that SRBDs can worsen CVD. The findings from the studies also suggest that positive airway treatment could improve both SRBDs and CVD. Conclusions: This review found a close relationship between SRBDs and CVD. Advanced practice registered nurses are in key positions to identify and help patients manage SRBDs. In particular, advanced practice registered nurses can educate staff and establish standards of practice to improve outcomes for patients with CVD. C1 [Moon, Chooza; Lauver, Diane R.; Bratzke, Lisa C.] Univ Wisconsin, Sch Nursing, 701 Highland Ave 3156, Madison, WI 53705 USA. [Phelan, Cynthia H.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Moon, C (reprint author), Univ Wisconsin, Sch Nursing, 701 Highland Ave 3156, Madison, WI 53705 USA. EM cmoon4@wisc.edu OI Moon, Chooza/0000-0002-4828-5143 FU National Institute of Nursing Research [R00NR012773]; Clinical and Translational Science Award (CTSA) program through NIH National Center for Advancing Translational Sciences [UL1TR000427] FX The project described was supported by award number R00NR012773 (Brain Alterations and Cognitive Impairment in Older Adults with Heart Failure) from the National Institute of Nursing Research and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences, grant UL1TR000427. NR 81 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0887-6274 EI 1538-9782 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD NOV-DEC PY 2016 VL 30 IS 6 BP 347 EP 362 DI 10.1097/NUR.0000000000000247 PG 16 WC Nursing SC Nursing GA EA4IG UT WOS:000386574200011 PM 27753673 ER PT J AU Miraflor, AP LeBoit, PE Hirschman, SA AF Miraflor, Allen P. LeBoit, Philip E. Hirschman, Scott A. TI Intraepidermal Merkel cell carcinoma with pagetoid Bowen's disease SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Editorial Material DE cutaneous neoplasm; squamous cell carcinoma in-situ; non-melanoma skin cancer; skin tumors; UV stress ID IN-SITU; NEUROENDOCRINE CARCINOMA; POLYOMAVIRUS; SKIN C1 [Miraflor, Allen P.] Dartmouth Hitchcock Med Ctr, Dept Pathol, 1 Med Ctr Dr, Lebanon, NH 03766 USA. [LeBoit, Philip E.] Univ Calif San Francisco, Dept Dermatopathol, 1701 Divisadero St,Suite 280, San Francisco, CA 94115 USA. [Hirschman, Scott A.] US Dept Vet Affairs, Dept Pathol, 215 N Main St, White River Jct, VT 05009 USA. RP Hirschman, SA (reprint author), US Dept Vet Affairs, Dept Pathol, 215 N Main St, White River Jct, VT 05009 USA. EM Scott.Hirschman@va.gov NR 26 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6987 EI 1600-0560 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD NOV PY 2016 VL 43 IS 11 BP 921 EP 926 DI 10.1111/cup.12813 PG 6 WC Dermatology; Pathology SC Dermatology; Pathology GA EA7AC UT WOS:000386779400001 PM 27758029 ER PT J AU Axon, RN Gebregziabher, M Dismuke, CE Hunt, KJ Yeager, D Ana, EJS Egede, LE AF Axon, R. Neal Gebregziabher, Mulugeta Dismuke, Clara E. Hunt, Kelly J. Yeager, Derik Ana, Elizabeth J. Santa Egede, Leonard E. TI Differential Impact of Homelessness on Glycemic Control in Veterans with Type 2 Diabetes Mellitus SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE diabetes mellitus; homelessness; healthcare disparities; access to care; Veterans ID EMERGENCY-DEPARTMENTS; HEALTH SYSTEM; LOS-ANGELES; ADULTS; CARE; INDIVIDUALS; PREVALENCE; DISEASE AB Veterans with evidence of homelessness have high rates of mental health and substance abuse disorders, but chronic medical conditions such as diabetes are also prevalent. We aimed to determine the impact of homelessness on glycemic control in patients with type 2 diabetes mellitus. Longitudinal analysis of a retrospective cohort. A national cohort of 1,263,906 Veterans with type 2 diabetes. Subjects with evidence of homelessness were identified using a combination of diagnostic and administrative codes. Odds for poor glycemic control using hemoglobin A1C (HbA1C) cutoff values of 8 % and 9 %. Homeless defined as a score based on the number of indicator variables for homelessness within a veterans chart. Veterans with evidence of homelessness had a significantly greater annual mean HbA1C aeyen 8 (32.6 % vs. 20.43 %) and HbA1C aeyen 9 (21.4 % vs. 9.9 %), tended to be younger (58 vs. 67 years), were more likely to be non-Hispanic black (39.1 %), divorced (43 %) or never married (34 %), to be urban dwelling (88.8 %), and to have comorbid substance abuse (46.7 %), depression (42.3 %), psychoses (39.7 %), liver disease (18.8 %), and fluid/electrolyte disorders (20.4 %), relative to non-homeless veterans (all p < 0.0001). Homelessness was modeled as an ordinal variable that scored the number of times a homelessness indicator was found in the Veterans medical record. We observed a significant interaction between homelessness and race/ethnicity on the odds of poor glycemic control. Homelessness, across all racial-ethnic groups, was associated with increased odds of uncontrolled diabetes at a cut-point of 8 % and 9 % for hemoglobin A1C ; however, the magnitude of the association was greater in non-Hispanic whites [8 %, OR 1.55 (1.47;1.63)] and Hispanics [8 %, OR 2.11 (1.78;2.51)] than in non-Hispanic blacks [8 %, OR 1.22 (1.15;1.28)]. Homelessness is a significant risk factor for uncontrolled diabetes in Veterans, especially among non-Hispanic white and Hispanic patients. While efforts to engage homeless patients in primary care services have had some success in recent years, these data suggest that broader efforts targeting management of diabetes and other chronic medical conditions remain warranted. C1 [Axon, R. Neal; Gebregziabher, Mulugeta; Dismuke, Clara E.; Hunt, Kelly J.; Yeager, Derik; Ana, Elizabeth J. Santa; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Axon, R. Neal; Dismuke, Clara E.] Med Univ South Carolina, Div Gen Internal Med, Dept Med, Charleston, SC USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Ana, Elizabeth J. Santa] Med Univ South Carolina, Dept Psychiat, Charleston, SC USA. [Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development (HSRD) program [IIR-06-219] FX This study was supported by grant #IIR-06-219 funded by the VHA Health Services Research and Development (HSR&D) program (PI: Leonard Egede). The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The manuscript represents the views of the authors and not those of the VA or HSR&D. NR 45 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2016 VL 31 IS 11 BP 1331 EP 1337 DI 10.1007/s11606-016-3786-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EA5SL UT WOS:000386683200016 PM 27418346 ER PT J AU Jacobs, EA Walker, CM Miller, T Fletcher, KE Ganschow, PS Imbert, D O'Connell, M Neuner, JM Schapira, MM AF Jacobs, Elizabeth A. Walker, Cindy M. Miller, Tamara Fletcher, Kathlyn E. Ganschow, Pamela S. Imbert, Diana O'Connell, Maria Neuner, Joan M. Schapira, Marilyn M. TI Development and Validation of the Spanish Numeracy Understanding in Medicine Instrument SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cross cultural research; health numeracy; health literacy; measurement; Spanish language ID FUNCTIONAL HEALTH LITERACY; ITEM RESPONSE THEORY; RISK COMMUNICATIONS; PRIMARY-CARE; SCALE; INFORMATION; FRAMEWORK; SKILLS; COMPREHENSION; ASSOCIATION AB The Spanish-speaking population in the U.S. is large and growing and is known to have lower health literacy than the English-speaking population. Less is known about the health numeracy of this population due to a lack of health numeracy measures in Spanish. we aimed to develop and validate a short and easy to use measure of health numeracy for Spanish-speaking adults: the Spanish Numeracy Understanding in Medicine Instrument (Spanish-NUMi). Items were generated based on qualitative studies in English- and Spanish-speaking adults and translated into Spanish using a group translation and consensus process. Candidate items for the Spanish NUMi were selected from an eight-item validated English Short NUMi. Differential Item Functioning (DIF) was conducted to evaluate equivalence between English and Spanish items. Cronbach's alpha was computed as a measure of reliability and a Pearson's correlation was used to evaluate the association between test scores and the Spanish Test of Functional Health Literacy (S-TOFHLA) and education level. Two-hundred and thirty-two Spanish-speaking Chicago residents were included in the study. The study population was diverse in age, gender, and level of education and 70 % reported Mexico as their country of origin. Two items of the English eight-item Short NUMi demonstrated DIF and were dropped. The resulting six-item test had a Cronbach's alpha of 0.72, a range of difficulty using classical test statistics (percent correct: 0.48 to 0.86), and adequate discrimination (item-total score correlation: 0.34-0.49). Scores were positively correlated with print literacy as measured by the S- TOFHLA (r = 0.67; p < 0.001) and varied as predicted across grade level; mean scores for up to eighth grade, ninth through twelfth grade, and some college experience or more, respectively, were 2.48 (SD +/- 1.64), 4.15 (SD +/- 1.45), and 4.82 (SD +/- 0.37). The Spanish NUMi is a reliable and valid measure of important numerical concepts used in communicating health information. C1 [Jacobs, Elizabeth A.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Walker, Cindy M.; Miller, Tamara] Univ Wisconsin, Dept Educ Psychol, Milwaukee, WI 53201 USA. [Fletcher, Kathlyn E.; Neuner, Joan M.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Fletcher, Kathlyn E.; Neuner, Joan M.] Zablocki VA Med Ctr, Milwaukee, WI USA. [Ganschow, Pamela S.; O'Connell, Maria] Rush Univ, Sch Med, Dept Med, Chicago, IL 60612 USA. [Imbert, Diana; Schapira, Marilyn M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res Program, Philadelphia, PA USA. RP Jacobs, EA (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA. EM eajacobs@medicine.wisc.edu RI imbert, daniel/H-7850-2014 FU National Cancer Institute of the National Institutes of Health [NC1R01CA115954]; American Cancer Society [121158-RSG-11-104-01-CPPB] FX This work was supported by grants from the National Cancer Institute of the National Institutes of Health NC1R01CA115954 and the American Cancer Society 121158-RSG-11-104-01-CPPB. NR 48 TC 1 Z9 1 U1 5 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2016 VL 31 IS 11 BP 1345 EP 1352 DI 10.1007/s11606-016-3759-2 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EA5SL UT WOS:000386683200018 PM 27312095 ER PT J AU McNamara, M Batur, P Walsh, JME Johnson, KM AF McNamara, Megan Batur, Pelin Walsh, Judith M. E. Johnson, Kay M. TI HPV Update: Vaccination, Screening, and Associated Disease SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE HPV; vaccination; screening; cervical cancer; prevention ID HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER; INTRAEPITHELIAL NEOPLASIA; UNITED-STATES; WOMEN; METAANALYSIS; PREVALENCE; GUIDELINES; RECOMMENDATIONS; PREDICTORS AB Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening. C1 [McNamara, Megan] Case Western Reserve Univ, Sch Med, Dept Med, 10701 East Blvd, Cleveland, OH 44106 USA. [McNamara, Megan] Louis Stokes Cleveland Vet Affairs Med Ctr, 10701 East Blvd, Cleveland, OH 44106 USA. [Batur, Pelin] Cleveland Clin, Dept Med & Primary Care Womens Hlth, Cleveland, OH 44106 USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94143 USA. [Johnson, Kay M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Johnson, Kay M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP McNamara, M (reprint author), Case Western Reserve Univ, Sch Med, Dept Med, 10701 East Blvd, Cleveland, OH 44106 USA.; McNamara, M (reprint author), Louis Stokes Cleveland Vet Affairs Med Ctr, 10701 East Blvd, Cleveland, OH 44106 USA. EM megan.mcnamara@va.gov NR 32 TC 1 Z9 1 U1 21 U2 21 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2016 VL 31 IS 11 BP 1360 EP 1366 DI 10.1007/s11606-016-3725-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EA5SL UT WOS:000386683200026 PM 27184752 ER PT J AU Blackburn, R Estrada, CA McCollum, D AF Blackburn, Reaford, Jr. Estrada, Carlos A. McCollum, David TI Empathy as a Diagnostic Tool in a 33-Year-Old Man with Eye Pain and Vision Loss: Exercises in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical reasoning; empathy; uveitis; syphilis; HIV infection ID CARE; SPECTRUM; MEDICINE; SYPHILIS; ERRORS C1 [Blackburn, Reaford, Jr.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.; McCollum, David] Univ Alabama Birmingham, 720 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, 720 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uabmc.edu NR 13 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2016 VL 31 IS 11 BP 1389 EP 1392 DI 10.1007/s11606-016-3797-9 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EA5SL UT WOS:000386683200031 PM 27456235 ER PT J AU Mihara, K AF Mihara, Kip TI Omphalolith: An Umbilical Concretion to Recognize SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical image; dermatology; dementia C1 [Mihara, Kip] San Francisco VA Med Ctr, Emergency Dept, 4150 Clement St,Mail Code 111A3, San Francisco, CA 94121 USA. [Mihara, Kip] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. RP Mihara, K (reprint author), San Francisco VA Med Ctr, Emergency Dept, 4150 Clement St,Mail Code 111A3, San Francisco, CA 94121 USA. EM kip.mihara@va.gov NR 3 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2016 VL 31 IS 11 BP 1396 EP 1396 DI 10.1007/s11606-016-3708-0 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EA5SL UT WOS:000386683200034 PM 27114363 ER PT J AU Podbielska, M Das, A Smith, AW Chauhan, A Ray, SK Inoue, J Azuma, M Nozaki, K Hogan, EL Banik, NL AF Podbielska, Maria Das, Arabinda Smith, Amena W. Chauhan, Ashok Ray, Swapan K. Inoue, Jun Azuma, Mitsuyoshi Nozaki, Kenkichi Hogan, Edward L. Banik, Naren L. TI Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE calpain; microglia; microgliosis; multiple sclerosis; neurodegeneration; neurons ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATION-MEDIATED NEURODEGENERATION; PROVIDES FUNCTIONAL NEUROPROTECTION; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; INTERFERON-GAMMA; REACTIVE MICROGLIOSIS; CYTOKINE PROFILE; OPTIC NEURITIS; AXONAL INJURY AB Activated microglia release pro-inflammatory factors and calpain into the extracellular milieu, damaging surrounding neurons. However, mechanistic links to progressive neurodegeneration in disease such as multiple sclerosis (MS) remain obscure. We hypothesize that persistent damaged/dying neurons may also release cytotoxic factors and calpain into the media, which then activate microglia again. Thus, inflammation, neuronal damage, and microglia activation, i. e., bi-directional interaction between neurons and microglia, may be involved in the progressive neurodegeneration. We tested this hypothesis using two in vitro models: (i) the effects of soluble factors from damaged primary cortical neurons upon primary rat neurons and microglia and (ii) soluble factors released from CD3/CD28 activated peripheral blood mononuclear cells of MS patients on primary human neurons and microglia. The first model indicated that neurons due to injury with pro-inflammatory agents (IFN-c) release soluble neurotoxic factors, including COX-2, reactive oxygen species, and calpain, thus activating microglia, which in turn released neurotoxic factors as well. This repeated microglial activation leads to persistent inflammation and neurodegeneration. The released calpain from neurons and microglia was confirmed by the use of calpain inhibitor calpeptin or SNJ-1945 as well as mu- and m-calpain knock down using the small interfering RNA (siRNA) technology. Our second model using activated peripheral blood mononuclear cells, a source of proinflammatory Th1/Th17 cytokines and calpain released from auto-reactive T cells, corroborated similar results in human primary cell cultures and confirmed calpain to be involved in progressive MS. These insights into reciprocal paracrine regulation of cell injury and calpain activation in the progressive phase of MS, Parkinson's disease, and other neurodegenerative diseases suggest potentially beneficial preventive and therapeutic strategies, including calpain inhibition. C1 [Podbielska, Maria; Das, Arabinda; Smith, Amena W.; Hogan, Edward L.; Banik, Naren L.] Med Univ South Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,309 CSB, Charleston, SC 29425 USA. [Podbielska, Maria; Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Podbielska, Maria] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Lab Signaling Prot, Wroclaw, Poland. [Chauhan, Ashok; Ray, Swapan K.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA. [Azuma, Mitsuyoshi] Senju Pharmaceut Co LTD, Kobe, Hyogo, Japan. [Nozaki, Kenkichi] Univ Alabama Birmingham, Sch Med, Dept Neurol, Birmingham, AL USA. RP Banik, NL (reprint author), Med Univ South Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,309 CSB, Charleston, SC 29425 USA. EM baniknl@musc.edu FU National Institute of Neurological Disorders - National Institutes of Health, Bethesda, MD, USA [NS-41088, NS-56176, NS-65456]; Veterans Affairs [5I01BX002349-02]; Kosciuszko Foundation; Polish-U.S Fulbright Commission FX We gratefully acknowledge the funding support in part by the R01 grants from the National Institute of Neurological Disorders - National Institutes of Health, Bethesda, MD, USA (NS-41088, NS-56176 and NS-65456); non-HHS Research Project (101) award from Veterans Affairs (5I01BX002349-02) for the work to NLB. Special thanks are to the Kosciuszko Foundation for the fellowship 2014/15 and to the Polish-U.S Fulbright Commission (2015/16 Senior Award Grant) to MP. The authors also thank Mrs. Katarzyna Izydorczyk for her excellent graphic skills in rendering the diagrams of the cell treatments and the Figure 8 depicting the mechanisms proposed for microglia-neuron interactions to drive progressive MS. We also thank Ms. Denise Matzelle for editorial assistance in the manuscript. The authors have no conflicting financial interests. Calpain inhibitor SNJ-1945 was obtained from Senju Pharmaceuticals, Kobe, Japan. NR 71 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD NOV PY 2016 VL 139 IS 3 BP 440 EP 455 DI 10.1111/jnc.13774 PG 16 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA EB0ZO UT WOS:000387076000009 PM 27529445 ER PT J AU Farris, SG Metrik, J Bonn-Miller, MO Kahler, CW Zvolensky, MJ AF Farris, Samantha G. Metrik, Jane Bonn-Miller, Marcel O. Kahler, Christopher W. Zvolensky, Michael J. TI Anxiety Sensitivity and Distress Intolerance as Predictors of Cannabis Dependence Symptoms, Problems, and Craving: The Mediating Role of Coping Motives SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID MARIJUANA USE MOTIVES; COGNITIVE-BEHAVIORAL THERAPY; BREATH-HOLDING DURATION; EARLY SMOKING LAPSE; USE DISORDERS; INCREMENTAL VALIDITY; TOLERANCE TREATMENT; YOUNG-ADULTS; VALIDATION; ALCOHOL AB Objective: The tendency to react with fear to anxiety related sensations (anxiety sensitivity) and the inability to tolerate distressing psychological or physiological states (distress intolerance) are implicated in the comorbidity between affective psychopathology and cannabis use disorders. Emotionally vulnerable cannabis users may be particularly apt to use cannabis to cope with distress, which may both lead to and maintain its problematic use (e.g., dependence, craving). The current study tested a comprehensive model of anxiety sensitivity and distress intolerance as predictors of the number of cannabis dependence symptoms and problems, and severity of cannabis craving following deprivation from cannabis, and the mediating role of cannabis coping motives. Method: Participants (n = 103; mean age = 21.2 years, SD = 4.3; 35.9% female) were non treatment-seeking frequent cannabis users. Data were cross-sectional in nature. Anxiety sensitivity was assessed via self-report, and distress intolerance was assessed via both self-report and breath-holding duration. Results: Greater perceived distress intolerance, but not breath-holding duration or anxiety sensitivity, was associated with a greater number of cannabis dependence symptoms and problems and elevated cannabis craving. These relations were mediated by cannabis coping motives. Conclusions: Findings provide specificity for the etiologic mechanisms related to emotional vulnerability and maintenance of cannabis problems. Perceived distress intolerance appears to be uniquely related to maladaptive coping motives for cannabis use, which could be meaningfully targeted in interventions for emotionally vulnerable cannabis users. C1 [Farris, Samantha G.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA. [Farris, Samantha G.] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Metrik, Jane] Providence Vet Affairs Med Ctr, Providence, RI USA. [Metrik, Jane; Kahler, Christopher W.] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. [Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA. [Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. RP Metrik, J (reprint author), Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. EM Jane_Metrik@brown.edu FU National Institute on Drug Abuse [R03 DA027484, F31-DA035564-03]; Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education FX This study was funded by National Institute on Drug Abuse Grant R03 DA027484, awarded to Jane Metrik and Valerie S. Knopik. Marcel O. Bonn Miller's work on this project was supported by the Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education. Samantha G. Farris is supported by a pre-doctoral National Research Service Award from the National Institute on Drug Abuse (F31-DA035564-03). The funding sources had no role other than financial support. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 70 TC 0 Z9 0 U1 7 U2 7 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD NOV PY 2016 VL 77 IS 6 BP 889 EP 897 PG 9 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA EA9TC UT WOS:000386986600006 PM 27797690 ER PT J AU Hill, MK Pishkenari, AK Braunberger, TL Armstrong, AW Dunnick, CA AF Hill, Mary K. Pishkenari, Azin Kheirandish Braunberger, Taylor L. Armstrong, April W. Dunnick, Cory A. TI Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; LACTOBACILLUS-ACIDOPHILUS L-92; MULTICENTER CLINICAL-TRIAL; VITAMIN-D SUPPLEMENTATION; LOW-DOSE CYCLOSPORINE; DOUBLE-BLIND; OUTCOME MEASURES; ADULT PATIENTS; TACROLIMUS OINTMENT AB Background: A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. Objective: We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. Methods: A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. Results: All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. Limitations: This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. Conclusion: Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence. C1 [Hill, Mary K.; Pishkenari, Azin Kheirandish] Univ Colorado, Sch Med, Aurora, CO USA. [Braunberger, Taylor L.] Univ North Dakota, Sch Med, Grand Forks, ND USA. [Armstrong, April W.] Univ Southern Calif, Dept Dermatol, Los Angeles, CA USA. [Dunnick, Cory A.] Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. [Dunnick, Cory A.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Denver, CO USA. RP Dunnick, CA (reprint author), Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. EM cory.dunnick@ucdenver.edu NR 160 TC 1 Z9 1 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD NOV PY 2016 VL 75 IS 5 BP 906 EP 917 DI 10.1016/j.jaad.2016.07.002 PG 12 WC Dermatology SC Dermatology GA EA6WJ UT WOS:000386769500017 PM 27615798 ER PT J AU Kraemer, K Cohen, ME Liu, YM Barnhart, DC Rangel, SJ Saito, JM Bilimoria, KY Ko, CY Hall, BL AF Kraemer, Kari Cohen, Mark E. Liu, Yaoming Barnhart, Douglas C. Rangel, Shawn J. Saito, Jacqueline M. Bilimoria, Karl Y. Ko, Clifford Y. Hall, Bruce L. TI Development and Evaluation of the American College of Surgeons NSQIP Pediatric Surgical Risk Calculator SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID SHARED DECISION-MAKING; MORTALITY; ADJUSTMENT; PREDICTION; VALIDATION; CHILDREN; QUALITY AB BACKGROUND: There is an increased desire among patients and families to be involved in the surgical decision-making process. A surgeon's ability to provide patients and families with patient-specific estimates of postoperative complications is critical for shared decision making and informed consent. Surgeons can also use patient-specific risk estimates to decide whether or not to operate and what options to offer patients. Our objective was to develop and evaluate a publicly available risk estimation tool that would cover many common pediatric surgical procedures across all specialties. STUDY DESIGN: American College of Surgeons NSQIP Pediatric standardized data from 67 hospitals were used to develop a risk estimation tool. Surgeons enter 18 preoperative variables (demographics, comorbidities, procedure) that are used in a logistic regression model to predict 9 postoperative outcomes. A surgeon adjustment score is also incorporated to adjust for any additional risk not accounted for in the 18 risk factors. RESULTS: A pediatric surgical risk calculator was developed based on 181,353 cases covering 382 CPT codes across all specialties. It had excellent discrimination for mortality (c-statistic = 0.98), morbidity (c-statistic = 0.81), and 7 additional complications (c-statistic > 0.77). The Hosmer-Lemeshow statistic and graphic representations also showed excellent calibration. CONCLUSIONS: The ACS NSQIP Pediatric Surgical Risk Calculator was developed using standardized and audited multi-institutional data from the ACS NSQIP Pediatric, and it provides empirically derived, patient-specific postoperative risks. It can be used as a tool in the shared decision-making process by providing clinicians, families, and patients with useful information for many of the most common operations performed on pediatric patients in the US. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.) C1 [Kraemer, Kari; Cohen, Mark E.; Liu, Yaoming; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Northwestern Med, Chicago, IL 60611 USA. [Barnhart, Douglas C.] Univ Utah, Div Pediat Surg, Primary Childrens Med Ctr, Salt Lake City, UT USA. [Rangel, Shawn J.] Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Boston, MA USA. [Saito, Jacqueline M.; Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kraemer, K (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM kkraemer@facs.org NR 18 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD NOV PY 2016 VL 223 IS 5 BP 685 EP 693 DI 10.1016/j.jamcollsurg.2016.08.542 PG 9 WC Surgery SC Surgery GA EA6TO UT WOS:000386762100002 PM 27666656 ER PT J AU Jovanovich, A Chonchol, M AF Jovanovich, Anna Chonchol, Michel TI Calcific Uremic Arteriolopathy Revisited SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID CALCIPHYLAXIS C1 [Jovanovich, Anna] Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO USA. [Jovanovich, Anna; Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Aurora, CO USA. RP Jovanovich, A (reprint author), 13199 East Montview Blvd,Suite 495, Aurora, CO 80045 USA. EM michel.chonchol@ucdenver.edu NR 12 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD NOV PY 2016 VL 27 IS 11 BP 3233 EP 3235 DI 10.1681/ASN.2016040480 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA EA3VV UT WOS:000386538300003 PM 27225039 ER PT J AU Karp, JF McGovern, J Marron, MM Gerszten, P Weiner, DK Okonkwo, D Kanter, AS AF Karp, Jordan F. McGovern, Jonathan Marron, Megan M. Gerszten, Peter Weiner, Debra K. Okonkwo, David Kanter, Adam S. TI Clinical and neuropsychiatric correlates of lumbar spinal surgery in older adults: results of a pilot study SO PAIN MANAGEMENT LA English DT Article DE aging; complications; lumbar spine; predictors; psychiatric; spinal stenosis ID LOW-BACK-PAIN; MINI-MENTAL-STATE; GAIT SPEED; PHYSICAL FUNCTION; ELDERLY-PEOPLE; WALKING SPEED; PRIMARY-CARE; PREDICTORS; STENOSIS; DEPRESSION AB Aim: To improve selection of older lumbar surgical candidates, we surveyed correlates of functioning and satisfaction with surgery. Materials & methods: Prospective sample at lumbar spine surgery clinic. Patients (n = 48) were evaluated before surgery and after 3 months. Dependent variables were functioning and surgical satisfaction. Results: Baseline variables associated with disability at 3 months included cognitive status and widespread pain. There was clinically significant improvement with moderate effects sizes for anxiety and depression at follow-up. Patients with at least a 30% improvement in disability had better physical health-related quality of life and were less likely to report widespread pain before surgery. Conclusion: Although preliminary, two novel potential predictors of lumbar surgery outcome include diminished cognitive functioning and widespread pain. Further study of these variables on post-surgical functioning and satisfaction may improve patient selection. C1 [Karp, Jordan F.; Marron, Megan M.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Karp, Jordan F.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15261 USA. [McGovern, Jonathan] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Gerszten, Peter; Okonkwo, David; Kanter, Adam S.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Karp, JF (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA.; Karp, JF (reprint author), VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15261 USA. EM karpjf@upmc.edu FU NIA NIH HHS [R01 AG033575] NR 42 TC 0 Z9 0 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-1869 EI 1758-1877 J9 PAIN MANAG JI Pain Manag. PD NOV PY 2016 VL 6 IS 6 BP 543 EP 552 DI 10.2217/pmt.16.9 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA EA5WK UT WOS:000386695000005 PM 27102978 ER PT J AU Elperin, JM Suriany, S Lee, GE French, SW Gukovskaya, AS Gukovsky, I Mareninova, OA AF Elperin, J. M. Suriany, S. Lee, G. E. French, S. W. Gukovskaya, A. S. Gukovsky, I. Mareninova, O. A. TI Downregulation of Atg4B Stimulates Autophagy and Ameliorates Alcohol-Induced Pancreatic Injury SO PANCREAS LA English DT Meeting Abstract C1 [Elperin, J. M.; Suriany, S.; Lee, G. E.; Gukovskaya, A. S.; Gukovsky, I.; Mareninova, O. A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Elperin, J. M.; Suriany, S.; Lee, G. E.; Gukovskaya, A. S.; Gukovsky, I.; Mareninova, O. A.] Univ Calif Los Angeles, Los Angeles, CA USA. [French, S. W.] Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2016 VL 45 IS 10 BP 1523 EP 1523 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA9QG UT WOS:000386978400141 ER PT J AU Takakura, K Mascarinas, E Decant, B Dawson, D Eibl, G Gukovskaya, A Grippo, P AF Takakura, K. Mascarinas, E. Decant, B. Dawson, D. Eibl, G. Gukovskaya, A. Grippo, P. TI Haploinsufficiency of Beclin1 Inhibits PanIN Development in a Kras(G12D) Mouse Model of Pancreatic Tumorigenesis SO PANCREAS LA English DT Meeting Abstract C1 [Takakura, K.; Gukovskaya, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Takakura, K.; Gukovskaya, A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mascarinas, E.; Decant, B.; Grippo, P.] Univ Illinois, Dept Med, Chicago, IL USA. [Dawson, D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Eibl, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2016 VL 45 IS 10 BP 1541 EP 1541 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA9QG UT WOS:000386978400214 ER PT J AU Yuan, J Qin, Y Malla, SR Geng, M Waldron, RT Mareninova, OA Lugea, A Pandol, SJ Gukovskaya, AS AF Yuan, J. Qin, Y. Malla, S. R. Geng, M. Waldron, R. T. Mareninova, O. A. Lugea, A. Pandol, S. J. Gukovskaya, A. S. TI Genetic Ablation of Mitochondrial Deacetylase Sirtuin 3 Exacerbates Cerulein Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 [Yuan, J.; Qin, Y.; Malla, S. R.; Geng, M.; Waldron, R. T.; Mareninova, O. A.; Lugea, A.; Pandol, S. J.; Gukovskaya, A. S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yuan, J.; Qin, Y.; Malla, S. R.; Geng, M.; Waldron, R. T.; Mareninova, O. A.; Lugea, A.; Pandol, S. J.; Gukovskaya, A. S.] Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. [Qin, Y.] Youjiang Med Univ Nationalities, Div Gastroenterol & Hepatol, Baise, Peoples R China. [Geng, M.] Quinnipiac Univ, Frank Netter H MD Sch Med, North Haven, CT USA. [Waldron, R. T.; Lugea, A.; Pandol, S. J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2016 VL 45 IS 10 BP 1550 EP 1550 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA9QG UT WOS:000386978400249 ER PT J AU Elicker, BM Jones, KT Naeger, DM Frank, JA AF Elicker, Brett M. Jones, Kirk T. Naeger, David M. Frank, James A. TI Imaging of Acute Lung Injury SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS); Diffuse alveolar damage (DAD); Acute interstitial pneumonia (AIP); Acute fibrinous organizing pneumonia (AFOP); Acute eosinophilic pneumonia (AEP) ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE INTERSTITIAL PNEUMONIA; DIFFUSE ALVEOLAR DAMAGE; ACUTE EOSINOPHILIC PNEUMONIA; IDIOPATHIC PULMONARY-FIBROSIS; THIN-SECTION CT; RESOLUTION COMPUTED-TOMOGRAPHY; ORGANIZING PNEUMONIA; ACUTE EXACERBATION; BERLIN DEFINITION AB Acute lung injury (ALI) is the clinical syndrome associated with histopathologic diffuse alveolar damage. It is a common cause of acute respiratory symptoms and admission to the intensive care unit. Diagnosis of ALI is typically based on clinical and radiographic criteria; however, because these criteria can be nonspecific, diagnostic uncertainty is common. A multidisciplinary approach that synthesizes clinical, imaging, and pathologic data can ensure an accurate diagnosis. Radiologists must be aware of the radiographic and computed tomographic findings of ALI and its mimics. This article discusses the multidisciplinary diagnosis of ALI from the perspective of the imager. C1 [Elicker, Brett M.] Univ Calif San Francisco, Cardiac & Pulm Imaging Sect, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. [Jones, Kirk T.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,Box 0102, San Francisco, CA 94143 USA. [Naeger, David M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. [Frank, James A.] San Francisco VA Med Ctr, Div Pulm Crit Care Allergy & Sleep, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. RP Elicker, BM (reprint author), Univ Calif San Francisco, Cardiac & Pulm Imaging Sect, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM brett.elicker@ucsf.edu NR 48 TC 1 Z9 1 U1 6 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD NOV PY 2016 VL 54 IS 6 BP 1119 EP + DI 10.1016/j.rcl.2016.05.006 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EA3ZG UT WOS:000386547200009 PM 27719979 ER PT J AU Mouallem, A Sarraf, D Chen, XJ Capuano, V Souied, EH Querques, G AF Mouallem, Alexandra Sarraf, David Chen, Xuejing Capuano, Vittorio Souied, Eric H. Querques, Giuseppe TI DOUBLE RETINAL PIGMENT EPITHELIUM TEARS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE anti-VEGF; fluorescein angiography; fundus autofluorescence; neovascular age-related macular degeneration; retinal pigment epithelium tear; spectral-domain optical coherence tomography; vascularized pigment epithelium detachment ID ANTI-VEGF THERAPY; PHOTODYNAMIC THERAPY; RANIBIZUMAB; MECHANISM AB Purpose: To describe the occurrence and treatment outcomes of double retinal pigment epithelium (RPE) tears in neovascular age-related macular degeneration and to elucidate the mechanism of tear development by means of multimodal imaging analysis. Methods: Fundus autofluorescence, spectral-domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography were retrospectively studied before and after the occurrence of first and second RPE tears and at the final visit. Results: Twelve eyes of 10 patients that developed double RPE tears, either simultaneously (6 eyes) or at variable intervals after repeated intravitreal anti-vascular endothelial growth factor administration (6 eyes), were included. First RPE tears developed after a mean of 4.5 +/- 2.7 anti-vascular endothelial growth factor injections; second RPE tears developed after a mean of 7.1 +/- 5.2 anti-vascular endothelial growth factor injections. Mean best-corrected visual acuity was 20/63 at baseline evaluation, 20/76 after occurrence of first tear, 20/90 after occurrence of second tear, and 20/95 at final visit (P > 0.05 for all). Multimodal imaging revealed in all cases a Type 1 neovascular lesion adherent to the posterior surface of the RPE and spanning a significant portion of the pigment epithelium detachment with variable orientation; after development of double tears, the RPE seemed retracted on both borders of the neovascular network. Conclusion: Double RPE tears may occur on opposite sides of a vascularized pigment epithelium detachment, in eyes with neovascular age-related macular degeneration after anti-vascular endothelial growth factor therapy, because of neovascular contraction of a Type 1 neovascular complex, adherent to the posterior surface of the RPE and spanning a significant portion of the pigment epithelium detachment area. C1 [Mouallem, Alexandra; Capuano, Vittorio; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France. [Sarraf, David; Chen, Xuejing] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Stein Eye Inst, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Sarraf, David] Kaiser Permanente Med Ctr, Woodland Hills, CA USA. RP Querques, G (reprint author), Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France. EM giuseppe.querques@hotmail.it NR 16 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD NOV PY 2016 VL 36 IS 11 BP 2197 EP 2204 PG 8 WC Ophthalmology SC Ophthalmology GA EB1AY UT WOS:000387079800028 PM 27145251 ER PT J AU Nuschke, A Rodrigues, M Rivera, J Yates, C Whaley, D Stolz, D Griffith, L Wells, A AF Nuschke, Austin Rodrigues, Melanie Rivera, Jaime Yates, Cecelia Whaley, Diana Stolz, Donna Griffith, Linda Wells, Alan TI Epidermal Growth Factor Tethered to beta-Tricalcium Phosphate Bone Scaffolds via a High-Affinity Binding Peptide Enhances Survival of Human Mesenchymal Stem Cells/Multipotent Stromal Cells in an Immune-Competent Parafascial Implantation Assay in Mice SO STEM CELLS TRANSLATIONAL MEDICINE LA English DT Article DE Multipotent stem cells; Mesenchymal stem cells; Surface-tethered epidermal growth factor; beta-Tricalcium phosphate; Stem cell survival ID FACTOR RECEPTOR; SIGNALING PATHWAY; IN-VIVO; MARROW; DIFFERENTIATION; ANGIOGENESIS; ACTIVATION; MOTILITY; HEART; FASL AB Mesenchymal stem cells/multipotent stromal cells (MSCs) are attractive candidates for cell therapies owing to their ability to differentiate into many lineages. However, these cells often fail to survive when implanted into a harsh wound environment, limiting efficacy in vivo. To improve MSC survival, we previously found that tethered epidermal growth factor (tEGF) molecules that restrict epidermal growth factor receptor (EGFR) signaling to the cell surface provide resistance to death signals. To adapt this system to wound healing, we tethered epidermal growth factor (EGF) to tricalcium phosphate (TCP) particle scaffolds, clinically used in bone healing. Human primary MSCs seeded on TCP and mixed into a collagen-based gel were injected in the perifascial space of immunocompetent mice with or without tEGF attached to the surface. We found that tethering EGF to the TCP scaffolds yielded approximately a fourfold increase in MSC survival compared with non-EGF scaffolds at 21 days, as well as significant improvements in survival in the short term at 2 and 7 days after implantation. Overall, our approach to sustaining EGFR signaling reduced MSC death in vivo and may be useful for future cell therapies where MSCs typically die on implantation. C1 [Nuschke, Austin; Rodrigues, Melanie; Yates, Cecelia; Whaley, Diana; Wells, Alan] Univ Pittsburgh, Dept Pathol, S713 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Whaley, Diana; Stolz, Donna] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA. [Yates, Cecelia] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA USA. [Nuschke, Austin; Yates, Cecelia; Stolz, Donna; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA. [Yates, Cecelia; Wells, Alan] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Rivera, Jaime; Griffith, Linda] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, S713 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM wellsa@upmc.edu FU NIH [GM063569, GM069668]; National Institute of Biomedical Imaging and Bioengineering-CATER T32 training grant [EB001026]; National Cancer Institute-Skin Biology and Cancer T32 training grant [CA175294] FX We thank the members of the Wells' Laboratory at the University of Pittsburgh and Griffith Laboratory at the Massachusetts Institute of Technology for their helpful and insightful comments on this project. This project was supported by NIH Grants GM063569 and GM069668. A.N. was supported by the National Institute of Biomedical Imaging and Bioengineering-funded CATER T32 (EB001026) and the National Cancer Institute-funded Skin Biology and Cancer T32 (CA175294) training grants. Services were provided in kind by the VA Pittsburgh Health System research and development service line. M.R. is currently affiliated with the Department of Plastic and Reconstructive Surgery, Stanford University, Palo Alto, California, USA. NR 33 TC 0 Z9 0 U1 6 U2 6 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 2157-6564 EI 2157-6580 J9 STEM CELL TRANSL MED JI Stem Cells Transl. Med. PD NOV PY 2016 VL 5 IS 11 BP 1580 EP 1586 DI 10.5966/sctm.2015-0326 PG 7 WC Cell & Tissue Engineering SC Cell Biology GA EA2HQ UT WOS:000386413800019 PM 27400798 ER PT J AU Arundel, C Lam, PH Khosla, R Blackman, MR Fonarow, GC Morgan, C Zeng, Q Fletcher, RD Butler, J Wu, WC Deedwania, P Love, TE White, M Aronow, WS Anker, SD Allman, RM Ahmed, A AF Arundel, Cherinne Lam, Phillip H. Khosla, Rahul Blackman, Marc R. Fonarow, Gregg C. Morgan, Charity Zeng, Qing Fletcher, Ross D. Butler, Javed Wu, Wen-Chih Deedwania, Prakash Love, Thomas E. White, Michel Aronow, Wilbert S. Anker, Stefan D. Allman, Richard M. Ahmed, Ali TI Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE 30-Day all-cause readmission; All-cause mortality; Cost; Heart failure; Medicare beneficiaries ID RENIN-ANGIOTENSIN INHIBITION; PRESERVED EJECTION FRACTION; ACUTE MYOCARDIAL-INFARCTION; CHRONIC KIDNEY-DISEASE; PROPENSITY SCORE; NATURAL-HISTORY; MORTALITY; TRIAL; DEATH; MODE AB BACKGROUND: Heart failure is the leading cause for 30-day all-cause readmission. We examined the impact of 30-day all-cause readmission on long-term outcomes and cost in a propensity score-matched study of hospitalized patients with heart failure. METHODS: Of the 7578 Medicare beneficiaries discharged with a primary diagnosis of heart failure from 106 Alabama hospitals (1998-2001) and alive at 30 days after discharge, 1519 had a 30-day all-cause readmission. Using propensity scores for 30-day all-cause readmission, we assembled a matched cohort of 1516 pairs of patients with and without a 30-day all-cause readmission, balanced on 34 baseline characteristics (mean age 75 years, 56% women, 24% African American). RESULTS: During 2-12 months of follow-up after discharge from index hospitalization, all-cause mortality occurred in 41% and 27% of matched patients with and without a 30-day all-cause readmission, respectively (hazard ratio 1.68; 95% confidence interval 1.48-1.90; P<.001). This harmful association of 30-day all-cause readmission with mortality persisted during an average follow-up of 3.1 (maximum, 8.7) years (hazard ratio 1.33; 95% confidence interval 1.22-1.45; P<.001). Patients with a 30-day all-cause readmission had higher cumulative all-cause readmission (mean, 6.9 vs 5.1; P<.001), a longer cumulative length of stay (mean, 51 vs 43 days; P<.001), and a higher cumulative cost (mean, $38,972 vs $34,025; P=.001) during 8.7 years of follow-up. CONCLUSIONS: Among Medicare beneficiaries hospitalized for heart failure, 30-day all-cause readmission was associated with a higher risk of subsequent all-cause mortality, higher number of cumulative all-cause readmission, longer cumulative length of stay, and higher cumulative cost. Published by Elsevier Inc. C1 [Arundel, Cherinne; Khosla, Rahul; Blackman, Marc R.; Fletcher, Ross D.; Ahmed, Ali] Vet Affairs Med Ctr, 50 Irving St NW, Washington, DC 20422 USA. [Lam, Phillip H.] Georgetown Univ Hosp, Washington Hosp Ctr, Washington, DC 20007 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Morgan, Charity; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL USA. [Zeng, Qing] George Washington Univ, Washington, DC 20052 USA. [Butler, Javed] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Wu, Wen-Chih] Vet Affairs Med Ctr, Providence, RI USA. [Deedwania, Prakash] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Love, Thomas E.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [White, Michel] Montreal Heart Inst, Quebec City, PQ, Canada. [Aronow, Wilbert S.] New York Med Coll, Valhalla, NY 10595 USA. [Anker, Stefan D.] Univ Med Ctr Gottingen, Dept Cardiol & Pneumol, Gottingen, Germany. [Allman, Richard M.] US Dept Vet Affairs, Geriatr & Extended Care Serv, Washington, DC USA. RP Ahmed, A (reprint author), Washington DC VA Med Ctr, Ctr Hlth & Aging, 50 Irving St NW, Washington, DC 20422 USA. EM aliahmedmdmph@gmail.com FU National Institutes of Health through National Heart, Lung, and Blood Institute [R01-HL085561, R01-HL085561-S, R01-HL097047] FX AA was supported in part by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S, and R01-HL097047) from the National Heart, Lung, and Blood Institute. NR 26 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD NOV PY 2016 VL 129 IS 11 BP 1178 EP 1184 DI 10.1016/j.amjmed.2016.06.018 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EA1ES UT WOS:000386335900033 PM 27401949 ER PT J AU Soler, ZM Kohli, P Storck, KA Schlosser, RJ AF Soler, Zachary M. Kohli, Preeti Storck, Kristina A. Schlosser, Rodney J. TI Olfactory Impairment in Chronic Rhinosinusitis Using Threshold, Discrimination, and Identification Scores SO CHEMICAL SENSES LA English DT Article DE olfaction; prevalence; sinusitis; Sniffin' Sticks ID ENDOSCOPIC SINUS SURGERY; ODOR DISCRIMINATION; TESTS; SMELL; DYSFUNCTION; QUALITY; DISEASE; LIFE AB Differences in testing modalities and cut-points used to define olfactory dysfunction contribute to the wide variability in estimating the prevalence of olfactory dysfunction in chronic rhinosinusitis (CRS). The aim of this study is to report the prevalence of olfactory impairment using each component of the Sniffin' Sticks test (threshold, discrimination, identification, and total score) with age-adjusted and ideal cut-points from normative populations. Patients meeting diagnostic criteria for CRS were enrolled from rhinology clinics at a tertiary academic center. Olfaction was assessed using the Sniffin' Sticks test. The study population consisted of 110 patients. The prevalence of normosmia, hyposmia, and anosmia using total Sniffin' Sticks score was 41.8%, 20.0%, and 38.2% using age-appropriate cut-points and 20.9%, 40.9%, and 38.2% using ideal cut-points. Olfactory impairment estimates for each dimension mirrored these findings, with threshold yielding the highest values. Threshold, discrimination, and identification were also found to be significantly correlated to each other (P < 0.001). In addition, computed tomography scores, asthma, allergy, and diabetes were found to be associated with olfactory dysfunction. In conclusion, the prevalence of olfactory dysfunction is dependent upon olfactory dimension and if age-adjusted cut-points are used. The method of olfactory testing should be chosen based upon specific clinical and research goals. C1 [Soler, Zachary M.; Kohli, Preeti; Storck, Kristina A.; Schlosser, Rodney J.] Med Univ South Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, 109 Bee St, Charleston, SC 29401 USA. RP Soler, ZM (reprint author), Med Univ South Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM solerz@musc.edu NR 25 TC 0 Z9 0 U1 7 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X EI 1464-3553 J9 CHEM SENSES JI Chem. Senses PD NOV PY 2016 VL 41 IS 9 BP 713 EP 719 DI 10.1093/chemse/bjw080 PG 7 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA DZ8NB UT WOS:000386126000492 ER PT J AU Snodgrass, MN Shields, J Rai, HM AF Snodgrass, Megan N. Shields, Jenna Rai, Hema TI Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS LA English DT Article DE anticoagulants; clinical pharmacology; factor Xa inhibitors; hypercoagulability; thrombocytopenia ID CASE SERIES; ANTIBODIES; HIT AB Objective: Heparin-induced thrombocytopenia (HIT) occurs in up to 5% of patients exposed to unfractionated heparin for 5 or more days. Direct thrombin inhibitors (DTIs) are currently the only Food and Drug Administration (FDA)-approved agents for the treatment of HIT. The purpose of this study is to determine whether fondaparinux is an appropriate first-line alternative anticoagulant in patients with suspected or confirmed HIT. Methods: A retrospective study was conducted by identifying all patients who received a DTI or fondaparinux during a 5 year period, August 2009-August 2014. Patients were included if they had a HIT panel/serotonin-release assay analysis (regardless of the result) and were initiated on a DTI or fondaparinux for alternative anticoagulation. The primary outcome was new, recurrent, or progressive thromboembolic event. Secondary outcomes included bleeding events, platelet count recovery, and hospital stay. Results: A total of 1022 patients were evaluated, and 47 patients met the inclusion criteria. Twelve patients were HIT positive and 35 were HIT negative. Seven (14.9%) of the 47 patients experienced a new thrombosis, none of whom were on fondaparinux only (FONDA). There were 4 new minor bleeds, with 1 bleed as a result of being on fondaparinux. FONDA treatment resulted in a slightly shorter median duration of hospital stay compared to the DTI-only group and the DTI followed by fondaparinux group. There is a potential for cost savings with fondaparinux due to the ease of administration and availability to be given in the outpatient setting. Conclusion: In this small retrospective review, fondaparinux appeared similarly efficacious and safe compared to DTIs for the treatment of suspected HIT. C1 [Snodgrass, Megan N.] Butler Vet Affairs Med Ctr, Cranberry Community Based Outpatient Clin, 900 Commonwealth Dr,Suite 900, Cranberry Township, PA 16066 USA. [Shields, Jenna; Rai, Hema] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Snodgrass, MN (reprint author), Butler Vet Affairs Med Ctr, Cranberry Community Based Outpatient Clin, 900 Commonwealth Dr,Suite 900, Cranberry Township, PA 16066 USA. EM megan.snodgrass3@va.gov NR 14 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1076-0296 EI 1938-2723 J9 CLIN APPL THROMB-HEM JI Clin. Appl. Thromb.-Hemost. PD NOV PY 2016 VL 22 IS 8 BP 712 EP 717 DI 10.1177/1076029616646873 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA DZ7BW UT WOS:000386019900002 PM 27179015 ER PT J AU Darst, BF Bilgel, M Koscik, RL Hermann, BP Jedynak, BM Johnson, SC Engelman, CD AF Darst, Burcu F. Bilgel, Murat Koscik, Rebecca L. Hermann, Bruce P. Jedynak, Bruno M. Johnson, Sterling C. Engelman, Corinne D. TI Using LASSO Regression to Identify Gene-Gene and Gene-Environment Interactions Influencing Cognitive Function in those with Increased Alzheimer's Risk SO GENETIC EPIDEMIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the International-Genetic-Epidemiology-Society CY OCT 24-26, 2016 CL Toronto, CANADA SP Int Genet Epidemiol Soc C1 [Darst, Burcu F.; Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Bilgel, Murat] Johns Hopkins Univ, Sch Engn, Dept Biomed Engn, Baltimore, MD USA. [Bilgel, Murat] NIA, Lab Behav Neurosci, NIH, Baltimore, MD 21224 USA. [Koscik, Rebecca L.; Hermann, Bruce P.; Johnson, Sterling C.; Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Hermann, Bruce P.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Hermann, Bruce P.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Jedynak, Bruno M.] Portland State Univ, Dept Math & Stat, Portland, OR 97207 USA. [Johnson, Sterling C.; Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 EI 1098-2272 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD NOV PY 2016 VL 40 IS 7 MA 59 BP 630 EP 631 PG 2 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA DZ7HF UT WOS:000386034800066 ER PT J AU Safdar, N Abbo, LM Knobloch, MJ Seo, SK AF Safdar, Nasia Abbo, Lilian M. Knobloch, Mary Jo Seo, Susan K. TI Research Methods in Healthcare Epidemiology: Survey and Qualitative Research SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID MIXED METHODS AB Surveys are one of the most frequently employed study designs in healthcare epidemiology research. Generally easier to undertake and less costly than many other study designs, surveys can be invaluable to gain insights into opinions and practices in large samples and may be descriptive and/or be used to test associations. In this context, qualitative research methods may complement this study design either at the survey development phase and/or at the interpretation/extension of results stage. This methods article focuses on key considerations for designing and deploying surveys in healthcare epidemiology and antibiotic stewardship, including identification of whether or not de novo survey development is necessary, ways to optimally lay out and display a survey, denominator measurement, discussion of biases to keep in mind particularly in research using surveys, and the role of qualitative research methods to complement surveys. We review examples of surveys in healthcare epidemiology and antimicrobial stewardship and review the pros and cons of methods used. A checklist is provided to help aid design and deployment of surveys in healthcare epidemiology and antimicrobial stewardship. C1 [Safdar, Nasia; Knobloch, Mary Jo] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA. [Abbo, Lilian M.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA. [Abbo, Lilian M.] Jackson Hlth Syst, Miami, FL USA. [Seo, Susan K.] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY 10021 USA. RP Safdar, N (reprint author), 5138 MFCB 1685 Highland Ave, Madison, WI 53703 USA. EM ns2@medicine.wisc.edu FU National Institutes of Health/National Cancer Institute Cancer Center [P30 CA008748]; Veterans Health Administration National Center for Patient Safety, Patient Safety Center of Inquiry, US Department of Veterans Affairs FX National Institutes of Health/National Cancer Institute Cancer Center Support (grant P30 CA008748 to S.K.S.); and Veterans Health Administration National Center for Patient Safety, Patient Safety Center of Inquiry, US Department of Veterans Affairs. NR 17 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2016 VL 37 IS 11 BP 1272 EP 1277 DI 10.1017/ice.2016.171 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EA2EA UT WOS:000386404400002 PM 27514583 ER PT J AU Paholpak, P Carr, AR Barsuglia, JP Barrows, RJ Jimenez, E Lee, GJ Mendez, MF AF Paholpak, Pongsatorn Carr, Andrew R. Barsuglia, Joseph P. Barrows, Robin J. Jimenez, Elvira Lee, Grace J. Mendez, Mario F. TI Person-Based Versus Generalized Impulsivity Disinhibition in Frontotemporal Dementia and Alzheimer Disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE disinhibition; frontotemporal dementia; Alzheimer disease; Frontal System Behavior Scale ID SUPERIOR TEMPORAL SULCUS; BEHAVIORAL-VARIANT; LOBAR DEGENERATION; SOCIAL COGNITION; ORBITOFRONTAL CORTEX; RATING-SCALE; FDG-PET; BRAIN; APATHY; MIND AB Background: While much disinhibition in dementia results from generalized impulsivity, in behavioral variant frontotemporal dementia (bvFTD) disinhibition may also result from impaired social cognition. Objective: To deconstruct disinhibition and its neural correlates in bvFTD vs. early-onset Alzheimer's disease (eAD). Methods: Caregivers of 16 bvFTD and 21 matched-eAD patients completed the Frontal Systems Behavior Scale disinhibition items. The disinhibition items were further categorized into (1) person-based subscale which predominantly associated with violating social propriety and personal boundary and (2) generalized-impulsivity subscale which included nonspecific impulsive acts. Subscale scores were correlated with grey matter volumes from tensor-based morphometry on magnetic resonance images. Results: In comparison to the eAD patients, the bvFTD patients developed greater person-based disinhibition (P < 0.001) but comparable generalized impulsivity. Severity of person-based disinhibition significantly correlated with the left anterior superior temporal sulcus (STS), and generalized-impulsivity correlated with the right orbitofrontal cortex (OFC) and the left anterior temporal lobe (aTL). Conclusions: Person-based disinhibition was predominant in bvFTD and correlated with the left STS. In both dementia, violations of social propriety and personal boundaries involved fronto-parieto-temporal network of Theory of Mind, whereas nonspecific disinhibition involved the OFC and aTL. C1 [Paholpak, Pongsatorn; Carr, Andrew R.; Barrows, Robin J.; Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Kaen, Thailand. [Carr, Andrew R.; Barsuglia, Joseph P.; Barrows, Robin J.; Jimenez, Elvira; Mendez, Mario F.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lee, Grace J.] Loma Linda Univ, Dept Psychol, Sch Behav Hlth, Loma Linda, CA 92350 USA. RP Paholpak, P (reprint author), Greater Los Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ppaholpak@yahoo.com FU National Institute on Aging (NIA) [5R01AG034499-05]; VA GRECC Advanced Fellowship in Geriatrics FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grant 5R01AG034499-05 from the National Institute on Aging (NIA). A. R. Carr and J. P. Barsuglia were funded by the VA GRECC Advanced Fellowship in Geriatrics. NR 51 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 EI 1552-5708 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD NOV PY 2016 VL 29 IS 6 BP 344 EP 351 DI 10.1177/0891988716666377 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA DZ7IS UT WOS:000386038900005 ER PT J AU Huang, JS Terrones, L Simmons, AN Kaye, W Strigo, I AF Huang, Jeannie S. Terrones, Laura Simmons, Alan N. Kaye, Walter Strigo, Irina TI Pilot Study of Functional Magnetic Resonance Imaging Responses to Somatic Pain Stimuli in Youth With Functional and Inflammatory Gastrointestinal Disease SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE functional magnetic resonance imaging; inflammatory bowel disease; interoception; irritable bowel syndrome ID IRRITABLE-BOWEL-SYNDROME; MAJOR DEPRESSIVE DISORDER; CHRONIC BACK-PAIN; QUALITY-OF-LIFE; BRAIN RESPONSES; ABDOMINAL-PAIN; VISCERAL PAIN; PLACEBO ANALGESIA; ANTICIPATION; ADOLESCENTS AB Background:Brain-gut axis signaling modifies gastrointestinal symptomatology. Altered neural processing of intestinal pain signals involves interoceptive brain regions in adults with functional and inflammatory gastrointestinal disorders. Although these disorders frequently present in childhood, there are no published studies in youth. We determined whether neural processing of somatic pain stimuli differs in adolescents and young adults (AYA) with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), as compared to healthy controls (HC).Methods:IBS and IBD AYA (16-20 years) underwent anticipated and thermal pain stimuli of low and high intensity on their forearm and simultaneous blood oxygen level-dependent functional magnetic resonance imaging. Data from adult HC were used for comparison. Subjects answered surveys evaluating alexithymia, anxiety, depression, and pain catastrophizing. Group data were compared using linear mixed effects and analysis of variance.Results:Study groups were similar by sex but not age. Significant group by pain condition interactions were observed in interoceptive brain regions during pain anticipation, and within perceptual brain regions during perceived pain. Higher activation within interoceptive brain regions during anticipated pain was observed in IBS compared with IBD and HC subjects. IBD patients demonstrated increased activation in perceptual brain regions during experienced pain as compared to IBS and HC.Conclusions:IBS and IBD AYA demonstrate altered neural processing of somatic pain compared with each other and with HC. Our results suggest that neuromodulatory interventions targeting interoceptive brain circuits in IBS and perceptual brain regions in IBD may be effective. C1 [Huang, Jeannie S.; Terrones, Laura] Rady Childrens Hosp, Dept Pediat, San Diego, CA USA. [Huang, Jeannie S.; Terrones, Laura] Univ Calif San Diego, San Diego, CA 92103 USA. [Simmons, Alan N.; Kaye, Walter] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Simmons, Alan N.] Vet Affairs Hlth Syst, Ctr Excellence Stress & Mental Hlth, San Francisco, CA USA. [Strigo, Irina] San Francisco VA Med Ctr, San Francisco, CA USA. RP Huang, JS (reprint author), 9500 Gilman Dr,MC 0984, La Jolla, CA 92093 USA. EM jshuang@ucsd.edu FU Clinical and Translational Research Institute, University of California San Diego; Price Foundation; Peterson Foundation; National Institutes of Health of CTSA [UL RR031980, UL1TR000100]; United States (US) Department of Veterans Affairs CS RD Service [I01-CX-000816] FX Funding received from the Clinical and Translational Research Institute, University of California San Diego, the Price Foundation, and the Peterson Foundation. The project described was partially supported by the National Institutes of Health, Grant UL RR031980 for years 1 and 2 of CTSA funding and/ or UL1TR000100 during year 3 and beyond of CTSA funding and in part by I01-CX-000816 from the United States (US) Department of Veterans Affairs CS R&D Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or VA. NR 50 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0277-2116 EI 1536-4801 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD NOV PY 2016 VL 63 IS 5 BP 500 EP 507 DI 10.1097/MPG.0000000000001390 PG 8 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA EA1KE UT WOS:000386350200021 PM 27574880 ER PT J AU Afari, N Gasperi, M Forsberg, CW Goldberg, J Buchwald, D Krieger, JN AF Afari, Niloofar Gasperi, Marianna Forsberg, Christopher W. Goldberg, Jack Buchwald, Dedra Krieger, John N. TI Heritability of Lower Urinary Tract Symptoms in Men: A Twin Study SO JOURNAL OF UROLOGY LA English DT Article DE lower urinary tract symptoms; quantitative trait; heritable; twins ID BENIGN PROSTATIC HYPERPLASIA; POPULATION-BASED SURVEY; QUALITY-OF-LIFE; OVERACTIVE BLADDER; DETERMINING ZYGOSITY; CONCORDANCE RATES; INCONTINENCE; WOMEN; ERA; AGE AB Purpose: Symptoms of urinary irritation, urgency, frequency and obstruction, known as lower urinary tract symptoms, are common in urological practice. However, little is known about the etiology or pathogenesis of lower urinary tract symptoms, especially the relative contributions of genetic and environmental factors to the development of these symptoms. We used a classic twin study design to examine the relative contributions of genetic and environmental factors to the occurrence of lower urinary tract symptoms in middle-aged men. Materials and Methods: Twins were members of the Vietnam Era Twin Registry. We used a mail survey to collect data on lower urinary tract symptoms using the I-PSS (International Prostate Symptom Score) instrument. Twin correlations and biometric modeling were used to determine the relative genetic and environmental contributions to variance in I-PSS total score and individual items. Results: Participants were 1,002 monozygotic and 580 dizygotic middle-aged male twin pairs (mean age 50.2 years, SD 3.0). Nearly 25% of the sample had an I-PSS greater than 8, indicating at least moderate lower urinary tract symptoms. The heritability of the total I-PSS was 37% (95% CI 32-42). Heritability estimates ranged from 21% for nocturia to 40% for straining, with moderate heritability (34% to 36%) for urinary frequency and urgency. Conclusions: Genetic factors provide a moderate contribution (20% to 40%) to lower urinary tract symptoms in middle-aged men, suggesting that environmental factors may also contribute substantially to lower urinary tract symptoms. Future research is needed to define specific genetic and environmental mechanisms that underlie the development of these symptoms and conditions associated with lower urinary tract symptoms. C1 [Afari, Niloofar; Gasperi, Marianna] VA Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Afari, Niloofar; Gasperi, Marianna] Univ Calif San Diego, San Diego, CA 92103 USA. [Forsberg, Christopher W.; Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Vietnam Era Twin Registry, Seattle, WA USA. [Goldberg, Jack; Krieger, John N.] Univ Washington, Seattle, WA 98195 USA. [Buchwald, Dedra] Washington State Univ, Elson S Floyd Coll Med, Seattle, WA USA. [Buchwald, Dedra] Washington State Univ, Elson S Floyd Coll Med, Spokane, WA USA. RP Afari, N (reprint author), 9500 Gilman Dr,0737, La Jolla, CA 92093 USA. EM nafari@ucsd.edu FU National Institutes of Health MAPP Research Network Grant [U01 DK082325] FX Supported by the National Institutes of Health MAPP Research Network Grant U01 DK082325. NR 30 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD NOV PY 2016 VL 196 IS 5 BP 1486 EP 1491 DI 10.1016/j.juro.2016.06.018 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DZ6EJ UT WOS:000385954100055 PM 27312318 ER PT J AU Zhong, NS Moon, HS Lee, KH Mahayiddin, AA Boonsawat, W Isidro, MGD Bai, CX Mueller, A Metzdorf, N Anzueto, A AF Zhong, Nanshan Moon, Hwa S. Lee, Kwan H. Mahayiddin, Aziah A. Boonsawat, Watchara Isidro, Marie G. D. Bai, ChunXue Mueller, Achim Metzdorf, Norbert Anzueto, Antonio TI TIOtropium Safety and Performance In Respimat((R)) (TIOSPIRTM): Analysis of Asian cohort of COPD patients SO RESPIROLOGY LA English DT Article DE chronic obstructive pulmonary disease; clinical respiratory medicine; clinical trials ID OBSTRUCTIVE PULMONARY-DISEASE; HEALTH OUTCOMES; TRIAL; EFFICACY; EXACERBATIONS; BRONCHODILATOR; PREVENTION; SALMETEROL; COUNTRIES; PACIFIC AB Background and objective The TIOtropium Safety and Performance In Respimat (TIOSPIR) trial showed similar safety and exacerbation efficacy profiles for tiotropium Respimat and HandiHaler in patients with COPD. The TIOSPIR results for patients in Asia are presented here. Methods TIOSPIR evaluated once-daily tiotropium Respimat 5 and 2.5 mu g with HandiHaler 18 mu g in patients with COPD. Primary endpoints included time to death and time to first COPD exacerbation. Safety and exacerbation efficacy profiles were determined for the Asian region, and for Asia (all treatment arms pooled) versus the rest of the world (RoW). ResultsIn Asia (n=2356), time to death was similar for Respimat 5 and 2.5 mu g versus HandiHaler 18 mu g (hazard ratio (HR) (95% CI): 0.96 (0.67, 1.38) and 1.23 (0.87, 1.73)). Risk of COPD exacerbation was similar for Respimat 5 mu g, but increased for 2.5 mu g versus HandiHaler 18 mu g (HR (95% CI): 0.99 (0.85, 1.15) and 1.17 (1.00, 1.35)). Time to death in Asia and RoW was similar (HR (95% CI): 1.15 (0.99, 1.35)). Time to first COPD exacerbation was longer (HR (95% CI): 0.84 (0.78, 0.89)) and exacerbation rates were lower in Asia, but severe exacerbations were more frequent than in the RoW. Risk of major adverse cardiovascular events was similar for both regions. ConclusionSimilar safety and exacerbation efficacy profiles were observed for tiotropium Respimat 5 mu g and HandiHaler 18 mu g in patients with COPD from Asia, analogous to the global analysis. Asian patients had lower risk of, and fewer exacerbations overall, but a higher proportion of severe exacerbations than in the RoW. Asian cohort analysis in TIOtropium Safety and Performance In Respimat In Respimat((R)) (TIOSPIRTM) COPD trial demonstrates that, analogous to the global analysis, tiotropium Respimat 5 mu g and HandiHaler 18 mu g have similar safety and exacerbation efficacy. However, patients in Asia had fewer, but more severe, exacerbations than patients from the rest of the world. C1 [Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China. [Moon, Hwa S.] Catholic Univ Korea, Dept Internal Med, Seoul, South Korea. [Lee, Kwan H.] Yeungnam Univ Med Ctr, Dept Internal Med, Daegu, South Korea. [Mahayiddin, Aziah A.] Kuala Lumpur Hosp, Inst Resp Med, Kuala Lumpur, Malaysia. [Boonsawat, Watchara] Khon Kaen Univ, Srinagarind Hosp, Div Resp Med, Dept Med, Khon Kaen, Thailand. [Isidro, Marie G. D.] West Visayas State Univ Med Ctr, Jaro Iloilo City, Philippines. [Bai, ChunXue] Shanghai ZhonShan Hosp, Dept Pulm Med, Shanghai, Peoples R China. [Mueller, Achim] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. [Metzdorf, Norbert] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr, Pulmonary Crit Care Div, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr, Pulmonary Crit Care Div, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 27 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 IS 8 BP 1397 EP 1403 DI 10.1111/resp.12856 PG 7 WC Respiratory System SC Respiratory System GA DZ4YD UT WOS:000385866900011 PM 27490162 ER PT J AU Safarpour, D Willis, AW AF Safarpour, Delaram Willis, Allison W. TI Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Review DE Parkinson disease; dementia; mild cognitive impairment; Parkinson disease with dementia; epidemiology ID MINI-MENTAL-STATE; TRANSCRANIAL MAGNETIC STIMULATION; MONTREAL COGNITIVE ASSESSMENT; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; DOUBLE-BLIND; DIAGNOSTIC-CRITERIA; SCREENING DEMENTIA; LEWY BODIES; LONG-TERM AB The prevalence of neurodegenerative diseases such as Parkinson disease (PD) will increase substantially, due to the aging of the population and improved treatments leading to better disease-related outcomes. Dementia is the most common nonmotor symptom in PD, and most patients with PD will have cognitive dysfunction and cognitive decline in the course of their disease. The development of cognitive dysfunction in PD greatly limits the ability to participate in activities of daily living and can be a tipping point for nursing home placement or major caregiver stress. Understanding the different causes of dementia and how to reduce the incidence and impact of secondary cognitive dysfunction in PD are necessary skills for primary care physicians and neurologists. In this review, we discuss the clinical epidemiology of dementia in PD with an emphasis on preventable cognitive dysfunction, present tools for outpatient evaluation of cognitive dysfunction, and describe current pharmacological treatments for dementia in PD. C1 [Safarpour, Delaram; Willis, Allison W.] Univ Penn, Perelman Sch Med, Dept Neurol, Blockley Hall,723,423 Guardian Dr, Philadelphia, PA 19104 USA. [Safarpour, Delaram] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Willis, Allison W.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Blockley Hall,723,423 Guardian Dr, Philadelphia, PA 19104 USA. [Willis, Allison W.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Willis, Allison W.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Willis, AW (reprint author), Univ Penn, Perelman Sch Med, Dept Neurol, Blockley Hall,723,423 Guardian Dr, Philadelphia, PA 19104 USA.; Willis, AW (reprint author), Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Blockley Hall,723,423 Guardian Dr, Philadelphia, PA 19104 USA. EM allison.willis@uphs.upenn.edu FU NINDS NIH HHS [K23 NS081087] NR 87 TC 0 Z9 0 U1 15 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD NOV PY 2016 VL 31 IS 7 BP 585 EP 594 DI 10.1177/1533317516653823 PG 10 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA DZ2VY UT WOS:000385701000006 PM 27295974 ER PT J AU Girard, TD Yende, S AF Girard, Timothy D. Yende, Sachin TI Cognitive Impairment and Critical Illness: A Chicken and an Egg SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE cognition disorders; critical illness; mild cognitive impairment C1 [Girard, Timothy D.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15260 USA. [Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA. [Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Girard, TD (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15260 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD NOV PY 2016 VL 44 IS 11 BP 2115 EP 2116 DI 10.1097/CCM.0000000000001934 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA DY9TL UT WOS:000385477900023 PM 27755075 ER PT J AU Sanchez, E Darvish, H Mesias, R Taghavi, S Firouzabadi, SG Walker, RH Tafakhori, A Paisan-Ruiz, C AF Sanchez, Elena Darvish, Hossein Mesias, Roxana Taghavi, Shaghyegh Firouzabadi, Saghar Ghasemi Walker, Ruth H. Tafakhori, Abbas Paisan-Ruiz, Coro TI Identification of a Large DNAJB2 Deletion in a Family with Spinal Muscular Atrophy and Parkinsonism SO HUMAN MUTATION LA English DT Article DE DNAJB2; spinal muscular atrophy; Parkinsonism; DnaJ domain deletion; WGS ID HEREDITARY MOTOR NEUROPATHY; SYNAPTIC PLASTICITY; INCLUSION FORMATION; NEUROTROPHIC FACTOR; DISEASE; TAU; PROTEASOME; DIAGNOSIS; MITOPHAGY; VARIANTS AB In this study, we described the identification of a large DNAJB2 (HSJ1) deletion in a family with recessive spinal muscular atrophy and Parkinsonism. After performing homozygosity mapping and whole genome sequencing, we identified a 3.8kb deletion, spanning the entire DnaJ domain of the HSJ1 protein, as the disease-segregating mutation. By performing functional assays, we showed that HSJ1b-related DnaJ domain deletion leads to loss of HSJ1b mRNA and protein levels, increased HSJ1a mRNA and protein expressions, increased cell death, protein aggregation, and enhanced autophagy. Given the role of HSJ1 proteins in the degradation of misfolded proteins, we speculated that enhanced autophagy might be promoted by the elevated HSJ1a expression seen in HSJ1b-deficient cells. We also observed a significant reduction in both tau and brain-derived neurotrophic factor levels, which may explain the dopaminergic deficits seen in one of the affected siblings. We concluded that HSJ1b deficiency leads to a complex neurological phenotype, possibly due to the accumulation of misfolded proteins, caused by the lack of the DnaJ domain activity. We thus expand the phenotypic and genotypic spectrums associated with DNAJB2 disease and suggest relevant disease-associated mechanisms. C1 [Sanchez, Elena; Mesias, Roxana; Walker, Ruth H.; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. [Darvish, Hossein; Taghavi, Shaghyegh] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran. [Mesias, Roxana] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, One Gustave L Levy Pl, New York, NY 10029 USA. [Firouzabadi, Saghar Ghasemi] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Tafakhori, Abbas] Imam Khomeini Hosp, Sch Med, Dept Neurol, Tehran, Iran. [Tafakhori, Abbas] Univ Tehran Med Sci, Iranian Ctr Neurol Res, Tehran, Iran. [Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. [Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, One Gustave L Levy Pl, New York, NY 10029 USA. [Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, One Gustave L Levy Pl, New York, NY 10029 USA. [Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Friedman Brain Inst, One Gustave L Levy Pl, New York, NY 10029 USA. RP Paisan-Ruiz, C (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. EM coro.paisan-ruiz@mssm.edu RI Paisan-Ruiz, Coro/C-2912-2009; Sanchez, Elena/B-4140-2017 OI Sanchez, Elena/0000-0002-7041-5485; Mesias, Roxana/0000-0002-6198-6809 FU Shahid Beheshti University of Medical Sciences; National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS) [R01NS079388] FX Contract Grant Sponsor: Shahid Beheshti University of Medical Sciences; National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS; R01NS079388). NR 42 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD NOV PY 2016 VL 37 IS 11 BP 1180 EP 1189 DI 10.1002/humu.23055 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA DZ4BZ UT WOS:000385804100008 PM 27449489 ER PT J AU Williams, EC Young, JP Achtmeyer, CE Hendershot, CS AF Williams, Emily C. Young, Jessica P. Achtmeyer, Carol E. Hendershot, Christian S. TI Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Pharmacogenetics; Alcohol use disorders; Alcohol use; Qualitative ID CENTERED MEDICAL HOME; HEALTH-CARE; NALTREXONE RESPONSE; SMOKING-CESSATION; CLINICAL-PRACTICE; GENOMIC MEDICINE; EVIDENCE DILEMMA; HEAVY DRINKING; PUBLIC-HEALTH; UNITED-STATES AB Background: Efforts to identify genetic moderators of pharmacotherapy response have generated interest in clinical applications of pharmacogenetic tests in alcohol use disorder (AUD) treatment. To date, no research on providers' interest in using pharmacogenetic tests in the context of AUD treatment has been reported. We conducted qualitative interviews with primary care providers from 5 clinics in the Veterans Health Administration (VA) to assess their interest in using a hypothetical genetic test to inform treatment of AUD with pharmacotherapy. Methods: Key contacts were used to recruit 24 providers from 5 primary care clinics associated with a single large VA medical facility. Participants completed 30-minute in-person semi-structured interviews focused on barriers and facilitators to provision of pharmacotherapy for AUD. Interviews included a hypothetical scenario regarding the availability of a genetic test to inform AUD pharmacotherapy provision and/or selection. Provider responses to the hypothetical scenario were recorded, transcribed and analyzed qualitatively using inductive content analysis. Data were independently coded by three investigators, and themes were identified via consensus. Results: Participants were generally interested in a genetic test to aid in AUD treatment planning. Five common themes were identified, including: perceived benefits of a pharmacogenetic test (e.g., aiding with therapeutic choice, positively impacting patient motivation for and engagement with AUD treatment), perceived drawbacks (e.g., limiting potential benefits of pharmacotherapy by reducing the target population for its receipt, adverse impacts of "negative" results), caveats to clinical utility (e.g., utility would depend on prognostic accuracy and/or medication characteristics), uncertainty as to whether such a test would impact clinical decision-making, and pragmatic barriers to use (costs and other resources, such as laboratory facilities). Conclusions: Primary care providers in this study generally believed a genetic test to aid in AUD treatment planning would be useful, due to its potential to hone treatment choice as well as to influence patient motivation and adherence to treatment. However, providers acknowledged that a test's utility would depend on the strength of its prognostic characteristics, its other benefits relative to standard care, and lack of pragmatic barriers. Published by Elsevier Inc. C1 [Williams, Emily C.; Young, Jessica P.; Achtmeyer, Carol E.] Vet Affairs VA Puget Sound Hlth Care Syst, HSR&D, Ctr Innovat Vet Ctr Value Driven Care, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Boxes 357,660,1959 NE Pacific St, Seattle, WA 98195 USA. [Achtmeyer, Carol E.] Vet Affairs VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle Div, 1660 S Columbian Way, Seattle, WA 98108 USA. [Hendershot, Christian S.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, 100 Stokes St,Bell Gateway Bldg, Toronto, ON M6J 1H4, Canada. [Hendershot, Christian S.] Univ Toronto, Dept Psychiat, 250 Coll St, Toronto, ON M5T 1R8, Canada. [Hendershot, Christian S.] Univ Toronto, Dept Psychol, 100 St George St,4th Floor, Toronto, ON M5S 3G3, Canada. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. EM Emily.Williams3@va.gov; Jessica.Young@va.gov; Carol.Achtmeyer@va.gov; christian.hendershot@utoronto.ca FU VA Health Services Research Development; VA Quality Enhancement Research Initiative [RRP 12-528]; Career Development Award from VA Health Services Research Development [CDA 12-276]; Canadian Institutes of Health Research [MSH-130189]; Ontario Mental Health Foundation; Canada Research Chairs program FX The authors gratefully acknowledge the participants of this study for generously allowing us to solicit and report on their perspectives. The parent study for this project was funded by VA Health Services Research & Development and VA Quality Enhancement Research Initiative (RRP 12-528). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). Dr. Hendershot is supported by the Canadian Institutes of Health Research (MSH-130189), the Ontario Mental Health Foundation, and the Canada Research Chairs program. NR 71 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV PY 2016 VL 70 BP 14 EP 20 DI 10.1016/j.jsat.2016.07.009 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DY7UX UT WOS:000385335900003 PM 27692183 ER PT J AU Yang, T Massa, SM Tran, KC Simmons, DA Rajadas, J Zeng, AY Jang, TC Carsanaro, S Longo, FM AF Yang, Tao Massa, Stephen M. Tran, Kevin C. Simmons, Danielle A. Rajadas, Jayakumar Zeng, Anne Y. Jang, Taichang Carsanaro, Sara Longo, Frank M. TI A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth SO NEUROPHARMACOLOGY LA English DT Article DE Neurotrophin receptors; Small molecule; Signaling ID NERVE GROWTH-FACTOR; TYROSINE-PHOSPHATASE RECEPTOR; PROTEIN-KINASE INHIBITION; SIGNALING PATHWAYS; NEURITE OUTGROWTH; RETT-SYNDROME; MOUSE MODEL; TRKB; LIGAND; AGONIST AB Neurotrophin (NT) receptors are coupled to numerous signaling networks that play critical roles in neuronal survival and plasticity. Several non-peptide small molecule ligands have recently been reported that bind to and activate specific tropomyosin-receptor kinase (Trk) NT receptors, stimulate their downstream signaling, and cause biologic effects similar to, though not completely overlapping, those of the native NT ligands. Here, in silico screening, coupled with low-throughput neuronal survival screening, identified a compound, LM22B-10, that, unlike prior small molecule Trk ligands, binds to and activates TrkB as well as TrkC. LM22B-10 increased cell survival and strongly accelerated neurite outgrowth, superseding the effects of brain-derived neurotrophic factor (BDNF), NT-3 or the two combined. Additionally, unlike the NTs, LM22B-10 supported substantial early neurite outgrowth in the presence of inhibiting glycoproteins. Examination of the mechanisms of these actions suggested contributions of the activation of both Trks and differential interactions with p75(NTR), as well as a requirement for involvement of the Trk extracellular domain. In aged mice, LM22B-10 activated hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increased hippocampal dendritic spine density. Thus, LM22B-10 may constitute a new tool for the study of TrkB and TrkC signaling and their interactions with p75(NTR), and provides groundwork for the development of ligands that stimulate unique combinations of Trk receptors and activity patterns for application to selected neuronal populations and deficits present in various disease states. (C) 2016 The Authors. Published by Elsevier Ltd. C1 [Yang, Tao; Tran, Kevin C.; Simmons, Danielle A.; Rajadas, Jayakumar; Zeng, Anne Y.; Jang, Taichang; Carsanaro, Sara; Longo, Frank M.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, 300 Pasteur Dr,Room H3160, Stanford, CA 94305 USA. [Massa, Stephen M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Massa, Stephen M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA 94121 USA. RP Longo, FM (reprint author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, 300 Pasteur Dr,Room H3160, Stanford, CA 94305 USA.; Massa, SM (reprint author), San Francisco Vet Affairs Healthcare Syst, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.; Massa, SM (reprint author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA. EM stephen.massa@ucsf.edu; longo@stanford.edu FU Institute for the Study on Aging/Alzheimer's Drug Discovery Foundation; Eastern Chapter of the North Carolina Alzheimer's Association; Jean Perkins Foundation; Horngren Family; Department of Defense (DOD) [DAMD17-03-1-0532]; Veterans Administration, Merit Review Award [BX000267] FX These studies were supported by the Institute for the Study on Aging/Alzheimer's Drug Discovery Foundation (FML), the Eastern Chapter of the North Carolina Alzheimer's Association (FML), the Jean Perkins Foundation (FML), the Horngren Family (FML), the Department of Defense (DOD DAMD17-03-1-0532) (SMM) and the Veterans Administration, Merit Review Award (BX000267) (SMM). NR 72 TC 0 Z9 0 U1 7 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD NOV PY 2016 VL 110 BP 343 EP 361 DI 10.1016/j.neuropharm.2016.06.015 PN A PG 19 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DY7OF UT WOS:000385318100034 PM 27334657 ER PT J AU Feder, A Mota, N Salim, R Rodriguez, J Singh, R Schaffer, J Schechter, CB Cancelmo, LM Bromet, EJ Katz, CL Reissman, DB Ozbay, F Kotov, R Crane, M Harrison, DJ Herbert, R Levin, SM Luft, BJ Moline, JM Stellman, JM Udasin, IG Landrigan, PJ Zvolensky, MJ Yehuda, R Southwick, SM Pietrzak, RH AF Feder, Adriana Mota, Natalie Salim, Ryan Rodriguez, Janice Singh, Ritika Schaffer, Jamie Schechter, Clyde B. Cancelmo, Leo M. Bromet, Evelyn J. Katz, Craig L. Reissman, Dori B. Ozbay, Fatih Kotov, Roman Crane, Michael Harrison, Denise J. Herbert, Robin Levin, Stephen M. Luft, Benjamin J. Moline, Jacqueline M. Stellman, Jeanne M. Udasin, Iris G. Landrigan, Philip J. Zvolensky, Michael J. Yehuda, Rachel Southwick, Steven M. Pietrzak, Robert H. TI Risk, coping and PTSD symptom trajectories in World Trade Center responders SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; World Trade Center; Responders; Trajectories; Risk; Coping ID POSTTRAUMATIC-STRESS-DISORDER; CENTER TERRORIST ATTACK; POLICE RESPONDERS; CENTER DISASTER; CENTER RESCUE; ENVIRONMENTAL-INFLUENCES; PROSPECTIVE COHORT; RECOVERY WORKERS; CLEANUP WORKERS; SOCIAL SUPPORT AB Trajectories of disaster-related posttraumatic stress disorder (PTSD) symptoms are often heterogeneous, and associated with common and unique risk factors, yet little is known about potentially modifiable psychosocial characteristics associated with low-symptom and recovering trajectories in disaster responders. A total of 4487 rescue and recovery workers (1874 police and 2613 non-traditional responders) involved during and in the aftermath of the unprecedented World Trade Center (WTC) attacks, were assessed an average of 3, 6, 8, and 12 years post-9/11/2001. Among police responders, WTC-related PTSD symptoms were characterized by four trajectories, including no/low-symptom (76.1%), worsening (12.1%), improving (7.5%), and chronic (4.4%) trajectories. In non-traditional responders, a five-trajectory solution was optimal, with fewer responders in a no/low-symptom trajectory (55.5%), and the remainder in subtly worsening (19.3%), chronic (10.8%), improving (8.5%), and steeply worsening (5.9%) trajectories. Consistent factors associated with symptomatic PTSD trajectories across responder groups included Hispanic ethnicity, pre-9/11 psychiatric history, greater WTC exposure, greater medical illness burden, life stressors and post-9/11 traumas, and maladaptive coping (e.g., substance use, avoidance coping). Higher perceived preparedness, greater sense of purpose in life, and positive emotion-focused coping (e.g., positive reframing, acceptance) were negatively associated with symptomatic trajectories. Findings in this unique cohort indicate considerable heterogeneity in WTC-related PTSD symptom trajectories over 12 years post-9/11/2001, with lower rates of elevated PTSD symptoms in police than in non-traditional responders. They further provide a comprehensive risk prediction model of PTSD symptom trajectories, which can inform prevention, monitoring, and treatment efforts in WTC and other disaster responders. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Feder, Adriana; Salim, Ryan; Rodriguez, Janice; Singh, Ritika; Schaffer, Jamie; Cancelmo, Leo M.; Katz, Craig L.; Ozbay, Fatih; Yehuda, Rachel] Icahn Sch Med, Dept Psychiat, New York, NY USA. [Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA. [Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Schechter, Clyde B.] Yeshiva Univ, Dept Family & Social Med, Albert Einstein Coll Med, Bronx, NY USA. [Bromet, Evelyn J.; Kotov, Roman] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Reissman, Dori B.] NIOSH, Off Director, Washington, DC USA. [Crane, Michael; Herbert, Robin; Levin, Stephen M.; Landrigan, Philip J.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Harrison, Denise J.] NYU, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10003 USA. [Luft, Benjamin J.] SUNY Stony Brook, Div Infect Dis, Dept Med, Stony Book, NY USA. [Moline, Jacqueline M.] Hofstra North Shore Long Isl Jewish Sch Med, Dept Occupat Med Epidemiol & Prevent, Great Neck, NY USA. [Stellman, Jeanne M.] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY 10027 USA. [Udasin, Iris G.] UMDNJ Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Piscataway, NJ USA. [Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Feder, A (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM adriana.feder@mssm.edu FU CDC/National Institute for Occupational Safety and Health (NIOSH) [200-2011-41919] FX This work was supported by the CDC/National Institute for Occupational Safety and Health (NIOSH) (A.F., R.H.P. and S.M.S., research contract # 200-2011-41919). The CDC/NIOSH did not contribute to study design; data collection, analysis or interpretation; writing of the report; or decision to submit the manuscript for publication. NR 51 TC 1 Z9 1 U1 11 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD NOV PY 2016 VL 82 BP 68 EP 79 DI 10.1016/j.jpsychires.2016.07.003 PG 12 WC Psychiatry SC Psychiatry GA DY1KN UT WOS:000384854000010 PM 27468166 ER PT J AU Okita, K Petersen, N Robertson, CL Dean, AC Mandelkern, MA London, ED AF Okita, Kyoji Petersen, Nicole Robertson, Chelsea L. Dean, Andy C. Mandelkern, Mark A. London, Edythe D. TI Sex Differences in Midbrain Dopamine D2-Type Receptor Availability and Association with Nicotine Dependence SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID REFERENCE TISSUE MODEL; SMOKING-CESSATION; BEHAVIORAL SENSITIZATION; CIGARETTE-SMOKING; MENSTRUAL-CYCLE; RELEASE; BRAIN; NEURONS; BINDING; PET AB Women differ from men in smoking-related behaviors, among them a greater difficulty in quitting smoking. Unlike female smokers, male smokers have lower striatal dopamine D2-type receptor availability (binding potential, BPND) than nonsmokers and exhibit greater smoking-induced striatal dopamine release. Because dopamine D2-type autoreceptors in the midbrain influence striatal dopamine release, a function that has been linked to addiction, we tested for sex differences in midbrain dopamine D2-type receptor BPND and in relationships between midbrain BPND, nicotine dependence and striatal dopamine D2-type receptor BPND. Positron emission tomography was used with [F-18]fallypride to measure BPND in a midbrain region, encompassing the substantia nigra and ventral tegmental area, in 18 daily smokers (7 women, 11 men) and 19 nonsmokers (10 women, 9 men). A significant sex-by-group interaction reflected greater midbrain BPND in female but not male smokers than in corresponding nonsmokers (F-1,F- 32 = 5.089, p = 0.03). Midbrain BPND was positively correlated with BPND in the caudate nucleus and putamen in nonsmokers and female smokers but not in male smokers and with nicotine dependence in female but not in male smokers. Striatal BPND was correlated negatively with nicotine dependence and smoking exposure. These findings extend observations on dopamine D2-type receptors in smokers and suggest a sex difference in how midbrain dopamine D2-type autoreceptors influence nicotine dependence. C1 [Okita, Kyoji; Petersen, Nicole; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Okita, Kyoji; Robertson, Chelsea L.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Robertson, Chelsea L.; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 740 Westwood Plaza,POB 175919, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu FU National Institute on Drug Abuse [R01 DA015179, R01 DA020726, P20 DA022539, K23 DA027734]; National Center for Research Resources [M01 RR00865]; Thomas P and Katherine K Pike Chair in Addiction Studies; Marjorie M Greene Trust; Department of Psychiatry, Graduate School of Medicine, Chiba University; [T32 DA024635] FX This research was supported, in part, by grants from the National Institute on Drug Abuse (R01 DA015179, R01 DA020726, P20 DA022539, EDL; K23 DA027734, ACD) and the National Center for Research Resources (M01 RR00865) and endowments from the Thomas P and Katherine K Pike Chair in Addiction Studies (EDL) and the Marjorie M Greene Trust. KO was partly supported by the Department of Psychiatry, Graduate School of Medicine, Chiba University, DOMONKAI fund. CLR was supported by T32 DA024635. The authors declare no conflict of interest. NR 57 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD NOV PY 2016 VL 41 IS 12 BP 2913 EP 2919 DI 10.1038/npp.2016.105 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DY6JR UT WOS:000385212700013 PM 27329684 ER PT J AU Jiang, X Peng, FH Liu, QQ Zhao, QH He, J Jiang, R Wang, L Xu, XQ Li, JH Ebrahimi, R Jing, ZC AF Jiang, Xin Peng, Fu-Hua Liu, Qian-Qian Zhao, Qin-Hua He, Jing Jiang, Rong Wang, Lan Xu, Xi-Qi Li, Jing-Hui Ebrahimi, Ramin Jing, Zhi-Cheng TI Optical coherence tomography for hypertensive pulmonary vasculature SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Chronic thromboembolic pulmonary hypertension; Optical coherence tomography; Pulmonary arterial hypertension ID INTRAVASCULAR ULTRASOUND; ARTERIAL-HYPERTENSION; MORPHOLOGY; PATHOLOGY AB Background: Optical coherence tomography (OCT) is an intravascular imaging modality capable of providing in situ images of tissues at near histologic resolution. In this study we examine the utility of OCT in identifying vascular changes related to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Methods and results: OCT of four different distal pulmonary arteries was performed during right heart catheterization in 87 patients, 64 patients with PAH and 23 patients with CTEPH. The mean luminal diameter measured by OCT for all patients was 2.26 mm. Intimal thickening was significantly increased in all PAH patients (0.26 +/- 0.05 mm in idiopathic PAH, 0.24 +/- 0.03 mm in connective tissue disease related PAH, 0.26 +/- 0.06 mm in congenital heart disease related PAH and 0.22 +/- 0.04 mm in CTEPH, respectively) compared with controls (0.13 +/- 0.03 mm) (all p < 0.05). An intimal thickness of >= 0.176 mm had a 91% positive predictive value for pulmonary hypertension. The anatomic abnormalities revealed by OCT tended to be severe in the idiopathic PAH group and mild in the CTEPH group. Signs of intravascular webs were found in 60.9% of CTEPH patients, but no other patients. Intimal thickness was moderately correlated with pulmonary arterial pressure and pulmonary vascular resistance (r = 0.423 and 0.439, respectively, p < 0.001). Conclusions: OCT provides important information for assessment of pulmonary arterial remodeling in patients with PAH and improves diagnostic capability of angiographically undetected distal-thrombotic lesions in patients with CTEPH. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Jiang, Xin; Peng, Fu-Hua; Liu, Qian-Qian; Xu, Xi-Qi; Li, Jing-Hui; Jing, Zhi-Cheng] Peking Union Med Coll, FuWai Hosp, State Key Lab Cardiovasc Dis, Beijing 100037, Peoples R China. [Jiang, Xin; Peng, Fu-Hua; Liu, Qian-Qian; Xu, Xi-Qi; Li, Jing-Hui; Jing, Zhi-Cheng] Chinese Acad Med Sci, Beijing 100037, Peoples R China. [Zhao, Qin-Hua; He, Jing; Jiang, Rong; Wang, Lan; Jing, Zhi-Cheng] Tongji Univ, Shanghai Pulm Hosp, Dept Cardiopulm Circulat, Sch Med, Shanghai 200433, Peoples R China. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Ebrahimi, Ramin] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Jing, ZC (reprint author), Chinese Acad Med Sci, FuWai Hosp, Peking Union Med Coll, State Key Lab Cardiovasc Dis, 167 Beilishi Rd, Beijing 100037, Peoples R China. EM jingzhicheng@vip.163.com FU Capital Medicine Developing Research Foundation [2014-SHF01] FX This study was partly supported by the Capital Medicine Developing Research Foundation (2014-SHF01). The sponsors had no involvement in the study design, data analysis, data interpretation, and writing or revision of the manuscript. All the authors have no relationships relevant to the contents of this paper to disclose. NR 18 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 1 PY 2016 VL 222 BP 494 EP 498 DI 10.1016/j.ijcard.2016.07.215 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX9FF UT WOS:000384698300090 PM 27505340 ER PT J AU Christofferson, DE Hertzberg, JS Beckham, JC Dennis, PA Hamlett-Berry, K AF Christofferson, Dana E. Hertzberg, Jeffrey S. Beckham, Jean C. Dennis, Paul A. Hamlett-Berry, Kim TI Engagement and abstinence among users of a smoking cessation text message program for veterans SO ADDICTIVE BEHAVIORS LA English DT Article DE Smoking; Tobacco; Cessation; mHealth; Engagement; Veteran ID RANDOMIZED-TRIAL; HEALTH-PROMOTION; UNITED-STATES; INTERVENTIONS; SMOKERS; METAANALYSIS; ATTRITION; TEXT2QUIT; EFFICACY; HISTORY AB Background: SmokefreeVET is a text messaging smoking cessation program available to veterans enrolled in the Veterans Health Administration. SmokefreeVET was developed in collaboration with the National Cancer Institute as part of the SmokefreeTXT initiative. Purpose: To evaluate the real world use of and effectiveness of the SmokefreeVET program for SmokefreeVET users who enrolled between 2013 and 2014. Methods: Demographics and smoking behavior of 1470 SmokefreeVET users who enrolled between 2013 and 2014 were analyzed. Latent growth mixture modeling was used to identify discrete classes of SmokefreeVET users based on engagement patterns. Multi-level modeling determined class differences in abstinence. Results: The average age of the SmokefreeVET user was 48, 75% of users were male, and 84% were daily smokers. After five weeks, 13% of all users reported abstinence from smoking. Five statistically distinct engagement classes of SmokefreeVET users were identified. Highly engaged classes were significantly less likely to opt-out and more likely to report abstinence. Over 60% of users who were classified as high engagers throughout the program reported abstinence 5 weeks after their quit date. Users were more likely to report abstinence after two weeks if they used smoking cessation medication than those that did not use medication (OR = 9.01, p < 0.001). Conclusions: SmokefreeVET may be effective at supporting abstinence among a real world group of highly engaged users. Smoking cessation medication use was also associated with abstinence in SmokefreeVET users. Engagement appears to be a critical component when assessing the efficacy of a text messaging smoking cessation intervention. Published by Elsevier Ltd. C1 [Christofferson, Dana E.; Hamlett-Berry, Kim] Vet Hlth Adm, Off Patient Care Serv, US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. [Hertzberg, Jeffrey S.; Beckham, Jean C.; Dennis, Paul A.] Durham VA Med Ctr, 508 Fulton St, Durham, NC 27705 USA. [Beckham, Jean C.] VA Mid Atlantic Mental Illness Res Educ & Clin Ct, 508 Fulton St, Durham, NC 27705 USA. [Beckham, Jean C.; Dennis, Paul A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 2301 Erwin Rd, Durham, NC 27705 USA. RP Christofferson, DE (reprint author), Vet Hlth Adm, Tobacco & Hlth Policy & Programs, Off Patient Care Serv, US Dept Vet Affairs, 810 Vermont Ave NW 10P4M, Washington, DC 20420 USA. EM dana.christofferson@va.gov FU Department of Veterans Affairs, Veterans Health Administration (VHA): Office of Public Health; Office of Research and Development, Clinical Science Research and Development; Durham Veterans Affairs Medical Center; VISN 6 Mid-Atlantic Mental Illness Research, Education and Clinical Center, Office of Mental Health Services FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA): Office of Public Health; Office of Research and Development, Clinical Science Research and Development; the Durham Veterans Affairs Medical Center; and the VISN 6 Mid-Atlantic Mental Illness Research, Education and Clinical Center, Office of Mental Health Services. VHA had no role in the design, analysis and interpretation of data, drafting of the manuscript, or the decision to submit for publication. NR 43 TC 1 Z9 1 U1 4 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD NOV PY 2016 VL 62 BP 47 EP 53 DI 10.1016/j.addbeh.2016.06.016 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DT2QQ UT WOS:000381325900008 PM 27318948 ER PT J AU Monteith, LL Bahraini, NH Matarazzo, BB Gerber, HR Soberay, KA Forster, JE AF Monteith, Lindsey L. Bahraini, Nazanin H. Matarazzo, Bridget B. Gerber, Holly R. Soberay, Kelly A. Forster, Jeri E. TI The influence of gender on suicidal ideation following military sexual trauma among Veterans in the Veterans Health Administration SO PSYCHIATRY RESEARCH LA English DT Article DE Suicidal ideation; Military; Gender; Sexual assault; Sexual harassment; Sexual violence; Posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; OEF/OIF VETERANS; CLINICAL-SAMPLE; RISK-FACTORS; DEPLOYMENT; PERSONNEL; ASSAULT; COMBAT; EXPERIENCES AB No studies have examined whether military sexual trauma, as measured and defined within the Veterans Health Administration (VHA), is associated with suicidal ideation among Veterans in VHA care, when taking prior suicide attempts into account. Research regarding the role of gender in this association is also limited. The present study examined: (1) whether military sexual trauma was associated with the presence of past-week suicidal ideation among 354 Veterans in VHA (310 men, 44 women); (2) whether gender moderated the association between military sexual trauma and suicidal ideation. Information regarding military sexual trauma, suicidal ideation, suicide attempt, and psychiatric diagnoses was obtained from self-report instruments and medical records. Adjusting for age, gender, combat, posttraumatic stress disorder, depressive disorders, negative affect, and lifetime suicide attempt, Veterans with military sexual trauma were significantly more likely to report suicidal ideation, compared to Veterans without military sexual trauma. Furthermore, the association between military sexual trauma and suicidal ideation was stronger for men compared to women. These results contribute to a growing literature identifying military sexual trauma as a risk factor for suicidal thoughts and behaviors among Veterans in VHA care and emphasize the importance of screening for suicidal ideation among survivors of military sexual trauma. Published by Elsevier Ireland Ltd. C1 [Monteith, Lindsey L.; Bahraini, Nazanin H.; Matarazzo, Bridget B.; Gerber, Holly R.; Soberay, Kelly A.; Forster, Jeri E.] Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. [Monteith, Lindsey L.; Bahraini, Nazanin H.; Matarazzo, Bridget B.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Bahraini, Nazanin H.; Forster, Jeri E.] Univ Colorado, Dept Phys Med & Rehabil, Anschutz Med Campus, Aurora, CO USA. [Forster, Jeri E.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. RP Monteith, LL (reprint author), Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. EM Lindsey.Monteith@va.gov NR 46 TC 0 Z9 0 U1 4 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD OCT 30 PY 2016 VL 244 BP 257 EP 265 DI 10.1016/j.psychres.2016.07.036 PG 9 WC Psychiatry SC Psychiatry GA DY0HA UT WOS:000384776700039 PM 27504921 ER PT J AU Habeck, M Tokhtaeva, E Nadav, Y Ben Zeev, E Ferris, SP Kaufman, RJ Bab-Dinitz, E Kaplan, JH Dada, LA Farfel, Z Tal, DM Katz, A Sachs, G Vagin, O Karlish, SJD AF Habeck, Michael Tokhtaeva, Elmira Nadav, Yotam Ben Zeev, Efrat Ferris, Sean P. Kaufman, Randal J. Bab-Dinitz, Elizabeta Kaplan, Jack H. Dada, Laura A. Farfel, Zvi Tal, Daniel M. Katz, Adriana Sachs, George Vagin, Olga Karlish, Steven J. D. TI Selective Assembly of Na,K-ATPase alpha(2)beta(2) Heterodimers in the Heart DISTINCT FUNCTIONAL PROPERTIES AND ISOFORM-SELECTIVE INHIBITORS SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SODIUM-POTASSIUM PUMP; CARDIAC NA/K ATPASE; NA+/K+-ATPASE; PICHIA-PASTORIS; K-ATPASE; ADHESION MOLECULE; CRYSTAL-STRUCTURE; ALPHA-2 ISOFORM; BETA-SUBUNIT; INTRAOCULAR-PRESSURE AB The Na, K-ATPase alpha(2) subunit plays a key role in cardiac muscle contraction by regulating intracellular Ca2+, whereas alpha(1) has a more conventional role of maintaining ion homeostasis. The beta subunit differentially regulates maturation, trafficking, and activity of alpha-beta heterodimers. It is not known whether the distinct role of alpha(2) in the heart is related to selective assembly with a particular one of the three beta isoforms. We show here by immunofluorescence and co-immunoprecipitation that alpha(2) is preferentially expressed with beta(2) in T-tubules of cardiac myocytes, forming alpha(2)beta(2) heterodimers. We have expressed human alpha(1)beta(1), alpha(2)beta(1), alpha(2)beta(2), and alpha(2)beta(3) in Pichia pastoris, purified the complexes, and compared their functional properties. alpha(2)beta(2) and alpha(2)beta(3) differ significantly from both alpha(2)beta(1) and alpha(1)beta(1) in having a higher K0.5K+ and lower K0.5Na+ for activating Na, K-ATPase. These features are the result of a large reduction in binding affinity for extracellular K+ and shift of the E1P-E2P conformational equilibrium toward E1P. A screen of perhydro-1,4-oxazepine derivatives of digoxin identified several derivatives (e.g. cyclobutyl) with strongly increased selectivity for inhibition of alpha(2)beta(2) and alpha(2)beta(3) over alpha(1)beta(1) (range 22-33-fold). Molecular modeling suggests a possible basis for isoform selectivity. The preferential assembly, specific T-tubular localization, and low K+ affinity of alpha(2)beta(2) could allow an acute response to raised ambient K+ concentrations in physiological conditions and explain the importance of alpha(2)beta(2) for cardiac muscle contractility. The high sensitivity of alpha(2)beta(2) to digoxin derivatives explains beneficial effects of cardiac glycosides for treatment of heart failure and potential of alpha(2)beta(2)-selective digoxin derivatives for reducing cardiotoxicity. C1 [Bab-Dinitz, Elizabeta; Farfel, Zvi; Tal, Daniel M.; Katz, Adriana; Karlish, Steven J. D.] Weizmann Inst Sci, Dept Biomol Sci, IL-7610001 Rehovot, Israel. [Ben Zeev, Efrat] Weizmann Inst Sci, Israel Natl Ctr Personalized Med, IL-7610001 Rehovot, Israel. [Farfel, Zvi] Tel Aviv Univ, Sch Med, IL-6997801 Tel Aviv, Israel. [Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Ferris, Sean P.; Kaufman, Randal J.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA. [Kaplan, Jack H.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA. [Dada, Laura A.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA. [Ferris, Sean P.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,Hlth Sci West 451,Box 0102, San Francisco, CA 94143 USA. [Kaufman, Randal J.] Sanford Burnham Prebys Med Discovery Inst, Rm 7103,10901 N Torrey Pines Rd, La Jolla, CA 92037 USA. RP Karlish, SJD (reprint author), Weizmann Inst Sci, Dept Biomol Sci, IL-7610001 Rehovot, Israel.; Vagin, O (reprint author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA.; Vagin, O (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. EM olgav@ucla.edu; Steven.Karlish@weizmann.ac.il OI Habeck, Michael/0000-0002-4586-0499 FU Israel Science Foundation [789/12]; US-Israel Binational Science Foundation [711993]; National Institutes of Health [R37-HL48129, RO1HL113350]; USVA [2I01BX001006, 1RO1DK105156-01] FX This work was supported by Israel Science Foundation (789/12) and US-Israel Binational Science Foundation (711993, to S. J. D. K.) and, in part, by National Institutes of Health Grants R37-HL48129 (to L. A. D.), RO1HL113350 (to L. A. D. and O. V.), USVA 2I01BX001006 (to G. S.), and 1RO1DK105156-01 (to G. S.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 76 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 28 PY 2016 VL 291 IS 44 BP 23159 EP 23174 DI 10.1074/jbc.M116.751735 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EB2XB UT WOS:000387224800026 PM 27624940 ER PT J AU Albert, RK Au, DH Blackford, AL Casaburi, R Cooper, JA Criner, GJ Diaz, P Fuhlbrigge, AL Gay, SE Kanner, RE MacIntyre, N Martinez, FJ Panos, RJ Piantadosi, S Sciurba, F Shade, D Stibolt, T Stoller, JK Wise, R Yusen, RD Tonascia, J Sternberg, AL Bailey, W AF Albert, Richard K. Au, David H. Blackford, Amanda L. Casaburi, Richard Cooper, J. Allen, Jr. Criner, Gerard J. Diaz, Philip Fuhlbrigge, Anne L. Gay, Steven E. Kanner, Richard E. MacIntyre, Neil Martinez, Fernando J. Panos, Ralph J. Piantadosi, Steven Sciurba, Frank Shade, David Stibolt, Thomas Stoller, James K. Wise, Robert Yusen, Roger D. Tonascia, James Sternberg, Alice L. Bailey, William CA Long-Term Oxygen Treatment Trial TI A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; 60 MM HG; EXERCISE; THERAPY; SCALE; VALIDITY; QUALITY; DYSPNEA; INDEX AB BACKGROUND Long-term treatment with supplemental oxygen has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation. METHODS We originally designed the trial to test whether long-term treatment with supplemental oxygen would result in a longer time to death than no use of supplemental oxygen among patients who had stable COPD with moderate resting desaturation (oxyhemoglobin saturation as measured by pulse oximetry [Spo(2)], 89 to 93%). After 7 months and the randomization of 34 patients, the trial was redesigned to also include patients who had stable COPD with moderate exercise-induced desaturation (during the 6-minute walk test, Spo(2) >= 80% for >= 5 minutes and < 90% for >= 10 seconds) and to incorporate the time to the first hospitalization for any cause into the new composite primary outcome. Patients were randomly assigned, in a 1: 1 ratio, to receive long-term supplemental oxygen (supplemental-oxygen group) or no long-term supplemental oxygen (no-supplemental-oxygen group). In the supplemental-oxygen group, patients with resting desaturation were prescribed 24-hour oxygen, and those with desaturation only during exercise were prescribed oxygen during exercise and sleep. The trial-group assignment was not masked. RESULTS A total of 738 patients at 42 centers were followed for 1 to 6 years. In a time-to-event analysis, we found no significant difference between the supplemental-oxygen group and the no-supplemental-oxygen group in the time to death or first hospitalization (hazard ratio, 0.94; 95% confidence interval [CI], 0.79 to 1.12; P = 0.52), nor in the rates of all hospitalizations (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio, 1.08; 95% CI, 0.98 to 1.19), and COPD-related hospitalizations (rate ratio, 0.99; 95% CI, 0.83 to 1.17). We found no consistent between-group differences in measures of quality of life, lung function, and the distance walked in 6 minutes. CONCLUSIONS In patients with stable COPD and resting or exercise-induced moderate desaturation, the prescription of long-term supplemental oxygen did not result in a longer time to death or first hospitalization than no long-term supplemental oxygen, nor did it provide sustained benefit with regard to any of the other measured outcomes. (Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services; LOTT ClinicalTrials.gov number, NCT00692198.) C1 [Albert, Richard K.] Univ Colorado, Denver, CO 80202 USA. [Au, David H.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.] Univ Washington, Seattle, WA 98195 USA. [Blackford, Amanda L.; Casaburi, Richard] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Shade, David; Tonascia, James; Sternberg, Alice L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Casaburi, Richard] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Piantadosi, Steven] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Cooper, J. Allen, Jr.] Birmingham VA Med Ctr, Birmingham, AL USA. [Cooper, J. Allen, Jr.; Bailey, William] Univ Alabama Birmingham, Birmingham, AL USA. [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA. [Sciurba, Frank] Univ Pittsburgh, Pittsburgh, PA USA. [Diaz, Philip] Ohio State Univ, Columbus, OH 43210 USA. [Panos, Ralph J.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Panos, Ralph J.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Stoller, James K.] Cleveland Clin, Cleveland, OH 44106 USA. [Fuhlbrigge, Anne L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Fuhlbrigge, Anne L.] Harvard Med Sch, Boston, MA USA. [Gay, Steven E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Kanner, Richard E.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA. [MacIntyre, Neil] Duke Univ, Med Ctr, Durham, NC USA. [Martinez, Fernando J.] Weill Cornell Med Ctr, New York, NY USA. [Stibolt, Thomas] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Yusen, Roger D.] Washington Univ, Sch Med, St Louis, MO 63130 USA. RP Wise, R (reprint author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care, 4B-72,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM rwise@jhmi.edu FU National Heart, Lung, and Blood Institute; Centers for Medicare and Medicaid Services FX Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services; LOTT ClinicalTrials.gov number, NCT00692198. NR 29 TC 2 Z9 3 U1 5 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 27 PY 2016 VL 375 IS 17 BP 1617 EP 1627 DI 10.1056/NEJMoa1604344 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EB2DX UT WOS:000387168900008 ER PT J AU Kaz, AM Wong, CJ Varadan, V Willis, JE Chak, A Grady, WM AF Kaz, Andrew M. Wong, Chao-Jen Varadan, Vinay Willis, Joseph E. Chak, Amitabh Grady, William M. TI Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use SO CLINICAL EPIGENETICS LA English DT Article DE Barrett's esophagus; Esophageal adenocarcinoma; DNA methylation; Obesity; Waist-to-hip ratio; Tobacco use ID FALSE DISCOVERY RATE; BODY-MASS INDEX; HEPATOCELLULAR-CARCINOMA; NEOPLASTIC PROGRESSION; THERAPEUTIC TARGET; COLORECTAL-CANCER; GENE-EXPRESSION; GASTRIC-CANCER; HUMAN GENOME; RISK-FACTORS AB Background: The risk of developing Barrett's esophagus (BE) and/or esophageal adenocarcinoma (EAC) is associated with specific demographic and behavioral factors, including gender, obesity/elevated body mass index (BMI), and tobacco use. Alterations in DNA methylation, an epigenetic modification that can affect gene expression and that can be influenced by environmental factors, is frequently present in both BE and EAC and is believed to play a role in the formation of BE and its progression to EAC. It is currently unknown whether obesity or tobacco smoking influences the risk of developing BE/EAC via the induction of alterations in DNA methylation. To investigate this possibility, we assessed the genome-wide methylation status of 81 esophageal tissues, including BE, dysplastic BE, and EAC epithelia using HumanMethylation450 BeadChips (Illumina). Results: We found numerous differentially methylated loci in the esophagus tissues when comparing males to females, obese to lean individuals, and smokers to nonsmokers. Differences in DNA methylation between these groups were seen in a variety of functional genomic regions and both within and outside of CpG islands. Several cancer-related pathways were found to have differentially methylated genes between these comparison groups. Conclusions: Our findings suggest obesity and tobacco smoking may influence DNA methylation in the esophagus and raise the possibility that these risk factors affect the development of BE, dysplastic BE, and EAC through influencing the epigenetic status of specific loci that have a biologically plausible role in cancer formation. C1 [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA. [Kaz, Andrew M.; Wong, Chao-Jen; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Varadan, Vinay; Chak, Amitabh] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. [Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. [Chak, Amitabh] Case Western Reserve Univ, Sch Med, Div Gastroenterol, Cleveland, OH 44106 USA. RP Kaz, AM (reprint author), VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA.; Kaz, AM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM Andrew.Kaz@va.gov FU National Institutes of Health [U54CA163060, U01CA152756, 5P30CA015704, U01CA086402, U01CA182940, P50CA150964]; Listwin Family Foundation; Mercer Island Rotary Club; VA Puget Sound Health Care System FX This work was supported by the National Institutes of Health (U54CA163060 to AK, AC, VV, and WG, U01CA152756, 5P30CA015704, U01CA086402, and U01CA182940 to WG, and P50CA150964 to VV); the Listwin Family Foundation to WG, and the Mercer Island Rotary Club to WG. This material is the result of work supported in part by resources from the VA Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 79 TC 1 Z9 1 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1868-7083 J9 CLIN EPIGENETICS JI Clin. Epigenetics PD OCT 27 PY 2016 VL 8 AR 111 DI 10.1186/s13148-016-0273-7 PG 16 WC Oncology SC Oncology GA EA0DH UT WOS:000386255200001 PM 27795744 ER PT J AU Zhang, X Jia, DY Ao, JP Liu, HJ Zang, Y Azam, M Habib, SL Li, J Ruan, XS Jia, H Wang, XY Li, BJ AF Zhang, Xin Jia, Deyong Ao, Junping Liu, Huijuan Zang, Yi Azam, Mohammad Habib, Samy L. Li, Jia Ruan, Xinsen Jia, Hao Wang, Xueying Li, Baojie TI Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia SO ONCOTARGET LA English DT Article DE Bisindolylmaleimide IX; BCR-ABL; chronic myeloid leukemia (CML) ID CHRONIC MYELOID-LEUKEMIA; PROTEIN-KINASE-C; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; CELL-DEATH; STEM/PROGENITOR CELLS; IMATINIB RESISTANCE; CDC25 PHOSPHATASES; TOPOISOMERASE-I; CANCER-THERAPY AB Chronic myeloid leukemia (CML) treatment with BCR-ABL inhibitors is often hampered by development of drug resistance. In a screen for novel chemotherapeutic drug candidates with genotoxic activity, we identified a bisindolylmaleimide derivative, IX, as a small molecule compound with therapeutic potential against CML including drug-resistant CML. We show that Bisindolylmaleimide IX inhibits DNA topoisomerase, generates DNA breaks, activates the Atm-p53 and Atm-Chk2 pathways, and induces cell cycle arrest and cell death. Interestingly, Bisindolylmaleimide IX is highly effective in targeting cells positive for BCR-ABL. BCR-ABL positive cells display enhanced DNA damage and increased cell cycle arrest in response to Bisindolylmaleimide IX due to decreased expression of topoisomerases. Cells positive for BCR-ABL or drug-resistant T315I BCR-ABL also display increased cytotoxicity since Bisindolylmaleimide IX inhibits B-Raf and the downstream oncogene addiction pathway. Mouse cancer model experiments showed that Bisindolylmaleimide IX, at doses that show little side effect, was effective in treating leukemia-like disorders induced by BCR-ABL or T315I BCR-ABL, and prolonged the lifespan of these model mice. Thus, Bisindolylmaleimide IX presents a novel drug candidate to treat drug-resistant CML via activating BCR-ABL dependent genotoxic stress response and inhibiting the oncogene addiction pathway activated by BCR-ABL. C1 [Zhang, Xin; Jia, Deyong; Liu, Huijuan; Ruan, Xinsen; Jia, Hao; Li, Baojie] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, BioX Inst, Shanghai, Peoples R China. [Ao, Junping] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China. [Zang, Yi; Li, Jia] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Natl Ctr Drug Screening, Shanghai, Peoples R China. [Azam, Mohammad] Cincinnati Childrens Hosp & Med Ctr, Canc & Blood Dis Inst, Div Pathol, Cincinnati, OH USA. [Azam, Mohammad] Cincinnati Childrens Hosp & Med Ctr, Canc & Blood Dis Inst, Div Hematol, Cincinnati, OH USA. [Azam, Mohammad] Cincinnati Childrens Hosp & Med Ctr, Canc & Blood Dis Inst, Div Canc Biol, Cincinnati, OH USA. [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Wang, Xueying] Natl Univ Singapore, Dept Biochem, Singapore, Singapore. [Li, Baojie] Tongji Univ, Shanghai East Hosp, Translat Med Ctr Stem Cell Therapy, Sch Med, Shanghai, Peoples R China. RP Li, BJ (reprint author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, BioX Inst, Shanghai, Peoples R China.; Li, BJ (reprint author), Tongji Univ, Shanghai East Hosp, Translat Med Ctr Stem Cell Therapy, Sch Med, Shanghai, Peoples R China. EM libj@sjtu.edu.cn RI Zang, Yi/C-5683-2014 OI Zang, Yi/0000-0001-9835-922X FU Natural Science Foundation of China [81130039, 81121001]; Ministry of Science and Technology of China (The National Key Scientific Program) [2012CB966901, 2014CB942900]; Shanghai Zhangjiang Stem Cell Research Project [ZJ2014-ZD-002] FX The work was supported by grants from Natural Science Foundation of China (81130039 and 81121001), the Ministry of Science and Technology of China (The National Key Scientific Program (2012CB966901 and 2014CB942900), and Shanghai Zhangjiang Stem Cell Research Project (ZJ2014-ZD-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 0 Z9 0 U1 5 U2 5 PU IMPACT JOURNALS LLC PI ORCHARD PARK PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD OCT 25 PY 2016 VL 7 IS 43 BP 69945 EP 69960 DI 10.18632/oncotarget.11566 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA EB5VI UT WOS:000387448300065 PM 27564101 ER PT J AU Luttrell, LM AF Luttrell, Louis M. TI GPCR Signaling Rides a Wave of Conformational Changes SO CELL LA English DT Editorial Material ID RECEPTOR AB The ability of structurally distinct ligands to "bias" G protein-coupled receptor signaling affords the opportunity to tailor efficacy to suit specific therapeutic needs. Furness et al. demonstrate that ligand structure controls not only which effectors are activated, but also the way they are activated and the kinetics of downstream signaling. C1 [Luttrell, Louis M.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA.; Luttrell, LM (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [R01 DK055524]; NIGMS NIH HHS [R01 GM095497] NR 6 TC 0 Z9 0 U1 9 U2 9 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD OCT 20 PY 2016 VL 167 IS 3 BP 602 EP 603 DI 10.1016/j.cell.2016.10.006 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EA1HW UT WOS:000386344100007 PM 27768883 ER PT J AU Shanmugasundaram, K Block, K AF Shanmugasundaram, Karthigayan Block, Karen TI Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review DE tumor heterogeneity; oxidative stress; NOX oxidases; mitochondrial electron transfer chain; renal cancer; high-throughput analysis ID HYPOXIA-INDUCIBLE FACTOR; MITOCHONDRIAL OXIDATIVE-METABOLISM; EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA EXPRESSION SIGNATURES; MESSENGER-RNA TRANSLATION; OXIDASE SUBUNIT NOX4; HUMAN KIDNEY CANCER; CELL CARCINOMA; NADPH OXIDASE; TGF-BETA AB Significance: The number of kidney cancers is growing 3-5% each year due to unknown etiologies. Intra-and inter-tumor mediators increase oxidative stress and drive tumor heterogeneity. Recent Advances: Technology advancement in state-of-the-art instrumentation and methodologies allows researchers to detect and characterize global landscaping modifications in genes, proteins, and pathophysiology patterns at the single-cell level. Critical Issues: We postulate that the sources of reactive oxygen species (ROS) and their activation within subcellular compartments will change over a timeline of tumor evolvement and contribute to tumor heterogeneity. Therefore, the complexity of intracellular changes within a tumor and ROS-induced tumor heterogeneity coupled to the advancement of detecting these events globally are limited at the level of data collection, organization, and interpretation using software algorithms and bioinformatics. Future Directions: Integrative and collaborative research, combining the power of numbers with careful experimental design, protocol development, and data interpretation, will translate cancer biology and therapeutics to a heightened level or leave the abundant raw data as stagnant and underutilized. C1 [Shanmugasundaram, Karthigayan; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Block, Karen] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM block@uthscsa.edu FU Veterans Administration Merit Award; NIH [P30 CA054174] FX The authors would like to thank Dr. Yves Gorin for the creative drawing of figures presented in this article. Grant support was provided by Veterans Administration Merit Award (K.B.) and NIH P30 CA054174 (K.B.). NR 167 TC 0 Z9 0 U1 6 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD OCT 20 PY 2016 VL 25 IS 12 BP 685 EP 701 DI 10.1089/ars.2015.6569 PG 17 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA DY8MH UT WOS:000385383800004 PM 27287984 ER PT J AU Martinez, BR Staboli, IM Kamonseki, DH Budiman-Mak, E Yi, LC AF Martinez, Bruna Reclusa Staboli, Isabela Maschk Kamonseki, Danilo Harudy Budiman-Mak, Elly Yi, Liu Chiao TI Validity and reliability of the Foot Function Index (FFI) questionnaire Brazilian-Portuguese version SO SPRINGERPLUS LA English DT Article DE Foot diseases; Questionnaires; Outcome assessment; Validation studies ID CROSS-CULTURAL ADAPTATION; CHRONIC ANKLE INSTABILITY; HEALTH-STATUS; VALIDATION; INSTRUMENTS; DISABILITY; TRANSLATION; CRITERIA; PAIN; TOOLS AB Purpose: To evaluate the validity and reliability of the Foot Function Index (FFI) in its Brazilian Portuguese version. Methods: The validity and reliability of the FFI were tested in 50 volunteers, with plantar fasciitis, metatarsalgia and chronic ankle sprain. The FFI validity process used the Short Form-36 (SF-36) and Foot and Ankle Outcome Score (FAOS) questionnaires. The correlation between FFI, SF-36 and FAOS was done using the Pearson's linear coefficient. The inter and intra-evaluator reliability was ascertained by means of the intraclass correlation coefficient (ICC) and the internal consistency by means of Cronbach's alpha coefficient. The scores were used to assess the standard error measurement (SEM), minimal detectable change (MDC) and ceiling floor and effects. Results: The validity process showed that there were correlations between FFI and the "pain" and "social aspects" subscales of SF-36 and all subscales of FAOS, except for "other symptoms". The Brazilian-Portuguese version of FFI showed excellent intra and interevaluator correlations, with an ICC range of 0.99-0.97 and score reliability that was considered highly satisfactory, with Cronbach's alpha range of 0.80-0.61. The SEMs for inter and intra-evaluator reliability were 1.32 and 1.08, respectively. The MDC was 2.42 (90 % confidence interval). No ceiling and floor effect were detected. Conclusions: The Brazilian-Portuguese version of the FFI questionnaire was found to be a valid and reliable instrument for foot function evaluation, and can be used both in scientific settings and in clinical practice. C1 [Martinez, Bruna Reclusa; Staboli, Isabela Maschk; Kamonseki, Danilo Harudy; Yi, Liu Chiao] Univ Fed Sao Paulo, Dept Human Movement Sci, Rua Silva Jardim,136, BR-11015020 Santos, SP, Brazil. [Budiman-Mak, Elly] US Dept Vet Affairs, Washington, DC USA. RP Yi, LC (reprint author), Univ Fed Sao Paulo, Dept Human Movement Sci, Rua Silva Jardim,136, BR-11015020 Santos, SP, Brazil. EM liu.unifesp@gmail.com NR 32 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2193-1801 J9 SPRINGERPLUS JI SpringerPlus PD OCT 18 PY 2016 VL 5 AR 1810 DI 10.1186/s40064-016-3507-4 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EH5JD UT WOS:000391808300015 PM 27812449 ER PT J AU Mechanick, JI Zhao, S Garvey, WT AF Mechanick, Jeffrey I. Zhao, Shan Garvey, W. Timothy TI The Adipokine-Cardiovascular-Lifestyle Network Translation to Clinical Practice SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review DE cardiovascular disease; diabetes; hypertension; lifestyle medicine; network; obesity; systems biology ID CORONARY-ARTERY-DISEASE; RETINOL-BINDING-PROTEIN; GELATINASE-ASSOCIATED LIPOCALIN; CARDIOMETABOLIC RISK-FACTORS; HUMAN NEUTROPHIL GELATINASE; TYPE-2 DIABETES-MELLITUS; NECROSIS-FACTOR-ALPHA; NORMAL-WEIGHT OBESITY; ALL-CAUSE MORTALITY; METABOLIC SYNDROME AB Adipokines are peptides, secreted by adipocytes and other cell types with targets in other tissues, participating in a complex network of humoral factors involved in obesity, insulin resistance, and cardiovascular (CV) disease. This review describes recent information about adipokine effects on the CV system. Rather than simply providing a listing of adipokines and their respective effects, network analysis is used to enhance understanding. Various relationships and emergent processes in the adipokine-CV system network are discussed, with the most significant interactors being responses to hypoxia, regulation of cell migration, effects on blood coagulation, and platelet activation. Clinical translation is provided through network representations of the "obesity paradox," "metabolically healthy obese," "metabolic syndrome," and beneficial role of lifestyle medicine. As more translatable information about the larger adipokine-CV-lifestyle network is acquired from laboratory and clinical research, the strategic and precise role of lifestyle intervention can be fashioned to improve CV outcomes. (C) 2016 by the American College of Cardiology Foundation. C1 [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, 1192 Pk Ave, New York, NY 10128 USA. [Zhao, Shan] Telequire, New York, NY USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Diabet Res Ctr, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Mechanick, JI (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, 1192 Pk Ave, New York, NY 10128 USA. EM jeffreymechanick@gmail.com FU Novo Nordisk; Eisai; Janssen; Vivus; Takeda; AstraZeneca; Alexion; Merck FX From the aDivision of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York; bTelequire, New York, New York; cDepartment of Nutrition Sciences and Diabetes Research Center, University of Alabama at Birmingham, Birmingham, Alabama; and the dGeriatric Research Education and Clinical Center, Birmingham VA Medical Center, Birmingham, Alabama. Dr. Mechanick has received honoraria for lectures and program development from Abbott Nutrition International. Dr. Garvey has received consulting fees from Novo Nordisk, Eisai, Janssen, Vivus, Takeda, AstraZeneca, Alexion, and Merck. Dr. Zhao has reported that he has no relationships relevant to the contents of this paper to disclose. Carl "Chip" Lavie, MD, served as Guest Editor for this paper. NR 169 TC 4 Z9 4 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 18 PY 2016 VL 68 IS 16 BP 1785 EP 1803 DI 10.1016/j.jacc.2016.06.072 PG 19 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA7OP UT WOS:000386821200011 PM 27737746 ER PT J AU Ozieh, MN Bishu, KG Walker, RJ Campbell, JA Egede, LE AF Ozieh, Mukoso N. Bishu, Kinfe G. Walker, Rebekah J. Campbell, Jennifer A. Egede, Leonard E. TI Geographic variation in access among adults with kidney disease: evidence from medical expenditure panel survey, 2002-2011 SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Geographic variation; Kidney disease; Access to care; MEPS ID SOCIOECONOMIC-STATUS; UNITED-STATES; CARE; TRANSPLANTATION; IMPACT; CKD; COSTS; MODEL AB Background: To understand geographic variation in access to care over time in patients with kidney disease. Methods: We analyzed 4404 (weighted sample of 4,251,129) adults with kidney disease from the United States using the Medical Expenditure Panel Survey over 10 years. Three dependent variables were created to investigate variation in access: usual source of care, overall medical access to care, which took into account usual source of care, ability to get care, and delay in care, and prescription access, which took into account ability to get prescriptions and delay in getting prescriptions. Multiple logistic regression was used with geographic region as the main independent variable, adjusting for relevant covariates. Results: Compared to the Northeast region, adults living in the Midwest (OR = 0.56; 95 % CI 0.35-0.89), South (OR = 0. 48; 95 % CI 0.32-0.72) and West (OR = 0.53; 95 % CI 0.34-0.84) had significantly lower odds of reporting usual source of care. For the combined access measure, compared to Northeast, adults in Midwest (OR = 0.60; 95 % CI 0.40-0.88), South (OR = 0.62; 95 % CI 0.44-0.88) and West (OR = 0.50; 95 % CI 0.34-0.72) had significantly lower odds of medical access to care. Region was not significantly associated with the odds of having prescription access, though a significant increase in prescription access was observed over time. Conclusions: Geographic variation in access to care among adults with kidney disease exists independent of income, education, insurance and comorbid conditions, with those in the South least likely to have a usual source of care and those in the West least likely to have overall access to care when compared to the Northeast United States. C1 [Ozieh, Mukoso N.; Bishu, Kinfe G.; Walker, Rebekah J.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Ozieh, Mukoso N.; Bishu, Kinfe G.; Walker, Rebekah J.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.; Egede, LE (reprint author), Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.; Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K24DK093699] FX This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant K24DK093699, Principal Investigator: Leonard Egede, MD). NR 31 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD OCT 18 PY 2016 VL 16 AR 585 DI 10.1186/s12913-016-1844-1 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DZ2OR UT WOS:000385681600006 PM 27756393 ER PT J AU Perez-Garcia, G Sosa, MAG De Gasperi, R Lashof-Sullivan, M Maudlin-Jeronimo, E Stone, JR Haghighi, F Ahlers, ST Elder, GA AF Perez-Garcia, Georgina Sosa, Miguel A. Gama De Gasperi, Rita Lashof-Sullivan, Margaret Maudlin-Jeronimo, Eric Stone, James R. Haghighi, Fatemeh Ahlers, Stephen T. Elder, Gregory A. TI Exposure to a Predator Scent Induces Chronic Behavioral Changes in Rats Previously Exposed to Low-level Blast: Implications for the Relationship of Blast-Related TBI to PTSD SO FRONTIERS IN NEUROLOGY LA English DT Article DE animal models; blast; postconcussion syndrome; post-traumatic stress disorder; rat; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; OVERPRESSURE; VETERANS; RISK; CARE AB Blast-related mild traumatic brain injury (mTBI) has been unfortunately common in veterans who served in the recent conflicts in Iraq and Afghanistan. The postconcussion syndrome associated with these mTBIs has frequently appeared in combination with post-traumatic stress disorder (PTSD). The presence of PTSD has complicated diagnosis, since clinically, PTSD and the postconcussion syndrome of mTBI have many overlapping symptoms. In particular, establishing how much of the symptom complex can be attributed to the psychological trauma associated with PTSD in contrast to the physical injury of traumatic brain injury has proven difficult. Indeed, some have suggested that much of what is now being called blast-related postconcussion syndrome is better explained by PTSD. The relationship between the postconcussion syndrome of mTBI and PTSD is complex. Association of the two disorders might be viewed as additive effects of independent psychological and physical traumas suffered in a war zone. However, we previously found that rats exposed to repetitive low-level blast exposure in the absence of a psychological stressor developed a variety of anxiety and PTSD-related behavioral traits that were present months following the last blast exposure. Here, we show that a single predator scent challenge delivered 8 months after the last blast exposure induces chronic anxiety related changes in blast-exposed rats that are still present 45 days later. These observations suggest that in addition to independently inducing PTSD-related traits, blast exposure sensitizes the brain to react abnormally to a subsequent psychological stressor. These studies have implications for conceptualizing the relationship between blast-related mTBI and PTSD and suggest that blast-related mTBI in humans may predispose to the later development of PTSD in reaction to subsequent psychological stressors. C1 [Perez-Garcia, Georgina; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA. [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma Operat & Undersea Med, Silver Spring, MD USA. [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA. [Stone, James R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA. [Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. RP Elder, GA (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Elder, GA (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Elder, GA (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. EM gregory.elder@va.gov FU NMRC [0000B999.0000.000.A1503]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award [1I01RX000996-01] FX This work was supported by NMRC work unit number 0000B999.0000.000.A1503 and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. ML-S, EM-J, and SA are military service members (or employees of the U.S. Government). This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that copyright protection under this title is not available for any work of the United States Government. Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. NR 39 TC 0 Z9 0 U1 2 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PD OCT 18 PY 2016 VL 7 AR 176 DI 10.3389/fneur.2016.00176 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DZ2BL UT WOS:000385647000001 PM 27803688 ER PT J AU Kobeissy, FH Hansen, K Neumann, M Fu, SP Jin, KL Liu, JL AF Kobeissy, Firas H. Hansen, Katharina Neumann, Melanie Fu, Shuping Jin, Kulin Liu, Jialing TI Deciphering the Role of Emx1 in Neurogenesis: A Neuroproteomics Approach SO FRONTIERS IN MOLECULAR NEUROSCIENCE LA English DT Article DE cofilin; VEGF; neural stem cell; 2D-PAGE/MS-MS; Boyden chamber assay ID ENDOTHELIAL GROWTH-FACTOR; NEURAL STEM-CELLS; ACTIN-DEPOLYMERIZING FACTOR; CEREBRAL-CORTEX; NEUROVASCULAR NICHE; BRAIN-DEVELOPMENT; ACIDIC CALPONIN; MUTANT MICE; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH AB Emx1 has long been implicated in embryonic brain development. Previously we found that mice null of Emx1 gene had smaller dentate gyri and reduced neurogenesis, although the molecular mechanisms underlying this defect was not well understood. To decipher the role of Emx1 gene in neural regeneration and the timing of its involvement, we determine the frequency of neural stem cells (NSCs) in embryonic and adult forebrains of Emx1 wild type (WT) and knock out (KO) mice in the neurosphere assay. Emx1 gene deletion reduced the frequency and self-renewal capacity of NSCs of the embryonic brain but did not affect neuronal or glial differentiation. Emx1 KO NSCs also exhibited a reduced migratory capacity in response to serum or vascular endothelial growth factor (VEGF) in the Boyden chamber migration assay compared to their WT counterparts. A thorough comparison between NSC lysates from Emx1 WT and KO mice utilizing 2D-PAGE coupled with tandem mass spectrometry revealed 38 proteins differentially expressed between genotypes, including the F-actin depolymerization factor Cofilin. A global systems biology and cluster analysis identified several potential mechanisms and cellular pathways implicated in altered neurogenesis, all involving Cofilin1. Protein interaction network maps with functional enrichment analysis further indicated that the differentially expressed proteins participated in neural-specific functions including brain development, axonal guidance, synaptic transmission, neurogenesis, and hippocampal morphology, with VEGF as the upstream regulator intertwined with Cofilin1 and Emx1 Functional validation analysis indicated that apart from the overall reduced level of phosphorylated Cofilin1 (p-Cofilin1) in the Emx1 KO NSCs compared to WT NSCs as demonstrated in the western blot analysis. VEGF was able to induce more Cofilin1 phosphorylation and FLK expression only in the latter. Our results suggest that a defect in Cofilin1 phosphorylation induced by VEGF or other growth factors might contribute to the reduced neurogenesis in the Emx1 null mice during brain development. C1 [Kobeissy, Firas H.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA. [Hansen, Katharina; Neumann, Melanie; Fu, Shuping; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Hansen, Katharina; Neumann, Melanie; Fu, Shuping; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Fu, Shuping] Nanjing Univ Chihese Med, Minister Educ, Key Lab Acupuncture & Med Res, Nanjing, Jiangsu, Peoples R China. [Jin, Kulin] Univ North Texas, Hlth Sci Ctr, Pharmacol & Neurosci, Ft Worth, TX USA. RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Liu, JL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM jialing.liu@ucsf.edu RI kobeissy, firas/E-7042-2017 OI kobeissy, firas/0000-0002-5008-6944 FU NIH grant [R01 NS071050, I01RX000655]; National Natural Science Foundation of China [81403479] FX This work was supported by NIH grant R01 NS071050 (JL), VA merit award I01RX000655 (JL), and National Natural Science Foundation of China No.81403479 (SF). NR 93 TC 0 Z9 0 U1 4 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5099 J9 FRONT MOL NEUROSCI JI Front. Molec. Neurosci. PD OCT 17 PY 2016 VL 9 AR 98 DI 10.3389/fnmol.2016.00098 PG 16 WC Neurosciences SC Neurosciences & Neurology GA DY9GV UT WOS:000385442800001 PM 27799894 ER PT J AU Wiley, CA Bissel, SJ Lesniak, A Dixon, CE Franks, J Stolz, DB Sun, M Wang, GJ Switzer, R Kochanek, PM Murdoch, G AF Wiley, Clayton A. Bissel, Stephanie J. Lesniak, Andrew Dixon, C. Edward Franks, Jonathan Stolz, Donna Beer Sun, Ming Wang, Guoji Switzer, Robert Kochanek, Patrick M. Murdoch, Geoffrey TI Ultrastructure of Diaschisis Lesions after Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE axonal injury; controlled cortical impact; electron microscopy; light microscopy; TBI ID CROSSED CEREBELLAR ATROPHY; CONTROLLED CORTICAL IMPACT; LATERAL GENICULATE-NUCLEUS; AXONAL INJURY; HEAD-INJURY; NEUROFILAMENT COMPACTION; NEURONAL DEGENERATION; CEREBRAL HEMIATROPHY; CELL-DEATH; APOPTOSIS AB We used controlled cortical impact in mice to model human traumatic brain injury (TBI). Local injury was accompanied by distal diaschisis lesions that developed within brain regions anatomically connected to the injured cortex. At 7 days after injury, histochemistry documented broadly distributed lesions, particularly in the contralateral cortex and ipsilateral thalamus and striatum. Reactive astrocytosis and microgliosis were noted in multiple neural pathways that also showed silver-stained cell processes and bodies. Wisteria floribunda agglutinin (WFA) staining, a marker of perineuronal nets, was substantially diminished in the ipsilateral, but less so in the contralateral cortex. Contralateral cortical silver positive diaschisis lesions showed loss of both phosphorylated and unphosphorylated neurofilament staining, but overall preservation of microtubule-associated protein (MAP)-2 staining. Thalamic lesions showed substantial loss of MAP-2 and unphosphorylated neurofilaments in addition to moderate loss of phosphorylated neurofilament. One animal demonstrated contralateral cerebellar degeneration at 7 days post-injury. After 21 days, the gliosis had quelled, however persistent silver staining was noted. Using a novel serial section technique, we were able to perform electron microscopy on regions fully characterized at the light microscopy level. Cell bodies and processes that were silver positive at the light microscopy level showed hydropic disintegration consisting of: loss of nuclear heterochromatin; dilated somal and neuritic processes with a paucity of filaments, tubules, and mitochondria; and increased numbers of electron-dense membranous structures. Importantly the cell membrane itself was still intact 3 weeks after injury. Although the full biochemical nature of these lesions remains to be deciphered, the morphological preservation of damaged neurons and processes raises the question of whether this is a reversible process. C1 [Wiley, Clayton A.; Bissel, Stephanie J.; Lesniak, Andrew; Wang, Guoji; Murdoch, Geoffrey] Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA. [Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Dept Neurosurg, Anesthesiol, Phys Med, Pittsburgh, PA 15213 USA. [Kochanek, Patrick M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA. [Kochanek, Patrick M.] Univ Pittsburgh, Rehabil & Crit Care Med, Pittsburgh, PA 15213 USA. [Franks, Jonathan; Stolz, Donna Beer; Sun, Ming] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA. [Dixon, C. Edward; Kochanek, Patrick M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dixon, C. Edward; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Pittsburgh, PA USA. [Switzer, Robert] NeuroSci Associates, Knoxville, TN USA. RP Wiley, CA (reprint author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA. EM wileyca@upmc.edu FU NINDS NIH HHS [R01 NS079061] NR 63 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD OCT 15 PY 2016 VL 33 IS 20 BP 1866 EP 1882 DI 10.1089/neu.2015.4272 PG 17 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA EA6YO UT WOS:000386775300007 PM 26914973 ER PT J AU Younossi, ZM Stepanova, M Sulkowski, M Foster, GR Reau, N Mangia, A Patel, K Brau, N Roberts, SK Afdhal, N Nader, F Henry, L Hunt, S AF Younossi, Zobair M. Stepanova, Maria Sulkowski, Mark Foster, Graham R. Reau, Nancy Mangia, Alessandra Patel, Keyur Brau, Norbert Roberts, Stuart K. Afdhal, Nezam Nader, Fatema Henry, Linda Hunt, Sharon TI Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and-3 Clinical Trials SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE health-related quality of life; fatigue; work productivity; hepatitis C; direct-acting antivirals ID QUALITY-OF-LIFE; TELAPREVIR COMBINATION TREATMENT; TREATMENT-NAIVE PATIENTS; WORK PRODUCTIVITY; ANTIVIRAL REGIMENS; INSULIN-RESISTANCE; PLUS SOFOSBUVIR; VIRUS-INFECTION; LIVER-DISEASE; HCV AB Background. Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described. Methods. PROs data were collected from participants of ASTRAL-2 and ASTRAL-3 studies before, during, and after treatment using 4 PRO instruments (Short Form-36, Chronic Liver Disease Questionnaire-HCV, Functional Assessment of Chronic Illness Therapy-Fatigue, and Work Productivity and Activity Index: Specific Health Problem), and compared between the SOF/VEL and SOF + RBV groups. Results. A total of 818 HCV patients were included: 78% treatment naive, 25% cirrhosis. The rates of nearly all adverse events were lower in the RBV-free SOF/VEL group (all P<.03). The SOF/VEL group also experienced improvement of their PROs by treatment week 4 (+1.8% on average across all PROs), which continued throughout treatment (+4.1%) and post-treatment (+5.5%). In contrast, those in the SOF + RBV group had a modest decline in their PROs starting at treatment week 4 (up to -3.7%), which lasted until the end of treatment (up to -6.4%). In multiple regression analysis, the association of a treatment regimen with end-of-treatment PROs was significant for nearly all PROs; the average beta was +5.0% for the use of SOF/VEL (reference: SOF + RBV). Conclusions. Patients receiving ribavirin-free SOF/VEL reported significantly better PRO scores during treatment compared with those receiving the RBV-containing regimen. Furthermore, the interferon-and ribavirin-free SOF/VEL regimen resulted in a rapid improvement of PROs in HCV GTs 2 and 3 patients during treatment and after achieving sustained virologic response. C1 [Younossi, Zobair M.; Nader, Fatema; Henry, Linda; Hunt, Sharon] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA. [Stepanova, Maria] Ctr Outcomes Res Liver Dis, Washington, DC USA. [Sulkowski, Mark] Johns Hopkins Univ, Baltimore, MD USA. [Foster, Graham R.] Queen Mary Univ London, London, England. [Reau, Nancy] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Mangia, Alessandra] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy. [Patel, Keyur] Univ Toronto Hlth Network, Toronto, ON, Canada. [Brau, Norbert] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Roberts, Stuart K.] Alfred Hlth, Melbourne, Vic, Australia. [Roberts, Stuart K.] Monash Univ, Melbourne, Vic, Australia. [Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Younossi, ZM (reprint author), Betty & Guy Beatty Ctr Integrated Res, Claude Moore Hlth Educ & Res Bldg,3300 Gallows Rd, Falls Church, VA 22042 USA. EM zobair.younossi@inova.org FU Gilead Sciences FX M. S., G. F., N. R., A. M., K. P., N. B., S. K. R., and N. A. have received research support and/or on advisory board or consultant to Gilead Sciences. NR 45 TC 5 Z9 5 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1042 EP 1048 DI 10.1093/cid/ciw496 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400010 PM 27444413 ER PT J AU Chalmers, JD Reyes, LF Aliberti, S Restrepo, MI AF Chalmers, James D. Reyes, Luis F. Aliberti, Stefano Restrepo, Marcos I. TI Empirical Coverage of Methicillin-Resistant Staphylococcus aureus in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID CARE-ASSOCIATED PNEUMONIA; PATHOGENS C1 [Chalmers, James D.] Univ Dundee, Sch Med, Dundee DD1 4HN, Scotland. [Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Reyes, Luis F.; Restrepo, Marcos I.] Audie L Murphy Mem VA Hosp, South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Aliberti, Stefano] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy. [Aliberti, Stefano] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cardiothorac Unit, Milan, Italy. [Aliberti, Stefano] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Adult Cyst Fibrosis Ctr, Milan, Italy. RP Restrepo, MI (reprint author), Audie L Murphy Mem VA Hosp, South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1145 EP U182 DI 10.1093/cid/ciw464 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400028 PM 27402822 ER PT J AU Walter, ND de Jong, BC Garcia, BJ Dolganov, GM Worodria, W Byanyima, P Musisi, E Huang, L Chan, ED Van, TT Antonio, M Ayorinde, A Kato-Maeda, M Nahid, P Leung, AM Yen, A Fingerlin, TE Kechris, K Strong, M Voskuil, MI Davis, JL Schoolnik, GK AF Walter, Nicholas D. de Jong, Bouke C. Garcia, Benjamin J. Dolganov, Gregory M. Worodria, William Byanyima, Patrick Musisi, Emmanuel Huang, Laurence Chan, Edward D. Van, Tran T. Antonio, Martin Ayorinde, Abigail Kato-Maeda, Midori Nahid, Payam Leung, Ann M. Yen, Andrew Fingerlin, Tasha E. Kechris, Katerina Strong, Michael Voskuil, Martin I. Davis, J. Lucian Schoolnik, Gary K. TI Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Mycobacterium tuberculosis/genetics; Mycobacterium tuberculosis/physiology; sputum/microbiology; tuberculosis; pulmonary/epidemiology; acquired immunodeficiency syndrome/immunology ID NITRIC-OXIDE; TRANSCRIPTIONAL ADAPTATION; ALTERNATIVE ACTIVATION; PULMONARY TUBERCULOSIS; DORMANCY REGULON; GENE-EXPRESSION; LUNG GRANULOMAS; DOSR REGULON; MOUSE MODEL; MACROPHAGES AB Background. It is unknown whether immunosuppression influences the physiologic state of Mycobacterium tuberculosis in vivo. We evaluated the impact of host immunity by comparing M. tuberculosis and human gene transcription in sputum between human immunodeficiency virus (HIV)-infected and uninfected patients with tuberculosis. Methods. We collected sputum specimens before treatment from Gambians and Ugandans with pulmonary tuberculosis, revealed by positive results of acid-fast bacillus smears. We quantified expression of 2179 M. tuberculosis genes and 234 human immune genes via quantitative reverse transcription-polymerase chain reaction. We summarized genes from key functional categories with significantly increased or decreased expression. Results. A total of 24 of 65 patients with tuberculosis were HIV infected. M. tuberculosis DosR regulon genes were less highly expressed among HIV-infected patients with tuberculosis than among HIV-uninfected patients with tuberculosis (Gambia, P < .0001; Uganda, P = .037). In profiling of human genes from the same sputa, HIV-infected patients had 3.4-fold lower expression of IFNG (P = .005), 4.9-fold higher expression of ARG1 (P = .0006), and 3.4-fold higher expression of IL10 (P = .0002) than in HIV-uninfected patients with tuberculosis. Conclusions. M. tuberculosis in HIV-infected patients had lower expression of the DosR regulon, a critical metabolic and immunomodulatory switch induced by NO, carbon monoxide, and hypoxia. Our human data suggest that decreased DosR expression may result from alternative pathway activation of macrophages, with consequent decreased NO expression and/or by poor granuloma formation with consequent decreased hypoxic stress. C1 [Walter, Nicholas D.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Pulm Sect, Denver, CO USA. [Walter, Nicholas D.; Garcia, Benjamin J.; Fingerlin, Tasha E.; Strong, Michael] Integrated Ctr Genes Environm & Hlth, Denver, CO USA. [Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs & Med, Denver, CO USA. [Walter, Nicholas D.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO USA. [Garcia, Benjamin J.; Strong, Michael] Univ Colorado Denver, Computat Biosci Program, Anschutz Med Campus, Aurora, CO USA. [Voskuil, Martin I.] Univ Colorado Denver, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO USA. [Kechris, Katerina] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [de Jong, Bouke C.] NYU, New York, NY USA. [Dolganov, Gregory M.; Van, Tran T.; Schoolnik, Gary K.] Stanford Univ, Med Ctr, Dept Microbiol & Immunol, Stanford, CA 94305 USA. [Leung, Ann M.] Stanford Univ, Med Ctr, Dept Radiol, Stanford, CA 94305 USA. [Huang, Laurence; Kato-Maeda, Midori; Nahid, Payam] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Huang, Laurence] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA. [Yen, Andrew] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Davis, J. Lucian] Yale Sch Med, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Davis, J. Lucian] Yale Sch Med, Dept Pulm Crit Care & Sleep Med, New Haven, CT USA. [de Jong, Bouke C.] Inst Trop Med, Antwerp, Belgium. [de Jong, Bouke C.; Antonio, Martin; Ayorinde, Abigail] MRC Labs, Serrekunda, Gambia. [Worodria, William; Byanyima, Patrick; Musisi, Emmanuel] Makerere Univ, UCSF Res Collaborat, Kampala, Uganda. RP Walter, ND (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Res 2, Anschutz Med Campus,Box C272,9th Flr, Aurora, CO 80045 USA. EM nicholas.walter@ucdenver.edu OI Garcia, Benjamin/0000-0001-5524-6946 FU European Research Council [INTERRUPTB 311725]; National Institutes of Health [UL1 RR025780, 2T15LM009451-06, R21AI101714, K23AI080147, K24HL087713, R01HL090335, 5R01AI104589, 2RO1 AI061505]; Veteran's Administration [CDA1IK2CX000914-01A1]; Boettcher Foundation Webb Waring Award FX This work was supported by the European Research Council Starting (grant INTERRUPTB 311725 to B. C. d. J.), the National Institutes of Health (grants UL1 RR025780 and 2T15LM009451-06 [to B. J. G.], R21AI101714 [to J. L. D.], K23AI080147 [to J. L. D.], K24HL087713 [to L. H.], R01HL090335 [to L. H.], 5R01AI104589 [to P. N.], and 2RO1 AI061505 [to M. I. V.]), the Veteran's Administration (CDA1IK2CX000914-01A1 to N. D. W.), and a Boettcher Foundation Webb Waring Award (to M. S.). NR 42 TC 2 Z9 2 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 IS 8 BP 1205 EP 1211 DI 10.1093/infdis/jiw364 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8UL UT WOS:000386147200016 PM 27534685 ER PT J AU Corbo, JM Delellis, TM Hill, LG Rindfuss, SL Nashelsky, J AF Corbo, Jason M. Delellis, Teresa M. Hill, Lucas G. Rindfuss, Sarah L. Nashelsky, Joan TI ACE Inhibitors or ARBs to Prevent CKD in Patients with Microalbuminuria SO AMERICAN FAMILY PHYSICIAN LA English DT Editorial Material ID DIABETES-MELLITUS C1 [Corbo, Jason M.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Delellis, Teresa M.] Univ Manchester, Coll Pharm Nat & Hlth Sci, Ft Wayne, IN USA. [Hill, Lucas G.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Rindfuss, Sarah L.] West Penn Hosp, Care Partner Clin, Allegheny Hlth Network, Pittsburgh, PA USA. [Nashelsky, Joan] Univ Iowa, Ctr Human Rights, Iowa City, IA USA. RP Corbo, JM (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM jason.Corbo@gmail.com NR 9 TC 0 Z9 0 U1 3 U2 3 PU AMER ACAD FAMILY PHYSICIANS PI KANSAS CITY PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA SN 0002-838X EI 1532-0650 J9 AM FAM PHYSICIAN JI Am. Fam. Physician PD OCT 15 PY 2016 VL 94 IS 8 BP 652 EP 653 PG 2 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA DZ5PR UT WOS:000385914500006 PM 27929222 ER PT J AU Halpern, SD French, B Small, DS Saulsgiver, K Harhay, MO Audrain-McGovern, J Loewenstein, G Asch, DA Volpp, KG AF Halpern, Scott D. French, Benjamin Small, Dylan S. Saulsgiver, Kathryn Harhay, Michael O. Audrain-McGovern, Janet Loewenstein, George Asch, David A. Volpp, Kevin G. TI Heterogeneity in the Effects of Reward- and Deposit-based Financial Incentives on Smoking Cessation SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE financial incentives; smoking cessation; behavior change; heterogeneity of treatment effect ID INSTRUMENTAL VARIABLES; TRIALS; SMOKERS; IDENTIFICATION; ABSTINENCE; DEPENDENCE; OUTCOMES; HEALTH; MODEL; RATES AB Rationale: Targeting different smoking cessation programs to smokers most likely to quit when using them could reduce the burden of lung disease. Objectives: To identify smokers most likely to quit using pure reward-based financial incentives or incentive programs requiring refundable deposits to become eligible for rewards. Methods: We conducted prespecified secondary analyses of a randomized trial in which 2,538 smokers were assigned to an $800 reward contingent on sustained abstinence from smoking, a refundable $150 deposit plus a $650 reward, or usual care. Measurements and Main Results: Using logistic regression, we identified characteristics of smokers that were most strongly associated with accepting their assigned intervention and ceasing smoking for 6 months. We assessed modification of the acceptance, efficacy, and effectiveness of reward and deposit programs by 11 prospectively selected demographic, smoking-related, and psychological factors. Predictors of sustained smoking abstinence differed among participants assigned to reward-versus deposit-based incentives. However, greater readiness to quit and less steep discounting of future rewards were consistently among the most important predictors. Deposit-based programs were uniquely effective relative to usual care among men, higher-income participants, and participants who more commonlyfailed to pay their bills (all interaction P values < 0.10). Relative to rewards, deposits were more effective among black persons (P = 0.022) and those who more commonly failed to pay their bills (P = 0.082). Relative to rewards, deposits were more commonly accepted by higher-income participants, men, white persons, and those who less commonly failed to pay their bills (all P < 0.05). Conclusions: Heterogeneity among smokers in their acceptance and response to different forms of incentives suggests potential benefits of targeting behavior-change interventions based on patient characteristics. C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Perelman Sch Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Audrain-McGovern, Janet] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA. [Asch, David A.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu OI Harhay, Michael/0000-0002-0553-674X FU National Institutes of Health [R01CA159932, RC2AG036592, F31HL127947] FX Supported by National Institutes of Health grants R01CA159932 (S.D.H.), RC2AG036592 (D.A.A. and K.G.V.), and F31HL127947 (M.O.H.) and by in-kind support from CVS Health. NR 38 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 15 PY 2016 VL 194 IS 8 BP 981 EP 988 DI 10.1164/rccm.201601-0108OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DY7VU UT WOS:000385338200013 PM 27064456 ER PT J AU Payabyab, EC Balasubramaniam, S Edgerly, M Velarde, M Merino, MJ Venkatesan, AM Leuva, H Litman, T Bates, SE Fojo, T AF Payabyab, Eden C. Balasubramaniam, Sanjeeve Edgerly, Maureen Velarde, Margarita Merino, Maria J. Venkatesan, Aradhana M. Leuva, Harshraj Litman, Thomas Bates, Susan E. Fojo, Tito TI Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters SO CLINICAL CANCER RESEARCH LA English DT Article ID ADRENAL-CORTICAL CARCINOMA; LONG-TERM SURVIVAL; LAPAROSCOPIC ADRENALECTOMY; GENOMIC CHARACTERIZATION; ONCOLOGIC OUTCOMES; ADJUVANT MITOTANE; PHASE-II; STAGE-I; THERAPY; TUMORS AB The development of new therapies has lagged behind for rare cancers without defined therapeutic targets. Adrenocortical cancer is no exception. Mitotane, an older agent considered "adrenolytic," is used both to control symptoms in advanced disease and as adjuvant therapy after surgical resection. Molecular characterization of adrenocortical cancer has deepened our understanding of this genetically complex disease while identifying subgroups whose importance remains to be determined. Unfortunately, such studies have yet to demonstrate a therapeutic target for drug development, and to date, no targeted therapy has achieved meaningful outcomes. Consequently, first-line therapy for metastatic disease remains a combination regimen of etoposide, doxorubicin, and cisplatinum established in a randomized clinical trial. In addition to evaluating recent studies in adrenocortical cancer, we raise one critical clinical issue-the risk of peritoneal dissemination following laparoscopic resection of adrenocortical cancer. In a retrospective case series of 267 patients referred to the NCI for the treatment of recurrent or advanced adrenocortical cancer, we found extensive peritoneal dissemination in 25 of the 45 patients (55.6%) who had undergone laparoscopic resection, compared with only 7 of the 222 patients (3%) who had undergone an open resection (P < 0.0001). Although this has been debated in the literature, our data argue for an end to laparoscopic resection of adrenocortical cancers to avoid peritoneal dissemination, a complication of laparoscopy that is uniformly fatal. (C) 2016 AACR. C1 [Payabyab, Eden C.] NCI, Surg Branch, NIH, Bldg 10, Bethesda, MD 20892 USA. [Payabyab, Eden C.] NCI, Thorac & GI Oncol Branch, NIH, Bethesda, MD 20892 USA. [Balasubramaniam, Sanjeeve] USDA, Div Oncol Prod 1, OHOP, CDER, Silver Spring, MD USA. [Edgerly, Maureen; Velarde, Margarita] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Merino, Maria J.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA. [Venkatesan, Aradhana M.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Div Diagnost Imaging, Houston, TX 77030 USA. [Leuva, Harshraj; Bates, Susan E.; Fojo, Tito] James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Litman, Thomas] Univ Copenhagen, Med Biostat, Copenhagen, Denmark. [Bates, Susan E.; Fojo, Tito] Columbia Univ, Dept Med, Med Ctr, Div Med Oncol, New York, NY 10032 USA. RP Fojo, T (reprint author), Columbia Univ, Dept Med, Med Ctr, Div Med Oncol, New York, NY 10032 USA.; Fojo, T (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. EM atf2116@cumc.columbia.edu OI Balasubramaniam, Sanjeeve/0000-0002-0643-2117 NR 57 TC 2 Z9 2 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 15 PY 2016 VL 22 IS 20 BP 4989 EP 5000 DI 10.1158/1078-0432.CCR-16-1570 PG 12 WC Oncology SC Oncology GA DZ1WP UT WOS:000385632700007 PM 27742785 ER PT J AU Tache, Y AF Tache, Yvette TI The vagal anti-inflammatory pathways to the viscera: from basic understanding to therapeutic implications SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Editorial Material ID VAGUS NERVE-STIMULATION C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu NR 11 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD OCT 15 PY 2016 VL 594 IS 20 BP 5769 EP 5770 DI 10.1113/JP271540 PG 2 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DY8RV UT WOS:000385399100006 PM 27739076 ER PT J AU Tromp, J Meyer, S Mentz, RJ O'Connor, CM Metra, M Dittrich, HC Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JGF Givertz, MM Bloomfield, DM van Veldhuisen, DJ Hillege, HL Voors, AA van der Meer, P AF Tromp, Jasper Meyer, Sven Mentz, Robert J. O'Connor, Christopher M. Metra, Marco Dittrich, Howard C. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. F. Givertz, Michael M. Bloomfield, Daniel M. van Veldhuisen, Dirk J. Hillege, Hans L. Voors, Adriaan A. van der Meer, Peter TI Acute heart failure in the young: Clinical characteristics and biomarker profiles SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Heart failure; Age; Young; Biomarker ID PRESERVED EJECTION FRACTION; GELATINASE-ASSOCIATED LIPOCALIN; SELECTIVE ADHESION MOLECULE; ENDOTHELIAL GROWTH-FACTOR; OLDER-ADULTS; AGE; COMORBIDITIES; DYSFUNCTION; OUTCOMES; TRIAL AB Background: Young patients (<50 years) exhibit specific characteristics in chronic heart failure (HF), but their phenotype in acute heart failure (AHF) is not well described. Methods and results: 2033 patients of the PROTECT trialwere divided into two groups: young patients (<= 50 years) and older patients (>50 years). Biomarkers from different pathophysiological domains were available in 1266 patients. Patients were compared with regard to clinical characteristics, biomarker profiles, and in-hospital (worsening renal function [WRF] and decongestion) and post-discharge (180-day survival) outcome. Young patients (n = 121) were mostly men, had fewer comorbidities with better renal function, and more often had a reduced ejection fraction. At admission, young patients were more likely to have jugular venous distension, but less rales and dyspnea compared with older patients. During hospitalization, young patients received higher loop diuretic doses and were decongested earlier than older patients. WRF occurred less frequently in young patients (5.9% vs. 13.3%, p = 0.020) and they were more often discharged alive. At 180 days, the mortality of young patients was lower than that of the older patients (9.9% vs. 18.1, p = 0.021). Biomarker levels indicative of inflammation and renal damage were lower in the young, although they exhibited higher BNP levels than older patients. Conclusions: Despite use of higher diuretic doses, young patients with AHF less often developed WRF during hospitalization and had better outcomes than older patients. Differences in biomarker levels between the age groups suggest distinct underlying pathophysiologies. (C) 2016 Published by Elsevier Ireland Ltd. C1 [Tromp, Jasper; Meyer, Sven; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.; van der Meer, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Meyer, Sven] Carl von Ossietzky Univ Oldenburg, European Med Sch Oldenburg Groningen, Heart Ctr Oldenburg, Dept Cardiol, Oldenburg, Germany. [Mentz, Robert J.] Duke Univ, Med Ctr, Durham, NC USA. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. RP van der Meer, P (reprint author), Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM p.van.der.meer@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU Amgen; Bayer; Cytokinetics; Medtronic; Merck; Novartis; St. Jude; Trevena; NovaCardia FX Dr. Cleland was on the Steering Committee for the PROTECT trial, served on the advisory board for MSD, and received payments for both. Dr. O'Connor is a consultant to Merck. Dr. Ponikowski has received honoraria from Merck; Dr. Davison and Dr. Cotter are employees of Momentum Research Inc., which was contracted to perform work on the study by Merck. Dr. Metra have received honoraria and reimbursements from NovaCardia, sponsors of the study, and Merck. Dr. Givertz has received institutional research support and served on a scientific Advisory Board for Merck. Dr. Teerlink has received research grants and consultation fees from: Amgen, Bayer, Cytokinetics, Medtronic, Merck, Novartis, St. Jude, Trevena. Dr. Bloomfield is an employee of Merck. Dr. Dittrich served as a consultant to Merck. Dr. Voors has received speaker and consultancy fees from Merck. All other authors have reported that they have no conflict of interest to declare and that they take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. NR 33 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD OCT 15 PY 2016 VL 221 BP 1067 EP 1072 DI 10.1016/j.ijcard.2016.06.339 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX9DA UT WOS:000384692600201 PM 27448534 ER PT J AU Jadhav, S Russo, S Cottier, S Schneiter, R Cowart, A Greenberg, ML AF Jadhav, Shyamalagauri Russo, Sarah Cottier, Stephanie Schneiter, Roger Cowart, Ashley Greenberg, Miriam L. TI Valproate Induces the Unfolded Protein Response by Increasing Ceramide Levels SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE ceramide; fatty acid metabolism; lipid metabolism; sphingolipid; unfolded protein response (UPR); inositol ID ENDOPLASMIC-RETICULUM MEMBRANE; SACCHAROMYCES-CEREVISIAE; BIPOLAR DISORDER; INOSITOL-BIOSYNTHESIS; STRESS-RESPONSE; SPHINGOLIPID HOMEOSTASIS; PHOSPHATASE SAC1P; GENE-EXPRESSION; FUMONISIN B-1; YEAST AB Bipolar disorder (BD), which is characterized by depression and mania, affects 1-2% of the world population. Current treatments are effective in only 40-60% of cases and cause severe side effects. Valproate (VPA) is one of the most widely used drugs for the treatment of BD, but the therapeutic mechanism of action of this drug is not understood. This knowledge gap has hampered the development of effective treatments. To identify candidate pathways affected by VPA, we performed a genome-wide expression analysis in yeast cells grown in the presence or absence of the drug. VPA caused up-regulation of FEN1 and SUR4, encoding fatty acid elongases that catalyze the synthesis of very long chain fatty acids (C24 to C26) required for ceramide synthesis. Interestingly, fen1 and sur4 mutants exhibited VPA sensitivity. In agreement with increased fatty acid elongase gene expression, VPA increased levels of phytoceramide, especially those containing C24-C26 fatty acids. Consistent with an increase in ceramide, VPA decreased the expression of amino acid transporters, increased the expression of ER chaperones, and activated the unfolded protein response element (UPRE), suggesting that VPA induces the UPR pathway. These effects were rescued by supplementation of inositol and similarly observed in inositol-starved ino1 cells. Starvation of ino1 cells increased expression of FEN1 and SUR4, increased ceramide levels, decreased expression of nutrient transporters, and induced the UPR. These findings suggest that VPA-mediated inositol depletion induces the UPR by increasing the de novo synthesis of ceramide. C1 [Jadhav, Shyamalagauri; Greenberg, Miriam L.] Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA. [Russo, Sarah; Cowart, Ashley] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Russo, Sarah; Cowart, Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Cottier, Stephanie; Schneiter, Roger] Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland. RP Greenberg, ML (reprint author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA. EM mgreenberg@wayne.edu FU National Institutes of Health [DK081367]; Swiss National Science Foundation; Graduate School of Wayne State University FX This work was supported by National Institutes of Health Grant DK081367 (to M. L. G.), the Swiss National Science Foundation (to R. S.), and the Graduate School of Wayne State University (to S. J.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 55 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 14 PY 2016 VL 291 IS 42 BP 22253 EP 22261 DI 10.1074/jbc.M116.752634 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA1DL UT WOS:000386332600036 PM 27590340 ER PT J AU Mayr, FB Yende, S AF Mayr, Florian B. Yende, Sachin TI Understanding the complex host response in sepsis: is diabetes the key? SO CRITICAL CARE LA English DT Editorial Material ID MELLITUS C1 [Mayr, Florian B.; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15260 USA. [Mayr, Florian B.; Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Room 2A128, Pittsburgh, PA 15240 USA. RP Mayr, FB (reprint author), Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15260 USA.; Mayr, FB (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Room 2A128, Pittsburgh, PA 15240 USA. EM mayrfb@upmc.edu NR 7 TC 0 Z9 0 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X EI 1364-8535 J9 CRIT CARE JI Crit. Care PD OCT 12 PY 2016 VL 20 AR 321 DI 10.1186/s13054-016-1494-z PG 2 WC Critical Care Medicine SC General & Internal Medicine GA DY4AP UT WOS:000385041700001 PM 27729067 ER PT J AU Mittakanti, HR Thomas, IC Shelton, JB Makarov, DV Skolarus, TA Cooperberg, MR Chung, BI Sonn, GA Brooks, JD Leppert, JT AF Mittakanti, Harsha R. Thomas, I-Chun Shelton, Jeremy B. Makarov, Danil V. Skolarus, Ted A. Cooperberg, Matthew R. Chung, Benjamin I. Sonn, Geoffrey A. Brooks, James D. Leppert, John T. TI Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter C1 [Mittakanti, Harsha R.; Thomas, I-Chun; Chung, Benjamin I.; Sonn, Geoffrey A.; Brooks, James D.; Leppert, John T.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Shelton, Jeremy B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Shelton, Jeremy B.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Makarov, Danil V.] Vet Adm New York Harbor Healthcare Syst, New York, NY USA. [Makarov, Danil V.] NYU, Langone Med Ctr, New York, NY USA. [Skolarus, Ted A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Skolarus, Ted A.] Vet Adm Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Cooperberg, Matthew R.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Cooperberg, Matthew R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Leppert, John T.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Mittakanti, HR (reprint author), Stanford Univ, Sch Med, Stanford, CA 94305 USA. OI Makarov, Danil/0000-0002-0565-9272 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 10 PY 2016 VL 34 IS 29 BP 3586 EP + DI 10.1200/JCO.2016.68.9216 PG 4 WC Oncology SC Oncology GA DZ4TJ UT WOS:000385852400024 ER PT J AU Weber, D Long, J Leonard, MB Zemel, B Baker, JF AF Weber, David Long, Jin Leonard, Mary B. Zemel, Babette Baker, Joshua F. TI Development of Novel Methods to Define Deficits in Appendicular Lean Mass Relative to Fat Mass SO PLOS ONE LA English DT Article ID MUSCLE MASS; RHEUMATOID-ARTHRITIS; ALTERNATIVE DEFINITIONS; FUNCTIONAL IMPAIRMENT; PHYSICAL PERFORMANCE; SARCOPENIC OBESITY; REFERENCE VALUES; HEALTH; DISABILITY; STRENGTH AB Background Recent studies suggest that adjustment of measures of lean mass for adiposity improves associations with physical function. Our objective was to develop and test a method to adjust appendicular lean mass for adiposity. Methods Whole-body DXA data in 14,850 adults in the National Health and Nutrition Examination Survey were used to generate sex-, and race-specific standard deviation scores (Z-Scores relative to age and T-scores relative to 25 year-olds) for appendicular lean mass index (ALMI, kg/m(2)) and fat mass index (FMI, kg/m(2)). Correlations between ALMI and FMI Z- and T-Scores were assessed within demographic categories. Fat-adjusted ALMI (ALMI(FMI)) scores were determined using residual methods. Sarcopenia was defined as a T-Score <-2.0 and low lean for age as a Z- Score <-1.0. Correlations with physical function were assessed in an at-risk population. Results Positive associations between ALMI and FMI Z- and T-Scores were significant (R >0.50; p<0.001) within all demographic categories. The impact of a unit greater FMI Z- score on ALMI Z- score was less in the elderly, men, white subjects, and among individuals with lower FMI (all tests for interaction p<0.001). There was fair agreement between ALMI and ALMIFMI estimates of sarcopenia and low lean for age [ Kappa: 0.46, 0.52, respectively (p<0.0001)]. Elderly subjects were likely to be re-classified as sarcopenic while young subjects were likely to be re-classified as normal using ALMIFMI. ALMIFMI T-scores resulted in approximately twice the number of subjects defined as sarcopenic, compared with ALMI T-Scores. (1299 v. 534). Among rheumatoid arthritis patients, ALMIFMI Z- scores correlated with physical function (Health Assessment Questionnaire: rho = -0.22, p = 0.04; Short Physical Performance Battery: rho = 0.27, p = 0.01); however, the ALMI Z-Score did not. Conclusions Adjustment of ALMI for the confounding association with FMI impacts the definition of lean mass deficits. These methods provide a practical tool for investigators and clinicians based on population-based reference data. C1 [Weber, David] Univ Rochester, Golisano Childrens Hosp, Div Endocrinol & Diabet, Rochester, NY 14627 USA. [Long, Jin; Zemel, Babette] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Long, Jin; Leonard, Mary B.] Stanford Univ, Dept Pediat & Med, Stanford, CA 94305 USA. [Baker, Joshua F.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Baker, JF (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.; Baker, JF (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.; Baker, JF (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Veterans Affairs Clinical Science Research and Development Career Development Award [IK2 CX000955]; NIH [K24 DK076808, K12 HD068373]; University of Pennsylvania Clinical and Translational Research Center [UL1 RR024134] FX Dr. Baker is supported by a Veterans Affairs Clinical Science Research and Development Career Development Award (IK2 CX000955). This work was also supported by NIH grants K24 DK076808 (MBL), K12 HD068373 (DRW) and the University of Pennsylvania Clinical and Translational Research Center (UL1 RR024134). NR 26 TC 0 Z9 0 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 10 PY 2016 VL 11 IS 10 AR e0164385 DI 10.1371/journal.pone.0164385 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ0CF UT WOS:000385504100053 PM 27723820 ER PT J AU Habtezion, A Edderkaoui, M Pandol, SJ AF Habtezion, Aida Edderkaoui, Mouad Pandol, Stephen J. TI Macrophages and pancreatic ductal adenocarcinoma SO CANCER LETTERS LA English DT Review DE Macrophages; Tumor associated macrophages; Pancreas cancer; Pancreatic ductal adenocarcinoma ID TUMOR-ASSOCIATED MACROPHAGES; PRE-METASTATIC NICHE; BONE-MARROW; INTRAEPITHELIAL NEOPLASIA; INFILTRATING MACROPHAGES; PREMETASTATIC NICHE; CHEMOKINE RECEPTOR; MALIGNANT-TUMORS; CANCER EXOSOMES; GROWTH-FACTORS AB Monocytes and macrophages make up part of the innate immune system and provide one of the first defenses against variety of treats. Macrophages can also modulate the adaptive immune system. Efficient sensing and response to tissue environmental cues highlights the complexity and dynamic nature of macrophages and their plasticity. Macrophages may have divergent roles depending on their polarity and stimulus received. Accumulating evidence demonstrates the critical role played by macrophages in tumor initiation, development, and progression. In this review, we discuss the characteristics of tumor associated macrophages (TAMs) and their role in pancreatic adenocarcinoma. In addition, we give an overview on recent advances related to the therapeutic implication associated with targeting TAMs in pancreas cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Habtezion, Aida] Stanford Univ, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA. [Edderkaoui, Mouad; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA USA. [Edderkaoui, Mouad; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA. [Edderkaoui, Mouad; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Habtezion, A (reprint author), Stanford Univ, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA. EM aidah@stanford.edu FU National Pancreas Foundation; Department of Veterans Affairs; NIH [DK092421, P01CA163200, P50 AA11999, K01AA019996] FX This work was supported in part by the National Pancreas Foundation Grant, Department of Veterans Affairs, NIH DK092421, NIH P01CA163200 and NIH P50 AA11999, and NIH K01AA019996. NR 92 TC 0 Z9 0 U1 3 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 EI 1872-7980 J9 CANCER LETT JI Cancer Lett. PD OCT 10 PY 2016 VL 381 IS 1 BP 211 EP 216 DI 10.1016/j.canlet.2015.11.049 PG 6 WC Oncology SC Oncology GA DW8WG UT WOS:000383935600024 PM 26708507 ER PT J AU Liu, S Cadaneanu, RM Zhang, BH Huo, LH Lai, K Li, XM Galet, C Grogan, TR Elashoff, D Freedland, SJ Rettig, M Aronson, WJ Knudsen, BS Lewis, MS Garraway, IP AF Liu, Sandy Cadaneanu, Radu M. Zhang, Baohui Huo, Lihong Lai, Kevin Li, Xinmin Galet, Colette Grogan, Tristan R. Elashoff, David Freedland, Stephen J. Rettig, Matthew Aronson, William J. Knudsen, Beatrice S. Lewis, Michael S. Garraway, Isla P. TI Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone SO PLOS ONE LA English DT Article ID EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; BASAL-CELLS; IN-VIVO; IDENTIFICATION; SUBPOPULATION; REGENERATION; POPULATIONS; PROGRESSION AB Background Benign human prostate tubule-initiating cells (TIC) and aggressive prostate cancer display common traits, including tolerance of low androgen levels, resistance to apoptosis, and microenvironment interactions that drive epithelial budding and outgrowth. TIC can be distinguished from epithelial and stromal cells that comprise prostate tissue via cell sorting based upon Epcam, CD44, and CD49f antigenic profiles. Fetal prostate epithelial cells (FC) possess a similar antigenic profile to adult TIC and are capable of inducing tubule formation. To identify the TIC niche in human prostate tissue, differential keratin (KRT) expression was evaluated. Results Gene expression data generated from Affymetrix Gene Chip human U133 Plus 2.0 array of sorted adult and fetal epithelial cells revealed KRT13 to be significantly enriched in FC and TIC compared to basal cells (BC) and luminal cells (LC) (p<0.001). Enriched KRT13 expression was confirmed by RT-PCR and cytospin immunostaining. Immunohistochemical analysis of KRT13 expression revealed rare KRT13(+) epithelia throughout prostatic ducts/acini in adult tissue specimens and differentiated tubules in 24-week recombinant grafts, In contrast, abundant KRT13 expression was observed in developing ducts/acini in fetal prostate and cord-like structures composing 8-week recombinant grafts. Immunostaining of a prostate tissue microarray revealed KRT13(+) tumor foci in approximately 9% of cases, and this subset displayed significantly shorter time to recurrence (p = 0.031), metastases (p = 0.032), and decreased overall survival (p = 0.004). Diagnostic prostate needle biopsies (PNBX) from untreated patients with concurrent bone metastases (clinical stage M1) displayed KRT13(+) tumor foci, as did bone metastatic foci. Conclusions The expression profile of KRT13 in benign fetal and adult prostate tissue and in recombinant grafts, as well as the frequency of KRT13 expression in primary and metastatic prostate cancer indicates that it may be a marker of a stem/progenitor-like cell state that is co-opted in aggressive tumor cells. KRT13 is enriched in benign stem-like cells that display androgen-resistance, apoptosis-resistance, and branching morphogenesis properties. Collectively our data demonstrate that KRT13 expression is associated with poor prognosis at multiple stages of disease progression and may represent an important biomarker of adverse outcome in patients with prostate cancer. C1 [Liu, Sandy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA. [Cadaneanu, Radu M.; Zhang, Baohui; Huo, Lihong; Lai, Kevin; Galet, Colette; Rettig, Matthew; Aronson, William J.; Garraway, Isla P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Li, Xinmin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grogan, Tristan R.; Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med Stat Core, Los Angeles, CA 90095 USA. [Freedland, Stephen J.] Durham VA Med Ctr, Dept Surg, Urol Sect, Durham, NC USA. [Rettig, Matthew; Aronson, William J.; Garraway, Isla P.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Aronson, William J.; Garraway, Isla P.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA 90073 USA. [Knudsen, Beatrice S.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. [Lewis, Michael S.] Greater Los Angeles Vet Affairs Hlth Syst, Dept Pathol, Los Angeles, CA USA. RP Garraway, IP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.; Garraway, IP (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.; Garraway, IP (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA 90073 USA. EM igarraway@mednet.ucla.edu FU Jean Perkins Foundation; Prostate Cancer Foundation (PCF) Creativity Award; Movember/PCF GAP1 Unique TMAs Project; Stephen Spielberg Team Science Award; DOD [PC131996, PC130244, PC030868]; NIH/NCI [P01 CA098912-09, U54 CA143931, P50CA09231]; NIH [R01CA131255, P50CA092131]; NIH/NCATS UCLA CTSI [UL1TR000124]; National Institutes of Health [CA-16042, AI-28697]; JCCC; UCLA AIDS Institute; David Geffen School of Medicine at UCLA FX This work was supported by Jean Perkins Foundation (IG); Prostate Cancer Foundation (PCF) Creativity Award (BK); Movember/PCF GAP1 Unique TMAs Project (IG, ML, and BK); Stephen Spielberg Team Science Award (BK); DOD PC131996 (IG, ML, and BK); DOD PC130244 (IG and ML); NIH/NCI P01 CA098912-09 (IG and BK); NIH/NCI U54 CA143931 (IG); NIH R01CA131255 and P50CA092131 (BK); NIH/NCATS UCLA CTSI Grant UL1TR000124 (TG and DE); DOD PC030868 (MR); NIH/NCI P50CA09231 (WA and MR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Flow cytometry/FACS was performed in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and is supported by National Institutes of Health awards CA-16042 and AI-28697, and by the JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA. Procurement of fetal tissues is supported by the Center for AIDS Research at UCLA, under the leadership of Dr. Dong Sun An. NR 35 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 6 PY 2016 VL 11 IS 10 AR e0163232 DI 10.1371/journal.pone.0163232 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ2UR UT WOS:000385697600019 PM 27711225 ER PT J AU Dean, DC Sojkova, J Hurley, S Kecskemeti, S Okonkwo, O Bendlin, BB Theisen, F Johnson, SC Alexander, AL Gallagher, CL AF Dean, Douglas C., III Sojkova, Jitka Hurley, Samuel Kecskemeti, Steven Okonkwo, Ozioma Bendlin, Barbara B. Theisen, Frances Johnson, Sterling C. Alexander, Andrew L. Gallagher, Catherine L. TI Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study SO PLOS ONE LA English DT Article ID WHITE-MATTER; MULTIPLE-SCLEROSIS; STEADY-STATE; BRAIN MICROSTRUCTURE; MAGNETIC-RESONANCE; IMAGE REGISTRATION; NERVOUS-SYSTEM; WATER; RELAXATION; DIFFUSION AB Alterations to myelin may be a core pathological feature of neurodegenerative diseases. Although white matter microstructural differences have been described in Parkinson's disease (PD), it is unknown whether such differences include alterations of the brain's myelin content. Thus, the objective of the current study is to measure and compare brain myelin content between PD patients and age-matched controls. In this cross-sectional study, 63 participants from the Longitudinal MRI in Parkinson's Disease study underwent brain MRI, Unified Parkinson's Disease Rating Scale (UPDRS) scoring, and cognitive asessments. Subjects were imaged with the mcDEPSOT (multi-component driven equilibrium single pulse observation of T1 and T2), a multicomponent relaxometry technique that quantifies longitudinal and transverse relaxation rates (R-1 and R-2, respectively) and the myelin water fraction (VFM), a surrogate for myelin content. A voxel-wise approach was used to compare R-1, R-2, and VFM measures between PD and control groups, and to evaluate relationships with age as well as disease duration, UPDRS scores, and daily levodopa equivalent dose. PD subjects had higher VFM than controls in frontal and temporal white matter and bilateral thalamus. Greater age was strongly associated with lower VFM in both groups, while an age-by-group interaction suggested a slower rate of VFM decline in the left putamen with aging in PD. Within the PD group, measures of disease severity, including UPDRS, daily levodopa equivalent dose, and disease duration, were observed to be related with myelin content in diffuse brain regions. The age-by-group interaction suggests that either PD or dopaminergic therapies allay observed age-related myelin changes. The relationships between VFM and disease severity measures suggests that VFM may provide a surrogate marker for microstructural changes related to Parkinson's disease. C1 [Dean, Douglas C., III; Kecskemeti, Steven; Alexander, Andrew L.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA. [Sojkova, Jitka; Theisen, Frances; Johnson, Sterling C.; Gallagher, Catherine L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Sojkova, Jitka; Theisen, Frances; Gallagher, Catherine L.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA. [Hurley, Samuel] Univ Oxford, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford, Oxon, England. [Okonkwo, Ozioma; Bendlin, Barbara B.; Johnson, Sterling C.; Gallagher, Catherine L.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA. RP Gallagher, CL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.; Gallagher, CL (reprint author), Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.; Gallagher, CL (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53706 USA. EM gallagher@neurology.wisc.edu FU U.S. Department of Veterans Affairs [101CX000555]; National Institute of Child Health and Human Development [T32 HD007489, P30 HD003352, R21 HD078119]; National Institute on Aging [R01 AG027161, P50 AG033514, R01 AG037639] FX This work was supported by the U.S. Department of Veterans Affairs 101CX000555 to CLG; National Institute of Child Health and Human Development T32 HD007489 to DCD; National Institute of Child Health and Human Development P30 HD003352 Waisman Center; National Institute on Aging R01 AG027161 to SCJ; National Institute on Aging P50 AG033514 University of Wisconsin Madison; National Institute of Child Health and Human Development R21 HD078119 to ALA and the National Institute on Aging R01 AG037639 to BBB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 76 TC 1 Z9 1 U1 4 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 5 PY 2016 VL 11 IS 10 AR e0163774 DI 10.1371/journal.pone.0163774 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ2UN UT WOS:000385697200057 PM 27706215 ER PT J AU Wong, SJ Gearhart, MD Taylor, AB Nanyes, DR Ha, DJ Robinson, AK Artigas, JA Lee, OJ Demeler, B Hart, PJ Bardwell, VJ Kim, CA AF Wong, Sarah J. Gearhart, Micah D. Taylor, Alexander B. Nanyes, David R. Ha, Daniel J. Robinson, Angela K. Artigas, Jason A. Lee, Oliver J. Demeler, Borries Hart, P. John Bardwell, Vivian J. Kim, Chongwoo A. TI KDM2B Recruitment of the Polycomb Group Complex, PRC1.1, Requires Cooperation between PCGF1 and BCORL1 SO STRUCTURE LA English DT Article ID INTERNAL TANDEM DUPLICATIONS; CLEAR-CELL SARCOMA; REPRESSIVE COMPLEX; H2A UBIQUITYLATION; CPG ISLANDS; REGULATOR; HOMOLOGS; PROTEINS; TARGETS; GENOME AB KDM2B recruits H2A-ubiquitinating activity of a non-canonical Polycomb Repression Complex 1 (PRC1.1) to CpG islands, facilitating gene repression. We investigated the molecular basis of recruitment using in vitro assembly assays to identify minimal components, subcomplexes, and domains required for recruitment. A minimal four-component PRC1.1 complex can be assembled by combining two separately isolated subcomplexes: the DNA-binding KDM2B/SKP1 heterodimer and the heterodimer of BCORL1 and PCGF1, a core component of PRC1.1. The crystal structure of the KDM2B/ SKP1/BCORL1/PCGF1 complex illustrates the crucial role played by the PCGF1/BCORL1 heterodimer. The BCORL1 PUFD domain positions residues preceding the RAWUL domain of PCGF1 to create an extended interface for interaction with KDM2B, which is unique to the PCGF1-containing PRC1.1 complex. The structure also suggests how KDM2B might simultaneously function in PRC1.1 and an SCF ubiquitin ligase complex and the possible molecular consequences of BCOR PUFD internal tandem duplications found in pediatric kidney and brain tumors. C1 [Wong, Sarah J.; Taylor, Alexander B.; Nanyes, David R.; Ha, Daniel J.; Robinson, Angela K.; Demeler, Borries; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Wong, Sarah J.; Taylor, Alexander B.; Nanyes, David R.; Ha, Daniel J.; Robinson, Angela K.; Demeler, Borries; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, CTRC, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Gearhart, Micah D.] Univ Minnesota, Masonic Canc Ctr, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA. [Gearhart, Micah D.] Univ Minnesota, Ctr Dev Biol, Minneapolis, MN 55455 USA. [Artigas, Jason A.; Lee, Oliver J.; Kim, Chongwoo A.] Midwestern Univ, Dept Biochem, 19555 North 59th Ave, Glendale, AZ 85308 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Kim, CA (reprint author), Midwestern Univ, Dept Biochem, 19555 North 59th Ave, Glendale, AZ 85308 USA. EM ckim@midwestern.edu FU Welch Foundation [AQ-1813, AQ-1399]; NIGMS of the NIH [R01GM114338]; NIH [F31GM099418, R01CA071540, P41GM103403]; Minnesota Masonic Charities; University of Minnesota Medical School; National Science Foundation [ACI-1339649]; XSEDE [MCB-070039]; Vice President for Research and a National Cancer Institute P30 Cancer Center Support Grant [CA054174]; DOE [DE-AC02-06CH11357] FX C.A.K. was supported by the Welch Foundation (AQ-1813) and the NIGMS of the NIH under award number R01GM114338. S.J.W. was supported by the NIH (F31GM099418). V.J.B. was supported by the NIH (R01CA071540) and funds from the Minnesota Masonic Charities, and the University of Minnesota Medical School. B.D. acknowledges support from the National Science Foundation (ACI-1339649) and XSEDE (MCB-070039). P.J.H. was supported by the Welch Foundation (AQ-1399). The University of Texas Health Science Center at San Antonio (UTHSCSA) X-ray Crystallography Core Laboratory is supported in part by the Vice President for Research and a National Cancer Institute P30 Cancer Center Support Grant (CA054174) awarded to the CTRC at UTHSCSA. NECAT beamline 24-ID-C is supported in part by the NIH (P41GM103403) and the DOE (DE-AC02-06CH11357 NR 27 TC 3 Z9 3 U1 2 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0969-2126 EI 1878-4186 J9 STRUCTURE JI Structure PD OCT 4 PY 2016 VL 24 IS 10 BP 1795 EP 1801 DI 10.1016/j.str.2016.07.011 PG 7 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA EA6UF UT WOS:000386763800018 PM 27568929 ER PT J AU Fried, LF Palevsky, PM AF Fried, Linda F. Palevsky, Paul M. TI Decreasing Prevalence of Chronic Kidney Disease in the United States: A Cause for Optimism SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Fried, Linda F.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu NR 10 TC 1 Z9 1 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 4 PY 2016 VL 165 IS 7 BP 521 EP + DI 10.7326/M16-1649 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DY0EY UT WOS:000384771300012 PM 27479750 ER PT J AU Ledoux, WR Pai, S Shofer, JB Wang, YN AF Ledoux, William R. Pai, Shruti Shofer, Jane B. Wang, Yak-Nam TI The association between mechanical and biochemical/histological characteristics in diabetic and non-diabetic plantar soft tissue SO JOURNAL OF BIOMECHANICS LA English DT Article DE Foot; Diabetes; Subcutaneous; Ulceration; Plantar soft tissue; Adipose ID LOWER-EXTREMITY AMPUTATION; PERIPHERAL NEUROPATHY; HEEL-PAD; STEREOLOGICAL METHODS; CONNECTIVE-TISSUE; FOOT ULCERS; FAT PADS; MELLITUS; THICKNESS; STIFFNESS AB Diabetes, and the subsequent complication of lower limb ulcers leading to potential amputation, remains an important health care problem in United States, even with declining amputation rates. It has been well documented that diabetes can alter the mechanical properties (i.e., increased stiffness) of the plantar soft tissue, although this finding is not universal. Similarly, biochemical, and histological changes have been found in the plantar soft tissue, but, as with the mechanical changes, these findings are not consistent across all studies. Our group's work has demonstrated that diabetes increases plantar soft tissue modulus and increases elastic septal thickness. The purpose of the current study was to explore the association between mechanical, biochemical and histological properties. Using previously collected data, a linear mixed effects regression was conducted. The correlations were weak; of the 32 that were tested, only 3 (modulus to septal thickness when location was accounted for, energy loss to total collagen, and energy loss to collagen/elastin ratio) were statistically significant, none with an R-2 greater than 0.10. The main differences in the means were increased tissue stiffness and increased septal wall thickness, both trends were supported in the literature. However, as the correlations were weak, it is likely that another unexamined biochemical factor (perhaps collagen crosslinking) is associated with the mechanical tissue changes. Published by Elsevier Ltd. C1 [Ledoux, William R.; Pai, Shruti; Shofer, Jane B.; Wang, Yak-Nam] VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, Seattle, WA 98108 USA. [Ledoux, William R.; Pai, Shruti] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Wang, Yak-Nam] Univ Washington, Appl Phys Lab, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@uw.edu FU National Institutes of Health [1R01 DK75633-03]; Department of Veterans Affairs, MID Service grant [A4843C] FX This study was supported by the National Institutes of Health grant 1R01 DK75633-03 and the Department of Veterans Affairs, MID Service grant A4843C. The authors have no conflicts to report. NR 42 TC 0 Z9 0 U1 9 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD OCT 3 PY 2016 VL 49 IS 14 BP 3328 EP 3333 DI 10.1016/j.jbiomech.2016.08.021 PG 6 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA EA9SG UT WOS:000386984400026 PM 27623704 ER PT J AU Koek, RJ Schwartz, HN Scully, S Langevin, JP Spangler, S Korotinsky, A Jou, K Leuchter, A AF Koek, Ralph J. Schwartz, Holly N. Scully, Stephenie Langevin, Jean-Philippe Spangler, Shana Korotinsky, Arkady Jou, Kevin Leuchter, Andrew TI Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Article DE Post-traumatic stress disorder; Treatment-refractory; Psychopharmacology; Extinction; Neuromodulation ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; TRANSCRANIAL MAGNETIC STIMULATION; VENLAFAXINE EXTENDED-RELEASE; COGNITIVE-BEHAVIOR THERAPY; QUALITY-OF-LIFE; COMBAT-RELATED PTSD; MAJOR DEPRESSIVE DISORDER; TERM-FOLLOW-UP; ADJUNCTIVE RISPERIDONE TREATMENT AB Post-traumatic stress disorder (PTSD) is a serious psychiatric consequence of trauma that occurs in a proportion of individuals exposed to life-threatening events. Trauma-focused psychotherapy is often recommended as first choice for those who do not recover spontaneously. But many individuals require medications. In the US, only paroxetine (PRX) and sertraline (SRT) are FDA approved for PTSD. But response and remission rates with these medications are low, so numerous other pharmacologic interventions have been tried. To date, there has not been a systematic review of the data on what are the best next-step pharmacologic strategies for individuals who fail standard treatments. To that end, we review 168 published trials of medications other than PRX or SRT and provide a detailed analysis of the 88/168 studies that describe alternative pharmacologic interventions in patients refractory to other treatment. We also review clinical factors relevant to treatment-refractory PTSD; the neurobiology of extinction, as well as evidence-based psychotherapy and neuromodulation strategies for this condition. Published by Elsevier Inc. C1 [Koek, Ralph J.; Schwartz, Holly N.; Spangler, Shana; Korotinsky, Arkady; Jou, Kevin] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Mental Hlth Serv, North Hill, CA USA. [Koek, Ralph J.; Korotinsky, Arkady; Jou, Kevin; Leuchter, Andrew] David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Scully, Stephenie] US Navy, Naval Med Ctr San Diego, San Diego, CA USA. [Langevin, Jean-Philippe] Greater VA Greater Los Angeles Healthcare Syst, Neurosurg Serv, 11301 Wilshire Blvd,Bldg 500,10H2, Los Angeles, CA 90073 USA. [Langevin, Jean-Philippe] David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA USA. [Spangler, Shana] VA Campus Toolkit, VA VITAL Program Director, North Hills, CA USA. [Leuchter, Andrew] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90024 USA. RP Koek, RJ (reprint author), 16111 Plummer St,116A-11, North Hills, CA 91343 USA. EM rkoek@ucla.edu; hollynschwartz@gmail.com; Stephenie.scully@gmail.com; Jean-philippe.langevin@va.gov; shana.spangler@va.gov; arkady.korotinsky@va.gov; kevin.jou@va.gov FU National Institutes of Health; Wyeth Pharmaceuticals; Novartis Pharmaceuticals; Seaside Therapeutics; Genentech; Shire Pharmaceuticals; Neuronetics; Eli Lilly and Company; Neurosigma; Aspect Medical Systems/Covidien; Shire FX This work was carried out without any research funding. AFL, within the past 5 years, has received research support from the National Institutes of Health, Wyeth Pharmaceuticals, Novartis Pharmaceuticals, Seaside Therapeutics, Genentech, Shire Pharmaceuticals, Neuronetics, Eli Lilly and Company, and Neurosigma. He has served as a consultant to NeoSync Inc., Brain Cells, Inc., Taisho Pharmaceuticals, Eli Lilly and Company, and Aspect Medical Systems/Covidien. He is Chief Scientific Officer of Brain Biomarker Analytics LLC (BBA). He owns stock options in NeoSync, Inc. and has equity interest in BBA. I.A.C., within the past 5 years, has received research support from Aspect Medical Systems/Covidien, National Institutes of Health, Neuronetics and Shire; he has been on the speakers' bureau for Neuronetics and the Medical Education Speakers Network; he has been an advisor/consultant/reviewer for Allergan, Covidien, Pfizer, Neuronetics, NeuroSigma, NIH (ITVS), US Department of Defense, US Department of Justice, VA (DSMB); his biomedical intellectual property is assigned to the Regents of the University of California, and he owns stock options in NeuroSigma. JPL Has filed a patent application for amygdala deep brain stimulation for post-traumatic stress disorder. None of the other authors have potential conflicts to declare. None of the authors have any conflicts to declare. NR 516 TC 4 Z9 4 U1 20 U2 73 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 EI 1878-4216 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD OCT 3 PY 2016 VL 70 BP 170 EP 218 DI 10.1016/j.pnpbp.2016.01.015 PG 49 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DP9YO UT WOS:000378854200020 PM 26854815 ER PT J AU Dweiri, YM Stone, MA Tyler, DJ McCallum, GA Durand, DM AF Dweiri, Yazan M. Stone, Matthew A. Tyler, Dustin J. McCallum, Grant A. Durand, Dominique M. TI Fabrication of High Contact-Density, Flat-Interface Nerve Electrodes for Recording and Stimulation Applications SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Neuroscience; Issue 116; Flat-Interface Nerve Electrodes (FINE); cuff electrode; Polyether ketone (PEEK); CAD; neural activity; multi-contact ID PERIPHERAL-NERVE; NEURAL INTERFACES; CUFF ELECTRODES; SCIATIC-NERVE; BLOOD-FLOW; COMPRESSION; CATS AB Many attempts have been made to manufacture multi-contact nerve cuff electrodes that are safe, robust and reliable for long term neuroprosthetic applications. This protocol describes a fabrication technique of a modified cylindrical nerve cuff electrode to meet these criteria. Minimum computer-aided design and manufacturing (CAD and CAM) skills are necessary to consistently produce cuffs with high precision (contact placement 0.51 +/- 0.04 mm) and various cuff sizes. The precision in spatially distributing the contacts and the ability to retain a predefined geometry accomplished with this design are two criteria essential to optimize the cuff's interface for selective recording and stimulation. The presented design also maximizes the flexibility in the longitudinal direction while maintaining sufficient rigidity in the transverse direction to reshape the nerve by using materials with different elasticities. The expansion of the cuff's cross sectional area as a result of increasing the pressure inside the cuff was observed to be 25% at 67 mm Hg. This test demonstrates the flexibility of the cuff and its response to nerve swelling post-implant. The stability of the contacts' interface and recording quality were also examined with contacts' impedance and signal-to-noise ratio metrics from a chronically implanted cuff (7.5 months), and observed to be 2.55 +/- 0.25 k Omega and 5.10 +/- 0.81 dB respectively. C1 [Dweiri, Yazan M.; Tyler, Dustin J.; McCallum, Grant A.; Durand, Dominique M.] Case Western Reserve Univ, Neural Engn Ctr, Cleveland, OH 44106 USA. [Stone, Matthew A.] US Dept Vet Affairs, Adv Platform Technol Ctr, Washington, DC USA. [Dweiri, Yazan M.] Jordan Univ Sci & Technol, Irbid, Jordan. RP Durand, DM (reprint author), Case Western Reserve Univ, Neural Engn Ctr, Cleveland, OH 44106 USA. EM DXD6@CASE.EDU FU Defense Advanced Research Projects Agency (DARPA) MTO; Naval Warfare Systems Center, Pacific [N66001-12-C-4173] FX This work was sponsored by the Defense Advanced Research Projects Agency (DARPA) MTO under the auspices of Dr. Jack Judy and Dr. Doug Weber through the Space and Naval Warfare Systems Center, Pacific Grant/Contract No. N66001-12-C-4173. We would like to thank Thomas Eggers for his help in the fabrication process, and Ronald Triolo, Matthew Schiefer, Lee Fisher and Max Freeburg for their contribution in the development of the composite nerve cuff design. NR 33 TC 0 Z9 0 U1 0 U2 0 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD OCT PY 2016 IS 116 AR e54388 DI 10.3791/54388 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EQ1QO UT WOS:000397844900031 ER PT J AU Zgierska, AE Burzinski, CA Cox, J Kloke, J Stegner, A Cook, DB Singles, J Mirgain, S Coe, CL Backonja, M AF Zgierska, Aleksandra E. Burzinski, Cindy A. Cox, Jennifer Kloke, John Stegner, Aaron Cook, Dane B. Singles, Janice Mirgain, Shilagh Coe, Christopher L. Backonja, Miroslav TI Mindfulness Meditation and Cognitive Behavioral Therapy Intervention Reduces Pain Severity and Sensitivity in Opioid-Treated Chronic Low Back Pain: Pilot Findings from a Randomized Controlled Trial SO PAIN MEDICINE LA English DT Article DE Chronic Low Back Pain; Mindfulness Meditation; Cognitive Behavioral Therapy; Long-Term Opioid Therapy ID CHRONIC NONCANCER PAIN; PHYSICIANS ASIPP GUIDELINES; PRIMARY-CARE; STRESS REDUCTION; IMMPACT RECOMMENDATIONS; NONMALIGNANT PAIN; AMERICAN SOCIETY; CLINICAL-TRIALS; HEALTH; COHORT AB Objective. To assess benefits of mindfulness meditation and cognitive behavioral therapy (CBT)based intervention for opioid-treated chronic low back pain (CLBP). Design. 26-week parallel-arm pilot randomized controlled trial (Intervention and Usual Care versus Usual Care alone). Setting. Outpatient. Subjects. Adults with CLBP, prescribed >= 30mg/day of morphine-equivalent dose (MED) for at least 3 months. Methods. The intervention comprised eight weekly group sessions (meditation and CLBP-specific CBT components) and 30minutes/day, 6 days/week of athome practice. Outcome measures were collected at baseline, 8, and 26 weeks: primary-pain severity (Brief Pain Inventory) and function/disability (Oswestry Disability Index); secondary-pain acceptance, opioid dose, pain sensitivity to thermal stimuli, and serum pain-sensitive biomarkers (Interferon-gamma; Tumor Necrosis Factor-a; Interleukins 1 beta and 6; C-reactive Protein). Results. Thirty-five (21 experimental, 14 control) participants were enrolled and completed the study. They were 51.8 +/- 9.7 years old, 80% female, with severe CLBP-related disability (66.7 +/- 11.4), moderate pain severity (5.8 +/- 1.4), and taking 148.3 +/- 129.2mg/day of MED. Results of the intention-to-treat analysis showed that, compared with controls, the meditation-CBT group reduced pain severity ratings during the study (P = 0.045), with between-group difference in score change reaching 1 point at 26 weeks (95% Confidence Interval: 0.2,1.9; Cohen's d = 0.86), and decreased pain sensitivity to thermal stimuli (P < 0.05), without adverse events. Exploratory analyses suggested a relationship between the extent of meditation practice and the magnitude of intervention benefits. Conclusions. Meditation-CBT intervention reduced pain severity and sensitivity to experimental thermal pain stimuli in patients with opioid-treated CLBP. Zgierska et al. C1 [Zgierska, Aleksandra E.; Burzinski, Cindy A.; Cox, Jennifer] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. [Kloke, John] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Singles, Janice; Mirgain, Shilagh] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped & Rehabil, Madison, WI USA. [Backonja, Miroslav] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Stegner, Aaron; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI USA. [Stegner, Aaron; Cook, Dane B.] Univ Wisconsin, Sch Educ, Dept Kinesiol, Madison, WI USA. [Coe, Christopher L.] Univ Wisconsin, Harlow Ctr Biol Psychol, Madison, WI USA. [Backonja, Miroslav] PRAHS Clin Res Co Lifetree, Salt Lake City, UT USA. RP Zgierska, AE (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. EM aleksandra.zgierska@fammed.wisc.edu FU National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism (NIAAA) [K23AA017508]; University of Wisconsin-Madison; Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX Dr. Zgierska's work was supported by the K23AA017508 from the National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism (NIAAA), and funds from the University of Wisconsin-Madison. The project was also supported by the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. NR 70 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD OCT PY 2016 VL 17 IS 10 BP 1865 EP 1881 DI 10.1093/pm/pnw006 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA ER4CT UT WOS:000398747400012 PM 26968850 ER PT J AU Wyles, D Brau, N Naggie, S Sulkowski, M Agarwal, K Patel, K Afdhal, N Liu, L Ding, X Huang, KC Osinusi, A McNally, J Brainard, D Mertens, M McHutchison, J AF Wyles, David Brau, Norbert Naggie, Susanna Sulkowski, Mark Agarwal, Kosh Patel, Keyur Afdhal, Nezam Liu, Lin Ding, Xiao Huang, Kuan-Chieh Osinusi, Anu McNally, John Brainard, Diana Mertens, Michael McHutchison, John TI SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Wyles, David] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA. [Brau, Norbert] James J Peters VA Med Ctr, Icahn Sch Med, Dept Med, New York, NY USA. [Naggie, Susanna] Duke Univ Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Sulkowski, Mark] Johns Hopkins Univ, Viral Hepatitis Ctr, Sch Med, Baltimore, MD USA. [Agarwal, Kosh] Kings Coll Hosp London, Inst Liver Studies, London, England. [Patel, Keyur] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC USA. [Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Hepatol, Boston, MA USA. [Liu, Lin; Ding, Xiao; Huang, Kuan-Chieh] Gilead Sci, Biostat, Foster City, CA USA. [Osinusi, Anu; McNally, John; Brainard, Diana; McHutchison, John] Clin Res, Gilead Sci, Foster City, CA USA. [Mertens, Michael] Med Affairs, Gilead Sci, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2016 VL 19 SU 7 MA P259 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM6AJ UT WOS:000395394900296 ER PT J AU Kajiwara, Y McKenzie, A Dorr, N Sosa, MAG Elder, G Schmeidler, J Dickstein, DL Bozdagi, O Zhang, B Buxbaum, JD AF Kajiwara, Yuji McKenzie, Andrew Dorr, Nate Sosa, Miguel A. Gama Elder, Gregory Schmeidler, James Dickstein, Dara L. Bozdagi, Ozlem Zhang, Bin Buxbaum, Joseph D. TI The human-specific CASP4 gene product contributes to Alzheimer-related synaptic and behavioural deficits SO HUMAN MOLECULAR GENETICS LA English DT Article ID BLOOD-BRAIN-BARRIER; MILD COGNITIVE IMPAIRMENT; AMYLOID BETA-PEPTIDE; MOUSE MODEL; INFLAMMASOME ACTIVATION; FUNCTIONAL DIFFERENCES; NLRP3 INFLAMMASOME; INSULIN-RESISTANCE; MICROGLIAL CELLS; COMMON VARIANTS AB Recent studies have indicated that innate immune signalling molecules are involved in late-onset Alzheimer's disease (LOAD) risk. Amyloid beta (Ab) accumulates in AD brain, and has been proposed to act as a trigger of innate immune responses. Caspase-4 is an important part of the innate immune response. We recently characterized transgenic mice carrying human CASP4, and observed that the mice manifested profound innate immune responses to lipopolysaccharide (LPS). Since these inflammatory processes are important in the aetiology of AD, we have now analysed the correlation of expression of caspase-4 in human brain with AD risk genes, and studied caspase-4 effects on AD-related phenotypes in APPswe/PS1deltaE9 (APP/PS1) mice. We observed that the expression of caspase-4 was strongly correlated with AD risk genes including TYROBP, TREM2, CR1, PSEN1, MS4A4A and MS4A6A in LOAD brains. Caspase-4 expression was upregulated in CASP4/APP/PS1 mice in a region-specific manner, including hippocampus and prefrontal cortex. In APP/PS1 mice, caspase-4 expression led to impairments in the reversal phase of a Barnes maze task and in hippocampal synaptic plasticity, without affecting soluble or aggregated Ab levels. Caspase-4 was expressed predominantly in microglial cells, and in the presence of CASP4, more microglia were clustered around amyloid plaques. Furthermore, our data indicated that caspase-4 modulates microglial cells in a manner that increases proinflammatory processes. We propose that microglial caspase-4 expression contributes to the cognitive impairments in AD, and that further study of caspase-4 will enhance our understanding of AD pathogenesis and may lead to novel therapeutic targets in AD. C1 [Kajiwara, Yuji; Sosa, Miguel A. Gama; Elder, Gregory; Schmeidler, James; Bozdagi, Ozlem; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. [McKenzie, Andrew; Zhang, Bin; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [McKenzie, Andrew; Zhang, Bin] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Dorr, Nate; Sosa, Miguel A. Gama] Icahn Sch Med Mt Sinai, Gen Med Res Serv, New York, NY 10029 USA. [Elder, Gregory] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA. [Elder, Gregory] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Dickstein, Dara L.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Dickstein, Dara L.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. RP Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM Joseph.Buxbaum@mssm.edu FU National Institute on Aging [AG046170]; Icahn School of Medicine at Mount Sinai Alzheimer Disease Research Center [AG005138-28] FX This work was supported by the National Institute on Aging [AG046170, MPI, Dr. E Shadt, B Zhang and JD Buxbaum]; and the Icahn School of Medicine at Mount Sinai Alzheimer Disease Research Center [AG005138-28, Dr. Mary Sano, PI, Drs. O Bozdagi and JD Buxbaum, PL]. NR 89 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD OCT 1 PY 2016 VL 25 IS 19 BP 4315 EP 4327 DI 10.1093/hmg/ddw265 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EN1YZ UT WOS:000395807800014 PM 27516385 ER PT J AU Basu, PP Fortuzi, K Shehi, E Kavali, L Aloysius, M Shah, N AF Basu, P. Patrick Fortuzi, Ked Shehi, Elona Kavali, Leena Aloysius, Mark Shah, Niraj TI Adult Sucrase-isomaltase Defi ciency (ASID); An Unrecognized Overlap with Functional Bowel Disease (FBD). an Observational Cross-sectional Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York Presbyterian, New York, NY USA. [Fortuzi, Ked; Shehi, Elona; Kavali, Leena] Kings Cty Hosp, Med Ctr, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1094 BP S478 EP S478 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601525 ER PT J AU Basu, PP Aloysius, M Fortuzi, K Kavali, L Shehi, E Shah, N AF Basu, P. Patrick Aloysius, Mark Fortuzi, Ked Kavali, Leena Shehi, Elona Shah, Niraj TI Low Titer Endomysial Antibody (EMA) in Non-celiac Population Segregated from a Community with Immune Mediated Vasculitis. an Observational Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] New York Presbyterian, Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Fortuzi, Ked; Kavali, Leena; Shehi, Elona] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1046 BP S455 EP S455 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601477 ER PT J AU Basu, PP Fortuzi, K Kavali, L Shehi, E John, N Aloysius, M Shah, N AF Basu, P. Patrick Fortuzi, Ked Kavali, Leena Shehi, Elona John, Nimy Aloysius, Mark Shah, Niraj TI Ombitasvir, Ritanavir Boost with Dastasbuvir and Prataspravir with or without Ribavirin in G1 Special Population in Hemodialysis in Chronic Hepatitis C Patients DROP C Trial: A Prospective Clinical Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] New York Presbyterian, Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York, NY USA. [Fortuzi, Ked; Kavali, Leena; Shehi, Elona; John, Nimy] Kings Cty Hosp, Med Ctr, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 880 BP S385 EP S386 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601313 ER PT J AU Francis, F Hashash, JG AF Francis, Fadi Hashash, Jana G. TI Incidental Diverticulitis on Surveillance Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Francis, Fadi] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 2620 BP S1321 EP S1321 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764604381 ER PT J AU Francis, F Frye, R Shaikh, O Hashash, JG AF Francis, Fadi Frye, Roy Shaikh, Obaid Hashash, Jana G. TI Cholelithiasis and Cirrhosis in a 28-Year-Old Man SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Francis, Fadi; Frye, Roy; Shaikh, Obaid] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1947 BP S929 EP S930 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603245 ER PT J AU GarzaOvalle, O Hughston, A Kowalewski, C Kundrotas, L AF GarzaOvalle, Oscar Hughston, Adam Kowalewski, Catherine Kundrotas, Leon TI Inflammatory Bowel Disease and Concomitant SAPHO Syndrome: A Challenging Treatment SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [GarzaOvalle, Oscar; Hughston, Adam] Univ Texas San Antonio, San Antonio, TX USA. [Kowalewski, Catherine; Kundrotas, Leon] Audie L Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1741 BP S833 EP S833 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603042 ER PT J AU Jacob, N Benhammou, JN Yu, C Shojamanesh, H Merchant, J Lewis, M Metz, DC Sedarat, A Pisegna, J AF Jacob, Noam Benhammou, Jihane N. Yu, Christine Shojamanesh, Homayoun Merchant, Juanita Lewis, Michael Metz, David C. Sedarat, Alireza Pisegna, Joseph TI Characteristics of Duodenal Neuroendocrine Tumors (DNETs) and Establishment of a Natural History and Genetics Registry SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Jacob, Noam; Benhammou, Jihane N.; Yu, Christine; Pisegna, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Shojamanesh, Homayoun] Univ Calif Davis, Sch Med, Mather, CA USA. [Merchant, Juanita] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Metz, David C.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sedarat, Alireza] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Sedarat, Alireza] VA GLAHS West Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Shojamanesh, Homayoun] VA Northern Calif Healthcare Syst, Mather, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1085 BP S474 EP S474 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601516 ER PT J AU Kaltenbach, T Gawron, A Gupta, S Shergill, A Dominitz, JA Soetikno, R Whooley, M Kahi, C AF Kaltenbach, Tonya Gawron, Andrew Gupta, Samir Shergill, Amandeep Dominitz, Jason A. Soetikno, Roy Whooley, Mary Kahi, Charles TI Screening Indication for Colonoscopy May Not Be Necessary to Measure Adenoma Detection Rates SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Kaltenbach, Tonya; Shergill, Amandeep; Whooley, Mary] Univ Calif San Francisco, VA San Francisco, San Francisco, CA 94143 USA. [Gawron, Andrew] Univ Utah, Sch Med, Salt Lake City, UT USA. [Gawron, Andrew] Salt Lake City VA Healthcare Syst, Salt Lake City, UT USA. [Gupta, Samir] Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA. [Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Soetikno, Roy] Singhealth, Singapore, Singapore. [Kahi, Charles] Roudebush VA Med Ctr, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 156 BP S73 EP S74 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600153 ER PT J AU Kumar, V Shah, Y Patel, D Khan, N AF Kumar, Vinayak Shah, Yash Patel, Dhruvan Khan, Nabeel TI Clinical Course of Patients with a New Age Threshold for Elderly Onset Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Kumar, Vinayak] Univ Penn, Perelman Sch Med, Collegeville, PA USA. [Shah, Yash; Khan, Nabeel] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Patel, Dhruvan] Mercy Catholic Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 585 BP S269 EP S269 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601020 ER PT J AU Leung, F Cadoni, S Falt, P Hsieh, YH Amato, A Erriu, M Fojtik, P Gallittu, P Hu, CT Koo, M Liggi, M Paggi, S Radaelli, F Rondonotti, E Smajstrla, V Tseng, CW Urban, O Leung, J AF Leung, Felix Cadoni, Sergio Falt, Premysl Hsieh, Yu-Hsi Amato, Arnaldo Erriu, Matteo Fojtik, Petr Gallittu, Paolo Hu, Chi-Tan Koo, Malcolm Liggi, Mauro Paggi, Silvia Radaelli, Franco Rondonotti, Emanuele Smajstrla, Vit Tseng, Chih-Wei Urban, Ondrej Leung, Joseph TI Randomized Controlled Trials Confirm Water Exchange to Be Significantly Superior in Quality of Bowel Cleansing and Adenoma Detection Rate Compared to Water Immersion and Air Insufflation, Even Aft er Split-Dose Preparation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Leung, Felix] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro] CTO Hosp, Digest Endoscopy Unit, Iglesias, Sardegna, Italy. [Falt, Premysl; Fojtik, Petr; Smajstrla, Vit; Urban, Ondrej] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Moravskoslezsky, Czech Republic. [Hsieh, Yu-Hsi; Tseng, Chih-Wei] Buddhist Tzu Chi Univ, Sch Med, Chiayi, Taiwan. [Hsieh, Yu-Hsi; Tseng, Chih-Wei] Dalin Tzu Chi Hosp, Div Gastroenterol, Buddhist Tzu Chi Med Fdn, Chiayi, Taiwan. [Amato, Arnaldo] Valduce Hosp, Gastroenterol, Como, Lombardia, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg, Cagliari, Sardegna, Italy. [Hu, Chi-Tan] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan. [Hu, Chi-Tan] Hualien Tzu Chi Hosp, Gastroenterol, Hualien, Taiwan. [Hu, Chi-Tan] Tzu Chi Univ, Hualien, Taiwan. [Koo, Malcolm] Dalin Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med Res, Chiayi, Taiwan. [Koo, Malcolm] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Paggi, Silvia; Radaelli, Franco; Rondonotti, Emanuele] Valduce Hosp, Div Gastroenterol, Como, Lombardia, Italy. [Leung, Joseph] Sacramento VA Med Ctr, Sacramento, CA USA. [Leung, Joseph] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 247 BP S116 EP S116 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600244 ER PT J AU Leung, J Pearcy, J Yen, AW Leung, F AF Leung, Joseph Pearcy, Jaymie Yen, Andrew W. Leung, Felix TI Cap-Assisted Total Water (CATW) Colonocopy Further Improved Proximal ADR Than Cap-Assisted Water Exchange (CAWE) Colonoscopy in Screening and Surveillance Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Leung, Joseph] Sacramento VA Med Ctr, VANCHCS, Sacramento, CA USA. [Pearcy, Jaymie; Yen, Andrew W.] Sacramento VA Med Ctr, Mather, CA USA. [Yen, Andrew W.] Univ Calif Davis, Sch Med, Mather, CA USA. [Leung, Felix] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 213 BP S102 EP S102 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600210 ER PT J AU Lin, L Yu, C Lally, K Oh, D Lewis, M May, F Pisegna, J AF Lin, Lisa Yu, Christine Lally, Kimberly Oh, David Lewis, Michael May, Folasade Pisegna, Joseph TI Colorectal Adenocarcinomas with Positive Immunohistochemical NET Features: A Descriptive Study of Their Clinical Behavior SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Lin, Lisa; Yu, Christine; May, Folasade; Pisegna, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lally, Kimberly] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Oh, David] Univ Calif Los Angeles, Los Angeles, CA USA. [Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 206 BP S99 EP S100 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600203 ER PT J AU Ohning, G Jensen, D Kovacs, O Ghassemi, K Jutabha, R Machicado, G Dulai, G Sedarat, A AF Ohning, Gordon Jensen, Dennis Kovacs, Omas Ghassemi, Kevin Jutabha, Rome Machicado, Gustavo Dulai, Gareth Sedarat, Alireza TI Long-term Outcomes in Patients with Diverticular Hemorrhage Based upon Initial Diagnosis with Urgent Colonoscopy and Different Treatments SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Ohning, Gordon; Jensen, Dennis; Sedarat, Alireza] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ohning, Gordon; Jensen, Dennis; Kovacs, Omas; Jutabha, Rome; Machicado, Gustavo; Dulai, Gareth; Sedarat, Alireza] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Ghassemi, Kevin] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Machicado, Gustavo] VA GLAHS West Los Angeles Healthcare Ctr, Van Nuys, CA USA. [Machicado, Gustavo; Dulai, Gareth] VA GLAHS West Los Angeles Healthcare Ctr, Downey, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 157 BP S74 EP S74 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600154 ER PT J AU Patel, D Khan, N Shah, Y Yang, YX AF Patel, Dhruvan Khan, Nabeel Shah, Yash Yang, Yu-Xiao TI A Prediction Model for Incident Moderate to Severe Anemia and Iron Deficiency Anemia in Patients with Newly Diagnosed Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Patel, Dhruvan] Mercy Catholic Med Ctr, Philadelphia, PA USA. [Khan, Nabeel; Shah, Yash] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Yang, Yu-Xiao] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 743 BP S333 EP S334 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601176 ER PT J AU Pimienta, M Lotshaw, E Elperin, J Malla, S Ohmuraya, M Mareninova, O Gukovskaya, A Gukovsky, I AF Pimienta, Michael Lotshaw, Ethan Elperin, Jason Malla, Sudarshan Ohmuraya, Masaki Mareninova, Olga Gukovskaya, Anna Gukovsky, Ilya TI p62/SQSTM1, a Key Autophagy Mediator, Is Regulated in Pancreatitis Through mTOR-Mediated Pathways SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Pimienta, Michael] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sherman Oaks, CA USA. [Pimienta, Michael] Southern Calif Res Ctr ALPD & Cirrhosis, Sherman Oaks, CA USA. [Lotshaw, Ethan; Malla, Sudarshan; Mareninova, Olga; Gukovskaya, Anna; Gukovsky, Ilya] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lotshaw, Ethan; Malla, Sudarshan; Mareninova, Olga; Gukovskaya, Anna; Gukovsky, Ilya] Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. [Elperin, Jason] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Calabasas, CA USA. [Elperin, Jason] Southern Calif Res Ctr ALPD & Cirrhosis, Calabasas, CA USA. [Ohmuraya, Masaki] Kumamoto Univ, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 32 BP S14 EP S14 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600032 ER PT J AU Singh, H Moghe, A Mcgrath, K Khalid, A Chennat, J Brand, R Fasanella, K AF Singh, Harkirat Moghe, Akshata Mcgrath, Kevin Khalid, Asif Chennat, Jennifer Brand, Randall Fasanella, Kenneth TI Annual Surveillance of Small Gastric Stomal Tumors Is Unnecessarily Frequent SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Singh, Harkirat; Moghe, Akshata; Mcgrath, Kevin; Chennat, Jennifer; Brand, Randall; Fasanella, Kenneth] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Khalid, Asif] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1119 BP S489 EP S489 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601550 ER PT J AU Turner, K Spechler, SJ Sonnenberg, A Genta, RM AF Turner, Kevin Spechler, Stuart J. Sonnenberg, Amnon Genta, Robert M. TI Incidental Goblet Cells at the Gastroesophageal Junction: Intestinal Metaplasia of the Esophagus or Stomach? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Turner, Kevin; Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX USA. [Spechler, Stuart J.] Dallas VA Med Ctr, Dallas, TX USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 464 BP S209 EP S209 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600459 ER PT J AU Turner, K Genta, RM Lash, R Sonnenberg, A AF Turner, Kevin Genta, Robert M. Lash, Richard Sonnenberg, Amnon TI Colorectal Polyps: Lesions of All Types Exist in Polyps of All Sizes SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Turner, Kevin; Genta, Robert M.; Lash, Richard] Miraca Life Sci Res Inst, Irving, TX USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 152 BP S72 EP S72 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600149 ER PT J AU Vachon, AI Francis, F Handzel, R Beasley, HS Holtzman, MP Hashash, JG AF Vachon, Ashley I. Francis, Fadi Handzel, Robert Beasley, H. Scott. Holtzman, Matthew P. Hashash, Jana G. TI Perforated Hemorrhagic Cholecystitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Vachon, Ashley I.; Handzel, Robert; Beasley, H. Scott.; Holtzman, Matthew P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Francis, Fadi] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1222 BP S536 EP S537 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764602071 ER PT J AU Wheat, CL Gunnink, E Paski, S Dominitz, JA Lynge, D Zhou, XH Zeliadt, S AF Wheat, Chelle L. Gunnink, Eric Paski, Shirley Dominitz, Jason A. Lynge, Dana Zhou, Xiao-Hua (Andrew) Zeliadt, Steven TI Variation in Complications and Costs from Colorectal Resections Across VA Facilities SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Wheat, Chelle L.; Gunnink, Eric; Paski, Shirley; Dominitz, Jason A.; Lynge, Dana; Zhou, Xiao-Hua (Andrew); Zeliadt, Steven] VA Puget Sound Healthcare Syst, Seattle, WA USA. FU VA Health Services Research & Development IIR research grant [IIR-10 365] FX This research is supported by a VA Health Services Research & Development IIR research grant IIR-10 365 (Zhou). NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 941 BP S408 EP S408 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601373 ER PT J AU Thompson, R Thornblade, LW Khor, S Flum, DR Sobel, M AF Thompson, Rachel Thornblade, Lucas W. Khor, Sara Flum, David R. Sobel, Michael TI Patterns of Inflammation in Patients with Hyperglycemia after Vascular Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 16-20, 2016 CL Washington, DC SP Amer Coll Surg C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Nebraska Med Ctr, Omaha, NE USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E61 EP E62 PG 2 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100132 ER PT J AU Elnahal, SM Peabody, H Ippolito, A Littlefield, P Clancy, C Shulkin, D AF Elnahal, S. M. Peabody, H. Ippolito, A. Littlefield, P. Clancy, C. Shulkin, D. TI Diffusing Oncology Care Model Best Practices Across America's Largest Integrated Hospital System SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Elnahal, S. M.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Peabody, H.] Atlas Res, Washington, DC USA. [Ippolito, A.; Littlefield, P.; Clancy, C.; Shulkin, D.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2980 BP E397 EP E398 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803294 ER PT J AU Hixon, AM Yu, GX Leser, JS Yagi, S Clarke, P Chiu, CY Tyler, KL AF Hixon, Alison M. Yu, Guixia Leser, J. Smith Yagi, Shigeo Clarke, Penny Chiu, Charles Y. Tyler, Kenneth L. TI A mouse model of enterovirus D68-induced paralysis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 14th International Symposium on NeuroVirology CY OCT 25-28, 2016 CL Toronto, CANADA C1 [Hixon, Alison M.] Univ Colorado, Med Scientist Training Program, Neurosci Program, Boulder, CO 80309 USA. [Yu, Guixia; Chiu, Charles Y.] Univ Calif San Francisco, Abbott Viral Diagnost & Discovery Ctr, Div Infect Dis, Dept Lab Med & Med, San Francisco, CA 94143 USA. [Leser, J. Smith; Clarke, Penny] Univ Colorado, Dept Neurol, Boulder, CO 80309 USA. [Yagi, Shigeo] Calif Dept Publ Hlth, Sacramento, CA USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Dept Med, Dept Microbiol & Immunol, Dept Neurol, Boulder, CO 80309 USA. EM alison.hixon@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 SU 1 MA P59 BP S29 EP S29 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA EK7GH UT WOS:000394093700060 ER PT J AU Heinz, AJ Cohen, NL Holleran, L Alvarez, JA Bonn-Miller, MO AF Heinz, Adrienne J. Cohen, Nicole L. Holleran, Lori Alvarez, Jennifer A. Bonn-Miller, Marcel O. TI Firearm Ownership Among Military Veterans With PTSD: A Profile of Demographic and Psychosocial Correlates SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; SUICIDE; RISK; METAANALYSIS; AGGRESSION; COLLECTION; HOSTILITY; PROGRAMS; VIOLENCE AB Post-traumatic stress disorder (PTSD), a condition that disproportionately affects military veterans, is associated with heightened rates of aggression and suicide. Although experience with firearms is common among this population, virtually nothing is known regarding who is more likely to own a firearm and whether firearm ownership is differentially associated with psychological and behavioral risk factors among veterans with PTSD. Of 465 veterans (79% male) entering PTSD treatment, 28% owned a firearm (median number of firearms among owners = 3, range = 1-40). Firearm owners reported higher income were less likely to be unemployed, and were more likely to be male, Caucasian, married, and living in permanent housing. Ownership was associated with higher combat exposure and driving aggression, yet lower rates of childhood and military sexual trauma, suicidal ideation, and incarceration. Ownership was not associated with previous suicide attempt, arrest history, number of traumas experienced, PTSD symptoms, or depression. Together, among a sample of treatment-seeking military veterans with PTSD, those who owned a firearm appeared to demonstrate greater stability across a number of domains of functioning. Importantly though, routine firearm safety discussions (e.g., accessibility restrictions; violence risk assessments) and bolstering of anger management skills remain critical when working with this high-risk population. C1 [Heinz, Adrienne J.; Cohen, Nicole L.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Heinz, Adrienne J.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Holleran, Lori] Palo Alto Univ, 1791 Arastradero Rd, Palo Alto, CA 94304 USA. [Alvarez, Jennifer A.] VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Menlo Pk, CA 94304 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. RP Heinz, AJ (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.; Heinz, AJ (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. FU Rehabilitation Research and Development Career Development Award-2 FX This work was supported by a Rehabilitation Research and Development Career Development Award-2 awarded to Dr. Heinz. NR 26 TC 0 Z9 0 U1 1 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1207 EP 1211 DI 10.7205/MILMED-D-15-00552 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700014 PM 27753553 ER PT J AU Metraux, S Treglia, D O'Toole, TP AF Metraux, Stephen Treglia, Dan O'Toole, Thomas P. TI Migration by Veterans Who Received Homeless Services From the Department of Veterans Affairs SO MILITARY MEDICINE LA English DT Article ID MOBILITY; CARE AB We examined migration patterns among 113,400 homeless veterans, focusing on the prevalence and the basic geographic patterns of this migration. Data were for all veterans who initiated use of Veterans Affairs homeless services in 2011 or 2012; and we followed them using Veterans Affairs administrative records for up to 2 years following this initial contact. Results showed that 15.3% of the veterans migrated across regions while homeless. Those who were homeless for longer periods were more likely to migrate, and migration, were it to occur, was most likely earlier on in veterans' homelessness episodes. There were no clear geographic correlates that explained the dynamics of this migration as, overall, in-migration tended to roughly balance out-migration in a region. These findings suggest that concerns about the extent of migration and its impact on localities are exaggerated, but also sets forth an agenda for more in-depth study of these data to gain a deeper and more expansive understanding of this phenomenon. C1 [Metraux, Stephen; Treglia, Dan; O'Toole, Thomas P.] Philadelphia VA Med Ctr Annex, US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave, Philadelphia, PA 19104 USA. RP Metraux, S (reprint author), Philadelphia VA Med Ctr Annex, US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave, Philadelphia, PA 19104 USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1212 EP 1217 DI 10.7205/MILMED-D-15-00504 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700015 PM 27753554 ER PT J AU Berg, KM Smith, SS Cook, JW Fiore, MC Jorenby, DE AF Berg, Kristin M. Smith, Stevens S. Cook, Jessica W. Fiore, Michael C. Jorenby, Douglas E. TI Identifying Opportunities to Improve Smoking Cessation Among Women Veterans at a Veterans Hospital SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; FEMALE VETERANS; MENTAL-HEALTH; LUNG HEALTH; TOBACCO USE; NICOTINE; PREDICTORS; SMOKERS; INTERVENTIONS AB While women Veterans have a higher prevalence of smoking than civilian women, little is known about their quitting behavior. Via a chart review, we characterized referral and enrollment patterns in tobacco cessation services (TCS), and quit attempts among 366 women Veteran smokers at a Midwestern Veterans Hospital. Cases receiving referrals to TCS (n = 183) were matched 1:1 to controls who did not (n = 183), by year of referral. Variables included age, marital status, urbanicity, smoking status, comorbidities, pregnancy, packs per day, number of prior smoking cessation medications, provider gender, provider type, and clinical location of referral placement. Of women Veteran smokers, 24% were referred to TCS, and tended to be older, heavier smokers, with more comorbidities, more prior cessation medication prescriptions, and more likely seen by a resident or attending physician. Only 54% of referred women enrolled, and these women were older, had more medical comorbidities and prior cessation medication prescriptions than nonenrolled women. Primary care providers were more likely to have patients enroll versus inpatient providers. Only 8% of enrolled women achieved abstinence at 6 months. Quit attempts were associated with the number of cessation medication prescriptions for enrolled women, and lighter smoking histories for nonenrolled women. C1 [Berg, Kristin M.; Smith, Stevens S.; Cook, Jessica W.; Fiore, Michael C.; Jorenby, Douglas E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. [Berg, Kristin M.] William S Middleton Mem Vet Adm Med Ctr, Adv Fellowship Womens Hlth, 2500 Overlook Terrace, Madison, WI 53705 USA. [Berg, Kristin M.] Univ Wisconsin, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. RP Berg, KM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA.; Berg, KM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Adv Fellowship Womens Hlth, 2500 Overlook Terrace, Madison, WI 53705 USA.; Berg, KM (reprint author), Univ Wisconsin, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. FU UW Center for Tobacco Research and Intervention; Division of General Internal Medicine; Advanced Fellowship in Women's Health through the VA; National Research Service Award from the Health Resources and Services Administration [T32HP10010] FX This project fulfilled degree requirements for KMB, supported by the UW Center for Tobacco Research and Intervention, the Division of General Internal Medicine, and the Advanced Fellowship in Women's Health through the VA. During the writing of this article, author KMB was supported by a National Research Service Award from the Health Resources and Services Administration [T32HP10010] to the University of Wisconsin Department of Family Medicine and Community Health. NR 35 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1340 EP 1347 DI 10.7205/MILMED-D-15-00469 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700034 PM 27753573 ER PT J AU Manber, R Buysse, DJ Edinger, J Krystal, A Luther, JF Wisniewski, SR Trockel, M Kraemer, HC Thase, ME AF Manber, Rachel Buysse, Daniel J. Edinger, Jack Krystal, Andrew Luther, James F. Wisniewski, Stephen R. Trockel, Mickey Kraemer, Helena C. Thase, Michael E. TI Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SLEEP-MAINTENANCE INSOMNIA; LATE-LIFE INSOMNIA; OLDER-ADULTS; METAANALYSIS; DISORDER; MODERATORS; MEDIATORS; COMPRESSION; EXPERIENCE; EDUCATION AB Objectives: The Treatment of Insomnia and Depression (TRIAD) study evaluated the efficacy of combining depression pharmacotherapy (using MED, an ecologically valid and generalizable antidepressant medication algorithm) with cognitive-behavioral therapy for insomnia (CBT-I) among individuals with comorbid insomnia and major depressive disorder (MDD) to determine if change in insomnia severity mediates antidepressant outcome. Methods: This 16-week, 3-site, randomized controlled trial (RCT) randomly assigned 150 participants (recruited between March 2009 and August 2013), who met DSM-IV-TR criteria for insomnia and MDD and were not receiving treatment for either, to receive depression pharmacotherapy plus 7 sessions of either CBT-I or a credible control therapy for insomnia (CTRL). Depression pharmacotherapy followed a standardized 2-step algorithm, which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence. Primary measures were the Hamilton Depression Rating Scale and the depression module of the Structured Clinical Interview for DSMIV Axis I Disorders, Research Version, Nonpatient Edition, administered by raters masked to treatment assignment, and the self-administered Insomnia Severity Index (ISI). Results: CBT-I was superior to CTRL in reducing insomnia severity (P=.028). The overall difference in depression remission between the treatments was not statistically significant (44% in CBT-I and 36% in CTRL; number needed to treat = 15). However, planned secondary analysis revealed that improvements in insomnia at week 6 mediated eventual remission from depression, with early change in ISI predicting depression remission in the CBT-I (P=.0002) but not in the CTRL arm (P=.26). Conclusions: CBT-I is an efficacious treatment for insomnia comorbid with MDD among patients treated with antidepressant medications. Improvement in insomnia may be related to the change in depression. Future studies should identify which patients are most likely to benefit from the addition of an insomnia-focused therapy to standard antidepressant treatments. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Manber, Rachel; Trockel, Mickey; Kraemer, Helena C.] Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Palo Alto, CA 94305 USA. [Buysse, Daniel J.; Kraemer, Helena C.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Edinger, Jack] Natl Jewish Hlth, Dept Med, Denver, CO USA. [Edinger, Jack; Krystal, Andrew] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Luther, James F.; Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Thase, Michael E.] Univ Penn, Sch Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Manber, R (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Palo Alto, CA 94305 USA. EM rmanber@stanford.edu FU US National Institutes of Health [MH078924, MH078961, MH079256] FX The study was supported by the following grants from the US National Institutes of Health: MH078924, MH078961, MH079256. Wyeth Pharmaceutical and Forest Laboratory donated medications to the study. NR 44 TC 1 Z9 1 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP E1316 EP + DI 10.4088/JCP.15m10244 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500016 PM 27788313 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E., Jr. Leverich, Gabriele S. Nolen, Willem A. TI Age at Onset of Bipolar Disorder Related to Parental and Grandparental Illness Burden SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ASTERISK-D-CHILD; UNITED-STATES; I DISORDER; PSYCHIATRIC-DISORDERS; MATERNAL DEPRESSION; SPECTRUM DISORDERS; MENTAL-DISORDERS; FOLLOW-UP; PSYCHOPATHOLOGY; RISK AB Objective: The age at onset of bipolar disorder varies greatly in different countries and continents. The association between load of family history of psychiatric illness and age at onset has not been adequately explored. Methods: 979 outpatients with bipolar disorder (from 4 sites in the United States and 3 in the Netherlands and Germany) gave informed consent and completed a questionnaire about their demographics, age at onset of illness, and family history of unipolar and bipolar disorder, alcohol and substance abuse comorbidity, suicide attempts, and "other" illnesses in their parents, 4 grandparents, and any offspring. We examined how the parental and grandparental burden of these illnesses related to the age at onset of the patients' bipolar disorder. Results: The burden of family psychiatric history was strongly related to an earlier age at onset of illness in both US and European patients (F-3,F-906 = 35.42, P<.0001). However, compared to the Europeans, patients in the United States had both more family history of most difficulties and notably earlier age at onset. Earlier age at onset was associated with a greater illness burden in the patient's offspring (t(568) = 4.1, P<.0001). Conclusions: More parental and grandparental psychiatric illness was associated with an earlier age at onset of bipolar disorder, which is earlier in the United States compared with Europe and is strongly related to a poor long-term prognosis. This apparent polygenic contribution to early onset deserves further study and therapeutic attempts at ameliorating the transgenerational impact. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, 5415 West Cedar Ln,Ste 201B, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Neurosci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Ln,Ste 201B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU Stanley Foundation FX The Stanley Foundation Bipolar Treatment Outcome Network was funded by the Stanley Foundation from 1995 to 2002 and patients were recruited and studied during this period. NR 48 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP E1309 EP E1315 DI 10.4088/JCP.15m09811 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500015 PM 27631141 ER PT J AU Wahl, TS Graham, LA Richman, J Morris, MS Hollis, RH Jones, CE Copeland, LA Itani, KM Burns, EA Hawn, MT AF Wahl, Tyler S. Graham, Laura A. Richman, Joshua Morris, Melanie S. Hollis, Robert H. Jones, Caroline E. Copeland, Laurel A. Itani, Kamal M. Burns, Edith A. Hawn, Mary T. TI Modified Frailty Index is Associated with 30-Day Surgical Readmissions SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Wahl, Tyler S.; Graham, Laura A.; Richman, Joshua; Morris, Melanie S.; Hollis, Robert H.; Jones, Caroline E.; Copeland, Laurel A.; Itani, Kamal M.; Burns, Edith A.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S113 EP S113 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500202 ER PT J AU Saipetch, C Sachs, E Haneef, Z AF Saipetch, Chutima Sachs, Ezekiel Haneef, Zulfi TI Epilepsy Five new things SO NEUROLOGY-CLINICAL PRACTICE LA English DT Review ID TEMPORAL-LOBE EPILEPSY; STEREOTACTIC LASER AMYGDALOHIPPOCAMPOTOMY; INTERSTITIAL THERMAL THERAPY; MARIJUANA USE; TRIAL; STIMULATION; ABLATION; CANNABIDIOL; SEIZURES; ADULTS AB Purpose of review: Technological advance has revolutionized epilepsy management recently. Herein, we review some recent developments. Recent findings: Responsive neurostimulation (Food and Drug Administration [FDA]-approved 2013) works by continuous analysis of brain rhythms and direct brain stimulation on detecting patterns thought to be epileptogenic, thereby aborting seizures. Cardio-responsive vagus nerve stimulation (FDA-approved 2015) is an improvement over traditional vagus nerve stimulation systems, taking advantage of the fact that 80% of seizures are associated with tachycardia. Automated tachycardia detection leads to vagus nerve stimulation to abort seizures. In MRI-guided stereotactic laser ablation (developed 2012), a directed laser emitting fiberoptic catheter is used to ablate epileptogenic lesions. The procedure can be completed in 3 to 4 hours, potentially under local anesthesia and with next-day discharge. Perampanel (FDA-approved 2012) is a promising new class of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-antagonist antiseizure therapy. Meanwhile, a millennia-old remedy for epilepsy, cannabis, is staging a comeback with recent legal and social permissiveness accelerating research into this use. Summary: The coming years will demonstrate how these recent advances in device and drug management will improve the care of epilepsy. C1 [Saipetch, Chutima; Haneef, Zulfi] Baylor Coll Med, Houston, TX 77030 USA. [Sachs, Ezekiel] Emory Univ, Atlanta, GA 30322 USA. [Haneef, Zulfi] VA Med Ctr, Houston, TX 77030 USA. RP Haneef, Z (reprint author), Baylor Coll Med, Houston, TX 77030 USA.; Haneef, Z (reprint author), VA Med Ctr, Houston, TX 77030 USA. EM zulfi.haneef@bcm.edu NR 25 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD OCT PY 2016 VL 6 IS 5 BP 444 EP 451 DI 10.1212/CPJ.0000000000000288 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA EJ3GX UT WOS:000393101700016 ER PT J AU Iafe, NA Phasukkijwatana, N Chen, XJ Sarraf, D AF Iafe, Nicholas A. Phasukkijwatana, Nopasak Chen, Xuejing Sarraf, David TI Retinal Capillary Density and Foveal Avascular Zone Area Are Age-Dependent: Quantitative Analysis Using Optical Coherence Tomography Angiography SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE foveal avascular zone; OCT angiography; OCTA; optical coherence tomography angiography; retinal capillary plexus ID ACUTE MIDDLE MACULOPATHY; MACULAR DEGENERATION; NONINVASIVE VISUALIZATION; FLUORESCEIN ANGIOGRAPHY; DIABETIC-RETINOPATHY; MOTION CORRECTION; VASCULAR DENSITY; NEOVASCULARIZATION; ISCHEMIA; SPECTRUM AB PURPOSE. The purpose of this study was to quantify retinal capillary density and the foveal avascular zone (FAZ) area in normal subjects according to age, using optical coherence tomography angiography (OCTA). METHODS. All eyes in this cross-sectional study underwent OCTA using RTVue XR Avanti with AngioVue. OCTA scans were analyzed and processed, and vessel density and FAZ dimensions were calculated. RESULTS. A total of 113 normal eyes from 70 subjects were included (30 males, 40 females; mean 48 +/- 20 years of age). The mean vessel density and FAZ dimensions were significantly smaller in the superficial retinal capillary plexus (SCP) than in the deep retinal capillary plexus (DCP), using quantitative OCTA analysis (all P<0.0001). With 3 x 3-mm scans, the mean vessel density was 13.431 +/- 1.758 mm(-1) in the SCP, 18.812 +/- 1.796 mm(-1) in the DCP, and 5.913 +/- 1.308 mm(-1) and 10.447 +/- 1.262 mm(-1) with 6 x 6-mm scans in the SCP and DCP, respectively. Mean FAZ areas were 0.289 +/- 0.108 mm(2) at the SCP and 0.614 +/- 0.200 mm(2) at the DCP. Age was a predictor of SCP and DCP vessel density and FAZ area in the SCP. Vessel density decreased 0.0393 mm(-1) (0.26%) per year in the SCP and 0.0574 mm(-1) (0.27%) per year in the DCP. FAZ areas increased 0.0014 mm(2) (0.63%) and 0.0011 mm(2) (0.20%) per year in the SCP and DCP, respectively. CONCLUSIONS. SCP and DCP vessel density decreased with increasing age, while FAZ area increased with age. Normal age-matched measurements provide important standardized values that may facilitate management of retinal vascular disorders. C1 [Iafe, Nicholas A.; Phasukkijwatana, Nopasak; Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA. [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), UCLA, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu NR 39 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5780 EP 5787 DI 10.1167/iovs.16-20045 PG 8 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600094 PM 27792812 ER PT J AU Yang, T Sun, Y Zhang, F AF Yang, Tuo Sun, Yang Zhang, Feng TI Anti-oxidative aspect of inhaled anesthetic gases against acute brain injury SO MEDICAL GAS RESEARCH LA English DT Review DE isoflurane; nuclear factor (erythroid-derived 2)-like 2; pre-conditioning; post-conditioning; sevoflurane; stroke; traumatic brain injury; xenon ID FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; VASCULAR COGNITIVE IMPAIRMENT; SUBARACHNOID HEMORRHAGE; RAT MODEL; OXIDATIVE STRESS; HEME OXYGENASE-1; HO-1 EXPRESSION; MURINE MODEL; NEUROPROTECTION AB Acute brain injury is a critical and emergent condition in clinical settings, which needs to be addressed urgently. Commonly acute brain injuries include traumatic brain injury, ischemic and hemorrhagic strokes. Oxidative stress is a key contributor to the subsequent injuries and impedes the reparative process after acute brain injury; therefore, facilitating an anti-oxidative approach is important in the care of those diseases. Readiness to deliver and permeability to blood brain barrier are essential for the use of this purpose. Inhaled anesthetic gases are a group of such agents. In this article, we discuss the anti-oxidative roles of anesthetic gases against acute brain injury. C1 [Yang, Tuo; Sun, Yang; Zhang, Feng] Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15260 USA. [Zhang, Feng] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Zhang, Feng] Taishan Med Univ, Key Lab Cerebral Microcirculat Univ Shandong, Tai An, Shandong, Peoples R China. RP Zhang, F (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15260 USA.; Zhang, F (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.; Zhang, F (reprint author), Taishan Med Univ, Key Lab Cerebral Microcirculat Univ Shandong, Tai An, Shandong, Peoples R China. EM zhanfx2@upmc.edu FU National Institutes of Health of USA [NS092810]; National Natural Science Foundation of China [81271276] FX This work was supported by grants from the National Institutes of Health of USA (No. NS092810 to FZ) and the National Natural Science Foundation of China (No. 81271276 to FZ). NR 55 TC 0 Z9 0 U1 1 U2 1 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 2045-9912 J9 MED GAS RES JI Med. Gas Res. PD OCT-DEC PY 2016 VL 6 IS 4 BP 223 EP 226 DI 10.4103/2045-9912.196905 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EI4FW UT WOS:000392449500007 PM 28217295 ER PT J AU Zhang, J Hall, NC Schoder, H Schwartz, LP Wilson, WH Kelloff, G Knopp, MV AF Zhang, J. Hall, N. C. Schoder, H. Schwartz, L. P. Wilson, W. H. Kelloff, G. Knopp, M. V. TI The Oncology Biomarker Qualification Initiative (OBQI): Multi-institutional Demonstration Using FDG-PET in Non-Hodgkin's Lymphoma SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Zhang, J.; Knopp, M. V.] Ohio State Univ, Columbus, OH 43210 USA. [Hall, N. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schoder, H.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Schwartz, L. P.] Columbia Univ, New York, NY USA. [Wilson, W. H.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Kelloff, G.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA OP687 BP S204 EP S204 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5GW UT WOS:000391801600505 ER PT J AU Hall, NC Wright, CL Gortanla, N Nagar, V Zhang, J Knopp, MV AF Hall, N. C. Wright, C. L. Gortanla, N. Nagar, V. Zhang, J. Knopp, M. V. TI Matched Pair Validation of Ultra-low-dose CT Compared to Low-dose CT for Oncologic F-18-FDG PET/CT SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Hall, N. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Wright, C. L.; Gortanla, N.; Nagar, V.; Zhang, J.; Knopp, M. V.] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA EP204 BP S322 EP S322 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5HE UT WOS:000391802400205 ER PT J AU Mata, IF Davis, MY Lopez, AN Dorschner, MO Martinez, E Yearout, D Cholerton, BA Hu, SC Edwards, KL Bird, TD Zabetian, CP AF Mata, Ignacio F. Davis, Marie Y. Lopez, Alexis N. Dorschner, Michael O. Martinez, Erica Yearout, Dora Cholerton, Brenna A. Hu, Shu-Ching Edwards, Karen L. Bird, Thomas D. Zabetian, Cyrus P. TI The Discovery of LRRK2 p.R1441S, a Novel Mutation for Parkinson's Disease, Adds to the Complexity of a Mutational Hotspot SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE movement disorders; genetics; neuropsychological ID R1441G MUTATION; KINASE-ACTIVITY; BASQUE COUNTRY; GENE; G2019S; PENETRANCE; VARIANTS; FAMILIES; CARRIERS; GTPASE AB Mutations in the LRRK2 gene result in autosomal dominant, late onset Parkinson's disease (PD). Three such mutations (p.R1441C, p.R1441G, and p.R1441H) are known to occur within codon 1441, and haplotype analyses indicate that each one has arisen independently on multiple occasions. We sequenced the entire coding region of 18 casual genes for PD or other parkinsonian neurodegenerative disorders in the proband of a family with autosomal dominant PD. We discovered a new missense mutation in the LRRK2 gene, c.4321C>A (p.R1441S). The mutation was predicted to be highly deleterious in silico (Combined Annotation Dependent Depletion score of 25.5) and segregated with disease in the pedigree. The clinical characteristics of affected family members were similar to those described in PD families with other mutations in LRRK2 codon 1441 and included resting tremor, rigidity, bradykinesia, unilateral onset, and a good response to levodopa. Age at onset ranged from 41 to 76. Two of the affected members of the pedigree underwent detailed, longitudinal neuropsychological testing, and both displayed evidence of mild cognitive deficits at or slightly preceding the onset of motor symptoms. LRRK2 p.R1441S represents the fourth pathogenic mutation observed within codon 1441 and its discovery adds to the remarkable complexity of a mutational hotspot within the ROC domain of the LRRK2 protein. (C) 2016 Wiley Periodicals, Inc. C1 [Mata, Ignacio F.; Davis, Marie Y.; Martinez, Erica; Yearout, Dora; Cholerton, Brenna A.; Hu, Shu-Ching; Bird, Thomas D.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Davis, Marie Y.; Yearout, Dora; Hu, Shu-Ching; Bird, Thomas D.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Lopez, Alexis N.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Dorschner, Michael O.; Cholerton, Brenna A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu FU Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [R01 NS065070, P50 NS062684] FX Grant sponsor: Department of Veterans Affairs (Merit Award); Grant number: #1I01BX000531; Grant sponsor: National Institutes of Health; Grant numbers: R01 NS065070, P50 NS062684. NR 44 TC 3 Z9 3 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD OCT PY 2016 VL 171 IS 7 BP 925 EP 930 DI 10.1002/ajmg.b.32452 PG 6 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PN UT WOS:000390662200002 PM 27111571 ER PT J AU Chao, J Rubinow, KB Kratz, M Amory, JK Matsumoto, AM Page, ST AF Chao, Jing Rubinow, Katya B. Kratz, Mario Amory, John K. Matsumoto, Alvin M. Page, Stephanie T. TI Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ANDROGEN-DEPRIVATION THERAPY; REDUCES INSULIN SENSITIVITY; PROSTATE-CANCER; CARDIOVASCULAR-DISEASE; TESTOSTERONE THERAPY; METABOLIC SYNDROME; BODY-COMPOSITION; HEART-DISEASE; ADULT MEN; OLDER MEN AB Context: T deprivation increases risk of insulin resistance in men, but whether this risk is independent of changes in body composition is unknown. Further, the metabolic roles of T and its metabolite estradiol have not been clearly defined in men. Objective: This study sought to establish the effects of selective sex steroid withdrawal on insulin sensitivity in healthy men. Design, Setting, and Participants: This was a double-blinded, placebo-controlled, randomized trial at an academic medical center of 56 healthy men, 19-55 years of age. Interventions: Subjects received the GnRH antagonist acyline plus one of the following: placebo gel (Castrate), 1.25 g testosterone gel (Low T/E), 5 g testosterone gel (Normal T/E), or 5 g testosterone gel with letrozole (Normal T/Low E) daily for 4 weeks. Body composition and glucose tolerance were assessed at baseline and end of treatment. Main Outcome Measure: Insulin sensitivity was quantified by the Matsuda index. Results: Predicted circulating sex steroid concentrations were achieved in all treatment groups. The time-by-group interaction for Matsuda index did not achieve significance in overall repeated measures ANOVA (baseline vs week 4; P = .16). A significant time-by-group interaction was observed for fat mass (P = .003), with changes in fat mass attributable predominantly to estrogen exposure in linear regression analysis (P = .016). Atime-by-group interaction also was observed for lean mass (P = .03) and influenced by androgen exposure (P = .003). Conclusions: Short-term sex steroid withdrawal in healthy men causes adverse changes in body composition. These findings support the role of estradiol as a determinant of adiposity in men. C1 [Chao, Jing; Rubinow, Katya B.; Amory, John K.; Page, Stephanie T.] Univ Washington, Sch Med, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Rubinow, Katya B.; Page, Stephanie T.] Univ Washington, Sch Med, Inst Diabet, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kratz, Mario] Fred Hutchinson Canc Res Ctr, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Page, ST (reprint author), Dept Med, Div Metab Endocrinol & Nutr, Hlth Sci, C-506,1959 NE Pacific St, Seattle, WA 98195 USA. EM page@uw.edu FU AbbVie Inc. (Chicago, IL); American Heart Association Clinical Research Program; Eunice Kennedy Shriver National Institute of Child Health and Development [6K12 HD053984, HD042454]; National Institute of Aging [RO1AG037603]; Robert McMillen Professorship in Lipid Research; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007247-37]; Department of Veterans Affairs FX Transdermal T gel and placebo gel were provided at no cost to the study by AbbVie Inc. (Chicago, IL), as an investigator-initiated grant. AbbVie Inc. had no input into the study design or conduct, data analyses, or manuscript preparation and provided no other financial support for the study. K.B.R. is supported by the American Heart Association Clinical Research Program and the Eunice Kennedy Shriver National Institute of Child Health and Development (6K12 HD053984). S.T.P. is supported by the Eunice Kennedy Shriver National Institute of Child Health and Development (HD042454), the National Institute of Aging (RO1AG037603), and the Robert McMillen Professorship in Lipid Research. J.C. received support through the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007247-37). A.M.M. is supported by the Department of Veterans Affairs. NR 32 TC 0 Z9 0 U1 2 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2016 VL 101 IS 10 BP 3724 EP 3731 DI 10.1210/jc.2016-1482 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG2CI UT WOS:000390849800027 PM 27482750 ER PT J AU Wang, RX Chu, GCY Mrdenovic, S Annamalai, AA Hendifar, AE Nissen, NN Tomlinson, JS Lewis, M Palanisamy, N Tseng, HR Posadas, EM Freeman, MR Pandol, SJ Zhau, HE Chung, LWK AF Wang, Ruoxiang Chu, Gina C. Y. Mrdenovic, Stefan Annamalai, Alagappan A. Hendifar, Andrew E. Nissen, Nicholas N. Tomlinson, James S. Lewis, Michael Palanisamy, Nallasivam Tseng, Hsian-Rong Posadas, Edwin M. Freeman, Michael R. Pandol, Stephen J. Zhau, Haiyen E. Chung, Leland W. K. TI Cultured circulating tumor cells and their derived xenografts for personalized oncology SO ASIAN JOURNAL OF UROLOGY LA English DT Review DE Cancer metastasis; Peripheral blood; Circulating tumor cell; ex vivo culture ID COLON-CANCER CELLS; EX-VIVO CULTURE; IN-VITRO CULTURE; PROSTATE-CANCER; PANCREATIC-CANCER; BREAST-CANCER; LUNG-CANCER; MESENCHYMAL TRANSITION; GASTRIC-CANCER; EP-CAM AB Recent cancer research has demonstrated the existence of circulating tumor cells (CTCs) in cancer patient's blood. Once identified, CTC biomarkers will be invaluable tools for clinical diagnosis, prognosis and treatment. In this review, we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample, to derive enough CTCs for accurate and reproducible characterization of the biophysical, biochemical, gene expressional and behavioral properties of the harvested cells. Because of tumor cell heterogeneity, it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis. By analyzing critical steps and technical issues in ex vivo CTC culture, we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells, relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. C1 [Wang, Ruoxiang; Chu, Gina C. Y.; Mrdenovic, Stefan; Hendifar, Andrew E.; Posadas, Edwin M.; Pandol, Stephen J.; Zhau, Haiyen E.; Chung, Leland W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA. [Annamalai, Alagappan A.; Nissen, Nicholas N.; Freeman, Michael R.; Chung, Leland W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Urooncol Res, Los Angeles, CA 90048 USA. [Tomlinson, James S.] West Angeles VA Hosp, Greater Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Lewis, Michael] West Los Angeles VA Hosp, Greater Los Angeles Vet Affairs Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Palanisamy, Nallasivam] Henry Ford Hlth Syst, Detroit, MI USA. [Tseng, Hsian-Rong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP Wang, RX (reprint author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA. EM Ruoxiang.wang@cshs.org OI Palanisamy, Nallasivam/0000-0002-0633-9772 FU US NIH/NCI [2PO1CA098912, UO1CA198900]; Cedars-Sinai Medical Center Board of Governors Cancer Research Chair FX This work is supported by US NIH/NCI research grant (2PO1CA098912), Cedars-Sinai Medical Center Board of Governors Cancer Research Chair (LWKC), and US NIH/NCI (UO1CA198900) (HRT/EMP). NR 104 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SINGAPORE PTE LTD PI SINGAPORE PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE SN 2214-3882 EI 2214-3890 J9 ASIAN J UROL JI ASIAN J. UROL. PD OCT PY 2016 VL 3 IS 4 SI SI BP 240 EP 253 DI 10.1016/j.ajur.2016.08.005 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA EG1VB UT WOS:000390819500010 ER PT J AU Hermann, BA Meyer, EC Schnurr, PP Batten, SV Walser, RD AF Hermann, Barbara A. Meyer, Eric C. Schnurr, Paula P. Batten, Sonja V. Walser, Robyn D. TI Acceptance and commitment therapy for co-occurring PTSD and substance use: A manual development study SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE LA English DT Article DE PTSD; Substance use; Acceptance and commitment therapy; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ACTION QUESTIONNAIRE-II; PSYCHOMETRIC PROPERTIES; EXPERIENTIAL AVOIDANCE; SMOKING-CESSATION; VETERANS; HEALTH; SCALE; DEPENDENCE AB We present the theoretical rationale for addressing comorbid posttraumatic stress disorder (PTSD) and substance use disorder (SUD) with Acceptance and Commitment Therapy (ACT). We then describe the development of a treatment manual of ACT for PTSD/SUD and the subsequent refinement to this manual following a feasibility study with a small sample of veterans. Treatment retention was similar to what has been observed in studies of other integrated treatments for PTSD/SUD. Overall treatment satisfaction was positive. Pilot outcomes are presented for descriptive purposes. We describe changes we made to the initial manual following the trial to bolster retention and improve the intervention. Revisions were based on feedback from therapists, consultants, and participants and examination of pilot outcome data. Additional strategies for adapting ACT to this challenging clinical presentation are offered. Published by Elsevier Inc. on behalf of Association for Contextual Behavioral Science. C1 [Hermann, Barbara A.; Schnurr, Paula P.] VA Med Ctr, Natl Ctr PTSD, Execut Div, 116D,215 North Main St, White River Jct, VT 05009 USA. [Hermann, Barbara A.; Schnurr, Paula P.] Geisel Sch Med, Dartmouth, NS, Canada. [Meyer, Eric C.] Waco VA Med Ctr, VA VISN Ctr Excellence Res Returning War Vet 17, 4800 Mem Dr 151C, Waco, TX 76711 USA. [Meyer, Eric C.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Batten, Sonja V.] Mental Hlth Serv 10P4M, VA Cent Off, 810 Vermont Ave,NW, Washington, DC 20420 USA. [Walser, Robyn D.] Palo Alto Hlth Care Syst NCPTSD 334, Disseminat & Training Div, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Batten, Sonja V.] Booz Allen Hamilton, Washington, DC USA. RP Hermann, BA (reprint author), US Dept Vet Affairs, Burlington Community Based Outpatient Clin, 128 Lakeside Ave,Suite 260, Burlington, VT 05401 USA. EM Barbara.Hermann@va.gov; Eric.C.Meyer@va.gov; Paula.P.Schnurr@clartmouth.edu; sonjavbatten@gmail.com; Robyn.Walser@va.gov NR 57 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2212-1447 EI 2212-1455 J9 J CONTEXTUAL BEHAV S JI J. Contextual Behav. Sci. PD OCT PY 2016 VL 5 IS 4 BP 225 EP 234 DI 10.1016/j.jcbs.2016.07.001 PG 10 WC Psychology, Clinical SC Psychology GA EF8KK UT WOS:000390577500004 ER PT J AU Batteiger, T Tu, WZ Tong, Y Wang, J Hoover, S Dixon, B Arno, J AF Batteiger, Teresa Tu, Wanzhu Tong, Yan Wang, Jane Hoover, Sarah Dixon, Brian Arno, Janet TI AN EVALUATION OF STD SERVICE LOCATIONS USING AN INTEGRATED REGISTRY OF ELECTRONIC HEALTH RECORDS WITH COUNTY STD PROGRAM FILES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Batteiger, Teresa] Indiana Univ Sch Med, Dept Internal Med, Div Infect Dis, Indianapolis, IN 46202 USA. [Tu, Wanzhu; Tong, Yan] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Wang, Jane; Hoover, Sarah] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Dixon, Brian] US Dept Vet Affairs, Ctr Hlth Informat & Commun, Hlth Serv Res & Dev Serv, Indianapolis, IN USA. [Arno, Janet] Bell Flower Clin, Marion Cty Publ Hlth Dept, Indianapolis, IN USA. EM tbatteig@iu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 10 BP S157 EP S157 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900118 ER PT J AU Dixon, B Tu, WZ Wang, J Batteiger, T Hoover, S Arno, J AF Dixon, Brian Tu, Wanzhu Wang, Jane Batteiger, Teresa Hoover, Sarah Arno, Janet TI A COMPREHENSIVE METROPOLITAN REGISTRY OF STD TESTING AND SERVICES FOR PRACTICE AND RESEARCH SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Dixon, Brian] Hlth Serv Res & Dev Serv, Ctr Hlth Informat & Commun, US Dept Vet Affairs, Indianapolis, IN USA. [Tu, Wanzhu] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Wang, Jane; Hoover, Sarah] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Batteiger, Teresa] Indiana Univ Sch Med, Dept Internal Med, Div Infect Dis, Indianapolis, IN 46202 USA. [Arno, Janet] Marion Cty Publ Hlth Dept, Bell Flower Clin, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 112 BP S186 EP S186 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900220 ER PT J AU Hall, KS Gregg, J Bosworth, HB Beckham, JC Hoerster, KD Sloane, R Morey, MC AF Hall, Katherine S. Gregg, Jeffrey Bosworth, Hayden B. Beckham, Jean C. Hoerster, Katherine D. Sloane, Richard Morey, Miriam C. TI Physical activity counseling promotes physical and psychological resilience in older veterans with posttraumatic stress disorder SO MENTAL HEALTH AND PHYSICAL ACTIVITY LA English DT Article DE Clinical; PTSD; RCT; Quality of life; SF-36; Physical function ID RANDOMIZED CONTROLLED-TRIAL; MILITARY VETERANS; MENTAL-HEALTH; PTSD SYMPTOMS; ADULTS; EXERCISE; FITNESS; METAANALYSIS; CARE; ASSOCIATION AB Individuals with posttraumatic stress disorder (PTSD) have elevated rates of morbidity, and a sedentary lifestyle can cause and aggravate the physical health needs of adults with PTSD. The primary aim of this paper was to explore the impact of physical activity (PA) counseling (vs. usual care) on physical and psychological outcomes among individuals with PTSD. A secondary aim was to compare these arm effects between those with and without PTSD. Methods: Older (>60 years) overweight veterans with impaired glucose tolerance were randomly assigned to an intervention or a usual care control arm. Of the 302 participants who underwent randomization, 67 (22%) had PTSD. Participants in the intervention arm received one in-person activity counseling session followed by regular PA telephone counseling over 12 months. Physical and psychological outcomes were assessed at baseline, 3, and 12 months. Results: Primary Aim (intervention vs. usual care among those with PTSD): PA increased on average from 80 min/week to 161 min/week among participants in the intervention arm (p = 0.01). Large, clinically meaningful improvements in six-minute walk test and psychological health were observed over the course of the intervention (p < 0.01). Secondary Aim (PTSD/No PTSD, intervention/usual care): participants with PTSD responded equally well to the intervention compared to participants without PTSD, though we observed significantly greater improvements in vitality and six-minute walk compared to participants without PTSD (p < 0.05). Conclusions: Given the epidemic of comorbid psychological illness and lifestyle-related disease among persons with PTSD, our findings support development and implementation of targeted PA interventions in this high-risk population. Published by Elsevier Ltd. C1 [Hall, Katherine S.; Sloane, Richard; Morey, Miriam C.] Durham A Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Hall, Katherine S.; Bosworth, Hayden B.; Morey, Miriam C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Hall, Katherine S.; Sloane, Richard; Morey, Miriam C.] Duke Univ, Med Ctr, Claude D Pepper Ctr Aging, Durham, NC USA. [Gregg, Jeffrey] Durham Vet Affairs Med Ctr, Mental Hlth Serv, Durham, NC USA. [Bosworth, Hayden B.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res & Dev, Durham, NC USA. [Beckham, Jean C.] Durham Vet Affairs Med Ctr, VA Res Serv, Vet Integrated Serv Network 6, Mental Illness Res Educ & Clin Ctr, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hall, KS (reprint author), Durham VAMC GRECC 182, 508 Fulton St, Durham, NC 27705 USA. EM katherine.hall@duke.edu FU VA Health Services Research and Development grant [IIR-06-252-3]; National Institute on Aging [AG028716]; Department of Veterans Affairs Career Development Awards [RRD CDA 2RX001316, HSRD CDA 12-263]; Department of Veterans Affairs Career Scientist Award [HSRD 08-027] FX This study was funded by a VA Health Services Research and Development grant (IIR-06-252-3; BLINDED) and National Institute on Aging grant AG028716. Drs. Hall and Hoerster are supported by Department of Veterans Affairs Career Development Awards (RR&D CDA 2RX001316 and HSR&D CDA 12-263, respectively). Dr. Bosworth is supported by a Department of Veterans Affairs Career Scientist Award (HSR&D 08-027). The Duke Claude D. Pepper Older American Independence Center (NIA P30AG028716) contributed to the intellectual content of this work.. The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the articles; and in the decision to submit it for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 40 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1755-2966 J9 MENT HEALTH PHYS ACT JI Ment. Health Phys. Act. PD OCT PY 2016 VL 11 BP 53 EP 59 DI 10.1016/j.mhpa.2016.10.001 PG 7 WC Psychiatry SC Psychiatry GA EF7MU UT WOS:000390514500008 PM 28458721 ER PT J AU Li, C Neugroschl, J Umpierre, M Martin, J Huang, QY Zeng, XY Cai, DM Sano, M AF Li, Clara Neugroschl, Judith Umpierre, Mari Martin, Jane Huang, QiYing Zeng, Xiaoyi Cai, Dongming Sano, Mary TI Recruiting US Chinese Elders Into Clinical Research for Dementia SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE elderly Chinese Americans; clinical study; dementia; aging; recruitment; minority AB Purpose: This study described and evaluated the rapid recruitment of elderly Chinese into clinical research at the Mount Sinai Alzheimer's Disease Research Center (MSADRC). Design and Methods: Methods of publicizing the study included lectures to local senior centers/churches and publications in local Chinese newspapers. The amount of time and success of these methods were evaluated. A "go to them" model of evaluation was used to enable participants to complete the study visit at locations where they were comfortable. Results: From January to December 2015, we recruited 98 participants aged 65 years or older who primarily speak Mandarin/Cantonese and reside in New York. The mean age and years of education was 73.93 +/- 6.34 and 12.79 +/- 4.58, respectively. The majority of participants were female (65.3%) and primarily Mandarin speaking (53.1%). Of all enrollees, 54.1% were recruited from community lectures, 29.6% through newspapers, 10.2% through word of mouth, and 6.1% from our clinical services. About 40.8% of participants underwent evaluations at the MSADRC, 44.9% at local senior centers/churches, and 14.3% at home. Implications: Given that the majority of our participants had low English proficiency, the use of bilingual recruiters probably allowed us to overcome the language barrier, facilitating recruitment. Our "go to them" model of evaluation is another important factor contributing to our successful recruitment. C1 [Li, Clara; Neugroschl, Judith; Umpierre, Mari; Martin, Jane; Huang, QiYing; Zeng, Xiaoyi; Cai, Dongming; Sano, Mary] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. RP Li, C (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Alzheimers Dis Res Ctr, One Gustave L Levy Pl,POB 1230, New York, NY 10029 USA. EM clara.li@mssm.edu OI Cai, Dongming/0000-0002-0601-6826 FU NIH National Institute on Aging [P50AG05138] FX Supported by NIH National Institute on Aging grant (P50AG05138). NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2016 VL 30 IS 4 BP 345 EP 347 DI 10.1097/WAD.0000000000000162 PG 3 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA EE0IQ UT WOS:000389258200009 PM 27819841 ER PT J AU Schmidt, MG John, JJ Freeman, KD Sharpe, PA Estelle, AA Michels, HT AF Schmidt, Michael G. John, Joseph J., Jr. Freeman, Katherine D. Sharpe, Peter A. Estelle, Adam A. Michels, Harold T. TI Perspectives from the field in response to "It is time to revise our approach to registering antimicrobial agents for health care settings" SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID RESISTANT STAPHYLOCOCCUS-AUREUS; COPPER SURFACES; SURVIVAL; ALLOYS; UNIT; INACTIVATION; NOROVIRUS; BACTERIA; REDUCE; STEEL C1 [Schmidt, Michael G.] Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,MSC 504, Charleston, SC 29425 USA. [John, Joseph J., Jr.] Ralph H Johnson VA, Dept Med, Charleston, SC USA. [Freeman, Katherine D.] Extrapolate LLC, Delray Beach, FL USA. [Sharpe, Peter A.] Irwin P Sharpe & Associates, Westfield, NJ USA. [Estelle, Adam A.; Michels, Harold T.] Copper Dev Assoc, New York, NY USA. RP Schmidt, MG (reprint author), Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,MSC 504, Charleston, SC 29425 USA. EM schm4647@gmail.com OI Schmidt, Michael G/0000-0002-7794-7265 NR 20 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2016 VL 44 IS 10 BP 1187 EP 1189 DI 10.1016/j.ajic.2016.04.249 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QP UT WOS:000389510400029 PM 27520787 ER PT J AU Becerra, MB Shirley, D Safdar, N AF Becerra, Monideepa B. Shirley, Daniel Safdar, Nasia TI Prevalence, risk factors, and outcomes of idle intravenous catheters: An integrative review SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Review DE Bloodstream infection; Patient outcomes; Idle lines; CLABSI ID CENTRAL VENOUS CATHETER; BLOOD-STREAM INFECTION; INTENSIVE-CARE-UNIT; PREVENTION; GUIDELINES AB Objective: Complications of intravenous catheters remain a major contributor to health care costs and are a patient safety problem. An intravenous catheter not actively in use-an idle catheter-may increase the risk of infectious and noninfectious complications. We conducted an integrative review of the available literature to evaluate the prevalence, risk factors, and outcomes associated with idle intravenous catheters. Methods: Searches of multiple computerized databases were conducted to identify studies on idle intravenous catheters. Data on definitions of idle catheter, type of catheter, prevalence, risk factors, and patient outcomes were extracted. Results: Thirteen studies met inclusion criteria and were included in the review. The location and setting of the studies were diverse, including cross-sectional, retrospective, and prospective, and were conducted in varied geographic locations. The definition of an idle catheter was variable across studies. Although studies varied in terms of line-days or number of catheters placed, the primary definition of idle device was based on number of days or percent of devices left in situ without use. Four studies evaluated patient outcomes associated with idle catheters and found increased risk of infection, intensive care unit admission, and phlebitis. Conclusions: Idle intravenous catheters are common and are associated with adverse outcomes. Prospective studies incorporating uniform definitions of idle catheters to test interventions to reduce idle catheter use are urgently needed. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Becerra, Monideepa B.] Calif State Univ San Bernardino, Dept Hlth Sci & Human Ecol, San Bernardino, CA 92407 USA. [Shirley, Daniel; Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin Madison, Dept Med, 1685 Highland Ave, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu FU VA MERIT award; VA Patient Safety Center; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative [PEC 15-248] FX NS is supported by a VA MERIT award and by the VA Patient Safety Center. The project reported here was also supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative (project No. PEC 15-248). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 31 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2016 VL 44 IS 10 BP E167 EP E172 DI 10.1016/j.ajic.2016.03.073 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QP UT WOS:000389510400001 PM 27425008 ER PT J AU Gaggar, A Patel, RP AF Gaggar, Amit Patel, Rakesh P. TI There is blood in the water: hemolysis, hemoglobin, and heme in acute lung injury SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE ARDS; heme; hemoglobin; inflammation; nitric oxide ID CELL-FREE HEMOGLOBIN; NITRIC-OXIDE; PULMONARY-HYPERTENSION; STORAGE LESION; HAPTOGLOBIN; DISEASE; MORTALITY; THERAPY; INFLAMMATION; HEMOPEXIN AB The major role of red blood cells (RBCs) is to deliver oxygen and remove carbon dioxide within organisms through the unique properties of hemoglobin. Although beneficial within RBCs, when outside hemoglobin and its breakdown products (heme, iron) induce proinflammatory responses affecting various cellular responses. Although these effects are considered to be prominent in disorders with increased hemolysis, recent evidence suggests that this process may be active in nonhemolytic disorders such as acute lung injury/acute respiratory distress syndrome. This perspectives article focuses on data related to red cell products in nonhemolytic disorders and the potential to target these factors in acute lung injury/acute respiratory distress syndrome. C1 [Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Patel, Rakesh P.] Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR 2,Rm 532, Birmingham, AL 35294 USA. [Patel, Rakesh P.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA. [Gaggar, Amit] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. RP Patel, RP (reprint author), Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR 2,Rm 532, Birmingham, AL 35294 USA. EM rakeshpatel@uabmc.edu NR 39 TC 0 Z9 0 U1 6 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD OCT 1 PY 2016 VL 311 IS 4 BP L714 EP L718 DI 10.1152/ajplung.00312.2016 PG 5 WC Physiology; Respiratory System SC Physiology; Respiratory System GA EE5IP UT WOS:000389640200004 PM 27542810 ER PT J AU Rogal, S Mankaney, G Udawatta, V Good, CB Chinman, M Zickmund, S Bielefeldt, K Jonassaint, N Jazwinski, A Shaikh, O Hughes, C Humar, A DiMartini, A Fine, MJ AF Rogal, Shari Mankaney, Gautham Udawatta, Viyan Good, Chester B. Chinman, Matthew Zickmund, Susan Bielefeldt, Klaus Jonassaint, Naudia Jazwinski, Alison Shaikh, Obaid Hughes, Christopher Humar, Abhinav DiMartini, Andrea Fine, Michael J. TI Association between opioid use and readmission following liver transplantation SO CLINICAL TRANSPLANTATION LA English DT Article DE narcotics; pain; rehabilitation; rehospitalization ID PALLIATIVE CARE; KIDNEY-TRANSPLANTATION; PAIN; DISEASE; VALIDATION; MANAGEMENT; CIRRHOSIS; ADULTS AB The aim of this study was to assess the independent association between pre-transplant prescription opioid use and readmission following liver transplantation. We reviewed the medical records of all patientsat a single medical center undergoing primary, single-organ, liver transplantation from 2004 to 2014. We assessed factors associated with hospital readmission 30days and 1year after hospital discharge using multivariable competing risk regression models. Among 1056 transplant recipients, 49 (4.6%) were prescribed pre-transplant prescription opioids. Readmission occurred in 421 (40%) patients within 30days and 689 (65%) within 1year. Patients with pre-transplant opioid use had a significantly higher risk of readmission at 30days (HR 1.7; 95% CI 1.1-2.5) and a non-significantly elevated risk at 1year (HR 1.4; 95% CI 1.0-1.9) when controlling for other potential confounders. Although pain was the major reason for readmission in only 12 (3%) patients at 30days and 33 (6%) patients at 1year, pre-transplant opioid use was significantly associated with pain-related readmission at both time points. In conclusion, prescription opioid use pre-transplantation was significantly associated with all-cause 30-day readmissions and pain-related readmissions at 30 days and 1 year. C1 [Rogal, Shari; Good, Chester B.; Zickmund, Susan; Fine, Michael J.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. [Rogal, Shari; Jonassaint, Naudia; Hughes, Christopher; Humar, Abhinav; DiMartini, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Rogal, Shari; Shaikh, Obaid] VA Pittsburgh Hlthcare Syst, Div Gastroenterol, Pittsburgh, PA USA. [Mankaney, Gautham; Udawatta, Viyan; Good, Chester B.; Zickmund, Susan; Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Chinman, Matthew] VA Pittsburgh Hlthcare Syst, VISN Mental Illness Res & Clin Ctr 4, Pittsburgh, PA USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA USA. [Rogal, Shari; Bielefeldt, Klaus; Jonassaint, Naudia; Jazwinski, Alison; Shaikh, Obaid] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nut, Pittsburgh, PA USA. [DiMartini, Andrea] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Rogal, S (reprint author), VA Pittsburgh Hlthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. EM rogalss@upmc.edu FU Gilead Sciences FX The authors of this manuscript have no conflict of interests to disclose as described by the American Journal of Transplantation. Although there are not any potential conflict of interests relevant to this manuscript, Drs. Rogal, Zickmund and Jonassaint report a grant (to the institution) from Gilead Sciences for projects related to hepatitis. NR 29 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD OCT PY 2016 VL 39 IS 10 BP 1222 EP 1229 DI 10.1111/ctr.12806 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA DZ3OT UT WOS:000385758800006 ER PT J AU Hess, PL Ho, PM AF Hess, Paul L. Ho, P. Michael TI Hypertension Management: Ripe for Disruption SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Editorial Material DE Editorials; hypertension; intensification; quality of care ID PERFORMANCE C1 [Hess, Paul L.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Cardiol Sect, Denver, CO USA. [Hess, Paul L.; Ho, P. Michael] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA. RP Hess, PL (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM paul.hess@ucdenver.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004681 DI 10.1161/JAHA.116.004681 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500058 ER PT J AU Ahmed, MI Guichard, JL Rajasekaran, NS Ahmad, S Mariappan, N Litovsky, S Gupta, H Lloyd, SG Denney, TS Powell, PC Aban, I Collawn, JF Davies, JE McGiffin, DC Dell'Italia, LJ AF Ahmed, Mustafa I. Guichard, Jason L. Rajasekaran, Namakkal S. Ahmad, Shama Mariappan, Nithya Litovsky, Silvio Gupta, Himanshu Lloyd, Steven G. Denney, Thomas S. Powell, Pamela Cox Aban, Inmaculada Collawn, James F. Davies, James E. McGiffin, David C. Dell'Italia, Louis J. TI Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE heart failure; mitochondria; cardiomyocyte; mitral regurgitation ID ALPHA-B-CRYSTALLIN; OXIDATIVE STRESS; IN-VIVO; INTERMEDIATE-FILAMENTS; EJECTION FRACTION; HEART-ASSOCIATION; CARDIOMYOPATHY; EXPRESSION; DYSFUNCTION; BLOCKADE AB Objective: Recent studies have demonstrated improved outcomes in patients receiving early surgery for degenerative mitral regurgitation ( MR) rather than adhering to conventional guidelines for surgical intervention. However, studies providing a mechanistic basis for these findings are limited. Methods: Left ventricular ( LV) myocardium from 22 patients undergoing mitral valve repair for American Heart Association class I indications was evaluated for desmin, the voltage-dependent anion channel, alpha-B-crystallin, and alpha, beta-unsaturated aldehyde 4-hydroxynonenal by fluorescence microscopy. The same was evaluated in 6 normal control LV autopsy specimens. Cardiomyocyte ultrastructure was examined by transmission electron microscopy. Magnetic resonance imaging with tissue tagging was performed in 55 normal subjects and 22 MR patients before and 6 months after mitral valve repair. Results: LV end-diastolic volume was 1.5-fold ( P<. 0001) higher and LV mass-to-volume ratio was lower in MR ( P =.004) hearts versus normal hearts and showed improvement 6 months after mitral valve surgery. However, LV ejection fraction decreased from 65% +/- 7% to 52% +/- 9% ( P<. 0001) and LV circumferential ( P<. 0001) and longitudinal strain decreased significantly below normal values ( P <.002) after surgery. Hearts with MR had a 53% decrease in desmin ( P<. 0001) and a 2.6-fold increase in desmin aggregates ( P<. 0001) versus normal, along with substantial, intense perinuclear staining of alpha, beta-unsaturated aldehyde 4-hydroxynonenal in areas of mitochondrial breakdown and clustering. Transmission electron microscopy demonstrated numerous electron-dense deposits, myofibrillar loss, Z-disc abnormalities, and extensive granulofilamentous debris identified as desmin-positive by immunogold transmission electron microscopy. Conclusions: Despite well-preserved preoperative LV ejection fraction, severe oxidative stress and disruption of cardiomyocyte desmin-mitochondrial sarcomeric architecture may explain postoperative LV functional decline and further supports the move toward earlier surgical intervention. C1 [Ahmed, Mustafa I.; Guichard, Jason L.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Rajasekaran, Namakkal S.; Litovsky, Silvio] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Ahmad, Shama; Mariappan, Nithya] Univ Alabama Birmingham, Dept Anesthesiol & Perioperat Med, Birmingham, AL USA. [Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Collawn, James F.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Davies, James E.] Univ Alabama Birmingham, Dept Surg, Div Thorac & Cardiovasc Surg, Birmingham, AL 35294 USA. [Gupta, Himanshu; Lloyd, Steven G.; Powell, Pamela Cox; Davies, James E.; Dell'Italia, Louis J.] Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Denney, Thomas S.] Auburn Univ, MRI Res Ctr, Auburn, AL 36849 USA. RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, 700 S 19th St, Birmingham, AL 35233 USA. EM louis.dellitalia@va.gov FU National Heart, Lung, and Blood Institute; Specialized Centers of Clinically Oriented Research [P50HL077100]; Department of Veterans Affairs Merit Review Award [1CX000993-01]; National Institutes of Health [P01 HL051952]; National Heart, Lung, and Blood Institute [5-T32-HL-072757, R01HL118067] FX This work was supported by the National Heart, Lung, and Blood Institute and the Specialized Centers of Clinically Oriented Research (grant No. P50HL077100 to L.J.D.) in cardiac dysfunction; by a Department of Veterans Affairs Merit Review Award (grant No. 1CX000993-01 to L.J.D.); by National Institutes of Health grant No. P01 HL051952 (to L.J.D.); and National Heart, Lung, and Blood Institute Training Grant Nos. 5-T32-HL-072757 (to J.L.G) and R01HL118067 (to R.N.S.). NR 35 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2016 VL 152 IS 4 BP 1059 EP + DI 10.1016/j.jtcvs.2016.06.017 PG 14 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EA6OO UT WOS:000386748700040 PM 27464577 ER PT J AU Sarraf, D London, NJS Khurana, RN Dugel, PU Gune, S Hill, L Tuomi, L AF Sarraf, David London, Nikolas J. S. Khurana, Rahul N. Dugel, Pravin U. Gune, Shamika Hill, Lauren Tuomi, Lisa TI Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration Post Hoc Analysis of the HARBOR Study SO OPHTHALMOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY MAY, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION; 2.0 MG RANIBIZUMAB; VISUAL-ACUITY; AFLIBERCEPT; THERAPY; MORPHOLOGY; EYES; VERTEPORFIN; RELEVANT AB Purpose: To analyze the effect of baseline presence and height of pigment epithelial detachments (PEDs) on visual and anatomic outcomes at 24 months in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab. Design: Post hoc analysis of HARBOR, a 24-month, phase III, randomized, multicenter, double-masked, active treatment-controlled study (clinicaltrials. gov identifier, NCT00891735). Participants: One thousand ninety-seven patients with neovascular AMD. Methods: Intravitreal ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN) after 3 monthly loading doses. Main Outcome Measures: We evaluated the effect of presence and height of baseline PED on several outcomes at 24 months, including best-corrected visual acuity (BCVA), change in PED height, resolution of PED, and number of injections in the PRN arms. Development of macular atrophy at month 24 by presence or absence of PED was evaluated. Results: Five hundred ninety-eight (54.5%) patients showed PED at baseline. In the ranibizumab 0.5-mg PRN group, mean numbers of injections were similar for patients with PED present or absent at baseline (14.0 vs. 12.5). Mean BCVA gains from baseline to 24 months were seen in all treatment groups and were comparable in patients with or without PED at baseline treated with ranibizumab 0.5 mg monthly (PED present at baseline, +9.0 letters; PED absent at baseline, +11.3 letters), 0.5 mg PRN (present, +8.4; absent, +7.9), 2.0 mg monthly (present, +7.1; absent, +11.1), or 2.0 mg PRN (present, +7.2; absent, +8.8). When analyzed by baseline PED height, mean BCVA gains were demonstrated and comparable in all treatment groups at 24 months except for patients treated with ranibizumab 2.0 mg monthly in the extra-large group (PEDs >= 352 mu m; mean BCVA change, -0.8 letters). At 24 months, 53.2% (0.5 mg monthly), 44.5% (0.5 mg PRN), 70.4% (2.0 mg monthly), and 57.3% (2.0 mg PRN) of patients showed complete resolution of PED. Conclusions: Ranibizumab 0.5 mg given monthly or PRN effectively treated PEDs in patients with neovascular AMD, and significant vision gains resulted regardless of PED status and height at baseline. In this analysis, there was no additional vision benefit with a higher dose of ranibizumab (2.0 mg). (C) 2016 by the American Academy of Ophthalmology. C1 [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [London, Nikolas J. S.] Retina Consultants San Diego, Poway, CA USA. [Khurana, Rahul N.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA. [Khurana, Rahul N.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Dugel, Pravin U.] Retinal Consultants Arizona, Retinal Res Inst, Phoenix, AZ USA. [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA USA. [Gune, Shamika; Hill, Lauren; Tuomi, Lisa] Genentech Inc, San Francisco, CA 94080 USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.com NR 36 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2016 VL 123 IS 10 BP 2213 EP 2224 DI 10.1016/j.ophtha.2016.07.007 PG 12 WC Ophthalmology SC Ophthalmology GA EE3QI UT WOS:000389509100020 PM 27566855 ER PT J AU Dobalian, A Stein, JA Radcliff, TA Riopelle, D Brewster, P Hagigi, F Der-Martirosian, C AF Dobalian, Aram Stein, Judith A. Radcliff, Tiffany A. Riopelle, Deborah Brewster, Pete Hagigi, Farhad Der-Martirosian, Claudia TI Developing Valid Measures of Emergency Management Capabilities within US Department of Veterans Affairs Hospitals SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE disasters; emergency preparedness; hospitals; quality improvement; United States Department of Veterans Affairs ID SURGE CAPACITY; DISASTER PREPAREDNESS; MASS CASUALTY; CARE; PERFORMANCE; MODEL AB Introduction Hospitals play a critical role in providing health care in the aftermath of disasters and emergencies. Nonetheless, while multiple tools exist to assess hospital disaster preparedness, existing instruments have not been tested adequately for validity. Hypothesis/Problem This study reports on the development of a preparedness assessment tool for hospitals that are part of the US Department of Veterans Affairs (VA; Washington, DC USA). Methods The authors evaluated hospital preparedness in six Mission Areas (MAs: Program Management; Incident Management; Safety and Security; Resiliency and Continuity; Medical Surge; and Support to External Requirements), each composed of various observable hospital preparedness capabilities, among 140 VA Medical Centers (VAMCs). This paper reports on two successive assessments (Phase I and Phase II) to assess the MAs' construct validity, or the degree to which component capabilities relate to one another to represent the associated domain successfully. This report describes a two-stage confirmatory factor analysis (CFA) of candidate items for a comprehensive survey implemented to assess emergency preparedness in a hospital setting. Results The individual CFAs by MA received acceptable fit statistics with some exceptions. Some individual items did not have adequate factor loadings within their hypothesized factor (or MA) and were dropped from the analyses in order to obtain acceptable fit statistics. The Phase II modified tool was better able to assess the pre-determined MAs. For each MA, except for Resiliency and Continuity (MA 4), the CFA confirmed one latent variable. In Phase I, two sub-scales (seven and nine items in each respective sub-scale) and in Phase II, three sub-scales (eight, four, and eight items in each respective sub-scale) were confirmed for MA 4. The MA 4 capabilities comprise multiple sub-domains, and future assessment protocols should consider re-classifying MA 4 into three distinct MAs. Conclusion The assessments provide a comprehensive and consistent, but flexible, approach for ascertaining health system preparedness. This approach can provide an organization with a clear understanding of areas for improvement and could be adapted into a standard for hospital readiness. C1 [Dobalian, Aram; Stein, Judith A.; Radcliff, Tiffany A.; Riopelle, Deborah; Hagigi, Farhad; Der-Martirosian, Claudia] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Dobalian, Aram; Riopelle, Deborah] US Dept Vet Affairs, Ctr Study Healthcare Innovat Implementat & Policy, North Hills, CA USA. [Radcliff, Tiffany A.] Texas A&M Univ, Dept Hlth Policy & Management, Sch Publ Hlth, College Stn, TX USA. [Brewster, Pete] US Dept Vet Affairs, Off Emergency Management, Vet Hlth Adm, Martinsburg, WV USA. [Hagigi, Farhad] Univ Calif Los Angeles, Dept Family Med, Geffen Sch Med, Los Angeles, CA USA. RP Dobalian, A (reprint author), VEMEC, 16111 Plummer St MS-152, North Hills, CA 91343 USA. EM aram.dobalian@va.gov NR 31 TC 2 Z9 2 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD OCT PY 2016 VL 31 IS 5 BP 475 EP 484 DI 10.1017/S1049023X16000625 PG 10 WC Emergency Medicine SC Emergency Medicine GA DZ2IR UT WOS:000385666000004 PM 27492572 ER PT J AU Blonigen, DM Bui, L Britt, JY Thomas, KM Timko, C AF Blonigen, Daniel M. Bui, Leena Britt, Jessica Y. Thomas, Katherine M. Timko, Christine TI Internalizing and Externalizing Personality Subtypes Predict Differences in Functioning and Outcomes Among Veterans in Residential Substance Use Disorder Treatment SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE substance use disorders; residential treatment; subtypes; internalizing; externalizing ID POSTTRAUMATIC-STRESS-DISORDER; SELF-EFFICACY; MILITARY VETERANS; MENTAL-DISORDERS; ALCOHOL-PROBLEMS; ABUSE TREATMENT; MODEL; VALIDATION; PTSD; QUESTIONNAIRE AB There is a long history of using personality to subtype patients in treatment for substance use disorders (SUD). However, no one has validated a typology of SUD patients using a structural model of normal-range personality, particularly indicating whether subtypes differ on treatment processes and outcomes. We developed a personality-based typology among 196 military veterans enrolled in residential SUD treatment at a Veterans Affairs medical center. Patients were assessed at treatment entry, 1 month into treatment, and at discharge from treatment. Personality was assessed using the Multidimensional Personality Questionnaire-Brief Form at treatment entry. Latent profile analyses identified a 3-group solution consisting of low pathology, internalizing, and externalizing groups. The internalizing group scored lowest on measures of functioning at treatment entry, whereas the externalizing group scored more poorly on treatment processes and outcomes over the course of their residential stay (e. g., more stressful relationships with other residents, lower program alliance). These findings support a clinically meaningful typology of SUD patients based on a 3-factor model of personality and can serve as a guide for future efforts aimed at developing targeted interventions that can address the individual differences of patients in this population. C1 [Blonigen, Daniel M.; Bui, Leena; Timko, Christine] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Britt, Jessica Y.] Palo Alto Univ, Palo Alto, CA USA. [Thomas, Katherine M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Timko, Christine] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Thomas, Katherine M.] Purdue Univ, Dept Psychol, W Lafayette, IN 47907 USA. RP Blonigen, DM (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat Implementat, 795 Willow Rd 152, Menlo Pk, CA 94025 USA. EM dmblonigen@gmail.com FU VA Clinical Science Research Development [CDA-2-008-10S]; VA Health Services Research Development [RCS-00-001] FX Dr. Blonigen was supported by a Career Development Award (CDA-2-008-10S) from VA Clinical Science Research & Development. Christine Timko was supported by a Research Career Scientist Award (RCS-00-001) from VA Health Services Research & Development. The views expressed are the authors' and do not necessarily reflect those of the VA. No conflicts of interest are reported by any of the authors listed on this article. NR 68 TC 0 Z9 0 U1 11 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD OCT PY 2016 VL 28 IS 10 BP 1186 EP 1197 DI 10.1037/pas0000250 PG 12 WC Psychology, Clinical SC Psychology GA EE0YX UT WOS:000389307700006 PM 26619089 ER PT J AU Greenland, JR Wong, CM Ahuja, R Wang, AS Uchida, C Golden, JA Hays, SR Leard, LE Rajalingam, R Singer, JP Kukreja, J Wolters, PJ Caughey, GH Tang, QZ AF Greenland, John R. Wong, Charissa M. Ahuja, Rahul Wang, Angelia S. Uchida, Chiyo Golden, Jeffrey A. Hays, Steven R. Leard, Lorriana E. Rajalingam, Raja Singer, Jonathan P. Kukreja, Jasleen Wolters, Paul J. Caughey, George H. Tang, Qizhi TI Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts SO TRANSPLANTATION LA English DT Article ID INTERNATIONAL SOCIETY; ADULT LUNG; TRANSPLANT RECIPIENTS; MESSENGER-RNA; HEART; REGISTRY; DIAGNOSIS; RESPONSES; BLOCKADE; THERAPY AB Background Acute cellular rejection is a major cause of morbidity after lung transplantation. Because regulatory T (Treg) cells limit rejection of solid organs, we hypothesized that donor-reactive Treg increase after transplantation with development of partial tolerance and decrease relative to conventional CD4(+) (Tconv) and CD8(+) T cells during acute cellular rejection. Methods To test these hypotheses, we prospectively collected 177 peripheral blood mononuclear cell specimens from 39 lung transplant recipients at the time of transplantation and during bronchoscopic assessments for acute cellular rejection. We quantified the proportion of Treg, CD4(+) Tconv, and CD8(+) T cells proliferating in response to donor-derived, stimulated B cells. We used generalized estimating equation-adjusted regression to compare donor-reactive T cell frequencies with acute cellular rejection pathology. Results An average of 16.5 9.0% of pretransplantation peripheral blood mononuclear cell Treg cell were donor-reactive, compared with 3.8% +/- 2.9% of CD4(+) Tconv and 3.4 +/- 2.6% of CD8(+) T cells. These values were largely unchanged after transplantation. Donor-reactive CD4(+) Tconv and CD8(+) T cell frequencies both increased 1.5-fold (95% confidence interval [95% CI], 1.3-1.6; P < 0.001 and 95% CI, 1.2-1.6; P = 0.007, respectively) during grade A2 rejection compared with no rejection. Surprisingly, donor-reactive Treg frequencies increased by 1.7-fold (95% CI, 1.4-1.8; P < 0.001). Conclusions Contrary to prediction, overall proportions of donor-reactive Treg cells are similar before and after transplantation and increase during grade A2 rejection. This suggests how A2 rejection can be self-limiting. The observed increases over high baseline proportions in donor-reactive Treg were insufficient to prevent acute lung allograft rejection. C1 [Greenland, John R.; Ahuja, Rahul; Caughey, George H.] Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA. [Greenland, John R.; Golden, Jeffrey A.; Hays, Steven R.; Leard, Lorriana E.; Singer, Jonathan P.; Wolters, Paul J.; Caughey, George H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wong, Charissa M.; Wang, Angelia S.; Golden, Jeffrey A.; Rajalingam, Raja; Kukreja, Jasleen; Tang, Qizhi] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Uchida, Chiyo] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Caughey, George H.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA USA. RP Greenland, JR (reprint author), San Francisco VA Med Ctr, Mail Stop 111D,4150 Clement St, San Francisco, CA 94121 USA. EM john.greenland@ucsf.edu OI Greenland, John/0000-0003-1422-8367 FU Nina Ireland Program in Lung Health; NIH [HL024136]; CSR&D Service of the VA Office of Research and Development [IK2CX001034]; NIH, through the UCSF Career Development Program in Omics of Lung Diseases [K12HL119997] FX This work was primarily funded by a grant from the Nina Ireland Program in Lung Health (QT), with additional support from NIH HL024136 (GHC). JRG was supported the CSR&D Service of the VA Office of Research and Development (IK2CX001034) and the NIH, through the UCSF Career Development Program in Omics of Lung Diseases (K12HL119997). NR 40 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD OCT PY 2016 VL 100 IS 10 BP 2090 EP 2098 DI 10.1097/TP.0000000000001191 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DZ2GV UT WOS:000385661200026 PM 27077597 ER PT J AU Viehman, JA Clancy, CJ Clarke, L Shields, RK Silveira, FP Kwak, EJ Vergidis, P Hughes, C Humar, A Nguyen, MH AF Viehman, J. Alexander Clancy, Cornelius J. Clarke, Lloyd Shields, Ryan K. Silveira, Fernanda P. Kwak, Eun J. Vergidis, Pascalis Hughes, Christopher Humar, Abhinav Nguyen, M. Hong TI Surgical Site Infections After Liver Transplantation: Emergence of Multidrug-Resistant Bacteria and Implications for Prophylaxis and Treatment Strategies SO TRANSPLANTATION LA English DT Article ID SOLID-ORGAN TRANSPLANTATION; BLOOD-STREAM INFECTIONS; RISK-FACTORS; KLEBSIELLA-PNEUMONIAE; INTRAABDOMINAL INFECTIONS; RECIPIENTS; SUSCEPTIBILITY; OUTCOMES; COLONIZATION; EPIDEMIOLOGY AB Background Perioperative antimicrobial prophylaxis is administered to liver transplant (LTx) recipients to prevent surgical site infections (SSIs), but regimens are not standardized, and there are limited effectiveness data. Prevention and treatment of SSIs have been complicated by the emergence of multidrug-resistant (MDR) pathogens. Methods We retrospectively reviewed SSIs among 331 LTx recipients at our center in 2010 to 2014. Results Culture-proven superficial and deep SSIs occurred in 3% and 15% of patients, respectively, at median 12.5 and 13.5 days post-LTx. Recipients with superficial SSIs and those without SSIs were similar in demographics, clinical characteristics, length of hospital stay, and mortality. Deep SSIs included abscesses (58%), peritonitis (28%), deep incisional infections (8%), and cholangitis (6%). Rates of deep SSIs were comparable among patients receiving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P = 0.61). Independent risk factors for deep SSIs were bile leak (P < 0.001) and operative time (P < 0.001). Enterobacteriaceae (42%), Enterococcus spp. (24%), and Candida spp. (15%) were predominant pathogens. Fifty-three percent of bacteria were MDR, including 95% of Enterococcus faecium and 55% of Enterobacteriaceae; 82% of deep SSIs were caused by bacteria resistant to antimicrobials used for prophylaxis, and 58% of patients were treated with an inactive empiric regimen. Deep SSIs were associated with longer lengths of stay (P < 0.001), and higher 90-day and long-term mortality rates (P < 0.001). Conclusions Deep SSIs, including those caused by MDR bacteria, were common after LTx despite prophylaxis with broad-spectrum antimicrobials. Rather than altering prophylaxis regimens, programs should devise empiric treatment regimens that are directed against the most common local pathogens. C1 [Viehman, J. Alexander; Silveira, Fernanda P.; Kwak, Eun J.; Vergidis, Pascalis; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Div Infect Dis, Falk Med Bldg,3601 Fifth Ave,7th Floor, Pittsburgh, PA 15213 USA. [Viehman, J. Alexander; Clancy, Cornelius J.; Shields, Ryan K.; Silveira, Fernanda P.; Kwak, Eun J.; Vergidis, Pascalis; Nguyen, M. Hong] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Clarke, Lloyd; Shields, Ryan K.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA. [Clarke, Lloyd] Univ Pittsburgh, Dept Pharm, Med Ctr, Pittsburgh, PA USA. [Hughes, Christopher; Humar, Abhinav] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Hughes, Christopher; Humar, Abhinav] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. RP Viehman, JA (reprint author), Univ Pittsburgh, Med Ctr, Div Infect Dis, Falk Med Bldg,3601 Fifth Ave,7th Floor, Pittsburgh, PA 15213 USA. EM viehmanja@upmc.edu NR 36 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD OCT PY 2016 VL 100 IS 10 BP 2107 EP 2114 DI 10.1097/TP.0000000000001356 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DZ2GV UT WOS:000385661200028 PM 27479167 ER PT J AU Kishan, AU Shaikh, T Wang, J Reiter, R Said, J Raghavan, G Nickols, N Aronson, W Sadeghi, A Kamrava, M Demanes, DJ Steinberg, ML Horwitz, EM Kupelian, PA King, CR AF Kishan, A. U. Shaikh, T. Wang, J. Reiter, R. Said, J. Raghavan, G. Nickols, N. Aronson, W. Sadeghi, A. Kamrava, M. Demanes, D. J. Steinberg, M. L. Horwitz, E. M. Kupelian, P. A. King, C. R. TI Clinical Outcomes for Patients With Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiation Therapy or Radical Prostatectomy: A Comparative Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kishan, A. U.; Wang, J.; Reiter, R.; Said, J.; Raghavan, G.; Aronson, W.; Kamrava, M.; Demanes, D. J.; King, C. R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Shaikh, T.; Horwitz, E. M.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Nickols, N.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA. [Sadeghi, A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Steinberg, M. L.; Kupelian, P. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2559 BP E229 EP E229 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802558 ER PT J AU Chang, E Ruder, T Setodji, C Saliba, D Hanson, M Zingmond, DS Wenger, NS Ganz, DA AF Chang, Emiley Ruder, Teague Setodji, Claude Saliba, Debra Hanson, Mark Zingmond, David S. Wenger, Neil S. Ganz, David A. TI Differences in Nursing Home Quality Between Medicare Advantage and Traditional Medicare Patients SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Medicare Advantage; nursing homes; quality measures ID FEE-FOR-SERVICE; POST-ACUTE CARE; HEALTH MAINTENANCE ORGANIZATIONS; ACUTE MYOCARDIAL-INFARCTION; MANAGED CARE; OF-CARE; ELDERLY-PATIENTS; DUAL ELIGIBLES; HOSPICE USE; BENEFICIARIES AB Background: Medicare Advantage (MA) enrollment is steadily growing, but little is known about the quality of nursing home (NH) care provided to MA enrollees compared to enrollees in traditional fee-for-service (FFS) Medicare. Objectives: To compare MA and FFS enrollees' quality of NH care. Design: Cross-sectional. Setting: US nursing homes. Participants: 2.17 million Medicare enrollees receiving care at an NH during 2011. Measurements: CMS methodology was used to calculate the 18 Nursing Home Compare quality measures as applicable for each enrollee. Results: Among Medicare enrollees using NH in 2011, 17% were in MA plans. Most quality scores were similar between MA and FFS. After adjusting for facility, beneficiary age and gender, CMS Hierarchical Condition Category score, and geographic region, short-stay MA enrollees had statistically significantly lower rates of new or worsening pressure ulcers [relative risk (RR) = 0.76, 95% confidence interval (CI) = 0.71-0.82] and new antipsychotic use (RR = 0.82, 95% CI = 0.80-0.83) but higher rates of moderate to severe pain (RR = 1.09, 95% CI = 1.07-1.12), compared with short-stay FFS enrollees. MA long-stay enrollees had lower rates of antipsychotic use (RR = 0.94, 95% CI = 0.93-0.96) but had higher rates of incontinence (RR = 1.08, 95% CI = 1.06-1.09) and urinary catheterization (RR = 1.10, 95% CI = 1.06-1.13), compared with long-stay FFS enrollees. Conclusion: Overall, we found few differences in NH quality scores between MA and FFS Medicare enrollees. MA enrollment was associated with better scores for pressure ulcers and antipsychotic use but worse scores for pain control, incontinence, and urinary catheterization. Results may be limited by residual case-mix differences between MA and FFS patients or by the small number of short-stay measures reported. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. C1 [Chang, Emiley; Saliba, Debra; Zingmond, David S.; Wenger, Neil S.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ruder, Teague; Setodji, Claude; Saliba, Debra; Hanson, Mark; Wenger, Neil S.; Ganz, David A.] RAND Corp, Santa Monica, CA USA. [Saliba, Debra; Ganz, David A.] VA Greater Los Angeles HSR&D Ctr Innovat, Sepulveda, CA USA. [Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] Los Angeles Jewish Home, Los Angeles, CA USA. RP Chang, E (reprint author), 911 Broxton Ave, Los Angeles, CA 90024 USA. EM emileychang@mednet.ucla.edu FU National Research Service - National Institutes of Health; Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Providers fellowship - Bureau of Health Professions; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services, Department of Health and Human Services [HHSM-500-2005-00028I, HHSM-500-T0004]; Centers for Medicare and Medicaid Services; Health Services Advisory Group; SCAN Health Plan FX Dr. Chang is currently supported by the National Research Service Award fellowship sponsored by the National Institutes of Health; she was previously supported by the Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Providers fellowship sponsored by the Bureau of Health Professions. The Centers for Medicare & Medicaid Services provided data and financial support for the study. The analyses upon which this publication is based were performed under HHSM-500-2005-00028I, Task Order Number HHSM-500-T0004 funded by the Centers for Medicare & Medicaid Services, Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government. The author assumes full responsibility for the accuracy and completeness of the ideas presented.; Dr. Chang has received an honorarium from SCAN Health Plan. Dr. Ganz is or recently has been part of the project team on contracts awarded to RAND from the Centers for Medicare and Medicaid Services and Health Services Advisory Group, and a contract awarded to UCLA from SCAN Health Plan. Dr. Wenger has been part of the project team on a contract awarded to RAND from the Centers for Medicare and Medicaid Services. The other authors have no conflicts of interest to declare. NR 50 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT 1 PY 2016 VL 17 IS 10 AR UNSP 960.e9 DI 10.1016/j.jamda.2016.07.017 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA ED7PO UT WOS:000389061400023 ER PT J AU Guerrero, EN Wang, HB Mitra, J Hegde, PM Stowell, SE Liachko, NF Kraemer, BC Garruto, RM Rao, KS Hegde, ML AF Guerrero, Erika N. Wang, Haibo Mitra, Joy Hegde, Pavana M. Stowell, Sara E. Liachko, Nicole F. Kraemer, Brian C. Garruto, Ralph M. Rao, K. S. Hegde, Muralidhar L. TI TDP-43/FUS in motor neuron disease: Complexity and challenges SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE TDP-43; FUS/TLS; Amyotrophic lateral sclerosis; RNA processing; Genome damage/repair ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; RNA-BINDING PROTEINS; PARKINSONISM-DEMENTIA COMPLEX; PRION-LIKE DOMAINS; LENGTH POLYGLUTAMINE EXPANSIONS; ARGININE METHYLTRANSFERASE 1; C9ORF72 REPEAT EXPANSION; HUMAN MYELOID-LEUKEMIA; NUCLEAR FACTOR TDP-43 AB Amyotrophic lateral sclerosis (ALS), a common motor neuron disease affecting two per 100,000 people worldwide, encompasses at least five distinct pathological subtypes, including, ALS-SOD1, ALS-C9orf72, ALS-TDP-43, ALS-FUS and Guam-ALS. The etiology of a major subset of ALS involves toxicity of the TAR DNA-binding protein-43 (TDP-43). A second RNA/DNA binding protein, fused in sarcoma/translocated in liposarcoma (FUS/TLS) has been subsequently associated with about 1% of ALS patients. While mutations in TDP-43 and FUS have been linked to ALS, the key contributing molecular mechanism(s) leading to cell death are still unclear. One unique feature of TDP-43 and FUS pathogenesis in ALS is their nuclear clearance and simultaneous cytoplasmic aggregation in affected motor neurons. Since the discoveries in the last decade implicating TDP-43 and FUS toxicity in ALS, a majority of studies have focused on their cytoplasmic aggregation and disruption of their RNA-binding functions. However, TDP-43 and FUS also bind to DNA, although the significance of their DNA binding in disease-affected neurons has been less investigated. A recent observation of accumulated genomic damage in TDP-43 and FUS-linked ALS and association of FUS with neuronal DNA damage repair pathways indicate a possible role of deregulated DNA binding function of TDP-43 and FUS in ALS. In this review, we discuss the different ALS disease subtypes, crosstalk of etiopathologies in disease progression, available animal models and their limitations, and recent advances in understanding the specific involvement of RNA/DNA binding proteins, TDP-43 and FUS, in motor neuron diseases. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Guerrero, Erika N.; Wang, Haibo; Mitra, Joy; Hegde, Pavana M.; Hegde, Muralidhar L.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA. [Guerrero, Erika N.; Rao, K. S.] Inst Sci Res & Technol Serv INDICASAT AIP, Ctr Neurosci, City Of Knowledge, Panama. [Guerrero, Erika N.; Rao, K. S.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur, India. [Stowell, Sara E.; Garruto, Ralph M.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA. [Garruto, Ralph M.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA. [Liachko, Nicole F.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Hegde, Muralidhar L.] Houston Methodist Neurol Inst, Houston, TX 77030 USA. [Hegde, Muralidhar L.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. RP Hegde, ML (reprint author), 6550 Fannin St,Smith 8-05, Houston, TX 77030 USA. EM mlhegde@houstonmethodist.org OI Guerrero, Erika/0000-0002-9838-3577; Hegde, Muralidhar/0000-0001-7333-8123 FU National Institutes of Health USPHS [R01 NS 088645]; Muscular Dystrophy Association [MDA 294842]; ALS Association [15-IIP-204]; Alzheimer's Association [NIRG-12-242135]; Melo Brain Funds; Institute for Training and Development of Human resources of Panama (IFARHU); National Secretariat for Science, Technology, and Innovation of Panama (SENACYT); National System on Investigation (SNI) grant of SENACYT; Department of Veterans Affairs [I01BX002619]; National Institutes of Health [R01NS064131]; Career Development Award 2 from the Department of Veterans Affairs [I01BX007080] FX The research in the Hegde laboratory is supported by grants from the National Institutes of Health USPHS R01 NS 088645, Muscular Dystrophy Association (MDA 294842), ALS Association (15-IIP-204), Alzheimer's Association (NIRG-12-242135) to M.L.H. and Melo Brain Funds (M.L.H. and K.S.R.). E.N.G. is supported by a Doctoral Scholarship granted by the Institute for Training and Development of Human resources of Panama (IFARHU) and the National Secretariat for Science, Technology, and Innovation of Panama (SENACYT). K.S.R. is supported by the National System on Investigation (SNI) grant of SENACYT. B.C.K. is supported by grants from the Department of Veterans Affairs [Merit Review Grant #I01BX002619] and National Institutes of Health [R01NS064131]. N.L. is supported by a Career Development Award 2 from the Department of Veterans Affairs [#I01BX007080]. The authors thank other members of the Hegde laboratory for their assistance. NR 295 TC 1 Z9 1 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD OCT-NOV PY 2016 VL 145 BP 78 EP 97 DI 10.1016/j.pneurobio.2016.09.004 PG 20 WC Neurosciences SC Neurosciences & Neurology GA ED3WT UT WOS:000388779900004 PM 27693252 ER PT J AU Rosenheck, RA Leslie, DL Sint, KJ Lin, HQ Li, Y McEvoy, JP Byerly, MJ Hamer, RM Swartz, MS Stroup, TS AF Rosenheck, Robert A. Leslie, Douglas L. Sint, Kyaw J. Lin, Haiqun Li, Yue McEvoy, Joseph P. Byerly, Matthew J. Hamer, Robert M. Swartz, Marvin S. Stroup, T. Scott TI Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; SCHIZOAFFECTIVE DISORDER; ORAL ANTIPSYCHOTICS; RELAPSE PREVENTION; OPEN-LABEL; RISPERIDONE; 2ND-GENERATION; UNCERTAINTY; OLANZAPINE; FRAMEWORK AB Objective: This study assessed the relative cost-effectiveness of haloperidol decanoate (HD), a first-generation long-acting injectable (LAI) antipsychotic, and paliperidone palmitate (PP), a second-generation LAI antipsychotic. Methods: A double-blind, randomized 18-month clinical trial conducted at 22 clinical research sites in the United States compared the cost-effectiveness of HD and PP among 311 adults with schizophrenia or schizoaffective disorder who had been clinically assessed as likely to benefit from an LAI antipsychotic. Patients were randomly assigned to monthly intramuscular injections of HD (25-200 mg) or PP (39-234 mg) for up to 24 months. Quality-adjusted life years (QALYs) were measured by a schizophrenia-specific algorithm based on the Positive and Negative Syndrome Scale and side-effect assessments; total health care costs were assessed from the perspective of the health system. Results: Mixed-model analysis showed that PP was associated with .0297 greater QALYs over 18 months (p=.03) and with $ 2,100 more in average costs per quarter for inpatient and outpatient services and medication compared with HD (p<.001). Bootstrap analysis with 5,000 replications showed an incremental cost-effectiveness ratio for PP of $ 508,241 per QALY (95% confidence interval=$122,390-$1,582,711). Net health benefits analysis showed a .98 probability of greater cost-effectiveness for HD compared with PP at an estimated value of $ 150,000 per QALY and a .50 probability of greater cost-effectiveness at $ 500,000 per QALY. Conclusions: HD was more cost-effective than PP, suggesting that PP's slightly greater benefits did not justify its markedly higher costs, which are likely to fall once the medication's patent expires. C1 [Rosenheck, Robert A.] Yale Med Sch, Dept Psychiat, New Haven, CT 06510 USA. [Rosenheck, Robert A.] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. [Leslie, Douglas L.] Penn State Univ, Coll Med, Dept Publ Hlth Sci & Psychiat, Hershey, PA USA. [Sint, Kyaw J.; Lin, Haiqun; Li, Yue] Yale Sch Publ Hlth, New Haven, CT USA. [McEvoy, Joseph P.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Byerly, Matthew J.] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Hamer, Robert M.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA. [Swartz, Marvin S.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Stroup, T. Scott] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. RP Rosenheck, RA (reprint author), Yale Med Sch, Dept Psychiat, New Haven, CT 06510 USA.; Rosenheck, RA (reprint author), US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. EM robert.rosenheck@yale.edu FU National Institute of Mental Health (NIMH); NIMH; AstraZeneca; Janssen Pharmaceutica; Otsuka; Wyeth Pharmaceuticals; Alkermes, Inc.; Alkermes; Auspex; Avanir; BoehringerIngelheim; Eli Lilly; Forum; GlaxoSmithKline; Hoffman LaRoche; Merck; Sunovion; University of North Carolina; Abbott; Acadia; Allergan; Alpharma; Cenerx; Corcept; EnabledMD; Epix; Johnson and Johnson; Novartis; Pfizer; PureTech-Ventures; Sanofi-Aventis; Schwartz; Takeda; Wyeth; Eli Lilly and Co; Genentech; Auspex Pharmaceuticals FX The study was funded by grants from the National Institute of Mental Health (NIMH) to Dr. McEvoy and Dr. Stroup and is registered as clinical trial NCT01136772. NIMH grant funds paid for all study medications. The following investigators conducted the study: Lawrence Adler, M.D., Glen Burnie, Maryland; Peter Buckley, M.D., Augusta, Georgia; Matthew Byerly, M.D., Dallas; Stanley Caroff, M.D., Philadelphia; Cherilyn DeSouza, M.D., Kansas City, Missouri; Dale D'Mello, M.D., Lansing, Michigan; Deepak D'Souza, M.D., New Haven, Connecticut; Fred Jarskog, M.D., Chapel Hill, North Carolina; Venkata Jasty, M.D., Detroit; Eric Konicki, M.D., Cleveland; Matthew Macaluso, M.D., Wichita, Kansas; J. Steven Lamberti, M.D., Rochester, New York; Joshua Kantrowitz, M.D., New York; Joseph McEvoy, M.D., Butner, North Carolina; Del Miller, M.D., Iowa City, Iowa; Robert Millet, M.D., Durham, North Carolina; Max Schubert, M.D., Waco, Texas; Martin Strassnig, M.D., Miami; Sriram Ramaswamy, M.D., Omaha; Andre Tapp, M.D., Tacoma, Washington; and Sarah Yasmin, M.D., Palo Alto, California. NIMH had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; and in the preparation, review, or approval of the manuscript. The funder had no role in the decision to submit the manuscript for publication.; Dr. Rosenheck has received research support from or been a consultant to AstraZeneca, Janssen Pharmaceutica, Otsuka, and Wyeth Pharmaceuticals and was testifying expert in Jones ex rel the State of Texas v Janssen Phamaceutica et al. Dr. Leslie has received research grant funding from Alkermes, Inc. Dr. McEvoy receives speaking honoraria, consultation and honorarium fees for educational lectures, advisory fees, or research grants from Alkermes, Auspex, Avanir, BoehringerIngelheim, Eli Lilly, Forum, GlaxoSmithKline, Hoffman LaRoche, Merck, Otsuka, and Sunovion. Dr. Byerly reports receiving consulting fees and research support from Otsuka. Prior to his death, Dr. Hamer had received advisory or consulting fees from, served on a data and safety monitoring board and an advisory board for, or was involved in a contract by the University of North Carolina involving Abbott, Acadia, Allergan, Alpharma, AstraZeneca, Cenerx, Corcept, Eli Lilly, EnabledMD, Epix, Johnson and Johnson, Novartis, Pfizer, PureTech-Ventures, Sanofi-Aventis, Schwartz, Takeda, and Wyeth. Dr. Hamer also had served as an expert witness in lawsuits involving Anesta, Barr, Caraco, Cephalon, Eurand, Forest, Lundbeck, Mylan, Sun, and Teva. Dr. Swartz reports having received research funding from Eli Lilly and Co. Dr. Stroup has participated in continuing medical education activities funded by Genentech and is an investigator in a clinical trial sponsored by Auspex Pharmaceuticals. The other authors report no financial relationships with commercial interests. NR 37 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT 1 PY 2016 VL 67 IS 10 BP 1123 EP 1129 DI 10.1176/appi.ps.201500447 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EC6TC UT WOS:000388268600023 ER PT J AU Mounessa, J Qin, R Dunnick, CA Dellavalle, RP AF Mounessa, Jessica Qin, Rosie Dunnick, Cory A. Dellavalle, Robert P. TI Chemoprevention of Keratinocyte Carcinomas: An Updated Review SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY LA English DT Review ID NONMELANOMA SKIN-CANCER; RENAL-TRANSPLANT RECIPIENTS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; PHASE-I CHEMOPREVENTION; HUMAN ACTINIC KERATOSES; PERILLYL ALCOHOL CREAM; BASAL-CELL CARCINOMA; DNA-REPAIR ENZYMES; DOUBLE-BLIND AB A well-established link between ultraviolet exposure and the carcinogenesis of keratinocyte carcinomas exists. Despite increased sun protection efforts, skin cancer remains the most common cancer in the USA. Numerous studies on the topic of chemoprevention investigate alternative topical, oral, and injectable agents to reduce skin cancer incidence in those at risk. Such agents include sunscreen, numerous vitamins and minerals, difluoromethylornithine, non-steroidal anti-inflammatory drugs, various peptides, field therapy, statins, and polyphenols. In this focused review, we discuss the risks and benefits of chemoprotective agents reported in clinical studies conducted in humans. We report several agents that may reduce skin cancer incidence in those at risk. C1 [Mounessa, Jessica] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Mounessa, Jessica; Dunnick, Cory A.; Dellavalle, Robert P.] Univ Colorado Hosp, Dept Dermatol, Aurora, CO 80045 USA. [Qin, Rosie] Duke Univ, Sch Med, 8 Duke Univ Med Ctr Greenspace, Durham, NC USA. [Dunnick, Cory A.; Dellavalle, Robert P.] Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado Hosp, Dept Dermatol, Aurora, CO 80045 USA.; Dellavalle, RP (reprint author), Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. EM Robert.Dellavalle@ucdenver.edu NR 74 TC 0 Z9 0 U1 3 U2 3 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1175-0561 EI 1179-1888 J9 AM J CLIN DERMATOL JI Am. J. Clin. Dermatol. PD OCT PY 2016 VL 17 IS 5 BP 475 EP 484 DI 10.1007/s40257-016-0208-2 PG 10 WC Dermatology SC Dermatology GA EC0UZ UT WOS:000387818000005 PM 27372106 ER PT J AU Kass, JI Giraldez, L Gooding, W Choby, G Kim, S Miles, B Teng, M Sikora, AG Johnson, JT Myers, EN Duvvuri, U Genden, EM Ferris, RL AF Kass, Jason I. Giraldez, Laureano Gooding, William Choby, Garret Kim, Seungwon Miles, Brett Teng, Marita Sikora, Andrew G. Johnson, Jonas T. Myers, Eugene N. Duvvuri, Umamaheswar Genden, Eric M. Ferris, Robert L. TI Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE oropharyngeal squamous cell carcinoma; transoral robotic surgery; oncologic outcomes ID TRANSORAL ROBOTIC SURGERY; QUALITY-OF-LIFE; HUMAN-PAPILLOMAVIRUS; LASER-MICROSURGERY; CANCER; HEAD; CHEMORADIATION; RADIATION; SURVIVAL AB Background. The purpose of this study was to characterize oncologic outcomes in early (T1-T2, N0) and intermediate (T1-T2, N1) oropharyngeal squamous cell carcinoma (SCC) after surgery. Methods. Patients with oropharyngeal SCC treated with surgery were identified from 2 academic institutions. Results. Of 188 patients, 143 met the inclusion criteria. Eighty-six (60%) had T1 to T2 N0 and 57 (40%) had T1 to T2 N1 disease. Sixty-five patients (45%) underwent a robotic-assisted resection, whereas the remaining had transoral (n = 60; 42%), mandible-splitting (n = 11; 8%), or transhyoid approaches (n = 7; 5%). Human papillomavirus (HPV) status was known for 97 patients (68%), and 54 (55%) were HPV positive. Three-year recurrence-free survival (RFS) was 82% (95% confidence interval [CI] = 0.75-0.89). Since 2008, HPV infection was protective of recurrence (log-rank p =.0334). A single node did not increase the risk of recurrence (p =.467) or chance of a second primary (p =.175). Conclusion. Complete surgical resection is effective therapy for early and intermediate oropharyngeal SCC. HPV-negative patients were at increased risk for locoregional recurrence or second primary disease. (C) 2016 Wiley Periodicals, Inc. C1 [Kass, Jason I.; Choby, Garret; Kim, Seungwon; Johnson, Jonas T.; Myers, Eugene N.; Duvvuri, Umamaheswar; Ferris, Robert L.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. [Kass, Jason I.; Giraldez, Laureano; Miles, Brett; Teng, Marita; Genden, Eric M.] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA. [Gooding, William] Univ Pittsburgh, Inst Canc, Biostat Facil, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. [Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Ferris, RL (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. EM ferrisrl@upmc.edu FU University of Pittsburgh Cancer Institute Biostatistics Facility [P30CA047904] FX Contract grant sponsor: This project was conducted using the University of Pittsburgh Cancer Institute Biostatistics Facility that is supported in part by award P30CA047904. NR 25 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD OCT PY 2016 VL 38 IS 10 BP 1467 EP 1471 DI 10.1002/hed.24456 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC7JM UT WOS:000388313600008 PM 27080244 ER PT J AU Haun, JN Chavez, M Nazi, KM Antinori, N AF Haun, Jolie N. Chavez, Margeaux Nazi, Kim M. Antinori, Nicole TI Developing a Health Information Technology Systems Matrix: A Qualitative Participatory Approach SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE veterans; patient-centered care; information resources; patient preferences; integrated delivery system; health information technology ID RECOMMENDATIONS; ORGANIZATIONS AB Background: The US Department of Veterans Affairs (VA) has developed various health information technology (HIT) resources to provide accessible veteran-centered health care. Currently, the VA is undergoing a major reorganization of VA HIT to develop a fully integrated system to meet consumer needs. Although extensive system documentation exists for various VA HIT systems, a more centralized and integrated perspective with clear documentation is needed in order to support effective analysis, strategy, planning, and use. Such a tool would enable a novel view of what is currently available and support identifying and effectively capturing the consumer's vision for the future. Objective: The objective of this study was to develop the VA HIT Systems Matrix, a novel tool designed to describe the existing VA HIT system and identify consumers' vision for the future of an integrated VA HIT system. Methods: This study utilized an expert panel and veteran informant focus groups with self-administered surveys. The study employed participatory research methods to define the current system and understand how stakeholders and veterans envision the future of VA HIT and interface design (eg, look, feel, and function). Directed content analysis was used to analyze focus group data. Results: The HIT Systems Matrix was developed with input from 47 veterans, an informal caregiver, and an expert panel to provide a descriptive inventory of existing and emerging VA HIT in four worksheets: (1) access and function, (2) benefits and barriers, (3) system preferences, and (4) tasks. Within each worksheet is a two-axis inventory. The VA's existing and emerging HIT platforms (eg, My HealtheVet, Mobile Health, VetLink Kiosks, Telehealth), My HealtheVet features (eg, Blue Button, secure messaging, appointment reminders, prescription refill, vet library, spotlight, vitals tracker), and non-VA platforms (eg, phone/mobile phone, texting, non-VA mobile apps, non-VA mobile electronic devices, non-VA websites) are organized by row. Columns are titled with thematic and functional domains (eg, access, function, benefits, barriers, authentication, delegation, user tasks). Cells for each sheet include descriptions and details that reflect factors relevant to domains and the topic of each worksheet. Conclusions: This study provides documentation of the current VA HIT system and efforts for consumers' vision of an integrated system redesign. The HIT Systems Matrix provides a consumer preference blueprint to inform the current VA HIT system and the vision for future development to integrate electronic resources within VA and beyond with non-VA resources. The data presented in the HIT Systems Matrix are relevant for VA administrators and developers as well as other large health care organizations seeking to document and organize their consumer-facing HIT resources. C1 [Haun, Jolie N.; Chavez, Margeaux; Antinori, Nicole] US Dept Vet Affairs, HSR&D Ctr Innovat Disabil & Rehabil Res, James A Haley VA Hosp, 8900 Grand Oak Circle,118M, Tampa, FL 33637 USA. [Haun, Jolie N.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. [Nazi, Kim M.] Dept Vet Affairs, Vet Hlth Adm, Vet & Consumers Hlth Informat Off, Albany, NY USA. RP Haun, JN (reprint author), US Dept Vet Affairs, HSR&D Ctr Innovat Disabil & Rehabil Res, James A Haley VA Hosp, 8900 Grand Oak Circle,118M, Tampa, FL 33637 USA. EM joliehaun@gmail.com OI Nazi, Kim/0000-0002-0966-5602 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service; National eHealth Quality Enhancement Research Initiative (QUERI) Coordinating Center [RRP 12-495]; Center of Innovation for Disability and Rehabilitation Research at the James A. Haley Veterans Hospital FX The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service, and National eHealth Quality Enhancement Research Initiative (QUERI) Coordinating Center (RRP 12-495) supported this study. This study was also supported in part by the Center of Innovation for Disability and Rehabilitation Research at the James A. Haley Veterans Hospital. The contents of this paper do not represent the views of the Department of Veterans Affairs or the US Government. The authors would like to acknowledge the efforts of the VA Human Factors team, including Nancy Wilck, Abigail Noonan, and Ashley Cook, for their significant contribution to the success of this project. We would also like to thank Susan Woods and Jeffrey Sartori for their generosity of time and consultation throughout the conceptualization and implementation of this project. NR 13 TC 0 Z9 0 U1 2 U2 2 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD OCT PY 2016 VL 18 IS 10 BP 111 EP 119 AR e266 DI 10.2196/jmir.6499 PG 9 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA EC2WT UT WOS:000387985700009 PM 27713112 ER PT J AU Mason, MC Garcia, JM Sansgiry, S Walder, A Berger, DH Anaya, DA AF Mason, Meredith C. Garcia, Jose M. Sansgiry, Shubhada Walder, Annette Berger, David H. Anaya, Daniel A. TI Preoperative cancer cachexia and short-term outcomes following surgery SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Cachexia; Postoperative complications; Surgical oncology; BMI ID QUALITY-OF-LIFE; WEIGHT-LOSS; COLORECTAL-CANCER; SURGICAL COMPLICATIONS; DOUBLE-BLIND; SURVIVAL; CHEMOTHERAPY; ASSOCIATION; DEFINITION; MECHANISMS AB Background: Cancer cachexia is an important measure of physiologic reserve associated with worse survival and represents an actionable factor for the cancer population. However, the incidence of cachexia in surgical cancer patients and its impact on postoperative outcomes are currently unknown. Methods: A prospective cohort study enrolling patients having elective cancer surgery (2012-2014) at a Veterans Affairs tertiary referral center. Preoperative cancer cachexia (weight loss >= 5% over 6-mo period before surgery) was the predictor of interest. The primary outcome was 60-d postoperative complications (VA Surgical Quality Improvement Program). Patients were grouped by body mass index (BMI) category (< 25, 25-29.9, >= 30), and interaction between cachexia and BMI was tested for the primary outcome. Multivariate logistic regression was used to examine the association between preoperative cachexia and postoperative complications. Results: Of 253 patients, 16.6% had preoperative cachexia, and 51.8% developed >= 1 postoperative complications. Complications were more common in cachectic patients (64.3% versus 49.3%, P = 0.07). This association varied by BMI category, and interaction analysis was significant for those with normal or underweight BMI (BMI < 25, P = 0.03). After multivariate modeling, in patients with normal or underweight BMI, preoperative cachexia was associated with higher odds of postoperative complications (odds ratios, 5.08 [95% confidence intervals, 1.18-21.88]; P = 0.029). Additional predictors of complications included major surgery (3.19 [1.24-8.21], P = 0.01), ostomy (4.43 [1.68-11.72], P = 0.003), and poor baseline performance status (2.31 [1.05-5.08], P = 0.03). Conclusions: Cancer cachexia is common in surgical patients, and is an important predictor of postoperative complications, though its effect varies by BMI. As a modifiable predictor of worse outcomes, future studies should examine the role of cachexia treatment before cancer surgery. (C) 2016 Elsevier Inc. All rights reserved. C1 [Mason, Meredith C.; Sansgiry, Shubhada; Walder, Annette; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston VA Ctr Innovat Qual Effectiveness & Safet, Dept Med, Houston, TX USA. [Mason, Meredith C.; Berger, David H.; Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Med, Seattle, WA USA. [Garcia, Jose M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Dept Med, Houston, TX USA. [Garcia, Jose M.] Baylor Coll Med, Houston, TX 77030 USA. [Anaya, Daniel A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA. RP Anaya, DA (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Sect Hepatobiliary Tumors, Dept Gastrointestinal Oncol, 12902 Magnolia Dr FOB2, Tampa, FL 33612 USA. EM Daniel.Anaya@moffitt.org FU Conquer Cancer Foundation of ASCO Career Development Award; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (MERIT grant) [BX000507, CX000174]; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This work was funded by a Conquer Cancer Foundation of ASCO Career Development Award (D.A.A.). This material is also based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (MERIT grants BX000507 and CX000174 to J.M.G.), and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, Baylor College of Medicine, American Society of Clinical Oncology or the Conquer Cancer Foundation. This source had no role in the preparation, review, or approval of the manuscript. NR 33 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2016 VL 205 IS 2 BP 398 EP 406 DI 10.1016/j.jss.2016.06.076 PG 9 WC Surgery SC Surgery GA EC2VG UT WOS:000387981700019 PM 27664889 ER PT J AU Dunlay, SM Strand, JJ Wordingham, SE Stulak, JM Luckhardt, AJ Swetz, KM AF Dunlay, Shannon M. Strand, Jacob J. Wordingham, Sara E. Stulak, John M. Luckhardt, Angela J. Swetz, Keith M. TI Dying With a Left Ventricular Assist Device as Destination Therapy SO CIRCULATION-HEART FAILURE LA English DT Article DE end-of-life care; heart failure; left ventricular assist device; morbidity; mortality ID OF-LIFE CARE; HEART-FAILURE; MEDICARE BENEFICIARIES; END; OUTCOMES; PLACE; PERSPECTIVES; IMPLANTATION; SUPPORT; HEALTH AB Background Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care. C1 [Dunlay, Shannon M.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN 55905 USA. [Dunlay, Shannon M.] Mayo Clin, Div Hlth Care Policy & Res, Dept Hlth Sci Res, Rochester, MN 55905 USA. [Strand, Jacob J.] Mayo Clin, Div Gen Internal Med, Dept Med, Rochester, MN 55905 USA. [Stulak, John M.; Luckhardt, Angela J.] Mayo Clin, Dept Surg, Div Cardiovasc Surg, Rochester, MN 55905 USA. [Wordingham, Sara E.] Mayo Clin, Dept Internal Med, Div Hematol & Med Oncol, Phoenix, AZ USA. [Swetz, Keith M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Dunlay, SM (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA. EM dunlay.shannon@mayo.edu FU National Institutes of Health (NIH) [K23 HL116643] FX Dr Dunlay is supported by a National Institutes of Health (NIH) Career Development Award (K23 HL116643). NR 21 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD OCT PY 2016 VL 9 IS 10 AR e003096 DI 10.1161/CIRCHEARTFAILURE.116.003096 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA8SW UT WOS:000386909900003 ER PT J AU Lambert, LJ Challa, AK Niu, AD Zhou, LH Tucholski, J Johnson, MS Nagy, TR Eberhardt, AW Estep, PN Kesterson, RA Grams, JM AF Lambert, Laura J. Challa, Anil K. Niu, Aidi Zhou, Lihua Tucholski, Janusz Johnson, Maria S. Nagy, Tim R. Eberhardt, Alan W. Estep, Patrick N. Kesterson, Robert A. Grams, Jayleen M. TI Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology SO DISEASE MODELS & MECHANISMS LA English DT Article DE Osteocalcin; Bone strength; Bone structure; Genetic animal models; Osteocalcin knockout ID CLEIDOCRANIAL DYSPLASIA; GENE; INHIBITION; EXPRESSION; DIFFERENTIATION; OSTEOPOROSIS; ADIPONECTIN; PROMOTER; PROTEIN; SYSTEM AB Osteocalcin, also known as bone gamma-carboxyglutamate protein (Bglap), is expressed by osteoblasts and is commonly used as a clinical marker of bone turnover. A mouse model of osteocalcin deficiency has implicated osteocalcin as a mediator of changes to the skeleton, endocrine system, reproductive organs and central nervous system. However, differences between mouse and human osteocalcin at both the genome and protein levels have challenged the validity of extrapolating findings from the osteocalcin-deficient mouse model to human disease. The rat osteocalcin (Bglap) gene locus shares greater synteny with that of humans. To further examine the role of osteocalcin in disease, we created a rat model with complete loss of osteocalcin using the CRISPR/Cas9 system. Rat osteocalcin was modified by injection of CRISPR/Cas9 mRNA into the pronuclei of fertilized single cell Sprague-Dawley embryos, and animals were bred to homozygosity and compound heterozygosity for the mutant alleles. Dual-energy X-ray absorptiometry (DXA), glucose tolerance testing (GTT), insulin tolerance testing (ITT), microcomputed tomography (mu CT), and a three-point break biomechanical assay were performed on the excised femurs at 5 months of age. Complete loss of osteocalcin resulted in bones with significantly increased trabecular thickness, density and volume. Cortical bone volume and density were not increased in null animals. The bones had improved functional quality as evidenced by an increase in failure load during the biomechanical stress assay. Differences in glucose homeostasis were observed between groups, but there were no differences in body weight or composition. This rat model of complete loss of osteocalcin provides a platform for further understanding the role of osteocalcin in disease, and it is a novel model of increased bone formation with potential utility in osteoporosis and osteoarthritis research. C1 [Lambert, Laura J.; Challa, Anil K.; Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Niu, Aidi; Zhou, Lihua; Tucholski, Janusz; Grams, Jayleen M.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Johnson, Maria S.; Nagy, Tim R.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Eberhardt, Alan W.; Estep, Patrick N.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. [Grams, Jayleen M.] Birmingham VA Med Ctr, Dept Surg, Birmingham, AL 35233 USA. RP Grams, JM (reprint author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.; Grams, JM (reprint author), Birmingham VA Med Ctr, Dept Surg, Birmingham, AL 35233 USA. EM jgrams@uab.edu FU Society for Surgery of the Alimentary Tract; Society of University Surgeons Foundation; University of Alabama at Birmingham (UAB) Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center; Department of Surgery; Department of Genetics; National Institutes of Health [P30CA13148, P30AR048311, P30DK074038, P30DK05336, P60DK079626]; National Institutes of Health Nutrition and Obesity Research Center [P30DK056336]; Diabetes Research Center [P30DK079626] FX This work was supported by the Society for Surgery of the Alimentary Tract; the Society of University Surgeons Foundation; and the University of Alabama at Birmingham (UAB) Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center, the Department of Surgery, and Department of Genetics. Services obtained from the UAB Transgenic and Genetically Engineered Model Systems Core Facility (R.A.K.) in this publication are supported by awards from the National Institutes of Health [grant numbers P30CA13148, P30AR048311, P30DK074038, P30DK05336, P60DK079626]. Services obtained from the UAB Small Animal Phenotyping Core (M.S.J. and T.R.N.) are supported by the National Institutes of Health Nutrition and Obesity Research Center [grant number P30DK056336] and the Diabetes Research Center [grant number P30DK079626]. NR 38 TC 4 Z9 4 U1 3 U2 3 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 1754-8403 EI 1754-8411 J9 DIS MODEL MECH JI Dis. Model. Mech. PD OCT 1 PY 2016 VL 9 IS 10 BP 1169 EP 1179 DI 10.1242/dmm.025247 PG 11 WC Cell Biology; Pathology SC Cell Biology; Pathology GA EB7OX UT WOS:000387579100011 PM 27483347 ER PT J AU Antonini, A Chaudhuri, KR Boroojerdi, B Asgharnejad, M Bauer, L Grieger, F Weintraub, D AF Antonini, A. Chaudhuri, K. R. Boroojerdi, B. Asgharnejad, M. Bauer, L. Grieger, F. Weintraub, D. TI Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE clinical trial; dopamine agonists; impulse control disorders; long-term treatment; Parkinson's disease; rotigotine transdermal patch ID PARKINSONS-DISEASE PATIENTS; RESTLESS LEGS SYNDROME; OPEN-LABEL EXTENSION; TRANSDERMAL SYSTEM; DOPAMINE AGONISTS; SYMPTOMS; TOLERABILITY; ASSOCIATION; MULTICENTER; PREVALENCE AB Background and purpose: Dopamine agonists in Parkinson's disease (PD) are associated with impulse control disorders (ICDs) and other compulsive behaviours (together called ICD behaviours). The frequency of ICD behaviours reported as adverse events (AEs) in long-term studies of rotigotine transdermal patch in PD was evaluated. Methods: This was a post hoc analysis of six open-label extension studies up to 6 years in duration. Analyses included patients treated with rotigotine for at least 6 months and administered the modified Minnesota Impulse Disorders Interview. ICD behaviours reported as AEs were identified and categorized. Results: For 786 patients, the mean (+/- SD) exposure to rotigotine was 49.4 +/- 17.6 months. 71 (9.0%) patients reported 106 ICD AEs cumulatively. Occurrence was similar across categories: 2.5% patients reported 'compulsive sexual behaviour', 2.3% 'buying disorder', 2.0% 'compulsive gambling', 1.7% 'compulsive eating' and 1.7% 'punding behaviour'. Examining at 6-month intervals, the incidence was relatively low during the first 30 months; it was higher over the next 30 months, peaking in the 54-60-month period. No ICD AEs were serious, and 97% were mild or moderate in intensity. Study discontinuation occurred in seven (9.9%) patients with ICD AEs; these then resolved in five patients. Dose reduction occurred for 23 AEs, with the majority (73.9%) resolving. Conclusions: In this analysis of >750 patients with PD treated with rotigotine, the frequency of ICD behaviour AEs was 9.0%, with a specific incidence time-line observed. Active surveillance as duration of treatment increases may help early identification and management; once ICD behaviours are present rotigotine dose reduction may be considered. C1 [Antonini, A.] IRCCS Hosp San Camillo, Parkinson Unit, Venice, Italy. [Chaudhuri, K. R.] Kings Coll Hosp London, Kings Coll, Natl Parkinson Fdn Int Ctr Excellence, London, England. [Boroojerdi, B.; Bauer, L.; Grieger, F.] UCB Pharma, Monheim, Germany. [Asgharnejad, M.] UCB Pharma, Raleigh, NC USA. [Weintraub, D.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, D.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Antonini, A (reprint author), IRCCS Hosp San Camillo, Parkinson Unit, Venice, Italy. EM angelo3000@yahoo.com FU UCB Pharma, Brussels, Belgium; UCB Pharma, Monheim am Rhein, Germany FX The authors thank the patients and their caregivers in addition to the investigators and their teams who contributed to the studies included in these analyses. The authors also acknowledge Emily Thompson, PhD, CMPP (Evidence Scientific Solutions, London, UK), for writing assistance which was funded by UCB Pharma, Brussels, Belgium; Cedric Laloyaux, PhD, CMPP (Strategic Publication Lead Neurology, UCB Pharma, Brussels, Belgium), for publication coordination; Elisabeth Dohin, MD (UCB Pharma, Brussels, Belgium), for scientific and medical input into the data analyses and interpretation; and Marc Derycke, MSc (UCB Pharma, Monheim am Rhein, Germany), for his contributions to the specifications and programming of the post hoc analyses. This post hoc analysis was supported by UCB Pharma, Monheim am Rhein, Germany. NR 32 TC 2 Z9 2 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD OCT PY 2016 VL 23 IS 10 BP 1556 EP 1565 DI 10.1111/ene.13078 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB4SR UT WOS:000387364300011 PM 27425586 ER PT J AU Kerlikowske, K Vachon, CM AF Kerlikowske, Karla Vachon, Celine M. TI Breast Density: More Than Meets the Eye SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID MAMMOGRAPHIC DENSITY; CANCER RISK; WOMEN; MODEL C1 [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Vachon, Celine M.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu NR 18 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD OCT PY 2016 VL 108 IS 10 AR djw128 DI 10.1093/jnci/djw128 PG 2 WC Oncology SC Oncology GA EA9FN UT WOS:000386947400012 ER PT J AU Seymann, GB Southern, W Burger, A Brotman, DJ Chakraborti, C Harrison, R Parekh, V Sharpe, BA Pile, J Hunt, D Leykum, LK AF Seymann, Gregory B. Southern, William Burger, Alfred Brotman, Daniel J. Chakraborti, Chayan Harrison, Rebecca Parekh, Vikas Sharpe, Bradley A. Pile, James Hunt, Daniel Leykum, Luci K. TI Features of Successful Academic Hospitalist Programs: Insights from the SCHOLAR (SuCcessful HOspitaLists in Academics and Research) Project SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID MEDICINE; MENTORSHIP; CARE AB BACKGROUND: As clinical demands increase, understanding the features that allow academic hospital medicine programs (AHPs) to thrive has become increasingly important. OBJECTIVE: To develop and validate a quantifiable definition of academic success for AHPs. METHODS: A working group of academic hospitalists was formed. The group identified grant funding, academic promotion, and scholarship as key domains reflective of success, and specific metrics and approaches to assess these domains were developed. Self-reported data on funding and promotion were available from a preexisting survey of AHP leaders, including total funding/group, funding/fulltime equivalent (FTE), and number of faculty at each academic rank. Scholarship was defined in terms of research abstracts presented over a 2-year period. Lists of top performers in each of the 3 domains were constructed. Programs appearing on at least 1 list (the SCHOLAR cohort [SuCcessful HOspitaLists in Academics and Research]) were examined. We compared grant funding and proportion of promoted faculty within the SCHOLAR cohort to a sample of other AHPs identified in the preexisting survey. RESULTS: Seventeen SCHOLAR programs were identified, with a mean age of 13.2 years (range, 6-18 years) and mean size of 36 faculty (range, 18-95). The mean total grant funding/program was $4 million (range, $0-$15 million), with mean funding/FTE of $364,000 (range, $0-$1.4 million); both were significantly higher than the comparison sample. The majority of SCHOLAR faculty (82%) were junior, a lower percentage than the comparison sample. The mean number of research abstracts presented over 2 years was 10.8 (range, 9-23). DISCUSSION: Our approach effectively identified a subset of successful AHPs. Despite the relative maturity and large size of the programs in the SCHOLAR cohort, they were comprised of relatively few senior faculty members and varied widely in the quantity of funded research and scholarship. (C) 2016 Society of Hospital Medicine C1 [Seymann, Gregory B.] Univ Calif San Diego, Dept Med, Div Hosp Med, 200 W Arbor Dr, San Diego, CA 92103 USA. [Southern, William] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Burger, Alfred] Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel, Dept Med, Div Hosp Med, New York, NY 10029 USA. [Brotman, Daniel J.] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA. [Chakraborti, Chayan] Tulane Univ, Dept Med, New Orleans, LA 70118 USA. [Harrison, Rebecca] Oregon Hlth & Sci Univ, Dept Hosp Med, Portland, OR 97201 USA. [Parekh, Vikas] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Sharpe, Bradley A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Pile, James] Cleveland Clin, Inst Med, Dept Hosp Med, Cleveland, OH 44106 USA. [Hunt, Daniel] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Leykum, Luci K.] UT Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. RP Seymann, GB (reprint author), Univ Calif San Diego, 200 W Arbor Dr, San Diego, CA 92103 USA. EM gseymann@ucsd.edu FU Society of Hospital Medicine; Society of General Internal Medicine; SHM Academic Committee; SGIM Academic Hospitalist Task Force FX The authors thank all of the AHP leaders who participated in the SCHOLAR project. They also thank the Society of Hospital Medicine and Society of General Internal Medicine and the SHM Academic Committee and SGIM Academic Hospitalist Task Force for their support of this work. NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD OCT PY 2016 VL 11 IS 10 BP 708 EP 713 DI 10.1002/jhm.2603 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EB0ZE UT WOS:000387074700007 PM 27189874 ER PT J AU Walling, AM Tisnado, D Ettner, SL Asch, SM Dy, SM Pantoja, P Lee, M Ahluwalia, SC Schreibeis-Baum, H Malin, JL Lorenz, KA AF Walling, Anne M. Tisnado, Diana Ettner, Susan L. Asch, Steven M. Dy, Sydney M. Pantoja, Philip Lee, Martin Ahluwalia, Sangeeta C. Schreibeis-Baum, Hannah Malin, Jennifer L. Lorenz, Karl A. TI Palliative Care Specialist Consultation Is Associated With Supportive Care Quality in Advanced Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Advanced cancer; quality; palliative care ID CELL LUNG-CANCER; RANDOMIZED CONTROLLED-TRIAL; OF-LIFE DISCUSSIONS; OLDER PATIENTS; HEALTH-CARE; INSTRUMENTAL VARIABLES; PRIVATE-SECTOR; END; OUTCOMES; PREDICTORS AB Context. Although recent randomized controlled trials support early palliative care for patients with advanced cancer, the specific processes of care associated with these findings and whether these improvements can be replicated in the broader health care system are uncertain. Objectives. The aim of this study was to evaluate the occurrence of palliative care consultation and its association with specific processes of supportive care in a national cohort of Veterans using the Cancer Quality ASSIST (Assessing Symptoms Side Effects and Indicators of Supportive Treatment) measures. Methods. We abstracted data from 719 patients' medical records diagnosed with advanced lung, colorectal, or pancreatic cancer in 2008 over a period of three years or until death who received care in the Veterans Affairs Health System to evaluate the association of palliative care specialty consultation with the quality of supportive care overall and by domain using a multivariate regression model. Results. All but 54 of 719 patients died within three years and 293 received at least one palliative care consult. Patients evaluated by a palliative care specialist at diagnosis scored seven percentage points higher overall (P < 0.001) and 11 percentage points higher (P < 0.001) within the information and care planning domain compared with those without a consult. Conclusion. Early palliative care specialist consultation is associated with better quality of supportive care in three advanced cancers, predominantly driven by improvements in information and care planning. This study supports the effectiveness of early palliative care consultation in three common advanced cancers within the Veterans Affairs Health System and provides a greater understanding of what care processes palliative care teams influence. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Walling, Anne M.; Tisnado, Diana; Lee, Martin; Schreibeis-Baum, Hannah; Malin, Jennifer L.; Lorenz, Karl A.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.; Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Walling, Anne M.; Ahluwalia, Sangeeta C.] RAND Hlth, Santa Monica, CA USA. [Pantoja, Philip] RAND Populat & Labor, Santa Monica, CA USA. [Tisnado, Diana] Calif State Univ Fullerton, Dept Hlth Sci, Fullerton, CA 92634 USA. [Ettner, Susan L.; Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Asch, Steven M.; Lorenz, Karl A.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Sch Med, Stanford, CA USA. [Dy, Sydney M.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. RP Walling, AM (reprint author), VA Greater Los Angeles Healthcare Syst, 911 Broxton Ave, Los Angeles, CA 90095 USA. EM awalling@mednet.ucla.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IIR 09-097]; National Institutes of Health (NIH)/National Center for Advancing Translational Science UCLA CTSI grant [UL1TR000124]; NIH Loan Repayment Program FX This article is based on work supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (Project # IIR 09-097). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. Since July 2013, Dr. Walling has also been supported by the National Institutes of Health (NIH)/National Center for Advancing Translational Science UCLA CTSI grant (UL1TR000124) and the NIH Loan Repayment Program. The funding source had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Drs Walling, Tisnado, Ettner, Asch, Dy, Lee, Ahluwalia, Schreibeis-Baum, and Pantoja do not have any relevant financial interests, activities, or relationships within the past three years to report. Dr. Malin is employed by and has stock ownership with Anthem. Dr. Lorenz is serving as a consultant to Otsuka Pharmaceuticals for data monitoring and safety in the evaluation of a Phase II trial of Sativex, a novel cannabinoid analgesic. NR 38 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2016 VL 52 IS 4 BP 507 EP 514 DI 10.1016/j.jpainsymman.2016.04.005 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EA7RZ UT WOS:000386830900007 PM 27401515 ER PT J AU Ritchie, CS Kelley, AS Cenzer, IS Smith, AK Wallhagen, ML Covinsky, KE AF Ritchie, Christine S. Kelley, Amy S. Cenzer, Irena Stijacic Smith, Alexander K. Wallhagen, Margaret L. Covinsky, Kenneth E. TI High Levels of Geriatric Palliative Care Needs in Hip Fracture Patients Before the Hip Fracture SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hip fracture; geriatric palliative care; multimorbidity ID OLDER-ADULTS; MORTALITY; VALIDATION; PATTERNS; INDEX AB Context. Most hip fracture care models are grounded in curative models where the goal is to return the patient to independent function. In many instances, however, hip fractures contribute to continued functional decline and mortality. Although the negative impact of hip fractures is appreciated once they have occurred, what is less understood is what proportion of older adults have high illness burden before experiencing hip fracture and might benefit from geriatric palliative care. Objectives. Using data from the Health and Retirement Study linked to Medicare claims (January 1992 through December 2010), we sought to understand the extent of premorbid illness burden before hip fracture. Methods. Characteristics were based on the interview before hip fracture. Features used to indicate need for geriatric palliative care included evidence of functional and medical vulnerability, pain, and depression. Results. Eight hundred fifty-six older adults who experienced a hip fracture were compared to 851 age-, gender-, and race-matched controls. Older adults with hip fractures had significantly more premorbid functional vulnerability (activities of daily living dependent 25.7% vs. 16.1% [P < 0.001]; dementia 16.2% vs. 7.3% (P < 0.001); use of helpers 41.2% vs. 28.7% [P < 0.001]). They also experienced more medical vulnerability (multimorbidity 43% vs. 29.8% [P < 0.001]; high health care utilization 30.0% vs. 20.9% [P < 0.001]; and poor prognosis 36.1% vs. 25.4% [P < 0.001] in controls). There was no difference in premorbid pain and depression between subsequent hip fracture patients and controls. Conclusions. A significant proportion of older adults have evidence of functional and medical vulnerability before hip fracture. For these individuals, integration of geriatric palliative care may be particularly important for optimizing quality of life and addressing the high morbidity experienced by this population. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Ritchie, Christine S.; Cenzer, Irena Stijacic; Smith, Alexander K.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Cenzer, Irena Stijacic; Smith, Alexander K.; Covinsky, Kenneth E.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Kelley, Amy S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Kelley, Amy S.] James J Peters VA Med Ctr, Bronx, NY USA. [Wallhagen, Margaret L.] UCSF, Dept Physiol Nursing, San Francisco, CA USA. [Ritchie, Christine S.] Jewish Home San Francisco Ctr Res Aging, San Francisco, CA USA. RP Ritchie, CS (reprint author), Univ Calif San Francisco, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM Christine.Ritchie@ucsf.edu FU National Institute for Nursing Research [R01 NR013347]; K07 Geriatric Academic Leadership Award from the National Institute on Aging [1K07AG31779-1A1]; K23 Beeson award from the National Institute on Aging [1K23AG040772, 1K23AG040774]; American Federation for Aging Research FX This project was funded by the National Institute for Nursing Research (R01 NR013347). Dr. Bitchier was funded by a K07 Geriatric Academic Leadership Award from the National Institute on Aging (1K07AG31779-1A1) and Dr. Smith was funded by a K23 Beeson award from the National Institute on Aging (1K23AG040772) and the American Federation for Aging Research. Dr. Kelley was funded by a K23 Beeson award from the National Institute on Aging (1K23AG040774) and the American Federation for Aging Research. NR 19 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2016 VL 52 IS 4 BP 533 EP 538 DI 10.1016/j.jpainsymman.2016.07.003 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EA7RZ UT WOS:000386830900010 PM 27521282 ER PT J AU Kale, MS Ornstein, KA Smith, CB Kelley, AS AF Kale, Minal S. Ornstein, Katherine A. Smith, Cardinale B. Kelley, Amy S. TI End-of-Life Discussions with Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE end-of-life care preparation; Medicare; discussion ID ADVANCE DIRECTIVES; HEALTH-CARE; MULTIMORBIDITY; OUTCOMES; FRAILTY; IMPACT; RACE AB ObjectivesTo determine the prevalence of end-of-life (EOL) conversations with older adults. DesignNational Health and Aging Trends Study (NHATS), a prospective, longitudinal survey of Medicare beneficiaries. SettingNationally representative. ParticipantsA sample drawn from Wave 2 of the NHATS. MeasurementsThe main outcome was the report of an EOL planning discussion, based upon the participant's response to the question Have you talked to anyone about the types of medical treatment you would want or not want if you became seriously ill in the future? ResultsSixty-one percent of the sample (n = 1,993 individuals, weighted n = 11,123,910) responded that they had discussed EOL treatment preferences with someone. In multivariate regression, factors associated with reporting an EOL discussion included being younger (adjusted odds ratio (AOR) = 1.70, 95% confidence interval (CI) = 1.17-2.47), having more education (high school degree: AOR = 1.45, 95% CI = 1.02-2.07; some college: AOR = 2.03, 95% CI = 1.40-2.95), and having multiple chronic conditions (AOR = 1.25, 95% CI = 1.01-1.55). Black race was associated with lower odds of reporting a discussion (AOR = 0.46, 95% CI = 0.33-0.65). ConclusionForty percent of a nationally representative sample of Medicare beneficiaries had not discussed their preferences regarding EOL medical treatment. Promoting these conversations in clinical and nonclinical settings will be important to ensure that health care is delivered to individuals in a person-centered manner. C1 [Kale, Minal S.; Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA. [Ornstein, Katherine A.; Smith, Cardinale B.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Smith, Cardinale B.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA. [Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Kale, MS (reprint author), Icahn Sch Med Mt Sinai, Div Gen Internal Med, One Gustave Levy Pl,Box 1087, New York, NY 10029 USA. EM minal.kale@mountsinai.org FU National Cancer Institute [K07 CA187071]; National Institute on Aging [K01AG047923]; K23 Beeson award from the National Institute on Aging [1K23AG040774]; American Federation for Aging Research FX Dr. Kale was supported with a grant from the National Cancer Institute (K07 CA187071) during the preparation of this manuscript. Dr. Ornstein was funded by a grant from the National Institute on Aging (K01AG047923). Dr. Kelley was funded by a K23 Beeson award from the National Institute on Aging (1K23AG040774) and the American Federation for Aging Research. NR 27 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2016 VL 64 IS 10 BP 1962 EP 1967 DI 10.1111/jgs.14285 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FJ UT WOS:000387018500034 PM 27549494 ER PT J AU Smith, AK Currow, DC Abernethy, AP Johnson, MJ Miao, YH Boscardin, WJ Ritchie, CS AF Smith, Alexander K. Currow, David C. Abernethy, Amy P. Johnson, Miriam J. Miao, Yinghui Boscardin, W. John Ritchie, Christine S. TI Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE breathlessness; older; decline ID OBSTRUCTIVE PULMONARY-DISEASE; DYSPNEA; MANAGEMENT; MECHANISMS; ILLNESS; CANCER; TRIAL AB ObjectivesTo determine the prevalence and outcomes of breathlessness in older Americans. SettingCommunity-dwelling older adults. ParticipantsIndividuals aged 70 and older in the nationally representative Health and Retirement Study (2008, follow-up through 2012) (N = 3,671; mean age 78). MeasurementsBreathlessness was assessed by asking the question, How often do you become short of breath while awake? Responses of often or sometimes were considered to represent a level of breathlessness sufficient to warrant clinical attention. The prevalence of breathlessness is described overall and in subpopulations, then rates of associated symptoms, well-being, and health services use of participants who were breathless are compared with rates of those who were not. The risk of decline in activities of daily living (ADLs) and death through 2012 was estimated by creating a multivariable Cox proportional hazards model, adjusting for age, sex, race and ethnicity, and education. ResultsTwenty-five percent of participants reported breathlessness. The prevalence of breathlessness was higher in certain subpopulations: chronic lung disease (63%), multimorbidity (2 chronic conditions) (45%), current smokers (38%), heart disease (36%), obesity (body mass index 30.0 kg/m(2)) (33%), and education less than high school (32%). Breathlessness was associated with higher rates of depression, anxiety, and severe fatigue; lower ratings of well-being; and higher rates of clinic and emergency department visits and hospitalizations (all P < .001). Breathlessness predicted ADL decline over 5 years (adjusted hazard ratio (aHR) = 1.43, 95% confidence interval (CI) = 1.22-1.68) and death (aHR 1.62, 95% CI = 1.32-2.02). ConclusionOne in four adults aged 70 and older in the United States experiences breathlessness, which is associated with lack of well-being, greater health services use, and a 40% greater risk of worsened function and 60% greater risk of death over the next 5 years. C1 [Smith, Alexander K.; Miao, Yinghui; Boscardin, W. John; Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Smith, Alexander K.; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA USA. [Currow, David C.; Miao, Yinghui] Flinders Univ S Australia, Discipline Support & Palliat Care, Bedford Pk, SA, Australia. [Abernethy, Amy P.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Abernethy, Amy P.] Duke Univ, Dept Med, Div Med Oncol, Durham, NC USA. [Johnson, Miriam J.] Univ Hull, Hull York Med Sch, Kingston Upon Hull, East Yorkshire, England. [Ritchie, Christine S.] Jewish Home San Francisco, San Francisco, CA USA. RP Smith, AK (reprint author), UCSF Div Geriatr, Med, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu OI Currow, David/0000-0003-1988-1250 FU National Institute on Aging [K23AG040772]; American Federation for Aging Research FX Dr. Smith was funded by a K23 Beeson award from the National Institute on Aging (K23AG040772) and the American Federation for Aging Research. NR 25 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2016 VL 64 IS 10 BP 2035 EP 2041 DI 10.1111/jgs.14313 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FJ UT WOS:000387018500044 PM 27603500 ER PT J AU King, BJ Steege, LM Winsor, K VanDenbergh, S Brown, CJ AF King, Barbara J. Steege, Linsey M. Winsor, Katie VanDenbergh, Shelly Brown, Cynthia J. TI Getting Patients Walking: A Pilot Study of Mobilizing Older Adult Patients via a Nurse-Driven Intervention SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospitalization; mobility; older adults; healthcare systems; qualitative evaluation ID ACUTE MEDICAL ILLNESS; PARTICIPATORY ERGONOMICS; HOSPITALIZATION; PROGRAM; CARE AB ObjectivesTo develop a system-based intervention including five components that target barriers to nurse-initiated patient ambulation. DesignPilot study of Mobilizing Older adult patients VIa a Nurse-driven intervention (MOVIN). SettingTwenty-six bed general medical unit. ParticipantsNursing staff (registered nurses and certified nursing assistants) were recruited to participate in focus groups. MeasurementsInformation on frequency and distance patients ambulated and nursing staff documentation of patient ambulation were retrieved from the electronic medical record. Regression discontinuity analysis was used to determine a difference between the preintervention and intervention periods in ambulation occurrence, ambulation distance, and percentage of numeric documentation of ambulation. Thematic analysis was used to analyze focus group interviews. ResultsA statistically significant increase in number of occurrences (t = 4.18, P = .001) and total distance (t = 2.75, P = .01) and a significantly higher positive slope in percentage of numeric documentation was found during the intervention than before the intervention. Thematic analysis identified three central categories (shifting ownership, feeling supported, making ambulation visible) that describe the effect of MOVIN on nursing staff behaviors and perceptions of the intervention. ConclusionDecreasing loss of independent ambulation in hospitalized older adults requires new and innovative approaches to addressing barriers that prevent nurse-initiated patient ambulation. MOVIN is a promising system-based intervention to promoting patient ambulation and improving outcomes for hospitalized older adults. C1 [King, Barbara J.; Steege, Linsey M.] Univ Wisconsin, Sch Nursing, 701 Highland Ave,Room 3179, Madison, WI 53705 USA. [Winsor, Katie; VanDenbergh, Shelly] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Brown, Cynthia J.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. RP King, BJ (reprint author), Univ Wisconsin, Sch Nursing, 701 Highland Ave,Room 3179, Madison, WI 53705 USA. EM bjking2@wisc.edu RI Steege, Linsey/S-3070-2016 OI Steege, Linsey/0000-0002-8508-7787; King, Barbara/0000-0003-0577-9028 NR 32 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2016 VL 64 IS 10 BP 2088 EP 2094 DI 10.1111/jgs.14364 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FJ UT WOS:000387018500051 PM 27548535 ER PT J AU Ko, MS Fung, KZ Shi, Y Espaldon, R Shergill, A Walter, LC AF Ko, Myung S. Fung, Kathy Z. Shi, Ying Espaldon, Roxanne Shergill, Amandeep Walter, Louise C. TI Barrett's Esophagus Commonly Diagnosed in Elderly Men with Limited Life Expectancy SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID MANAGEMENT C1 [Ko, Myung S.; Shi, Ying; Espaldon, Roxanne; Shergill, Amandeep; Walter, Louise C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Fung, Kathy Z.; Shi, Ying; Espaldon, Roxanne; Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Fung, Kathy Z.; Shi, Ying; Espaldon, Roxanne; Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shergill, Amandeep] San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA. RP Ko, MS (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. FU National Institute on Aging, National Institutes of Health Award [K24AG041180] FX This work was supported by National Institute on Aging, National Institutes of Health Award K24AG041180 to Dr. Louise Walter. NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2016 VL 64 IS 10 BP E109 EP E111 DI 10.1111/jgs.14409 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FJ UT WOS:000387018500021 PM 27685424 ER PT J AU Chen, Y Seepersaud, R Bensing, BA Sullam, PM Rapoport, TA AF Chen, Yu Seepersaud, Ravin Bensing, Barbara A. Sullam, Paul M. Rapoport, Tom A. TI Mechanism of a cytosolic O-glycosyltransferase essential for the synthesis of a bacterial adhesion protein SO PROTEIN SCIENCE LA English DT Meeting Abstract CT 30th Anniversary Symposium of the Protein-Society CY JUL 16-19, 2016 CL Baltimore, MD SP Protein Soc C1 [Chen, Yu; Rapoport, Tom A.] Harvard Med Sch, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA. [Chen, Yu; Rapoport, Tom A.] Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0961-8368 EI 1469-896X J9 PROTEIN SCI JI Protein Sci. PD OCT PY 2016 VL 25 SU S1 BP 90 EP 91 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EB1YJ UT WOS:000387152400146 ER PT J AU Hussain, SS Kumar, AP Ghosh, R AF Hussain, Suleman S. Kumar, Addanki P. Ghosh, Rita TI Food-based natural products for cancer management: Is the whole greater than the sum of the parts? SO SEMINARS IN CANCER BIOLOGY LA English DT Review DE Food-based extracts; Active compounds; Cancer prevention; Cancer therapy; Adjuvants ID HUMAN PROSTATE-CANCER; GRAPE SEED EXTRACT; RANDOMIZED CLINICAL-TRIAL; ENDOTHELIAL GROWTH-FACTOR; PLACEBO-CONTROLLED TRIAL; HUMAN COLORECTAL-CANCER; GREEN TEA CATECHINS; CELLS IN-VITRO; PHASE-II; BLACK-RASPBERRIES AB The rise in cancer incidence and mortality in developing countries together with the human and financial cost of current cancer therapy mandates a closer look at alternative ways to overcome this burgeoning global healthcare problem. Epidemiological evidence for the association between cancer and diet and the long latency of most cancer progression have led to active exploration of whole and isolated natural chemicals from different naturally occurring substances in various preclinical and clinical settings. In general the lack of systemic toxicities of most 'whole' and 'isolated' natural compounds, their potential to reduce toxic doses and potential to delay the development of drug-resistance makes them promising candidates for cancer management. This review article examines the suggested molecular mechanisms affected by these substances focusing to a large extent on prostate cancer and deliberates on the disparate results obtained from cell culture, preclinical and clinical studies in an effort to highlight the use of whole extracts and isolated constituents for intervention. As such these studies underscore the importance of factors such as treatment duration, bioavailability, route of administration, selection criteria, standardized formulation and clinical end points in clinical trial design with both entities. Overall lack of parallel comparison studies between the whole natural products and their isolated compounds limits decisive conclusions regarding the superior utility of one over the other. We suggest the critical need for rigorous comparative research to identify which one of the two or both entities from nature would be best qualified to take on the mantle of cancer management. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Hussain, Suleman S.; Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Hussain, Suleman S.; Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pharmacol, San Antonio, TX 78229 USA. [Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Mol Med, San Antonio, TX 78229 USA. [Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Kumar, Addanki P.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kumar, AP; Ghosh, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kumara3@uthscsa.edu; ghoshr@uthscsa.edu OI Hussain, Suleman/0000-0003-1342-143X FU CTRC at UT Health Science Center San Antonio (UTHSCSA) through NCI support grant [2P30 CA 054174-17]; [AT007448]; [CPRITRP150166]; [CA149516] FX Supported by funds from AT007448 and CPRITRP150166 (APK) CA149516 (RG) and by the CTRC at UT Health Science Center San Antonio (UTHSCSA) through NCI support grant #2P30 CA 054174-17. NR 139 TC 2 Z9 2 U1 14 U2 14 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1044-579X EI 1096-3650 J9 SEMIN CANCER BIOL JI Semin. Cancer Biol. PD OCT PY 2016 VL 40-41 BP 233 EP 246 DI 10.1016/j.semcancer.2016.06.002 PG 14 WC Oncology SC Oncology GA EA9UA UT WOS:000386989000014 PM 27397504 ER PT J AU Tostanoski, LH Chiu, YC Andorko, JI Guo, M Zeng, XB Zhang, PP Royal, W Jewell, CM AF Tostanoski, Lisa H. Chiu, Yu-Chieh Andorko, James I. Guo, Ming Zeng, Xiangbin Zhang, Peipei Royal, Walter, III Jewell, Christopher M. TI Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance SO ACS NANO LA English DT Article DE polyelectrolyte multilayers; immunology and vaccines; self-assembly; autoimmunity and tolerance; biomaterials; human patients and clinical data; nanotechnology ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS; DNA VACCINATION; IMMUNE SIGNALS; ANTIGEN; CAPSULES; DELIVERY; MICROCAPSULES; ENCAPSULATION AB Recent studies demonstrate that excess signaling through inflammatory pathways (e.g., toll-like receptors, TLRs) contributes to the pathogenesis of human auto immune diseases, including lupus, diabetes, and multiple sclerosis (MS). We hypothesized that codelivery of a regulatory ligand of TLR9, GpG oligonucleotide, along with myelin the "self" molecule attacked in MS might restrain the pro-inflammatory signaling typically present during myelin presentation, redirecting T cell differentiation away from inflammatory populations and toward tolerogenic phenotypes such as regulatory T cells. Here we show that myelin peptide and GpG can be used as modular building blocks for co-assembly into immune polyelectrolyte multilayers (iPEMs). These nanostructured capsules mimic attractive features of biomaterials, including tunable cargo loading and codelivery, but eliminate all carriers and synthetic polymers, components that often exhibit intrinsic inflammatory properties that could exacerbate autoimmune disease. In vitro, iPEMs assembled from myelin and GpG oligonucleotide, but not myelin and a control oligonucleotide, restrain TLR9 signaling, reduce dendritic cell activation, and polarize myelin specific T cells toward tolerogenic phenotype and function. In mice, iPEMs blunt myelin-triggered inflammatory responses, expand regulatory T cells, and eliminate disease in a common model of MS. Finally, in samples from human MS patients, iPEMs bias myelin-triggered immune cell function toward tolerance. This work represents a unique opportunity to use PEMs to regulate immune function and promote tolerance, supporting iPEMs as a carrier-free platform to alter TLR function to reduce inflammation and combat autoimmunity. C1 [Tostanoski, Lisa H.; Chiu, Yu-Chieh; Andorko, James I.; Zeng, Xiangbin; Zhang, Peipei; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, 8228 Paint Branch Dr, College Pk, MD 20742 USA. [Guo, Ming; Royal, Walter, III] Univ Maryland, Sch Med, Dept Neurol, 655 West Baltimore St, Baltimore, MD 21201 USA. [Royal, Walter, III] US Dept Vet Affairs, Multiple Sclerosis Ctr Excellence East, 655 West Baltimore St, Baltimore, MD 21201 USA. [Jewell, Christopher M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St,HSF I Suite 380, Baltimore, MD 21201 USA. [Jewell, Christopher M.] US Dept Vet Affairs, 10 North Greene St, Baltimore, MD 21201 USA. [Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, 22 South Greene St, Baltimore, MD 21201 USA. RP Jewell, CM (reprint author), Univ Maryland, Fischell Dept Bioengn, 8228 Paint Branch Dr, College Pk, MD 20742 USA.; Jewell, CM (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St,HSF I Suite 380, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), US Dept Vet Affairs, 10 North Greene St, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), Marlene & Stewart Greenebaum Canc Ctr, 22 South Greene St, Baltimore, MD 21201 USA. EM cmjewell@umd.edu FU National Multiple Sclerosis Society [RG-1501-02968, PP2103]; NSF [1351688, DGE1322106]; University of Maryland Venture Fund; Maryland Innovation Initiative; Veterans Affairs [I01BX007080, RX000293]; NIH [T32 CA154274, T32 AI089621]; Damon Runyon Foundation [DRR3415]; Young Investigator of the Alliance for Cancer Gene Therapy [15051543]; Melanoma Research Alliance [348963] FX The authors thank L. Hester at the University of Maryland Cytokine Core Laboratory for her assistance with analysis of human PBMC samples and K. Gaskell at the University of Maryland Department of Chemistry & Biochemistry for her assistance with atomic force microscopy analyses. The authors acknowledge the VALOMS Investigators. This work was supported by the National Multiple Sclerosis Society award nos. RG-1501-02968 and PP2103, NSF CAREER award no. 1351688, the University of Maryland Venture Fund, the Maryland Innovation Initiative, and Veterans Affairs nos. I01BX007080 and RX000293. L.H.T. is a NSF Graduate Fellow no. DGE1322106. Y.C. is a trainee on NIH Grant no. T32 CA154274. J.I.A. is a trainee on NIH Grant no. T32 AI089621 and a Graduate Fellow of the American Association of Pharmaceutical Scientists. C.M.J. is a Damon Runyon-Rachleff Innovator supported by the Damon Runyon Foundation (no. DRR3415) and a Young Investigator of the Alliance for Cancer Gene Therapy (no. 15051543) and the Melanoma Research Alliance (no. 348963). NR 45 TC 3 Z9 3 U1 15 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 EI 1936-086X J9 ACS NANO JI ACS Nano PD OCT PY 2016 VL 10 IS 10 BP 9334 EP 9345 DI 10.1021/acsnano.6b04001 PG 12 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA EA2LK UT WOS:000386423600033 ER PT J AU Fuehrlein, BS Mota, N Arias, AJ Trevisan, LA Kachadourian, LK Krystal, JH Southwick, SM Pietrzak, RH AF Fuehrlein, Brian S. Mota, Natalie Arias, Albert J. Trevisan, Louis A. Kachadourian, Lorig K. Krystal, John H. Southwick, Steven M. Pietrzak, Robert H. TI The burden of alcohol use disorders in US military veterans: results from the National Health and Resilience in Veterans Study SO ADDICTION LA English DT Article DE Alcohol use disorder; anxiety disorder; comorbidity; dual diagnosis; epidemiology; military; mood disorder; veterans ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; AT-RISK DRINKING; EPIDEMIOLOGIC SURVEY; AUDIT-C; MENTAL-HEALTH; UNITED-STATES; DSM-IV; PSYCHIATRIC-DISORDERS; GENERAL-POPULATION AB AimsTo analyze data from a large, contemporary, nationally representative sample of US veterans to evaluate: (1) the prevalence of life-time alcohol use disorder (AUD) and past-year AUD; (2) common psychiatric comorbidities associated with life-time AUD; and (3) correlates of life-time and past-year probable AUD. DesignData were analyzed from the National Health and Resilience in Veterans Study (NHRVS), a web-based survey of a random probability sample of a contemporary, nationally representative sample of US military veterans. SettingUnited States. ParticipantsNationally representative sample of 3157 US veterans aged 21years and older. MeasurementsLife-time alcohol abuse and dependence were assessed according to DSM-IV diagnostic criteria using the Mini International Neuropsychiatric Interview, and combined into a single variable: AUD. Past-year probable AUD was assessed using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C). Correlates of AUD, including psychiatric comorbidities, suicidality and demographic characteristics, were also assessed. FindingsThe prevalence of life-time AUD and past-year probable AUD was 42.2% [95% confidence interval (CI)=40.5-43.9%)] and 14.8% (95% CI=13.6-16.0%), respectively. Compared with veterans without AUD, those with life-time AUD had substantially elevated rates of life-time and current mood and anxiety disorders [odds ratios (ORs)=2.6-4.1], drug use disorder (OR=10.7), life-time suicide attempt (OR=4.1) and current suicidal ideation (OR=2.1). Younger age, male sex, lower education, lower annual household income and greater number of life-time traumatic events were associated independently with life-time AUD. Younger age, male sex, unpartnered marital status and a life-time diagnosis of major depressive disorder were associated independently with past-year probable AUD. ConclusionsMore than 40% of US military veterans have a life-time history of alcohol use disorder. Veterans with a life-time history of alcohol use disorder have substantial comorbid psychiatric burden, including elevated rates of suicidal ideation and attempts. Certain socio-demographic (e.g. younger age, male sex, lower education) and clinical (e.g. trauma burden, history of depression) characteristics are associated with increased risk of AUD. C1 [Fuehrlein, Brian S.; Arias, Albert J.; Trevisan, Louis A.; Kachadourian, Lorig K.; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Fuehrlein, Brian S.; Mota, Natalie; Arias, Albert J.; Trevisan, Louis A.; Kachadourian, Lorig K.; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Natl Ctr PTSD, Clin Neurosci Div, US Dept Vet Affairs, West Haven, CT USA. RP Fuehrlein, BS (reprint author), VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. EM fuehrlein@gmail.com NR 62 TC 2 Z9 2 U1 11 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD OCT PY 2016 VL 111 IS 10 BP 1786 EP 1794 DI 10.1111/add.13423 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DW5UV UT WOS:000383713500021 PM 27061707 ER PT J AU Matteini, AM Tanaka, T Karasik, D Atzmon, G Chou, WC Eicher, JD Johnson, AD Arnold, AM Callisaya, ML Davies, G Evans, DS Holtfreter, B Lohman, K Lunetta, KL Mangino, M Smith, AV Smith, JA Teumer, A Yu, L Arking, DE Buchman, AS Chibinik, LB De Jager, PL Evans, DA Faul, JD Garcia, ME Gillham-Nasenya, I Gudnason, V Hofman, A Hsu, YH Ittermann, T Lahousse, L Liewald, DC Liu, YM Lopez, L Rivadeneira, F Rotter, JI Siggeirsdottir, K Starr, JM Thomson, R Tranah, GJ Uitterlinden, AG Volker, U Volzke, H Weir, DR Yaffe, K Zhao, W Zhuang, WV Zmuda, JM Bennett, DA Cummings, SR Deary, IJ Ferrucci, L Harris, TB Kardia, SLR Kocher, T Kritchevsky, SB Psaty, BM Seshadri, S Spector, TD Srikanth, VK Windham, BG Zillikens, MC Newman, AB Walston, JD Kiel, DP Murabito, JM AF Matteini, Amy M. Tanaka, Toshiko Karasik, David Atzmon, Gil Chou, Wen-Chi Eicher, John D. Johnson, Andrew D. Arnold, Alice M. Callisaya, Michele L. Davies, Gail Evans, Daniel S. Holtfreter, Birte Lohman, Kurt Lunetta, Kathryn L. Mangino, Massimo Smith, Albert V. Smith, Jennifer A. Teumer, Alexander Yu, Lei Arking, Dan E. Buchman, Aron S. Chibinik, Lori B. De Jager, Philip L. Evans, Denis A. Faul, Jessica D. Garcia, Melissa E. Gillham-Nasenya, Irina Gudnason, Vilmundur Hofman, Albert Hsu, Yi-Hsiang Ittermann, Till Lahousse, Lies Liewald, David C. Liu, Yongmei Lopez, Lorna Rivadeneira, Fernando Rotter, Jerome I. Siggeirsdottir, Kristin Starr, John M. Thomson, Russell Tranah, Gregory J. Uitterlinden, Andre G. Voelker, Uwe Voelzke, Henry Weir, David R. Yaffe, Kristine Zhao, Wei Zhuang, Wei Vivian Zmuda, Joseph M. Bennett, David A. Cummings, Steven R. Deary, Ian J. Ferrucci, Luigi Harris, Tamara B. Kardia, Sharon L. R. Kocher, Thomas Kritchevsky, Stephen B. Psaty, Bruce M. Seshadri, Sudha Spector, Timothy D. Srikanth, Velandai K. Windham, B. Gwen Zillikens, M. Carola Newman, Anne B. Walston, Jeremy D. Kiel, Douglas P. Murabito, Joanne M. TI GWAS analysis of handgrip and lower body strength in older adults in the CHARGE consortium SO AGING CELL LA English DT Article DE aging; genomewide association; meta-analysis; muscle strength; older adults; SNP ID MUSCLE STRENGTH; C/EBP-BETA; OXIDATIVE STRESS; SKELETAL-MUSCLE; GENE-EXPRESSION; GRIP STRENGTH; ASSOCIATION; HEALTH; AGE; POLYMORPHISMS AB Decline in muscle strength with aging is an important predictor of health trajectory in the elderly. Several factors, including genetics, are proposed contributors to variability in muscle strength. To identify genetic contributors to muscle strength, a meta-analysis of genomewide association studies of handgrip was conducted. Grip strength was measured using a handheld dynamometer in 27581 individuals of European descent over 65years of age from 14 cohort studies. Genomewide association analysis was conducted on similar to 2.7 million imputed and genotyped variants (SNPs). Replication of the most significant findings was conducted using data from 6393 individuals from three cohorts. GWAS of lower body strength was also characterized in a subset of cohorts. Two genomewide significant (P-value< 5x10(-8)) and 39 suggestive (P-value< 5x10(-5)) associations were observed from meta-analysis of the discovery cohorts. After meta-analysis with replication cohorts, genomewide significant association was observed for rs752045 on chromosome 8 (=0.47, SE=0.08, P-value=5.20x10(-10)). This SNP is mapped to an intergenic region and is located within an accessible chromatin region (DNase hypersensitivity site) in skeletal muscle myotubes differentiated from the human skeletal muscle myoblasts cell line. This locus alters a binding motif of the CCAAT/enhancer-binding protein- (CEBPB) that is implicated in muscle repair mechanisms. GWAS of lower body strength did not yield significant results. A common genetic variant in a chromosomal region that regulates myotube differentiation and muscle repair may contribute to variability in grip strength in the elderly. Further studies are needed to uncover the mechanisms that link this genetic variant with muscle strength. C1 [Matteini, Amy M.; Walston, Jeremy D.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Tanaka, Toshiko; Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Translat Gerontol Branch, Gerontol Res Ctr, Baltimore, MD 21224 USA. [Karasik, David; Chou, Wen-Chi; Hsu, Yi-Hsiang; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Dept Med, Hebrew SeniorLife, Inst Aging Res, Boston, MA 02215 USA. [Karasik, David; Chou, Wen-Chi; Hsu, Yi-Hsiang; Ferrucci, Luigi; Kiel, Douglas P.] Harvard Med Sch, Boston, MA USA. [Karasik, David] Bar Ilan Univ, Fac Med Galilee, IL-13010 Safed, Israel. [Atzmon, Gil] Albert Einstein Coll Med, Inst Aging Res, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10467 USA. [Atzmon, Gil] Albert Einstein Coll Med, Inst Aging Res, Dept Genet, 1300 Morris Pk Ave, Bronx, NY 10467 USA. [Atzmon, Gil] Univ Haifa, Dept Human Biol, Haifa, Israel. [Eicher, John D.; Johnson, Andrew D.] NHLBI, Populat Sci Branch, Bldg 10, Bethesda, MD 20892 USA. [Eicher, John D.; Johnson, Andrew D.; Lunetta, Kathryn L.; Seshadri, Sudha; Murabito, Joanne M.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Arnold, Alice M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Callisaya, Michele L.; Srikanth, Velandai K.] Monash Univ, Stroke & Ageing Res Grp, Dept Med, Sch Clin Sci, Clayton, Vic, Australia. [Callisaya, Michele L.; Thomson, Russell; Srikanth, Velandai K.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia. [Davies, Gail; Liewald, David C.; Deary, Ian J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemol, Edinburgh, Midlothian, Scotland. [Davies, Gail; Lopez, Lorna] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland. [Evans, Daniel S.; Tranah, Gregory J.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Holtfreter, Birte; Kocher, Thomas] Univ Med Greifswald, Dept Restorat Dent Periodontol & Endodointol, Ctr Oral Hlth, Unit Periodontol, Greifswald, Germany. [Lohman, Kurt; Liu, Yongmei] Wake Forest Sch Med, Div Publ Hlth Sci, Ctr Human Genet, Winston Salem, NC USA. [Lunetta, Kathryn L.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Mangino, Massimo; Gillham-Nasenya, Irina; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England. [Mangino, Massimo] Guys & St Thomas Fdn Trust, NIHR Biomed Res Ctr, London, England. [Smith, Albert V.; Gudnason, Vilmundur; Siggeirsdottir, Kristin] Icelandic Heart Assoc, Kopavogur, Iceland. [Smith, Jennifer A.; Zhao, Wei; Kardia, Sharon L. R.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Teumer, Alexander; Ittermann, Till; Voelzke, Henry] Univ Med Greifswald, Inst Community Med, Greifswald, Germany. [Yu, Lei; Buchman, Aron S.; Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL USA. [Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Buchman, Aron S.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Chibinik, Lori B.; De Jager, Philip L.] Brigham & Womens Hosp, Dept Neurol, Program Translat NeuroPsychiatr Genom, 75 Francis St, Boston, MA 02115 USA. [Chibinik, Lori B.; De Jager, Philip L.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Evans, Denis A.] Rush Univ, Inst Hlth Aging, Med Ctr, Chicago, IL 60612 USA. [Evans, Denis A.] Rush Univ, Dept Internal Med, Med Ctr, Chicago, IL 60612 USA. [Faul, Jessica D.; Weir, David R.] Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI USA. [Garcia, Melissa E.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland. [Hofman, Albert; Lahousse, Lies; Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Hsu, Yi-Hsiang] Harvard Sch Publ Hlth, Dept Med Mol & Integrat Physiol Sci, Boston, MA USA. [Lahousse, Lies] Univ Ghent, Dept Resp Med, Ghent, Belgium. [Lahousse, Lies] Ghent Univ Hosp, Ghent, Belgium. [Rivadeneira, Fernando; Uitterlinden, Andre G.; Zillikens, M. Carola] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands. [Rivadeneira, Fernando; Uitterlinden, Andre G.] NCHA, NGI, Rotterdam, Netherlands. [Rotter, Jerome I.] Univ Calif Los Angeles, Dept Pediat, Div Genom Outcome, Los Angeles, CA 90024 USA. [Rotter, Jerome I.] Univ Calif Los Angeles, Dept Med, Inst Translat Genom & Populat Sci, Los Angeles Biomed Res Inst,Harbor UCLA Med Ctr, Los Angeles, CA 90024 USA. [Starr, John M.] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Voelker, Uwe] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany. [Voelzke, Henry] German Ctr Cardiovasc Res DZHK, Greifswald, Germany. [Voelzke, Henry] German Ctr Diabet Res DZD, Greifswald, Germany. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Zhuang, Wei Vivian] Creighton Univ, Sch Med, Ctr Hlth Policy & Eth, Publ Hlth Program, Omaha, NE USA. [Zmuda, Joseph M.; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland. [Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Windham, B. Gwen] Univ Mississippi, Med Ctr, Dept Med, Div Geriatr, Jackson, MS 39216 USA. [Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. RP Matteini, AM (reprint author), Johns Hopkins Ctr Aging & Hlth, 2024 East Monument St,Suite 2-126, Baltimore, MD 21287 USA. EM amatteini@jhmi.edu RI Callisaya, Michele/I-2333-2013; Thomson, Russell/H-5653-2012 OI Callisaya, Michele/0000-0003-2122-1622; Thomson, Russell/0000-0003-4949-4120; Smith, Jennifer/0000-0002-3575-5468; Lahousse, Lies/0000-0002-3494-4363; Karasik, David/0000-0002-8826-0530 FU Johns Hopkins University Claude D. Pepper Older Americans Independence Center (NIA) [P30 AG021334]; Wellcome Trust [FP7/2007-2013]; National Institute for Health Research, National Institute of Diabetes and Digestive and Kidney Diseases [DK063491]; German Federal Ministry of Education and Research [01ZZ0103, 01ZZ0403, 01ZZ9603, 031S2061A, 03ZIK012]; National Institutes of Health [HHSN268200625226C, HHSN268200782096C, N01AG12 100, UL1RR025005]; Biotechnology and Biological Sciences Research Council; National Health and Medical Research Council [NHMRC 100089, NHMRC 1034483, NHMRC 1061457, NHMRC 403000, NHMRC491109, NHMRC606543]; National Institute on Aging [1R01AG032098-01A1, 263 MD 821336, 263 MD 9164, AG016495, AG033193, AG08122, N01AG62101, N01AG 62103, N01AG62106, P30AG10161]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR41398, R01-AR051124, RC2ARO58973, U01 AR45580, U01 AR45 583, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654]; National Heart, Lung, and Blood Institute [HHSN268200800007C, HHSN268201100005C, HH5N268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HH5N268201100010C, HHSN268201100011C, HHSN268201100012C, HHSN268201200036C]; National Human Genome Research Institute [U01 HG004402]; Medical Research Council, Research Institute for Diseases in the Elderly [014-93-015, RIDE2]; Netherlands Organization for Scientific Research NWO Investments [050-060-810, 175.010.2005.011, 911-03-012]; National Center for Research Resources [UL1 RR024140, N02HL64278, N01-AG-1-2100, HHSN27120 120022C, HL105756, N01HC85083, N01HC85086, RC1 AG035835]; NIA Intramural Research Program; Hjartavernd (the Icelandic Heart Association); Althingi (the Icelandic Parliament); Research Foundation Flanders (FWO); UK Biotechnology and Biological Sciences Research Council; Royal Society; Chief Scientist Office of the Scottish Government, Age UK (The Disconnected Mind project), Lifelong Health and Wellbeing Initiative) [MR/K026992/1]; Medical Research Council; Netherlands Organization of Scientific Research NWO Investments [050-060-810, 175.010.2005.011, 911-03-012]; Research Institute for Diseases in the Elderly [014-93-015]; RIDE2; Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA) [050-060-810]; The National Institute on Aging [R01 AG005394, R01 AG005407, R01 AG0275747, R01 AG027576, R01 AR35582, R01 AR35583, R01AG 023629, R01AG040039, R01AG15819, R01AG17917, R01AG24480, R01AG29451, R01AG30146, R01AR35584, RC2 AG036495, U01 AG 18197, U01-AG027810, U01A0009740]; The National Heart, Lung, and Blood Institute [N01HC25195, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, R01HL086694, R01HL087641, R01HL103612, R01HL120393, R01HL59367, U01 HL080295] FX Johns Hopkins University Claude D. Pepper Older Americans Independence Center (NIA Grant/Award Number P30 AG021334), Wellcome Trust, (Grant/Award Number: 'FP7/2007-2013') National Institute for Health Research, National Institute of Diabetes and Digestive and Kidney Diseases, (Grant/Award Number: 'DK063491') German Federal Ministry of Education and Research, (Grant/Award Number: '01ZZ0103','01ZZ0403','01ZZ9603', '031S2061A','03ZIK012'), National Institutes of Health, (Grant/Award Number: 'HHSN268200625226C','HHSN268200782096C','N01AG12 100','UL1RR025005'), Biotechnology and Biological Sciences Research Council, National Health and Medical Research Council, (Grant/Award Number: 'NHMRC 100089','NHMRC 1034483','NHMRC 1061457','NHMRC 403000','NHMRC491109','NHMRC606543'), National Institute on Aging, (Grant/Award Number: '1R01AG032098-01A1','263 MD 821336'.'263 MD 9164 ','AG016495','AG033193,',AG08122','N01AG62101','N01AG 62103','N01AG62106','P30AG10161','R01 AG005394','R01 AG005407', 'R01 AG0275747','R01 AG027576','R01 AR35582','R01 AR35583','R01AG 023629','R01AG040039','R01AG15819','R01AG17917','R01AG24480', 'R01AG29451','R01AG30146','R01AR35584','RC2 AG036495','U01 AG 18197','U01-AG027810','U01A0009740'), National Institute of Arthritis and Musculoskeletal and Skin Diseases, (Grant/Award Number: 'R01 AR41398','R01-AR051124','RC2ARO58973','U01 AR45580','U01 AR45 583','U01 AR45614','U01 AR45632','U01 AR45647','U01 AR45654') National Heart, Lung, and Blood Institute, (Grant/Award Number: 'HHSN268200800007C','HHSN268201100005C','HH5N268201100006C','HHSN2682011 00007C','HHSN268201100008C','HHSN268201100009C','HH5N268201100010C','HHS N268201100011C','HHSN26820 1100012C','HHSN268201200036C','N01HC25195','N01HC55222','N01HC85079','N0 1HC85080','N01HC85081','N01HC85082','R01HL0866 94','R01HL087641','R01HL103612','R01HL120393','R01HL59367','U01 HL080295'), National Human Genome Research Institute, (Grant/Award Number: 'U01 HG004402') Medical Research Council, Research Institute for Diseases in the Elderly, (Grant/Award Number '014-93-015','RIDE2') Netherlands Organization for Scientific Research NWO Investments, (Grant/Award Number: '050-060-810','175.010.2005.011','911-03-012'), National Center for Research Resources, (Grant/Award Number: 'UL1 RR024140'). "N02HL64278", "N01-AG-1-2100", "HHSN27120 120022C", "HL105756", "N01HC85083", "N01HC85086", "RC1 AG035835", NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), the Althingi (the Icelandic Parliament), Research Foundation Flanders (FWO), UK Biotechnology and Biological Sciences Research Council, The Royal Society, The Chief Scientist Office of the Scottish Government, Age UK (The Disconnected Mind project), Lifelong Health and Wellbeing Initiative: "MR/K026992/1", Medical Research Council, Netherlands Organization of Scientific Research NWO Investments: "nr." 175.010.2005.011", "911-03-012", "050-060-810", Research Institute for Diseases in the Elderly: "014-93-015"; "RIDE2", Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA): "nr. 050-060-810." NR 32 TC 2 Z9 2 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD OCT PY 2016 VL 15 IS 5 BP 792 EP 800 DI 10.1111/acel.12468 PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DW5VN UT WOS:000383715600001 PM 27325353 ER PT J AU Strong, R Miller, RA Antebi, A Astle, CM Bogue, M Denzel, MS Fernandez, E Flurkey, K Hamilton, KL Lamming, DW Javors, MA de Magalhaes, JP Martinez, PA McCord, JM Miller, BF Muller, M Nelson, JF Ndukum, J Rainger, GE Richardson, A Sabatini, DM Salmon, AB Simpkins, JW Steegenga, WT Nadon, NL Harrison, DE AF Strong, Randy Miller, Richard A. Antebi, Adam Astle, Clinton M. Bogue, Molly Denzel, Martin S. Fernandez, Elizabeth Flurkey, Kevin Hamilton, Karyn L. Lamming, Dudley W. Javors, Martin A. de Magalhaes, Joao Pedro Martinez, Paul Anthony McCord, Joe M. Miller, Benjamin F. Muller, Michael Nelson, James F. Ndukum, Juliet Rainger, G. Ed Richardson, Arlan Sabatini, David M. Salmon, Adam B. Simpkins, James W. Steegenga, Wilma T. Nadon, Nancy L. Harrison, David E. TI Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an -glucosidase inhibitor or a Nrf2-inducer SO AGING CELL LA English DT Article DE acarbose; fish oil; metformin; NDGA; Protandim; rapamycin; UDCA; 17--estradiol ID GENETICALLY HETEROGENEOUS MICE; NORDIHYDROGUAIARETIC ACID; URSODEOXYCHOLIC ACID; DIETARY RESTRICTION; METFORMIN ACTION; FISH-OIL; IN-VIVO; RAPAMYCIN; MECHANISM; EXTENDS AB The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin - the latter with and without rapamycin, and two drugs previously examined: 17--estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17--estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male-specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The -glucosidase inhibitor, acarbose, at a concentration previously tested (1000ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies. C1 [Strong, Randy; Fernandez, Elizabeth; Martinez, Paul Anthony] Univ Texas Hlth Sci Ctr San Antonio, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Strong, Randy; Fernandez, Elizabeth; Martinez, Paul Anthony] Univ Texas Hlth Sci Ctr San Antonio, Res Serv, South Texas Vet Hlth Care Syst, Dept Pharmacol, San Antonio, TX 78229 USA. [Strong, Randy; Fernandez, Elizabeth; Martinez, Paul Anthony; Nelson, James F.; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78229 USA. [Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA. [Antebi, Adam; Denzel, Martin S.] Max Planck Inst Biol Ageing, D-50931 Cologne, Germany. [Astle, Clinton M.; Bogue, Molly; Flurkey, Kevin; Ndukum, Juliet; Harrison, David E.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. [Hamilton, Karyn L.; Miller, Benjamin F.] Colorado State Univ, Ft Collins, CO 80523 USA. [Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [de Magalhaes, Joao Pedro] Univ Liverpool, Sch Biol Sci, Crown St, Liverpool L69 7ZB, Merseyside, England. [McCord, Joe M.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Muller, Michael] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England. [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Rainger, G. Ed] Univ Birmingham, Ctr Cardiovasc Sci, Sch Clin & Expt Med, Sch Med, Birmingham, W Midlands, England. [Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Oklahoma City, OK 73104 USA. [Richardson, Arlan] VA Med Ctr, Oklahoma City, OK 73104 USA. [Sabatini, David M.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. [Sabatini, David M.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Sabatini, David M.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA. [Sabatini, David M.] Broad Inst Harvard & MIT, Seven Cambridge Ctr, Cambridge, MA 02142 USA. [Sabatini, David M.] MIT, David H Koch Inst Integrative Canc Res, Cambridge, MA 02139 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Simpkins, James W.] West Virginia Univ, Ctr Basic & Translat Stroke Res, Morgantown, WV 26506 USA. [Steegenga, Wilma T.] Univ Wageningen & Res Ctr, Div Human Nutr, Wageningen, Netherlands. [Nadon, Nancy L.] NIH, Div Aging Biol, Bethesda, MD 20892 USA. [de Magalhaes, Joao Pedro] Univ Liverpool, Inst Ageing & Chron Dis, Integrat Genom Ageing Grp, Liverpool L7 8TX, Merseyside, England. RP Strong, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM strong@uthscsa.edu RI de Magalhaes, Joao Pedro/B-4741-2010 OI de Magalhaes, Joao Pedro/0000-0002-6363-2465 FU National Institute on Aging [AG013319, AG022303, AG022307, AG022308, AG024824, CA034196] FX National Institute on Aging, (Grant / Award Number: 'AG013319', 'AG022303', 'AG022307', 'AG022308', 'AG024824', 'CA034196'). NR 45 TC 1 Z9 1 U1 11 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD OCT PY 2016 VL 15 IS 5 BP 872 EP 884 DI 10.1111/acel.12496 PG 13 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DW5VN UT WOS:000383715600009 PM 27312235 ER PT J AU Rodriguez-Garcia, M Shen, Z Kappes, J Ochsenbauer, C Wira, CR AF Rodriguez-Garcia, Marta Shen, Zheng Kappes, John Ochsenbauer, Christina Wira, Charles R. TI Characterization of Dendritic Cells with Rapid HIV Capture Potential from the Human Female Reproductive Tract SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Rodriguez-Garcia, Marta; Shen, Zheng; Wira, Charles R.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Kappes, John; Ochsenbauer, Christina] Univ Alabama Birmingham, Birmingham, AL USA. [Kappes, John] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA15.03 BP 79 EP 79 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600136 ER PT J AU Singh, B Kulawiec, M Owens, KM Singh, A Singh, KK AF Singh, B. Kulawiec, M. Owens, K. M. Singh, A. Singh, K. K. TI Sustained early disruption of mitochondrial function contributes to arsenic-induced prostate tumorigenesis SO BIOCHEMISTRY-MOSCOW LA English DT Article DE arsenic; mitochondria; mtOXPHOS; genomic instability; tumorigenic transformation; prostate cancer ID INDUCED MALIGNANT-TRANSFORMATION; DRINKING-WATER; EPITHELIAL-CELLS; CANCER-MORTALITY; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MAMMALIAN-CELLS; RISK-ASSESSMENT; LUNG-CANCER; WEST-BENGAL AB Arsenic is a well-known human carcinogen that affects millions of people worldwide, but the underlying mechanisms of carcinogenesis are unclear. Several epidemiological studies have suggested increased prostate cancer incidence and mortality due to exposure to arsenic. Due to lack of an animal model of arsenic-induced carcinogenesis, we used a prostate epithelial cell culture model to identify a role for mitochondria in arsenic-induced prostate cancer. Mitochondrial morphology and membrane potential was impacted within a few hours of arsenic exposure of non-neoplastic prostate epithelial cells. Chronic arsenic treatment induced mutations in mitochondrial genes and altered mitochondrial functions. Human non-neoplastic prostate epithelial cells continuously cultured for seven months in the presence of 5 A mu M arsenite showed tumorigenic properties in vitro and induced tumors in SCID mice, which indicated transformation of these cells. Protein and mRNA expression of subunits of mtOXPHOS complex I were decreased in arsenic-transformed cells. Alterations in complex I, a main site for reactive oxygen species (ROS) production as well as increased expression of ROS-producing NOX4 in arsenic-transformed cells suggested a role of oxidative stress in tumorigenic transformation of prostate epithelial cells. Whole genome cGH array analyses of arsenic-transformed prostate cells identified extensive genomic instability. Our study revealed mitochondrial dysfunction induced oxidative stress and decreased expression of p53 in arsenic-transformed cells as an underlying mechanism of the mitochondrial and nuclear genomic instability. These studies suggest that early changes in mitochondrial functions are sustained during prolong arsenic exposure. Overall, our study provides evidence that arsenic disruption of mitochondrial function is an early and key step in tumorigenic transformation of prostate epithelial cells. C1 [Singh, B.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Kulawiec, M.; Owens, K. M.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA. [Singh, A.] SUNY Buffalo, Dept Pediat, Buffalo, NY 12246 USA. [Singh, K. K.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA. [Singh, K. K.] UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Genet, Birmingham, AL 35294 USA. [Singh, K. K.] UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Pathol, Birmingham, AL 35294 USA. [Singh, K. K.] UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Environm Hlth, Birmingham, AL 35294 USA. [Singh, K. K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Singh, KK (reprint author), Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.; Singh, KK (reprint author), UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Genet, Birmingham, AL 35294 USA.; Singh, KK (reprint author), UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Pathol, Birmingham, AL 35294 USA.; Singh, KK (reprint author), UAB Comprehens Canc Ctr, Ctr Free Rad Biol, Dept Environm Hlth, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. EM kksingh@uab.edu FU Veterans Administration [1I01BX001716] FX This study was supported by grant from Veterans Administration 1I01BX001716. NR 97 TC 0 Z9 0 U1 2 U2 2 PU MAIK NAUKA/INTERPERIODICA/SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0006-2979 EI 0320-9725 J9 BIOCHEMISTRY-MOSCOW+ JI Biochem.-Moscow PD OCT PY 2016 VL 81 IS 10 BP 1089 EP 1100 DI 10.1134/S0006297916100072 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA4DF UT WOS:000386558100007 PM 27908234 ER PT J AU Meester, RGS Zauber, AG Doubeni, CA Jensen, CD Quinn, VP Helfand, M Dominitz, JA Levin, TR Corley, DA Lansdorp-Vogelaar, I AF Meester, Reinier G. S. Zauber, Ann G. Doubeni, Chyke A. Jensen, Christopher D. Quinn, Virginia P. Helfand, Mark Dominitz, Jason A. Levin, Theodore R. Corley, Douglas A. Lansdorp-Vogelaar, Iris TI Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Colorectal Neoplasms; Screening and Early Detection; Occult Blood; Time Factors ID OCCULT-BLOOD-TEST; COST-EFFECTIVENESS ANALYSIS; ADENOMA DETECTION RATE; SOCIETY TASK-FORCE; MEDICARE POPULATION; LARGE-INTESTINE; LARGE-BOWEL; ASYMPTOMATIC ADULTS; AMERICAN-COLLEGE; POLYPECTOMY RATE AB BACKGROUND & AIMS: Delays in diagnostic testing after a positive result from a screening test can undermine the benefits of colorectal cancer (CRC) screening, but there are few empirical data on the effects of such delays. We used microsimulation modeling to estimate the consequences of time to colonoscopy after a positive result from a fecal immunochemical test (FIT). METHODS: We used an established microsimulation model to simulate an average-risk United States population cohort that underwent annual FIT screening (from ages 50 to 75 years), with follow-up colonoscopy examinations for individuals with positive results (cutoff, 20 mu g/g) at different time points in the following 12 months. Main evaluated outcomes were CRC incidence and mortality; additional outcomes were total life-years lost and net costs of screening. RESULTS: For individuals who underwent diagnostic colonoscopy within 2 weeks of a positive result from an FIT, the estimated lifetime risk of CRC incidence was 35.5/1000 persons, and mortality was 7.8/1000 persons. Every month added until colonoscopy was associated with a 0.1/1000 person increase in cancer incidence risk (an increase of 0.3%/month, compared with individuals who received colonoscopies within 2 weeks) and mortality risk (increase of 1.4%/month). Among individuals who received colonoscopy examinations 12 months after a positive result from an FIT, the incidence of CRC was 27.0/1000 persons (increase of 4%, compared with 2 weeks), and mortality was 9.1/1000 persons (increase of 16%). Total years of life gained for the entire screening cohort decreased from an estimated 93.7/1000 persons with an almost immediate follow-up colonoscopy (cost savings of $ 208 per patient, compared with no colonoscopy) to 84.8/1000 persons with follow-up colonoscopies at 12 months (decrease of 9%; cost savings of $ 100/patient, compared with no colonoscopy). CONCLUSIONS: By using a microsimulation model of an average-risk United States screening cohort, we estimated that delays of up to 12 months after a positive result from an FIT can produce proportional losses of up to nearly 10% in overall screening benefits. These findings indicate the importance of timely follow-up colonoscopy examinations of patients with positive results from FITs. C1 [Meester, Reinier G. S.; Lansdorp-Vogelaar, Iris] Erasmus MC, Univ Med Ctr, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Doubeni, Chyke A.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Doubeni, Chyke A.] Univ Penn, Perelman Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA. [Doubeni, Chyke A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Doubeni, Chyke A.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Jensen, Christopher D.; Levin, Theodore R.; Corley, Douglas A.] Kaiser Permanente, Div Res, Oakland, CA USA. [Quinn, Virginia P.] Kaiser Permanente Southern Calif, Res & Evaluat, Pasadena, CA 91101 USA. [Helfand, Mark] Vet Affairs Portland Healthcare Syst, Portland, OR USA. [Dominitz, Jason A.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Meester, RGS (reprint author), Erasmus MC, Univ Med Ctr, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM r.meester@erasmusmc.nl FU National Cancer Institute at the United States National Institutes of Health [U54 CA163262, U01 CA152959, U01 CA151736, U24 CA171524, P30 CA008748]; VA Puget Sound Health Care System FX Supported by grants from the National Cancer Institute at the United States National Institutes of Health (#U54 CA163262 and also U01 CA152959, U01 CA151736, U24 CA171524, and P30 CA008748). This material is the result of work supported in part by resources from the VA Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the National Cancer Institute or of the Department of Veterans Affairs. NR 61 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2016 VL 14 IS 10 BP 1445 EP + DI 10.1016/j.cgh.2016.05.017 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA6SO UT WOS:000386759500016 PM 27211498 ER PT J AU Williams, JS Walker, RJ Smalls, BL Hill, R Egede, LE AF Williams, Joni S. Walker, Rebekah J. Smalls, Brittany L. Hill, Rachel Egede, Leonard E. TI Patient-Centered Care, Glycemic Control, Diabetes Self-Care, and Quality of Life in Adults with Type 2 Diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID HEALTH; INTERVENTION; VALIDITY; IMPACT AB Background: The Affordable Care Act places a newfound emphasis on patient-centered medical home and patient-centered care (PCC). The purpose of this study was to evaluate the relationship between PCC, diabetes self-care, glycemic control, and quality of life (QOL) in a sample of adults with type 2 diabetes. Methods: Six hundred fifteen patients were recruited from two adult primary care clinics in the southeastern United States. Primary outcome variables were self-care behaviors (medication adherence, diet, exercise, blood sugar testing, and foot care), glycemic control, and QOL (physical component summary [PCS] score and mental component summary [MCS] score of SF12). PCC was assessed using a modified 7-item Picker Patient Experience Questionnaire. Regression modeling was used to assess independent associations while adjusting for relevant covariates. Results: In adjusted analyses, PCC was significantly associated with PCS QOL (=-0.03, 95% confidence interval [CI] -0.05 to -0.01), MCS QOL (=0.09, 95% CI 0.04-0.14), medication adherence (=0.12, 95% CI 0.08-0.17), general diet (=0.12, 95% CI 0.07-0.17), specific diet (=0.05, 95% CI 0.01-0.08), blood sugar testing (=0.09, 95% CI 0.04-0.15), and foot care (=0.12, 95% CI 0.07-0.18). Conclusion: PCC is associated with diabetes self-management and QOL, but was not significantly associated with glycemic control in patients with diabetes. PCC may be an important factor in self-care behaviors, but the process of focusing care around the patient may need to expand throughout the healthcare system before changes in outcomes such as glycemic control are noted. C1 [Williams, Joni S.; Walker, Rebekah J.; Hill, Rachel; Egede, Leonard E.] Med Univ South Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. [Williams, Joni S.; Walker, Rebekah J.; Hill, Rachel; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr HEROIC, Charleston, SC USA. [Smalls, Brittany L.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA. RP Egede, LE (reprint author), Med Univ South Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: L.E.E.). NR 33 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD OCT PY 2016 VL 18 IS 10 BP 644 EP 649 DI 10.1089/dia.2016.0079 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA3BM UT WOS:000386473000007 PM 27541872 ER PT J AU Ioannou, GN Beste, LA Chang, M Green, P Lowy, E Tsui, J Su, F Berry, K AF Ioannou, George N. Beste, Lauren A. Chang, Michael Green, Pamela Lowy, Elliott Tsui, Judith Su, Feng Berry, Kristin TI Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir and Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir-Based Antiviral Regimens for Hepatitis C in 17,847 patients in the Veterans Affairs National Healthcare System SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.; Tsui, Judith; Su, Feng] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George N.; Beste, Lauren A.; Green, Pamela; Lowy, Elliott; Berry, Kristin] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Chang, Michael] Vet Affairs Portland Healthcare Syst, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 21 BP 11A EP 11A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800022 ER PT J AU Coombes, JD Manka, PP Swiderska-Syn, M Reid, D Riva, A Claridge, LC Dolle, L Younis, R Briones, MA Kitamura, N Mehta, K Mi, ZY Kuo, PC Williams, R Diehl, AM van Grunsven, LA Chokshi, S Canbay, A Flamant, F Gauthier, K Eksteen, B Syn, WK AF Coombes, Jason D. Manka, Paul P. Swiderska-Syn, Marzena Reid, Danielle Riva, Antonio Claridge, Lee C. Dolle, Laurent Younis, Rasha Briones, Marco A. Kitamura, Naoto Mehta, Kosha Mi, Zhiyong Kuo, Paul C. Williams, Roger Diehl, Anna Mae van Grunsven, Leo A. Chokshi, Shilpa Canbay, Ali Flamant, Frederic Gauthier, Karine Eksteen, Bertus Syn, Wing-Kin TI Cholangiocyte chemokine secretion and macrophage accumulation is mediated by osteopontin in murine liver models SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Coombes, Jason D.; Manka, Paul P.; Younis, Rasha; Briones, Marco A.; Kitamura, Naoto; Mehta, Kosha; Williams, Roger; Syn, Wing-Kin] Kings Coll London, Inst Hepatol, Regenerat & Repair, London, England. [Manka, Paul P.; Canbay, Ali] Univ Hosp Essen, Gastroenterol & Hepatol, Essen, Germany. [Swiderska-Syn, Marzena; Diehl, Anna Mae] Duke Univ, Med & Gastroenterol, Durham, NC USA. [Reid, Danielle; Eksteen, Bertus] Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada. [Riva, Antonio; Williams, Roger; Chokshi, Shilpa] Kings Coll London, Inst Hepatol, Viral Hepatitis & Alcohol Res Grp, London, England. [Claridge, Lee C.] Leeds Teaching Hosp NHS Trust, Dept Hepatol, Leeds, W Yorkshire, England. [Dolle, Laurent; van Grunsven, Leo A.] Vrije Univ Brussels, Liver Cell Biol, Brussels, Belgium. [Mi, Zhiyong; Kuo, Paul C.] Loyola Univ, Dept Surg, Chicago, IL 60611 USA. [Flamant, Frederic; Gauthier, Karine] Ecole Normale Super Lyon, Inst Genom Fonct Lyon, Lyon, France. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 168 BP 89A EP 90A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800169 ER PT J AU Beste, LA Green, P Berry, K Ioannou, GN AF Beste, Lauren A. Green, Pamela Berry, Kristin Ioannou, George N. TI Effectiveness of direct antiviral agents for hepatitis C virus in 624 patients with hepatocellular carcinoma in the Veterans Affairs Healthcare System SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Beste, Lauren A.; Green, Pamela; Berry, Kristin] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 169 BP 90A EP 90A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800170 ER PT J AU Moon, AM Green, P Berry, K Ioannou, GN AF Moon, Andrew M. Green, Pamela Berry, Kristin Ioannou, George N. TI Towards eradication of hepatitis C virus infection in the Veterans Affairs national healthcare system: a study of 107,079 antiviral treatment regimens administered from 1999-2015 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Moon, Andrew M.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Green, Pamela; Berry, Kristin] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 227 BP 120A EP 120A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800228 ER PT J AU Briones, MA Coombes, JD Mellone, M Rispoli, R Tolosa, E Manka, PP Kitamura, N Quaglia, A Canbay, A Alpini, G Glaser, SS Williams, R Papa, S Fernandez-Zapico, ME Syn, WK AF Briones, Marco A. Coombes, Jason D. Mellone, Massimiliano Rispoli, R. Tolosa, Ezequiel Manka, Paul P. Kitamura, Naoto Quaglia, Alberto Canbay, Ali Alpini, Gianfranco Glaser, Shannon S. Williams, Roger Papa, Salvatore Fernandez-Zapico, Martin E. Syn, Wing-Kin TI The role of osteopontin isoforms in cholangiocarcinoma SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Syn, Wing-Kin] Med Univ South Carolina, Med, Charleston, SC USA. [Briones, Marco A.; Coombes, Jason D.; Manka, Paul P.; Kitamura, Naoto; Williams, Roger; Papa, Salvatore] Kings Coll London, Inst Hepatol, Fac Life Sci & Med, Div Transplantat Immunol & Mucosal Biol, London, England. [Syn, Wing-Kin] Ralph H Johnson VAMC, Gastroenterol, Charleston, SC USA. [Mellone, Massimiliano] Univ Southampton, Canc Sci Unit, London, England. [Rispoli, R.] John Radcliffe Hosp Oxford, Weatherall Inst Mol Med, Oxford, England. [Tolosa, Ezequiel; Fernandez-Zapico, Martin E.] Mayo Clin, Oncol, Rochester, MN USA. [Manka, Paul P.; Canbay, Ali] Univ Hosp Essen, Gastroenterol & Hepatol, Essen, Germany. [Alpini, Gianfranco; Glaser, Shannon S.] Cent Texas Vet Hlth Care Syst, Med, Temple, TX USA. [Alpini, Gianfranco; Glaser, Shannon S.] Texas A&M Hlth Sci Ctr, Med, Temple, TX USA. [Quaglia, Alberto] Kings Coll London, Liver Pathol, London, England. [Papa, Salvatore] Univ Leeds, Inst Canc & Pathol, Leeds, W Yorkshire, England. [Fernandez-Zapico, Martin E.] Mayo Clin, Gastroenterol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 463 BP 235A EP 235A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801205 ER PT J AU Ebel, N Hsu, E Berry, K Horslen, S Ioannou, GN AF Ebel, Noelle Hsu, Evelyn Berry, Kristin Horslen, Simon Ioannou, George N. TI Waitlist and post-transplantation outcomes in liver transplant registrants and recipients ages 18-24 years old: analysis of the UNOS database SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ebel, Noelle; Hsu, Evelyn; Horslen, Simon] Seattle Childrens Hosp, Seattle, WA USA. [Ebel, Noelle; Hsu, Evelyn; Horslen, Simon] Univ Washington, Sch Med, Pediat, Seattle, WA USA. [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 668 BP 332A EP 332A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801408 ER PT J AU Mehta, K Briones, MA Manka, PP Coombes, JD Williams, R Patel, VB Syn, WK AF Mehta, Kosha Briones, Marco A. Manka, Paul P. Coombes, Jason D. Williams, Roger Patel, Vinood B. Syn, Wing-Kin TI Iron enhances hepatic fibrogenesis through TGF-beta activation SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Syn, Wing-Kin] Med Univ South Carolina, Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Ralph H Johnson VAMC, Gastroenterol, Charleston, SC USA. [Mehta, Kosha; Briones, Marco A.; Manka, Paul P.; Coombes, Jason D.; Williams, Roger] Kings Coll London, Fac Life Sci, Inst Hepatol, Div Transplantat Immunol & Mucosal Biol, London, England. [Mehta, Kosha; Patel, Vinood B.] Univ Westminster, Biomed Sci, London, England. [Manka, Paul P.] Univ Hosp Essen, Gastroenterol & Hepatol, Essen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 727 BP 360A EP 360A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801467 ER PT J AU Butt, AA Ren, Y AF Butt, Adeel A. Ren, Yanjie TI Comparing Child-Pugh, MELD and FIB-4 Scores to Predict Mortality, Hepatic Decompensation and Hepatocellular Carcinoma in HCV Infected Persons: ERCHIVES Study SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Butt, Adeel A.] Weill Cornell Med Coll, Div Infect Dis, Mars, PA USA. [Ren, Yanjie] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 742 BP 367A EP 367A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802013 ER PT J AU Jain, V Otero, D Gavrancic, T Liu, Q Marcus, S Brau, N AF Jain, Varun Otero, Diana Gavrancic, Tatjana Liu, Qing Marcus, Sonja Brau, Norbert TI Spontaneous Clearance of Chronic HCV Infection is More Frequent in HIV/HCV Coinfection and in HCV Genotype 2 and 3 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Jain, Varun; Otero, Diana; Gavrancic, Tatjana; Liu, Qing; Brau, Norbert] James J Peters VA Med Ctr, Program Med, Bronx, NY USA. [Jain, Varun; Otero, Diana; Gavrancic, Tatjana; Liu, Qing; Brau, Norbert] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Marcus, Sonja] James J Peters VA Med Ctr, Res Program, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 779 BP 384A EP 384A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802049 ER PT J AU Benhammou, J Yu, CY Kawamoto, JK Dixit, V Pimstone, N Sheinbaum, AJ Pisegna, JR AF Benhammou, Jihane Yu, Christine Y. Kawamoto, Jenna K. Dixit, Vivek Pimstone, Neville Sheinbaum, Alan J. Pisegna, Joseph R. TI Hepatitis C SVR is not affected by the metabolic syndrome or diabetes in patients treated at a single VA hospital clinic SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Benhammou, Jihane; Yu, Christine Y.] Univ Calif Los Angeles, Santa Monica, CA USA. [Kawamoto, Jenna K.; Dixit, Vivek; Pimstone, Neville; Sheinbaum, Alan J.; Pisegna, Joseph R.] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 787 BP 387A EP 388A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802056 ER PT J AU Tran, TT Feld, JJ Foster, GR Naik, S Eggleton, ES Zhang, J Natha, M Llewellyn, J Kreter, B Brainard, DM Wyles, DL Sulkowski, MS Rogal, SS AF Tran, Tram T. Feld, Jordan J. Foster, Graham R. Naik, Sarjita Eggleton, Edward S. Zhang, Jie Natha, Macky Llewellyn, Joseph Kreter, Bruce Brainard, Diana M. Wyles, David L. Sulkowski, Mark S. Rogal, Shari S. TI Gender Differences in Patients Treated for HCV: Efficacy and Safety of Sofosbuvir/Velpatasvir in Women SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Tran, Tram T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Feld, Jordan J.] Univ Toronto, Toronto, ON, Canada. [Foster, Graham R.] Queen Marys Univ London, London, England. [Naik, Sarjita; Eggleton, Edward S.; Zhang, Jie; Natha, Macky; Llewellyn, Joseph; Kreter, Bruce; Brainard, Diana M.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Wyles, David L.] Univ Calif San Diego, San Diego, CA 92103 USA. [Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA. [Rogal, Shari S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 857 BP 422A EP 422A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802125 ER PT J AU Butt, AA Ren, Y Marks, KM Shaikh, OS Sherman, KE AF Butt, Adeel A. Ren, Yanjie Marks, Kristen M. Shaikh, Obaid S. Sherman, Kenneth E. TI Does Paritaprevir/ritonavir, Ombitasvir, Dasabuvir Combination Increase the Risk of Hepatic Decompensation and Renal Insufficiency in Patients with Cirrhosis? SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Butt, Adeel A.; Marks, Kristen M.] Weill Cornell Med Coll, Div Infect Dis, Mars, PA USA. [Ren, Yanjie; Shaikh, Obaid S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sherman, Kenneth E.] Univ Cincinnatti, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 902 BP 451A EP 451A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802169 ER PT J AU Tsui, J Williams, E Green, P Berry, K Su, F Ioannou, GN AF Tsui, Judith Williams, Emily Green, Pamela Berry, Kristin Su, Feng Ioannou, George N. TI Alcohol use and hepatitis C virus treatment outcomes among 15,151 patients receiving direct antiviral agents SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Tsui, Judith; Su, Feng; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Williams, Emily; Green, Pamela; Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 911 BP 457A EP 458A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802178 ER PT J AU Butt, AA Yan, P Marks, KM Shaikh, OS Sherman, KE AF Butt, Adeel A. Yan, Peng Marks, Kristen M. Shaikh, Obaid S. Sherman, Kenneth E. TI Real-world SVR Rates for Paretaprevir/ritonavir, Ombitasvir, Dasabuvir vs. Sofosbuvir/ledipasvir Regimens With and Without Ribavirin SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Butt, Adeel A.; Marks, Kristen M.] Weill Cornell Med Coll, Div Infect Dis, Mars, PA USA. [Yan, Peng; Shaikh, Obaid S.] VA Pittsburgh Healtcare Syst, Pittsburgh, PA USA. [Sherman, Kenneth E.] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 930 BP 468A EP 468A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802197 ER PT J AU Fuchs, M Morgan, TR Charafeddine, M Brau, N Schmidt, WN Kozal, M Naggie, S Cheung, R Pilot-Matias, T Yu, Y Richards, K Mullally, V Cohen, DE Monto, A Toro, DH AF Fuchs, Michael Morgan, Timothy R. Charafeddine, Mariem Brau, Norbert Schmidt, Warren N. Kozal, Michael Naggie, Susanna Cheung, Ramsey Pilot-Matias, Tami Yu, Yao Richards, Kristine Mullally, Victoria Cohen, Daniel E. Monto, Alexander Toro, Doris H. TI An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Fuchs, Michael] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Long Beach, CA USA. [Charafeddine, Mariem; Pilot-Matias, Tami; Yu, Yao; Richards, Kristine; Mullally, Victoria; Cohen, Daniel E.] AbbVie Inc, N Chicago, IL USA. [Brau, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Schmidt, Warren N.] Iowa City VA Healthcare Syst, Iowa City, IA 5 USA. [Kozal, Michael] VA Connecticut Healthcare Syst, New Haven, CT USA. [Kozal, Michael] Yale Univ, Sch Med, New Haven, CT USA. [Naggie, Susanna] Durham VA Med Ctr, Durham, NC USA. [Cheung, Ramsey] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA. [Toro, Doris H.] VA Caribbean Healthcare Syst, San Juan, PR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 963 BP 488A EP 488A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802230 ER PT J AU Golden-Mason, LM Giugliano, S Campbell, EL Cheng, LL Collins, CA Rosen, HR AF Golden-Mason, Lucy M. Giugliano, Silvia Campbell, Eric L. Cheng, Linling Collins, Christine A. Rosen, Hugo R. TI Advanced Nonalcoholic Steatohepatitis (NASH) Associated with Activated, Proinflammatory Phenotypes of Circulating Neutrophils SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Golden-Mason, Lucy M.; Giugliano, Silvia; Campbell, Eric L.; Cheng, Linling; Collins, Christine A.; Rosen, Hugo R.] Univ Colorado, GI Hepatol, Aurora, CO USA. [Golden-Mason, Lucy M.; Collins, Christine A.; Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1158 BP 583A EP 583A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802425 ER PT J AU Giugliano, S Kriss, M Golden-Mason, LM Wilson, C Rosen, HR AF Giugliano, Silvia Kriss, Michael Golden-Mason, Lucy M. Wilson, Cara Rosen, Hugo R. TI Alcohol Exposure Differentially Regulates Immune Responses of Liver Endothelial Cells and Hepatic Stellate Cells to E. coli Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Giugliano, Silvia; Kriss, Michael; Golden-Mason, Lucy M.; Rosen, Hugo R.] Univ Colorado, Div Gastroenterol & Hepatol, Anschutz Med Campus, Aurora, CO USA. [Wilson, Cara] Univ Colorado, Div Infect Dis, Anschutz Med Campus, Aurora, CO USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1225 BP 615A EP 615A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803032 ER PT J AU Jay, CL Washburn, K Halff, GA Abrahamian, G Pugh, J AF Jay, Colleen L. Washburn, Kenneth Halff, Glenn A. Abrahamian, Greg Pugh, Jacqueline TI Graft quality matters: KDPI is more predictive of survival than SLK compared with liver transplant alone in a propensity score matched cohort SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Jay, Colleen L.; Halff, Glenn A.; Abrahamian, Greg] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, San Antonio, TX 78229 USA. [Washburn, Kenneth] Ohio State Univ, Med Ctr, Comprehens Transplant Ctr, Columbus, TX USA. [Pugh, Jacqueline] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1381 BP 691A EP 691A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803188 ER PT J AU McMahan, R Porsche, C McGettigan, B Rosen, HR AF McMahan, Rachel Porsche, Cara McGettigan, Brett Rosen, Hugo R. TI Oxidized low-density lipoprotein (oxLDL) induces a pro-inflammatory/pro-fibrotic response from liver sinusoidal endothelial cells that is attenuated by activation of the nuclear bile acid receptor FXR SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [McMahan, Rachel; Porsche, Cara; McGettigan, Brett; Rosen, Hugo R.] Univ Colorado Denver, Gastroenterol & Hepatol, Aurora, CO USA. [Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1500 BP 749A EP 749A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803307 ER PT J AU Golden-Mason, LM McMahan, R Cheng, LL Rosen, HR AF Golden-Mason, Lucy M. McMahan, Rachel Cheng, Linling Rosen, Hugo R. TI Group 2 Innate Lymphoid Cells (ILC2s) are Altered in Fatty Liver Disease SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Golden-Mason, Lucy M.; McMahan, Rachel; Cheng, Linling; Rosen, Hugo R.] Univ Colorado, GI Hepatol, Aurora, CO USA. [Golden-Mason, Lucy M.; Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1506 BP 751A EP 752A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803313 ER PT J AU Chen, HQ Li, Y Sherban, A Nocon, A Luo, T Wang, H Bin Gao, Zang, MW AF Chen, Hanqing Li, Yu Sherban, Alex Nocon, Allison Luo, Ting Wang, Hua Bin Gao Zang, Mengwei TI Pharmacological and Molecular inhibition of mTORC1 Activation Reduces Ethanol-Induced ER Stress and Ameliorates Alcoholic Liver Injury in Mice SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chen, Hanqing; Li, Yu; Sherban, Alex; Nocon, Allison; Luo, Ting] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Wang, Hua; Bin Gao] NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA. [Chen, Hanqing; Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Chen, Hanqing; Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Zang, Mengwei] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1515 BP 756A EP 756A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803322 ER PT J AU Rubin, J Dave, S Aulakh, H Bacchus, A Earnest, GE Gager, K Tubbs, R Zejnullahu, K Dulay, M AF Rubin, Jessica Dave, Shravan Aulakh, Hardeep Bacchus, Alicia Earnest, Gillian E. Gager, Krista Tubbs, Ruth Zejnullahu, Kreshnik Dulay, Maya TI Improving Age-Based Hepatitis C Screening at a Veterans Affairs Primary Care Clinic SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Rubin, Jessica; Dave, Shravan; Aulakh, Hardeep; Bacchus, Alicia; Zejnullahu, Kreshnik] UCSF, San Francisco, CA USA. [Earnest, Gillian E.; Gager, Krista; Tubbs, Ruth; Dulay, Maya] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1745 BP 862A EP 862A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804107 ER PT J AU Rogal, SS Andrea, R Calgaro, L Daley, MB McCarthy, R Jonassaint, NL Zickmund, S AF Rogal, Shari S. Andrea, Reid Calgaro, Linda Daley, Molly B. McCarthy, Rory Jonassaint, Naudia L. Zickmund, Susan TI Primary Care and Hepatology Provider Attitudes Towards Hepatitis C Treatment Candidacy and Adherence SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Rogal, Shari S.; Calgaro, Linda; Daley, Molly B.; McCarthy, Rory; Zickmund, Susan] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rogal, Shari S.; Jonassaint, Naudia L.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Rogal, Shari S.; Jonassaint, Naudia L.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Andrea, Reid] Washington DC VA Healthcare Syst, Div Gastroenterol Hepatol & Nutr, Washington, DC USA. [Zickmund, Susan] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1755 BP 866A EP 867A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804117 ER PT J AU Su, F Green, P Berry, K Ioannou, GN AF Su, Feng Green, Pamela Berry, Kristin Ioannou, George N. TI The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Su, Feng; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Green, Pamela; Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1913 BP 946A EP 947A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804273 ER PT J AU Belperio, PS Bhattacharya, D Shahoumian, TA Loomis, TP Goetz, MB Mole, LA Backus, LI AF Belperio, Pamela S. Bhattacharya, Debika Shahoumian, Troy A. Loomis, Timothy P. Goetz, Matthew B. Mole, Larry A. Backus, Lisa I. TI Effectiveness of Ledipasvir/Sofosbuvir +/- Ribavirin and Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir +/- Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Belperio, Pamela S.; Shahoumian, Troy A.; Loomis, Timothy P.; Mole, Larry A.; Backus, Lisa I.] Vet Affairs Palo Alto Hlth Care Syst, Populat Hlth Serv, Palo Alto, CA USA. [Bhattacharya, Debika; Goetz, Matthew B.] Vet Affairs Greater Los Angeles Hlth Care Syst, Med, Los Angeles, CA USA. [Bhattacharya, Debika; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Backus, Lisa I.] Palo Alto Hlth Care Syst, Dept Vet Affairs, Med, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1935 BP 957A EP 958A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804295 ER PT J AU Su, F Greene, P Berry, K Ioannou, GN AF Su, Feng Greene, Pamela Berry, Kristin Ioannou, George N. TI High Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection in Elderly Patients in a National Healthcare System SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Su, Feng; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Greene, Pamela; Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1940 BP 960A EP 960A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804300 ER PT J AU DiNapoli, EA Cinna, C Whiteman, KL Fox, L Appelt, CJ Kasckow, J AF DiNapoli, Elizabeth A. Cinna, Christopher Whiteman, Karen L. Fox, Lauren Appelt, Cathleen J. Kasckow, John TI Mental health treatment preferences and challenges of living with multimorbidity from the veteran perspective SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE multimorbidity; veteran; self-management; mental health; treatment preferences ID CARDIOVASCULAR-DISEASE RISK; RANDOMIZED CONTROLLED-TRIAL; BIPOLAR DISORDER; PRIMARY-CARE; COLLABORATIVE CARE; DEPRESSION; ILLNESS; SERVICES; OUTCOMES; SYSTEM AB Objective: To explore middle-aged and older veterans' current disease-management practices, mental health treatment preferences, and challenges of living with multiple chronic health conditions (i.e., multimorbidity). Methods: Semi-structured qualitative interviews and self-report measures were collected from 28 middle-aged and older (50 years of age or older) veterans with multimorbidity. Results: Our sample of veterans with multimorbidity was, on average, mildly depressed and anxious with elevated stress and disability. Veterans acknowledged the interaction of physical and emotional symptoms, which caused greater difficulty with health care management and daily functioning. Veterans had many concerns regarding their physical and emotional health conditions, such as continued disease progression and the addition of other emotional and physical health complications. Veterans also identified specific self-care approaches for disease management (e.g., medication, healthy lifestyle practices, and psychological stress management techniques), as well as barriers to engaging in care (e.g., money, transportation, and stigma). Participants preferred a combination of medication, psychotherapy, and healthy lifestyle practices for mental health treatment. The majority of participants (88.5%) agreed that these mental health treatments would be beneficial to integrate into disease management for older veterans with multimorbidity. Lastly, veterans provided an array of recommendations for improving Veteran's Administration services and reducing mental health stigma. Conclusions: These findings provide support for patient-centered approaches and integrated mental and physical health self-management in the Veteran's Administration for middle-aged and older veterans with multiple chronic conditions. Copyright (C) 2016 John Wiley & Sons, Ltd. C1 [DiNapoli, Elizabeth A.; Cinna, Christopher; Fox, Lauren; Appelt, Cathleen J.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15261 USA. [DiNapoli, Elizabeth A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Cinna, Christopher; Appelt, Cathleen J.] Duquesne Univ, Grad Ctr Social & Publ Policy, Pittsburgh, PA 15219 USA. [Whiteman, Karen L.] Dartmouth Ctr Hlth & Aging, Lebanon, NH USA. [Whiteman, Karen L.] CDC Hlth Promot Res Ctr Dartmouth, Lebanon, NH USA. [Whiteman, Karen L.] Geisel Sch Med Dartmouth, Dept Psychiat, Pittsburgh, PA USA. [Appelt, Cathleen J.] Duquesne Univ, Dept Sociol, Pittsburgh, PA 15219 USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Kasckow, John] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Kasckow, John] VA Pittsburgh Healthcare Syst, Behav Hlth, Pittsburgh, PA USA. [Kasckow, John] VA Pittsburgh Ctr Hlth & Equ Promot, Pittsburgh, PA USA. RP DiNapoli, EA (reprint author), VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15261 USA.; DiNapoli, EA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. EM Elizabeth.Dinapoli2@va.gov FU VISN 4 MIRECC Pilot Project FX This project was funded by VISN 4 MIRECC Pilot Project (PI: DiNapoli). The attitudes expressed are those of the authors and do not necessarily reflect those of the Pittsburgh VA Healthcare System, Department of Veterans Affairs, or US government. NR 29 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD OCT PY 2016 VL 31 IS 10 BP 1097 EP 1104 DI 10.1002/gps.4550 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EB0KY UT WOS:000387033900002 PM 27442187 ER PT J AU Goodson, JT Haeffel, GJ Raush, DA Hershenberg, R AF Goodson, Jason T. Haeffel, Gerald J. Raush, David A. Hershenberg, Rachel TI The Safety Behavior Assessment Form: Development and Validation SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE safety behaviors; anxiety; scale construction; Veterans ID PANIC DISORDER; SOCIAL PHOBIA; PSYCHOMETRIC PROPERTIES; ANXIETY DISORDERS; MAINTENANCE; EXPOSURE; THERAPY; SEEKING; SCALE; AGORAPHOBIA AB ObjectiveTo develop and validate an easy to administer measure of safety behaviors called the Safety Behavior Assessment Form (SBAF). MethodWe provide reliability and validity evidence from four studies. The first study used a cross-sectional design with a sample consisting of both clinical (U.S. military Veterans; n = 42) and nonclinical participants (undergraduates; n = 198). Study 2 used a cross-sectional design with a sample of U.S. military Veterans (n = 215). Study 3 used a pre-post treatment design with a sample of U.S. military Veterans (n = 42). Study 4 used a 2-time-point longitudinal design with a sample of undergraduates (n = 77). ResultsThe SBAF demonstrated strong levels of internal consistency and test-retest reliability in all four studies. The SBAF also demonstrated predictive and discriminant validity. In Study 3, the SBAF predicted anxious, but not depressive, treatment outcomes in a sample of Veterans. In Study 4, the SBAF predicted prospective changes in anxiety over a 2-week interval in a sample of undergraduates even after controlling for a competing measure of safety behaviors. ConclusionResults of these four studies indicate that the SBAF is a reliable and valid measure of safety behaviors that can be used in both clinical and nonclinical settings. C1 [Goodson, Jason T.; Raush, David A.; Hershenberg, Rachel] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Goodson, Jason T.; Raush, David A.; Hershenberg, Rachel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Haeffel, Gerald J.] Univ Notre Dame, Notre Dame, IN 46556 USA. RP Goodson, JT (reprint author), Philadelphia VA Med Ctr, Behav Hlth 116, 3900 Woodland & Univ Ave, Philadelphia, PA 19104 USA. EM Jason.Goodson@va.gov NR 41 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD OCT PY 2016 VL 72 IS 10 BP 1099 EP 1111 DI 10.1002/jclp.22325 PG 13 WC Psychology, Clinical SC Psychology GA DW5TO UT WOS:000383710000009 PM 27228035 ER PT J AU Sacks, GD Ulloa, JG Shew, SB AF Sacks, Greg D. Ulloa, Jesus G. Shew, Stephen B. TI Is there a relationship between hospital volume and patient outcomes in gastroschisis repair? SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article DE Volume outcome; Gastroschisis; Newborn surgery; Regionalization ID MORTALITY; SURGERY; ESOPHAGECTOMY; OPERATIONS; IMPACT; CARE AB Purpose: Given the well-established relationship between surgical volume and outcomes for many surgical procedures, we examined whether the same relationship exists for gastroschisis closure. Methods: We conducted a retrospective analysis of infants who underwent gastroschisis closure between 1999 and 2007 using a California birth-linked cohort. Hospitals were divided into terciles based on the number of gastroschisis closures performed annually. Using regression techniques, we examined the effects of hospital volume on patient mortality and length of stay while controlling for patient and hospital confounders. Results: We identified 1537 infants who underwent gastroschisis repair at 55 hospitals, 4 of which were high-volume and 42 of which were low-volume. The overall in-hospital mortality rate was 4.8% and the median length of stay was 46.5 days. After controlling for other factors, patients treated at high-volume hospitals had significantly lower odds of inpatient mortality (OR 0.40; 95% CI 0.21, 0.76). There was a near-significant trend towards shorter hospital length of stay at highvolume hospitals (p=0.066). Conclusions: Patients who undergo gastroschisis closure at high-volume hospitals in California experience lower odds of in-hospital mortality compared to those treated at low-volume hospitals. These findings offer initial evidence to support policies that limit the number of hospitals providing complex newborn surgical care. (C) 2016 Elsevier Inc. All rights reserved. C1 [Sacks, Greg D.; Shew, Stephen B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza B7-11, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Ulloa, Jesus G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ulloa, Jesus G.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza B7-11, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu FU Robert Wood Johnson Foundation (RWJF)/Veterans Affairs Clinical Scholars program at the University of California, Los Angeles FX GDS and JGU were supported by the Robert Wood Johnson Foundation (RWJF)/Veterans Affairs Clinical Scholars program at the University of California, Los Angeles. RWJF had no role in the preparation, review, or approval of the manuscript. NR 28 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 EI 1531-5037 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD OCT PY 2016 VL 51 IS 10 BP 1650 EP 1654 DI 10.1016/j.jpedsurg.2016.04.009 PG 5 WC Pediatrics; Surgery SC Pediatrics; Surgery GA EA4MT UT WOS:000386587500014 PM 27139881 ER PT J AU Bethel, M Weaver, FM Bailey, L Miskevics, S Svircev, JN Burns, SP Hoenig, H Lyles, K Carbone, LD AF Bethel, M. Weaver, F. M. Bailey, L. Miskevics, S. Svircev, J. N. Burns, S. P. Hoenig, H. Lyles, K. Carbone, L. D. TI Risk factors for osteoporotic fractures in persons with spinal cord injuries and disorders SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Clinical; Comorbidities; Fractures; SCI-related; Spinal cord injury ID BONE-MINERAL DENSITY; LOWER-EXTREMITY FRACTURES; POPULATION-BASED-COHORT; POSTMENOPAUSAL WOMEN; HIP FRACTURE; LUMBAR SPINE; OPIOID USE; MEN; ASSOCIATION; METAANALYSIS AB Clinical risk factors for fracture were explored among Veterans with a spinal cord injury. At the end of 11 years of follow-up, the absolute risk of fracture was approximately 20 %. Among the clinical and SCI-related factors explored, a prior history of fracture was strongly associated with incident fracture. Few studies to date have comprehensively addressed clinical risk factors for fracture in persons with spinal cord injury (SCI). The purpose of this study was to identify risk factors for incident osteoporotic fractures in persons with a SCI that can be easily determined at the point of care. The Veteran's Affairs Spinal Cord Dysfunction Registry, a national database of persons with a SCI, was used to examine clinical and SCI-related risk factors for fracture. Incident fractures were identified in a cohort of persons with chronic SCI, defined as SCI present for at least 2 years. Cox regression models were used to estimate the risk of incident fractures. There were 22,516 persons with chronic SCI included in the cohort with 3365 incident fractures. The mean observational follow-up time for the overall sample was 6.2 years (median 6.0, IQR 2.9-11.0). The mean observational follow-up time for the fracture group was 3.9 years (median 3.3, IQR 1.4-6.1) and 6.7 years (median 6.7, IQR 3.1-11.0) for the nonfracture group. By the end of the study, which included predominantly older Veterans with a SCI observed for a relatively short period of time, the absolute (i.e., cumulative hazard) for incident fractures was 0.17 (95%CI 0.14-0.21). In multivariable analysis, factors associated with an increased risk of fracture included White race, traumatic etiology of SCI, paraplegia, complete extent of SCI, longer duration of SCI, use of anticonvulsants and opioids, prevalent fractures, and higher Charlson Comorbidity Indices. Women aged 50 and older were also at higher risk of sustaining an incident fracture at any time during the 11-year follow-up period. There are multiple clinical and SCI-related risk factors which can be used to predict fracture in persons with a SCI. Clinicians should be particularly concerned about incident fracture risk in persons with a SCI who have had a previous fracture. C1 [Bethel, M.; Carbone, L. D.] Charlie Norwood Vet Affairs Med Ctr, Augusta, GA 30904 USA. [Bethel, M.; Carbone, L. D.] Augusta Univ, Dept Med, Med Coll Georgia, 1120 15th St, Augusta, GA 30912 USA. [Weaver, F. M.; Bailey, L.; Miskevics, S.] Edward J Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA. [Weaver, F. M.] Loyola Univ, Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA. [Bailey, L.] Univ Illinois, Sch Publ Hlth, Dept Epidemiol & Biostat, Chicago, IL USA. [Svircev, J. N.; Burns, S. P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Svircev, J. N.; Burns, S. P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hoenig, H.] Durham VA Med Ctr, Durham, NC USA. [Lyles, K.] Duke Univ, Dept Med, Durham, NC USA. [Lyles, K.] VAMC, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Bethel, M (reprint author), Charlie Norwood Vet Affairs Med Ctr, Augusta, GA 30904 USA.; Bethel, M (reprint author), Augusta Univ, Dept Med, Med Coll Georgia, 1120 15th St, Augusta, GA 30912 USA. EM mbethel@gru.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development [IIR 11-103-3] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development IIR 11-103-3. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 65 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD OCT PY 2016 VL 27 IS 10 BP 3011 EP 3021 DI 10.1007/s00198-016-3627-2 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DZ2LM UT WOS:000385673300011 PM 27230522 ER PT J AU Honda, JR Hasan, NA Davidson, RM Williams, MD Epperson, LE Reynolds, PR Smith, T Iakhiaeva, E Bankowski, MJ Wallace, RJ Chan, ED Falkinham, JO Strong, M AF Honda, Jennifer R. Hasan, Nabeeh A. Davidson, Rebecca M. Williams, Myra D. Epperson, L. Elaine Reynolds, Paul R. Smith, Terry Iakhiaeva, Elena Bankowski, Matthew J. Wallace, Richard J., Jr. Chan, Edward D. Falkinham, Joseph O., III Strong, Michael TI Environmental Nontuberculous Mycobacteria in the Hawaiian Islands SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AVIUM COMPLEX; LUNG-DISEASE; UNITED-STATES; EPIDEMIOLOGY; INFECTIONS; WATER; INTRACELLULARE; ABSCESSUS; PATHOGENS; CHELONAE AB Lung disease caused by nontuberculous mycobacteria (NTM) is an emerging infectious disease of global significance. Epidemiologic studies have shown the Hawaiian Islands have the highest prevalence of NTM lung infections in the United States. However, potential environmental reservoirs and species diversity have not been characterized. In this cross-sectional study, we describe molecular and phylogenetic comparisons of NTM isolated from 172 household plumbing biofilms and soil samples from 62 non-patient households and 15 respiratory specimens. Although non-uniform geographic sampling and availability of patient information were limitations, Mycobacterium chimaera was found to be the dominant species in both environmental and respiratory specimens. In contrast to previous studies from the continental U.S., no Mycobacterium avium was identified. Mycobacterium intracellulare was found only in respiratory specimens and a soil sample. We conclude that Hawai'i's household water sources contain a unique composition of Mycobacterium avium complex (MAC), increasing our appreciation of NTM organisms of pulmonary importance in tropical environments. C1 [Honda, Jennifer R.; Chan, Edward D.; Strong, Michael] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO 80045 USA. [Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Honda, Jennifer R.; Hasan, Nabeeh A.; Davidson, Rebecca M.; Epperson, L. Elaine; Reynolds, Paul R.; Chan, Edward D.; Strong, Michael] Natl Jewish Hlth, Denver, CO 80206 USA. [Williams, Myra D.; Smith, Terry; Iakhiaeva, Elena; Falkinham, Joseph O., III] Virginia Tech, Blacksburg, VA USA. [Bankowski, Matthew J.] Diagnost Lab Serv Inc, Aiea, HI USA. [Bankowski, Matthew J.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Pathol & Trop Med, Honolulu, HI 96822 USA. [Bankowski, Matthew J.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Med Microbiol, Honolulu, HI 96822 USA. [Bankowski, Matthew J.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Pharmacol, Honolulu, HI 96822 USA. [Wallace, Richard J., Jr.] Univ Texas Hlth Sci Ctr, Tyler, TX USA. RP Honda, JR (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO 80045 USA.; Honda, JR (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.; Honda, JR (reprint author), Natl Jewish Hlth, Denver, CO 80206 USA. EM Jennifer.Honda@ucdenver.edu FU NIH Biomedical Informatics training grant [2T15LM009451-06]; Amon G. Carter Foundation FX JRH acknowledges the University of Colorado AMC Division of Pulmonary Medicine and the Shoot for the Cure Foundation. NAH acknowledges the NIH Biomedical Informatics training grant 2T15LM009451-06. MS acknowledges the Boettcher Webb-Waring Foundation and the Potts Memorial Foundation. Finally, the University of Texas Health Science Center and National Jewish Health would like to acknowledge support from the Amon G. Carter Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005068 DI 10.1371/journal.pntd.0005068 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200048 PM 27780201 ER PT J AU Pereira, TA Syn, WK Amancio, FF Cunha, PHD Caporali, JFM Trindade, GVD Santos, ET Souza, MM Andrade, ZA Witek, RP Secor, WE Pereira, FEL Lambertucci, JR Diehl, AM AF Pereira, Thiago Almeida Syn, Wing-Kin Amancio, Frederico Figueiredo Diniz Cunha, Pedro Henrique Morais Caporali, Julia Fonseca de Melo Trindade, Guilherme Vaz Santos, Elisangela Trindade Souza, Marcia Maria Andrade, Zilton Araujo Witek, Rafal P. Secor, William Evan Lima Pereira, Fausto Edmundo Lambertucci, Jose Roberto Diehl, Anna Mae TI Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID GRANULOMA-FORMATION; LIVER; INFLAMMATION; INFECTION; RESPONSES; FIBROSIS; INJURY; CELLS AB Background Symptomatic acute schistosomiasis mansoni is a systemic hypersensitivity reaction against the migrating schistosomula and mature eggs after a primary infection. The mechanisms involved in the pathogenesis of acute schistosomiasis are not fully elucidated. Osteopontin has been implicated in granulomatous reactions and in acute hepatic injury. Our aims were to evaluate if osteopontin plays a role in acute Schistosoma mansoni infection in both human and experimentally infected mice and if circulating OPN levels could be a novel biomarker of this infection. Methodology/Principal Findings Serum/plasma osteopontin levels were measured by ELISA in patients with acute (n = 28), hepatointestinal (n = 26), hepatosplenic (n = 39) schistosomiasis and in uninfected controls (n = 21). Liver osteopontin was assessed by immunohistochemistry in needle biopsies of 5 patients. Sera and hepatic osteopontin were quantified in the murine model of schistosomiasis mansoni during acute (7 and 8 weeks post infection, n = 10) and chronic (30 weeks post infection, n = 8) phase. Circulating osteopontin levels are increased in patients with acute schistosomiasis (p = 0.0001). The highest levels of OPN were observed during the peak of clinical symptoms (7-11 weeks post infection), returning to baseline level once the granulomas were modulated (>12 weeks post infection). The plasma levels in acute schistosomiasis were even higher than in hepatosplenic patients. The murine model mirrored the human disease. Macrophages were the major source of OPN in human and murine acute schistosomiasis, while the ductular reaction maintains OPN production in hepatosplenic disease. Soluble egg antigens from S. mansoni induced OPN expression in primary human kupffer cells. Conclusions/Significance S. mansoni egg antigens induce the production of OPN by macrophages in the necroticexudative granulomas characteristic of acute schistosomiasis mansoni. Circulating OPN levels are upregulated in human and murine acute schistosomiasis and could be a noninvasive biomarker of this form of disease. C1 [Pereira, Thiago Almeida; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA. [Pereira, Thiago Almeida; Amancio, Frederico Figueiredo; Diniz Cunha, Pedro Henrique; Morais Caporali, Julia Fonseca; de Melo Trindade, Guilherme Vaz; Lambertucci, Jose Roberto] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. [Pereira, Thiago Almeida; Santos, Elisangela Trindade; Souza, Marcia Maria; Andrade, Zilton Araujo] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Patol Expt, Salvador, BA, Brazil. [Pereira, Thiago Almeida] NIAID, Immunopathogesis Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, Liver Regenerat & Repair Res Grp, London, England. [de Melo Trindade, Guilherme Vaz] Natl Univ Ireland, Sch Med, Dept Physiol, Galway, Ireland. [Witek, Rafal P.] Thermo Fisher Sci, Frederick, MD USA. [Secor, William Evan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lima Pereira, Fausto Edmundo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Vitoria, ES, Brazil. RP Diehl, AM (reprint author), Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA.; Lambertucci, JR (reprint author), Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. EM jrlambertu@gmail.com; annamae.diehl@duke.edu FU National Institutes of Health [R01-DK-077794]; National Institutes of Health (Division of Intramural Research, NIAID, NIH); Duke University; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) FX This work was supported by National Institutes of Health (grant number R01-DK-077794 (to AMD); Division of Intramural Research, NIAID, NIH (to TAP)); the Duke University Endowment (the Florence McAlister Professorship) (to AMD), the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq) (to TAP, FELP, JRL and ZAA); and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (to JRL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005057 DI 10.1371/journal.pntd.0005057 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200038 PM 27755536 ER PT J AU Oh, JY Hamm, J Xu, X Genschmer, K Zhong, M Lebensburger, J Marques, MB Kerby, JD Pittet, JF Gaggar, A Patel, RP AF Oh, Joo-Yeun Hamm, Jennifer Xu, Xin Genschmer, Kristopher Zhong, Ming Lebensburger, Jeffrey Marques, Marisa B. Kerby, Jeffrey D. Pittet, Jean-Francois Gaggar, Amit Patel, Rakesh P. TI Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices SO REDOX BIOLOGY LA English DT Article DE Exosomes; Microparticles; Hemin ID SICKLE-CELL-DISEASE; NITRIC-OXIDE BIOAVAILABILITY; ACUTE CHEST SYNDROME; STORAGE LESION; MOUSE MODELS; FERRYL IRON; HEMOPEXIN; ASSOCIATION; HAPTOGLOBIN; HEMOLYSIS AB Cell-free heme (CFH) and hemoglobin (Hb) have emerged as distinct mediators of acute injury characterized by inflammation and microcirculatory dysfunction in hemolytic conditions and critical illness. Several reports have shown changes in Hb and CFH in specific pathophysiological settings. Using PBS, plasma from patients with sickle cell disease, acute respiratory distress syndrome (ARDS) patients and supernatants from red cells units, we found that commonly used assays and commercially available kits do not distinguish between CFH and Hb. Furthermore, they suffer from a variety of false-positive interferences and limitations (including from bilirubin) that lead to either over-or underestimation of CFH and/or Hb. Moreover, commonly used protocols to separate CFH and Hb based on molecular weight (MWt) are inefficient due to CFH hydrophobicity. In this study, we developed and validated a new approach based on absorbance spectrum deconvolution with least square fitting analyses that overcomes these limitations and simultaneously measures CFH and Hb in simple aqueous buffers, plasma or when associated with red cell derived microvesicles. We show how incorporating other plasma factors that absorb light over the visible wavelength range (specifically bilirubin), coupled with truncating the wavelength range analyzed, or addition of mild detergent significantly improves fits allowing measurement of oxyHb, CFH and metHb with >90% accuracy. When this approach was applied to samples from SCD patients, we observed that CFH levels are higher than previously reported and of similar magnitude to Hb. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license C1 [Marques, Marisa B.; Patel, Rakesh P.] Univ Alabama Birmingham, Dept Pathol, BMR 2,Room 532,901 19th St South, Birmingham, AL 35294 USA. [Hamm, Jennifer; Lebensburger, Jeffrey] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA. [Xu, Xin; Genschmer, Kristopher; Zhong, Ming; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kerby, Jeffrey D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA. [Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Perioperat Med, Birmingham, AL 35294 USA. [Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL 35294 USA. [Patel, Rakesh P.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Kerby, Jeffrey D.; Gaggar, Amit] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Zhong, Ming] Shandong Univ, Qili Hosp, Dept Cardiol, Jinan, Shandong, Peoples R China. RP Patel, RP (reprint author), Univ Alabama Birmingham, Dept Pathol, BMR 2,Room 532,901 19th St South, Birmingham, AL 35294 USA. EM rakeshpatel@uabmc.edu OI Marques, Marisa/0000-0002-6689-7856 NR 39 TC 2 Z9 2 U1 9 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD OCT PY 2016 VL 9 BP 167 EP 177 DI 10.1016/j.redox.2016.08.003 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA6RQ UT WOS:000386757000019 PM 27566280 ER PT J AU Byon, CH Heath, JM Chen, YB AF Byon, Chang Hyun Heath, Jack M. Chen, Yabing TI Redox signaling in cardiovascular pathophysiology: A focus on hydrogen peroxide and vascular smooth muscle cells SO REDOX BIOLOGY LA English DT Review DE Oxidative stress; Hydrogen peroxide; Vascular smooth muscle cells; Calcification; Runx2 ID LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; MITOCHONDRIAL RESPIRATORY-CHAIN; OXIDATIVE DNA-DAMAGE; PROTEIN-KINASE-C; E-DEFICIENT MICE; REACTIVE OXYGEN; ENDOTHELIAL-CELLS; GROWTH-FACTOR; SUPEROXIDE-PRODUCTION AB Oxidative stress represents excessive intracellular levels of reactive oxygen species (ROS), which plays a major role in the pathogenesis of cardiovascular disease. Besides having a critical impact on the development and progression of vascular pathologies including atherosclerosis and diabetic vasculopathy, oxidative stress also regulates physiological signaling processes. As a cell permeable ROS generated by cellular metabolism involved in intracellular signaling, hydrogen peroxide (H2O2) exerts tremendous impact on cardiovascular pathophysiology. Under pathological conditions, increased oxidase activities and/or impaired antioxidant systems results in uncontrolled production of ROS. In a pro-oxidant environment, vascular smooth muscle cells (VSMC) undergo phenotypic changes which can lead to the development of vascular dysfunction such as vascular inflammation and calcification. Investigations are ongoing to elucidate the mechanisms for cardiovascular disorders induced by oxidative stress. This review mainly focuses on the role of H2O2 in regulating physiological and pathological signals in VSMC. (C) 2016. Published by Elsevier B.V. C1 [Byon, Chang Hyun; Heath, Jack M.; Chen, Yabing] Dept Pathol, Birmingham, AL 35294 USA. [Chen, Yabing] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Chen, Yabing] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Chen, YB (reprint author), Univ Alabama Birmingham, Dept Pathol, 614 Shelby Biomed Res Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA. EM ybchen@uab.edu FU National Institutes of Health [HL092215, DK100847]; Veterans Administration [BX000369, BX001591] FX Due to the scope and limitation, we apologize for not being able to include all the important work in the field. The authors thank Jay M McDonald, MD and Victor Darley-Usmar, PhD (University of Alabama at Birmingham, UAB) for critical review. The original research programs of the authors are supported by grants from the National Institutes of Health, HL092215, DK100847 and Veterans Administration BX000369 and BX001591 (project 2) to YC. NR 159 TC 2 Z9 2 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD OCT PY 2016 VL 9 BP 244 EP 253 DI 10.1016/j.redox.2016.08.015 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA6RQ UT WOS:000386757000026 PM 27591403 ER PT J AU Han, JY Weisbrod, RM Shao, D Watanabe, Y Yin, XY Bachschmid, MM Seta, F Janssen-Heininger, YMW Matsui, R Zang, MW Hamburg, NM Cohen, RA AF Han, Jingyan Weisbrod, Robert M. Shao, Di Watanabe, Yosuke Yin, Xiaoyan Bachschmid, Markus M. Seta, Francesca Janssen-Heininger, Yvonne M. W. Matsui, Reiko Zang, Mengwei Hamburg, Naomi M. Cohen, Richard A. TI The redox mechanism for vascular barrier dysfunction associated with metabolic disorders: Glutathionylation of Rac1 in endothelial cells SO REDOX BIOLOGY LA English DT Article DE Protein S-glutathionylation; Glutaredoxin-1; Actin cytoskeleton; Small Rho GTPase Rac1; Endothelial barrier function; ApoE-deficient mice ID REVERSIBLE S-GLUTATHIONYLATION; NITRIC-OXIDE SYNTHASE; FREE FATTY-ACIDS; INSULIN-RESISTANCE; OXIDATIVE STRESS; DIABETES-MELLITUS; THIOL-OXIDATION; UP-REGULATION; IN-VIVO; KINASE AB Background: Oxidative stress is implicated in increased vascular permeability associated with metabolic disorders, but the underlying redox mechanism is poorly defined. S-glutathionylation, a stable adduct of glutathione with protein sulfhydryl, is a reversible oxidative modification of protein and is emerging as an important redox signaling paradigm in cardiovascular physiopathology. The present study determines the role of protein S-glutathionylation in metabolic stress-induced endothelial cell permeability. Methods and results: In endothelial cells isolated from patients with type-2 diabetes mellitus, protein S-glutathionylation level was increased. This change was also observed in aortic endothelium in ApoE deficient (ApoE(-I-)) mice fed on Western diet. Metabolic stress-induced protein S-glutathionylation in human aortic endothelial cells (HAEC) was positively correlated with elevated endothelial cell permeability, as reflected by disassembly of cell-cell adherens junctions and cortical actin structures. These impairments were reversed by adenoviral overexpression of a specific de-glutathionylation enzyme, glutaredoxin-1 in cultured HAECs. Consistently, transgenic overexpression of human Glrx-1 in ApoE(-/-)mice fed the Western diet attenuated endothelial protein S-glutathionylation, actin cytoskeletal disorganization, and vascular permeability in the aorta. Mechanistically, glutathionylation and inactivation of Rac1, a small RhoGPase, were associated with endothelial hyperpermeability caused by metabolic stress. Glutathionylation of Rac1 on cysteine 81 and 157 located adjacent to guanine nucleotide binding site was required for the metabolic stress to inhibit Racl activity and promote endothelial hyperpermeability. Conclusions: Glutathionylation and inactivation of Racl in endothelial cells represent a novel redox mechanism of vascular barrier dysfunction associated with metabolic disorders. (C) 2016 The Authors. Published by Elsevier B.V. C1 [Han, Jingyan; Shao, Di; Watanabe, Yosuke; Bachschmid, Markus M.; Seta, Francesca; Matsui, Reiko; Cohen, Richard A.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect,Evans Dept Med, Boston, MA 02118 USA. [Weisbrod, Robert M.; Hamburg, Naomi M.] Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA. [Weisbrod, Robert M.; Hamburg, Naomi M.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. [Yin, Xiaoyan] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA. [Janssen-Heininger, Yvonne M. W.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA. [Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Dept Mol Med, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. RP Han, JY (reprint author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect,Evans Dept Med, Boston, MA 02118 USA. EM jingyanh@bu.edu OI Seta, Francesca/0000-0001-7985-5615; Bachschmid, Markus Michael/0000-0002-0748-5528 FU AHA [SDG20140036, 1UL1TR001430, T32 HL07224, R37 HL104017] FX This study is supported by AHA SDG20140036 (J.H.), 1UL1TR001430 (BU CTSI), T32 HL07224, and R37 HL104017 (R.A.C.). NR 63 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD OCT PY 2016 VL 9 BP 306 EP 319 DI 10.1016/j.redox.2016.09.003 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA6RQ UT WOS:000386757000032 PM 27693992 ER PT J AU Tukey, MH Clark, JA Bolton, R Kelley, MJ Slatore, CG Au, DH Wiener, RS AF Tukey, Melissa H. Clark, Jack A. Bolton, Rendelle Kelley, Michael J. Slatore, Christopher G. Au, David H. Wiener, Renda Soylemez TI Readiness for Implementation of Lung Cancer Screening A National Survey of Veterans Affairs Pulmonologists SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: To mitigate the potential harms of screening, professional societies recommend that lung cancer screening be conducted in multidisciplinary programs with the capacity to provide comprehensive care, from screening through pulmonary nodule evaluation to treatment of screen-detected cancers. The degree to which this standard can be met at the national level is unknown. Objectives: To assess the readiness of clinical facilities in a national healthcare system for implementation of comprehensive lung cancer screening programs, as compared with the ideal described in policy recommendations. Methods: This was a cross-sectional, self-administered survey of staff pulmonologists in pulmonary outpatient clinics in Veterans Health Administration facilities. Measurements and Main Results: The facility-level response rate was 84.1% (106 of 126 facilities with pulmonary clinics); 88.7% of facilities showed favorable provider perceptions of the evidence for lung cancer screening, and 73.6% of facilities had a favorable provider-perceived local context for screening implementation. All elements of the policy recommended infrastructure for comprehensive screening programs were present in 36 of 106 facilities (34.0%); the most common deficiencies were the lack of on-site positron emission tomography scanners or radiation oncology services. Overall, 26.5% of Veterans Health Administration facilities were ideally prepared for lung cancer screening implementation (44.1% if the policy recommendations for on-site positron emission tomography scanners and radiation oncology services were waived). Conclusions: Many facilities may be less than ideally positioned for the implementation of comprehensive lung cancer screening programs. To ensure safe, effective screening, hospitals may need to invest resources or coordinate care with facilities that can offer comprehensive care for screening through downstream evaluation and treatment of screen-detected cancers. C1 [Tukey, Melissa H.] Brown Univ, Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02912 USA. [Clark, Jack A.; Bolton, Rendelle; Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Affairs Hosp, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70 152, Bedford, MA 01730 USA. [Clark, Jack A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Kelley, Michael J.] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA. [Kelley, Michael J.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA. [Kelley, Michael J.] Duke Univ, Med Ctr, Dept Med, Durham, NC USA. [Slatore, Christopher G.] Vet Affairs Portland Hlth Care Syst, Ctr Improve Veteran Involvement Care, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Innovat Veteran Ctr & Value Driven Care, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm Crit Care Med, Seattle, WA 98195 USA. [Wiener, Renda Soylemez] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. RP Wiener, RS (reprint author), Edith Nourse Rogers Mem Vet Affairs Hosp, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70 152, Bedford, MA 01730 USA. EM rwiener@bu.edu OI Wiener, Renda/0000-0001-7712-2135 FU Veterans Health Administration (VA) QUERI [RRP 12-533]; Edith Nourse Rogers Memorial Veterans Affairs Hospital, Bedford, Massachusetts; Veterans Affairs Portland Health Care System, Portland, Oregon; Veterans Affairs Puget Sound Health Care System, Seattle, Washington FX Supported by Veterans Health Administration (VA) QUERI RRP 12-533; the study was also supported with resources from the Edith Nourse Rogers Memorial Veterans Affairs Hospital, Bedford, Massachusetts, the Veterans Affairs Portland Health Care System, Portland, Oregon, and Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD OCT PY 2016 VL 13 IS 10 BP 1794 EP 1801 DI 10.1513/AnnalsATS.201604-294OC PG 8 WC Respiratory System SC Respiratory System GA DZ8KG UT WOS:000386118700021 PM 27409524 ER PT J AU Kadri, SS Rhee, C Magda, G Strich, JR Cai, RM Sun, JF Decker, BK O'Grady, NP AF Kadri, Sameer S. Rhee, Chanu Magda, Gabriela Strich, Jeffrey R. Cai, Rongman Sun, Junfeng Decker, Brooke K. O'Grady, Naomi P. TI Synergy, Salary, and Satisfaction: Benefits of Training in Critical Care Medicine and Infectious Diseases Gleaned From a National Pilot Survey of Dually Trained Physicians SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE critical care; infectious diseases; survey ID UNITED-STATES; EMERGENCY PHYSICIANS; MORTALITY; CONSULTATIONS; SUBSPECIALTY; CHALLENGES; PREVENTION; PULMONARY; EDUCATION; THERAPY AB A survey of physicians trained in critical care medicine (CCM) and infectious diseases (ID) suggested this combination is synergistic and satisfying. However, most respondents had to train in individual specialties at separate institutions. Avenues for CCM-ID training should be considered.Methods.aEuro integral All physicians trained and/or certified in both CCM and ID to date in the United States were sent a Web-based questionnaire in 2015. Responses enabled a cross-sectional analysis of physician demographics and training and practice characteristics and satisfaction. Results.aEuro integral Of 202 CCM-ID physicians, 196 were alive and reachable. The response rate was 79%. Forty-six percent trained and 34% practice in the northeastern United States. Only 40% received dual training at the same institution. Eighty-three percent identified as either an intensivist with ID expertise (44%) or as equally an intensivist and ID physician (38%). Median salary was $265 000 (interquartile range [IQR], $215 000-$350 000). Practice settings were split between academic (45%) and community settings (42%). Two-thirds are clinicians but 62% conduct some research and 26% practice outpatient ID. Top reasons to dually specialize included clinical synergy (70%), procedural activity (50%), and less interest in pulmonology (49%). Although 38% cited less proficiency with bronchoscopy as a disadvantage, 87% seldom need pulmonary consultation in the intensive care unit. Median career satisfaction was 4 (IQR, 4-5) out of 5, and 76% would dually train again. Conclusions.aEuro integral CCM-ID graduates prefer the acute care setting, predominantly CCM or a combination of CCM and ID. They find combination training and practice to be synergistic and satisfying, but most have had to seek CCM and ID training independently at separate institutions. Given these findings, avenues for combined training in CCM-ID should be considered. C1 [Kadri, Sameer S.; Cai, Rongman; Sun, Junfeng; O'Grady, Naomi P.] NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,B10 2C-145, Bethesda, MD 20892 USA. [Rhee, Chanu] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Rhee, Chanu] Harvard Med Sch, Dept Populat Med, Boston, MA USA. [Rhee, Chanu] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Magda, Gabriela] Georgetown Univ Hosp, Medstar, Dept Med, Washington, DC 20007 USA. [Strich, Jeffrey R.] NIAID, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Decker, Brooke K.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. RP Kadri, SS (reprint author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,B10 2C-145, Bethesda, MD 20892 USA. EM sameer.kadri@nih.gov FU National Institutes of Health FX This work was supported by intramural funds from the National Institutes of Health. NR 34 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 868 EP 875 DI 10.1093/cid/ciw441 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100009 PM 27358351 ER PT J AU Razzak, A Smith, D Zahid, M Papachristou, G Khalid, A AF Razzak, Anthony Smith, Dineen Zahid, Maliha Papachristou, Georgios Khalid, Asif TI Effect of quality metric monitoring and colonoscopy performance SO ENDOSCOPY INTERNATIONAL OPEN LA English DT Article ID INCREASED ADENOMA DETECTION; SCREENING COLONOSCOPY; WITHDRAWAL TIMES; DETECTION RATES; FOLLOW-UP; CANCER; PROGRAM; INDICATORS; MORTALITY; IMPACT AB Background and aims: Adenoma detection rate (ADR) and cecal withdrawal time (CWT) have been identified as measures of colonoscopy quality. This study evaluates the impact of monitoring these measures on provider performance. Methods: Six blinded gastroenterologists practicing at a Veterans Affairs Medical Center were prospectively monitored over 9 months. Data for screening, adenoma surveillance, and fecal occult blood test positive (FOBT+) indicated colonoscopies were obtained, including exam preparation quality, cecal intubation rate, CWT, ADR, adenomas per colonoscopy (APC), and adverse events. Metrics were continuously monitored after a period of informed CWT monitoring and informed CWT+ADR monitoring. The primary outcome was impact on ADR and APC. Results: A total of 1671 colonoscopies were performed during the study period with 540 before informed monitoring, 528 during informed CWT monitoring, and 603 during informed CWT+ADR monitoring. No statistically significant impact on ADR was noted across each study phase. Multivariate regression revealed a trend towards fewer adenomas removed during the CWT monitoring phase (OR=0.79; 95%CI 0.62-1.02, P=0.065) and a trend towards more adenomas removed during the CWT+ADR monitoring phase when compared to baseline (OR=1.26; 95%CI 0.99-1.61, P=0.062). Indication for examination and provider were significant predictors for higher APC. Provider-specific data demonstrated a direct relationship between high ADR performers and increased CWT. Conclusions: Monitoring quality metrics did not significantly alter colonoscopy performance across a small heterogeneous group of providers. Non-significant trends towards higher APC were noted with CWT+ADR monitoring. Providers with a longer CWT had a higher ADR. Further studies are needed to determine the impact of monitoring on colonoscopy performance. C1 [Razzak, Anthony; Papachristou, Georgios; Khalid, Asif] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Smith, Dineen] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Zahid, Maliha] Univ Pittsburgh, Pittsburgh, PA USA. RP Khalid, A (reprint author), M2,C Wing,PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu NR 19 TC 0 Z9 0 U1 1 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 2364-3722 EI 2196-9736 J9 ENDOSC INT OPEN JI Endosc. Int. Open PD OCT PY 2016 VL 4 IS 10 BP E1023 EP E1027 DI 10.1055/s-0042-110787 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA0XQ UT WOS:000386313200001 PM 27747273 ER PT J AU Richard, MLL Brandon, D Lou, N Sato, S Caldwell, T Nowling, TK Gilkeson, G Zhang, XK AF Richard, Mara L. Lennard Brandon, Danielle Lou, Ning Sato, Shuzo Caldwell, Tomika Nowling, Tamara K. Gilkeson, Gary Zhang, Xian K. TI Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Cytokines; G-CSF; Fli-1; Gene regulation; Inflammation; Transcriptional factors ID FLI-1 TRANSCRIPTION FACTOR; DNA-BINDING; G-CSF; ETS FAMILY; NEUTROPHIL MOBILIZATION; RHEUMATOID-ARTHRITIS; DECREASED EXPRESSION; PROGENITOR CELLS; LUPUS NEPHRITIS; MRL/LPR MICE AB Fli-1 has emerged as a critical regulator of inflammatory mediators, including MCP-1, CCL5, and IL-6. The cytokine, granulocyte colony stimulating factor (G-CSF) regulates neutrophil precursor maturation and survival, and activates mature neutrophils. Previously, a significant decrease in neutrophil infiltration into the kidneys of Fli-1(+/-) lupusprone mice was observed. In this study, a significant decrease in G-CSF protein expression was detected in stimulated murine and human endothelial cells when expression of Fli-1 was inhibited. The murine G-CSF promoter contains numerous putative Fli-1 binding sites and several regions within the proximal promoter are significantly enriched for Fli-1 binding. Transient transfection assays indicate that Fli-1 drives transcription from the G-CSF promoter and mutation of the Fli-1 DNA binding domain resulted in a 94% loss of transcriptional activation. Mutation of a known acetylation site, led to a significant increase in G-CSF promoter activation. The histone acetyltransferases p300/CBP and p300/CBP associated factor (PCAF) significantly decrease Fli-1 specific activation of the G-CSF promoter. Thus, acetylation appears to be an important mechanism behind Fli-1 driven activation of the G-CSF promoter. These results further support the theory that Fli-1 plays a major role in the regulation of several inflammatory mediators, ultimately affecting inflammatory disease pathogenesis. C1 [Richard, Mara L. Lennard; Brandon, Danielle; Lou, Ning; Sato, Shuzo; Caldwell, Tomika; Nowling, Tamara K.; Gilkeson, Gary; Zhang, Xian K.] Med Univ South Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA. [Gilkeson, Gary; Zhang, Xian K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29464 USA. [Lou, Ning] Shandong Univ, Jinan Cent Hosp, Jinan, Shangdong, Peoples R China. RP Zhang, XK (reprint author), Med Univ South Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA.; Zhang, XK (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29464 USA. EM zhangjo@musc.edu FU National Institute of Health (NIAMS) [AR056670]; MUSC Multidisciplinary Clinical Research Center; American Association of Immunologists (AAI) FX The authors would like to thank Mercedes Zapata-Garcia for her technical support and Dr. Maria Trojanowska (Boston University, School of Medicine Arthritis Center, Boston, MA) who provided several expression vectors. This research study was supported by the National Institute of Health grant (NIAMS, AR056670 to X.K.Z.). This study was supported in part by a pilot project program from MUSC Multidisciplinary Clinical Research Center (X.K.Z.). M.L.R is a recipient of the Careers in Immunology Fellowship from the American Association of Immunologists (AAI) in 2015. Author contributions - M.L.R. and X.K.Z. conceived the study, designed the experiments, and prepared the manuscript, M.L.R. designed all of the primers, obtained or cloned the constructs used, and performed all of the transfection experiments, the LPS stimulated ChIP assay, and mRNA analysis, D.B. and N.L. performed the siRNA experiments and ELISA, S.S. and T.C. performed the ChIP assay, T.K.N. and G.G. contributed supplies, made suggestions regarding the experimental design and assisted in editing the final manuscript. NR 53 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD OCT PY 2016 VL 46 IS 10 BP 2322 EP 2332 DI 10.1002/eji.201646315 PG 11 WC Immunology SC Immunology GA DZ9VV UT WOS:000386229600006 ER PT J AU Schure, MB Goins, RT AF Schure, Marc B. Goins, R. Turner TI An Examination of the Disablement Process Among Older American Indians: The Native Elder Care Study SO GERONTOLOGIST LA English DT Article DE Disablement process; American Indians; Structural equation modeling ID CHRONIC PAIN; SOCIAL SUPPORT; DEPRESSIVE SYMPTOMS; DISABILITY; ADULTS; HEALTH; PREDICTORS; IMPACT; RACE; INTERVENTIONS AB Purpose of the Study: Older American Indians disproportionately suffer from poorer physical and mental health and have greater disability compared to their racial and ethnic counterparts. The purpose of this study was to examine the disablement process among older American Indians. Design and Methods: Data analyzed were from the Native Elder Care Study, which included in-person interviews with 505 community-dwelling American Indians aged >= 55 years. We used structural equation modeling to examine the contributive direct and indirect effects of health, demographic, and psychosocial risk factors on disability. Results: Pathology had direct and indirect effects through social support and depressive symptoms on chronic pain intensity. Pathology also had direct and indirect effects on disability. Chronic pain intensity was a significant mediator between pathology and functional limitations. With contributive effects of older age and female sex, greater functional limitations were associated with increased disability. Implications: Our results support the theorized main pathway of the Disablement Process Model with our sample of older American Indians. Our findings support the importance of taking into account intra and extraindividual factors in assessing the prevalence and incidence of disability for older American Indians. C1 [Schure, Marc B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Goins, R. Turner] Western Carolina Univ, Coll Hlth & Human Sci, Dept Social Work, Cullowhee, NC 28723 USA. RP Schure, MB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. EM Mark.Schure@va.gov NR 48 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2016 VL 56 IS 5 BP 948 EP 955 DI 10.1093/geront/gnv001 PG 8 WC Gerontology SC Geriatrics & Gerontology GA DZ7XI UT WOS:000386081600018 PM 26035880 ER PT J AU Dubin, RF Guajardo, I Ayer, A Mills, C Donovan, C Beussink, L Scherzer, R Ganz, P Shah, SJ AF Dubin, Ruth F. Guajardo, Isabella Ayer, Amrita Mills, Claire Donovan, Catherine Beussink, Lauren Scherzer, Rebecca Ganz, Peter Shah, Sanjiv J. TI Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease SO HYPERTENSION LA English DT Article DE cardiovascular disease; echocardiography; heart failure ID PRESERVED EJECTION FRACTION; FLOW-MEDIATED VASODILATATION; HEART-FAILURE; HEMODIALYSIS-PATIENTS; ASYMMETRIC DIMETHYLARGININE; DEPENDENT VASODILATION; CARDIOVASCULAR-DISEASE; DIETARY PHOSPHORUS; SYSTOLIC FUNCTION; MASS AB Patients with end-stage renal disease (ESRD) suffer high rates of heart failure and cardiovascular mortality, and we lack a thorough understanding of what, if any, modifiable factors contribute to cardiac dysfunction in these high-risk patients. To evaluate endothelial function as a potentially modifiable cause of cardiac dysfunction in ESRD, we investigated cross-sectional associations of macro- and microvascular dysfunction with left and right ventricular dysfunction in a well-controlled ESRD cohort. We performed comprehensive echocardiography, including tissue Doppler imaging and speckle-tracking echocardiography of the left and right ventricle, in 149 ESRD patients enrolled in an ongoing prospective, observational study. Of these participants, 123 also underwent endothelium-dependent flow-mediated dilation of the brachial artery (macrovascular function). Microvascular function was measured as the velocity time integral of hyperemic blood flow after cuff deflation. Impaired flow-mediated dilation was associated with higher left ventricular mass, independently of age and blood pressure: per 2-fold lower flow-mediated dilation, left ventricular mass was 4.1% higher (95% confidence interval, 0.49-7.7; P=0.03). After adjustment for demographics, blood pressure, comorbidities, and medications, a 2-fold lower velocity time integral was associated with 9.5% higher E/e ratio (95% confidence interval, 1.0-16; P=0.03) and 6.7% lower absolute right ventricular longitudinal strain (95% confidence interval, 2.0-12; P=0.003). Endothelial dysfunction is a major correlate of cardiac dysfunction in ESRD, particularly diastolic and right ventricular dysfunction, in patients whose volume status is well controlled. Future investigations are needed to determine whether therapies targeting the vascular endothelium could improve cardiac outcomes in ESRD. C1 [Dubin, Ruth F.; Guajardo, Isabella; Ayer, Amrita; Scherzer, Rebecca] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Mills, Claire; Donovan, Catherine; Ganz, Peter] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vasc Excellence, Div Cardiol, San Francisco, CA USA. [Beussink, Lauren; Shah, Sanjiv J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA. RP Dubin, RF (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM ruth.dubin@ucsf.edu FU National Institutes of Health [K23 DK092354, R03 DK104013]; University of California, San Francisco (UCSF); National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 TR000004]; [R01 HL107577]; [R01 HL127028] FX National Institutes of Health (K23 DK092354 and R03 DK104013 [to R.F.D.]; University of California, San Francisco (UCSF) Resource Allocation Program Pilot Grant for Junior Investigators [to R.F.D.]; and R01 HL107577 and R01 HL127028 [to S.J.S.]). This project was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR000004. NR 42 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD OCT PY 2016 VL 68 IS 4 BP 913 EP 920 DI 10.1161/HYPERTENSIONAHA.116.07489 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DX1LB UT WOS:000384127800018 PM 27550915 ER PT J AU Quinn, JF AF Quinn, Joseph F. TI Do omega-3 Fatty Acids Regulate Cerebral beta Amyloid? SO JAMA NEUROLOGY LA English DT Editorial Material ID DOCOSAHEXAENOIC ACID; ALZHEIMER-DISEASE; MOUSE MODEL; TRIAL; PATHOLOGY C1 [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM quinnj@ohsu.edu NR 13 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD OCT 1 PY 2016 VL 73 IS 10 BP 1183 EP 1184 DI 10.1001/jamaneurol.2016.2534 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA DZ8LO UT WOS:000386122100006 PM 27533600 ER PT J AU Davis, MY Johnson, CO Leverenz, JB Weintraub, D Trojanowski, JQ Chen-Plotkin, A Van Deerlin, VM Quinn, JF Chung, KA Peterson-Hiller, AL Rosenthal, LS Dawson, T Albert, MS Goldman, JG Stebbins, GT Bernard, B Wszolek, ZK Ross, OA Dickson, DW Eidelberg, D Mattis, PJ Niethammer, M Yearout, D Hu, SC Cholerton, BA Smith, M Mata, IF Montine, TJ Edwards, KL Zabetian, CP AF Davis, Marie Y. Johnson, Catherine O. Leverenz, James B. Weintraub, Daniel Trojanowski, John Q. Chen-Plotkin, Alice Van Deerlin, Vivianna M. Quinn, Joseph F. Chung, Kathryn A. Peterson-Hiller, Amie L. Rosenthal, Liana S. Dawson, Tedm. Albert, Marilyn S. Goldman, Jennifer G. Stebbins, Glenn T. Bernard, Bryan Wszolek, Zbigniew K. Ross, Owen A. Dickson, Dennis W. Eidelberg, David Mattis, Paul J. Niethammer, Martin Yearout, Dora Hu, Shu-Ching Cholerton, Brenna A. Smith, Megan Mata, Ignacio F. Montine, Thomas J. Edwards, Karen L. Zabetian, Cyrus P. TI Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease SO JAMA NEUROLOGY LA English DT Article ID GLUCOCEREBROSIDASE MUTATIONS; GAUCHER-DISEASE; RATING-SCALE; IMPAIRMENT; COHORT AB IMPORTANCE Parkinson disease (PD) is heterogeneous in symptom manifestation and rate of progression. Identifying factors that influence disease progression could provide mechanistic insight, improve prognostic accuracy, and elucidate novel therapeutic targets. OBJECTIVE To determine whether GBA mutations and the E326K polymorphism modify PD symptom progression. DESIGN, SETTING, AND PARTICIPANTS The entire GBA coding region was screened for mutations and E326K in 740 patients with PD enrolled at 7 sites from the PD Cognitive Genetics Consortium. Detailed longitudinal motor and cognitive assessments were performed with patients in the on state. MAIN OUTCOMES AND MEASURES Linear regression was used to test for an association between GBA genotype and motor progression, with the Movement Disorder Society-sponsored version of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score at the last assessment as the outcome and GBA genotype as the independent variable, with adjustment for levodopa equivalent dose, sex, age, disease duration, MDS-UPDRS III score at the first assessment, duration of follow-up, and site. Similar methods were used to examine the association between genotype and tremor and postural instability and gait difficulty (PIGD) scores. To examine the effect of GBA genotype on cognitive progression, patients were classified into those with conversion to mild cognitive impairment or dementia during the study (progression) and those without progression. The association between GBA genotype and progression status was then tested using logistic regression, adjusting for sex, age, disease duration, duration of follow-up, years of education, and site. RESULTS Of the total sample of 733 patients who underwent successful genotyping, 226 (30.8%) were women and 507 (69.2%) were men (mean [SD] age, 68.1 [8.8] years). The mean (SD) duration of follow-up was 3.0 (1.7) years. GBA mutations (beta = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (beta = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (beta = 4.01; 95% CI, 1.95-6.07; P = 1.5 x 10(-4)) were associated with a more rapid decline in MDS-UPDRS III score. Combined GBA variants (beta = 0.38; 95% CI, 0.23-0.53; P = .01) and E326K (beta = 0.64; 95% CI, 0.43-0.86; P = .002) were associated with faster progression in PIGD scores, but not in tremor scores. A significantly higher proportion of E326K carriers (10 of 21 [47.6%]; P = .01) and GBA variant carriers (15 of 39 [38.5%]; P = .04) progressed to mild cognitive impairment or dementia. CONCLUSIONS AND RELEVANCE GBA variants predict a more rapid progression of cognitive dysfunction and motor symptoms in patients with PD, with a greater effect on PIGD than tremor. Thus, GBA variants influence the heterogeneity in symptom progression observed in PD. C1 [Davis, Marie Y.; Hu, Shu-Ching; Cholerton, Brenna A.; Mata, Ignacio F.; Zabetian, Cyrus P.] Puget Sound Hlth Care Syst, 1660 S Columbian Way,GRECC S-182, Seattle, WA 98108 USA. [Davis, Marie Y.; Johnson, Catherine O.; Yearout, Dora; Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Neurol Inst, Cleveland, OH 44106 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Chen-Plotkin, Alice] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Portland VA Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Rosenthal, Liana S.; Dawson, Tedm.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Neurodegenerat & Stem Cell Programs, Baltimore, MD USA. [Rosenthal, Liana S.; Dawson, Tedm.; Albert, Marilyn S.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Dawson, Tedm.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA. [Dawson, Tedm.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA. [Goldman, Jennifer G.; Stebbins, Glenn T.; Bernard, Bryan] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Wszolek, Zbigniew K.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Ross, Owen A.; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Eidelberg, David; Mattis, Paul J.; Niethammer, Martin] Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY USA. [Eidelberg, David; Mattis, Paul J.] Northwell Hlth, Dept Neurol, Manhasset, NY USA. [Cholerton, Brenna A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA USA. [Smith, Megan; Edwards, Karen L.] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA. RP Zabetian, CP (reprint author), Puget Sound Hlth Care Syst, 1660 S Columbian Way,GRECC S-182, Seattle, WA 98108 USA. EM zabetian@u.washington.edu FU Department of Veterans Affairs [1I01BX000531]; Michael J. Fox Foundation; NIH [K23 NS060949, P50 NS038377, P50 NS053488, P50 NS062684, P50 NS071675, P50 NS072187, R01 NS035069, R01 NS065070]; Dolsen Foundation; Jane and Lee Seidman Fund FX This study was supported by grant 1I01BX000531 from the Department of Veterans Affairs, the Michael J. Fox Foundation, grants K23 NS060949, P50 NS038377, P50 NS053488, P50 NS062684, P50 NS071675, P50 NS072187, R01 NS035069, and R01 NS065070 from the NIH, the Dolsen Foundation, and the Jane and Lee Seidman Fund. NR 36 TC 3 Z9 3 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD OCT 1 PY 2016 VL 73 IS 10 BP 1217 EP 1224 DI 10.1001/jamaneurol.2016.2245 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DZ8LO UT WOS:000386122100011 PM 27571329 ER PT J AU Kaczkurkin, AN Asnaani, A Hall-Clark, B Peterson, AL Yarvis, JS Foa, EB AF Kaczkurkin, Antonia N. Asnaani, Anu Hall-Clark, Brittany Peterson, Alan L. Yarvis, Jeffrey S. Foa, Edna B. CA STRONG STAR Consortium TI Ethnic and racial differences in clinically relevant symptoms in active duty military personnel with posttraumatic stress disorder SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Race; Ethnicity; PTSD; Depression; Alcohol; Anger ID IDENTIFICATION TEST AUDIT; PSYCHOMETRIC PROPERTIES; AFRICAN-AMERICAN; ALCOHOL-USE; RACIAL/ETHNIC DIFFERENCES; SERVICE MEMBERS; COMBAT VETERANS; UNITED-STATES; WAR VETERANS; IRAQ WAR AB Previous research has shown racial/ethnic differences in Vietnam veterans on symptoms related to post traumatic stress disorder (PTSD). The current study explored racial/ethnic differences in PTSD symptoms and clinically relevant symptoms. Resilience and social support were tested as potential moderators of racial/ethnic differences in symptoms. The sample included 303 active duty male service members seeking treatment for PTSD. After controlling for age, education, military grade, and combat exposure, Hispanic/Latino and African American service members reported greater PTSD symptoms compared to non-Hispanic White service members. Higher alcohol consumption was endorsed by Hispanic/Latino service members compared to non-Hispanic White or African American service members, even after controlling for PTSD symptom severity. No racial/ethnic differences were found with regard to other variables. These results suggest that care should be made to thoroughly assess PTSD patients, especially those belonging to minority groups, for concurrent substance use problems that may impede treatment utilization or adherence. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Kaczkurkin, Antonia N.; Asnaani, Anu; Foa, Edna B.] Univ Penn, Dept Psychiat, 3535 Market St, Philadelphia, PA 19104 USA. [Hall-Clark, Brittany; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, 7400 Merton Minter, San Antonio, TX 78229 USA. [Peterson, Alan L.] Univ Texas San Antonio, 1 UTSA Circle, San Antonio, TX 78249 USA. [Yarvis, Jeffrey S.] Carl R Darnall Army Med Ctr, 36000 Darnall Loop, Ft Hood, TX 76544 USA. RP Kaczkurkin, AN (reprint author), Ctr Treatment & Study Anxiety, Dept Psychiat, 3535 Market St,Suite 600 North, Philadelphia, PA 19104 USA. EM antoniak@mail.med.upenn.edu; aasnaani@mail.med.upenn.edu; hallclark@uthscsa.edu; petersona3@uthscsa.edu; jeffrey.s.yarvis.mil@mail.mil; foa@mail.med.upenn.edu FU U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-0111, W81XWH-08-02-109, W81XWH-08-02-0114] FX This study was conducted with support from the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-02-0111 (Edna B. Foa), W81XWH-08-02-109 (Alan L. Peterson), and W81XWH-08-02-0114 (Brett T. Litz). The views expressed in this article are solely those of the authors and do not reflect an endorsement by or the official policy of the U.S. Army, the Department of Defense, the Department of Veterans Affairs, or the U.S. Government. NR 59 TC 0 Z9 0 U1 10 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD OCT PY 2016 VL 43 BP 90 EP 98 DI 10.1016/j.janxdis.2016.09.004 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DZ8FQ UT WOS:000386106700011 PM 27639110 ER PT J AU Sivak, WN Bourne, DA Miller, MP Manders, EK AF Sivak, Wesley N. Bourne, Debra A. Miller, Matthew P. Manders, Ernest K. TI Simplified Calvarial Reconstruction: Coverage of Bare Skull With GammaGraft Promotes Granulation and Facilitates Skin Grafting SO JOURNAL OF CRANIOFACIAL SURGERY LA English DT Article DE Allograft skin; calvarial defect; scalp reconstruction; skin graft ID SCALP DEFECTS; DERMIS AB Repair of scalp defects with exposed calvaria remains a difficult clinical problem. Herein, we present a simple alternative method of scalp reconstruction. Coverage of bare skull with GammaGraft (Promethean LifeSciences, Inc, Pittsburgh, PA) promotes the evolution of granulation tissue and permits subsequent skin grafting without need for burring, drilling, or other manipulation of the outer table of the calvaria. A retrospective review of patients undergoing scalp reconstruction utilizing GammaGraft and subsequent skin grafting was performed at our institution. From our cohort, 5 patients treated with GammaGraft and subsequent skin grafting had both immediate and long-term follow-up available. Indications for scalp reconstruction included erosions of prior skin grafts and direct excision of full-thickness scalp and pericranium. Average time to definitive skin grafting was 3 weeks; repeat application of GammaGraft was required in some patients with reapplication to subsequent smaller wounds as healing occurred. Complications were minor and consisted of ongoing wound drainage. Alternative flap reconstruction was not required in any patient due to treatment failures. No major complications, wound infections, or early reoperations occurred in any of the patients; 1 patient to date has required repeat reconstruction due to recurrent disease. Coverage of bare skull with GammaGraft and subsequent skin grafting provides a simple and elegant solution to an often too difficult clinical problem. Confirmed by results in out limited series, the utilization of GammaGraft in calvarial reconstruction represents an alternative method in surgical care of complex scalp defects with exposed bone. C1 [Sivak, Wesley N.; Bourne, Debra A.; Miller, Matthew P.; Manders, Ernest K.] Univ Pittsburgh, Dept Plast Surg, 3550 Terrace St,Scaife Hall,Suite 6B, Pittsburgh, PA 15261 USA. [Manders, Ernest K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Manders, Ernest K.] McGowan Inst Regenerat Med, Pittsburgh, PA USA. RP Manders, EK (reprint author), Univ Pittsburgh, Dept Plast Surg, 3550 Terrace St,Scaife Hall,Suite 6B, Pittsburgh, PA 15261 USA. EM mandersek@upmc.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1049-2275 EI 1536-3732 J9 J CRANIOFAC SURG JI J. Craniofac. Surg. PD OCT PY 2016 VL 27 IS 7 BP 1808 EP 1809 DI 10.1097/SCS.0000000000003037 PG 2 WC Surgery SC Surgery GA EA1KW UT WOS:000386352100103 PM 27557466 ER PT J AU Chao, LL AF Chao, Linda L. TI Associations Between the Self-Reported Frequency of Hearing Chemical Alarms in Theater and Visuospatial Function in Gulf War Veterans SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SPATIAL MENTAL-IMAGERY; SURFACE-BASED ANALYSIS; LONG-DISTANCE TRANSIT; SUBWAY SARIN ATTACK; PESTICIDE APPLICATORS; ALZHEIMER-DISEASE; WEAPONS FALLOUT; NERVOUS-SYSTEM; RISK-FACTORS; EXPOSURE AB Objective:The aim of this study was to examine the relationship between the self-reported frequencies of hearing chemical alarms during deployment and visuospatial function in Gulf War (GW) veterans.Methods:The relationship between the self-reported frequency of hearing chemical alarms, neurobehavioral, and volumetric brain imaging data was examined with correlational, regression, and mediation analyses.Results:The self-reported frequency of hearing chemical alarms was inversely associated with and significantly predicted performance on a visuospatial task (ie, Block Design) over and above potentially confounding variables, including concurrent, correlated GW-related exposures. This effect was partially mediated by the relationship between hearing chemical alarms and lateral occipital cortex volume.Conclusions:Exposure to substances that triggered chemical alarms during GW deployment likely had adverse effects on veterans' brain structure and function, warranting further investigation of whether these GW veterans are at an increased risk for dementia. C1 San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Chao, LL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU VA grant [CX000798] FX This study supported by VA grant no. CX000798 entitled "Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure." NR 47 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2016 VL 58 IS 10 BP 1014 EP 1020 DI 10.1097/JOM.0000000000000851 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1HQ UT WOS:000386343500008 PM 27513172 ER PT J AU LaHue, SC Comella, CL Tanner, CM AF LaHue, Sara C. Comella, Cynthia L. Tanner, Caroline M. TI The best medicine? The influence of physical activity and inactivity on Parkinson's disease SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; exercise; metabolic syndrome; physical activity; disease modification ID BODY-MASS INDEX; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-LESIONED MOUSE MODEL; RANDOMIZED CONTROLLED-TRIAL; BASAL GANGLIA INJURY; TREADMILL EXERCISE; ECONOMIC-EVALUATION; METABOLIC SYNDROME; FUTURE RISK; PROSPECTIVE COHORT; COGNITIVE DECLINE AB The incidence of Parkinson's disease (PD) is expected to increase as our population ages and will likely strain the projected capacity of our health care system. Despite being the most common movement disorder, there have been few noninvasive therapeutic advances for people with PD since the first levodopa clinical trial in 1961. The study of PD pathogenesis, combined with an appreciation for the biochemical mechanisms by which physical activity and exercise may impact physiology, has resulted in emerging hypotheses for new modifiable risk factors for PD. Physical activity and exercise as a means of preventing PD, or maintaining the functionality of people with PD, are a promising area of investigation. Conversely, physical inactivity is implicated in many disease states, some of which are also correlated with the development of PD, such as metabolic syndrome. The primary relationship between these diseases is likely rooted in heightened inflammation and oxidative stress at the cellular level. Physical activity and exercise as a means of attenuating inflammation have led to increased interest in related potential therapeutic targets for PD. Ultimately, these findings may translate into low-cost, universally available therapies for PD disease modification or prevention. (c) 2016 International Parkinson and Movement Disorder Society C1 [LaHue, Sara C.] Kaiser Permanente San Francisco Med Ctr, San Francisco, CA USA. [Comella, Cynthia L.] Rush Presbyterian St Lukes Med Ctr, Neurol Sci, Chicago, IL USA. [Tanner, Caroline M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Tanner, CM (reprint author), Univ Calif San Francisco, Dept Neurol, Movement Disorders & Neuromodulat Ctr, 1635 Divisadero St,Suite 515, San Francisco, CA 94115 USA. EM caroline.tanner@ucsf.edu FU NIH [R01NS074343, U54NS065701]; Dystonia Medical Research Foundation; Allergan Inc.; Impax Pharmaceuticals; Ipsen Biopharmaceuticals, Inc; Medtronic Inc.; Merz Pharmaceuticals; US World Meds; Acadia Pharmaceuticals; Teva Neurosciences; Parkinson's Disease Foundation; Michael J. Fox Foundation; Department of Defense; National Institutes of Health FX Dr. LaHue has no disclosures. Dr. Comella serves on the editorial board of Clinical Neuropharmacology, Sleep Medicine, and Continuum. She receives research support from the NIH R01NS074343, U54NS065701, Dystonia Medical Research Foundation, Allergan Inc., Ipsen Biopharmaceuticals, Inc, and Merz Pharmaceutical. She receives compensation/honoraria for services as a consultant or an advisory committee member from Allergan, Inc, Impax Pharmaceuticals, Ipsen Biopharmaceuticals, Inc, Medtronic Inc., Merz Pharmaceuticals, US World Meds, Acadia Pharmaceuticals, and Teva Neurosciences. She receives royalties from Cambridge, Humana Press, and Wolters Kluwer. She receives research support from the Parkinson's Disease Foundation. Dr. Tanner, serves on the editorial boards of the Annals of Neurology, Journal of Parkinson's Disease, Parkinsonism and Related Disorders, and NPJ Parkinson's Disease. She serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dysphonia Association as a voluntary consultant and has provided paid consulting services to Ultragenyx Pharmaceuticals, Neurocrine Biosciences, Cynapsus, and Adamas. She has received compensation for serving on Data Monitoring Committees from Biotie Therapeutics, Voyager Therapeutics, and Intec Pharma. She receives grant support from the Michael J. Fox Foundation, the Parkinson's Disease Foundation, the Department of Defense, and the National Institutes of Health. NR 118 TC 1 Z9 1 U1 19 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD OCT PY 2016 VL 31 IS 10 BP 1444 EP 1454 DI 10.1002/mds.26728 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA DZ7MG UT WOS:000386049400003 PM 27477046 ER PT J AU McCleery, A Lee, J Fiske, AP Ghermezi, L Hayata, JN Hellemann, GS Horan, WP Kee, KS Kern, RS Knowlton, BJ Subotnik, KL Ventura, J Sugar, CA Nuechterlein, KH Green, MF AF McCleery, Amanda Lee, Junghee Fiske, Alan P. Ghermezi, Livon Hayata, Jacqueline N. Hellemann, Gerhard S. Horan, William P. Kee, Kimmy S. Kern, Robert S. Knowlton, Barbara J. Subotnik, Kenneth L. Ventura, Joseph Sugar, Catherine A. Nuechterlein, Keith H. Green, Michael F. TI Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processing SO SCHIZOPHRENIA RESEARCH LA English DT Article DE MSCEIT; RAD; Cross-lagged panel analyses; Psychosis; Illness duration; Social cognition ID FACIAL AFFECT RECOGNITION; BIPOLAR DISORDER; NEUROCOGNITION; METAANALYSIS; INTELLIGENCE; 1ST-EPISODE; RELIABILITY; IMPAIRMENT; PSYCHOSIS; SYMPTOMS AB Background: Individuals with schizophrenia exhibit marked and disproportional impairment in social cognition, which is associated with their level of community functioning. However, it is unclear whether social cognitive impairment is stable over time, or if impairment worsens as a function of illness chronicity. Moreover, little is known about the longitudinal associations between social cognition and community functioning. Method: Forty-one outpatients with schizophrenia completed tests of emotion processing (Mayer-Salovey-Caruso Emotional Intelligence Test, MSCEIT) and social perception (Relationships Across Domains, RAD) at baseline and approximately five years later. Stability of performance was assessed using paired t-tests and correlations. Longitudinal associations between social cognition and community functioning (Role Functioning Scale, RFS) were assessed using cross-lagged panel correlation analysis. Results: Performance on the two social cognition tasks were stable over follow-up. There were no significant mean differences between assessment points [p's >= 0.20, Cohen'sd's <= \0.20\], and baseline performance was highly correlated with performance at follow-up [rho's >= 0.70, ICC >= 0.83, p's < 0.001]. The contemporaneous association between social cognition and community functioning was moderately large at follow-up [rho = 0.49, p = 0.002]. However, baseline social cognition did not show a significant longitudinal influence on follow-up community functioning [z=0.31, p=0.76]. Conclusions: These data support trait-like stability of selected areas of social cognition in schizophrenia. Cross-lagged correlations did not reveal a significant unidirectional influence of baseline social cognition on community functioning five years later. However, consistent with the larger literature, a moderately large cross-sectional association between social cognition and community functioning was observed. Based on stability and cross-sectional associations, these results suggest that social cognition might have short-term implications for functional outcome rather than long-term consequences. (C) 2016 Elsevier B.V. All rights reserved. C1 [McCleery, Amanda; Lee, Junghee; Ghermezi, Livon; Hayata, Jacqueline N.; Hellemann, Gerhard S.; Horan, William P.; Kern, Robert S.; Subotnik, Kenneth L.; Ventura, Joseph; Sugar, Catherine A.; Nuechterlein, Keith H.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [McCleery, Amanda; Knowlton, Barbara J.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [McCleery, Amanda; Lee, Junghee; Horan, William P.; Kern, Robert S.; Sugar, Catherine A.; Green, Michael F.] Greater Los Angeles VA Healthcare Syst, MIRECC VISN 22, Los Angeles, CA USA. [Fiske, Alan P.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA. [Kee, Kimmy S.] Calif State Univ Channel Isl, Dept Psychol, Camarillo, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. RP McCleery, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Semel Inst Neurosci & Human Behav, 300 Med Plaza,Room 2240, Los Angeles, CA 90095 USA. EM amccleery@mednet.ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU National Institutes of Health (NIH) [T32MH096682-03]; NIH [P50MH066286, R01MH037705]; Janssen Scientific Affairs [RIS-NAP-4009] FX A. McCleery is supported by an institutional fellowship from the National Institutes of Health (NIH; T32MH096682-03). Subject recruitment and data collection were supported by grants P50MH066286 and R01MH037705 from NIH (K.H. Nuechterlein, PI) and RIS-NAP-4009 from Janssen Scientific Affairs (K.H. Nuechterlein, PI). NR 43 TC 0 Z9 0 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2016 VL 176 IS 2-3 BP 467 EP 472 DI 10.1016/j.schres.2016.07.008 PG 6 WC Psychiatry SC Psychiatry GA DX1LZ UT WOS:000384130200060 PM 27443808 ER PT J AU Lee, CS Randhawa, S Lee, AY Lam, DL Van Gelder, RN AF Lee, Cecilia S. Randhawa, Sandeep Lee, Aaron Y. Lam, Deborah L. Van Gelder, Russell N. TI Patterns of Laboratory Testing Utilization Among Uveitis Specialists SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID CARE AB PURPOSE: To examine the range of practice in laboratory testing utilization among a subset of uveitis specialists using a scenario-based survey. DESIGN: Cross-sectional survey. METHODS: A web-based survey consisting of 13 patient scenarios was presented to the Executive Committee and Trustees of the American Uveitis Society. The participants were allowed to choose preferred testing in a free-form manner. The patterns of test utilization were studied and the cost of the testing was calculated based on Noridian Medicare reimbursal rates for Seattle, Washington. RESULTS: Nearly all providers recommended some testing for all scenarios. Forty-five different tests, including laboratory investigations and imaging and diagnostic procedures, were ordered. The mean number of tests ordered per scenario per provider was 5.47 +/- 2.71. There was limited consensus among providers in test selection, with most tests in each scenario ordered by fewer than half of the providers. Average cost of testing per scenario per provider was $282.80, with 4 imaging tests (fluorescein angiography, magnetic resonance imaging, chest radiograph, and chest computed tomography) together contributing 59.9% of the total testing costs. CONCLUSIONS: Uveitis specialists have a high rate of laboratory testing utilization in their evaluation of new patients. There is substantial variability in the evaluations obtained between providers. Imaging tests account for the majority of evaluation cost. The low agreement on specific testing plans suggests need for evidence based practice guidelines for the evaluation of uveitis patients. (C) 2016 Elsevier Inc. All rights reserved. C1 [Lee, Cecilia S.; Randhawa, Sandeep; Lee, Aaron Y.; Lam, Deborah L.; Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Ophthalmol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA. [Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Biol Struct, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA. [Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Pathol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA. [Lee, Aaron Y.; Lam, Deborah L.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Randhawa, Sandeep] Oakland Univ, William Beaumont Sch Med, Dept Ophthalmol, Rochester, MN USA. RP Van Gelder, RN (reprint author), Univ Washington, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA. EM russvg@uw.edu OI Van Gelder, Russell/0000-0001-5368-3659; Lee, Aaron/0000-0002-7452-1648 FU RESEARCH TO PREVENT BLINDNESS (NEW YORK, NY); NEI (Bethesda, MD) [K23EY024921, P30-EY001730] FX UNRESTRICTED GRANT FROM RESEARCH TO PREVENT BLINDNESS (NEW YORK, NY); NEI K23EY024921, P30-EY001730 (Bethesda, MD). NR 16 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD OCT PY 2016 VL 170 BP 161 EP 167 DI 10.1016/j.ajo.2016.08.004 PG 7 WC Ophthalmology SC Ophthalmology GA DZ5KF UT WOS:000385900300021 PM 27521608 ER PT J AU Krishnan, S Karg, PE Boninger, ML Vodovotz, Y Constantine, G Sowa, GA Brienza, DM AF Krishnan, Shilpa Karg, Patricia E. Boninger, Michael L. Vodovotz, Yoram Constantine, Greg Sowa, Gwendolyn A. Brienza, David M. TI Early Detection of Pressure Ulcer Development Following Traumatic Spinal Cord Injury Using Inflammatory Mediators SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Biomarkers; Early diagnosis; Pressure ulcer; Rehabilitation; Risk factors; Spinal cord injuries ID RISK-FACTORS; WOUND FLUID; EXPRESSION; CYTOKINES; ALPHA; MODEL; INTERLEUKIN-10; NEUTROPHILS; RECOVERY; BLOOD AB Objective: To identify changes in concentrations of inflammatory mediators in plasma and urine after traumatic spinal cord injury (SCI) and before the occurrence of a first pressure ulcer. Design: Retrospective; secondary analysis of existing data. Setting: Acute hospitalization and inpatient rehabilitation sites at a university medical center. Participants: Individuals with a pressure ulcer and plasma samples (n=17) and individuals with a pressure ulcer and urine samples (n=15) were matched by age and plasma/urine sample days to individuals with SCI and no pressure ulcer (N= 35). Interventions: Not applicable. Main Outcome Measures: Plasma and urine samples were assayed in patients with SCI, capturing samples within 4 days after the SCI to a week before the formation of the first pressure ulcer. The Wilcoxon signed-rank test was performed to identify changes in the inflammatory mediators between the 2 time points. Results: An increase in concentration of the chemokine interferon-gamma-induced protein of 10kd/CXCL10 in plasma (P<.01) and a decrease in concentration of the cytokine interferon-alpha in urine (P =.01) were observed before occurrence of a first pressure ulcer (similar to 4d) compared with matched controls. Conclusions: Altered levels of inflammatory mediators in plasma and urine may be associated with pressure ulcer development after traumatic SCI. These inflammatory mediators should be explored as possible biomarkers for identifying individuals at risk for pressure ulcer formation. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Krishnan, Shilpa; Karg, Patricia E.; Boninger, Michael L.; Brienza, David M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA. [Boninger, Michael L.; Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.; Brienza, David M.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Boninger, Michael L.; Vodovotz, Yoram; Constantine, Greg] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Vodovotz, Yoram] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Constantine, Greg; Brienza, David M.] Univ Pittsburgh, Dept Math, Pittsburgh, PA USA. [Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15261 USA. [Krishnan, Shilpa] Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA. RP Krishnan, S (reprint author), Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA. EM shikrish@utmb.edu OI Brienza, David/0000-0001-6335-2925; Boninger, Michael/0000-0001-6966-919X; Krishnan, Shilpa/0000-0002-9419-0495 FU National Institute on Disability and Rehabilitation Research (NIDRR), Rehabilitation Engineering Research Center on Spinal Cord Injury [H133E070024]; NIDRR [H133P110012]; U.S. Agency for Healthcare Research and Quality [1R24HS022134]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90SI5008] FX Supported primarily by the National Institute on Disability and Rehabilitation Research (NIDRR), Rehabilitation Engineering Research Center on Spinal Cord Injury (grant no. H133E070024); and by the NIDRR (grant no. H133P110012) and the U.S. Agency for Healthcare Research and Quality (grant no. 1R24HS022134).; The contents of this publication were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant no. 90SI5008). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this publication do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government. NR 39 TC 1 Z9 1 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2016 VL 97 IS 10 BP 1656 EP 1662 DI 10.1016/j.apmr.2016.01.003 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DY7TX UT WOS:000385333300008 PM 26820323 ER PT J AU Hogaboom, NS Worobey, LA Boninger, ML AF Hogaboom, Nathan S. Worobey, Lynn A. Boninger, Michael. L. TI Transfer Technique Is Associated With Shoulder Pain and Pathology in People With Spinal Cord Injury: A Cross-Sectional Investigation SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Rehabilitation; Shoulder pain; Spinal cord injuries; Tendinopathy; Wheelchairs ID MANUAL WHEELCHAIR USERS; ROTATOR CUFF; INDEX WUSPI; INDIVIDUALS; PARAPLEGIA; PREVALENCE; IDENTIFICATION; TETRAPLEGIA; ULTRASOUND; KINETICS AB Objectives: To evaluate how transfer technique and subject characteristics relate to ultrasound measures of shoulder soft tissue pathology and self-reported shoulder pain during transfers in a sample of wheelchair users with spinal cord injury (SCI). Design: Cross-sectional observational study. Setting: Research laboratory, national and local veterans' wheelchair sporting events. Participants: A convenience sample of wheelchair users (N=76) with nonprogressive SCI. Participants were aged >18 years, >1 year postinjury, and could complete repeated independent wheelchair transfers without the use of their leg muscles. Interventions: Not applicable. Main Outcome Measures: Transfer pain items from the Wheelchair User's Shoulder Pain Index; transfer technique assessed using the Transfer Assessment Instrument (TM); and shoulder pathology markers examined using the Ultrasound Shoulder Pathology Rating Scale (USPRS). Results: Better transfer technique (higher TAI) correlated with less injury (lower USPRS) (partial eta(2)=.062, P<.05) and less pain during transfers (partial eta(2)=.049, P<.10). Greater age was the strongest predictor of greater pathology (USPRS total: partial eta(2)=.225, supraspinatus grade: partial eta(2)=.174, P<.01). An interaction between technique and weight was found (P<.10): participants with lower body weights showed a decrease in pathology markers with better transfer technique (low weight: R-2=.422, P<.05; middle weight: R-2=.200, P<.01), while those with higher weight showed little change with technique (R-2=.018, P>.05). Conclusions: Participants with better transfer technique exhibited less shoulder pathology and reported less pain during transfers. The relationship between technique and pathology was strongest in lower-weight participants. While causation cannot be proven because of study design, it is possible that using a better transfer technique and optimizing body weight could reduce the incidence of shoulder pathology and pain. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Hogaboom, Nathan S.; Worobey, Lynn A.; Boninger, Michael. L.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Hogaboom, Nathan S.; Boninger, Michael. L.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Worobey, Lynn A.; Boninger, Michael. L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Boninger, ML (reprint author), Human Engn Res Labs, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Worobey, Lynn/0000-0001-8795-6061; Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [H133N110011]; National Science Foundation Graduate Research Fellowship [1247842] FX This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, Veterans Affairs Pittsburgh Healthcare System. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. This project was supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) (grant no. H133N110011). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). This material is based on work supported by the National Science Foundation Graduate Research Fellowship (grant no. 1247842). The contents of this publication do not necessarily reflect the view of the National Science Foundation or the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government. NR 33 TC 1 Z9 1 U1 4 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2016 VL 97 IS 10 BP 1770 EP 1776 DI 10.1016/j.apmr.2016.03.026 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DY7TX UT WOS:000385333300022 PM 27117384 ER PT J AU Worobey, LA Kirby, RL Heinemann, AW Krobot, EA Dyson-Hudson, TA Cowan, RE Pedersen, JP Shea, M Boninger, ML AF Worobey, Lynn A. Kirby, R. Lee Heinemann, Allen W. Krobot, Emily A. Dyson-Hudson, Trevor A. Cowan, Rachel E. Pedersen, Jessica Presperin Shea, Mary Boninger, Michael. L. TI Effectiveness of Group Wheelchair Skills Training for People With Spinal Cord Injury: A Randomized Controlled Trial SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Motor skills; Rehabilitation; Spinal cord injuries; Wheelchairs ID LENGTH-OF-STAY; MANUAL WHEELCHAIR; MEDICAL REHABILITATION; PROGRAM; COMMUNITY; USERS; CLINICIAN; EFFICACY; MOBILITY; OUTCOMES AB Objective: To assess the effectiveness of group wheelchair skills training to elicit improvements in wheelchair skills. Design: Randomized double-blinded controlled trial. Setting: Four Spinal Cord Injury Model Systems Centers. Participants: Manual wheelchair users with spinal cord injury (N=114). Intervention: Six 90-minute group Wheelchair Skills Training Program (WSTP) classes or two 1-hour active control sessions with 6 to 10 people per group. Main Outcome Measures: Baseline (t1) and 1-month follow-up (t2) Wheelchair Skills Test Questionnaire (WST-Q) (Version 4.2) for capacity and performance and Goal Attainment Scale (GAS) score. Results: Follow-up was completed by 79 participants (WSTP: n=36, active control: n=43). No differences were found between missing and complete cases. Many users were highly skilled at baseline with a WST-Q capacity interquartile range of 77% to 97%. There were no differences between groups at baseline in WST-Q measures or demographics. Compared with the active control group, the WSTP group improved in WST-Q capacity advanced score (P=.02) but not in WST-Q capacity or WST-Q performance total scores (P=.068 and P=.873, respectively). The average GAS score (0% at t1) for the WSTP group at t2 was 65.6%+/- 34.8%. Higher GAS scores and WST-Q capacity scores were found for those who attended more classes and had lower baseline skills. Conclusions: Group training can improve advanced wheelchair skills capacity and facilitate achievement of individually set goals. Lower skill levels at baseline and increased attendance were correlated with greater improvement. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Worobey, Lynn A.; Krobot, Emily A.; Boninger, Michael. L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Kirby, R. Lee] Dalhousie Univ, Div Phys Med & Rehabil, Halifax, NS, Canada. [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Heinemann, Allen W.; Pedersen, Jessica Presperin] Rehabilitat Inst Chicago, Chicago, IL USA. [Dyson-Hudson, Trevor A.] Kessler Fdn, W Orange, NJ USA. [Dyson-Hudson, Trevor A.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. [Cowan, Rachel E.] Univ Miami, Dept Neurol Surg, Miami, FL USA. [Shea, Mary] Kessler Inst Rehabil, W Orange, NJ USA. RP Worobey, LA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM law93@pitt.edu OI Worobey, Lynn/0000-0001-8795-6061; Heinemann, Allen/0000-0003-2782-7326 FU National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90DP0025] FX Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) (grant no. 90DP0025). NR 21 TC 2 Z9 2 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2016 VL 97 IS 10 BP 1777 EP 1784 DI 10.1016/j.apmr.2016.04.006 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DY7TX UT WOS:000385333300023 PM 27153762 ER PT J AU Tsai, CY Boninger, ML Hastings, J Cooper, RA Rice, L Koontz, AM AF Tsai, Chung-Ying Boninger, Michael. L. Hastings, Jennifer Cooper, Rory A. Rice, Laura Koontz, Alicia M. TI Immediate Biomechanical Implications of Transfer Component Skills Training on Independent Wheelchair Transfers SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Activities of daily living; Rehabilitation; Shoulder pain; Spinal cord injuries; Training support; Wheelchairs ID SPINAL-CORD-INJURY; SITTING PIVOT TRANSFERS; UPPER EXTREMITY PAIN; UPPER-LIMB FUNCTION; SHOULDER PAIN; NERVE ENTRAPMENTS; JOINT KINEMATICS; USERS; INDIVIDUALS; KINETICS AB Objective: To evaluate the immediate effects of transfer training based on the Transfer Assessment Instrument (TM) on the upper limb biomechanics during transfers. Design: Pre-post intervention. Setting: Biomechanics laboratory. Participants: Full-time manual wheelchair users (N=24) performed 5 transfers to a level height bench, while their natural transfer skills were scored using the TM, and their biomechanical data were recorded. Intervention: Participants with 2 or more component skill deficits were invited to return to receive personalized transfer training. Main Outcome Measures: TM part 1 summary scores and biomechanical variables calculated at the shoulder, elbow, and wrist joints were compared before and immediately after transfer training. Results: Sixteen of the 24 manual wheelchair users met the criteria for training, and 11 manual wheelchair users came back for the revisit. Their TM part 1 summary scores improved from 6.31.98 to 9.92.25. They had significantly smaller elbow range of motion, shoulder resultant moment, and rates of rise of elbow and wrist resultant forces on their trailing side during transfers after training (P<.05). On the leading side, shoulder maximum internal rotation and elevation angles, and shoulder resultant moments and rates of rise of shoulder resultant force and moment decreased after training (P<.04). Conclusions: The TAI-based training showed short-term beneficial biomechanical effects on wheelchair users' upper limbs, such as better shoulder positioning and lower joint loadings. If the skills are practiced longer-term, they may help protect the upper limbs from developing pain and injuries. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Tsai, Chung-Ying; Boninger, Michael. L.; Cooper, Rory A.; Koontz, Alicia M.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Tsai, Chung-Ying; Boninger, Michael. L.; Cooper, Rory A.; Koontz, Alicia M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael. L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael. L.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Hastings, Jennifer] Univ Puget Sound, Dept Phys Therapy, Tacoma, WA 98416 USA. [Rice, Laura] Univ Illinois, Coll Appl Hlth Sci, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU Department of Veterans Affairs [B7149I]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90SI5008] FX Supported by the Department of Veterans Affairs (grant no. B7149I).; The contents of this publication were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant number 90SI5008). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this paper do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government NR 48 TC 1 Z9 1 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2016 VL 97 IS 10 BP 1785 EP 1792 DI 10.1016/j.apmr.2016.03.009 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DY7TX UT WOS:000385333300024 PM 27084267 ER PT J AU Gibson, CJ Thurston, RC Matthews, KA AF Gibson, Carolyn J. Thurston, Rebecca C. Matthews, Karen A. TI Cortisol dysregulation is associated with daily diary-reported hot flashes among midlife women SO CLINICAL ENDOCRINOLOGY LA English DT Article ID MENOPAUSAL VASOMOTOR SYMPTOMS; OLDER POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; SALIVARY CORTISOL; FUTURE-DIRECTIONS; MINERAL DENSITY; TRANSITION; FLUSHES; HEALTH; INFLAMMATION AB Objective Hot flashes are reported by 70-80% of women during the menopause transition. It has been proposed that cortisol dysregulation is involved in hot flashes, but the relationship between cortisol and hot flashes has received little empirical attention. This study examined the relationship between cortisol and daily self-reported hot flashes. Design For 7 days, participants used electronic diaries to report their hot flash frequency, severity and bothersomeness, along with mood and health behaviours, multiple times each day. Participants also provided hair samples for cortisol assays at baseline and morning and bedtime saliva samples for salivary cortisol collection over 3 days during the observation period. Hierarchical linear regression was used to examine the relationships between cortisol and hot flashes. Participants Forty-four women (41% African American, 39% non-Hispanic White) who reported daily hot flashes were enrolled. Measurements Salivary cortisol, hair cortisol and the frequency, severity and bothersomeness of daily diary-reported hot flashes were measured in this study. Results Controlling for health and demographic variables, higher hair cortisol was associated with a higher frequency of hot flashes (beta = 0.05, P = 0.01). A flatter diurnal cortisol slope was associated with greater hot flash severity (beta = 0.09, P = 0.03) and bother (beta = 0.10, P = 0.01). Hair cortisol was no longer significant after adjusting for depression or disturbed sleep; all other associations persisted. Conclusion Cortisol dysregulation was related to more frequent, severe and bothersome daily self-reported hot flashes. These findings support a potential role of the HPA axis in the aetiology and phenomenology of these common menopause symptoms. C1 [Gibson, Carolyn J.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Gibson, Carolyn J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Thurston, Rebecca C.; Matthews, Karen A.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Thurston, Rebecca C.; Matthews, Karen A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Thurston, Rebecca C.; Matthews, Karen A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Gibson, CJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Carolyn.Gibson2@va.gov FU University of Pittsburgh Department of Psychology; American Psychological Society Dissertation Award; University of Pittsburgh Institute for Clinical Research Education Predoctoral Fellowship in Clinical and Translational Research [8 TL1 TR 145-7] FX Support for this study came from small grants from the University of Pittsburgh Department of Psychology, the American Psychological Society Dissertation Award and the University of Pittsburgh Institute for Clinical Research Education Predoctoral Fellowship in Clinical and Translational Research (8 TL1 TR 145-7) (CJG). NR 36 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD OCT PY 2016 VL 85 IS 4 BP 645 EP 651 DI 10.1111/cen.13076 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DZ4IH UT WOS:000385821400020 PM 27059154 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies SO CURRENT RHEUMATOLOGY REPORTS LA English DT Review DE Serious infection; Hospitalized infection; Infection; Biologics; Tumor-necrosis factor inhibitors; TNFi; Non-TNF biologic; Etanercept; Infliximab; Adalimumab; Golimumab; Certolizumab pegol; Rituximab; Abatacept; Tocilizumab ID RADIOGRAPHIC JOINT DAMAGE; NECROSIS FACTOR THERAPY; ANTI-TNF; WORK DISABILITY; INCREASED RISK; DISEASE; ETANERCEPT; REGISTER; AGENTS AB Biologic use is a major advance in the treatment of several autoimmune conditions, including rheumatoid arthritis. In this review, we summarize key studies of serious/hospitalized infections in rheumatoid arthritis (RA). RA is a risk factor for infections. High RA disease activity is associated with higher risk of serious infection. The risk of serious infections with tumor necrosis factor inhibitor (TNFi) biologics is increased in the first 6 months of initiating therapy, and this risk was higher compared to the use of traditional disease-modifying anti-rheumatic drugs (DMARDs). Emerging data also suggest that biologics may differ from each other regarding the risk of serious or hospitalized infections. Past history of serious infections, glucocorticoid dose, and older age were other important predictors of risk of serious infections in patients treated with biologics. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology; Birmingham VA Medical Center FX This material is the result of work supported by research funds from UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. NR 28 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD OCT PY 2016 VL 18 IS 10 AR 61 DI 10.1007/s11926-016-0609-5 PG 9 WC Rheumatology SC Rheumatology GA DY8UN UT WOS:000385407000001 PM 27613285 ER PT J AU Landa, Y Mueser, K Jacobs, M Jespersen, R Wyka, K AF Landa, Yulia Mueser, Kim Jacobs, Michael Jespersen, Rachel Wyka, Katarzyna TI Adaptation of CBT for Psychosis Training for Family Caregivers of Youth at Risk for Psychosis SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Landa, Yulia; Jacobs, Michael; Jespersen, Rachel] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Landa, Yulia; Jespersen, Rachel] James J Peter Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, Bronx, NY USA. [Landa, Yulia; Jespersen, Rachel; Wyka, Katarzyna] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Mueser, Kim] Boston Univ, Boston, MA 02215 USA. [Wyka, Katarzyna] CUNY, Sch Publ Hlth, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 18 EP 18 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800044 ER PT J AU Loewy, R Fisher, M Schlosser, D Carter, C Niendam, T Ragland, JD Biaganti, B Amirfathi, F Vinogradov, S AF Loewy, Rachel Fisher, Melissa Schlosser, Danielle Carter, Cameron Niendam, Tara Ragland, J. Daniel Biaganti, Bruno Amirfathi, Felix Vinogradov, Sophia TI Improved Cognition and Positive Symptoms with Targeted Auditory Processing Training in Recent-Onset Schizophrenia SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Loewy, Rachel; Schlosser, Danielle; Biaganti, Bruno; Amirfathi, Felix] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. [Carter, Cameron; Niendam, Tara; Ragland, J. Daniel] Univ Calif Davis, Davis, CA 95616 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 114 EP 114 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800338 ER PT J AU Fallah, A Weil, AG Wang, S Lewis, E Baca, CB Mathern, GW AF Fallah, Aria Weil, Alexander G. Wang, Shelly Lewis, Evan Baca, Christine B. Mathern, Gary W. TI Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Seizures; Tuberous Sclerosis Complex; Antiseizure drugs; Ketogenic diet; Vagal nerve stimulator; Resective surgery ID VAGUS NERVE-STIMULATION; GIANT-CELL ASTROCYTOMAS; TERM-FOLLOW-UP; KETOGENIC DIET; INTRACTABLE EPILEPSY; REFRACTORY EPILEPSY; SURGERY; PREDICTORS; EFFICACY; AGE AB Background: The management of drug-resistant epilepsy in children with Tuberous Sclerosis Complex (TSC) is challenging because of the multitude of treatment options, wide range of associated costs, and uncertainty of seizure outcomes. The most cost-effective approach for children whose epilepsy has failed to improve with first-line medical therapy is uncertain. Methods: A review of MEDLINE from 1990 to 2015 was conducted. A cost-utility analysis, from a third-party payer perspective, was performed for children with drug-resistant epilepsy that had failed to improve with 2 antiseizure drugs (ASDs) and that was amenable to resective epilepsy surgery, across a time-horizon of 5 years. Four strategies were included: (1) resective epilepsy surgery, (2) vagus nerve stimulator (VNS) implantation, (3) ketogenic diet, and (4) addition of a third ASD (specifically, carbamazepine). The incremental cost per quality-adjusted life year (QALY) gained was analyzed. Results: Given a willingness-to-pay (WTP) of $100,000 per QALY, the addition of a third ASD ($6600 for a gain of 4.14 QALYs) was the most cost-effective treatment strategy. In a secondary analysis, if the child whose epilepsy had failed to improve with 3 ASDs, ketogenic diet, addition of a fourth ASD, and resective epilepsy surgery were incrementally cost-effective treatment strategies. Vagus nerve stimulator implantation was more expensive yet less effective than alternative strategies and should not be prioritized. Conclusions: The addition of a third ASD is a universally cost-effective treatment option in the management of children with drug-resistant epilepsy that has failed to improve with 2 ASDs. For children whose epilepsy has failed to improve with 3 ASDs, the most cost-effective treatment depends on the health-care resources available reflected by the WTP. (C) 2016 Elsevier Inc. All rights reserved. C1 [Fallah, Aria; Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 300 Stein Plaza,Suite 525, Los Angeles, CA 90095 USA. [Fallah, Aria; Mathern, Gary W.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Weil, Alexander G.] Univ Montreal, Dept Surg, Div Pediat Neurosurg, Montreal, PQ, Canada. [Wang, Shelly] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada. [Wang, Shelly] Harvard TH Chan Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA. [Lewis, Evan] Univ Toronto, Hosp Sick Children, Div Pediat Neurol, Toronto, ON, Canada. [Baca, Christine B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Baca, Christine B.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. RP Fallah, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 300 Stein Plaza,Suite 525, Los Angeles, CA 90095 USA. EM afallah@mednet.ucla.edu FU Davies/Randall endowed chair for epilepsy research at UCLA; RE children's project FX Gary W. Mathern was supported in part by the Davies/Randall endowed chair for epilepsy research at UCLA and the RE children's project. NR 48 TC 0 Z9 0 U1 4 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD OCT PY 2016 VL 63 BP 79 EP 88 DI 10.1016/j.yebeh.2016.07.034 PG 10 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DZ0LO UT WOS:000385531100014 PM 27591681 ER PT J AU Vardeny, O Claggett, B Packer, M Zile, MR Rouleau, J Swedberg, K Teerlink, JR Desai, AS Lefkowitz, M Shi, V McMurray, JJ Solomon, SD AF Vardeny, Orly Claggett, Brian Packer, Milton Zile, Michael R. Rouleau, Jean Swedberg, Karl Teerlink, John R. Desai, Akshay S. Lefkowitz, Martin Shi, Victor McMurray, John J. V. Solomon, Scott D. CA Prospective Comparison ARNI ACEI D TI Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Chronic heart failure; Neprilysin inhibitor; Clinical trial; Sacubitril; Valsartan ID BETA-BLOCKER THERAPY; INHIBITION; NEPRILYSIN; OUTCOMES AB AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril. Methods and resultsIn a post-hoc analysis from PARADIGM-HF, we characterized patients by whether they received the maximal dose (200 mg sacubitril/valsartan or 10 mg enalapril twice daily) throughout the trial or had any dose reduction to lower doses (100/50/0 mg sacubitril/valsartan or 5/2.5/0 mg enalapril twice daily). The treatment effect for the primary outcome was estimated, stratified by dose level using time-updated Cox regression models. In the two treatment arms, participants with a dose reduction (43% of those randomized to enalapril and 42% of those randomized to sacubitril/valsartan) had similar baseline characteristics and similar baseline predictors of the need for dose reduction. In a time-updated analysis, any dose reduction was associated with a higher subsequent risk of the primary event [hazard ratio (HR) 2.5, 95% confidence interval (CI) 2.2-2.7]. However, the treatment benefit of sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70-0.93, P < 0.001) to that observed in patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71-0.88, P < 0.001). ConclusionsIn PARADIGM-HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event. The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of enalapril was similar to that of patients who remained on target doses of both drugs. C1 [Vardeny, Orly] Univ Wisconsin, Sch Pharm, Pharm Practice Div, 425 N Charter St, Madison, WI 53706 USA. [Claggett, Brian; Desai, Akshay S.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02445 USA. [Packer, Milton] Baylor Univ, Med Ctr, Div Cardiol, Dallas, TX USA. [Packer, Milton] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA. [Zile, Michael R.] Med Univ South Carolina, Charleston, NC USA. [Zile, Michael R.] Ralph H Johnston Vet Adm Med Ctr, Charleston, NC USA. [Rouleau, Jean] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada. [Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden. [Swedberg, Karl] Imperial Coll, Natl Heart & Lung Inst, London, England. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lefkowitz, Martin; Shi, Victor] Novartis Pharmaceut, E Hanover, NJ USA. [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02445 USA. EM ssolomon@rics.bwh.harvard.edu OI mcmurray, john/0000-0002-6317-3975 FU NHLBI NIH HHS [R01 HL123478] NR 13 TC 7 Z9 7 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD OCT PY 2016 VL 18 IS 10 BP 1228 EP 1234 DI 10.1002/ejhf.580 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DZ2ZB UT WOS:000385710500004 PM 27283779 ER PT J AU Ye, SQ Qian, M Zhao, B Buchsbaum, R Sacco, RL Levin, B Di Tullio, MR Mann, DL Pullicino, PM Freudenberger, RS Teerlink, JR Mohr, JP Graham, S Labovitz, AJ Estol, CJ Lok, DJ Ponikowski, P Anker, SD Lip, GYH Thompson, JLP Homma, S AF Ye, Siqin Qian, Min Zhao, Bo Buchsbaum, Richard Sacco, Ralph L. Levin, Bruce Di Tullio, Marco R. Mann, Douglas L. Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Mohr, J. P. Graham, Susan Labovitz, Arthur J. Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. Lip, Gregory Y. H. Thompson, John L. P. Homma, Shunichi CA WARCEF Investigators TI CHA(2)DS(2)-VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Warfarin; Sinus rhythm; Stroke; Bleeding ID ATRIAL-FIBRILLATION; STROKE; RISK; WARFARIN; ASPIRIN; TRIAL; THROMBOEMBOLISM; RATIONALE; DESIGN; WARCEF AB AimsThe aim of this study was to determine whether the CHA(2)DS(2)-VASc score can predict adverse outcomes such as death, ischaemic stroke, and major haemorrhage, in patients with systolic heart failure in sinus rhythm. Methods and resultsCHA(2)DS(2)-VASc scores were calculated for 1101 patients randomized to warfarin and 1123 patients randomized to aspirin. Adverse outcomes were defined as death or ischaemic stroke, death alone, ischaemic stroke alone, and major haemorrhage. Using proportional hazards models, we found that each 1-point increase in the CHA(2)DS(2)-VASc score was associated with increased hazard of death or ischaemic stroke events [hazard ratio (HR) for the warfarin arm = 1.21, 95% confidence interval (CI) 1.13-1.30, P < 0.001; for aspirin, HR = 1.20, 95% CI 1.11-1.29, P < 0.001]. Similar increased hazards for higher CHA(2)DS(2)-VASc scores were observed for death alone, ischaemic stroke alone, and major haemorrhage. Overall performance of the CHA(2)DS(2)-VASc score was assessed using c-statistics for full models containing the risk score, treatment assignment, and score-treatment interaction, with the c-statistics for the full models ranging from 0.57 for death to 0.68 for major haemorrhage. ConclusionsThe CHA(2)DS(2)-VASc score predicted adverse outcomes in patients with systolic heart failure in sinus rhythm, with modest prediction accuracy. C1 [Ye, Siqin; Di Tullio, Marco R.; Homma, Shunichi] Columbia Univ, Dept Med, Med Ctr, Div Cardiol, New York, NY USA. [Qian, Min; Zhao, Bo; Buchsbaum, Richard; Levin, Bruce; Thompson, John L. P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA. [Mann, Douglas L.] Washington Univ, Dept Med, St Louis, MO USA. [Pullicino, Patrick M.] Univ Kent, Kent Inst Med & Hlth Sci, Canterbury, Kent, England. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Div Cardiol, Dept Med, Allentown, PA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Mohr, J. P.] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA. [Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA. [Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. [Lok, Dirk J.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands. [Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] Univ Med Ctr Gottingen, Dept Cardiol & Pneumol, Innovat Clin Trials, Gottingen, Germany. [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. RP Ye, SQ (reprint author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 West 168th St,PH 9-320, New York, NY 10032 USA. EM sy2357@cumc.columbia.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU NHLBI NIH HHS [K23 HL121144]; NINDS NIH HHS [U01 NS039143, U01 NS043975] NR 18 TC 4 Z9 4 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD OCT PY 2016 VL 18 IS 10 BP 1261 EP 1266 DI 10.1002/ejhf.613 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DZ2ZB UT WOS:000385710500010 PM 27444219 ER PT J AU Grubisha, MJ Lin, CW Tseng, GC Penzes, P Sibille, E Sweet, RA AF Grubisha, Melanie J. Lin, Chien-Wei Tseng, George C. Penzes, Peter Sibille, Etienne Sweet, Robert A. TI Age-dependent increase in Kalirin-9 and Kalirin-12 transcripts in human orbitofrontal cortex SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE dendritic complexity; human ageing; Kalirin; postmortem ID GDP/GTP EXCHANGE FACTOR; SPINE MORPHOGENESIS; PREFRONTAL CORTEX; DENDRITIC SPINES; EXPRESSION; BRAIN; SCHIZOPHRENIA; DISEASE; PLASTICITY; REGRESSION AB KALRN (KAL) is a Rho GEF that is highly involved in regulation of the actin cytoskeleton within dendrites. There are several isoforms of the protein that arise from differential splicing of KALRN's 66 exons. KAL isoforms have different functions in development. For example, overexpression of the KAL9 and KAL12 isoforms induce dendritic elongation in early development. However, in mature neurons KAL9 overexpression reduces dendritic length, a phenotype also observed in normal human ageing. We therefore hypothesized that KAL9 would have increased expression with age, and undertook to evaluate the expression of individual KALRN exons throughout the adult lifespan. Postmortem human brain grey matter from Brodmann's area (BA) 11 and BA47 derived from a cohort of 209 individuals without psychiatric or neurodegenerative disease, ranging in age from 16 to 91 years, were analysed for KALRN expression by Affymetrix exon array. Analysis of the exon array data in an isoform-specific manner, as well as confirmatory isoform-specific qPCR studies, indicated that the longer KAL9 and KAL12 isoforms demonstrated a statistically significant, but modest, increase with age. The small magnitude of the age effect suggests that inter-individual factors other than age likely contribute to a higher degree to KAL9 and KAL12 expression. In contrast to KAL9 and KAL12, global KALRN expression did not increase with age. Our work suggests that global measures of KALRN gene expression may be misleading and future studies should focus on isoform-specific quantification. C1 [Grubisha, Melanie J.; Sibille, Etienne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Lin, Chien-Wei; Tseng, George C.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sibille, Etienne] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA. [Sibille, Etienne] Univ Toronto, Campbell Family Mental Hlth Res Inst, Dept Psychiat, CAMH, Toronto, ON, Canada. [Sibille, Etienne] Univ Toronto, Campbell Family Mental Hlth Res Inst, Dept Pharmacol, CAMH, Toronto, ON, Canada. [Sibille, Etienne] Univ Toronto, Campbell Family Mental Hlth Res Inst, Dept Toxicol, CAMH, Toronto, ON, Canada. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.; Sweet, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU NIH [MH071533, AG027224]; VAPHS [BX000542, MH093723, MH071316, MH097216] FX This work was supported by NIH grants MH071533 (RAS), AG027224 (RAS), VAPHS grant BX000542 (RAS), MH093723 (ES), MH071316 (PP) and MH097216 (PP). We thank Dr. C. Sue Johnston for assistance with the clinical data and the research staff of the Translational Neuroscience Program for technical assistance. These results were presented, in part, at the 2015 Annual Meeting of the Society of Biological Psychiatry, Toronto, ON, as well as at the 2015 American Psychiatric Association's Research Colloquium for Junior Investigators in Toronto, ON. NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD OCT PY 2016 VL 44 IS 7 BP 2483 EP 2492 DI 10.1111/ejn.13351 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DY8QE UT WOS:000385394100010 PM 27471199 ER PT J AU Daskalakis, NP Cohen, H Nievergelt, CM Baker, DG Buxbaum, JD Russo, SJ Yehuda, R AF Daskalakis, Nikolaos P. Cohen, Hagit Nievergelt, Caroline M. Baker, Dewleen G. Buxbaum, Joseph D. Russo, Scott J. Yehuda, Rachel TI New translational perspectives for blood-based biomarkers of PTSD: From glucocorticoid to immune mediators of stress susceptibility SO EXPERIMENTAL NEUROLOGY LA English DT Review DE PTSD; Stress; Individual differences; Glucocorticoids; Immune system; Biomarkers; Novel treatments ID PERIPHERAL MONONUCLEAR LEUKOCYTES; CHILDHOOD SEXUAL ABUSE; GENE-EXPRESSION; ANIMAL-MODEL; HPA-AXIS; INDIVIDUAL-DIFFERENCES; PSYCHIATRIC-DISORDERS; SYNAPTIC PLASTICITY; CYTOKINE PRODUCTION; RECEPTOR PATHWAY AB Although biological systems have evolved to promote stress-resilience, there is variation in stress-responses. Understanding the biological basis of such individual differences has implications for understanding Posttraumatic Stress Disorder (PTSD) etiology, which is a maladaptive response to trauma occurring only in a subset of vulnerable individuals. PTSD involves failure to reinstate physiological homeostasis after traumatic events and is due to either intrinsic or trauma-related alterations in physiological systems across the body. Master homeostatic regulators that circulate and operate throughout the organism, such as stress hormones (e.g., glucocorticoids) and immune mediators (e.g., cytokines), are at the crossroads of peripheral and central susceptibility pathways and represent promising functional biomarkers of stress-response and target for novel therapeutics. (C) 2016 Elsevier Inc. All rights reserved. C1 [Daskalakis, Nikolaos P.; Buxbaum, Joseph D.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA. [Cohen, Hagit] Ben Gurion Univ Negev, Fac Hlth Sci, Minist Hlth Mental Hlth Ctr, Anxiety & Stress Res Unit, Beer Sheva, Israel. [Nievergelt, Caroline M.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Nievergelt, Caroline M.; Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Buxbaum, Joseph D.; Russo, Scott J.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Daskalakis, NP (reprint author), Dept Psychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu OI Daskalakis, Nikolaos/0000-0003-1660-9112; russo, scott/0000-0002-6470-1805 FU U.S. Army Medical Research and Materiel Command [W81XWH-08-2-0021, W81XWH-13-1-0071]; Brain & Behavior Research Foundation grant [NARSAD 23670]; Marine Corps; Navy Bureau of Medicine and Surgery (BUMED); VA Health Research and Development (HSRD); Navy BUMED; US National Institute of Mental Health [RO1 MH090264, RO1 MH104559]; Johnson & Johnson International Mental Health Research Organization Rising Star Award, an Irma T. Hirschl/Monique Weill-Caulier Trust Research Award FX This work was supported by U.S. Army Medical Research and Materiel Command grants W81XWH-08-2-0021 and W81XWH-13-1-0071 (to RY) and Brain & Behavior Research Foundation grant NARSAD 23670 (to NPD). MRS and MRS-II (including RNA-seq) were funding by the Marine Corps, Navy Bureau of Medicine and Surgery (BUMED), VA Health Research and Development (HSR&D) and Navy BUMED, respectively (DGB, CMN). SJR was supported by US National Institute of Mental Health grants RO1 MH090264 and RO1 MH104559, the Johnson & Johnson International Mental Health Research Organization Rising Star Award, an Irma T. Hirschl/Monique Weill-Caulier Trust Research Award. RY is a co-inventor of the following patent: Genes associated with posttraumatic-stress disorder. WO 2010029176 A1". NR 94 TC 1 Z9 1 U1 10 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2016 VL 284 SI SI BP 133 EP 140 DI 10.1016/j.expneurol.2016.07.024 PN B PG 8 WC Neurosciences SC Neurosciences & Neurology GA DY7UJ UT WOS:000385334500003 PM 27481726 ER PT J AU Hendrickson, RC Raskind, MA AF Hendrickson, Rebecca C. Raskind, Murray A. TI Noradrenergic dysregulation in the pathophysiology of PTSD SO EXPERIMENTAL NEUROLOGY LA English DT Review DE Prazosin; Posttraumatic stress disorder (PTSD); Noradrenergic ID POSTTRAUMATIC-STRESS-DISORDER; SALIVARY ALPHA-AMYLASE; CORTICOTROPIN-RELEASING-FACTOR; CENTRAL-NERVOUS-SYSTEM; HEART-RATE-VARIABILITY; COMBAT-RELATED PTSD; REDUCES ALCOHOL-DRINKING; LOCUS-COERULEUS ACTIVITY; PITUITARY-ADRENAL AXIS; TRAUMATIC BRAIN-INJURY AB A central role for noradrenergic dysregulation in the pathophysiology of post-traumatic stress disorder (PTSD) is increasingly suggested by both clinical and basic neuroscience research. Here, we integrate recent findings from clinical and animal research with the earlier literature. We first review the evidence for net upregulation of the noradrenergic system and its responsivity to stress in individuals with PTSD. Next, we trace the evidence that the o noradrenergic receptor antagonist prazosin decreases many of the symptoms of PTSD from initial clinical observations, to case series, to randomized controlled trials. Finally, we review the basic science work that has begun to explain the mechanism for this efficacy, as well as to explore its possible limitations and areas for further advancement. We suggest a view of the noradrenergic system as a central, modifiable link in a network of interconnected stress-response systems, which also includes the amygdala and its modulation by medial prefrontal cortex. Particular attention is paid to the evidence for bidirectional signaling between noradrenaline and corticotropin-releasing factor (CRF) in coordinating these interconnected systems. The multiple different ways in which the sensitivity and reactivity of the noradrenergic system may be altered in PTSD are highlighted, as is the evidence for possible heterogeneity in the pathophysiology of PTSD between different individuals who appear clinically similar. We conclude by noting the importance moving forward of improved measures of noradrenergic functioning in clinical populations, which will allow better recognition of clinical heterogeneity and further assessment of the functional implications of different aspects of noradrenergic dysregulation. Published by Elsevier Inc. C1 VISN 20 Northwest Network, MIRECC, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hendrickson, RC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 MIRECC, Seattle, WA 98108 USA. EM rhend@uw.edu FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the Puget Sound Veterans Affairs Health Care System; Puget Sound Veterans Affairs Health Care System Mental Illness Research, Education, and Clinical Center (MIRECC); Department of Defense [W81XWH-12-2-0094] FX The writing of this manuscript was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the Puget Sound Veterans Affairs Health Care System, the Puget Sound Veterans Affairs Health Care System Mental Illness Research, Education, and Clinical Center (MIRECC) and the Department of Defense (W81XWH-12-2-0094). NR 177 TC 1 Z9 1 U1 11 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2016 VL 284 SI SI BP 181 EP 195 DI 10.1016/j.expneurol.2016.05.014 PN B PG 15 WC Neurosciences SC Neurosciences & Neurology GA DY7UJ UT WOS:000385334500007 PM 27222130 ER PT J AU Smith, AW Rohrer, B Wheless, L Samantaray, S Ray, SK Inoue, J Azuma, M Banik, NL AF Smith, Amena W. Rohrer, Baerbel Wheless, Lee Samantaray, Supriti Ray, Swapan K. Inoue, Jun Azuma, Mitsuyoshi Banik, Naren L. TI Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE axonal degeneration; calpain and cell death; oligodendrocytes; optic nerve; retinal ganglion cells; visual acuity ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MAJOR DEPRESSIVE DISORDER; MULTIPLE-SCLEROSIS; AXONAL INJURY; PATTERN ELECTRORETINOGRAM; NEUROFILAMENT PROTEINS; COHERENCE TOMOGRAPHY; NEUTRAL PROTEINASE; IN-VITRO; SYSTEM AB Optic neuritis (ON), inflammation of the optic nerve, is strongly associated with multiple sclerosis. ON pathology is characterized by attack of autoreactive T cells against optic nerve antigens, resulting in demyelination, death of retinal ganglion cells, and cumulative visual impairment. A model of experimental autoimmune encephalomyelitis (EAE) was utilized to study the onset and progression of ON and the neuroprotective efficacy of oral treatment with the calpain inhibitor SNJ 1945. EAE was actively induced in B10. PL mice with myelin basic protein on Days 0 and 2, and mice received twice daily oral dosing of SNJ 1945 from Day 9 until sacrificing (Day 26). Visual function was determined by electroretinogram recordings and daily measurement of optokinetic responses (OKR) to a changing pattern stimulus. Optic nerve and retinal histopathology was investigated by immunohistochemical and luxol fast blue staining. EAE mice manifested losses in OKR thresholds, a measurement of visual acuity, which began early in the disease course. There was a significant bias toward unilateral OKR impairment among EAE-ON eyes. Treatment with SNJ 1945, initiated after the onset of OKR threshold decline, improved visual acuity, pattern electroretinogram amplitudes, and paralysis, with attenuation of retinal ganglion cell death. Furthermore, calpain inhibition spared oligodendrocytes, prevented degradation of axonal neurofilament protein, and attenuated reactive astrocytosis. The trend of early, unilateral visual impairment in EAE-ON parallels the clinical presentation of ON exacerbations associated with multiple sclerosis. Calpain inhibition may represent an ideal candidate therapy for the preservation of vision in clinical ON. C1 [Smith, Amena W.; Rohrer, Baerbel] Med Univ South Carolina, Dept Neurosci, 96 Jonathan Lucas St,MSC606, Charleston, SC 29425 USA. [Rohrer, Baerbel; Banik, Naren L.] Med Univ South Carolina, Dept Ophthalmol, 96 Jonathan Lucas St,MSC606, Charleston, SC 29425 USA. [Rohrer, Baerbel; Banik, Naren L.] Alex Pharmaceut, Cheshire, CT USA. [Rohrer, Baerbel; Ray, Swapan K.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, 96 Jonathan Lucas St,MSC606, Columbia, SC 29425 USA. [Wheless, Lee] Med Univ South Carolina, Med Div Biostat & Epidemiol, Charleston, SC USA. [Samantaray, Supriti; Banik, Naren L.] Med Univ South Carolina, Dept Neurol & Neurosurg, Charleston, SC USA. [Inoue, Jun; Azuma, Mitsuyoshi] Senju Pharmaceut Co Ltd, Kobe, Hyogo, Japan. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ South Carolina, 96 Jonathan Lucas St,MSC606, Charleston, SC 29425 USA.; Rohrer, B (reprint author), MUSC, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. EM rohrer@musc.edu FU BLRD VA [I01 BX002349, I01 BX003050]; NEI NIH HHS [R01 EY019320]; NINDS NIH HHS [R01 NS041088, R01 NS056176, R01 NS065456]; RRD VA [I01 RX000444] NR 66 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD OCT PY 2016 VL 139 IS 2 BP 270 EP 284 DI 10.1111/jnc.13770 PG 15 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DZ3SJ UT WOS:000385769200012 PM 27513991 ER PT J AU Cooke, KJ Franklin, JE Painter, J Rodgers, J AF Cooke, Kelly J. Franklin, John E. Painter, John Rodgers, James TI Effects of Combat and Military Training on End-of-Life Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter C1 [Cooke, Kelly J.] ProHlth Care, Dept Palliat Med, Waukesha, WI USA. [Franklin, John E.] Charleston Vet Affairs Med Ctr, Dept Geriatr & Palliat Med, Charleston, SC USA. [Painter, John] Charleston Vet Affairs Med Ctr, Dept Palliat Med, Charleston, SC USA. [Rodgers, James] Houston Vet Affairs Med Ctr, Dept Psychol, Houston, TX USA. [Cooke, Kelly J.] Cent Texas Vet Affairs Med Ctr, Temple, TX USA. RP Cooke, KJ (reprint author), ProHealthcare, Dept Palliat Med, 721 Amer Ave,Suite 508, Waukesha, WI 53188 USA. EM kelly.cooke@phci.org NR 9 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT PY 2016 VL 19 IS 10 BP 1025 EP 1027 DI 10.1089/jpm.2015.0363 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DY8JQ UT WOS:000385376500002 ER PT J AU Mehta, SH Tanner, CM AF Mehta, Shyamal H. Tanner, Caroline M. TI Role of Neuroinflammation in Parkinson Disease: The Enigma Continues SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID HLA REGION; ASSOCIATION; RISK; BRAIN; PD C1 [Mehta, Shyamal H.] Mayo Clin, Dept Neurol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. [Tanner, Caroline M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Mehta, SH (reprint author), Mayo Clin, Dept Neurol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM mehta.shyamal@mayo.edu NR 19 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2016 VL 91 IS 10 BP 1328 EP 1330 DI 10.1016/j.mayocp.2016.08.010 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DZ6AQ UT WOS:000385944400005 PM 27712631 ER PT J AU Lytle, MC Blosnich, JR Kamen, C AF Lytle, Megan C. Blosnich, John R. Kamen, Charles TI The Association of Multiple Identities with Self-Directed Violence and Depression among Transgender Individuals SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID BEHAVIORS; SUICIDE; HEALTH; VICTIMIZATION; YOUTH; GAY AB Transgender individuals have a high prevalence of self-directed violence; however, there is scant literature focusing on their unique experiences. The differences in self-harm, suicidal ideation, suicide attempt, and depression based on racial/ethnic identity and sexual orientation were examined among transgender individuals. Data were gathered from the Fall 2008 and Spring 2009 National College Health Assessment. Across racial/ethnic identities, greater proportions of transgender students endorsed self-directed violence than their cisgender peers. Among transgender individuals, sexual minorities were more likely to report suicidal ideation than their heterosexual peers, and racial/ethnic minorities had higher odds of attempting suicide than non-Hispanic White individuals. C1 [Lytle, Megan C.] Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kamen, Charles] Univ Rochester, Med Ctr, Canc Control Unit, Rochester, NY 14642 USA. RP Lytle, MC (reprint author), Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. EM megan_lytle@urmc.rochester.edu FU University of Rochester CTSA award from National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR000095]; Health Services Research and Development through Department of Veterans Affairs; Center for Health Equity Research and Promotion [TPP 72-013]; National Cancer Institute [UG1 CA189961, K07 CA190529] FX Megan C. Lytle received support from the University of Rochester CTSA award number KL2TR000095 from the National Center for Advancing Translational Sciences of the National Institutes of Health; John R. Blosnich was supported by a postdoctoral fellowship from Health Services Research and Development through the Department of Veterans Affairs and the Center for Health Equity Research and Promotion (TPP 72-013); and Charles Kamen received support from National Cancer Institute grants UG1 CA189961 and K07 CA190529. The opinions expressed in this work are those of the authors and do not necessarily represent those of the funders, institutions, the Department of Veterans Affairs, or the U.S. Government. NR 27 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD OCT PY 2016 VL 46 IS 5 BP 535 EP 544 DI 10.1111/sltb.12234 PG 10 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DZ2XO UT WOS:000385706300003 PM 26916366 ER PT J AU Etchill, E Sperry, J Zuckerbraun, B Alarcon, L Brown, J Schuster, K Kaplan, L Piper, G Peitzman, A Neal, MD AF Etchill, Eric Sperry, Jason Zuckerbraun, Brian Alarcon, Louis Brown, Joshua Schuster, Kevin Kaplan, Lewis Piper, Greta Peitzman, Andrew Neal, Matthew D. TI The confusion continues: results from an American Association for the Surgery of Trauma survey on massive transfusion practices among United States trauma centers SO TRANSFUSION LA English DT Article ID BLOOD-CELL TRANSFUSION; ACTIVATED FACTOR-VII; EXSANGUINATION PROTOCOL; SCORING SYSTEMS; COAGULOPATHY; HEMORRHAGE; VALIDATION; PATIENT; TRIAL; THROMBOELASTOGRAPHY AB BACKGROUNDMassive transfusion practices have undergone several recent developments. We sought to examine institutional practices guiding hemostatic resuscitation in the setting of massive hemorrhage. STUDY DESIGN AND METHODSA 37-question online survey was sent to American Association for the Surgery of Trauma members. RESULTSA total of 191 surgeons from 125 institutions completed the survey. Level I and II centers composed 70 and 18% of responding sites, respectively. A total of 123 institutions have a massive transfusion protocol (MTP); 54% report having an MTP for less than 5 years. The number of coolers and units of red blood cells, plasma, and platelets are highly variable. Tranexamic acid is part of the MTP at 64% of centers; 26% continue to use recombinant activated Factor VII. MTP activation occurs more than five times per month at 32% of centers. MTPs are utilized for nontrauma patients in 82% of institutions. Point-of-care prothrombin time, international normalized ratio, and partial thromboplastin time testing is utilized in 37% of institutions. Only 9% routinely utilize thromboelastography or rotational thromboelastometry (TEG/ROTEM) within their MTP. Just 7% use a validated scoring system to guide MTP activation. The incorporation of TEG/ROTEM into the MTP is associated with the use of a scoring system in regression analysis (p=0.024). CONCLUSIONMost institutions regularly activate recently implemented MTPs for trauma and nontrauma indications; however, few use validated scoring systems for MTP activation. MTP content is highly variable. Few institutions use TEG, while most have incorporated tranexamic acid into their protocol. The lack of consistent practices underscores the need for outcome-based studies to guide transfusion practices. C1 [Etchill, Eric; Sperry, Jason; Zuckerbraun, Brian; Alarcon, Louis; Brown, Joshua; Peitzman, Andrew; Neal, Matthew D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Schuster, Kevin] Yale Univ, Sch Med, New Haven, CT USA. [Kaplan, Lewis] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kaplan, Lewis] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Piper, Greta] NYU Med Ctr, New York, NY 10016 USA. RP Neal, MD (reprint author), Univ Pittsburgh, Surg & Crit Care Med, Div Trauma & Acute Care Surg, Dept Surg,Sch Med, F1272-1 PUH 200 Lothrop St, Pittsburgh, PA 15213 USA. EM nealm2@upmc.edu OI Etchill, Eric/0000-0002-5381-648X NR 39 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2016 VL 56 IS 10 BP 2478 EP 2486 DI 10.1111/trf.13755 PG 9 WC Hematology SC Hematology GA DZ4NG UT WOS:000385834800013 PM 27515056 ER PT J AU Tong, YS Phillips, MR Conner, KR AF Tong, Yongsheng Phillips, Michael R. Conner, Kenneth R. TI DSM-IV Axis II personality disorders and suicide and attempted suicide in China SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID CONTROL PSYCHOLOGICAL AUTOPSY; RISK-FACTORS; MENTAL-DISORDERS; PREDICTORS; SEVERITY; SAMPLE AB Background There are meagre data on Axis II personality disorders and suicidal behaviour in China. Aims To describe the prevalence of Axis II personality disorders in suicides and suicide attempts in China and to estimate risk. for these outcomes associated with personality disorders. Method People who died by suicide (n = 151), people who attempted suicide (n = 118) and living community controls (n = 140) were randomly sampled from four Chinese counties and studied using the Structured Clinical Interviews for DSM-IV-TR Axis I Disorders (SCID-I) and Axis II Personality Disorders (SCID-II). We also determined the prevalence of subthreshold versions of ten DSM-IV personality disorders. Results Axis II personality disorders were present in 7% of the suicide group, 6% of the suicide attempt group and 1% of the control group. Threshold and subthreshold personality disorders had adjusted odds ratios (point estimates) in the range of 2.7-8.0 for suicide and for suicide attempts. Conclusions Axis II personality disorders may confer increased risk for suicidal behaviour in China, but their low prevalence in the community and among people with suicidal behaviour suggests that other personality constructs such as select dimensional traits may be a more fruitful avenue for understanding and preventing suicide in China. C1 [Tong, Yongsheng; Phillips, Michael R.] Beijing Hui Long Guan Hosp, Beijing Suicide Res & Prevent Ctr, Beijing 100096, Peoples R China. [Tong, Yongsheng] WHO Collaborating Ctr Res & Training Suicide Prev, Beijing, Peoples R China. [Tong, Yongsheng; Conner, Kenneth R.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai, Peoples R China. [Phillips, Michael R.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Phillips, Michael R.] Emory Univ, Dept Publ Hlth, Atlanta, GA 30322 USA. [Conner, Kenneth R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. RP Tong, YS (reprint author), Beijing Hui Long Guan Hosp, Beijing Suicide Res & Prevent Ctr, Beijing 100096, Peoples R China.; Phillips, MR (reprint author), Shanghai Mental Hlth Ctr, Shanghai 201108, Peoples R China. EM timystong@pku.org.cn; mphillipschina@outlook.com FU American Foundation of Suicide Prevention; PHS by National Natural Science Foundation of China (NSFC) [5D43TW009101, 81371501]; Beijing Municipal Science & Technology Commission [Z131107002213075]; Beijing Municipal Health Bureau [QN2008-017]; National Natural Science Foundation of China (NSFC) [81371502] FX This study was supported by the grant from the American Foundation of Suicide Prevention (M.R.P. principal investigator (PI)). Y.T. was supported in part by PHS grants 5D43TW009101 (E.D. Caine, PI) by National Natural Science Foundation of China (NSFC, No.81371501), Beijing Municipal Science & Technology Commission (No.Z131107002213075) and Beijing Municipal Health Bureau (QN2008-017). M.R.P. was supported in part by the National Natural Science Foundation of China (NSFC, No. 81371502). The funding institutions had no role in the design, conduct, analysis or write-up of the project NR 43 TC 0 Z9 0 U1 2 U2 2 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD OCT PY 2016 VL 209 IS 4 BP 321 EP 328 DI 10.1192/bjp.bp.114.151076 PG 8 WC Psychiatry SC Psychiatry GA DY3BP UT WOS:000384966100010 ER PT J AU Boscia, F Begum, G Pignataro, G Sirabella, R Cuomo, O Casamassa, A Sun, DD Annunziato, L AF Boscia, Francesca Begum, Gulnaz Pignataro, Giuseppe Sirabella, Rossana Cuomo, Ornella Casamassa, Antonella Sun, Dandan Annunziato, Lucio TI Glial Na+-dependent Ion Transporters in Pathophysiological Conditions SO GLIA LA English DT Review DE astrocytes; microglia; oligodendrocytes; Na+/Ca2+ exchanger; Na+/H+ exchanger; Na+/K+ ATPase; Na+-HCO3- cotransporter; Na+-K+-Cl- cotransporter ID FOCAL CEREBRAL-ISCHEMIA; K+-CL-COTRANSPORTER; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; CATION-CHLORIDE COTRANSPORTERS; INTRACELLULAR PH REGULATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; CULTURED RAT ASTROCYTES; EXCHANGER ISOFORM 1 AB Sodium dynamics are essential for regulating functional processes in glial cells. Indeed, glial Na+ signaling influences and regulates important glial activities, and plays a role in neuron-glia interaction under physiological conditions or in response to injury of the central nervous system (CNS). Emerging studies indicate that Na+ pumps and Na+-dependent ion transporters in astrocytes, microglia, and oligodendrocytes regulate Na+ homeostasis and play a fundamental role in modulating glial activities in neurological diseases. In this review, we first briefly introduced the emerging roles of each glial cell type in the pathophysiology of cerebral ischemia, Alzheimer's disease, epilepsy, Parkinson's disease, Amyotrophic Lateral Sclerosis, and myelin diseases. Then, we discussed the current knowledge on the main roles played by the different glial Na+-dependent ion transporters, including Na+/K+ ATPase, Na+/Ca2+ exchangers, Na+/H+ exchangers, Na+-K+-Cl- cotransporters, and Na+-HCO3- cotransporter in the pathophysiology of the diverse CNS diseases. We highlighted their contributions in cell survival, synaptic pathology, gliotransmission, pH homeostasis, and their role in glial activation, migration, gliosis, inflammation, and tissue repair processes. Therefore, this review summarizes the foundation work for targeting Na+-dependent ion transporters in glia as a novel strategy to control important glial activities associated with Na+ dynamics in different neurological disorders. C1 [Boscia, Francesca; Pignataro, Giuseppe; Sirabella, Rossana; Cuomo, Ornella; Casamassa, Antonella; Annunziato, Lucio] Univ Naples Federico II, Div Pharmacol, Dept Neurosci Reprod & Odontostomatol Sci, Sch Med, Via Pansini 5, I-80131 Naples, Italy. [Begum, Gulnaz; Sun, Dandan] Univ Pittsburgh, Sch Med, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. RP Annunziato, L (reprint author), Univ Naples Federico II, Div Pharmacol, Dept Neurosci Reprod & Odontostomatol Sci, Sch Med, Via Pansini 5, I-80131 Naples, Italy.; Sun, DD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA. EM sund@upmc.edu; lannunzi@unina.it OI PIGNATARO, GIUSEPPE/0000-0002-7290-4397 FU MIUR [PON01_01602, PON03PE_00146_1]; Regione Campania [POR Campania FESR 2007-2013 MOVIE, B25C1300024007]; Fondazione Italiana Sclerosi Multipla [FISM 2012/R1, FISM2015/R6]; NIH [RO1 NS048216, RO1 NS38118]; VA [101BX002891] FX Grant sponsor: MIUR; Grant numbers: PON01_01602, PON03PE_00146_1 to L.A.; Grant sponsor: Regione Campania; Grant number: POR Campania FESR 2007-2013 MOVIE (B25C1300024007) to L.A.; Grant sponsor: Fondazione Italiana Sclerosi Multipla; Grant numbers: FISM 2012/R1 and FISM2015/R6 to F.B.; Grant sponsor: NIH; Grant numbers: RO1 NS048216 and RO1 NS38118 to D.S.; Grant sponsor: VA; Grant number: 101BX002891 to D.S. NR 216 TC 1 Z9 1 U1 6 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD OCT PY 2016 VL 64 IS 10 BP 1677 EP 1697 DI 10.1002/glia.23030 PG 21 WC Neurosciences SC Neurosciences & Neurology GA DY2OV UT WOS:000384932800008 PM 27458821 ER PT J AU Psotka, MA von Maltzahn, R Anatchkova, M Agodoa, I Chau, D Malik, FI Patrick, DL Spertus, JA Wiklund, I Teerlink, JR AF Psotka, Mitchell A. von Maltzahn, Robyn Anatchkova, Milena Agodoa, Irene Chau, Dina Malik, Fady I. Patrick, Donald L. Spertus, John A. Wiklund, Ingela Teerlink, John R. TI Patient-Reported Outcomes in Chronic Heart Failure Applicability for Regulatory Approval SO JACC-HEART FAILURE LA English DT Article DE chronic heart failure; clinical management; European Medicines Agency; Food and Drug Administration; patient-reported outcomes; regulatory approval ID QUALITY-OF-LIFE; HEALTH-STATUS; LABEL CLAIMS; SELF-CARE; HOSPITALIZATION; RESPONSIVENESS; QUESTIONNAIRE; ASSOCIATION; INSTRUMENTS; TRIALS AB OBJECTIVES The study sought to review the characteristics of existing patient-reported outcome (PRO) instruments used with chronic heart failure (HF) patients and evaluate their potential to support an approved U.S. Food and Drug Administration (FDA) product label claim. BACKGROUND PROs, including symptoms and their associated functional limitations, contribute substantially to HF patient morbidity. PRO measurements capture the patient perspective and can be systematically assessed with structured questionnaires, however rigorous recommendations have been set by the FDA regarding the acceptability of PRO measures as a basis for product label claims. METHODS Extensive searches of databases and specialty guidelines identified PRO instruments used in patients with chronic HF. Information on critical properties recommended by the FDA guidance were systematically extracted and used to evaluate the selected PRO instruments. RESULTS Nineteen PRO instruments used with chronic HF patients were identified. The Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire were the most extensively evaluated and validated in studies of this population. However, judged by criteria listed in the FDA PRO guidance, no existing PRO measure met all of the criteria to support a product label claim in the United States. CONCLUSIONS Currently available chronic HF PRO measures do not fulfill all the recommendations provided in the FDA PRO guidance and therefore may not support an FDA-approved product label claim. Future investigations are merited to develop a PRO measure for use in patients with chronic HF in accordance with the FDA guidance. (C) 2016 by the American College of Cardiology Foundation. C1 [Psotka, Mitchell A.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Psotka, Mitchell A.; Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. [von Maltzahn, Robyn; Wiklund, Ingela] Evidera, London, England. [Anatchkova, Milena] Evidera, Bethesda, MD USA. [Agodoa, Irene; Chau, Dina] Amgen Inc, Thousand Oaks, CA USA. [Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. [Patrick, Donald L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Spertus, John A.] Univ Missouri, Dept Biomed & Hlth Informat, Kansas City, MO USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu NR 43 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD OCT PY 2016 VL 4 IS 10 BP 791 EP 804 DI 10.1016/j.jchf.2016.04.010 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DY0KO UT WOS:000384785900006 PM 27395351 ER PT J AU Solomon, SD Claggett, B Packer, M Desai, A Zile, MR Swedberg, K Rouleau, J Shi, V Lefkowitz, M McMurray, JJV AF Solomon, Scott D. Claggett, Brian Packer, Milton Desai, Akshay Zile, Michael R. Swedberg, Karl Rouleau, Jean Shi, Victor Lefkowitz, Martin McMurray, John J. V. TI Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation The PARADIGM-HF Trial SO JACC-HEART FAILURE LA English DT Article DE heart failure; neprilysin inhibition; renin angiotensin system ID HEART-FAILURE; NEPRILYSIN; INHIBITION AB OBJECTIVES This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability. BACKGROUND Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blacker should be delayed until occurrence of clinical decompensation. METHODS Outcomes were compared among patients who had prior hospitalization within 3 months of screening (n = 1,611 [19%]), between 3 and 6 months (n = 1,009 [12%]), between 6 and 12 months (n = 886 [11%]), >12 months (n = 1,746 [21%]), or who had never been hospitalized (n = 3,125 [37%D. RESULTS Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular death or heart failure (HF) hospitalization during the course of the trial. Despite the increased risk associated with more recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect to cardiovascular or all-cause mortality. CONCLUSIONS Patients with recent HF decompensation requiring hospitalization were more likely to experience cardiovascular death or HF hospitalization, than those who had never been hospitalized. Patients who were clinically stable, as shown by a remote HF hospitalization (>3 months prior to screening) or by lack of any prior HF hospitalization, were as likely to benefit from sacubitril/valsartan therapy as more recently hospitalized patients. (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255) (C) 2016 by the American College of Cardiology Foundation. C1 [Solomon, Scott D.; Claggett, Brian; Desai, Akshay] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. [Packer, Milton] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA. [Zile, Michael R.] Med Univ South Carolina, Charleston, SC USA. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden. [Rouleau, Jean] Univ Montreal, Montreal, PQ, Canada. [Shi, Victor; Lefkowitz, Martin] Novartis, E Hanover, NJ USA. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu OI mcmurray, john/0000-0002-6317-3975 NR 8 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD OCT PY 2016 VL 4 IS 10 BP 816 EP 822 DI 10.1016/j.jchf.2016.05.002 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DY0KO UT WOS:000384785900009 PM 27395349 ER PT J AU Keller, AC Badani, H McClatchey, PM Baird, NL Bowlin, JL Bouchard, R Perng, GC Reusch, JEB Kaufer, BB Gilden, D Shahzad, A Kennedy, PGE Cohrs, RJ AF Keller, Amy C. Badani, Hussain McClatchey, P. Mason Baird, Nicholas L. Bowlin, Jacqueline L. Bouchard, Ron Perng, Guey-Chuen Reusch, Jane E. B. Kaufer, Benedikt B. Gilden, Don Shahzad, Aamir Kennedy, Peter G. E. Cohrs, Randall J. TI Varicella zoster virus infection of human fetal lung cells alters mitochondrial morphology SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE Varicella zoster virus; IE63; Mitochondria; Mitochondria morphology; Mitochondria swelling ID EARLY 63 PROTEIN; INHIBITS APOPTOSIS; HIGH-EFFICIENCY; HUMAN NEURONS; IE63 PROTEIN; DNA; TRANSCRIPTION; REPLICATION; SEQUENCES; TRANSPORT AB Varicella zoster virus (VZV) is a ubiquitous alphaherpesvirus that establishes latency in ganglionic neurons throughout the neuraxis after primary infection. Here, we show that VZV infection induces a time-dependent significant change in mitochondrial morphology, an important indicator of cellular health, since mitochondria are involved in essential cellular functions. VZV immediate-early protein 63 (IE63) was detected in mitochondria-rich cellular fractions extracted from infected human fetal lung fibroblasts (HFL) by Western blotting. IE63 interacted with cytochrome c oxidase in bacterial 2-hybrid analyses. Confocal microscopy of VZV-infected HFL cells at multiple times after infection revealed the presence of IE63 in the nucleus, mitochondria, and cytoplasm. Our data provide the first evidence that VZV infection induces alterations in mitochondrial morphology, including fragmentation, which may be involved in cellular damage and/or death during virus infection. C1 [Keller, Amy C.; McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado, Div Endocrinol, Sch Med, Aurora, CO 80045 USA. [Badani, Hussain; Baird, Nicholas L.; Bowlin, Jacqueline L.; Gilden, Don; Cohrs, Randall J.] Univ Colorado, Dept Neurol, Sch Med, 12700 E 19th Ave,Box B182, Aurora, CO 80045 USA. [Bouchard, Ron; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA. [Perng, Guey-Chuen] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan, Taiwan. [Perng, Guey-Chuen] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan. [Kaufer, Benedikt B.] Freie Univ, Inst Virol, Berlin, Germany. [Gilden, Don; Cohrs, Randall J.] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA. [Shahzad, Aamir] Univ Vienna, Dept Biomol Struct Chem, Max F Perutz Labs, Vienna, Austria. [Kennedy, Peter G. E.] Univ Glasgow, Queen Elizabeth Univ Hosp, Inst Neurol Sci, Dept Neurol, Glasgow, Lanark, Scotland. RP Cohrs, RJ (reprint author), Univ Colorado, Dept Neurol, Sch Med, 12700 E 19th Ave,Box B182, Aurora, CO 80045 USA.; Cohrs, RJ (reprint author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA. EM Randall.cohrs@ucdenver.edu OI Perng, Oscar/0000-0001-7510-4486 FU Public Health Service from the National Institutes of Health [AG093716, AG032958, NS082228]; VA Merit grant; CCTSI [UL1RR025780]; Center for Women's Health Research; National Institutes of Health [NS007321, 1P01HL14985] FX This work was supported by Public Health Service grants AG093716 (D.G.), AG032958 (D.G. and R.J.C.), and NS082228 (R.J.C.) from the National Institutes of Health, and VA Merit grant, CCTSI (UL1RR025780) and the Center for Women's Health Research (J.E.B.R.). Drs. H. Badani and N.L. Baird were supported by training grant NS007321 to Dr. Gilden from the National Institutes of Health. Dr. Keller was supported by training fellowship 1P01HL14985 from the National Institutes of Health. Mr. McClatchey is supported by a VA Merit grant (J.E.B.R.). NR 45 TC 0 Z9 0 U1 5 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 IS 5 BP 674 EP 682 DI 10.1007/s13365-016-0457-0 PG 9 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA DY4JM UT WOS:000385064800016 PM 27245593 ER PT J AU Ioannou, GN AF Ioannou, George N. TI How can we improve prioritization for liver transplantation in patients with hepatocellular carcinoma? SO LIVER TRANSPLANTATION LA English DT Editorial Material ID WAITING-LIST; DROPOUT ASSESSMENT; MODEL; CANDIDATES; MORTALITY; POLICY C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Ctr, Div Gastroenterol, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Ctr, Dept Med, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Ctr, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Ioannou, George N.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, S-111 Gastro,1660 South Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD OCT PY 2016 VL 22 IS 10 BP 1321 EP 1323 DI 10.1002/lt.24604 PG 3 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA DY0UP UT WOS:000384812000002 PM 27541631 ER PT J AU Yeh, CK AF Yeh, C-K TI Cellular senescence and aging SO ORAL DISEASES LA English DT Editorial Material ID CELLS; CLEARANCE; CANCER C1 [Yeh, C-K] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res, Educ & Clin Ctr, San Antonio, TX USA. [Yeh, C-K] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Yeh, C-K] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res, Educ & Clin Ctr, San Antonio, TX USA.; Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.; Yeh, CK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. NR 16 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1354-523X EI 1601-0825 J9 ORAL DIS JI Oral Dis. PD OCT PY 2016 VL 22 IS 7 BP 587 EP 590 DI 10.1111/odi.12483 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DW4MS UT WOS:000383617900002 PM 27015433 ER PT J AU Butt, AA Yan, P Marks, K Shaikh, OS Sherman, KE AF Butt, A. A. Yan, P. Marks, K. Shaikh, O. S. Sherman, K. E. CA ERCHIVES Study Team TI Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HEPATITIS-C VIRUS; TREATMENT-NAIVE; SOFOSBUVIR; THERAPY; LEDIPASVIR; CIRRHOSIS; ABT-450/R-OMBITASVIR; COMBINATION; DASABUVIR; TRIAL AB BackgroundRibavirin is a key component of several hepatitis C virus (HCV) treatment regimens. However, its utility in combination with newer directly acting anti-viral agents regimens is unclear. AimTo determine the SVR rates with paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) regimen ribavirin and compare this with sofosbuvir/simeprevir and sofosbuvir/ledipasvir regimens. MethodsWe used Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a well-established national cohort of HCV-infected Veterans to identify HCV genotype 1 infected persons initiated on the above regimens. We excluded those with HIV coinfection, positive HBsAg and missing HCV RNA. ResultsWe identified 1235 persons on PrOD (75.5% ribavirin), 1254 on sofosbuvir/simeprevir (16.9% ribavirin) and 4247 on sofosbuvir/ledipasvir (23.3% ribavirin). Among HCV genotype 1a infected persons, ribavirin was prescribed to 99.2% on PrOD, 18.2% on sofosbuvir/simeprevir and 23.3% on sofosbuvir/ledipasvir. The SVR rates ranged from 92.6% to 100% regardless of the treatment regimen, presence of cirrhosis or HCV subtype, except in PrOD group without ribavirin, HCV genotype 1a without cirrhosis (SVR 80%, N = 5). There were minor, clinically insignificant differences in SVR rates in those treated with or without ribavirin in each of the treatment groups, regardless of presence of cirrhosis at baseline. In multivariable logistic regression analysis, ribavirin use was not associated with achieving SVR in any group. ConclusionsIn HCV genotype 1 infected persons, PrOD, sofosbuvir/simeprevir and sofosbuvir/ledipasvir regimens, are associated with high rates of SVR in actual clinical settings, which are comparable to clinical trials results (except PrOD genotype 1a with cirrhosis where the number was too small). The benefit of adding ribavirin to these regimens in the ERCHIVES treated cohort is not established. C1 [Butt, A. A.; Yan, P.; Shaikh, O. S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, A. A.] Hamad Med Corp, Hamad Healthcare Qual Inst, Doha, Qatar. [Butt, A. A.; Marks, K.] Weill Cornell Med Coll, New York, NY USA. [Shaikh, O. S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Sherman, K. E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. RP Butt, AA (reprint author), POB 3050, Doha, Qatar. EM aabutt@hamad.qa FU AbbVie FX This study was funded by AbbVie through an investigator initiated grant to the institution (Veterans Research Foundation of Pittsburgh, Pittsburgh, PA, USA). NR 26 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD OCT PY 2016 VL 44 IS 7 BP 728 EP 737 DI 10.1111/apt.13748 PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA DW4QR UT WOS:000383628600008 PM 27459341 ER PT J AU Kwan, SW Talenfeld, AD Brunner, MC AF Kwan, Sharon W. Talenfeld, Adam D. Brunner, Michael C. TI The Top Three Health Care Developments Impacting the Practice of Interventional Radiology in the Next Decade SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE health care trends; health economics; interventional radiology; payment models; population demographics; precision medicine ID IMPROVING DIVERSITY; REPRESENTATION; INCLUSION; CANCER AB OBJECTIVE. We discuss three health care trends that will have a profound impact on interventional radiology (IR) in the next decade. CONCLUSION. Precision medicine, representing the next frontier of medicine, will bring opportunities and challenges to the field. Significant changes in payment models may prove beneficial to the subspecialty if proactive steps are taken by its members. Finally, shifts in population demographics are predicted to increase demand for services while intensifying the need to cultivate a complementary workforce. C1 [Kwan, Sharon W.] Univ Washington, Med Ctr, Intervent Radiol Sect, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. [Talenfeld, Adam D.] Weill Cornell Med Coll, Div Intervent Radiol, Dept Radiol, New York, NY USA. [Talenfeld, Adam D.] New York Presbyterian Hosp, New York, NY USA. [Brunner, Michael C.] William S Middleton Mem Vet Adm Med Ctr, Dept Radiol, Madison, WI USA. [Brunner, Michael C.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Kwan, SW (reprint author), Univ Washington, Med Ctr, Intervent Radiol Sect, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM shakwan@uw.edu FU National Institutes of Health, National Center for Advancing Translational Sciences [KL2 TR000421]; Association of University Radiologists (GE Radiology Research Academic Fellowship); Clinical and Translational Science Center at Weill Cornell Medical College [UL1 TR000457] FX S. W. Kwan receives funding from the National Institutes of Health, National Center for Advancing Translational Sciences (grant KL2 TR000421). A. D. Talenfeld receives funding from the Association of University Radiologists (GE Radiology Research Academic Fellowship) and from the Clinical and Translational Science Center at Weill Cornell Medical College (grant UL1 TR000457). NR 31 TC 0 Z9 0 U1 3 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD OCT PY 2016 VL 207 IS 4 BP 731 EP 736 DI 10.2214/AJR.16.16435 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX7LF UT WOS:000384568100018 ER PT J AU Ana, EJS LaRowe, SD Armeson, K Lamb, KE Hartwell, K AF Ana, Elizabeth J. Santa LaRowe, Steven D. Armeson, Kent Lamb, Kayla E. Hartwell, Karen TI Impact of group motivational interviewing on enhancing treatment engagement for homeless Veterans with nicotine dependence and other substance use disorders: A pilot investigation SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; HEALTH; POPULATIONS; PROGRAMS; EFFICACY AB BackgroundPrior studies have shown that Group Motivational Interviewing (GMI) for dually diagnosed patients holds promise for increasing treatment engagement. ObjectivesThe current study evaluated the impact of a novel GMI protocol that included tobacco-specific components (referred to as Tobacco GMI or T-GMI) targeting enhanced engagement in smoking cessation treatment. MethodsThirty-seven primary alcohol and nicotine-dependent cigarette smoking homeless Veterans with co-morbid psychiatric conditions were recruited to receive four GMI sessions over 4 consecutive days. The first 16 participants received standard GMI, aimed at enhancing engagement in substance abuse treatment and for reducing substance use, while the remaining 21 participants received a modified tobacco-specific GMI protocol (T-GMI) that included additional content specific to cessation of tobacco use and enhancing smoking cessation treatment, in addition to the standard substance abuse content of GMI. ResultsParticipants in T-GMI were more likely to attend tobacco cessation programming (p=.05), as well as to attend combined tobacco cessation programming with prescribed nicotine replacement therapy (p=.03), compared to those in standard GMI. Differences between treatment conditions with respect to alcohol and illicit drug use outcomes were not significant, although overall substance use declined over time in both groups. Conclusions and Scientific SignificanceResults suggest that inclusion of tobacco-specific components in the context of GMI for substance abuse may enhance treatment engagement for tobacco cessation behaviors among dually diagnosed nicotine dependent homeless patients, a highly vulnerable population for which interventional resources targeting engagement in smoking cessation treatment has historically been lacking. (Am J Addict 2016;25:533-541) C1 [Ana, Elizabeth J. Santa; LaRowe, Steven D.; Lamb, Kayla E.; Hartwell, Karen] Ralph H Johnson VAMC, Charleston, SC USA. [Ana, Elizabeth J. Santa; LaRowe, Steven D.; Hartwell, Karen] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Armeson, Kent] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA. RP Ana, EJS (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, MSC 861,109 Bee St, Charleston, SC 29401 USA. EM santaana@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU American Cancer Society; MUSC Hollings Cancer Center Institutional Research Grant [IRG-97-219-14]; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; Clinical Science Research and Development Career Development Award from the United States (U.S.) Department of Veterans Affairs (Clinical Sciences Research and Development) [CDA-2, CDA-2-016-08S] FX This work was supported in part by the American Cancer Society, MUSC Hollings Cancer Center Institutional Research Grant #IRG-97-219-14, the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313), and by a Clinical Science Research and Development Career Development Award (CDA-2) to Dr. Santa Ana (CDA-2-016-08S) from the United States (U.S.) Department of Veterans Affairs (Clinical Sciences Research and Development). NR 39 TC 0 Z9 0 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD OCT PY 2016 VL 25 IS 7 BP 533 EP 541 DI 10.1111/ajad.12426 PG 9 WC Substance Abuse SC Substance Abuse GA DY0SU UT WOS:000384807300003 ER PT J AU Zhang, J Xie, FL Yun, HF Chen, L Muntner, P Levitan, EB Safford, MM Kent, ST Osterman, MT Lewis, JD Saag, K Singh, JA Curtis, JR AF Zhang, Jie Xie, Fenglong Yun, Huifeng Chen, Lang Muntner, Paul Levitan, Emily B. Safford, Monika M. Kent, Shia T. Osterman, Mark T. Lewis, James D. Saag, Kenneth Singh, Jasvinder A. Curtis, Jeffrey R. TI Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article DE Rheumatoid Arthritis; DMARDs (biologic); Cardiovascular Disease ID ACUTE MYOCARDIAL-INFARCTION; MORTALITY; DISEASE; THERAPY; EVENTS; CLAIMS AB Objectives To compare the coronary heart disease risk among patients with rheumatoid arthritis (RA) initiating common biologic disease-modifying antirheumatic drugs of different mechanisms. Methods We conducted a retrospective cohort study of patients with RA enrolled in Medicare, a public health plan covering >90% of US residents 65years or older, from 2006 to 2012 who (1) initiated a biologic, (2) had complete medical and pharmacy coverage for at least 12months before biologic initiation and (3) were free of coronary heart disease at the time of initiation. We compared the incidence rates (IRs) of (1) acute myocardial infarction (AMI) and (2) a composite outcome of AMI or coronary revascularisation and used multivariable adjusted Cox regression models to examine the associations between the type of biologic and the two outcomes. Results We identified 47193 eligible patients with RA with mean age 64 (SD 13) years; 85% were women. Crude IRs for AMI ranged from 5.7 to 8.8 cases per 1000 person-years (PYs). AMI risk was significantly elevated among antitumour necrosis factor (anti-TNF) initiators overall (adjusted HR (aHR) 1.3; 95% CI 1.0 to 1.6) and individually among etanercept (aHR 1.3; 95% CI 1.0 to 1.8) and infliximab (aHR 1.3; 95% CI 1.0 to 1.6) compared with abatacept initiators. Crude IRs for the composite outcome ranged from 7.6 to 14.5 per 1000 PYs. Tocilizumab initiators were at reduced risk of the composite outcome compared with abatacept initiators (aHR 0.64, 95% CI 0.41 to 0.99). Discussion Findings from this observational study of patients with RA suggested that anti-TNF biologics may be associated with higher AMI risk compared with abatacept. C1 [Zhang, Jie; Yun, Huifeng; Muntner, Paul; Levitan, Emily B.; Kent, Shia T.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Xie, Fenglong; Yun, Huifeng; Chen, Lang; Saag, Kenneth; Singh, Jasvinder A.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Sch Med, Birmingham, AL 35294 USA. [Safford, Monika M.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. [Osterman, Mark T.; Lewis, James D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, NY USA. RP Zhang, J (reprint author), Univ Alabama Birmingham, Dept Immunol & Rheumatol, FOT 802,510 20th St South, Birmingham, AL 35294 USA. EM jcurtis@uab.edu FU UCB; Takeda; Savient; Regeneron; Allergan; Amgen, Inc.; Abbvie; Amgen; BMS; Janssen; Pfizer; Roche; Bayer; Nestle Health Science; AstraZeneca; Lilly; Merck FX MTO is an advisory board member for Takeda, Lycera, Janssen, AbbVie and UCB, and has received research grant support from UCB. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron and Allergan. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. MMS has received funding for investigator-initiated research from Amgen, Inc. and consults for diaDexus and Medscape. EBL receives research funding from Amgen, Inc and has served as a consultant for Amgen and Robinson Calcagnie Robinson Shapiro Davis. JRC has received research grant funding and consulting monies from Abbvie, Amgen, BMS, Janssen, Pfizer, Roche and UCB. JDL has received research funding from Takeda, AbbVie, Bayer and Nestle Health Science. JDL has served as a consultant to Amgen, Takeda, Lilly, Shire, Nestle Health Science, Merck, Janssen, Immune Pharmaceuticals, AstraZeneca, Pfizer and AbbVie. STK has received research support from Amgen. KS has received research funding from Amgen, AstraZeneca, Lilly and Merck and has served as a consultant to Amgen, AstraZeneca, Bayer, Merck, Pfizer and Roche/Genentech. NR 23 TC 8 Z9 9 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD OCT PY 2016 VL 75 IS 10 BP 1813 EP 1818 DI 10.1136/annrheumdis-2015-207870 PG 6 WC Rheumatology SC Rheumatology GA DX5RH UT WOS:000384438900022 PM 26792814 ER PT J AU England, BR Sokolove, J Robinson, WH Thiele, GM Ganti, AK Sayles, H Michaud, K Caplan, L Davis, LA Cannon, GW Sauer, B Singh, N Solow, EB Reimold, AM Kerr, GS Schwab, P Baker, JF Mikuls, TR AF England, Bryant R. Sokolove, Jeremy Robinson, William H. Thiele, Geoffrey M. Ganti, Apar K. Sayles, Harlan Michaud, Kaleb Caplan, Liron Davis, Lisa A. Cannon, Grant W. Sauer, Brian Singh, Namrata Solow, E. Blair Reimold, Andreas M. Kerr, Gail S. Schwab, Pascale Baker, Josh F. Mikuls, Ted R. TI Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID CELL LUNG-CANCER; DISEASE-ACTIVITY; COMPETING RISK; ADULT PATIENTS; INFLAMMATION; SURVIVAL; ANTIBODY; METAANALYSIS; VALIDATION; MALIGNANCY AB ObjectiveTo examine the potential of circulating cytokines and chemokines as biomarkers of cancer mortality risk in patients with rheumatoid arthritis (RA). MethodsMale participants in the Veterans Affairs RA registry were followed up from the time of enrollment until death or December 2013. Cytokines and chemokines were measured in banked serum obtained at the time of enrollment, using a bead-based multiplex assay, and a previously developed cytokine score was calculated. Vital status and cause of death were determined through the National Death Index. Associations of cytokines with cancer mortality were examined using multivariable competing-risks regression. ResultsAmong 1,190 men with RA, 60 cancer deaths (30 of which were attributable to lung cancer) occurred over 5,307 patient-years of follow-up. The patients had a mean age of 64.5 years, had established disease (median duration 8.7 years), were seropositive for rheumatoid factor (81%) or anti-cyclic citrullinated peptide antibody (77%), and frequently had a history of smoking (82% current or former). Seven of 17 analytes examined were individually associated with cancer mortality. The cytokine score was associated with overall cancer (subhazard ratio [SHR] 1.42, 95% confidence interval [95% CI] 1.08-1.85) and lung cancer (SHR 1.86, 95% CI 1.57-2.19) mortality in multivariable analyses. Those in the highest quartile of cytokine scores had a >2-fold increased risk of overall cancer mortality (P=0.039) and a 6-fold increased risk of lung cancer mortality (P=0.028) relative to the lowest quartile. A synergistic interaction between current smoking and high cytokine score was observed. ConclusionSerum cytokines and chemokines are associated with cancer and lung cancer mortality in men with RA, independent of multiple factors including age, smoking status, and prevalent cancer. C1 [England, Bryant R.; Thiele, Geoffrey M.; Ganti, Apar K.; Sayles, Harlan; Michaud, Kaleb; Mikuls, Ted R.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [England, Bryant R.; Thiele, Geoffrey M.; Ganti, Apar K.; Sayles, Harlan; Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Sokolove, Jeremy; Robinson, William H.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Sokolove, Jeremy; Robinson, William H.] Stanford Univ, Palo Alto, CA 94304 USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Davis, Lisa A.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. [Davis, Lisa A.] Denver Hlth Med Ctr, Denver, CO USA. [Cannon, Grant W.; Sauer, Brian] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Cannon, Grant W.; Sauer, Brian] Univ Utah, Sch Med, Salt Lake City, UT USA. [Singh, Namrata] Iowa City VA Hlth Care Syst, Iowa City, IA USA. [Singh, Namrata] Univ Iowa, Iowa City, IA USA. [Solow, E. Blair; Reimold, Andreas M.] Dallas VA Med Ctr, Dallas, TX USA. [Solow, E. Blair; Reimold, Andreas M.] Univ Texas Southwestern Med Ctr, Dallas, TX USA. [Kerr, Gail S.] Washington DC VA Med Ctr, Washington, DC USA. [Kerr, Gail S.] Georgetown Howard Univ Ctr Clin & Translat Sci, Washington, DC USA. [Schwab, Pascale] Portland VA Hlth Care Syst, Portland, OR USA. [Schwab, Pascale] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Baker, Josh F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Josh F.] Univ Penn, Philadelphia, PA 19104 USA. RP Mikuls, TR (reprint author), 983025 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu OI England, Bryant R./0000-0002-9649-3588 FU Rheumatology Research Foundation; VA Clinical Science Research and Development Career Development award [IK2-CX000955]; VA Clinical Science Research and Development Merit award FX Dr. England's work was supported by a Rheumatology Research Foundation Resident Research Preceptorship award. Dr. Baker's work was supported by VA Clinical Science Research and Development Career Development award IK2-CX000955. Dr. Mikuls' work was supported by a VA Clinical Science Research and Development Merit award. NR 34 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2016 VL 68 IS 10 BP 2394 EP 2402 DI 10.1002/art.39735 PG 9 WC Rheumatology SC Rheumatology GA DY0XL UT WOS:000384819400007 PM 27111000 ER PT J AU Shieh, Y Hu, DL Ma, L Huntsman, S Gard, CC Leung, JWT Tice, JA Vachon, CM Cummings, SR Kerlikowske, K Ziv, E AF Shieh, Yiwey Hu, Donglei Ma, Lin Huntsman, Scott Gard, Charlotte C. Leung, Jessica W. T. Tice, Jeffrey A. Vachon, Celine M. Cummings, Steven R. Kerlikowske, Karla Ziv, Elad TI Breast cancer risk prediction using a clinical risk model and polygenic risk score SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Single nucleotide polymorphisms; Risk assessment; Cancer surveillance and screening ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; MAMMOGRAPHIC DENSITY; WOMEN; GUIDELINES; VARIANTS; INTERVAL AB Breast cancer risk assessment can inform the use of screening and prevention modalities. We investigated the performance of the Breast Cancer Surveillance Consortium (BCSC) risk model in combination with a polygenic risk score (PRS) comprised of 83 single nucleotide polymorphisms identified from genome-wide association studies. We conducted a nested case-control study of 486 cases and 495 matched controls within a screening cohort. The PRS was calculated using a Bayesian approach. The contributions of the PRS and variables in the BCSC model to breast cancer risk were tested using conditional logistic regression. Discriminatory accuracy of the models was compared using the area under the receiver operating characteristic curve (AUROC). Increasing quartiles of the PRS were positively associated with breast cancer risk, with OR 2.54 (95 % CI 1.69-3.82) for breast cancer in the highest versus lowest quartile. In a multivariable model, the PRS, family history, and breast density remained strong risk factors. The AUROC of the PRS was 0.60 (95 % CI 0.57-0.64), and an Asian-specific PRS had AUROC 0.64 (95 % CI 0.53-0.74). A combined model including the BCSC risk factors and PRS had better discrimination than the BCSC model (AUROC 0.65 versus 0.62, p = 0.01). The BCSC-PRS model classified 18 % of cases as high-risk (5-year risk aeyen3 %), compared with 7 % using the BCSC model. The PRS improved discrimination of the BCSC risk model and classified more cases as high-risk. Further consideration of the PRS's role in decision-making around screening and prevention strategies is merited. C1 [Shieh, Yiwey; Hu, Donglei; Huntsman, Scott; Tice, Jeffrey A.; Ziv, Elad] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Box 0320,1545 Divisadero St, San Francisco, CA 94143 USA. [Ma, Lin] Univ Calif San Francisco, Box 1793,550 16th St, San Francisco, CA 94158 USA. [Gard, Charlotte C.] New Mexico State Univ, Dept Econ Appl Stat & Int Business, MSC 3CQ,POB 30001, Las Cruces, NM 88003 USA. [Leung, Jessica W. T.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, 1515 Holcombe Blvd,Unit 1350, Houston, TX 77030 USA. [Vachon, Celine M.] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, 200 First St SW,Charlton Bldg 6-239, Rochester, MN 55905 USA. [Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, Box 0560,550 16th St,2nd Floor, San Francisco, CA 94159 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,Mailing Code 111A1, San Francisco, CA 94121 USA. RP Shieh, Y (reprint author), Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Box 0320,1545 Divisadero St, San Francisco, CA 94143 USA. EM yiwey.shieh@ucsf.edu FU National Cancer Institute [P01 CA154292, K24 CA169004, HHSN261201100031C]; DaCosta Fund for the Prevention of Breast Cancer; California Pacific Medical Center; Eli Lilly Foundation; National Research Service Award through the National Institutes of Health [T32 HP19025] FX K. Kerlikowske received support for the Breast Cancer Surveillance Consortium from the National Cancer Institute, grant P01 CA154292. E. Ziv received support from the National Cancer Institute under grant K24 CA169004. S.R. Cummings received support for the collection of blood specimens from the DaCosta Fund for the Prevention of Breast Cancer, the Clinical Research in Clinical Care (CRCLE) funds provided by the California Pacific Medical Center, and by a grant from the Eli Lilly Foundation. Y. Shieh was supported by a National Research Service Award through the National Institutes of Health T32 HP19025. Data collection for this work was supported by the National Cancer Institute-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 47 TC 2 Z9 2 U1 8 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD OCT PY 2016 VL 159 IS 3 BP 513 EP 525 DI 10.1007/s10549-016-3953-2 PG 13 WC Oncology SC Oncology GA DW4KY UT WOS:000383613100011 PM 27565998 ER PT J AU Morris, BJ Klausner, JD Krieger, JN Willcox, BJ Crouse, PD Pollock, N AF Morris, Brian J. Klausner, Jeffrey D. Krieger, John N. Willcox, Bradley J. Crouse, Pierre D. Pollock, Neil TI Canadian Pediatrics Society position statement on newborn circumcision: a risk-benefit analysis revisited SO CANADIAN JOURNAL OF UROLOGY LA English DT Article DE male circumcision; policy; risk-benefit; Canadian Pediatrics Society ID SIMPLEX-VIRUS TYPE-2; URINARY-TRACT-INFECTIONS; HUMAN-PAPILLOMAVIRUS INFECTION; MEDICAL MALE CIRCUMCISION; GENITAL ULCER DISEASE; HIV-NEGATIVE MEN; RANDOMIZED-TRIAL; FEMALE PARTNERS; MYCOPLASMA-GENITALIUM; PENILE CANCER AB Introduction: The Canadian Pediatrics Society (CPS) recently released a position statement on early infant (newborn) male circumcision (EIMC). It concluded that since benefits do not exceed risks, circumcision should only be performed on boys in high-risk populations or circumstances. This contradicts recommendations by the American Academy of Pediatrics and the Centers for Disease Control and Prevention (CDC) whose policies each support more widespread implementation of EIMC. Here we review the CPS statement, particularly its risk benefit analysis, to determine the basis for this disparity. Materials and methods: We performed a risk-benefit analysis based on relevant literature retrieved from PubMed reporting frequency of each condition, giving emphasis to data from meta-analyses and randomized controlled trials. Results: Although the CPS recognized some of the benefits of EIMC, its inclusion of weak studies of adverse events led to these being over-estimated, greatly exceeding the figure of <0.5% found in a recent large, technically robust, CDC study. The CPS under-estimated benefits by omitting balanitis, balanoposthitis, prostate cancer, some sexually transmitted infections and candidiasis, and failing to consider lifetime prevalence of urinary tract infections in uncircumcised males. In contrast, our more inclusive risk-benefit analysis found benefits exceed risks by approximately 100 to 1 and that lack of EIMC contributes to adverse medical conditions, some potentially fatal, in approximately half of uncircumcised males. Conclusions: The 2015 CPS position statement on EIMC is at odds with the evidence. The CPS conclusions stem from errors in its risk-benefit analysis. In light of our findings we recommend the CPS issue a revised statement. C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Sydney, NSW, Australia. [Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia. [Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA. [Krieger, John N.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. [Willcox, Bradley J.] Univ Hawaii, Dept Res, Kuakini Med Ctr, Honolulu, HI 96822 USA. [Crouse, Pierre D.] Intramed Med Ctr, Calgary, AB, Canada. [Pollock, Neil] Pollock Clin, New Westminster, BC, Canada. [Pollock, Neil] Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada. RP Morris, BJ (reprint author), Univ Sydney, Bldg F13, Sydney, NSW 2006, Australia. NR 92 TC 4 Z9 4 U1 2 U2 4 PU CANADIAN J UROLOGY PI ST LAURENT PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA SN 1195-9479 J9 CAN J UROL JI Can. J. Urol. PD OCT PY 2016 VL 23 IS 5 BP 8495 EP 8502 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DX9IB UT WOS:000384705700014 PM 27705739 ER PT J AU Wong, SPY Hebert, PL Laundry, RJ Hammond, KW Liu, CF Burrows, NR O'Hare, AM AF Wong, Susan P. Y. Hebert, Paul L. Laundry, Ryan J. Hammond, Kenric W. Liu, Chuan-Fen Burrows, Nilka R. O'Hare, Ann M. TI Decisions about Renal Replacement Therapy in Patients with Advanced Kidney Disease in the US Department of Veterans Affairs, 2000-2011 SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID UNITED-STATES; MAINTENANCE DIALYSIS; OLDER-ADULTS; END; INITIATION; SURVIVAL; FAILURE; COHORT; CARE; PREVALENCE AB Background and objectives It is not known what proportion of United States patients with advanced CKD go on to receive RRT. In other developed countries, receipt of RRT is highly age dependent and the exception rather than the rule at older ages. Design, setting, participants, & measurements We conducted a retrospective study of a national cohort of 28,568 adults who were receiving care within the US Department of Veteran Affairs and had a sustained eGFR, <15 ml/min per 1.73 m(2) between January 1, 2000 to December 31, 2009. We used linked administrative data from the US Renal Data System, US Department of Veteran Affairs, and Medicare to identify cohort members who received RRT during follow-up through October 1, 2011 (n=19,165). For a random 25% sample of the remaining 9403 patients, we performed an in-depth review of their VA-wide electronic medical records to determine the treatment status of their CKD. Results Two thirds (67.1%) of cohort members received RRT on the basis of administrative data. On the basis of the results of chart review, we estimate that an additional 7.5% (95% confidence interval, 7.2% to 7.8%) of cohort members had, in fact, received dialysis, that 10.9% (95% confidence interval, 10.6% to 11.3%) were preparing for and/or discussing dialysis but had not started dialysis at most recent follow-up, and that a decision had been made not to pursue dialysis in 14.5% (95% confidence interval, 14.1% to 14.9%). The percentage of cohort members who received or were preparing to receive RRT ranged from 96.2% (95% confidence interval, 94.4% to 97.4%) for those <45 years old to 53.3% (95% confidence interval, 50.7% to 55.9%) for those aged >= 85 years old. Results were similar after stratification by tertile of Gagne comorbidity score. Conclusions In this large United States cohort of patients with advanced CKD, the majority received or were preparing to receive RRT. This was true even among the oldest patients with the highest burden of comorbidity. C1 [Wong, Susan P. Y.; O'Hare, Ann M.] Univ Washington, Dept Med, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA. [Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Hammond, Kenric W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Hammond, Kenric W.] Univ Washington, Dept Biomed Informat & Biomed Educ, Seattle, WA 98195 USA. [Hebert, Paul L.; Laundry, Ryan J.; Liu, Chuan-Fen; O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [Burrows, Nilka R.] Ctr Dis Control & Prevent, Chron Kidney Dis Initiat, Div Diabet Translat, Atlanta, GA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU Veterans Affairs (VA) Health Services Research and Development grants [IIR 09-094, IIR 12-126]; VA Puget Sound [IAA 15FED1505101-0001]; Centers for Disease Control and Prevention [IAA 15FED1505101-0001]; Clinical Scientist in Nephrology Fellowship from American Kidney Fund; VA Health Services Research and Development Service; National Institutes of Health; Centers for Disease Control and Prevention FX This work was supported by Veterans Affairs (VA) Health Services Research and Development grants IIR 09-094 (principal investigator P.L.H.) and IIR 12-126 (principal investigator A.M.O.) and Interagency Agreement between the VA Puget Sound and the Centers for Disease Control and Prevention IAA 15FED1505101-0001 (principal investigator A.M.O.). S.P.Y.W. is supported by the Clinical Scientist in Nephrology Fellowship from the American Kidney Fund. C.-F.L. receives research funding from the VA Health Services Research and Development Service. A.M.O. receives research funding from the National Institutes of Health, the Centers for Disease Control and Prevention, and the VA Health Services Research and Development Service. A.M.O. also receives an honorarium from the American Society of Nephrology and royalties from UpToDate. NR 28 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD OCT PY 2016 VL 11 IS 10 BP 1825 EP 1833 DI 10.2215/CJN.03760416 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DY1BS UT WOS:000384830500016 PM 27660306 ER PT J AU Liu, KD Palevsky, PM AF Liu, Kathleen D. Palevsky, Paul M. TI RRT in AKI: Start Early or Wait? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID RENAL-REPLACEMENT THERAPY; ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; CONTINUOUS VENOVENOUS HEMOFILTRATION; ACCELERATED INITIATION; FAILURE; DIALYSIS; STANDARD C1 [Liu, Kathleen D.] Univ Calif San Francisco, Sch Med, Div Nephrol, San Francisco, CA USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM Palevsky@pitt.edu NR 25 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD OCT PY 2016 VL 11 IS 10 BP 1867 EP 1871 DI 10.2215/CJN.06690616 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA DY1BS UT WOS:000384830500020 PM 27672218 ER PT J AU Woodward, Z Williams, JL Sonnenberg, A AF Woodward, Zibing Williams, J. Lucas Sonnenberg, Amnon TI Length of endoscopic workup in gastrointestinal bleeding SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE colonoscopy; epidemiology; esophago-gastro-duodenoscopy; gastrointestinal bleeding; hemostasis; outcome research ID MANAGEMENT AB BackgroundThe number of procedures utilized in the general management of gastrointestinal bleeding (GIB) has not been investigated previously. We used the National Endoscopic Database of the Clinical Outcomes Research Initiative for an observational study to analyze the average length of workup in GIB.MethodsThe electronic database was queried for all patients aged 18 years and older who underwent an endoscopic evaluation for any bleeding indication between 2000 and 2014. Data were stratified by indication, type, and number of endoscopies per patient, and length of workup.ResultsA total of 603807 endoscopic procedures among 451470 individual patients were used in the workup of GIB, with 152337 procedures among 113030 patients (25%) being performed as a secondary procedure. The average length was 2.40.9 procedures per workup in procedural sequences involving multiple endoscopies. The length of workup was independent of the initial type of GIB. An esophago-gastro-duodenoscopy (EGD), followed by a colonoscopy or a colonoscopy, followed by an EGD were the most frequent combinations. In another substantial fraction of two consecutive procedures, the first and the second procedure were identical. This pattern applied not only to EGD and colonoscopy but also to flexible sigmoidoscopy, enteroscopy, and video capsule endoscopy.ConclusionThe majority of patients with GIB require only one type of endoscopy to manage their bleeding. However, in a quarter of patients, on average, 2.4 procedures are needed. Previous trials assessing the outcomes of individual types of endoscopy may have exaggerated their overall success rates in diagnosing and treating GIB. C1 Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, Div Gastroenterol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01] FX This project was supported by funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132, and R33-DK61778-01. In addition, the Practice Network (CORI) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. NR 12 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD OCT PY 2016 VL 28 IS 10 BP 1166 EP 1171 DI 10.1097/MEG.0000000000000693 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX5WR UT WOS:000384453900009 PM 27585290 ER PT J AU Helgeson, VS Mascatelli, K Seltman, H Korytkowski, M Hausmann, LRM AF Helgeson, Vicki S. Mascatelli, Katilyn Seltman, Howard Korytkowski, Mary Hausmann, Leslie R. M. TI Implications of Supportive and Unsupportive Behavior for Couples With Newly Diagnosed Diabetes SO HEALTH PSYCHOLOGY LA English DT Article DE Type 2 diabetes; support; unmitigated communion; daily diary ID ILLNESS SELF-MANAGEMENT; UNMITIGATED COMMUNION; SOCIAL SUPPORT; INVISIBLE SUPPORT; MARITAL QUALITY; OLDER-ADULTS; SPOUSES USE; STRESS; DISTINCTIONS; ADHERENCE AB Objective: To examine the relation between daily diary reports of diabetes-specific social interactions to patient and partner mood and patient self-care behaviors, and whether relations are moderated by unmitigated communion. Method: Participants were 70 couples in which 1 person had been diagnosed with Type 2 diabetes in the past 3 years. They were interviewed in-person at baseline and completed daily diary reports on an iPad. Daily diary questionnaires measured support, mood, and self-care behavior (patients only). Unmitigated communion, a personality trait characterized by an overinvolvement in others to the exclusion of the self, was measured at baseline. Results: Multilevel statistical modeling revealed that daily fluctuations in partner emotional support were related to daily fluctuations in happy mood, more exercise, and dietary compliance. Partner controlling behavior was related to poor mood but was unrelated to self-care. Relations of support and controlling behavior to mood were strongest for individuals high (vs. low) in unmitigated communion. Conclusion: Patients newly diagnosed with Type 2 diabetes who felt understood and cared for by partners reported a better mood and were more likely to take care of themselves on a daily basis, whereas patients whose partners were controlling on a daily basis reported poorer mood. Patients characterized by unmitigated communion were most affected by partner supportive and unsupportive behavior. C1 [Helgeson, Vicki S.; Mascatelli, Katilyn; Seltman, Howard] Carnegie Mellon Univ, Dept Psychol, 5000 Forbes Ave, Pittsburgh, PA 15213 USA. [Korytkowski, Mary] Univ Pittsburgh, Med Ctr, Div Endocrinol, Pittsburgh, PA 15260 USA. [Hausmann, Leslie R. M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. RP Helgeson, VS (reprint author), Carnegie Mellon Univ, Dept Psychol, 5000 Forbes Ave, Pittsburgh, PA 15213 USA. EM vh2e@andrew.cmu.edu FU National Institutes of Health [R01 DK095780, UL1TR000005] FX This research was supported by the National Institutes of Health Grant R01 DK095780 and received recruiting assistance from the University of Pittsburgh Clinical and Translational Science Institute, which is supported by the National Institutes of Health Grant UL1TR000005. We are grateful to Tiona Jones and Gianna Davis for interviewing the patients for this study and to Pamela Snyder for recruiting the patients and overseeing the study protocol. NR 53 TC 0 Z9 0 U1 11 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD OCT PY 2016 VL 35 IS 10 BP 1047 EP 1058 DI 10.1037/hea0000388 PG 12 WC Psychology, Clinical; Psychology SC Psychology GA DX6XU UT WOS:000384530200001 PM 27280364 ER PT J AU Cotter, G Davison, BA Milo, O Bourge, RC Cleland, JGF Jondeau, G Krum, H O'Connor, CM Metra, M Parker, JD Torre-Amione, G van Veldhuisen, DJ Kobrin, I Rainisio, M Senger, S Edwards, C McMurray, JJV Teerlink, JR AF Cotter, Gad Davison, Beth A. Milo, Olga Bourge, Robert C. Cleland, John G. F. Jondeau, Guillaume Krum, Henry O'Connor, Christopher M. Metra, Marco Parker, John D. Torre-Amione, Guillermo van Veldhuisen, Dirk J. Kobrin, Isaac Rainisio, Maurizio Senger, Stefanie Edwards, Christopher McMurray, John J. V. Teerlink, John R. CA VERITAS Investigators TI Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; length of stay; prognosis ID SHORT-TERM OUTCOMES; OF-STAY; READMISSION; TEZOSENTAN; MORTALITY; SURVIVAL; TRENDS; TRIAL; HF AB Background: The length of hospital stay (LOS) is important in patients admitted for acute heart failure (AHF) because it prolongs an unpleasant experience for the patients and adds substantially to health care costs. Methods and Results: We examined the association between LOS and baseline characteristics, 10-day post-discharge HF readmission, and 90-day post-discharge mortality in 1347 patients with AHF enrolled in the VERITAS program. Longer LOS was associated with greater HF severity and disease burden at baseline; however, most of the variability of LOS could not be explained by these factors. LOS was associated with a higher HF risk of both HF readmission (odds ratio for 1-day increase: 1.08; 95% confidence interval [CI] 1.01-1.16; P = .019) and 90-day mortality (hazard ratio for 1-day increase: 1.05; 95% CI 1.02-1.07; P < .001), although these associations are partially explained by concurrent end-organ damage and worsening heart failure during the first days of admission. Conclusions: In patients who have been admitted for AHF, longer length of hospital stay is associated with a higher rate of short-term mortality. C1 [Cotter, Gad; Davison, Beth A.; Milo, Olga; Senger, Stefanie; Edwards, Christopher] Momentum Res, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. [Bourge, Robert C.] Univ Alabama Birmingham, Birmingham, AL USA. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Cleland, John G. F.] Imperial Coll, Royal Brompton & Harefield Hosp NHS Trust, Natl Heart & Lung Inst, London, England. [Jondeau, Guillaume] Hop Bichat Claude Bernard, Serv Cardiol, Paris, France. [Krum, Henry] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, Australia. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Metra, Marco] Univ Brescia, Piazza Spedali Civili, Brescia, Italy. [Parker, John D.] Mt Sinai Hosp, Div Cardiol, Toronto, ON, Canada. [Torre-Amione, Guillermo] Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. [van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Kobrin, Isaac] Kobrin Associates, Basel, Switzerland. [Rainisio, Maurizio] Abanovus, San Remo, Italy. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Cotter, G (reprint author), Momentum Res, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM gadcotter@momentum-research.com.Manuscript OI Cleland, John/0000-0002-1471-7016; Parker, John/0000-0003-1949-2669; Senger, Stefanie/0000-0003-4144-1040; mcmurray, john/0000-0002-6317-3975 FU Actelion; Amgen; Bayer; Cytokinetics; Novartis; Trevena; ResMed FX Dr Kobrin served as a head of clinical development in Actelion during the VERITAS trials. Dr Teerlink received research grants/consulting fees from: Actelion, Amgen, Bayer, Cytokinetics, Novartis, and Trevena. Dr Cotter, Dr Davison, Dr Milo, Dr Senger, and Mr Edwards are employees of Momentum Research, which has provided consulting services to NovaCardia, Merck, Corthera, Novartis, Singulex, ChanRx, Laguna Pharmaceuticals, Sorbent Therapeutics, Celyad, Trevena, Amgen, and Anexon. Dr Metra has received consulting honoraria from Bayer, Novartis, Servier. Dr Cleland has received research funding and personal honoraria from Actelion, Amgen, Novartis, and Trevena. Dr Jondeau received consulting fees from Novartis and ResMed. Dr Krum was a member of the VERITAS steering committee paid by Actelion. The other authors report no conflicts. NR 19 TC 1 Z9 1 U1 2 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2016 VL 22 IS 10 BP 815 EP 822 DI 10.1016/j.cardfail.2015.12.017 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DY0JG UT WOS:000384782500012 PM 26721775 ER PT J AU Finkelstein, M Goldstein, NE Horton, JR Eshak, D Lee, EJ Kohli-Seth, R AF Finkelstein, Mark Goldstein, Nathan E. Horton, Jay R. Eshak, David Lee, Eric J. Kohli-Seth, Roopa TI Developing triggers for the surgical intensive care unit for palliative care integration SO JOURNAL OF CRITICAL CARE LA English DT Article DE Palliative care; Quality improvement; Outcomes assessment; Critical care; Patient care ID PROLONGED STAY; ADVISORY BOARD; MORTALITY; LIFE; ICU; CONSULTATION; READMISSION; SURGEONS; LENGTH; IMPACT AB Purpose: Despite the growing acceptance of palliative care as a component of high-quality care for patients with serious illness, it remains underutilized in the surgical critical care setting. This article provides insight into a model for palliative care integration into the surgical intensive care unit (SICU), using triggers. Methods: We performed a prospective cohort study after the implementation of a new set of palliative care triggers in the SICU of an 1170-bed tertiary medical center over the course of 9 months. We aimed to determine the ability of these triggers to identify patients who would benefit from palliative care consultation. Results: There were 517 SICU admissions during the period of interest. Of this cohort, patients who had not yet been discharged at the time of analysis were excluded (n = 25), and the remaining underwent analysis (n = 492). Factors significantly associated with hospital death or hospice discharge were repeat SICU admission, metastatic/advanced cancer, SICU physician referral, and the matching of 2 or more secondary criteria. Conclusions: A series of triggers can help identify patients who may benefit from palliative care consultation. This approach can be used in intensive care settings to facilitate palliative care integration. (C) 2016 Elsevier Inc. All rights reserved. C1 [Finkelstein, Mark; Eshak, David] Icahn Sch Med Mt Sinai, One Gustave Levy Pl,Box 1264, New York, NY 10029 USA. [Goldstein, Nathan E.; Horton, Jay R.; Lee, Eric J.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Care Ctr, Bronx, NY USA. [Kohli-Seth, Roopa] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA. RP Kohli-Seth, R (reprint author), Icahn Sch Med Mt Sinai, One Gustave Levy Pl,Box 1264, New York, NY 10029 USA. EM roopa.kohli-seth@mountsinai.org FU American Federation for Aging Research; National Institute on Aging FX We thank the American Federation for Aging Research and the National Institute on Aging for the funding that made this research possible. NR 18 TC 1 Z9 1 U1 6 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 EI 1557-8615 J9 J CRIT CARE JI J. Crit. Care PD OCT PY 2016 VL 35 BP 7 EP 11 DI 10.1016/j.jcrc.2016.04.010 PG 5 WC Critical Care Medicine SC General & Internal Medicine GA DX9KM UT WOS:000384714000003 PM 27481729 ER PT J AU Callon, W Beach, MC Saha, S Chander, G Wilson, IB Laws, MB Sharp, V Cohn, J Moore, R Korthuis, PT AF Callon, Wynne Beach, Mary Catherine Saha, Somnath Chander, Geetanjali Wilson, Ira B. Laws, Michael Barton Sharp, Victoria Cohn, Jonathan Moore, Richard Korthuis, P. Todd TI Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-provider communication; HIV/AIDS; substance use ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADDICTION SEVERITY INDEX; ILLICIT DRUG-USE; ALCOHOL-USE; ANTIRETROVIRAL ADHERENCE; PROVIDER COMMUNICATION; PSYCHIATRIC-DISORDERS; MEDICATION ADHERENCE; TREATMENT OUTCOMES; UNITED-STATES AB Substance use is associated with higher rates of antiretroviral non-adherence and poor HIV outcomes. This study examined how HIV care providers assess substance use, and which questions elicit accurate patient disclosures. We conducted a conversation analysis of audio-recorded encounters between 56 providers and 162 patients living with HIV (PLWH) reporting active substance use in post-encounter interviews (cocaine or heroin use in the past 30 days, > 4 days intoxicated in past 30 days, or AUDIT score aeyen 8). We assessed the frequency of substance use discussion, characterized the types of questions used by providers, and determined the frequency of accurate patient disclosure by question type. In 55 reports of active substance use, providers already knew about the use (n = 16) or patients disclosed unpromptednn = 39). Among the remaining 155 instances of substance use in which providers had the opportunity to elicit disclosure, 78 reports (50 %) of substance use were not discussed. Of the remaining 77 reports in which the provider asked about substance use, 55 (71 %) patients disclosed and 22 (29 %) did not disclose. Questions were classified as: open-ended (n = 18, "How's the drinking going?"); normalizing (n = 14, "When was the last time you used?"); closed-ended (n = 36, "Have you used any cocaine?"); leading towards non-use (n = 9, "Have you been clean?"). Accurate disclosure followed 100 % of open-ended and normalizing questions, 58 % of closed-ended questions, and 22 % of leading questions. After adjusting for drug type, closed-ended questions were 41 % less likely (p < 0.001), and 'leading' questions 78 % less likely (p = 0.016) than broad and normalizing questions to elicit disclosures. Providers in this sample missed almost half of the opportunities to identify and discuss substance use with PLWH. Providers can increase the probability of patient disclosure by using open-ended or normalizing questions that ask about the "last time" that the patient used drugs or alcohol. C1 [Callon, Wynne; Beach, Mary Catherine; Chander, Geetanjali; Moore, Richard] Johns Hopkins Univ, Sch Med, 2024 East Monument St, Baltimore, MD 21205 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. [Wilson, Ira B.; Laws, Michael Barton] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Sharp, Victoria] St Lukes Roosevelt, New York, NY USA. [Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. RP Callon, W (reprint author), Johns Hopkins Univ, Sch Med, 2024 East Monument St, Baltimore, MD 21205 USA. EM wcallon1@jhmi.edu FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012]; National Institute of Drug Abuse [K23 DA019809, K24 DA037804]; Department of Veterans Affairs FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019809). Dr. Saha was supported by the Department of Veterans Affairs, and Dr. Beach was supported by the National Institute of Drug Abuse (K24 DA037804). None of the funders had a role in the design and conduct of this analysis, nor was it subject to their final approval. None of the authors have any relevant financial conflicts of interest. NR 48 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2016 VL 31 IS 10 BP 1141 EP 1147 DI 10.1007/s11606-016-3733-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DW4FF UT WOS:000383597200008 PM 27197974 ER PT J AU Schapira, MM Sprague, BL Klabunde, CN Tosteson, ANA Bitton, A Chen, JS Beaber, EF Onega, T MacLean, CD Harris, K Howe, K Pearson, L Feldman, S Brawarsky, P Haas, JS AF Schapira, Marilyn M. Sprague, Brian L. Klabunde, Carrie N. Tosteson, Anna N. A. Bitton, Asaf Chen, Jane S. Beaber, Elisabeth F. Onega, Tracy MacLean, Charles D. Harris, Kimberly Howe, Kathleen Pearson, Loretta Feldman, Sarah Brawarsky, Phyllis Haas, Jennifer S. CA PROSPR Consortium TI Inadequate Systems to Support Breast and Cervical Cancer Screening in Primary Care Practice SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Annual Research Meeting of the Academy-Health CY JUN, 2015 CL Minneapolis, MN SP Acad Hlth DE breast cancer screening; cervical cancer screening; patient-centered medical home ID CENTERED MEDICAL HOME; QUALITY-OF-CARE; PREVENTIVE SERVICES; PHYSICIANS; PARTICIPATION; INTERVENTIONS; METAANALYSIS; IMPROVEMENT; STRATEGIES; CONTEXT AB Despite substantial resources devoted to cancer screening nationally, the availability of clinical practice-based systems to support screening guidelines is not known. To characterize the prevalence and correlates of practice-based systems to support breast and cervical cancer screening, with a focus on the patient-centered medical home (PCMH). Web and mail survey of primary care providers conducted in 2014. The survey assessed provider (gender, training) and facility (size, specialty training, physician report of National Committee for Quality Assurance (NCQA) PCMH recognition, and practice affiliation) characteristics. A hierarchical multivariate analysis clustered by clinical practice was conducted to evaluate characteristics associated with the adoption of practice-based systems and technology to support guideline-adherent screening. Primary care physicians in family medicine, general internal medicine, and obstetrics and gynecology, and nurse practitioners or physician assistants from four clinical care networks affiliated with PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium research centers. The prevalence of routine breast cancer risk assessment, electronic health record (EHR) decision support, comparative performance reports, and panel reports of patients due for routine screening and follow-up. There were 385 participants (57.6 % of eligible). Forty-seven percent (47.0 %) of providers reported NCQA recognition as a PCMH. Less than half reported EHR decision support for breast (48.8 %) or cervical cancer (46.2 %) screening. A minority received comparative performance reports for breast (26.2 %) or cervical (19.7 %) cancer screening, automated reports of patients overdue for breast (18.7 %) or cervical (16.4 %) cancer screening, or follow-up of abnormal breast (18.1 %) or cervical (17.6 %) cancer screening tests. In multivariate analysis, reported NCQA recognition as a PCMH was associated with greater use of comparative performance reports of guideline-adherent breast (OR 3.23, 95 % CI 1.58-6.61) or cervical (OR 2.56, 95 % CI 1.32-4.96) cancer screening and automated reports of patients overdue for breast (OR 2.19, 95 % CI 1.15-41.7) or cervical (OR. 2.56, 95 % CI 1.26-5.26) cancer screening. Providers lack systems to support breast and cervical cancer screening. Practice transformation toward a PCMH may support the adoption of systems to achieve guideline-adherent cancer screening in primary care settings. C1 [Schapira, Marilyn M.] Univ Penn, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Sprague, Brian L.; MacLean, Charles D.; Howe, Kathleen] Univ Vermont, Burlington, VT USA. [Klabunde, Carrie N.] NIH, Off Dis Prevent, Off Director, Bldg 10, Bethesda, MD 20892 USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Geisel Sch Med Dartmouth, Lebanon, NH USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Norris Cotton Canc Ctr, Lebanon, NH USA. [Bitton, Asaf; Feldman, Sarah] Harvard Med Sch, Boston, MA USA. [Bitton, Asaf; Chen, Jane S.; Harris, Kimberly; Feldman, Sarah; Brawarsky, Phyllis] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. RP Schapira, MM (reprint author), Univ Penn, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.; Schapira, MM (reprint author), Philadelphia VA Med Ctr, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU NCI NIH HHS [P30 CA023108, U01 CA163304, U54 CA163303, U54 CA163307, U54 CA163313] NR 39 TC 2 Z9 2 U1 9 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2016 VL 31 IS 10 BP 1148 EP 1155 DI 10.1007/s11606-016-3726-y PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DW4FF UT WOS:000383597200009 PM 27251058 ER PT J AU Bhambhvani, P Hage, F Iskandrian, A AF Bhambhvani, Pradeep Hage, Fadi Iskandrian, Ami TI A quick glance at selected topics in this issue SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Cardiac; imaging; women AB A quick glance at selected topics in this issue aims to highlight selected articles and provide a quick review to the reader. C1 [Bhambhvani, Pradeep] Univ Alabama Birmingham, Dept Radiol, Div Mol Imaging & Therapeut, Birmingham, AL 35294 USA. [Hage, Fadi; Iskandrian, Ami] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL USA. [Hage, Fadi] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Bhambhvani, P (reprint author), Univ Alabama Birmingham, Dept Radiol, Div Mol Imaging & Therapeut, Birmingham, AL 35294 USA. EM pbhambhvani@uabmc.edu OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2016 VL 23 IS 5 BP 942 EP 943 DI 10.1007/s12350-016-0629-6 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DX7GW UT WOS:000384555800002 PM 27495780 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI A selection of recent original research papers SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1900 Univ BLVD, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2016 VL 23 IS 5 BP 947 EP 949 DI 10.1007/s12350-016-0589-x PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DX7GW UT WOS:000384555800004 PM 27464896 ER PT J AU Guichard, JL Hage, FG AF Guichard, Jason L. Hage, Fadi G. TI Guidelines in review: 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients with Chest Pain: A joint document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review C1 [Guichard, Jason L.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 326,1900 Univ Blvd, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Guichard, JL (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 326,1900 Univ Blvd, Birmingham, AL 35294 USA. EM guichard@uab.edu FU Astellas Pharma FX Dr Hage reports research grant support from Astellas Pharma. NR 1 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2016 VL 23 IS 5 BP 1142 EP 1146 DI 10.1007/s12350-016-0469-4 PG 5 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DX7GW UT WOS:000384555800032 PM 27000877 ER PT J AU Lester, D El-Hajj, S Farag, AA Bhambhvani, P Tauxe, L Heo, J Iskandrian, AE Hage, FG AF Lester, Davis El-Hajj, Stephanie Farag, Ayman A. Bhambhvani, Pradeep Tauxe, Lindsey Heo, Jaekyeong Iskandrian, Ami E. Hage, Fadi G. TI Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Myocardial perfusion imaging; transient ischemic dilation; regadenoson; outcomes ID CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR CAVITY; TEMPORAL TRENDS; SPECT; ADENOSINE; DILATATION; RATIO; FREQUENCY; TL-201; EVENTS AB Transient ischemic dilation (TID) of the left ventricle seen on myocardial perfusion imaging (MPI) is sometimes used as a marker of severe coronary artery disease. The prognostic value of TID obtained using regadenoson, a selective adenosine A2A receptor agonist, as a stress agent for MPI has not been studied. TID ratio was measured using an automated software program on consecutive patients with normal and abnormal perfusion pattern on regadenoson MPI at a single institution. An abnormal TID was defined as greater than 1.33. The primary outcome was a composite of cardiac death, non-fatal myocardial infarction (MI), and late coronary revascularization (CR, > 90 days after MPI). The study population consisted of 887 patients (62 +/- 12 years, 66% male, 48% diabetes, 46% prior CR, 75% with abnormal perfusion pattern, left ventricular ejection fraction-LVEF 55 +/- 6%). An abnormal TID was present in 51 (6%) patients. Baseline characteristics were not different based on the presence or absence of TID. Early CR (aecurrency sign90 days) was performed in 11 (22%) patients with vs 92 (11%) patients without TID (P = .04). During a mean follow-up of 29 +/- 19 months, the primary outcome occurred in 271 (31%) patients (22% cardiac death, 6% MI, 9% late CR). TID was associated with increased risk of the primary outcome (log-rank P = .017), an association largely driven by late CR. In a Cox proportional model adjusted for multiple variables including perfusion defect size (PDS) and LVEF, the hazard ratio for TID was 1.92 (95% CI 1.20-3.08, P = .007). In the subset of patients with normal perfusion pattern, there was no association between TID and outcomes. TID on regadenoson MPI carries important prognostic information that is independent from PDS and LVEF, but this association is restricted to patients with abnormal perfusion on imaging. C1 [Lester, Davis] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [El-Hajj, Stephanie; Farag, Ayman A.; Tauxe, Lindsey; Heo, Jaekyeong; Iskandrian, Ami E.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Bhambhvani, Pradeep] Univ Alabama Birmingham, Div Mol Imaging & Therapeut, Birmingham, AL USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU Astellas Pharma USA FX Drs. Hage and Iskandrian have received research grants from Astellas Pharma USA. NR 32 TC 4 Z9 4 U1 5 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2016 VL 23 IS 5 BP 1147 EP 1155 DI 10.1007/s12350-015-0272-7 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DX7GW UT WOS:000384555800033 PM 26490267 ER PT J AU Farag, AA Hashim, T Hage, FG AF Farag, Ayman A. Hashim, Taimoor Hage, Fadi G. TI Myocardial perfusion imaging after gastric bypass surgery SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article C1 [Farag, Ayman A.; Hashim, Taimoor; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1720 2nd Ave S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1720 2nd Ave S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2016 VL 23 IS 5 BP 1171 EP 1172 DI 10.1007/s12350-015-0357-3 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DX7GW UT WOS:000384555800037 PM 26662285 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E., Jr. Leverich, Gabriele S. Nolen, Willem A. TI Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of psychiatric disorders SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Family history; Depression; Substance abuse; Childhood abuse; Age of onset of bipolar disorder; Heat map ID TREATMENT ENHANCEMENT PROGRAM; GLUCOCORTICOID-RECEPTOR; UNITED-STATES; I DISORDER; STEP-BD; CLINICAL-FEATURES; INITIAL TREATMENT; MOOD DISORDER; SEXUAL-ABUSE; LIFE STRESS AB Background: Family history and adversity in childhood are two replicated risk factors for early onset bipolar disorder. However, their combined impact has not been adequately studied. Methods: Based on questionnaire data from 968 outpatients with bipolar disorder who gave informed consent, the relationship and interaction of: 1) parental and grandparental total burden of psychiatric illness; and 2) the degree of adversity the patient experienced in childhood on their age of onset of bipolar disorder was examined with multiple regression and illustrated with a heat map. Results: The familial loading and child adversity vulnerability factors were significantly related to age of onset of bipolar and their combined effect was even larger. A heat map showed that at the extremes (none of each factor vs high amounts of both) the average age of onset differed by almost 20 years (mean = 25.8 vs 5.9 years of age). Limitations: The data were not based on interviews of family members and came from unverified answers on a patient questionnaire. Conclusions: Family loading for psychiatric illness and adversity in childhood combine to have a very large influence on age of onset of bipolar disorder. These variables should be considered in assessment of risk for illness onset in different populations, the need for early intervention, and in the design of studies of primary and secondary prevention. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, 5415 West Cedar Ln,Suite 201B, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Paracelsus Med Univ, Salzburg, Austria. [Suppes, Trisha] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Ln,Suite 201B, Bethesda, MD 20814 USA. EM Robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 NR 77 TC 1 Z9 1 U1 6 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD OCT PY 2016 VL 81 BP 63 EP 70 DI 10.1016/j.jpsychires.2016.06.008 PG 8 WC Psychiatry SC Psychiatry GA DY1LB UT WOS:000384855400009 PM 27392070 ER PT J AU Smagula, SF Wallace, ML Anderson, SJ Karp, JF Lenze, EJ Mulsant, BH Butters, MA Blumberger, DM Diniz, BS Lotrich, FE Dew, MA Reynolds, CF AF Smagula, Stephen F. Wallace, Meredith L. Anderson, Stewart J. Karp, Jordan F. Lenze, Eric J. Mulsant, Benoit H. Butters, Meryl A. Blumberger, Daniel M. Diniz, Breno S. Lotrich, Francis E. Dew, Mary Amanda Reynolds, Charles F., III TI Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Aripiprazole; Late-life depression; Moderators; Combined moderators; Personalized medicine ID RATING-SCALE; VALIDITY; RELIABILITY; PREDICTORS; REMISSION; TRIALS AB Personalizing treatment for late-life depression requires identifying and integrating information from multiple factors that influence treatment efficacy (moderators). We performed exploratory moderator analyses using data from a multi-site, randomized, placebo-controlled, double-blind trial of aripiprazole augmentation. Patients (n = 159) aged >= 60 years had major depressive disorder that failed to remit with venlafaxine monotherapy. We examined effect sizes of 39 potential moderators of aripiprazole (vs. placebo) augmentation efficacy using the outcome of percentage reduction in depressive symptom after 12 weeks. We then incorporated information from the individually relevant variables in combined moderators. A larger aripiprazole treatment effect was related to: white race, better physical function, better performance on Trail-Making, attention, immediate, and delayed memory tests, greater psychomotor agitation and suicidality symptoms, and a history of adequate antidepressant pharmacotherapy. A smaller aripiprazole treatment effect was observed in patients with: more pain and more work/activity impairment and libido symptoms. Combining information from race and Trail-Making test performance (base combined moderator (M-b*)) produced a larger effect size (Spearman effect size = 0.29 (95% confidence interval (CI): 0.15, 0.42)) than any individual moderator. Adding other individually relevant moderators in the full combined moderator (M-f*) further improved effect size (Spearman effect size = 0.39 (95% CI: 0.25, 0.52)) and identified a sub-group benefiting more from placebo plus continuation venlafaxine monotherapy than adjunctive aripiprazole. Combining moderators can help clinicians personalize depression treatment. We found the majority of our patients benefited from adjunctive aripiprazole, but a smaller subgroup that is identifiable using clinical measures appeared to benefit more from continuation venlafaxine plus placebo. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Smagula, Stephen F.; Wallace, Meredith L.; Karp, Jordan F.; Butters, Meryl A.; Lotrich, Francis E.; Dew, Mary Amanda; Reynolds, Charles F., III] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, 3811 OHara St, Pittsburgh, PA 15217 USA. [Anderson, Stewart J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Karp, Jordan F.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lenze, Eric J.] Washington Univ, Sch Med, Dept Psychiat, Hlth Mind Lab, St Louis, MO 63110 USA. [Mulsant, Benoit H.; Blumberger, Daniel M.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Mulsant, Benoit H.; Blumberger, Daniel M.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Diniz, Breno S.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Reynolds, Charles F., III] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. RP Smagula, SF (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, 3811 OHara St, Pittsburgh, PA 15217 USA. EM sfs26@pitt.edu OI Diniz, Breno/0000-0003-0653-1905 FU National Institute of Mental Health [R01MH083660, R01MH083648, R01MH083643, P30MH90333, T32MH19986] FX This research was sponsored by the following National Institute of Mental Health grants: R01MH083660, R01MH083648, R01MH083643, P30MH90333, T32MH19986. NR 23 TC 3 Z9 3 U1 3 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD OCT PY 2016 VL 81 BP 112 EP 118 DI 10.1016/j.jpsychires.2016.07.005 PG 7 WC Psychiatry SC Psychiatry GA DY1LB UT WOS:000384855400015 PM 27438687 ER PT J AU Johnson, E AF Johnson, Earl TI A Response Letter to the McCreery et al (2016) Article "Stability of Audiometric Thresholds for Children with Hearing Aids Applying the American Academy of Audiology Pediatric Amplification Guideline: Implications for Safety" SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Letter ID TEMPORARY; SUSCEPTIBILITY; NOISE; DSL C1 [Johnson, Earl] US Dept Vet Affairs, Audiol & Speech Pathol, Mountain Home, TN 37684 USA. RP Johnson, E (reprint author), US Dept Vet Affairs, Audiol & Speech Pathol, Mountain Home, TN 37684 USA. NR 19 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 EI 2157-3107 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD OCT PY 2016 VL 27 IS 9 BP 778 EP 779 DI 10.3766/jaaa.16048 PG 2 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA DX8IB UT WOS:000384630200009 PM 27718353 ER PT J AU Ojeda, L Pina-Watson, B Gonzalez, G AF Ojeda, Lizette Pina-Watson, Brandy Gonzalez, Gerardo TI The Role of Social Class, Ethnocultural Adaptation, and Masculinity Ideology on Mexican American College Men's Well-Being SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE familismo; male roles; acculturation; socioeconomic status; life satisfaction ID SEX-ROLE ATTITUDES; LIFE SATISFACTION; ETHNIC-IDENTITY; FAMILY SUPPORT; SELF-EFFICACY; DAY LABORERS; ACCULTURATION; SCALE; INTERSECTIONALITY; PREDICTORS AB Limited research has taken an intersectional approach in which masculinity, ethnicity, and social class are collectively considered in understanding Latino men's well-being. This study aims to address this gap by examining the role of perceived social class, familismo, acculturation, enculturation, Mexican American attitudinal marginalization, and masculinity ideology on well-being for 134 Mexican American college men ranging in age from 17 to 42 years (M = 20.64, SD = 3.92). Hierarchical multiple regression results indicated that men felt more satisfied with their lives when they perceived themselves to be of higher social class, adhered to familismo and to Mexican culture, expressed lower levels of marginalized attitudes toward Mexican American cultural norms, and had less traditional male role attitudes. The model collectively accounted for 26% of the variance in well-being, with perceived social class being the strongest predictor. The implications for practice and research are discussed in relation to understanding Latino men's well-being within the context of intersectionality and masculinity. C1 [Ojeda, Lizette] Texas A&M Univ, Dept Educ Psychol, MS 4225, College Stn, TX 77843 USA. [Pina-Watson, Brandy] Texas Tech Univ, Dept Psychol Sci, Lubbock, TX 79409 USA. [Gonzalez, Gerardo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ojeda, L (reprint author), Texas A&M Univ, Dept Educ Psychol, MS 4225, College Stn, TX 77843 USA. EM lizetteojeda@tamu.edu NR 49 TC 0 Z9 0 U1 9 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 EI 1939-151X J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD OCT PY 2016 VL 17 IS 4 BP 373 EP 379 DI 10.1037/men0000023 PG 7 WC Psychology, Social SC Psychology GA DX8PE UT WOS:000384650200007 ER PT J AU Jabra-Rizk, MA Kong, EF Tsui, C Nguyen, MH Clancy, CJ Fidel, PL Noverr, M AF Jabra-Rizk, Mary Ann Kong, Eric F. Tsui, Christina Hong Nguyen, M. Clancy, Cornelius J. Fidel, Paul L., Jr. Noverr, Mairi TI Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework SO INFECTION AND IMMUNITY LA English DT Review ID VULVO-VAGINAL CANDIDIASIS; SECRETED ASPARTYL PROTEINASE; INTRAVENOUS CHALLENGE MODEL; INVASIVE FUNGAL-INFECTIONS; INTRAORAL DENTURE SYSTEM; T-CELLS; OROPHARYNGEAL CANDIDIASIS; IMMUNODEFICIENT MICE; ORAL CANDIDIASIS; BLOOD-STREAM AB Historically, the nature and extent of host damage by a microbe were considered highly dependent on virulence attributes of the microbe. However, it has become clear that disease is a complex outcome which can arise because of pathogen-mediated damage, host-mediated damage, or both, with active participation from the host microbiota. This awareness led to the formulation of the damage response framework (DRF), a revolutionary concept that defined microbial virulence as a function of host immunity. The DRF outlines six classifications of host damage outcomes based on the microbe and the strength of the immune response. In this review, we revisit this concept from the perspective of Candida albicans, a microbial pathogen uniquely adapted to its human host. This fungus commonly colonizes various anatomical sites without causing notable damage. However, depending on environmental conditions, a diverse array of diseases may occur, ranging from mucosal to invasive systemic infections resulting in microbe-mediated and/or host-mediated damage. Remarkably, C. albicans infections can fit into all six DRF classifications, depending on the anatomical site and associated host immune response. Here, we highlight some of these diverse and site-specific diseases and how they fit the DRF classifications, and we describe the animal models available to uncover pathogenic mechanisms and related host immune responses. C1 [Jabra-Rizk, Mary Ann; Kong, Eric F.; Tsui, Christina] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA. [Jabra-Rizk, Mary Ann; Kong, Eric F.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Kong, Eric F.] Univ Maryland, Grad Program Life Sci, Mol Microbiol & Immunol Program, Baltimore, MD 21201 USA. [Hong Nguyen, M.; Clancy, Cornelius J.] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Fidel, Paul L., Jr.; Noverr, Mairi] Louisiana State Univ, Sch Dent, Hlth Sci Ctr, Ctr Excellence Oral & Craniofacial Biol, New Orleans, LA 70119 USA. RP Jabra-Rizk, MA (reprint author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.; Jabra-Rizk, MA (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. EM mrizk@umaryland.edu FU HHS \ National Institutes of Health (NIH) [DE14424, DE022069, AI116025] FX This work, including the efforts of Mary Ann Jabra-Rizk, was funded by HHS vertical bar National Institutes of Health (NIH) (DE14424). This work, including the efforts of Mairi C. Noverr, was funded by HHS vertical bar National Institutes of Health (NIH) (DE022069 and AI116025). NR 166 TC 2 Z9 3 U1 6 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD OCT PY 2016 VL 84 IS 10 BP 2724 EP 2739 DI 10.1128/IAI.00469-16 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DX0TK UT WOS:000384077800001 PM 27430274 ER PT J AU Adhi, M Bonini, MA Louzada, RN Kuehlewein, L de Carlo, TE Baumal, CR Witkin, AJ Sadda, SR Sarraf, D Reichel, E Duker, JS Waheed, NK AF Adhi, Mehreen Bonini Filho, Marco A. Louzada, Ricardo N. Kuehlewein, Laura de Carlo, Talisa E. Baumal, Caroline R. Witkin, Andre J. Sadda, Srinivas R. Sarraf, David Reichel, Elias Duker, Jay S. Waheed, Nadia K. TI Retinal Capillary Network and Foveal Avascular Zone in Eyes with Vein Occlusion and Fellow Eyes Analyzed With Optical Coherence Tomography Angiography SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE retinal vein occlusion; optical coherence tomography angiography; foveal avascular zone; perifoveal retinal capillary plexus; vascular perfusion ID ACUTE MIDDLE MACULOPATHY; FLUORESCEIN ANGIOGRAPHY; MICROANGIOGRAPHY; ISCHEMIA; SPECTRUM AB PURPOSE. To evaluate the perifoveolar retinal capillary network at different depths and to quantify the foveal avascular zone (FAZ) in eyes with retinal vein occlusion (RVO) compared with their fellow eyes and healthy controls using spectral-domain optical coherence tomography angiography (SD-OCTA). METHODS. We prospectively recruited 23 patients with RVO including 15 eyes with central RVO (CRVO) and 8 eyes with branch RVO (BRVO), their fellow eyes, and 8 age-matched healthy controls (8 eyes) for imaging on prototype OCTA software within RTVue-XR Avanti. The 3 x 3 mm and 6 x 6 mm en face angiograms of superficial and deep retinal capillary plexuses were segmented. Perifoveolar retinal capillary network was analyzed and FAZ was quantified. RESULTS. Decrease in vascular perfusion at the deep plexus was observed in all eyes with CRVO (8/8, 100%) and BRVO (6/6, 100%) without cystoid macular edema, and in 8 of 15 (53%) and 2 of 8 (25%) of the fellow eyes, respectively. Vascular tortuosity was observed in 13 of 15 (87%) CRVO and 5 of 8 (63%) BRVO eyes. Collaterals were seen in 10 of 15 (67%) CRVO and 5 of 8 (63%) BRVO eyes. Mean FAZ area was larger in eyes with RVO than their fellow eyes (1.13 +/- 0.25 mm(2) versus 0.58 +/- 0.28 mm(2); P = 0.007) and controls (1.13 +/- 0.25 mm(2) versus 0.30 +/- 0.09 mm(2); P < 0.0001), and in fellow eyes of RVO patients when compared to controls (0.58 +/- 0.28 mm(2) versus 0.30 +/- 0.09 mm(2); P = 0.01). CONCLUSIONS. Spectral-domain OCTA reveals abnormalities at different levels of perifoveolar retinal capillary network and is able to quantify the FAZ in RVO. Longitudinal studies may be considered to evaluate the clinical utility of OCTA in RVO and other retinal vascular diseases. C1 [Adhi, Mehreen; Bonini Filho, Marco A.; Louzada, Ricardo N.; de Carlo, Talisa E.; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elias; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA. [Adhi, Mehreen; de Carlo, Talisa E.] MIT, Dept Elect Engn, Cambridge, MA 02139 USA. [Adhi, Mehreen; de Carlo, Talisa E.] MIT, Dept Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Adhi, Mehreen; de Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Bonini Filho, Marco A.; Louzada, Ricardo N.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil. [Louzada, Ricardo N.] Univ Fed Goias, Ophthalm Ctr Reference CEROF, Goiania, Go, Brazil. [Kuehlewein, Laura; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA. [Sarraf, David] Stein Eye Inst, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Waheed, NK (reprint author), Tufts Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA. EM nadiakwaheed@gmail.com FU Massachusetts Lions Club Research Fund; CAPES Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil FX Supported by Massachusetts Lions Club Research Fund and the CAPES Foundation (MABF, RNL), Ministry of Education of Brazil, Brasilia, DF, Brazil. NR 29 TC 0 Z9 0 U1 4 U2 4 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUL PY 2016 VL 57 IS 9 BP OCT486 EP OCT494 DI 10.1167/iovs.15-18907 PG 9 WC Ophthalmology SC Ophthalmology GA DW9MY UT WOS:000383985400050 PM 27442342 ER PT J AU Chen, P Steinman, MA AF Chen, Pei Steinman, Michael A. TI Perception of primary care physicians on the impact of comprehensive geriatric assessment: what is the next step? SO ISRAEL JOURNAL OF HEALTH POLICY RESEARCH LA English DT Editorial Material DE Comprehensive geriatric assessment; Primary care; Consultative medicine; Medical education ID INCREASE ADHERENCE; RANDOMIZED-TRIAL; RECOMMENDATIONS; INTERVENTION AB Older adults are at high risk of developing multimorbidity, and the high levels of clinical and psychosocial complexity in this population pose special challenges for primary care physicians (PCPs). As a way to improve the care for the older adults, a number of health systems have developed programs to provide comprehensive geriatric assessment (CGA), which generally refers to an intensive interprofessional evaluation and management of geriatric syndromes with the goals of maximizing health in aging. Sternberg and Bentur examined the impact of CGA as perceived by PCPs, the PCPs attitude toward CGA, and their satisfaction with CGA. In this commentary, we seek to provide additional context to the current state of outpatient consultative CGA and how it relates to the findings in the study by Sternberg and Bentur. The knowledge gained from this study begs for future investigations, especially in the areas of PCPs' understanding of outpatient consultative CGA, the perceived benefit in health outcomes and actual health outcomes, perceived needs in geriatric consultation, preference in management of complex geriatric syndromes, and interests in continuing education in geriatrics. Insight into these factors could allow for improvement of the current outpatient consultative CGA model and allow for adaption of the model to local needs. C1 [Chen, Pei; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. RP Chen, P (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM pei.chen@ucsf.edu FU Geriatric Workforce Enhancement Program, a Health Resources and Service Administration grant [U1QHP28727]; National Institutes of Health [K24AG049057, P30AG044281] FX Pei Chen is funded by the Geriatric Workforce Enhancement Program, a Health Resources and Service Administration grant (U1QHP28727). Michael A. Steinman is funded by the National Institutes of Health (K24AG049057 and P30AG044281). NR 15 TC 0 Z9 0 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2045-4015 J9 ISR J HEALTH POLICY JI Isr. J. Health Policy Res. PD OCT 1 PY 2016 VL 5 AR 46 DI 10.1186/s13584-016-0106-3 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DX6PT UT WOS:000384506300001 PM 27733902 ER PT J AU Jotwani, V Scherzer, R Estrella, MM Jacobson, LP Witt, MD Palella, F Macatangay, B Bennett, M Parikh, CR Ix, JH Shlipak, M AF Jotwani, Vasantha Scherzer, Rebecca Estrella, Michelle M. Jacobson, Lisa P. Witt, Mallory D. Palella, Frank Macatangay, Bernard Bennett, Michael Parikh, Chirag R. Ix, Joachim H. Shlipak, Michael TI Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE tenofovir disoproxil fumarate; kidney; biomarker; nephrotoxicity ID GLOMERULAR-FILTRATION-RATE; KIDNEY INJURY; PLASMA-CONCENTRATIONS; ANTIRETROVIRAL-NAIVE; MOLECULE-1 KIM-1; FUNCTION DECLINE; RENAL TOXICITY; URINARY; PHARMACOKINETICS; NECROSIS AB Tenofovir disoproxil fumarate (TDF) can cause kidney damage, but current clinical tests are insensitive for detecting toxicity. Among 884 HIV-infected men enrolled in the Multicenter AIDS Cohort Study, we measured urine biomarkers specific for tubular damage (interleukin-18, kidney injury molecule-1, procollagen type III N-terminal propeptide) and albuminuria. In adjusted analyses, each year of TDF exposure was independently associated with 3.3% higher interleukin-18 (95% CI: 0.8% to 5.8%), 3.4% higher kidney injury molecule-1 (1.1% to 5.7%), and 3.1% higher procollagen type III N-terminal propeptide (0.8% to 5.5%), but not with albuminuria (2.8%; 20.6% to 6.2%). Biomarkers of tubular damage may be more sensitive than albuminuria for detecting toxicity from TDF and other medications. C1 [Jotwani, Vasantha; Scherzer, Rebecca; Shlipak, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Jotwani, Vasantha; Scherzer, Rebecca; Shlipak, Michael] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Witt, Mallory D.] Harbor UCLA Med Ctr, Dept Med, Div HIV Med, Torrance, CA 90509 USA. [Witt, Mallory D.] Harbor UCLA, Los Angeles Biomed Res Inst, Torrance, CA USA. [Palella, Frank] Northwestern Univ, Dept Med, Div Infect Dis, Chicago, IL 60611 USA. [Macatangay, Bernard] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA. [Bennett, Michael] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Dept Med, Cincinnati, OH 45229 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Program Appl Translat Res, New Haven, CT 06520 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Dept Med, Nephrol Sect, San Diego, CA USA. RP Jotwani, V (reprint author), San Francisco VA Med Ctr, 4150 Clement St Box 111A1, San Francisco, CA USA. EM vasantha.jotwani@ucsf.edu FU Veterans Affairs Medical Center, San Francisco, CA [5 F32 DK103451-02]; National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Deafness and Communication Disorders (NIDCD); [1 R01 AG034853-01A2] FX The MACS Kidney Study is funded by grant 1 R01 AG034853-01A2 (PI, Shlipak), which was administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, CA, and by grant 5 F32 DK103451-02 (PI, Jotwani), which was administered by the University of California, San Francisco. Data in this article were collected by the Multicenter AIDS Cohort Study (MACS) with centers at Baltimore (U01-AI35042): The Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (PI), Jay Bream, Todd Brown, Barbara Crain, Adrian Dobs, Richard Elion, Richard Elion, Michelle Estrella, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), John P. Phair, Sheila Badri, Dana Gabuzda, Frank J. Palella, Jr., Sudhir Penugonda, Susheel Reddy, Matthew Stephens, Linda Teplin; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martinez-Maza (Co-PI), Aaron Aronow, Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaz Hussain, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (Co-PI), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Gypsyamber D'Souza (Co-PI), Alison, Abraham, Keri Althoff, Jennifer Deal, Priya Duggal, Sabina Haberlen, Alvaro Muoz, Derek Ng, Janet Schollenberger, Eric C. Seaberg, Sol Su, Pamela Surkan. Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH), Johns Hopkins ICTR, or NCATS. The MACS website is located at http://www.statepi.jhsph.edu/macs/macs.html. NR 52 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2016 VL 73 IS 2 BP 177 EP 181 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DX1EW UT WOS:000384109800013 PM 27088295 ER PT J AU Herrin, M Tate, JP Akgun, KM Butt, AA Crothers, K Freiberg, MS Gibert, CL Leaf, DA Rimland, D Rodriguez-Barradas, MC Ruser, CB Herold, KC Justice, AC AF Herrin, Melissa Tate, Janet P. Akgun, Kathleen M. Butt, Adeel A. Crothers, Kristina Freiberg, Matthew S. Gibert, Cynthia L. Leaf, David A. Rimland, David Rodriguez-Barradas, Maria C. Ruser, Chris B. Herold, Kevan C. Justice, Amy C. TI Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE diabetes; HIV; weight gain; obesity; veterans; inflammation ID INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; RISK-FACTORS; BODY-MASS; OBESITY; MELLITUS; COHORT; HAART; INFLAMMATION AB Background: The health implications of weight gain after antiretroviral therapy (ART) for HIV infection are not well characterized and may differ from weight gain among uninfected individuals. We use data from the Veterans Aging Cohort Study to determine whether weight gain after ART has a similar association with incident type 2 diabetes mellitus (DM) as weight gained among HIV-uninfected (uninfected) individuals. Methods: We explored associations of weight gain and incident diabetes (A1c >= 6.5%), in the Veterans Aging Cohort Study, a national observational study of HIV-infected (HIV+) individuals demographically matched 1: 2 to uninfected controls. From 2000 to 2011, weight change was assessed in the year following ART initiation for HIV+ individuals and date of first available body mass index for uninfected individuals. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for baseline body mass index using Cox regression. Results: HIV+ individuals had lower prevalence of DM at baseline (12% HIV+, 23% uninfected) and lower incident diabetes (5% HIV +, 11% uninfected). The association of weight gain with risk of DM was linear for HIV+ and uninfected but the slope of the association was steeper for HIV+. For each 5 pounds of weight gained, HIV+ had 14% increased risk of DM (HR, 1.14; 95% CI: 1.10 to 1.17) and uninfected individuals had 8% increased risk (HR, 1.08; 95% CI: 1.07 to 1.10) (P < 0.01 for interaction). Conclusions: Weight gained in the first year after ART initiation is associated with greater risk of DM than that among uninfected individuals. HIV+ individuals initiating ART who are not underweight should avoid substantial weight gain. C1 [Herrin, Melissa; Tate, Janet P.; Ruser, Chris B.; Justice, Amy C.] VA Connecticut Healthcare Syst, Internal Med, West Haven, CT USA. [Herrin, Melissa; Tate, Janet P.; Ruser, Chris B.] Yale Univ, Sch Med, Internal Med, New Haven, CT USA. [Akgun, Kathleen M.] VA Connecticut Healthcare Syst, Dept Internal Med & Gen Internal Med, West Haven, CT USA. [Akgun, Kathleen M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Infect Dis, Doha, Qatar. [Butt, Adeel A.; Freiberg, Matthew S.] VA Pittsburgh Healthcare Syst, Infect Dis, Pittsburgh, PA USA. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Crothers, Kristina] Univ Washington, Sch Med, Pulm & Crit Care Med, Seattle, WA USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Cardiovasc Med, Nashville, TN 37212 USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Internal Med Infect Dis, Washington, DC 20052 USA. [Gibert, Cynthia L.] Vet Affairs Med Ctr, Med Serv Infect Dis, Internal Med Infect Dis, 50 Irving St NW, Washington, DC 20422 USA. [Leaf, David A.] VA Greater Los Angeles Healthcare Syst, Infect Dis, Los Angeles, CA USA. [Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis, Los Angeles, CA 90095 USA. [Rimland, David] VA Med Ctr, Infect Dis, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Infect Dis, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Affairs VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Herold, Kevan C.] Yale Univ, Sch Med, Yale Diabet Ctr, Immunol,Endocrinol, New Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, Internal Med, New Haven, CT USA. RP Justice, AC (reprint author), Vet Affairs Med Ctr, West Haven 950 Campbell Ave,Bldg 35a Room 2-212, West Haven, CT 06516 USA. EM amy.justice2@va.gov OI Crothers, Kristina/0000-0001-9702-0371 FU National Institutes of Health: AHRQ [R01-HS018372]; National Institute on Alcohol Abuse and Alcoholism [U24-AA020794, U01-AA020790, U01-A020795, U01-AA020799, U24-AA022001, U24 AA022007, U10 AA013566-completed]; National Heart and Lung Blood Institute [R01-HL095136, R01-HL090342]; National Institute of Allergy and Infectious Disease [U01-A1069918]; National Institute on Drug Abuse [R01DA035616]; Veterans Health Administration Office of Research and Development [VA REA 08-266]; VA IRR Merit Award; VISN1 CDA [V1CDA2012-20] FX Supported by National Institutes of Health: AHRQ (R01-HS018372), National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U01-A020795, U01-AA020799, U24-AA022001, U24 AA022007, and U10 AA013566-completed), National Heart and Lung Blood Institute (R01-HL095136; R01-HL090342), National Institute of Allergy and Infectious Disease (U01-A1069918), National Institute on Drug Abuse (R01DA035616), and the Veterans Health Administration Office of Research and Development (VA REA 08-266, VA IRR Merit Award; VISN1 CDA (V1CDA2012-20)). NR 44 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2016 VL 73 IS 2 BP 228 EP 236 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DX1EW UT WOS:000384109800020 PM 27171741 ER PT J AU Lanier-Bohan, EM Heath, SL AF Lanier-Bohan, Elaine M. Heath, Susan L. TI Patient and Caregiver Perspectives of Preoperative Teaching for Deep Brain Stimulation Surgery SO JOURNAL OF NEUROSCIENCE NURSING LA English DT Article DE deep brain stimulation; dystonia; essential tremor; Parkinson disease; preoperative teaching ID PRIMARY HEADACHE DISORDERS; SUBTHALAMIC NUCLEUS; PSYCHOEDUCATIONAL INTERVENTIONS; PARKINSON-DISEASE; METAANALYSIS; OUTCOMES; NEUROMODULATION; NEUROSTIMULATION; MECHANISMS; HISTORY AB Deep brain stimulation (DBS) has developed into an important therapy for Parkinson disease, essential tremor, and dystonia with more nurses in varied settings often preparing patients and families for this type of surgery. This exploratory study sought to obtain patient and caregiver perspectives of the current DBS teaching for Parkinson disease, essential tremor, and dystonia; to improve the teaching; and to standardize the education. Using survey methodology, 41 patients with movement disorder and 32 caregivers completed surveys about the preoperative instructions they received. Data analysis calculated frequencies for response rate, demographic information, multiple-choice questions, and Likert scale responses. Fill-in questions were summarized. Results overall showed that, because of the teaching, two thirds of patients and nearly two thirds of caregivers felt fully prepared for the DBS surgery. Patients' and caregivers' suggested recommendations for nurses and surgeons included requests for specific information such as attention to delivery of the education, more individualized care during the education, attention to pain during and after procedure, and postdischarge follow-up. The study identified unmet patient and caregiver needs, resulted in changes in practice, and serves as a guide toward standardization of educational approach and/or content. C1 [Lanier-Bohan, Elaine M.; Heath, Susan L.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA. [Lanier-Bohan, Elaine M.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. RP Lanier-Bohan, EM (reprint author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA.; Lanier-Bohan, EM (reprint author), Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. EM elainelb1949@gmail.com NR 29 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0888-0395 EI 1945-2810 J9 J NEUROSCI NURS JI J. Neurosci. Nurs. PD OCT PY 2016 VL 48 IS 5 BP 247 EP 255 DI 10.1097/JNN.0000000000000221 PG 9 WC Clinical Neurology; Nursing SC Neurosciences & Neurology; Nursing GA DX4BT UT WOS:000384324600005 PM 27579958 ER PT J AU Small, A Gist, D Souza, D Dalton, J Magny-Normilus, C David, D AF Small, Alison Gist, Diana Souza, Danielle Dalton, Joanne Magny-Normilus, Cherlie David, Daniel TI Using Kotter's Change Model for Implementing Bedside Handoff: A Quality Improvement Project SO JOURNAL OF NURSING CARE QUALITY LA English DT Article ID IMPROVING PATIENT SAFETY; SHIFT HANDOFFS; HEALTH-CARE; MNEMONICS C1 [Small, Alison; Gist, Diana; Souza, Danielle] Beth Israel Deaconess Med Ctr, Dept Nursing, Deaconness Rd, Boston, MA 02215 USA. [Dalton, Joanne; Magny-Normilus, Cherlie] Regis Coll, Sch Nursing, Weston, MA USA. [David, Daniel] San Francisco VA Med Ctr, Palliat & Extended Care Serv, San Francisco, CA USA. RP Small, A (reprint author), Beth Israel Deaconess Med Ctr, Dept Nursing, Deaconness Rd, Boston, MA 02215 USA. EM asmall@bidmc.harvard.edu NR 35 TC 0 Z9 0 U1 8 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1057-3631 EI 1550-5065 J9 J NURS CARE QUAL JI J. Nurs. Care Qual. PD OCT-DEC PY 2016 VL 31 IS 4 BP 304 EP 309 DI 10.1097/NCQ.0000000000000212 PG 6 WC Nursing SC Nursing GA DX1NW UT WOS:000384135100003 PM 27500693 ER PT J AU Taber, DJ Gebregziabher, M Hunt, KJ Srinivas, T Chavin, KD Baliga, PK Egede, LE AF Taber, David J. Gebregziabher, Mulugeta Hunt, Kelly J. Srinivas, Titte Chavin, Kenneth D. Baliga, Prabhakar K. Egede, Leonard E. TI Twenty years of evolving trends in racial disparities for adult kidney transplant recipients SO KIDNEY INTERNATIONAL LA English DT Article DE African American; graft loss; kidney transplant; racial disparities ID RENAL-ALLOGRAFT SURVIVAL; DELAYED GRAFT FUNCTION; AFRICAN-AMERICAN; ETHNIC DISPARITIES; PATIENT SURVIVAL; RECEIVING SIROLIMUS; STEROID WITHDRAWAL; ORGAN TRANSPLANT; UNITED-STATES; OUTCOMES AB Disparities in outcomes for African American (AA) kidney transplant recipients have persisted for 40 years without a comprehensive analysis of evolving trends in the risks associated with this disparity. Here we analyzed U.S. transplant registry data, which included adult Caucasian or AA solitary kidney recipients undergoing transplantation between 1990 and 2009 comprising 202,085 transplantations. During this 20-year period, the estimated rate of 5-year graft loss decreased from 27.6% to 12.8%. Notable trends in baseline characteristics that significantly differed by race over time included the following: increased prevalence of diabetes from 2001 to 2009 in AAs (5-year slope difference: 3.4%), longer time on the waiting list (76.5 more days per 5 years in AAs), fewer living donors in AAs from 2003 to 2009 (5-year slope difference: -3.36%), more circulatory death donors in AAs from 2000-09 (5-year slope difference: 1.78%), and a slower decline in delayed graft function in AAs (5-year slope difference: 0.85%). The absolute risk difference between AAs and Caucasians for 5-year graft loss significantly declined over time (-0.92% decrease per 5 years), whereas the relative risk difference actually significantly increased (3.4% increase per 5 years). These results provide a mixed picture of both promising and concerning trends in disparities for AA kidney transplant recipients. Thus, although the disparity for graft loss has significantly improved, equity is still far off, and other disparities, including living donation rates and delayed graft function rates, have widened during this time. C1 [Taber, David J.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ South Carolina, Div Transplant Surg, Coll Med, Charleston, SC USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm Serv, Charleston, SC USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ South Carolina, Dept Publ Hlth Sci, Coll Med, Charleston, SC USA. [Srinivas, Titte] Med Univ South Carolina, Div Transplant Nephrol, Coll Med, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ South Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK099440. NR 44 TC 1 Z9 1 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD OCT PY 2016 VL 90 IS 4 BP 878 EP 887 DI 10.1016/j.kint.2016.06.029 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA DX4ZE UT WOS:000384388800024 PM 27555121 ER PT J AU Sullivan, DR Forsberg, CW Ganzini, L Au, DH Gould, MK Provenzale, D Lyons, KS Slatore, CG AF Sullivan, D. R. Forsberg, C. W. Ganzini, L. Au, D. H. Gould, M. K. Provenzale, D. Lyons, K. S. Slatore, C. G. TI Depression symptom trends and health domains among lung cancer patients in the CanCORS study SO LUNG CANCER LA English DT Article DE Lung cancer; Depression symptoms; Risk factors; Health domains; Quality of life; Survival ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIALS; CARE OUTCOMES RESEARCH; EARLY PALLIATIVE CARE; OLDER-ADULTS; MAJOR DEPRESSION; PSYCHOLOGICAL DISTRESS; AFRICAN-AMERICANS; SOCIAL SUPPORT; BREAST-CANCER AB Objectives: Among lung cancer patients depression symptoms are common and impact outcomes. The aims of this study were to determine risk factors that contribute to persistent or new onset depression symptoms during lung cancer treatment, and examine interactions between depression symptoms and health domains that influence mortality. Materials and methods: Prospective observational study in five healthcare systems and 15 Veterans Affairs medical centers. Patients in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium with lung cancer were eligible. The 8-item Center for Epidemiologic Studies Depression (CES-D) scale was administered at baseline and follow-up. Scores >= 4 indicated elevated depressive symptoms. Health domains were measured using validated instruments. We applied logistic regression and Cox proportional hazards modeling to explore the association between depression symptoms, health domains, and mortality. Results: Of 1790 participants, 38% had depression symptoms at baseline and among those still alive, 31% at follow-up. Risk factors for depression symptoms at follow-up included younger age (OR=2.81), female sex (OR = 1.59), low income (OR = 1.45), not being married (OR = 1.74) and current smoking status (OR = 1.80); high school education was associated with reduced odds of depression symptoms at follow-up, compared with lesser educational attainment (OR=0.74) (all p values <0.05). Patients with depression symptoms had worse health-related quality of life, vitality, cancer-specific symptoms, and social support than patients without depression symptoms (all p < 0.001). The association between depression symptoms and increased mortality is greater among patients with more lung cancer symptoms (p = 0.008) or less social support (p = 0.04). Conclusions: Patient risk factors for depression symptoms at follow-up were identified and these subgroups should be targeted for enhanced surveillance. Patients with depression symptoms suffer across all health domains; however, only more lung cancer symptoms or less social support are associated with worse mortality among these patients. These potentially modifiable health domains suggest targets for possible intervention in future studies. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Sullivan, D. R.; Slatore, C. G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Sullivan, D. R.; Forsberg, C. W.; Ganzini, L.; Slatore, C. G.] Vet Affairs Portland Hlth Care Syst, Hlth Serv Res & Dev, Portland, OR USA. [Ganzini, L.] Oregon Hlth & Sci Univ, Dept Psychiat, Div Geriatr Psychiat, Portland, OR 97201 USA. [Au, D. H.] Univ Washington, Hlth Serv Res & Dev Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Au, D. H.] Univ Washington, Dept Med, Seattle, WA USA. [Gould, M. K.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Gould, M. K.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. [Provenzale, D.] Durham VA Med Ctr, VA Cooperat Studies Program Epidemiol Ctr Durham, Durham, NC USA. [Provenzale, D.] Duke Univ, Durham, NC USA. [Lyons, K. S.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Slatore, C. G.] Vet Affairs Portland Hlth Care Syst, Sect Pulm & Crit Care Med, Portland, OR USA. RP Sullivan, DR (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, UHN67, Portland, OR 97239 USA. EM sullivad@ohsu.edu OI Sullivan, Donald/0000-0003-3266-3389 FU American Lung Association [SB-164388-N]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [5KL2TR000152-08]; National Center for Research Resources through the OHSU Oregon Clinical & Translational Research Institute (OCTRI) [UL1TR000128]; National Cancer Institute (NCI) of the NIH [K07CA190706]; VA HSR&D Career Development Award [CDA 09-025, CDP 11-227]; National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA 093326]; Department of Veteran's Affairs grant [VA HSRD CRS-02-164] FX This work was supported by a generous grant from the American Lung Association (SB-164388-N; PI: Slatore). DR Sullivan was supported by 5KL2TR000152-08 funded through the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and National Center for Research Resources through the OHSU Oregon Clinical & Translational Research Institute (OCTRI)UL1TR000128 and National Cancer Institute (NCI) of the NIH under Award Number K07CA190706. CG Slatore was supported by VA HSR&D Career Development Award (CDA 09-025 and CDP 11-227). Drs. Sullivan, Ganzini, and Slatore are supported by resources from the Portland VA Portland Health Care System, Oregon. The work of the CanCORS consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI supported Primary Data Collection and Research Centers (Dana-Farber Cancer Institute/Cancer Research Network U01 CA093332, Harvard Medical School/Northern California Cancer Center U01 CA093324, RAND/UCLA U01 CA093348, University of Alabama at Birmingham U01 CA093329, University of Iowa U01 CA093339, University of North Carolina U01 CA 093326) and by a Department of Veteran's Affairs grant to the Durham VA Medical Center VA HSRD CRS-02-164). The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis, interpretation of data, or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. DRS, CWF, LG, DHA, DP, KSL, CGS declare no potential conflicts of interest including relevant financial interests, activities, relationships, and affiliations. MKG receives honoraria from UpToDate. NR 85 TC 0 Z9 0 U1 5 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD OCT PY 2016 VL 100 BP 102 EP 109 DI 10.1016/j.lungcan.2016.08.008 PG 8 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DW8YQ UT WOS:000383941800016 PM 27597288 ER PT J AU Chinsongkram, B Chaikeeree, N Saengsirisuwan, V Horak, FB Boonsinsukh, R AF Chinsongkram, Butsara Chaikeeree, Nithinun Saengsirisuwan, Vitoon Horak, Fay B. Boonsinsukh, Rumpa TI Responsiveness of the Balance Evaluation Systems Test (BESTest) in People With Subacute Stroke SO PHYSICAL THERAPY LA English DT Article ID QUALITY-OF-LIFE; POSTURAL ASSESSMENT SCALE; MENTAL-STATE-EXAMINATION; PSYCHOMETRIC PROPERTIES; STANDING BALANCE; MINI-BESTEST; COMMUNITY BALANCE; MOBILITY SCALE; SHORT-FORM; RELIABILITY AB Background. The reliability and convergent validity of the Balance Evaluation Systems Test (BESTest) in people with subacute stroke have been established, but its responsiveness to rehabilitation has not been examined. Objective. The study objective was to compare the responsiveness of the BESTest with those of other clinical balance tools in people with subacute stroke. Design. This was a prospective cohort study. Methods. Forty-nine people with subacute stroke (mean age=57.8 years, SD=11.8) participated in this study. Five balance measures-the BESTest, the Mini-BESTest, the Berg Balance Scale, the Postural Assessment Scale for Stroke Patients, and the Community Balance and Mobility Scale (CB&M)-were used to measure balance performance before and after rehabilitation or before discharge from the hospital, whichever came first. The internal responsiveness of each balance measure was classified with the standardized response mean (SRM); changes in Berg Balance Scale scores of greater than 7 were used as the external standard for determining the external responsiveness. Analysis of the receiver operating characteristic curve was used to determine the accuracy and cutoff scores for identifying participants with balance improvement. Results. Participants received 13.7 days (SD=9.3, range=5-44) of physical therapy rehabilitation. The internal responsiveness of all balance measures, except for the CB&M, was high (SRM=0.9-1.2). The BESTest had a higher SRM than the Mini-BESTest and the CB&M, indicating that the BESTest was more sensitive for detecting balance changes than the Mini-BESTest and the CB&M. In addition, compared with other balance measures, the BESTest had no floor, ceiling, or responsive ceiling effects. The results also indicated that the percentage of participants with no change in scores after rehabilitation was smaller with the BESTest than with the Mini-BESTest and the CB&M. With regard to the external responsiveness, the BESTest had higher accuracy, sensitivity, specificity, and posttest accuracy than the Postural Assessment Scale for Stroke Patients and the CB&M for identifying participants with balance improvement. Changes in BESTest scores of 10% or more indicated changes in balance performance. Limitations. A limitation of this study was the difference in the time periods between the first and the second assessments across participants. Conclusions. The BESTest was the most sensitive scale for assessing balance recovery in participants with subacute stroke because of its high internal and external responsiveness and lack of floor and ceiling effects. C1 [Chinsongkram, Butsara] Rangsit Univ, Fac Phys Therapy, Pathum Thani, Thailand. [Chaikeeree, Nithinun; Boonsinsukh, Rumpa] Srinakharinwirot Univ, Fac Hlth Sci, Div Phys Therapy, 63 Moo 7, Nakhonnayok, Thailand. [Saengsirisuwan, Vitoon] Mahidol Univ, Fac Sci, Dept Physiol, Bangkok, Thailand. [Horak, Fay B.] Oregon Hlth & Sci Univ, Balance Disorders Lab, Dept Neurol, Beaverton, OR USA. [Horak, Fay B.] Portland VA Med Ctr, Portland, OR USA. RP Boonsinsukh, R (reprint author), Srinakharinwirot Univ, Fac Hlth Sci, Div Phys Therapy, 63 Moo 7, Nakhonnayok, Thailand. EM rumpa@swu.ac.th FU Thailand Research Fund; Office of the Higher Education Commission, Srinakharinwirot University [RSA5580002]; NIH and VA Merit Award [AG006457, 1075] FX This project was supported by the Thailand Research Fund, the Office of the Higher Education Commission, Srinakharinwirot University (grant no. RSA5580002), and by NIH and VA Merit Award 1075 (grant no. AG006457). NR 46 TC 1 Z9 1 U1 17 U2 17 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD OCT PY 2016 VL 96 IS 10 BP 1638 EP 1647 DI 10.2522/ptj.20150621 PG 10 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA DX5AA UT WOS:000384391000016 PM 27103226 ER EF